RefID PtID RegimenName IsolateYear Country Subtype Children FirstAA LastAA AASeq Author RefYear MedlineID Journal Title 169 6556 AZT3TCNVP 2005 U.S. B 0 1 301 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSIPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLKWGLTTPDKKHQKEPPFLWMGYELHPDTWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEIVPLTEEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 6873 AZT3TCNVP 2000 U.S. B 0 1 300 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQEFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKVEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTEVIPLTEEAE Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 7979 AZT3TCNVP 2000 U.S. B 0 1 288 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKA Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 8373 D4T3TCEFV 2001 U.S. B 0 1 249 PISPIGTVPVKLKPGMDGPRVKQWPLTEEKIKALVEICTEMEKDGKISRVGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSDPLDKDFRKYTAFTIPSINNKTPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPD* Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 9714 AZT3TCEFV 2008 U.S. B 0 1 301 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGVRYQYNVLPQGWKGSPAIFQASMTKILEPFRKQNPDIIIYQYVDDLYIGSDLEIGQHRTKIEELRQHLSRWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIVLPKKETWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVIPLTEEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 14230 ABC3TCNVP 2006 U.S. B 0 1 301 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKRKDSTEWRKLVDFRELNKRTQDFWEIQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMTICQYVDDLYVASDLEIGQHREKIKELRQHLLRWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIMLPDKDCWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEVIPLTEEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 14435 D4T3TCNVP 2002 U.S. B 0 1 301 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKKKSITVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPEMIIYQYVDDLYVASDLEIGQHRAKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKIKQLCKLIRGTKALTEVVPLTKEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 14452 D4T3TCNVP 2002 U.S. B 0 1 252 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALVEICTELEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNEIPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSW Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 16399 D4T3TCNVP 2003 U.S. B 0 1 300 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVLDVGDAYFSVPLDKDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRKQNPDIVICQYVDDLYVGSDLEIEQHRTKIEELRQHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVIPLTEEAE Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 17628 AZT3TCNVP 2003 U.S. B 0 1 301 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLLVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVVPLTEEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 17637 D4T3TCEFV 2004 U.S. B 0 1 300 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKHNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDLQKLVGKLNWASQIYAGNKVKNLCKLLRGTKSLTEVVPLTEEAE Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 20990 D4T3TCEFV 2004 U.S. B 0 1 300 PISPIDTVPVRLKPGMDGPRVKQWPLTEEKIKALIEICTEMEKEGKILKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRIKVEELRQHLSKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVIQLTEEAE Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 21108 AZT3TCNVP 2004 U.S. B 0 1 300 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDREFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPELIIYQYMDDLYVGSDLEIGQHRIKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTEVVPLTKEAE Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 22129 AZT3TCNVP 2004 U.S. B 0 1 300 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVPPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLKGAKALTDIITLTKEAE Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 22145 ABC3TCNVP 2004 U.S. B 0 1 300 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPYRKQNPDIVIYQYMDDLYVGSDLEIGQHRVKVEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEVIPLTKEAE Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 22190 AZT3TCEFV 2004 U.S. B 0 1 300 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVASDLEIGQHRTKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVRQLCKLLRGTKALTEVIPLTEEAE Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 23836 TDFFTCEFV 2006 U.S. B 0 1 300 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRIKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVVPLTEEAE Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 25035 AZT3TCEFV 2007 U.S. B 0 1 301 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPSGLKRNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQFSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRGHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKNLCKLLRGTKALTEVVPLTEEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 25052 D4T3TCNVP 2005 U.S. B 0 1 300 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILQPFREQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTSPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCRLLRGTKALTEVIPLTEEAE Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 25127 D4T3TCNVP 2005 U.S. B 0 1 251 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRHHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDS Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 25633 D4T3TCNVP 2005 U.S. B 0 1 340 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKNSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPGIVIYQYMDDLYVGSDLEIGQHRTKVEELRQHLLKWGFTTPDQKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQGQGQWTYQ Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 25691 ABC3TCEFV 2005 U.S. B 0 1 368 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIRKKDSTKWRKLVDFRELNKRTQEFWEVQLGIPHPAGLTKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDLVIYQYMDDLLVGSDLEIGQHRTKIEELRQHLLTWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 26286 AZT3TCNVP 2005 U.S. G 0 1 270 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQNLVGKLNWASQI Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 27758 D4T3TCNVP 2006 U.S. B 0 1 301 PISPIETVPVTLKPGMDGPRIKQWPLTEEKIKALMEICTEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQEFXEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDQNFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPDMIIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVIPLTKEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 27849 TDFFTCEFV 2006 U.S. B 0 1 305 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIRKLVGKLNWASQIYAGIKVRQLCKLLRGTKALTEVIPLTAEAELELAE Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 27931 AZT3TCNVP 2008 U.S. B 0 1 301 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLQKKKSATVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRKQNPDLVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVVPLTEEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 30247 TDFFTCEFV 2007 U.S. B 0 1 301 PISPIETVPVNLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRQQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRHHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDIWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGTKALTEVVPLTTEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 35520 TDFFTCEFV 2009 U.S. B 0 1 300 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILDPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRHLCKLLRGAKALTEVVPLTKEAE Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 35596 TDFFTCEFV 2009 U.S. D 0 1 302 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPIFAIKKKDSDKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVICQYMDDLYVASDLEIGQHRIKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKCIRGTKALTEIVPLTEEAELE Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 35639 D4T3TCNVP 2007 U.S. B 0 1 300 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKDGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRKQNPDIVICQYVDDLYVGSDLEIGQHRTKIEELRQHLLGWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYVGIKVKQLCKLLRGTKSLTEVVPLTAEAE Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 37945 ABC3TCNVP 2007 U.S. B 0 1 301 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHREKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVRQLCKLLRGTKALTEVVPLTAEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 38014 D4T3TCNVP 2007 U.S. B 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRQNPDIVICQYVDDLYVGSDLEIGQHRTKIEELRNHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIRVKQLCKLIRGTKALTEVVPLTKEAELELAENREILKEPVHGVYYDPSKELIAEVQKQGEGQWSYQLYQEPFKILKTGKYARTRGTHTNDVKQLTEVVQKVSTESIVIWGKTPKFKLPIQRETWETWWTEYWQATWIPEWEFVNTPLLVKLWYQLEKEPIEGAETFYVDGAANRETKLGRAGYVTNRGRQKVVSLADTTNQKTELQAIYIALQDSGSEVNIVTDSQYALGIIQAYPDRSESELVNQIIEQLIKKEKVYLAWVPAHKGIGGNEQVDKLVSSGIRKVL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 38030 TDFFTCEFV 2011 U.S. C 0 1 301 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 38127 TDFFTCEFV 2007 U.S. B 0 1 301 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRIKVEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTKEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 39127 TDFFTCEFV 2007 U.S. B 0 1 301 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICLEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVIQLTEEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 39139 D4T3TCEFV 2007 U.S. B 0 1 301 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALMEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSAKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILDPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLTWGFTTPDKKHQKDPPFLWMGYELHPDKWTVQPIMLPKKDSWTVNDIQKLVEKLNWASHIYAGIKVKQLCKLLRGAKSLTEVIPLTEEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 42072 D4T3TCEFV 2007 U.S. B 0 1 301 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIILPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVIPLTEEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 42670 D4T3TCEFV 2008 U.S. B 0 1 300 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAVFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKVEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEVIPLTEEAE Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 56153 TDFFTCEFV 2011 U.S. B 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKITALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDLVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGTKALTEVISLTEEAELELAENREILREPVHGVYYDPSKDIIAELQKQGQGQWTYQIYQEPFKNLKTGKYARMKGAHTNDVRQLTEAVQKISQESIVIWGKTPKFKLPIQKETWEAWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIIGAETFYVDGAANRETKLGKAGYVTNRGRQKVVSIADTTNQKTELQAIHLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKEKVYLAWVPAHKGIGGNEQVDKLVSAGIRKVL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 57404 TDFFTCEFV 2008 U.S. B 0 1 299 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIEIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLAWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKSLTEVVPLTEEA Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 57423 TDFFTCEFV 2011 U.S. B 0 1 301 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALLEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNRRTQDFWEVQLGIPHPAGLQKNKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEVVIYQYVDDLYVGSDLEIGQHRIKIEELRQHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPVVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVVPLTEEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 61472 TDFFTCEFV 2009 U.S. B 0 1 302 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKKNPDIVIYQYVDDLLVGSDLELGEHRTKIEELREHLSKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVVPLSQEAELE Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 61483 TDFFTCEFV 2010 U.S. B 0 1 301 PISPIKTVPVKLKPGMDGPKVKQWPLSEEKINALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMEIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLKGAKALTEVVPLTAEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 61612 TDFFTCEFV 2009 U.S. B 0 1 301 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSITVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMVKILEPFRKQNPDIEICQYIDDLLVGSDLEIGQHRKKIEELREHLLKWGFTTPDNKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEVVPLTEEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 61631 TDFFTCNVP 2009 U.S. B 0 1 301 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSIPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMMKILEPFRKQNPDVVICQYVDDLYVASDLEIGQHREKIEKLRQHLLGWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVIPLTEEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 61707 TDFFTCEFV 2012 U.S. B 0 1 299 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSITVLDVGDAYFSVPLDRDFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPTIFQSSMTKILEPFRKLNPDIVIYQYMDDLYVGSDLEIGQHRIKVEQLREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLIRGTKALTEVVPLTKEA Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 70464 TDFFTCEFV 2011 U.S. B 0 1 299 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPYREQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRHHLLTWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEIIPLTEEA Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 70564 TDF3TCEFV 2009 U.S. C 0 1 301 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDVVPLTEEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 70642 TDFFTCEFV 2012 U.S. B 0 1 301 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPVVLPEKNSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTEVVPLTEEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 70647 TDFFTCEFV 2011 U.S. B 0 1 301 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILDPFRKQNPDLVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLNWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVIPLTEEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 70689 TDFFTCEFV 2010 U.S. B 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPIFAIKKKGSTKWRKLLDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYIDDLHVGSDLEIGEHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQFYPGIKVKQLCRLLRGTKALTEVVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYAGMRGTHTNDVKQLTEAVQKIAKESIVIWGKTPKFRLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKMGKAGYVTNRGRQKVVQLTDTTNQKTELQAIYLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKEKIYLAWVPAHKGIGGNEQVDKLVSSGIRRIL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 75682 TDFFTCEFV 2011 U.S. B 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLLDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKHNPDIVIYQYIDDLYVASDLEIEQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQEHGQWTYQIYQEPFKNLKTGKYAKMRGAHTNDVKQLTEAVQKIATESIVIWGKTPKFRLPIQKETWEAWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIEGAETFYVDGAANRETKLGKAGYVTNKGRQKVVSLTDTTNQKTELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESEVVNQIIEQLIQKEKVYLAWVPAHKGIGGNEQIDKLVSAGIRKVL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 79959 TDFFTCEFV 2010 U.S. B 0 1 301 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDREFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRERNPEIVIYQYMDDLYVGSDLEIEQHREKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKIKQLCKLLRGTKALTEVIPLTEEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 80037 TDFFTCEFV 2010 U.S. B 0 1 301 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDQKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVVPLTEEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 80084 TDFFTCEFV 2012 U.S. B 0 1 301 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKQNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKHNPELVIYQYMDDLYVGSDLEIGQHRTKVEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPILLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKNLCKLLRGAKSLTEVIPLTEEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 80134 TDFFTCEFV 2011 U.S. B 0 1 560 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTEWRKLMDFRELNKRTQDFWEIQLGIPHPAGIKKRRSVTILDVGDAYFSVSLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKQNPDIDICQYVDDLYIGSDLEIGQHRAKIEELRQHLLRWGLTTPDKKYQKEPPLRWMGYELHPDKWTIQPIVLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKTLTEVVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQSQWTYQIYQEPFKNLKTGKYARSRGAHTNDVKQLAEAVQKVATESIVIWGKTPKFRLPIQKETWEVWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTDRGRQKVIPLTDTTNQQTELHAINLALQDSGSEVNIVTDSQYALGIIQAQPDKSESEIVNQIIEQLIKKEKIYLTWVPAHKGIGGNEQVDKLVSNGIRRVL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 82182 AZT3TCNVP 2011 U.S. B 0 1 302 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKIAKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTVPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLTWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGTKALTEVVPLTAEAELE Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 82275 TDFFTCEFV 2011 U.S. B 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKRKDGNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRIKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPEKWTVQPIVLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVRQLTEAVQKISTESIVIWGKTPKFRLPIQKETWELWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPILGAETFYVDGASNKETKLGKAGYVTDRGRQKVVSLTDTTNQKTELQAIYLALQDSVLEVNIVTDSQYALGIIQAQPDKSESELVSQIIEELIKKEKVYLAWVPAHKGIGGNEKVDKLVSSGIRKVL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 82287 TDFFTCEFV 2012 U.S. B 0 1 299 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIEQHRIKIEELRRHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIELPKKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVIPLTEEA Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 82324 TDFFTCEFV 2011 U.S. B 0 1 299 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISRVGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDQDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILNPFRKQNPDMVIYQYMDDLYVGSDLDIGQHRAKIEELRQHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDSWTVNDIQKLVGKLNWASQIYSGIKVRQLCKLLRGTKALTEIIPLTEEA Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 82352 AZT3TCEFV 2011 U.S. B 0 1 301 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKESPFLWMGYELHPDKWTVQPINLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDVIPLTQEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 90492 D4T3TCNVP 2011 U.S. B 0 1 301 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIEQHRTKIEELRHHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGTKALTEVIPLTEEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 101695 ABC3TCEFV 2012 U.S. B 0 1 301 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALIEICTELEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLLVGSDLEIGQHRGKIEELRQHLLRWGLFTPDKKHQKEPPFFWMGYELHPDKWTVQPIVLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTEEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 101796 TDFFTCNVP 2013 U.S. B 0 1 301 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFVIKRKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNRSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVICQYVDDLYVGSDLEIEQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVIPLTEEAEL Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 169 112985 TDFFTCEFV 2013 U.S. B 0 1 299 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFREQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEIVPLTKEA Stanford, A 1998 Unpublished Reverse transcriptase and protease sequences. 842 7302 AZT3TCEFV 1998 U.S. B 0 1 229 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLKIEQHRAKIEELREHLLKWGFTTPDKKHQKEPPFRW Bacheler, LT 2000 10952598 AAC Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. 842 7303 AZT3TCEFV 1998 U.S. B 0 1 229 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLW Bacheler, LT 2000 10952598 AAC Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. 842 7304 AZT3TCEFV 1998 U.S. B 0 1 229 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLW Bacheler, LT 2000 10952598 AAC Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. 842 7305 AZT3TCEFV 1998 U.S. B 0 1 229 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTILSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDMVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLW Bacheler, LT 2000 10952598 AAC Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. 842 7306 AZT3TCEFV 1998 U.S. B 0 1 229 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKIEKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKQNPDIVIYQYVDDLYVSSDLEIGQHRAKIEELRQHLLRWGFTTPDKKHQKEPPFLW Bacheler, LT 2000 10952598 AAC Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. 842 7307 AZT3TCEFV 1998 U.S. B 0 1 229 PISPIETVPVRLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLW Bacheler, LT 2000 10952598 AAC Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. 842 7308 AZT3TCEFV 1998 U.S. B 0 1 229 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPEIVIYQYVDDLYVGSDLEIEQHRTKIEELRQHLLQWGLTTPDKKHQKEPPFLW Bacheler, LT 2000 10952598 AAC Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. 842 7309 AZT3TCEFV 1998 U.S. B 0 1 229 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKEDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILGPFRKQNPELVIYQYMGDLYVGSDLELGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLW Bacheler, LT 2000 10952598 AAC Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. 842 7310 AZT3TCEFV 1998 U.S. B 0 1 229 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKHNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLW Bacheler, LT 2000 10952598 AAC Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. 842 7311 AZT3TCEFV 1998 U.S. B 0 1 229 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMKKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLRWGFTTPDKKHQKEPPFLW Bacheler, LT 2000 10952598 AAC Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. 842 7312 AZT3TCEFV 1998 U.S. B 0 1 229 PISPIETVPVKLKPGMDGPKVKQWPLTEEKTKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEHPFLW Bacheler, LT 2000 10952598 AAC Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. 842 7314 AZT3TCEFV 1998 U.S. B 0 1 229 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSIPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHREKIEKLRQHLLRWGLTTPDKKHQKEPPFLW Bacheler, LT 2000 10952598 AAC Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. 842 7316 AZT3TCEFV 1998 U.S. B 0 1 229 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSIPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILDPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEDLREHLLKWGLTTPDKKHQKEPPFLW Bacheler, LT 2000 10952598 AAC Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. 842 7317 AZT3TCEFV 1998 U.S. B 0 1 229 PISPIETVPVRLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDMVIYQYMDDLYVGSDLEIGQHREKIEELRQHLLKWGFTTPDKKHQKEHPFLW Bacheler, LT 2000 10952598 AAC Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. 842 7318 AZT3TCEFV 1998 U.S. B 0 1 229 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQEFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIEQHRTKIEQLRAHLLRWGFTTPDKKHQKEPPFLW Bacheler, LT 2000 10952598 AAC Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. 842 7319 AZT3TCEFV 1998 U.S. B 0 1 229 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLW Bacheler, LT 2000 10952598 AAC Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. 863 8177 AZT3TCNVP 2000 Greece CRF04_cpx 0 41 246 MEKEGKISKIGPENPYNTPIFAIHKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQHSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLRWGFTTPDQKYQKEPPFHWMGYELHPDTWTVQPIQL Papa, A 2002 11955641 Virus Res HIV-1 subtypes and circulating recombinant forms (CRFs) in Northern Greece. 870 1618 AZT3TCNVP 1998 U.S. B 0 1 301 PISPIETVPVRLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIRKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLLVGSDLEIGQHRTKIAELRQHLLRWGLTTPDQKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKVNWASQIYPGIKVKHLCKRLRGTEALTEVVPLTEEAEL Gonzales, MJ 2001 11574914 J Infect Dis HIV-1 reverse transcriptase and protease subtypes: Classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population. 870 4586 AZT3TCEFV 1999 U.S. B 0 1 303 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSVNNETPGVRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPELVIYQYMDDLYVGSDLEIGQHRKKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVVPLTAEAELEL Gonzales, MJ 2001 11574914 J Infect Dis HIV-1 reverse transcriptase and protease subtypes: Classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population. 870 4741 D4T3TCNVP 1999 U.S. B 0 1 300 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKLKALVEICTEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRVKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLKGAKALTEIIPLTTEAE Gonzales, MJ 2001 11574914 J Infect Dis HIV-1 reverse transcriptase and protease subtypes: Classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population. 870 5279 AZT3TCNVP 1999 U.S. B 0 1 286 PISPIETVPVKLKPGMGGPKVKQWPLTEEKIKALVDICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGA Gonzales, MJ 2001 11574914 J Infect Dis HIV-1 reverse transcriptase and protease subtypes: Classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population. 870 6616 D4T3TCEFV 2000 U.S. B 0 1 300 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRIKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLKGTKALTEVVPLTAEGE Gonzales, MJ 2001 11574914 J Infect Dis HIV-1 reverse transcriptase and protease subtypes: Classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population. 892 8886 AZT3TCNVP 1999 France F 0 16 239 MDGPRVKQWPLTEEKIKALTEICSELEKEGKISKIGLENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILDPFRAKNPDIVIYQYVDDLYVGSDLEIGQHRTKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPENW Yahi, N 2001 11294661 J Infect Dis Use of drug resistance sequence data for the systematic detection of non-B human immunodeficiency virus type 1 (HIV-1) subtypes: How to create a sentinel site for monitoring the genetic diversity of HIV-1 at a country scale. 951 9928 AZT3TCNVP 2001 U.S. B 0 1 300 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALIEICTEMEKEGKISKIGPENPYNTPVFAIKRKDGTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIMICQYVDDLYVGSDLEIGQHRTKVEELRQHLLKWGFTTPDNKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDVIPLTEEAE Gonzales, MJ 2003 12660525 AIDS Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. 979 19360 AZT3TCNVP 2002 Brazil F 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICREMEEEGKISKIGPENPYNTPVFAIKKKNSNRWRKLVDFRDLNKRTQDFWEIQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDKEFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRTKNPDIIICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFFTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLKGAKALTDIVPLTVEAELELAENREILKEPVHGVYYDPSKDLIAEIQKHGQG Rodrigues, R 2005 15780815 J Clin Virol Prevalence of ARV resistance mutations and impact of genotyping test in HIV patients with advance disease in Sao Paulo, Brazil. 992 14055 AZT3TCNVP 2002 U.K. C 0 1 333 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRARNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDVIPLTEEAELELAENREILKEPVHGAFYDPSKDLIAEIQKQG Weber, J 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 992 14059 AZT3TCNVP 2002 U.K. C 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYTGIKVKQLCKLLRGTKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQGHG Weber, J 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 992 14081 AZT3TCNVP 2002 U.K. C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQG Weber, J 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 992 14127 AZT3TCNVP 2002 U.K. A 0 1 334 PISPINTVPVKLKPGMDGPKIKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRSKNPEIIIYQYMDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKDPVHGVYYDPAKDLIAEIQKQGQ Weber, J 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 992 14130 AZT3TCEFV 2002 U.K. CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICIEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSVNNETPGVRYQYNVLPQGWKGSPSIFQASMTKILEPFRTDNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVTLTQEAELELAETREILKEPVHGVYYDPAKDLVAEIQKQGQ Weber, J 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 992 14131 AZT3TCNVP 2001 U.K. A 0 1 321 PISPIDTVPVKLKPGMDGPKIKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEVIIYQYMDDLYVGSDLEIGQHRTKVEELREHLLKWGFTAPDKKHQKERPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLIRGAKALTDIVTLTEEAELELAENREILKDPVHGXYYAP Weber, J 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 992 18740 AZT3TCNVP 2003 U.K. CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKDICADREKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQELWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQSIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Weber, J 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 992 18749 AZT3TCNVP 2003 U.K. A 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSQAIFQSSMTRILDPFRTRNPEIVIYQYMDDLYVGSDLEIEQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNEIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKDPVHGVYYDPSKDLIAEIQKQGQ Weber, J 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 992 18751 AZT3TCNVP 2003 U.K. C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDCWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Weber, J 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 992 18757 TDF3TCNVP 2003 U.K. A 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICMEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNGTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPDLIICQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIELPEKERWTVNDIQKLVGKLNWASQIYPGIKVKHLCKLLRGAKALTEIVPLTEEAELELAENREILKDPVHGVY*DPSKDLIAEIQKQGQ Weber, J 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 992 18758 AZT3TCNVP 2003 U.K. C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKAICEELEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQG Weber, J 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 997 21665 AZT3TCEFV 2003 Zimbabwe C 0 1 319 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGTKALTDIVPLTEEAELELAENREILKEPVHGVYY Kantor, R 2002 12512512 ARHR HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy. 1112 19425 AZT3TCEFV 2000 Uganda A 0 1 206 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGMRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPDIIIYQYVDDLYVGSDLEIGQHRTKIEELR Richard, N 2004 15157354 ARHR High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. 1112 19451 AZT3TCEFV 1999 Uganda A 0 1 206 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVAFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIIIYQYMDDLYVGSDLEIGQHRTKVEELR Richard, N 2004 15157354 ARHR High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. 1112 19478 AZT3TCEFV 2000 Uganda D 0 1 206 PISPIETVPVKLKPGMDGPKVKQWPLTREKIEALVEICTEMEKDGKISRIGPENPYNTPIFALKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELR Richard, N 2004 15157354 ARHR High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. 1112 19479 AZT3TCNVP 2000 Uganda D 0 1 206 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKLKALTEICTEMEREGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPEMVIYQYVDDLYVGSDLEIGQHRTKIEELR Richard, N 2004 15157354 ARHR High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. 1112 19480 AZT3TCEFV 2000 Uganda D 0 1 206 PISPIEPVPVKLKPGMDGPKVKQWPLTEEKIRALTAICKGLEEEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFKKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELR Richard, N 2004 15157354 ARHR High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. 1115 22602 AZT3TCEFV 2002 U.S. B 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYMDDLYVGSDLEIEQHRTKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP PacOaks 2004 Unpublished Sequences from Pacific Oaks. 1115 22868 D4T3TCNVP 2002 U.S. B 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP PacOaks 2004 Unpublished Sequences from Pacific Oaks. 1115 22871 AZT3TCEFV 2003 U.S. B 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP PacOaks 2004 Unpublished Sequences from Pacific Oaks. 1115 22876 D4T3TCNVP 2001 U.S. B 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIIIYQYVDDLYVGSDLEIGQHRTKIEELRHHLLEWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP PacOaks 2004 Unpublished Sequences from Pacific Oaks. 1115 23372 D4T3TCNVP 2001 U.S. B 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRIKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLP PacOaks 2004 Unpublished Sequences from Pacific Oaks. 1125 20440 AZT3TCNVP 2002 France B 0 1 239 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALLELCTELEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNQTPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIIVYQYVDDLYVGSDLEIGQHRTKIEELRQHLLRWGFYTPDKEHQKEPPFLWMGYELHPDKW Montes, B 2004 15097148 JAIDS Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B. 1125 20497 AZT3TCNVP 2000 France B 0 38 242 CTEMEKEGKISKIGPENPYNTPVFAIKKKISTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILGPFRKQNPDIVIYQYVDDLYVASDLEIGQHRTKIEELRQPLLRWGFTTPDKKHQKEPPFLWMGYELHPNKWTVQ Montes, B 2004 15097148 JAIDS Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B. 1125 20571 AZT3TCNVP 2002 France A 0 28 239 EEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEGFRKYTAFTIPSTNNETPGIRFQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIIIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKW Montes, B 2004 15097148 JAIDS Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B. 1163 12593 AZT3TCNVP 2002 Brazil C 0 1 234 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAQNPGIVIYQYMDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYEL Soares, EA 2003 14657764 JAIDS Epidemiologic and molecular characterization of human immunodeficiency virus type 1 in southern Brazil. 1167 4859 AZT3TCNVP 2004 U.S. B 0 1 302 PISPIETVPVKLKPGMDGPRVKQWPLTEEKINALIEICAELEEEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKQRKSVTVLDMGDAYFSVPLDKDFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIEICQYVDDLYVGSDLEIEQHRTKIEELRQHLWKWGFYTPDKKHQKEPPFRWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLKGAKALTEIIPLTEEAELE Rhee, SY 2005 15995959 J Infect Dis HIV-1 protease and reverse transcriptase mutations: Correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. 1167 7103 D4T3TCEFV 2003 U.S. B 0 1 300 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDLVIYQYMDDLYVGSDLEIGQHRTKIEELRKHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKSLTEVIPLTEEAE Rhee, SY 2005 15995959 J Infect Dis HIV-1 protease and reverse transcriptase mutations: Correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. 1167 14363 AZT3TCEFV 2002 U.S. B 0 1 303 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVALDKDFRKYTAFTIPSINNGTPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDMVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLRWGFTTPDKKHQKEHPFLWLGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCRLLRGTKALTEVIPLTEEAELEL Rhee, SY 2005 15995959 J Infect Dis HIV-1 protease and reverse transcriptase mutations: Correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. 1167 14363 AZT3TCEFV 2003 U.S. B 0 1 300 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDMVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCRLLRGTKALTEVIPLTEEAE Rhee, SY 2005 15995959 J Infect Dis HIV-1 protease and reverse transcriptase mutations: Correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. 1167 14460 AZT3TCNVP 2002 U.S. B 0 1 301 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGRKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVASDLEIGQHRTKIEELRQHLSRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKSLTEVIPLTEEAEL Rhee, SY 2005 15995959 J Infect Dis HIV-1 protease and reverse transcriptase mutations: Correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. 1167 16210 TDF3TCEFV 2003 U.S. B 0 1 300 PISPIETVPVKLKPGMDGPKVRQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLDENFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVCSDLEIGQHRAKIKELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLIRGAKGLTEVVPLTEEAE Rhee, SY 2005 15995959 J Infect Dis HIV-1 protease and reverse transcriptase mutations: Correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. 1167 18393 D4T3TCEFV 2004 U.S. B 0 1 301 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILDPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRSKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIILPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKSLTEVIPLTEEAEL Rhee, SY 2005 15995959 J Infect Dis HIV-1 protease and reverse transcriptase mutations: Correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. 1181 9600 AZT3TCEFV 2000 U.K. C 0 1 226 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLNKKKSMTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRMQNPDIVIYQYVDDLYVASDLEIGQHRQKIEELREHLLKWGFTTPDKKHQKEPP Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 9613 AZT3TCNVP 2001 U.K. D 0 1 234 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSLNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYVDDLYVASDLEIGQHRIKIKELREHLLKWGFTTPDKKHQKEPPFLWMGYEL Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 9615 AZT3TCNVP 2000 U.K. C 0 1 234 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDLVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYEL Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 9622 AZT3TCNVP 2001 U.K. A 0 1 234 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEMIIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYEL Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 9628 AZT3TCNVP 2001 U.K. C 0 1 234 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEELEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKAMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRRKNPDIVIYQYVDDLYVASDLEIGQHRAKVEELREHLWKWGFYTPDEKHQKEPPFLWMGYEL Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 9629 AZT3TCNVP 2001 U.K. A 0 1 234 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIIYQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFITPDEKHQKEPPFLWMGYEL Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 10229 AZT3TCEFV 2001 Israel C 0 37 247 ICEEMEKEGKISKIGPENPYNTPIFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 10515 AZT3TCEFV 2001 Thailand CRF01_AE 0 20 251 KAKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPEIVIYQYMDDLYVASDLEIGQHRAKIEELRAHLLSWGFFTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKGS Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 10523 AZT3TCEFV 2001 Thailand CRF01_AE 0 20 256 QVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLXKEKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPELIIYQYVDDLYVGSDLEIEQHRTKIEELRAHLWTWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 10528 AZT3TCEFV 2001 Thailand CRF01_AE 0 21 255 VKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLHESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDQKHQKEPPFLWMGYELHPDTWTVQPIELPERDSWTVN Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 10540 D4T3TCEFV 2001 Thailand CRF01_AE 0 16 258 MDGPRVKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNNPVFAIKRKDGIRWRKLIDLRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYYSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRIKNPEIGIYQYMDDLYVESDLEIGQHRTKVKELRAHLLSWGFTTPDEKHQEEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDTP Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 10554 D4T3TCEFV 2001 Thailand CRF01_AE 0 39 234 QEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYEL Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 10564 D4T3TCNVP 2001 Thailand CRF01_AE 0 15 256 FVAGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEVVIYQYVDDLYVASDLEIGQHRIKIDELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDSWTVQPIELPEKDSWTVND Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 10582 D4T3TCNVP 2002 Thailand CRF01_AE 0 18 255 GPKVKQWPLTEEKIKALTEICNELEEAGKISKIGPENPYNTPIFAIKKKDSDKWRKLLDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMIIYQYMDDLYVASDLEIGQHRTKIEELRAHLWNWGFYTPDEKHQQEPPFRWMGYELHPDRWTVQPIELPEKDSWTVN Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 10595 AZT3TCNVP 2002 Thailand CRF01_AE 0 17 256 GWPKVKQWPLTKEKIIALTEICKELEEAGKISKIGPENPYNTPIFAIKKKNSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSIPLHEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYMDDLYVASDLEIEQHRTKIEELRAHLWAWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVND Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 12191 AZT3TCEFV 2002 U.K. C 0 1 234 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQHPEVVIYQYVDDLYVGSDLEIGQHRETIEKLREHLLRWGFTTPDKKHQKEPPFLWLGYEL Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 12204 D4T3TCNVP 2001 U.K. C 0 1 234 PISPIETVPVKLKTGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVQNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYEL Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 12223 AZT3TCNVP 2002 U.K. A 0 1 225 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNEKPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEP Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 13044 D4T3TCEFV 2001 Portugal G 0 1 324 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKE Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 13093 AZT3TCEFV 2001 Portugal G 0 1 324 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICEEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLQKKTSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEHPFLWMGYELHPDTWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKE Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 13128 AZT3TCNVP 2001 Portugal G 0 1 320 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKKNPEIVIYQYMDDLYVGSDLEKEQHRAKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYD Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 13172 AZT3TCNVP 2001 Portugal G 0 1 333 PISPIKTVPVKLKPGMDGPKVKQWPLTKEKIIALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIQVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 13188 AZT3TCEFV 2001 Portugal G 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDEXFRRYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLXWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVALTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 13212 AZT3TCEFV 2001 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKRKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 13219 AZT3TCEFV 2002 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPSGLQKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLIRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 13226 AZT3TCEFV 2002 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICXEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLDIGQHRAKIEELRKHLLSWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 13235 AZT3TCNVP 2002 Portugal G 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQSIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKGLTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGK Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 13288 D4T3TCEFV 2002 Portugal CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMDICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKRNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVAXTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 13698 AZT3TCEFV 2002 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAVFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFYTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVVQLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 13701 D4T3TCNVP 2002 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVIYQYVDDLYVASDLEIGQHRAKIEELREHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 19162 AZT3TCNVP 2003 U.K. C 0 1 234 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALKEICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFSEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQHSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYEL Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 19163 AZT3TCNVP 2002 U.K. C 0 1 234 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPGIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGFFTPDQKHQKEPPFLWMGYEL Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 19164 AZT3TCNVP 1998 U.K. C 0 1 234 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYVDDLYVGSDLEIKQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYEL Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 19165 AZT3TCNVP 2002 U.K. C 0 1 234 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDLVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKKPPFLWMGYEL Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 19166 AZT3TCEFV 2003 U.K. D 0 1 234 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRKQNPEMVIYQYVDDLYVGSDLEIGQHRIKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYEL Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 19168 AZT3TCEFV 2002 U.K. C 0 1 234 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTRNPDMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYEL Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 19169 AZT3TCNVP 2003 U.K. F 0 1 230 PISSIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKRSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPYRTKNPDIVIYQYVDDLYVSSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWM Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 19170 AZT3TCEFV 2003 U.K. D 0 1 234 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEDEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKQNPEMVIYQYVDDLYVGSDLEIGQHRMKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYEL Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 19173 AZT3TCNVP 2002 U.K. A 0 1 225 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNEKPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEP Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 19175 AZT3TCNVP 2003 U.K. C 0 1 235 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSIPLDEGFRKYTAFTIPSTNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELH Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 19176 AZT3TCEFV 2003 U.K. C 0 1 229 PISPITTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLLWGFTTPDKKHQKEPPFFW Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 19177 AZT3TCEFV 2003 U.K. C 0 1 234 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIEALTAICAEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNEIPGIRYQYNVLPQGWKGSPAIFQHSMTKILEPFRTQNPEIVICQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKCQKEPPFLWMGYEL Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 19178 TDF3TCNVP 2003 U.K. CRF02_AG 0 1 234 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVLDVGDAYFSVPLDQDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAENPEIVICQYMDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPLLWMGYEL Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 19180 ABC3TCEFV 2002 U.K. C 0 1 234 PISPIETVPVKLKPGMDDPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPNTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKVEELRGHLLKWGFTTPDKKHQKEPPFLWMGYEL Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 19181 AZT3TCEFV 2002 U.K. A 0 1 234 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKLSKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPDIIIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYEL Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 19182 AZT3TCNVP 2002 U.K. A 0 1 234 PISPIETVPVTLKPGMDGPKIKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMIKILEPFRSQNPEIVIYQYMDDLYVGSDLEIGQHRAKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYEL Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 19184 AZT3TCNVP 2002 U.K. A 0 1 234 PISPIETVPVTLKPGMDGPRVKQWPLTEEKIKALTEICTEMKKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPGIIIYQYVDDLYVASDLEIGQHRTKVEELRDHLLSWGLTTPDKKHQKEPPFLWMGYEL Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 19185 AZT3TCNVP 2003 U.K. C 0 1 234 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALKEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDLWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPTIFQSSMTKILEPFRAQNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYEL Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 19186 AZT3TCNVP 2002 U.K. C 0 1 234 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLCEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELVIIQYVDDLYVASDLEIGQHRAKIKELREHLLKWGFTTPEQKHQKEPPFLWMGYEL Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 19187 AZT3TCNVP 2002 U.K. C 0 1 235 PISPIETIPVKLKPGMDGPKVKQWPLTEEKLRAITAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFFTPDKKYQKEPPFLWMGYELH Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 19188 AZT3TCEFV 2002 U.K. C 0 1 230 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTEICEDMEKEGKITRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHHKEPPFCWM Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 19189 AZT3TCNVP 2003 U.K. D 0 1 234 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICLEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGMRYQYNVLPQGWKGSPAIFQSSMIKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRIKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYEL Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20622 D4T3TCNVP 2002 Thailand CRF01_AE 0 19 256 PKVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPIFAIKKKNSTRWRKLMDFRELNKRTQDFWEVQLGIPHPAGLEKKESVPVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYIDDLYVASDLEIGQHRIKIDELRAHLLNWGFFTPDQKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVND Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20623 AZT3TCNVP 2002 Thailand CRF01_AE 0 18 258 GPKVKQWPLTEEKLKALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDIGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIIICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFRWMGYELHPDRWTVQPIVLPEKDSWTVNDIQ Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20639 D4T3TCNVP 2002 Thailand CRF01_AE 0 17 254 DGPKVKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIGQHKAKIEELRAHLLSWGFFTPDQKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTV Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20641 AZT3TCNVP 2002 Thailand CRF01_AE 0 17 255 DGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQSNVLPQGWKGSAAIFQSSMIKILEPFRRKNPEMVIYQYVDDLLVGSDLEIGQHRTKIEELRAHLLSWGFTTPDQKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVN Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20642 D4T3TCNVP 2002 Thailand CRF01_AE 0 18 255 GPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRIKIEELRAHLLSWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVN Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20643 D4T3TCNVP 2002 Thailand CRF01_AE 0 17 258 DGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEMVICQYMDDLYVGSDLEIGQHRTKIEELRAHLLNWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQ Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20645 D4T3TCNVP 2002 Thailand CRF01_AE 0 17 250 DGPKVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYMDDLYVGSDLEIGQHRIKIEELRAHLLSWGFFTPEKKHQKEPPFLWMGYELHPDKWTVQPIELPEKD Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20649 AZT3TCNVP 2002 Thailand CRF01_AE 0 16 254 MDGPKVKQWPLTEEKIKALTEICKEMEQEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSITNETPGIRYQYNVLPQGWKGSPTIFQSSMTKILEPFRIKNPEVDICQYVDDLYVGSDLEIGQHRIKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTV Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20667 D4T3TCNVP 2002 Thailand CRF01_AE 0 18 253 GPKVKQWPLTEEKIKALTEICKEMEEEGKISRIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYMDDLYVGSDLEIGQHRTKVEELRAHLLSWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWT Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20681 D4T3TCEFV 2002 Thailand CRF01_AE 0 18 253 GPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRLKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDSWTVQPIELPEKDSWT Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20682 D4T3TCEFV 2002 Thailand CRF01_AE 0 21 252 VKQWPLTEEKIKAITEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKLMDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIIQYVDDLYVASDLEIGQHRRKIEELRAHLLSWGFFTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSW Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20683 AZT3TCNVP 2002 Thailand CRF01_AE 0 16 255 VDGPKVKQWPLTEEKIRALTEICKELEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKLTDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMIICQYMDDLYVASDLEIEQHRTKIEELRAHLLNWGFYTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPYKDSWTVN Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20685 D4T3TCNVP 2002 Thailand CRF01_AE 0 18 250 GPKVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYIDDLYVASDLEIGQHRAKIKELRAHLWSWGFVTPDQKHQEEPPLLWMGYELHPDRWTVQPIELPEKD Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20700 D4T3TCNVP 2002 Thailand CRF01_AE 0 18 256 GPKVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPIFAIKKKNSTRWRKIVDFRELNKRTQDFWEIQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKIKNPEMVIYQYIDDLYVASDLEIGQHRTKIEELRAHLLSWGFFTPEQKHQKEPPFLWMGYELHPDKWTVQPIELPEKYSWTVND Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20705 D4T3TCEFV 2002 Thailand CRF01_AE 0 18 251 GPKVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPIFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEMVIYQYMDDLYVGSDLEIGQHRIKIEELRNHLLRWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDS Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20721 AZT3TCNVP 2002 Thailand B 0 20 252 KVKQWPLTEEKIKALIEICPELEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLERKKSVTVLDVGDAYFSIPLDKDFRKYTAFTIPSVNNETPGVRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYVDDLYIASDLEIGQHRTKIEELRQHLWKWGFYTPDKKHQKEPPFLWMGYELHLDTWTVQPIELPEKDSW Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20725 D4T3TCNVP 2002 Thailand CRF01_AE 0 18 255 GPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVN Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20726 AZT3TCNVP 2002 Thailand CRF01_AE 0 20 250 KVKQWPLTEEKIKALTEICKEMEQEGKISRIGPENPYNTPVFVIKKKDSDKWRKLIDLRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDIGDAYYSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYMDDLYVGSDLEIGQHRIKIEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKD Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20752 AZT3TCNVP 2002 Thailand B 0 20 250 KVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKNKSVSVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRNKNPEMVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKD Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20759 D4T3TCNVP 2002 Thailand CRF01_AE 0 18 256 GPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKNKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKKYPEIVIYQYVDDLYVASDLEIGQHRDKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVND Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20778 AZT3TCEFV 2002 Thailand CRF01_AE 0 17 255 DGPKVKQWPLTEEKIKALTEICKELEKEGKISKIGPENPYNTPIFAIKRKDKTKWRKLIDFRVLNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYYSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIEQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVN Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20793 D4T3TCNVP 2002 Thailand CRF01_AE 0 27 253 TEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEMVICQYIDDLYVGSDLEIEQHRAKIEELRDHLLSGVFTTPGKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWT Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20798 D4T3TCNVP 2002 Thailand CRF01_AE 0 17 257 DGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIIIYQYMDDLYVGSDLEIGQRRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDI Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20799 D4T3TCNVP 2002 Thailand CRF01_AE 0 18 255 GPKVKQWPLTKEKIKALTEICKELEEDGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEMVIYQYIDDLYVGSDLEIGQHRTKVEELRAHLWKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVN Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20800 D4T3TCEFV 2002 Thailand CRF01_AE 0 20 255 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKNSDRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFFTPEQKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVN Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20805 AZT3TCNVP 2002 Thailand CRF01_AE 0 17 255 DGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDQKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVN Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20807 AZT3TCEFV 2002 Thailand CRF01_AE 0 17 256 DGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRIKIDELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVND Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20810 AZT3TCNVP 2002 Thailand CRF01_AE 0 18 249 GPKVKQWPLTEEKIKALTDICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVICQYVDDLYVGSDLEIGQHRTKVEELRAHLMRWGFTTPDEKHQKEPPFLWMGYELHPDRWTVQPIELPEK Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20812 D4T3TCEFV 2002 Thailand CRF01_AE 0 18 250 GPKVKQWPLTEEKIKALTQICKELEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLPKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRIKIEELRAHLWKWGFYTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKD Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20813 AZT3TCEFV 2002 Thailand CRF01_AE 0 18 251 GPKVKQWPLTEEKIKALTEICREMEEEGKISKIGPENPYNTPVFAIKKKDSSKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDS Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20815 D4T3TCNVP 2002 Thailand CRF01_AE 0 18 256 GPKVKQWPLTEEKIKALTEICKEMEAEGKISKIGPENPYNTPIFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEIDIYQYMDDLYVASDLEIGQHRIKIEELRAHLLSWGFFTPDEKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVND Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20817 AZT3TCEFV 2002 Thailand CRF01_AE 0 18 249 GPKVKQWPLTAEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVASDLEIEQHRTKIEELRAHLLHWGFFTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEK Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20834 D4T3TCNVP 2002 Thailand CRF01_AE 0 17 258 DGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVHLGIPHPAGLHKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVASDLEIGQHRIKIEELRAHLLSWGFFTPDQKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQ Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20852 AZT3TCEFV 2002 Thailand CRF01_AE 0 17 255 DGPKVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLRWGFFTPDKKHQKEPPLLWMGYELHPDRWTVQPIELPEKDSWTVN Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20857 AZT3TCEFV 2002 Thailand CRF01_AE 0 18 255 GPKVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLPKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFYTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVN Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20859 D4T3TCNVP 2002 Thailand CRF01_AE 0 21 255 VKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYYSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRIKNPEMIICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDDWTVN Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20860 AZT3TCEFV 2002 Thailand CRF01_AE 0 17 255 DGPKVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPVFAIRKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSLTVLDVGDAYFSIPLDKNFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIVIYQYVDDLLVGSDLEIEQHRTKIEELRAHLWNWGFFTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVN Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20862 AZT3TCEFV 2002 Thailand CRF01_AE 0 19 255 PKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDQKHQKEHPFLWMGYELHPDRWTVQPIELPQKDSWTVN Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20866 D4T3TCEFV 2002 Thailand CRF01_AE 0 19 250 PKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSVTVLDIGDAYFSVPLHESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIDIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPVELPEKD Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20875 D4T3TCNVP 2002 Thailand CRF01_AE 0 17 257 DGPKVKQWPLTEEKIKVLTEICKKMEEEGKISKIGPENPYNTPVFVIKKKNSTEWRKLTDFRELNKRTQDFWEIQLGIPHPAGLEKKKSVTILDVGDAYFSCPLDESFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTRILEPFRKNNPEMVICQYMDDLYVACDLEIGQHRIKIEELRDHLLRWGFTTPDKKHQKEPPFHWMGYELHPDRWTVQPIELPEKDSWTVNDI Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20876 D4T3TCNVP 2002 Thailand CRF01_AE 0 18 256 GPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSSRWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEMVICQYMDDLYVASDLEIGQHRAKIEELRAHLLSWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVND Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20881 D4T3TCNVP 2002 Thailand CRF01_AE 0 21 255 VKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRVKNPEMVIYQYMDDLYVGSDLEIGQHRIKIEELRAHLLRWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVN Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20884 AZT3TCNVP 2002 Thailand CRF01_AE 0 19 254 PKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEIVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFYTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTV Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20886 D4T3TCEFV 2002 Thailand CRF01_AE 0 18 255 GPRVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRTKNPEVVIYQYVDDLYVGSDLEIGQHRTKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVN Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20888 D4T3TCNVP 2002 Thailand CRF01_AE 0 18 256 GPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFFTPDEKHQKEPPFRWMGYELHPDRWTVQPIELPEKDSWTVND Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20890 D4T3TCEFV 2002 Thailand CRF01_AE 0 18 257 GPKVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPIFAIYKKNSTRWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRIKNPEIIIYQYVDDLLVGSDLEIGQHRTKIEELRAHLLSWGFFTPEQKHQKEPPFHWMGYELHPDKWTVQPIELPEKDSWTVNDI Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20893 D4T3TCNVP 2002 Thailand CRF01_AE 0 18 256 GPKVKQWPLTKEKIKALTEICEELEKDGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQCSMTKILEPFRLKNPEMVIYQYVDDLYVASDLEIGQHRTKIEELRAHLWSWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVND Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20919 D4T3TCNVP 2002 Thailand CRF01_AE 0 18 250 GPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNNRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKD Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20923 D4T3TCNVP 2003 Thailand CRF01_AE 0 16 256 MDGPRVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPVFAIKKKNSTRWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVASDLEIEQHRIKIKELRDYLLKWGFFTPEQKHQKEPPFHWMGYELHPDRWTVQPIQLPEKDSWTVND Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20925 D4T3TCNVP 2003 Thailand CRF01_AE 0 18 256 GPKVKQWPLTEEKIKALTEICDELEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKIVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNGTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVASDLEIGQHRAKIEELRAHLLNWGFFTPEQKHQKEPPFLWMGYELHPDRWTVQPIKLPDKDSWTVND Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20938 D4T3TCNVP 2003 Thailand CRF01_AE 0 17 257 DGPKVKQWPLTEEKIKALTEICKELEQDGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYMDDLYVASDLEIGQHRTKVEELRAHLWKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDI Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20939 AZT3TCNVP 2003 Thailand CRF01_AE 0 17 256 DGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPEMVIYQYVDDLLIGSDLEIEQHRAKIDELRAHLLSWGFYTPDEKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVND Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20940 D4T3TCNVP 2003 Thailand CRF01_AE 0 16 256 MDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFKMKNPEMVICQYIDDLYVGSDLDIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVND Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20948 D4T3TCNVP 2003 Thailand CRF01_AE 0 17 249 DGPRVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFVIKRKDGTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYYSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRTKNPEMVICQYMDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEK Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 20949 D4T3TCNVP 2003 Thailand CRF01_AE 0 17 250 DGPKVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPIFAIKKKNSTRWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIVQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFFTPEQKHQKEPPFHWMGYELHPDKWTVQPIELPEKD Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 21268 D4T3TCNVP 2003 Thailand CRF01_AE 0 20 258 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYMDDLYVGSDLEIGQHRRKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIALPEKDSWTVNDIQ Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25323 AZT3TCEFV 2004 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKENWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKELLAEVQKQG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25325 AZT3TCEFV 2002 Portugal C 0 1 311 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITRIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPSIFQSTMTKILAPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLTWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIQLTDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILK Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25340 AZT3TCEFV 2003 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPKIEIYQYMDDLYVGSDLEIGQHREKVEELRKHLLSWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGTYYDPSKELIAEVQKQG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25342 AZT3TCNVP 2004 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTTEAELELAENREILKEPVHGVYYEPSKELIAEVQKQGLG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25351 AZT3TCNVP 2004 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTKEKIKALTEICLELEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTTEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25369 AZT3TCNVP 2004 Portugal C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDENFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPIHGVYYDPSKDLIAEIQKQG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25375 AZT3TCNVP 2004 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEVIICQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25380 D4T3TCEFV 2004 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTLPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFYTPDKKHQKEHPFIWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25399 AZT3TCEFV 2003 Portugal G 0 1 329 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKELIAKV Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25418 TDF3TCEFV 2004 Portugal C 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALREICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTRILEPFRAKNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLIRGVKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQ Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25424 AZT3TCNVP 2003 Portugal G 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLETGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNEIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQGQ Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25448 AZT3TCEFV 2003 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLIALTDICTEMEREGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPSGIKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQHSMTKILEPFRMQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFITPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEIVPLTAEAELELAENREILKEPVHGVYYEPSKDLIAEVPNQGLG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25453 AZT3TCNVP 2003 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRAKIKELRAHLLSWGFYTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25455 AZT3TCNVP 2003 Portugal G 0 1 314 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRMKNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLKGAKALTDIVPLTAEAELELAENREILKEPV Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25457 AZT3TCEFV 2003 Portugal K 0 1 334 PISPIETVPVKLKPGMDGPRIKQWPLTEEKIRALREICTEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNQTPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTENPEMEIYQYVDDLYVSSDLEIGKHRAKIEELREHLLRWGFSTPDNKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEIVPLTVEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQ Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25472 AZT3TCEFV 2003 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICSEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPILLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25473 AZT3TCEFV 2003 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGLTTPDKKHQKEPPFLWMGYELHPDNWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25477 TDF3TCEFV 2003 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICADMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIEIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKGLTETVPLTAEAELELAENREILREPVHGVYYEPSKELIAEVQKQGPG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25479 TDF3TCEFV 2004 Portugal CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICLEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVGSDLELGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25483 AZT3TCEFV 2004 Portugal C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLAEEKIKALTEICEELEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLLDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLIRGAKALTEIVTLTDEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25486 D4T3TCNVP 2004 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAEMELAENREILKEPVHGVYYDPSKEIIAEVQKQGPG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25491 AZT3TCEFV 2004 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRRYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRMKNPEVVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGLTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25492 TDF3TCEFV 2004 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPSGIKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIQVKQLCKLLRGAKALTDTVPLTAEAEMELAENREILKEPVHGVYYEPSKELIAEVQKQG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25500 AZT3TCNVP 2004 Portugal G 0 1 333 PISPIETVPVKLRPGMDGPKVKQWPLTKEKIKALTEICLEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKNSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25501 AZT3TCNVP 2004 Portugal G 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKNNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRKHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDVVPLTAEAEMELAENREILKEPVHGVYYDPSKELIAEVQKQGQ Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25502 AZT3TCEFV 2004 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPEIEIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFSTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILREPVHGVYYDPSKDLIAEVQKQG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25503 AZT3TCNVP 2004 Portugal G 0 1 306 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTDMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIQNPEMVICQYMDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKYQKEPPFRWMGYELHPDKWTVQPIQLPNKESWTVNDIQKLVGKLNWASQIYPGIKTKQLCKLLRGAKALTDIVPLTAEAELELEEN Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25504 D4T3TCEFV 2004 Portugal CRF02_AG 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICTEMEKEGKISKIGPENPYNTPIFAIKKKNSDRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMEIYQYVDDLYVGSDLEIGQHRAKIKELREHLLRWGLTTPDQKHQKEPPFLWMGYELHPDTWTVQPIQLPEKDSWTVNDIQKLVGKLNWACQIYPGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25514 D4T3TCEFV 2004 Portugal U 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPGIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTMQPIQLPDKESWTVNDIQKLVGKLNWASQIYSGIKVRQLCKLLRGAKALTDVIPLTAEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQ Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25516 TDF3TCEFV 2004 Portugal C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYVDDLCVGSDLKIEQHRAKIEGLREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILREPVHGVYYDPSKELIAEIQKQG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25519 AZT3TCEFV 2004 Portugal K 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICIELEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQRNKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEIVIYQYVDDLYIGSDLEIGQHRAKIEELRGYLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGLG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25521 AZT3TCNVP 2004 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDERFRKYTAFTIPSTNNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKDPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25522 AZT3TCNVP 2004 Portugal G 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICMEMEKEGKISKIGPENPYNTPIFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGLATPDQKHQKEPPFHWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDVIPLTEEAELELAENREILREPVHGVYYDPSKELIAEVQKQGQ Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25524 AZT3TCEFV 2004 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPILLPNKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25525 TDF3TCNVP 2004 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIENPEIVICQYIDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIIPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25527 AZT3TCEFV 2004 Portugal CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQTSMTKILEPFRKKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRGHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVALTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQNQGQ Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25532 D4T3TCNVP 2004 Portugal C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTQNPEIIIYQYVDDLYVASDLEIGQHRAKIKELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1181 25538 AZT3TCNVP 2004 Portugal K 0 1 335 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIIALTEICKEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYMDDLYVGSDLEIEQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVIPLTAEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGEG Non-B Workgroup 2005 15839752 PLoS Med Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 1185 21667 D4T3TCNVP 2003 Zimbabwe C 0 1 263 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSTMIKILEPFRTKNPEIVIYQYMDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIQLPEKDSWTVNDIQKLVGK Johnston, E 2003 12805470 J Virol High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. 1197 24091 D4T3TCEFV 2003 U.S. B 0 1 296 PISPIETVPVKLKPGMDGPKDKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYMDDLYVGSDLEIGQHRAKIEKLRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQTIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVIPLT Weber, J 2005 15750116 J Clin Microbiol Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation. 1197 24093 TDF3TCEFV 2002 U.S. B 0 1 297 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFVIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIIIYQYVDDLLVGSDLETGQHRAKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVIALSK Weber, J 2005 15750116 J Clin Microbiol Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation. 1242 26201 AZT3TCEFV 2003 Spain B 0 38 247 CAELEKEGKIEKIGPENPYNTPIFAIKKKNSTRWRKITDFRELNKRTQDFWEVQLGIPHPAGLPKRKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRKQNPDIVIYQYVDDLYIASDLEIEQHRAKIEELRQHLLKWGFFTPEQKHQKEPPFHWMGYELHPDKWTVHPIVLP Garcia-Bujalance, S 2005 16081972 J Clin Microbiol Comparison between sequence analysis and a line probe assay for testing genotypic resistance of human immunodeficiency virus type 1 to antiretroviral drugs. 1285 8092 AZT3TCEFV 2001 U.S. B 0 1 300 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPELVIYQYMDDLHVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGTKALTEVVPLTEEAE Rhee, SY 2006 17065321 PNAS Genotypic predictors of human immunodeficiency virus type 1 drug resistance. 1290 32327 D4T3TCEFV 2002 Singapore CRF01_AE 0 1 400 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKNSTEWRKLMDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMDIYQYVDDLYVASDLEIGQHRTKIEELRAHLFSWGFTTPDKKYQKEPPLRWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKTPVHGVYYDPSKDLVAEVQKQGQDQWTYQIYQEPFKNLKTGKYARKRSAHTNDVRQLTEVVQKISTESIVIWGKTPKFRLPIQRETWET Hsu, LY 2005 15608517 JAIDS Characterization of mutations in CRF01_AE virus isolates from antiretroviral treatment naive and experienced patients in Singapore. 1290 32351 D4T3TCEFV 2002 Singapore CRF01_AE 0 1 400 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILRTPVHGVYYDPSKDLVAEVQKQGQDQWTYQIFQEPFKNLKTGKYARKRSAHTNDVRQLTEVVQKIATESIVTWGKTPKFRLPIQKETWDT Hsu, LY 2005 15608517 JAIDS Characterization of mutations in CRF01_AE virus isolates from antiretroviral treatment naive and experienced patients in Singapore. 1290 32380 AZT3TCEFV 2002 Singapore CRF01_AE 0 1 400 PISPVDSIPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPEMIIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILRNPVHGVYYDPSKDLVAEVQKQGQDQWTYQIYQEPFKNLKTGKYARKRSAHTNDVRQLTEVVQKIATESIVIWGKTPKFRLPIQKETWET Hsu, LY 2005 15608517 JAIDS Characterization of mutations in CRF01_AE virus isolates from antiretroviral treatment naive and experienced patients in Singapore. 1290 32382 AZT3TCEFV 2003 Singapore CRF01_AE 0 1 400 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVSSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVPLTEEAELELAENREILKTPVHGVYYDPSKDLVAEVQKQGQDQWTYQIFQEPFKNLKTGKYARKRSAHTNDVRQLTEVVQKIALESIVIWGKIPKFRLPIQKETWET Hsu, LY 2005 15608517 JAIDS Characterization of mutations in CRF01_AE virus isolates from antiretroviral treatment naive and experienced patients in Singapore. 1479 31804 AZT3TCEFV 2002 Cameroon CRF02_AG 0 1 436 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTAICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQASMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVTMTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVKQLVEVVQKVSTESIVIWGKTPKFRLPIQKETWETWWLEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIIG Laurent, C 2006 16707062 Emerg Infect Dis Antiretroviral drug resistance and routine therapy, Cameroon. 1479 31805 AZT3TCEFV 2002 Cameroon CRF02_AG 0 1 438 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPKKDSWTVNDIQKLVGKLNWASQIYAGIRVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVKQLTEVVQKAATESIVIWGKTPKFRLPIQRETWEAWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKDPIAGAE Laurent, C 2006 16707062 Emerg Infect Dis Antiretroviral drug resistance and routine therapy, Cameroon. 1479 31811 D4T3TCEFV 2002 Cameroon F 0 1 438 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPELVIYQYVDDLYVGSDLEIGQHRTKIEELREHLLRWGFYTPDKKHQKEPPFLWLGYELHPDKWTVQAIQLPDKSSWTVNDIQKLVGKLNWASQIYPGIRVKQMCKLLRGAKALTDVVPLTAEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGQGQWTYQIYQELHKNLKTGKYAKSRSAHTNDVKQLTEVVQKIATESIVIWGKVPKFRLPIQKETWEIWWTEYWQATWIPEWEFVNTPPLVKLWYQLETDPIVGAE Laurent, C 2006 16707062 Emerg Infect Dis Antiretroviral drug resistance and routine therapy, Cameroon. 1479 31815 AZT3TCEFV 2002 Cameroon CRF02_AG 0 1 429 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICAELENEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKNRSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPEMVIYQYIDDLYVGSDLEIEQHRAKIEELRGHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALSDIVTLTEEAELELAENREILKDPVHGVYYDPAKDLVAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVKQLTEVVQKVATESIVIWGKTPKFRLPIQKETWEAWWMDYWQATWIPEWEFVNTPPLVKLWYQL Laurent, C 2006 16707062 Emerg Infect Dis Antiretroviral drug resistance and routine therapy, Cameroon. 1479 31822 D4T3TCNVP 2003 Cameroon A 0 1 433 PISPVETVPVALKPGMDGPKVKQWPLTKEKLEALTEICKEMEKEGKITRIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILDPFRAKNPDIVICQYVDDLYVGSDLEIEQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKGSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLIRGTKALTDVVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKRRSAHTNDVKQLIEVVQKVATESIVIWGKTPKFRLPIQKETWETWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKTP Laurent, C 2006 16707062 Emerg Infect Dis Antiretroviral drug resistance and routine therapy, Cameroon. 1479 31823 AZT3TCEFV 2003 Cameroon CRF02_AG 0 1 432 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICVEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRVKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLTWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPAKDLVAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVRQLTEVVQKVATESIVIWGKTPKFRLPIQKETWETWWQEYWQATWIPEWEFVNTPPLVKLWYQLEKD Laurent, C 2006 16707062 Emerg Infect Dis Antiretroviral drug resistance and routine therapy, Cameroon. 1480 31826 AZT3TCEFV 2003 Malaysia CRF01_AE 0 20 247 RVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRIQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAVFQSSMTKILEPFRIKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Tee, KK 2006 16404607 Med Microbiol Immunol Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia. 1480 31831 AZT3TCEFV 2003 Malaysia CRF01_AE 0 40 247 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKIKNPEIVIYQYMDDLLVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Tee, KK 2006 16404607 Med Microbiol Immunol Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia. 1480 31834 AZT3TCEFV 2004 Malaysia CRF01_AE 0 20 247 RVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKDPPFLWMGYELHPDKWTVQPIELP Tee, KK 2006 16404607 Med Microbiol Immunol Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia. 1480 31836 AZT3TCEFV 2003 Malaysia CRF01_AE 0 20 247 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYMDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Tee, KK 2006 16404607 Med Microbiol Immunol Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia. 1480 31837 AZT3TCEFV 2003 Malaysia CRF01_AE 0 20 247 RVKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPDLVICQYMDDLYVGSDLAIGQHRIKIEELRAHLLSWGFTTPDKKHQKEHPFRWMGYELHPDRWTVQPIELP Tee, KK 2006 16404607 Med Microbiol Immunol Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia. 1480 31838 AZT3TCEFV 2004 Malaysia CRF01_AE 0 20 247 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Tee, KK 2006 16404607 Med Microbiol Immunol Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia. 1480 31839 AZT3TCEFV 2003 Malaysia CRF01_AE 0 20 247 KVKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPIFAIKKKDGTTWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVIDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYMDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Tee, KK 2006 16404607 Med Microbiol Immunol Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia. 1480 31845 AZT3TCEFV 2003 Malaysia CRF01_AE 0 20 247 KVKQWPLTEEKIKALTEICKELEEDGKISKIGPENPYNTPVFAIRKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDIGDAYFSIPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMEIYQYVDDLLIGSDLEIEQHRAKIEELRAYLWSCGFFTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Tee, KK 2006 16404607 Med Microbiol Immunol Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia. 1480 31849 AZT3TCEFV 2004 Malaysia CRF01_AE 0 20 247 KVKQWPLTEEKIKAITEICKELEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKYQKEPPFRWMGYELHPDRWTVQPIELP Tee, KK 2006 16404607 Med Microbiol Immunol Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia. 1480 31850 AZT3TCEFV 2004 Malaysia CRF01_AE 0 20 247 KVKQWPLTEEKIKALTEICKEMEKEGKISKVGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRIKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Tee, KK 2006 16404607 Med Microbiol Immunol Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia. 1480 31851 AZT3TCEFV 2004 Malaysia CRF01_AE 0 20 247 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDMGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCTMTKILEPFRKQNPDIDIYQYMDDLYVGSDLEIGQHRIKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Tee, KK 2006 16404607 Med Microbiol Immunol Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia. 1480 31852 AZT3TCEFV 2004 Malaysia B 0 20 247 KVKQWPLPEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPDIDVYQYMDDLYVGSDLEIGQHRAKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Tee, KK 2006 16404607 Med Microbiol Immunol Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia. 1505 37303 AZT3TCNVP 2001 Chile B 0 1 277 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLHVGSDLEIEQHRTKIEELRQHLLRWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIILPEKDSWTVNDIQKLVGKLNWASQIYAGIKVR Rios, M 2007 17457921 J Med Virol Antiretroviral drug resistance and phylogenetic diversity of HIV-1 in Chile. 1505 37360 AZT3TCNVP 2002 Chile B 0 1 277 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPGIVICQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVK Rios, M 2007 17457921 J Med Virol Antiretroviral drug resistance and phylogenetic diversity of HIV-1 in Chile. 1508 37552 AZT3TCNVP 2004 Kenya A 1 1 220 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSITVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIIICQYMDDLYVASDLEIGQHRAKIEELRAHLLSWGFITPDEK Lwembe, R 2007 17516531 J Med Virol Anti-retroviral drug resistance-associated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure. 1508 37553 AZT3TCNVP 2004 Kenya A 1 1 220 PISPVKTVPVQLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYVDDLYVGSDLDIGQHRIKIEELREHLLKWGFTTPDKK Lwembe, R 2007 17516531 J Med Virol Anti-retroviral drug resistance-associated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure. 1508 37556 AZT3TCEFV 2004 Kenya A 1 1 220 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALMEICTEMEKEGKISKIGPENPYNTPIFAIKKKDGNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFYTPDKK Lwembe, R 2007 17516531 J Med Virol Anti-retroviral drug resistance-associated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure. 1508 37557 AZT3TCNVP 2003 Kenya G 1 1 220 PISPIETVPVKLKSGMDGPKVKQWPLTEEKLKALTDICTEMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDKK Lwembe, R 2007 17516531 J Med Virol Anti-retroviral drug resistance-associated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure. 1515 37828 D4T3TCEFV 2004 Cote d'Ivoire CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKEKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRMKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Seyler, C 2007 17502726 AIDS Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa. 1515 37849 AZT3TCEFV 2004 Cote d'Ivoire CRF02_AG 0 1 283 PISPIETVPVKLKPGTDGPRVEQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMIKILEPFRTKNPEIVIYQYMDDLYVGSDLEIGQHRAKVEELRDHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLI Seyler, C 2007 17502726 AIDS Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa. 1515 37861 D4T3TCEFV 2004 Cote d'Ivoire CRF02_AG 0 1 268 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQSIQLPEKDSWTVNDIQKLVGKLNWAS Seyler, C 2007 17502726 AIDS Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa. 1573 39475 AZT3TCEFV 1999 U.S. B 0 37 247 VCTEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPDMVIYQYMDDLYVGSDLEIGQHRIKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Shafer, RW 2003 14668456 N Engl J Med Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. 1573 39490 AZT3TCEFV 2000 U.S. B 0 37 247 VCTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKAFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPYRKQNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Shafer, RW 2003 14668456 N Engl J Med Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. 1573 39923 AZT3TCEFV 2000 U.S. B 0 37 247 VCTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLP Shafer, RW 2003 14668456 N Engl J Med Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. 1573 39929 AZT3TCEFV 1999 U.S. B 0 37 247 VCTEMEREGKIERIGPENPYNTPVFAIKKKDSSKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Shafer, RW 2003 14668456 N Engl J Med Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. 1573 40034 AZT3TCEFV 2001 U.S. B 0 1 274 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALMEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSTNNETPGTRYQYNVLPQGWKGSPAIFQCSMLKILEPFRKQNPDLVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGI Shafer, RW 2003 14668456 N Engl J Med Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. 1573 40229 AZT3TCEFV 1999 U.S. B 0 37 247 VCTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Shafer, RW 2003 14668456 N Engl J Med Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. 1573 40235 AZT3TCEFV 1999 U.S. B 0 37 247 VCTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Shafer, RW 2003 14668456 N Engl J Med Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. 1573 40267 AZT3TCEFV 2000 U.S. B 0 1 324 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALMEICTELEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIEQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKD Shafer, RW 2003 14668456 N Engl J Med Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. 1573 40272 AZT3TCEFV 2000 U.S. B 0 1 324 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGMRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYIDDLYVGSDLEIGQHRIKIDELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKD Shafer, RW 2003 14668456 N Engl J Med Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. 1573 40329 AZT3TCEFV 2000 U.S. B 0 37 247 VCTEMEKEGKISKIGPQNPYNTPVFAIKKKDSTRWGKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Shafer, RW 2003 14668456 N Engl J Med Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. 1573 40341 AZT3TCEFV 2000 U.S. B 0 37 247 VCTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFREQNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLP Shafer, RW 2003 14668456 N Engl J Med Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. 1573 40349 AZT3TCEFV 2000 U.S. B 0 37 247 VSTEMEKEGKISRVGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTTFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPDLVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Shafer, RW 2003 14668456 N Engl J Med Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. 1584 40731 D4T3TCNVP 2004 India C 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKIATESIVIWGKTPKFRLPIQKETWET Sen, S 2007 17961120 ARHR High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. 1584 40733 AZT3TCNVP 2004 India C 0 1 422 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPELVIYQYMDDLYVGSDLEIGKHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKIAMESIVIWGKIPKFRLPIQKETWETWCTDYWQATWIPEWEFVNTPPL Sen, S 2007 17961120 ARHR High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. 1584 40735 AZT3TCNVP 2004 India C 0 1 451 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVRQLTEAVQKIAMESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKDPIAGAETFYVDGAANRETK Sen, S 2007 17961120 ARHR High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. 1584 40736 D4T3TCNVP 2004 India C 0 1 484 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTQNPELVIYQYMDDLYVGSDLEIGQHRAKIEKLREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDVIPLTEEAELELAENREILKEPVHGAYYDPSKELIAEIQKQGNDQWTYQIFQEPFKNLKTGKYAKMRAAHTNDVKQLTEAVQKIAMESIVIWGKTPKFRLPIQKETWEAWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKDPIAGVETFYVDGAASRETKMGKAGYVTDRGREKIVSLTETTNQKAELQAIYL Sen, S 2007 17961120 ARHR High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. 1584 40737 D4T3TCNVP 2004 India C 0 1 354 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDELEKEGKISKIGPENPYNTPIFAIKKKGGTRWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVICQYVDDLYVASDLEIGQHRAKIEELRQYLWKWGFFTPDWKHQKEPPFHWMGYDLHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQDQWTYQIYQEPFKILKTGKY Sen, S 2007 17961120 ARHR High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. 1584 40738 AZT3TCNVP 2004 India C 0 1 403 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRARNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRHLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKIAIESIVIWGKTPKFRLPIQKKTWETWWT Sen, S 2007 17961120 ARHR High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. 1584 40739 D4T3TCNVP 2004 India C 0 1 402 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNGTPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPDIVIYQYVDDLYVASDLEIEQHRAKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCRLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGEDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTDAVQKIARECIVVWGKTPKFRLPIQKETWETWW Sen, S 2007 17961120 ARHR High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. 1584 40744 D4T3TCNVP 2004 India C 0 1 406 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTEICNELEKEGKISKIGPENPYNTPIFAIKKKNSTQWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPELVIYQYVDDLYVGSDLEIGQHRAKIAELREYLLKWGFFTPDKKHQEEPPLLWMGYELHPDKWTVQPINLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGAKALTDIVPLTKEAELELAENREIIKQPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDIKQLTEVVQKIAQESIVIWGKTPKFKLPIQKETWETWWTDYW Sen, S 2007 17961120 ARHR High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. 1584 40745 AZT3TCNVP 2004 India C 0 1 401 PISPIETVPVKLKPGMDGPKVKQWPLSKEKIKALTEICDELEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLMDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPEFVVYQYVDDLYVASDLEIGQHRAKIEELREYLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQDQWTYQIFQEPFKNLKTGKYAKRRTAHTNDVKQLTEAVQKIAMESIVIWGKTPKFRLPIQKETWEAW Sen, S 2007 17961120 ARHR High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. 1584 40746 D4T3TCNVP 2004 India C 0 1 461 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEALRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIIPLTEEAELELAENREILKEQVHGAYYDPSKELIAELQKQGQDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKIAMESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPDWEFVNTPPLVKLWYRLETEPIAGAETFYVDGAASRETKLGKAGYVTDR Sen, S 2007 17961120 ARHR High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. 1584 40747 AZT3TCNVP 2004 India A 0 1 401 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIIYQYVDDLYVASDLEIKEHRAKIKELRAHLWSWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVITLTEEAELELAENREILKDPVHGVYYDPSKDLIAEIQKQGNDQWTYQIYQEPFKNLKTGKYARQRSAHTNDVKQLVEVVQKVAMESIVIWGKTPKFKLPIQKETWETW Sen, S 2007 17961120 ARHR High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. 1584 40749 AZT3TCNVP 2004 India C 0 1 338 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFGELNKRTQDFWEIQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGKHRAKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGYDQWT Sen, S 2007 17961120 ARHR High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. 1584 40750 AZT3TCNVP 2004 India C 0 1 440 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILAPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQDQWTYQIYQEPFKILKTGKYAKMRTAHTNDVKQLTEAVQKIARESIVIWGRTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKDPIAGVETF Sen, S 2007 17961120 ARHR High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. 1584 40751 AZT3TCNVP 2004 India C 0 1 412 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMLKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDVKQLTEAVQKISMESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIP Sen, S 2007 17961120 ARHR High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. 1584 40752 AZT3TCNVP 2004 India C 0 1 406 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNELEKDGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVIDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKYPEIVICQYVDDLYVASDLEIGQHRAKIEELREHLWKWGFYTPEEKHQKEPPFHWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQGEGQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTAVVQKIAMESIVIWGKTPKFRLPIQKETWETWWTDYW Sen, S 2007 17961120 ARHR High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. 1584 40756 D4T3TCNVP 2004 India C 0 1 403 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLYEEFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILQPFRERNPEIIICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQGQDQWTYQIYQEPFKILKTGKYAKMRTAHTNDVKQLTEAVQKIARESIVIWGKTPKFRLPIQKETWETWWT Sen, S 2007 17961120 ARHR High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. 1584 40757 D4T3TCNVP 2004 India C 0 1 385 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIEALKAICDEMEKEGKLTKIGPENPYNTPIFAIKKKNSARWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIIIYQYVDDLYVASDLEIGQHRAKIKELREHLLKWGFTTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGNDQWTYQIYQEPFKNLRTGKYAKMRTAHTNDVKQLTEAVQKIAMESIVIWGK Sen, S 2007 17961120 ARHR High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. 1584 40759 AZT3TCNVP 2004 India C 0 1 485 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLQKKRSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPEIVICQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFFTPDEKHQKEPPFHWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGYDQWTYQIYQEPFKNLKTGKYAKMRNAHTNDVKQLTEAVQKIAMESIVIWGKTPKFRLPIQKETWEAWWTDYWQATWIPEWEFVNTPPLVKLWYRLETEPIAGAETFYVDGAASRETKTGKAGYVTDRGRQKIVSLTETTNQKTELQAIYLA Sen, S 2007 17961120 ARHR High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. 1584 40762 D4T3TCNVP 2004 India C 0 1 484 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAVFQSSMTKILEPFRKQNPEIIICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDVKQLTEAVQKIAMESIVIWGKTPKFRLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKDPIVGAETFYVDGAASRETKIGKAGYVTDRGRQKIVSLTETTNQKTELQAIYL Sen, S 2007 17961120 ARHR High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. 1592 41572 AZT3TCNVP 2004 Brazil B 0 1 229 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYVDDLYVGSDLEIGQHRTKIEELREHLLRWGFTTPDKKHQKEPPFLW Eyer-Silva, WA 2007 17992366 Mem Ins Oswaldo Cruz Autochthonous horizontal transmission of a CRF02_AG strain revealed by a human immunodeficiency virus type 1 diversity survey in a small city in inner state of Rio de Janeiro, Southeast Brazil. 1592 41575 AZT3TCNVP 2005 Brazil B 0 1 237 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRTKVEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPD Eyer-Silva, WA 2007 17992366 Mem Ins Oswaldo Cruz Autochthonous horizontal transmission of a CRF02_AG strain revealed by a human immunodeficiency virus type 1 diversity survey in a small city in inner state of Rio de Janeiro, Southeast Brazil. 1592 41578 AZT3TCEFV 2004 Brazil B 0 1 227 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYMDDLLVGSDLEIEQHRTKIEELRQHLLRWGFTTPDKQHQKEPPF Eyer-Silva, WA 2007 17992366 Mem Ins Oswaldo Cruz Autochthonous horizontal transmission of a CRF02_AG strain revealed by a human immunodeficiency virus type 1 diversity survey in a small city in inner state of Rio de Janeiro, Southeast Brazil. 1592 41581 AZT3TCNVP 2005 Brazil F 0 1 230 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILDPFRAKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWM Eyer-Silva, WA 2007 17992366 Mem Ins Oswaldo Cruz Autochthonous horizontal transmission of a CRF02_AG strain revealed by a human immunodeficiency virus type 1 diversity survey in a small city in inner state of Rio de Janeiro, Southeast Brazil. 1592 41583 D4T3TCEFV 2004 Brazil B 0 1 228 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGEHRTKIEELRQHLLKWGFTTPDKKHQKEPPFL Eyer-Silva, WA 2007 17992366 Mem Ins Oswaldo Cruz Autochthonous horizontal transmission of a CRF02_AG strain revealed by a human immunodeficiency virus type 1 diversity survey in a small city in inner state of Rio de Janeiro, Southeast Brazil. 1592 41588 AZT3TCNVP 2004 Brazil B 0 1 233 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYE Eyer-Silva, WA 2007 17992366 Mem Ins Oswaldo Cruz Autochthonous horizontal transmission of a CRF02_AG strain revealed by a human immunodeficiency virus type 1 diversity survey in a small city in inner state of Rio de Janeiro, Southeast Brazil. 1592 41589 AZT3TCEFV 2006 Brazil B 0 1 232 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDLVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGLTTPDKKHQKEPPFLWMGY Eyer-Silva, WA 2007 17992366 Mem Ins Oswaldo Cruz Autochthonous horizontal transmission of a CRF02_AG strain revealed by a human immunodeficiency virus type 1 diversity survey in a small city in inner state of Rio de Janeiro, Southeast Brazil. 1592 41590 AZT3TCEFV 2006 Brazil B 0 1 234 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRTKVEELRQHLLKWGFTTPDKKHQKEPPFLWMGYEL Eyer-Silva, WA 2007 17992366 Mem Ins Oswaldo Cruz Autochthonous horizontal transmission of a CRF02_AG strain revealed by a human immunodeficiency virus type 1 diversity survey in a small city in inner state of Rio de Janeiro, Southeast Brazil. 1592 41593 AZT3TCEFV 2005 Brazil B 0 1 233 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYE Eyer-Silva, WA 2007 17992366 Mem Ins Oswaldo Cruz Autochthonous horizontal transmission of a CRF02_AG strain revealed by a human immunodeficiency virus type 1 diversity survey in a small city in inner state of Rio de Janeiro, Southeast Brazil. 1592 41599 AZT3TCEFV 2004 Brazil B 0 1 229 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRDLNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPEMTIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLW Eyer-Silva, WA 2007 17992366 Mem Ins Oswaldo Cruz Autochthonous horizontal transmission of a CRF02_AG strain revealed by a human immunodeficiency virus type 1 diversity survey in a small city in inner state of Rio de Janeiro, Southeast Brazil. 1592 41600 AZT3TCEFV 2005 Brazil F 0 1 232 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILDPFRAKNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGY Eyer-Silva, WA 2007 17992366 Mem Ins Oswaldo Cruz Autochthonous horizontal transmission of a CRF02_AG strain revealed by a human immunodeficiency virus type 1 diversity survey in a small city in inner state of Rio de Janeiro, Southeast Brazil. 1592 41601 AZT3TCEFV 2005 Brazil B 0 1 228 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDGNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLQWGFTTPDKKHQKEPPFL Eyer-Silva, WA 2007 17992366 Mem Ins Oswaldo Cruz Autochthonous horizontal transmission of a CRF02_AG strain revealed by a human immunodeficiency virus type 1 diversity survey in a small city in inner state of Rio de Janeiro, Southeast Brazil. 1592 41602 AZT3TCEFV 2005 Brazil F 0 1 231 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILDPFRAKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMG Eyer-Silva, WA 2007 17992366 Mem Ins Oswaldo Cruz Autochthonous horizontal transmission of a CRF02_AG strain revealed by a human immunodeficiency virus type 1 diversity survey in a small city in inner state of Rio de Janeiro, Southeast Brazil. 1592 41603 AZT3TCEFV 2004 Brazil F 0 1 237 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILDPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRNHLLRWGFTTPDKKHQKEPPFLWMGYELHPD Eyer-Silva, WA 2007 17992366 Mem Ins Oswaldo Cruz Autochthonous horizontal transmission of a CRF02_AG strain revealed by a human immunodeficiency virus type 1 diversity survey in a small city in inner state of Rio de Janeiro, Southeast Brazil. 1592 41609 AZT3TCEFV 2004 Brazil U 0 1 238 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILDPFRAKNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDK Eyer-Silva, WA 2007 17992366 Mem Ins Oswaldo Cruz Autochthonous horizontal transmission of a CRF02_AG strain revealed by a human immunodeficiency virus type 1 diversity survey in a small city in inner state of Rio de Janeiro, Southeast Brazil. 1592 41613 AZT3TCEFV 2005 Brazil B 0 1 231 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQGSMTKILEPFRKRNPEIVIYQYMDDLYVGSDLEIEQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMG Eyer-Silva, WA 2007 17992366 Mem Ins Oswaldo Cruz Autochthonous horizontal transmission of a CRF02_AG strain revealed by a human immunodeficiency virus type 1 diversity survey in a small city in inner state of Rio de Janeiro, Southeast Brazil. 1592 41615 AZT3TCEFV 2005 Brazil B 0 1 233 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDADFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYE Eyer-Silva, WA 2007 17992366 Mem Ins Oswaldo Cruz Autochthonous horizontal transmission of a CRF02_AG strain revealed by a human immunodeficiency virus type 1 diversity survey in a small city in inner state of Rio de Janeiro, Southeast Brazil. 1592 41617 AZT3TCNVP 2005 Brazil B 0 1 230 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWM Eyer-Silva, WA 2007 17992366 Mem Ins Oswaldo Cruz Autochthonous horizontal transmission of a CRF02_AG strain revealed by a human immunodeficiency virus type 1 diversity survey in a small city in inner state of Rio de Janeiro, Southeast Brazil. 1592 41618 AZT3TCEFV 2005 Brazil B 0 1 230 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWM Eyer-Silva, WA 2007 17992366 Mem Ins Oswaldo Cruz Autochthonous horizontal transmission of a CRF02_AG strain revealed by a human immunodeficiency virus type 1 diversity survey in a small city in inner state of Rio de Janeiro, Southeast Brazil. 1592 41619 AZT3TCEFV 2005 Brazil F 0 1 230 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILNPFRTKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWM Eyer-Silva, WA 2007 17992366 Mem Ins Oswaldo Cruz Autochthonous horizontal transmission of a CRF02_AG strain revealed by a human immunodeficiency virus type 1 diversity survey in a small city in inner state of Rio de Janeiro, Southeast Brazil. 1603 43085 D4T3TCEFV 2005 South Africa C 0 40 247 EMEKEGKITKIGPDNPYNTPIFAIKKKNSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPELVIYQYVDDLYVASDLQIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43087 AZT3TCEFV 2005 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRASNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43088 D4T3TCNVP 2005 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVICQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43089 D4T3TCEFV 2005 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAENPDIVIYQYMDDLYVGSDLEIKEHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43090 D4T3TCEFV 2005 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43095 D4T3TCEFV 2005 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIEQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43096 D4T3TCEFV 2005 South Africa C 0 40 247 ELEKEGKISKIGPENPYNTPVFAIKKKGSNRWRKLVDFRELNKKTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLYEGFRKYTAFTIPSINNETPGIRFQYNVLPQGWKGSSAIFQCSMTKILEPFRAQNPEIVICQYIDDLYVASDLEIGQHRAKIKELREHLLKWGFFTPDEKHQEEPPFHWMGYELHPDTWTVXPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43097 AZT3TCEFV 2005 South Africa C 0 40 247 EMEKEGKIEKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDKEFRKYTAFTIPSTNNETPGITYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEVVIYQYVDDLYVQSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43098 D4T3TCEFV 2005 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43099 D4T3TCEFV 2006 South Africa C 0 40 241 DMEKEGKITKIGPENPYNTPIFAIKKKDGTEWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTV Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43100 AZT3TCEFV 2006 South Africa C 0 40 247 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYICSDLEIGQHRAKIEELREHLLKWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43102 D4T3TCNVP 2006 South Africa C 0 40 247 EMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43103 D4T3TCEFV 2006 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFSEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDIVIYQYVDDLLVGSDLEIGQHRAKVEELREHLLRWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIVLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43106 D4T3TCEFV 2006 South Africa C 0 40 247 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSLNNRTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPGIVIYQYVDDLYVGSDLEIGQHRAKIKELRDHLLKWGFFTPDKKHQKEPPFLWMGYELHPDKWTVRPIRLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43108 D4T3TCEFV 2006 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSIPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43109 D4T3TCEFV 2005 South Africa C 0 40 247 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPRIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIIIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPILLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43110 AZT3TCEFV 2005 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPDIVIYQYMDDLYVGSDLEIGQHRAKIDELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPILLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43111 D4T3TCEFV 2005 South Africa U 0 40 247 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHREKIAELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43112 D4T3TCEFV 2005 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKVEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPEKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43113 D4T3TCEFV 2005 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPEIDIYQYVDDLYVGSDLEIMQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43115 D4T3TCEFV 2005 South Africa C 0 40 247 EMEEEGKITKIGPENPYNTPIFAIKKKNSDRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVIYQYVDDLYVGSDLDIGQHRAKIKELREHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43116 AZT3TCEFV 2005 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEMVIYQYVDDLYVGSDLEIGQHREKIEELREHLLKWGFITPDEKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43117 AZT3TCNVP 2005 South Africa C 0 40 247 EMEKEGKITRIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRAKNPEIVIIQYVDDLYVGSDLEIEQHRAKIEELREHLLRWGLFTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43118 AZT3TCEFV 2005 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMVKILEPFRADNPEIVIYQYVDDLYVGSDLEIGQHRIKIEELRAHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43121 D4T3TCNVP 2005 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYVDDLYVGSDLEIGQHREKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43122 D4T3TCEFV 2005 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43124 AZT3TCEFV 2005 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLRWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43125 AZT3TCNVP 2005 South Africa C 0 40 247 EMEKEGKITRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGRRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVICQYVDDLYVGSDLEIGQHRAKVEELREHLLSWGLTTPDKKYQKEPPFRWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43128 D4T3TCEFV 2005 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLNKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43129 D4T3TCEFV 2005 South Africa C 0 40 247 EMEKEGTITKIGPENPYNTPVFVIKKKDSTKWTKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43130 AZT3TCEFV 2005 South Africa C 0 40 247 EMEKGGKITKIGPENPYNTPIFAIKKKNSTKWTKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLHVGSDLEIGQHREKVEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPVQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43131 D4T3TCEFV 2005 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKITDFRELNKRTQDFWEVQLGIPHPGGIKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIKQHRAKIEELREHLLKWGFTTPDEKHQKEHPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43132 AZT3TCNVP 2005 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSINNEKPGIRYQYNVLPEGWKGSPAIFQSSMTRILEPFRLQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43133 AZT3TCEFV 2005 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSRSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVASDLEIGQHRVKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43134 AZT3TCEFV 2005 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQDTMTKILAPFRAKNPEIIIFQYVDDLYVGSDLEIEQHRAKIKELREHLLRWGFYTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43135 D4T3TCNVP 2005 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSMNNETPGTRYQYNVLPQGWKGSPAIFQYSMTRILEPFRIRNPEIIIVQYVDDLYVGSDLEIGQHRAKIEK*REHL*KWGFTTPDKKHQKAPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43139 D4T3TCEFV 2005 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43147 D4T3TCEFV 2006 South Africa C 0 40 247 DMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIRILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKVEELRAHLLKWGLTTPDTKYQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43150 AZT3TCEFV 2006 South Africa C 0 40 244 EMEREGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQASMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43151 D4T3TCEFV 2006 South Africa C 0 40 245 EMEKEGKITKIGPDNPYNTPVFAIKKKNSDRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTQNPEMVIYQYVDDLYVASDLEIGQHRAKIKELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIV Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43153 D4T3TCEFV 2006 South Africa C 0 40 247 ELEKEGKITIIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLQKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEMVIYQYVDDLYVGSDLEIGQHRAKIDELRAYLLKWGFYTPDKKYQKEHPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43155 D4T3TCEFV 2006 South Africa C 0 40 246 EMEKEGKITKIGPENPYNTPIFAIKKKDSNKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYMDDLYVASDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIEL Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43156 D4T3TCEFV 2006 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAANPEIVIYQYVDDLYVGSDLELGKHREKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPEKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43157 D4T3TCEFV 2006 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43158 D4T3TCEFV 2006 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRGHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43159 AZT3TCEFV 2006 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43162 D4T3TCEFV 2006 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43163 D4T3TCEFV 2006 South Africa C 0 40 246 EMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEDLRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQL Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43166 D4T3TCEFV 2006 South Africa C 0 40 247 DMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEDQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTRILEPFRAQNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43168 D4T3TCEFV 2006 South Africa C 0 40 247 DMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPDIDIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43171 D4T3TCEFV 2006 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43173 D4T3TCEFV 2006 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLGKNKSVTILDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRSKNPELIIYQYVDDLYVGSDLEIEQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43176 D4T3TCEFV 2006 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRAKNPELVIYQYVDDLCVGSDLEIEQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVLPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43178 D4T3TCEFV 2006 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRRKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKFLEPFRTQNPEIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43183 D4T3TCEFV 2006 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPTIFQSSMIKILEPFRAQNPEIDIYQYVDDLLVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43186 D4T3TCEFV 2006 South Africa C 0 40 247 ELEKVGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43188 D4T3TCEFV 2006 South Africa C 0 40 244 EMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIEQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43189 D4T3TCEFV 2006 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLTDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVRPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43190 AZT3TCEFV 2006 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDPDFRKYTAFTVPSINNQTPGIRYEYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLLVGSDLEIGPHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43191 D4T3TCEFV 2006 South Africa C 0 40 244 EMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43193 D4T3TCEFV 2006 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLNKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDLVIYQYVDDLYVSSDLEITKHRAKVEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43196 D4T3TCEFV 2006 South Africa C 0 40 247 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43197 D4T3TCEFV 2006 South Africa C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQEEPPFLWMGYELHPDKWTVQPIQLP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1603 43198 D4T3TCEFV 2006 South Africa C 0 40 243 EMEKEGKITKIGPENPYNTPVFAIKKKDGTRWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKRKSMTVLDVGDAYFSVPLYEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIDIYQYVDDLYVGSDLEIGQHRAKIKELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQP Marconi, VC 2008 18419495 Clin Infect Dis Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. 1634 45948 D4T3TCNVP 2003 China CRF01_AE 0 1 199 PISPVDTVPVTLKPGMDGPKVKQWPLTEETIKALTEICEEMEKEGEISNIGPENPYNTPIFAIKKRDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHR Liu, J 2007 17619115 Arch Virol Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian province, China. 1634 45949 D4T3TCNVP 2003 China CRF01_AE 0 1 199 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIKAITEICQEMEKEGKISKIGPENPYNTPIFAIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEKVICQYMDDLYVGFDLEIGQHR Liu, J 2007 17619115 Arch Virol Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian province, China. 1634 45950 D4T3TCNVP 2003 China CRF01_AE 0 1 199 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDIGDAYFSVPLHESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEVVIYQYMDDLYVGSDLEIGQHR Liu, J 2007 17619115 Arch Virol Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian province, China. 1634 45951 D4T3TCNVP 2003 China CRF01_AE 0 1 199 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVASDLEIGQHR Liu, J 2007 17619115 Arch Virol Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian province, China. 1634 45952 D4T3TCNVP 2003 China CRF01_AE 0 1 199 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKGGTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYMDDLYVGSDLEIGQHR Liu, J 2007 17619115 Arch Virol Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian province, China. 1634 45953 D4T3TCNVP 2003 China CRF01_AE 0 1 199 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHR Liu, J 2007 17619115 Arch Virol Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian province, China. 1634 45954 D4T3TCNVP 2003 China CRF01_AE 0 1 199 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFKIKNPEMVIYQYMDDLYVGSDLEIEQHR Liu, J 2007 17619115 Arch Virol Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian province, China. 1634 45955 D4T3TCNVP 2003 China CRF01_AE 0 1 199 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQGLLEVQLGIPHPAGLKKKKSISVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSCMTKILEPFRIKNPEIIIYQYMDDLLVGSDLEIGQHR Liu, J 2007 17619115 Arch Virol Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian province, China. 1634 45956 D4T3TCNVP 2003 China CRF01_AE 0 1 199 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFALKKKDSTQWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMIIYQYMDDLYVGSDLEIGQHR Liu, J 2007 17619115 Arch Virol Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian province, China. 1634 45957 D4T3TCNVP 2003 China CRF01_AE 0 1 199 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICREMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGFKRKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPEMIIYQYMDDLYVGSDLEIGQHR Liu, J 2007 17619115 Arch Virol Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian province, China. 1634 45958 D4T3TCNVP 2003 China CRF01_AE 0 1 199 PISTIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGFKKKKSITVLDVGDAYFSIPLDKNFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVICQYMDDLYVGSDLEIGQHR Liu, J 2007 17619115 Arch Virol Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian province, China. 1634 45959 D4T3TCNVP 2003 China CRF01_AE 0 1 199 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIIIYQYMDDLYVGSDLEIGQHR Liu, J 2007 17619115 Arch Virol Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian province, China. 1634 45960 D4T3TCNVP 2003 China CRF01_AE 0 1 199 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSITVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIIIYQYMDDLYVGSDLQIGQHR Liu, J 2007 17619115 Arch Virol Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian province, China. 1634 45961 D4T3TCNVP 2003 China CRF01_AE 0 1 199 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRMKNPEMVIYQYMDDLYVGSDLKIGQHR Liu, J 2007 17619115 Arch Virol Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian province, China. 1636 46047 AZT3TCNVP 2006 Mali CRF02_AG 0 1 440 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICADMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYIAFTIPSVNNETPGVRYQYNVLPQGWKGSPAI~SGSMTKILEPFRAKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQAIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKRRSAHTNDVKQLTEVVQKVATESIVIWGKTPKFRLPIQKETWEAWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKDPIAGAETF Sylla, M 2008 18389909 Antivir Ther Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso. 1636 46050 D4T3TCEFV 2006 Mali CRF02_AG 0 1 534 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTEICTDMEKEGKISRVGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILKPFRTENPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKRRSAHTNDVKQLTGVVQKISMESIVIWGKIPKFRLPIQRETWEAWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKDPIIGAETFYVDGAANRETKLGKAGYVTDKGRQKVISLTETTNQKTELHAIHLALQDSGSEVNIVTDSQYALGIIQAQPDSSESEIVNLIIEELIGKDKVYLS Sylla, M 2008 18389909 Antivir Ther Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso. 1636 46051 AZT3TCEFV 2006 Mali CRF02_AG 0 1 442 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEHPFRWMGYELHPDKWTVQTIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVKQLTEVVQKVTTESIIIWGKTPKFRLPIQKETWETWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKDPIVGAETFYV Sylla, M 2008 18389909 Antivir Ther Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso. 1636 46053 AZT3TCNVP 2006 Mali CRF06_cpx 0 1 456 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTILDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPYRTKNPEIVIYQYVDDLYVSSDLEIGQHRAKIEELREHLWKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEIVTLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPYKNLKTGKYARTKSAHTNDVKQLTEAVQKIAQESIIIWGKTPKFRLPIQKETWDIWWTNYWQATWIPEWEFVNTPPLVKLWYQLETEPIVGAETFYVDGAADRKTKEGKAG Sylla, M 2008 18389909 Antivir Ther Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso. 1636 46056 AZT3TCEFV 2006 Mali CRF02_AG 0 1 440 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLELGQHRAKIEELRDHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEIVPLTEEAELELAENREILKEPVHGVYYDPAKDLVAEIQKQGQDQWTYQIFQEPFKNLKTGKYAKKRSAHTNDVKQLTEVVQKVATESIVIWGKTPKFRLPIQRETWETWWMEYWQATWLPEWEFVNTPPLVKLWYQLETDPIVGAETF Sylla, M 2008 18389909 Antivir Ther Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso. 1636 46065 D4T3TCEFV 2006 Mali CRF02_AG 0 1 437 PISPIETVPVKLKPGMDGPRVKQWPLTKEKIKALTEICTELEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQASMTKILAPFRTSNPEIEIYQYVDDLYVGSDLEIGQHRAKIKELREHLLRWGFYTPDKKHQQEPPFRWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVVTLTEEAELELAENREILKDPVHGVYYDPSKDLVAEIQKQGQGQWTYQIYQEPFKNLKTGKYARKTSAHTNDVRQLVEVVQKVVTESIVIWGKAPKFKLPIQKETWETWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKDPIAGA Sylla, M 2008 18389909 Antivir Ther Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso. 1636 46066 AZT3TCNVP 2006 Burkina Faso CRF02_AG 0 1 539 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFFTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVVPLTEEAELELAENREILKEPVHGVYYDPTKELVAEIQKQGQDQWTYQIYQEPFKNLKTGKYSKKRSAHTNDVKQLTEVVQKVAQESIVIWGKTPKFRLPIQRDTWEAWWTEYWQATWIPDWEFVNTPPLVKLWYQLEKDPIVGAETFYVDGAANRETKLGKAGYVTDRGRQKIVSLPETTNQKTELHAIHLALQDSGSEVNIVTDSQYALGIIQAHPDRSESELVNQILEKLIEKDKVYLSWVPAH Sylla, M 2008 18389909 Antivir Ther Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso. 1636 46067 AZT3TCNVP 2006 Burkina Faso A 0 1 440 PISPVKTVPVTLKPGMDGPKVKQWPLTEEKIKALTAICKELEEEGKISKIGPDNPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEQKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNATPGIRYQYNVLPQGWKGSPAIFQDSMTKILEPFRSQNPDIIIYQYVDDLYVASDLEIGQHRAKIEELRAHLWKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVTLTEEAELELAENREILKDPVHGVYYDPSKDLVAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVRQLVEVVQKVVTESIVIWGKAPKFRLPIQKETWETWWMEYWQATYIPEWEFVNTPPLVKLWYQLEKDPIAGAETF Sylla, M 2008 18389909 Antivir Ther Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso. 1636 46068 AZT3TCNVP 2006 Burkina Faso CRF06_cpx 0 1 476 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKKNPEMVICQYVDDLYVGSDLEIGQHRAKIDELREHLLKWGFFTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAEFELAENREILKEPVHGVYYDPSKDLIAEIQKQGRDQWTYQIYQEAHKNLKTGKYARMRSAHTNDVKQLTEVVQKIAIESIVIWGKTPKFRLPIQKETWETWWTEYWQATWIPDWEFINTPPLVKLWYQLETEPIVGAETFYVDGAANRETRNGKAGYVTDRGRQKVVSLTETTNQK Sylla, M 2008 18389909 Antivir Ther Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso. 1636 46069 AZT3TCNVP 2006 Burkina Faso CRF06_cpx 0 1 496 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIRALTEICLEMEKEGKITRIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILAPFREKFPEMVICQYVDDLYVASDLEIGQHRARIEELRKHLLTWGFITPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGLGQWTYQIYQEPNKNLKTGKYARMKSAHTNDVKQLTEAVQKIALESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLETEPIIGAETFYVDGAASRETKMGKAGYVTDKGRQKVVSLTETTNQKTELQAINLALQDSGPEVNIV Sylla, M 2008 18389909 Antivir Ther Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso. 1636 46072 AZT3TCNVP 2006 Burkina Faso CRF06_cpx 0 1 440 PISPIETVPVKLKPGMDGPRVKQWPLTKEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFCEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCRLLRGAKALTDIVPLTAEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQGQGQWTYQIYQETHKNLKTGKYARMKSAHTNDVKQLTEAVQKIAMESIVIWGKIPKFRLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLETEPIVGAETF Sylla, M 2008 18389909 Antivir Ther Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso. 1636 46073 D4T3TCNVP 2006 Burkina Faso CRF06_cpx 0 1 440 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEMEICQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFFTPDKKHQKEPPFLWMGYELHPDKWTMQPIQLPDKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCRLLRGTKALTDVVPLTAEAELELAENREILKEPVYGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPHKNLKTGKYARIKSAHTNDVKQLTEAVQKIALESIVIWGKTPKFRLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLETEPIVGAETF Sylla, M 2008 18389909 Antivir Ther Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso. 1636 46074 AZT3TCNVP 2006 Burkina Faso CRF06_cpx 0 1 247 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKVLEPFRLKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFYTPDEKHQKEPPFLWMGYELPPDQWTVQPIQLP Sylla, M 2008 18389909 Antivir Ther Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso. 1636 46075 D4T3TCNVP 2006 Burkina Faso CRF06_cpx 0 1 458 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIRALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDQDFRKYTAFTIGSINNETPGIRYQYNVLPQGWKGSPTIFQSSMTKILEPFRKKNPEMVICQYVDDLYVGSDLEIQQHRAKIEELREHLLKWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQGQWTYQIYQEPHKNLKTGKYAKIRSAHTNDVKQLVEAVQKIALESIVIWGKTPKFRLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLETEPIVGAETFYVDGAANRETKKGKAGYV Sylla, M 2008 18389909 Antivir Ther Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso. 1636 46076 AZT3TCNVP 2006 Burkina Faso CRF02_AG 0 1 552 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEKDGKISKIGPENPYNTPVFAIKKKDSDKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKVATIIDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQARHDKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELRGHLLKWGFYTPDKKHQQEPPLRWLGYELHPDKWTVQSIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVKQLTEVVQKVATESIVIWGKIPKFRLPIQKETWDTWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKDPIVGAETFYVDGAANRETKLGKAGYVTDRGRQKVISLPETTNQKTELHAIYLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEKLIGKDKVYLSWVPAHKGIGGNEQVDKLV Sylla, M 2008 18389909 Antivir Ther Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso. 1636 46078 AZT3TCEFV 2006 Burkina Faso CRF02_AG 0 1 440 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPALFQASMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIKLPDKEHWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTEIVTLTEEAELELAENKEILKEPVHGVYYDPTKDLVAEIQKQGQDQWTYQIYQEPFKILKTGKYAKQRSAHTNDVKQLTEVVQKVSTESIVIWGKTPKFRLPIQKETWETWWREYWQATWIPEWEFVNTPPLVKLWYQLEKDPIMGAETF Sylla, M 2008 18389909 Antivir Ther Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso. 1636 46082 AZT3TCEFV 2006 Mali CRF02_AG 0 1 440 PISPIETVPVQLKPGMDGPKVKQWPLTEEKIKALTEICLEMEKEGKISRIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPRVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILQPFRTKNPEMVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGFTTPDQKHQKEPPFLWMGYELHPDKWTVQQIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQDQWTYQIYQEPFKILKTGKYAKRRSAHTNDVKQLTEVVQKVTMESIVIWGKAPKFRLPIQKETWEAWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKDPIVGAETF Sylla, M 2008 18389909 Antivir Ther Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso. 1636 46084 D4T3TCNVP 2006 Mali CRF02_AG 0 1 440 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILQPFRTENPELVIYQYVDDLLIGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYAGIRVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPAKDLVAEIQKQGQGQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVKQLTEVVQKVATESIIIWGKTPKFRLPIQKETWEAWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKDPIVGAETF Sylla, M 2008 18389909 Antivir Ther Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso. 1636 46085 AZT3TCEFV 2006 Mali CRF02_AG 0 1 440 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEIQLGIPHPGGLKKKKSVTIIDVGDAYFSVPLYEDFRKYTAFTIPSVNNESPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTNNPEIEICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVKQLTEVVQKVATESIVIWGKTPKFRLPIQRETWDAWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKDPILGAETF Sylla, M 2008 18389909 Antivir Ther Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso. 1636 46090 D4T3TCNVP 2006 Mali A 0 1 441 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIEALTAICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGEAYFSVPLDESFRKYTAFTIPSRNNETPGVRYQYNVLPQGWKGSPAIFQYSMTKILEPFRTKNPEIIIYQYVDDLYVASDLEIGEHRTKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKDPVHGVYYDPSKDLVAEIQKQGQDQWTYQIYQEPFKNLKTGKYARKRSAHTNDVRQLVEVVQKVVTESIVIWGKTPRFKLPIQKETWETWWMEYWQATYIPEWEFVNTPPLVKLWYQLEKDPIIGAETFY Sylla, M 2008 18389909 Antivir Ther Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso. 1636 46092 AZT3TCNVP 2006 Burkina Faso CRF06_cpx 0 1 441 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICMEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPELVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFFTPDKKYQKEPPFLWLGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQVYQEPHKNLKTGKYARIKSAHTNDIKQLTEAVQKIAIESIVIWGKIPKFRLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLETEPIVGAETFY Sylla, M 2008 18389909 Antivir Ther Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso. 1651 14872 AZT3TCNVP 2002 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGQITKIGPENPYNTPIFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSXNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEMVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFITPDXKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIIPLTEEAELELAENREILKEPVHGAFYDPSKDLIAEIQKQG Pillay, V 2008 19000027 ARHR HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. 1651 14883 AZT3TCNVP 2002 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTLQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIIPLTEEAELELAENREILREPVHGVYYDPSKELIAEIQKQG Pillay, V 2008 19000027 ARHR HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. 1651 14886 D4T3TCEFV 2002 South Africa C 0 1 333 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIRALTEICREMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPGIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKESPLLWLGYELHPDKWTVQPIQLPDKENWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQG Pillay, V 2008 19000027 ARHR HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. 1651 14895 AZT3TCNVP 2002 South Africa C 0 1 334 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEMVICQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQ Pillay, V 2008 19000027 ARHR HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. 1651 14897 AZT3TCNVP 2002 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPYRTKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRHLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQG Pillay, V 2008 19000027 ARHR HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. 1651 56439 D4T3TCNVP 2002 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVIYQYVDDLYVASDLEIGQHRAKIEELREHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Pillay, V 2008 19000027 ARHR HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. 1651 56453 AZT3TCEFV 2003 South Africa C 0 30 333 KLKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSLNNDTPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIQVRNLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Pillay, V 2008 19000027 ARHR HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. 1651 56454 AZT3TCEFV 2003 South Africa C 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEELEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMLKILEPFRTKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKHLCRLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQ Pillay, V 2008 19000027 ARHR HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. 1653 56476 D4T3TCNVP 2006 Central African Republic CRF02_AG 1 41 240 MEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVICQYVDDLYVGFDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWT Gody, JC 2008 19202461 JAIDS High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations. 1653 56477 D4T3TCNVP 2006 Central African Republic G 1 1 320 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICNEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNERPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKDPVHGVYYD Gody, JC 2008 19202461 JAIDS High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations. 1653 56478 D4T3TCNVP 2006 Central African Republic G 1 41 240 LEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPYRAKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFFTPDKKHQKEPPFLWMGYELHPDKWT Gody, JC 2008 19202461 JAIDS High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations. 1653 56479 D4T3TCNVP 2006 Central African Republic A 1 41 240 LEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLDKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVICQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWT Gody, JC 2008 19202461 JAIDS High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations. 1653 56480 D4T3TCNVP 2006 Central African Republic CRF01_AE 1 1 334 PISPIETIPVTLKPGMDGPKVKQWPLTEEKIKALTEICREMEEEGKISKIGPENPYNTPVFAIKRKDGTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLRKKKSVTVLDVGDAYFSVPLHESFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPYRAKNPDIVICQYVDDLYVGSDLEIGQHRTKVEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIRVKQLCKLLRGAKTLTDIVTLTEEAELELAENREILKTPVHGVYYDPSKDLVAEIQKQGQ Gody, JC 2008 19202461 JAIDS High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations. 1653 56481 D4T3TCNVP 2006 Central African Republic CRF06_cpx 1 41 240 MEREGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWT Gody, JC 2008 19202461 JAIDS High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations. 1653 56486 D4T3TCNVP 2006 Central African Republic J 1 41 240 MEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHREKVEELRGHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWT Gody, JC 2008 19202461 JAIDS High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations. 1653 56487 D4T3TCNVP 2006 Central African Republic J 1 41 240 MEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSITILDVGDAYFSVPLDPDFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPELVICQYVDDLYVGSDLEIGQHRQKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWT Gody, JC 2008 19202461 JAIDS High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations. 1653 56488 D4T3TCNVP 2006 Central African Republic CRF11_cpx 1 41 240 MEKEGKISKIGPENPYNTPVFAIKKKDSPKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKTKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVICQYMDDLYVGSDLEIGQHRKKVEELREHLLKWGFDTPDKKHQKEPPFLWMGYELHPDKWT Gody, JC 2008 19202461 JAIDS High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations. 1653 56490 D4T3TCEFV 2006 Central African Republic CRF02_AG 1 41 240 MEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWT Gody, JC 2008 19202461 JAIDS High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations. 1653 56493 D4T3TCNVP 2006 Central African Republic A 1 41 240 MEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEKFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSRNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWT Gody, JC 2008 19202461 JAIDS High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations. 1653 56494 D4T3TCNVP 2006 Central African Republic A 1 41 240 MEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHKNFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRSQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRNHLLKWGFTTPDKKHQKKPPFLWMGYELHPDKWT Gody, JC 2008 19202461 JAIDS High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations. 1653 56495 D4T3TCNVP 2006 Central African Republic J 1 41 240 MEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRCNPEIVIYQYMDDLYVGSDLEIGQHREKVEELRKHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWT Gody, JC 2008 19202461 JAIDS High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations. 1653 56496 D4T3TCNVP 2006 Central African Republic CRF11_cpx 1 41 240 MEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKSFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPNIVIYQYMDDLYVGSDLEIGQHREKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWT Gody, JC 2008 19202461 JAIDS High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations. 1654 63801 D4T3TCNVP 2003 Ghana CRF02_AG 0 1 323 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTGNPEMVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQHIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVVLTEEAELELAENREILKEPVHGVYYDPTK Delgado, E 2008 18645511 JAIDS High prevalence of unique recombinant forms of HIV-1 in Ghana: Molecular epidemiology from an antiretroviral resistance study. 1654 63852 AZT3TCNVP 2003 Ghana CRF02_AG 0 1 326 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPIFAIKKKESTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDEKFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQTSMTRILEPFRTKNPELVICQYVDDLYVGSDLEIGQHRAKIEELRDHLLRWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVTLTEEAELELAENREILKEPVHGVYYDPTKDLI Delgado, E 2008 18645511 JAIDS High prevalence of unique recombinant forms of HIV-1 in Ghana: Molecular epidemiology from an antiretroviral resistance study. 1676 58789 AZT3TCNVP 2006 Russia A 0 1 301 PISPIETVPVALKPGMDGPKVKQWPLTEEKIKALMDICQEMEKEGKISKIGPENPYNTPVFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRLKNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDVVTLTEEAEL Thomson, MM 2009 19363451 JAIDS Molecular epidemiology of HIV-1 in St Petersburg, Russia: Predominance of subtype A, former Soviet Union variant, and identification of intrasubtype subclusters. 1676 58804 AZT3TCEFV 2006 Russia B 0 1 301 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEVIPLTKEAEL Thomson, MM 2009 19363451 JAIDS Molecular epidemiology of HIV-1 in St Petersburg, Russia: Predominance of subtype A, former Soviet Union variant, and identification of intrasubtype subclusters. 1676 58806 AZT3TCEFV 2006 Russia A 0 1 301 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRLKNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLASWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVTLTEEAEL Thomson, MM 2009 19363451 JAIDS Molecular epidemiology of HIV-1 in St Petersburg, Russia: Predominance of subtype A, former Soviet Union variant, and identification of intrasubtype subclusters. 1676 58818 AZT3TCNVP 2006 Russia B 0 1 301 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKGSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVLDVGDAYFSVPLDEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRTKVEELRQHLLRWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGTKSLTEVVPLTKEAEL Thomson, MM 2009 19363451 JAIDS Molecular epidemiology of HIV-1 in St Petersburg, Russia: Predominance of subtype A, former Soviet Union variant, and identification of intrasubtype subclusters. 1676 58821 AZT3TCNVP 2006 Russia B 0 1 301 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDVVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLIRGTKALTEVVPLTEEAEL Thomson, MM 2009 19363451 JAIDS Molecular epidemiology of HIV-1 in St Petersburg, Russia: Predominance of subtype A, former Soviet Union variant, and identification of intrasubtype subclusters. 1676 58822 AZT3TCNVP 2006 Russia A 0 1 301 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICKEMEKEGKISKIGPENPYNTPVFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMIKILEPFRLKNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVTLTEEAEL Thomson, MM 2009 19363451 JAIDS Molecular epidemiology of HIV-1 in St Petersburg, Russia: Predominance of subtype A, former Soviet Union variant, and identification of intrasubtype subclusters. 1676 58830 AZT3TCEFV 2006 Russia A 0 1 301 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICMEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVTLTEEAEL Thomson, MM 2009 19363451 JAIDS Molecular epidemiology of HIV-1 in St Petersburg, Russia: Predominance of subtype A, former Soviet Union variant, and identification of intrasubtype subclusters. 1676 58831 AZT3TCEFV 2006 Russia A 0 1 301 PISPIKTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIVIYQYMDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVTLTEEAEL Thomson, MM 2009 19363451 JAIDS Molecular epidemiology of HIV-1 in St Petersburg, Russia: Predominance of subtype A, former Soviet Union variant, and identification of intrasubtype subclusters. 1679 59061 D4T3TCNVP 2005 Chad CRF11_cpx 0 42 240 EKEGKISKIGPENPYNTPVFAIKKKDSAKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPEIVICQYVDDLYVASDLEIGQHREKVEELRKHLLKWGFFTPDKKHQKEPPFLWMGYELHPDKWT Koyalta, D 2009 19480574 Clin Infect Dis High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. 1679 59062 D4T3TCNVP 2005 Chad CRF02_AG 0 41 240 MEKEGKISKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRDHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWT Koyalta, D 2009 19480574 Clin Infect Dis High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. 1679 59064 D4T3TCNVP 2005 Chad F 0 41 240 MEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQFSMTKILEPFRTKNPDIIIYQYMDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWT Koyalta, D 2009 19480574 Clin Infect Dis High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. 1679 59066 D4T3TCNVP 2005 Chad CRF02_AG 0 41 240 MEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVASDLEIGQHRTKIEELRAHLLNWGFTTPDKKHQKEPPFLWMGYELHPDKWT Koyalta, D 2009 19480574 Clin Infect Dis High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. 1679 59069 D4T3TCNVP 2005 Chad CRF13_cpx 0 41 240 MEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDETFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHREKVEELRKHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWT Koyalta, D 2009 19480574 Clin Infect Dis High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. 1679 59070 D4T3TCNVP 2005 Chad F 0 41 240 MEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNRRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRSKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFQWMGYELHPDKWT Koyalta, D 2009 19480574 Clin Infect Dis High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. 1679 59071 D4T3TCNVP 2005 Chad D 0 41 240 MEKEGKISRIGPDNPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDANFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWT Koyalta, D 2009 19480574 Clin Infect Dis High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. 1679 59073 D4T3TCNVP 2005 Chad CRF01_AE 0 41 240 MEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWT Koyalta, D 2009 19480574 Clin Infect Dis High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. 1679 59075 D4T3TCNVP 2005 Chad F 0 41 240 MEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDEEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKHNPEIVIYQYMDDLYVGSDLEIGQHRIKIEELREHLLKWGFTTPDKKHQREPPFLWMGYELHPDKWT Koyalta, D 2009 19480574 Clin Infect Dis High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. 1679 59076 D4T3TCNVP 2005 Chad CRF11_cpx 0 41 240 MEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQTSMTKILEPFRKNNPEIVIYQYVDDLYVASDLEIGQHREKIEELRKHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWT Koyalta, D 2009 19480574 Clin Infect Dis High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. 1679 59078 D4T3TCNVP 2005 Chad G 0 41 240 MEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPRGNNETPGIRFQYNGLPQGWKGSPAIFQCSMTKILEPFRRKNPELVICQYMDDLYVGSDLEIGQHRAKIDELREHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWT Koyalta, D 2009 19480574 Clin Infect Dis High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. 1679 59079 D4T3TCNVP 2005 Chad G 0 41 240 MEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDKSFRKYTAFTIPSVNNERPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRRKNPELVIYQYVDDLYVGSDLEIGQHRAKIDELREHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWT Koyalta, D 2009 19480574 Clin Infect Dis High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. 1679 59080 D4T3TCNVP 2005 Chad CRF11_cpx 0 41 240 MEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVPDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQFSMTKILEPFRKHNPEIVIYQYVDDLYVASDLEIGQHREKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWT Koyalta, D 2009 19480574 Clin Infect Dis High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. 1679 59081 D4T3TCNVP 2005 Chad A 0 41 240 MEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILAPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWT Koyalta, D 2009 19480574 Clin Infect Dis High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. 1679 59083 D4T3TCNVP 2005 Chad CRF02_AG 0 41 240 MEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWT Koyalta, D 2009 19480574 Clin Infect Dis High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. 1679 59085 D4T3TCNVP 2005 Chad CRF11_cpx 0 41 240 MEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYMDDLYVGSDLEIGQHREKVEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWT Koyalta, D 2009 19480574 Clin Infect Dis High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. 1679 59086 D4T3TCNVP 2005 Chad A 0 41 240 MEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIIIYQYVDDLYVSSDLEIGQHRAKIEELRAHLLSWGFFTPDKKHQKEPPFLWMGYELHPDRWT Koyalta, D 2009 19480574 Clin Infect Dis High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. 1679 59088 D4T3TCNVP 2005 Chad G 0 41 240 MEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLRKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKENPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWT Koyalta, D 2009 19480574 Clin Infect Dis High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. 1679 59090 D4T3TCNVP 2005 Chad D 0 41 240 MEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEVVIYQYMDDLYVGSDLEIGEHRAKIEKLREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWT Koyalta, D 2009 19480574 Clin Infect Dis High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. 1679 59091 D4T3TCNVP 2005 Chad CRF11_cpx 0 41 240 MEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKHNPEIVIYQYMDDLYVGSDLEIGQHREKVEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWT Koyalta, D 2009 19480574 Clin Infect Dis High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. 1679 59092 D4T3TCNVP 2005 Chad F 0 41 240 MEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRAKNPEMVICQYIDDLYVGSDLEIEQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWT Koyalta, D 2009 19480574 Clin Infect Dis High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. 1679 59093 D4T3TCNVP 2005 Chad F 0 41 240 MEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQHSMTKILEPFRTKNPDIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFFTPDKKHQKEPPFLWMGYELHPDKWT Koyalta, D 2009 19480574 Clin Infect Dis High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. 1679 59094 D4T3TCNVP 2005 Chad U 0 41 240 MEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKDNPEMVIYQYMDDLYVGSDLEIEQHREKIEELRKHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWT Koyalta, D 2009 19480574 Clin Infect Dis High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. 1679 59096 D4T3TCNVP 2005 Chad CRF02_AG 0 41 240 MEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKGTQDFWKVQTGIPHPAGLKKKRSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWT Koyalta, D 2009 19480574 Clin Infect Dis High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. 1679 59097 D4T3TCNVP 2005 Chad F 0 41 240 MEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRAKNPEMVICQYIDDLYVGSDLEIEQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWT Koyalta, D 2009 19480574 Clin Infect Dis High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. 1685 59300 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKITRIGPDNPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVICQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFFTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59301 D4T3TCNVP 2007 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKTKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYVDDLYVGSDLEIGKHREKIEELRGHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59302 D4T3TCNVP 2007 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQHSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHREKIDELREHLLTWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59303 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILAPFRAKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59304 D4T3TCNVP 2007 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVICQYVDDLYVGSDLEIGQHRAKIEELRQHLLRWGFTTPDQKHQKEPPFHWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59305 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKGGTRWRKISDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRTQNPDIIICQYVDDLYVGSDLEIEQHRAKIKELREHLFKWGFFTPEEKHQEEPPFHWMGYELHPDKWTVHPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59306 D4T3TCNVP 2006 Malawi C 0 38 247 CEELEKDGKITKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDEGFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRARNPEMIIYQYVDDLLVGSDLELNQHRAKIEELREHLSKWGFYTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59307 D4T3TCNVP 2007 Malawi C 0 38 247 CEELEKDGKISKIGPENPYNTPIFAIKKKNSDKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSIPLDENFRKYTAFTIPSMNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILAPYRAQNPDIVIYQYVDDLYVGSDLETGQHRAKVEELRDHLWKWGFYTPDRKHQKEPPFHWMGYELHPDTWTVQTIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59308 D4T3TCNVP 2006 Malawi C 0 38 247 CEELEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59309 D4T3TCNVP 2006 Malawi C 0 38 247 CEELEKDGKISKIGPENPYNTPVFAIKKKNSDKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTILDVGDAYFSIPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPDIVICQYVDDLYVGSDLEIGQHRAKIKELREHLWKWGFYTPDKKYQKEPPFHWMGYELHPDKWTVQPIMLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59310 D4T3TCNVP 2006 Malawi C 0 38 247 CEKMEKEGKITKIGPENPYNTPVFVIKKKDSTEWRKLTDFRELNKRTQDFWEVQLGIPHPAGLEKKRSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRTRNPDLVICQYVDDLYVASDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFHWMGYELHPDKWTVQPIKLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59311 D4T3TCNVP 2006 Malawi C 0 38 247 CEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEITQHRAKIDQLREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59312 D4T3TCNVP 2007 Malawi C 0 40 247 EMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSRNNETPGVRYQYNVLPQGWKGSPAIFQSSMMKILEPFRAKNPEIVICQYVDDLYVGSDLELMQHRAKVEELREHLLKWGFTTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59313 D4T3TCNVP 2007 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFVIKRKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYMDDLYVASDLEIVQHRAKVEKLREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59314 D4T3TCNVP 2006 Malawi C 0 38 247 *KKMEEEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLLVGSDLEIGPHREKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59315 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFYTPDKKHQKEPPFLWMGYELHPDKWTIQPIKLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59316 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKISKIGPDNPYNTPVFAIKRKDG~RWRKLIDLRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYYSVPLDESFRKYTAFTLPSINNETPGIRYQYNVLPMGWKGSAAIFQQSMTKILEPFRTQNPDIVIIQYMDDLYVGSDLEIGQHRAKIEELRRHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59317 D4T3TCNVP 2006 Malawi C 0 40 247 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPSGLEKKKSVTVLDVGDAYFSVPLHEXFRKYTAFTIPSINNATPGVRYQYNVLPQGWKGSPAIFQCSMTKILEPFRARNPGLIICQYVDDLYVGSDLEIRQHRAKIKELREHLLKWGFYTPDKKYQKEPPFRWLGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59318 D4T3TCNVP 2007 Malawi C 0 38 247 CEEMEKEGKISKIGPDNPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPEMVIYQYVDDLYVASDLEIKQHREKIEELREHLLKWGFTTPDQKHQKEPPFQWMGYELHPDTWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59319 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNATPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPGIVIYQYMDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59320 D4T3TCNVP 2006 Malawi C 0 38 247 CDEMEKEGKISKIGPENPYNTPVFVIKNKDGTKWRKLTDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPEIVICQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDRKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59321 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFVIKRKDGIKWRKLIDLRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYYSIPLDENFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFKTQNPELVICQYMDDLYVASDLEIGQHRAKIEKLREHLLKWGLTTPDKKHQQEPPFRWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59322 D4T3TCNVP 2007 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYYSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59323 D4T3TCNVP 2006 Malawi C 0 38 247 CDEMEKEGKITKIGPENPYNTPVFVIKKKDGNKWRKLIDLRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDIGDAYYSIPLDENFRKYTAFTIPSINNETPGVRYQYNVLPMGWKGSPAIFQSSLIKILEPFRAQNPDIVICQYMDDLYVGSDLEIGQHRAKVEELREHLLKWGLYTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59324 D4T3TCNVP 2006 Malawi C 0 38 247 CEELEKDGKITKIGPENPYNTPVFAIKKKDGTKWRKIVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTILDVGDAYFSIPLDESFRKYTAFTIPSLNNGTPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRERNPEMVIYQYVDDLYVGSDLEIDQHRAKIKELREHLWKWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59325 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLAWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59326 D4T3TCNVP 2006 Malawi C 0 38 247 CEELEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNEIPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTENPEIVIVQYIDDLYVGSDLEIGQHRAKIEELRGHLLKWGFYTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59327 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQASMTKILEPFRTANPDIVIYQYMDDLYVGSDLEIGQHRAKIDELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59328 D4T3TCNVP 2006 Malawi C 0 38 247 CEELEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDVNFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDMVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLRWGFYTPDKKHQKEPPFLWMGYELHPDRWTVQPIMLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59329 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFVIKRKDGTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYYSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRTRNPDIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59330 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYMDDLYVGSDLEIKQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59331 D4T3TCNVP 2006 Malawi C 0 38 247 CAEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPTIFQSSMTKILEPFRAKNPDIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59332 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKRKDGTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRTQNPGIVICQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQQEPPFRWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59333 D4T3TCNVP 2006 Malawi C 0 38 247 CEELEKDGKISKIGPENPYNTPIFAIKKKNSNKWRKLVDFRELNKRTQDFWEVQLGIPHPGGVKKKKSVTVLDVGDAYFSIPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRAKNPGIVIYQYVDDLLVGSDLEIVQHRAKIEELREYLWKRGFYTPEKKHQKEPPFLWMGYELHPDKWTVQPIVLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59334 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKFSKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSTMTKILEPFRAQNPELVICQYVDDLYVGSDLEIGQHRKKIKELRTHLWKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59335 D4T3TCNVP 2006 Malawi C 0 38 247 CEELEKDGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSIPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEMVIYQYVDDLYVGSDLEIEQHRAKIEELREHLWKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59336 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKITKIGPDNPYNTPVFAIKRKDS~KWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTLPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYVDDLYVASDLEVTQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59337 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEVIIYQYVDDLYVASDLEIGQHRAKIEKLREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59338 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKYPDIVIVQYVDDLYVGSDLEIGQHREKIEELRAHLLKWGFFTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59339 D4T3TCNVP 2006 Malawi C 0 38 247 CAEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPGIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59340 D4T3TCNVP 2006 Malawi C 0 38 247 CEELEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLTDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTIIDVGDAYFSVPLDEDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSTMIKILEPFRAKNPEIVICQYVDDLYVGSDLEIEQHRAKIEELREHLLKWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59341 D4T3TCNVP 2006 Malawi C 0 38 246 CEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVICQYVDDLYVGSDLEIGQHRAKIKELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQL Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59342 D4T3TCNVP 2007 Malawi C 0 38 247 CEELEKDGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPELDICQYMDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59343 D4T3TCNVP 2007 Malawi C 0 38 247 CEELEKEGKISKIGPENPYNTPIFAIKKKNSXRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNEIPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIIIIQYVDDLYVGSDLEIKQHRAKIEELREYLLKWGFFTPEWKHQKEPPFHWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59344 D4T3TCNVP 2007 Malawi C 0 38 247 CDEMEKEGKISKIGPENPYNTPVFAIKRKDGTKWRKLVDFRELNRRTQDFWEIQLGIPHPAGLRKKKSVTVLDVGDAYFSVPLDEGFRQYTAFTLPSINNETPGIRYQYNVLPMGWKGSPAIFQYSMTKILEPFRTKNPDIVICQYIDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQEEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59345 D4T3TCNVP 2007 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSMPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRKQNPDIVICQYVDDLYVASDLEIGQHRAKIKELREHLLRWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59346 D4T3TCNVP 2007 Malawi C 0 38 247 CAEMEKDGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPGIVICQYVDDLYVASDLEIEQHRAKIEELREHLSKWGLYTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59347 D4T3TCNVP 2007 Malawi C 0 40 247 EMEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLRKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDQKHQKEPPFLWMGYELHPDKWTVQPILLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59348 D4T3TCNVP 2007 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59349 D4T3TCNVP 2007 Malawi C 0 38 247 CEDMEKEGKITKIGPENPYNTPVFAIKRKDG~NWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELTICQYMDDLYVGSDLEIGQHRARIEELREHLLKWGFTTPDRKYQKEPPFLWMGYELHPDKWTVQTIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59350 D4T3TCNVP 2007 Malawi C 0 38 247 CKEMEEEGKITKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRGHLLKWGFYTPDKKHQKEPPFLWMGYELHPDRWTVQPIVLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59351 D4T3TCNVP 2007 Malawi C 0 38 247 CEEMEKDGKITRIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTILDVGDAYFSIPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIIICQYVDDLYVGSDLEIGQHRAKIKELRDYLWKWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59352 D4T3TCNVP 2007 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKSSGEWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSIPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKYQKEPPFLWMGYELHPDKWTMQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59353 D4T3TCNVP 2005 Malawi C 0 38 247 CEEMEKEGKITRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRTQNPDIIICQYVDDLYVASDLEIKQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDRWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59355 D4T3TCNVP 2006 Malawi C 0 38 247 CEKMEKEGKITKIGPENPYNTPVFVIKKKNSTEWRKLTDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSMNNETPGIRYQYNVLPMGWKGSPSIFQSSMIKILEPFRAQNPEIVICHYVDDLYVASDLEITQHRAKIEELREHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59356 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKGSNRWRKLMDLRELNRRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSINNEIPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDHKHQKEPPFRWMGYELHPDKWTVQPIKLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59357 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNATPGIRYCYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59358 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFVIKRKDGTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTLPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRTKNPDIVIIQYVDDLYVGSDLEIGQHRAKVEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59359 D4T3TCNVP 2006 Malawi C 0 38 247 CEELEKEGKISKIGPENPYNTPIFAIKKKGSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVICQYVDDLYVGSDLEIGQHRAKIKELRAHLLKWGFYTPDKKHQEEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59360 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQNFWEVQLGIPHPGGLKKKKSVTVLDLGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVICQYVDDLYVGSDLEIGQHRAKIVELREHLLRWGFTTPEKKHQKEPPFLWMGYELHPEKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59361 D4T3TCNVP 2006 Malawi C 0 38 247 CEELEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQTITLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59362 D4T3TCNVP 2006 Malawi C 0 40 247 ELEKDGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSIPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQDSMTKILEPFRAQNPEIIIIQYVDDLYVGSDLEIEQHREKIKELREYLWKWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59363 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKITKIGPDNPYNTPVFAIKRKDS~KWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSAAIFQSSMTKILEPFRAQNPEIVICQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDRKYQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59364 D4T3TCNVP 2006 Malawi C 0 38 247 CDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTQNPDIVIVQYVDDLYVGSDLETGQHRAKIEELREHLLRWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59365 D4T3TCNVP 2006 Malawi C 0 38 247 CEELEKDGKITKIGPENPYNTPVFAIKKKNSTKWRKISDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSIPLDEDFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPSIFQASMTRILEPFRAQNPDIIIIQYVDDLYVGSDLEIGQHRAKIEELRAHLWKWGFYTPENKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59366 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGLPHPGGLEKRKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVASDLEMGQHRAKIEELRDHLLKWGLFTPDQKHQKEHPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59367 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKISKIGPENPYNTPVFVIKRKDGIKWRKLIDLRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYYSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYVDDLYVGSDLEIGQHRAKVEQLREHLLKWGLTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59368 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYVDDLYVASDLDIGQHRKKVEELRQHLLKWGFTTPDNKYQKEPPFLWMGYELHPEKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59369 D4T3TCNVP 2006 Malawi C 0 38 247 CKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLYVASDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59370 D4T3TCNVP 2007 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKRKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFRWMGYELHPHKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59371 D4T3TCNVP 2007 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQDSMTKILEPFRAQNPDIVICQYVDDLYVGSDLEIVQHRAKIEELREHLLRWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59372 D4T3TCNVP 2007 Malawi C 0 38 247 CEEMEKEGKISRIGPDNPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGLPHPAGLEKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRAKNPEMVIYQYVDDLWVGSDLEIGQHRAKIEELRNHLLKWGFFTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59373 D4T3TCNVP 2007 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPIFAIKRKDGTRWRKLIDLRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYYSVPLDESFRKYTAFTLPSTNNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRAKNPEMVICQYIDDLYVGSDLEIGQHRAKIEDLRQHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59374 D4T3TCNVP 2007 Malawi C 0 38 246 CEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKSKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPELVIYQYVDDLYVGSDLEIGQHRAKIEELRRHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQL Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59375 D4T3TCNVP 2007 Malawi C 0 38 247 CEEMEKEGKITKIGPDNPYNTPVFVIKRKDGIKWRKLIDLRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYYSIPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRAKNPEIVIVQYVDDLYVGSDLEIGQHRAKVEELRDHLFKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59376 D4T3TCNVP 2007 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRKKIEELRAHLLKWGFSTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59377 D4T3TCNVP 2007 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVIDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPDIDIYQYVDDLYVGSDLEIGQHRAKVEELRRHLLEWGFFTPDKKHQKEPPFLWLGYELHPDKWTVQPIVLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59378 D4T3TCNVP 2007 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKYPDIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPITLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59379 D4T3TCNVP 2007 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFVIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKNNKSVTVLDVGDAYYSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMIKILEPFRIKNPDIVICHYVDDLYVGSDLEIGEHRAKVEQLREHLLKWGLTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59380 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYVDDLLVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59381 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKISKIGPDNPYNTPVFAIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSTNNEAPGIRYQYNVLPMGWKGSPAIFQDSMTKILEPFRTQNPDIDICQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQQEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59382 D4T3TCNVP 2006 Malawi C 0 38 247 CEELEKDGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYVDDLLVGSDLEIGQHRAKIEELREYLWKWGFYTPDNKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59383 D4T3TCNVP 2007 Malawi C 0 38 247 CEELEKDGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQDSMTKILEPFRTKNPEIVICQYVDDLYVASDLEIGQHRAKIDELREYLLKWGFYTPDNKYQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59384 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQDSMTKILAPFRAQNPEFIICQYVDDLYVASDLEIGQHRAKIKELREYLWKWGFYTPEEKHQKEPPFHWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59385 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPIFAIKRKDG~KWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSAAIFQSSMTKILEPFRAQNPEIVICQYMDDLYVASDLEIGQHRAKVEKLRAHLSKWGLTTPDRKYQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59386 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDANFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59387 D4T3TCNVP 2006 Malawi C 0 38 247 CEEMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSTNNQTPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKYPEMVIYQYVDDLYVGSDLEIMQHRAKIEELREYLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPITLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59388 D4T3TCNVP 2007 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPIFAIKKKGGTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIIICQYVDDLYVGSDLEIGQHRQKIKELREHLLKWGFTTPEEKHQKEPPFHWMGYELHPDKWTVQPIKLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59389 D4T3TCNVP 2007 Malawi C 0 38 247 CEELEKEGKITKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPNIVIYQYVDDLYVASDLEIGQHRAKIEELREHLWRWGFFTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59390 D4T3TCNVP 2007 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKVLEPFRAKNPEIIIYQYVDDLLVGSDLEITQHRAKVEELREHLLKWGFFTPDQKHQKEPPFLWMGYELHPDKWTVQPIRLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59391 D4T3TCNVP 2007 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFFTPDKKYQKEPPFLWMGYELHPDKWTVQPIKLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59392 D4T3TCNVP 2007 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYYSVPLDESFRKYTAFTIPSINNATPGVRYQYNVLPMGWKGSPAIFQSSMTRILEPFRIKNPDIVIYQYVDDLYVESDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1685 59393 D4T3TCNVP 2007 Malawi C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFVIKRKDGTRWRKLIDFRELNKRTQDFWEVQLGIPHPSGLKKKKSMTVLDVGDAYYSVPLDEDFRKYTAFTIPSINNEAPGIRYQYNVLPMGWKGSPSIFQSSMTKILEPFRAKNPEMVIYQYMDDLCVGSDLEITQHRAKVEELRKYLLRWGFTTPDEKYQKDPPFLWMGYELHPDKWTVQTIQLP Hosseinipour, MC 2009 19417582 AIDS The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. 1711 63977 ABC3TCNVP 2008 Thailand CRF01_AE 0 1 332 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIRALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSNKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAFFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLAQGWKGSPAIFQSSMTKILEPYRRKNPEMVIIQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGTKALTDVVPLTEEAELELAENREILRNPVHGVYYDPSKDLIAEIQKQ Rosen-Zvi, M 2008 18586740 Bioinformatics Selecting anti-HIV therapies based on a variety of genomic and clinical factors. 1748 69991 D4T3TCEFV 2008 South Africa C 0 1 328 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRAQNPELVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDVQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAK Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 69993 AZT3TCEFV 2008 South Africa C 0 1 323 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPEIVIYQYVDDLYVGSDLEIGQHRAKVEQLREHLLRWGFTTPDKKHQKEHPFLWMRYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRELCKLLRGAKALTDIVPLTEEAELELAENKEILKEPVHGVYYDPSK Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 69994 D4T3TCEFV 2008 South Africa C 0 1 320 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALMEICDELEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIIPLTEEAELELAENREILKQPVHGVYYD Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 69995 D4T3TCEFV 2008 South Africa C 0 1 321 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEREGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIMQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIQVRHMCKLLRGTKALTDVVPLTEEAELELAENREILKEPVHGVYYDP Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 69996 D4T3TCEFV 2008 South Africa C 0 1 330 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDLVIYQYVDDLYVGSDLEIGQHRAKIKELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKIRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQ Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 69997 AZT3TCNVP 2008 South Africa C 0 1 304 PISPIETIPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVICQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDVVPLTEEAELELA Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 69998 D4T3TCEFV 2008 South Africa C 0 1 302 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIQALKEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGVKVRNLCRLLRGAKALTDIVPLTEEAELE Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 69999 AZT3TCEFV 2008 South Africa C 0 1 308 PISPIETIPVKLKPGMDGPRVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFRWLGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIIPLTQEAELELAENRE Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70000 D4T3TCNVP 2008 South Africa C 0 1 322 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYIGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPS Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70001 D4T3TCEFV 2008 South Africa C 0 1 306 PISPIETVPVQLKPGMDGPKVKQWPLTEEKIKALMAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLYEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPTIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIIPLTEEAELELAEN Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70002 D4T3TCNVP 2008 South Africa C 0 1 308 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTNNPEMVIYQYVDDLYVGSDLEIGQHRAKVEELRIHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGTKALTEVVTLTEEAELELAENRE Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70003 AZT3TCEFV 2008 South Africa C 0 1 290 PISPIEAVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTLPSTNNAAPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQSIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLKGAKALT Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70004 AZT3TCNVP 2008 South Africa C 0 1 324 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPRVNNQTPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFKAKNPELVIYQYVDDLYVASDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIQVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKD Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70005 AZT3TCEFV 2008 South Africa C 0 1 323 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALAEICKEMEKEGKIEKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQXFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKTLTDIVPLTEEAEFELAENREILKEPVHGVYYDPSK Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70006 D4T3TCEFV 2008 South Africa K 0 1 321 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTELEKEGKISRIGPENPYNNPVFAIKKKDGTKWRKISDFRELNKRTQDFWEVQLGIPHPAGLEKRKSVTILDVGDAYFSIPLDESFRKYTAFTIPSINNEVPGIRYQYNVLPQGWKGSPAIFQDSMTKILEPFRTKNPEMVICQYVDDLYVASDLEIGQHRAKIDELREHLWKWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIKLPEKDDWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKSLTEVVPLTAEAELELAENREILKEPVHGVYYDP Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70007 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNSDIVIYQYVDDLYVASDLEKGQHRAKIEELRTHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDTWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDVVPLTEEAELELAENREILKEPVHGVYYDPSKDLMAELQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70008 AZT3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNAIPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIEIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDTSKELMAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70009 AZT3TCEFV 2008 South Africa C 0 1 333 PICPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEELEKDGKITKIGPDNPYNTPIFAIKKKNSDKWRKVVDFRELNKRTQDFWEIQLGIPHPAGLKQNKSVTVLDMGDAYFSVLLDESFRKYTAFTIPSINNRTPGIRYQYNVLPQGWKGSPSIFQASMTKILEPFKKQNPDLEIYQYVDDLYVGSDLEIGQHRAKIKELRDHLWKWGFYTPDKKHQKEPPFLWLGYELHPDKWTVQPICLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKHLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70010 AZT3TCEFV 2008 South Africa C 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFVIKKKDGTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNSKLVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFSTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQGQ Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70011 AZT3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKIKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYVDDLLVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREIFKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70012 AZT3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKNNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70013 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVICQYMDDLYVASDLEIGQHRTKIEELRDHLLKWGFTTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70014 D4T3TCNVP 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSIPLDSDFRKYTAFTIPSTNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDLVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKGSWTVNDIQKLVGKLNWASQIYPGIRVKHLCKLLRGAKALTDIVPLTAEAELELAENREILREPVHGVYYDPSKDLIAEVQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70015 D4T3TCEFV 2008 South Africa C 0 1 333 PISSIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPTKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70016 D4T3TCEFV 2008 South Africa C 0 1 315 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVIYQYMDDLYVGSDLEIGQHRSKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKEDWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEIVPLTAEAELELAENREILKEPVH Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70017 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70018 D4T3TCEFV 2008 South Africa C 0 1 323 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKRKDGIKWRMLADLRELNKRTQDFSEVQLGIPHPAGLRKKKSVTVLDVGDAYYSVPLDEDFRKYTAFTIPSINNATPGIRYQYNVLPMGWKGSAAIFQSSMTKILEPFKAQNPDIGIYQYMDDLYVESDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSK Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70019 D4T3TCEFV 2008 South Africa C 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMEICKEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTVPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIQVRQLCKLLRGAKALTEIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70020 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQDSMTKILEPFRAKNPDIVIYQYVDDLHVGSDLEIGQHREKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGTKALTDIVPLTEEAELELAENREILKEPVQGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70021 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTIQPIQLPEKEAWTVNDIQKLVGKLNWASQIYPGVKVKQLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70022 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTILDVGDAYFSVPLDEDFSKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKILRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70023 D4T3TCEFV 2008 South Africa C 0 1 319 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKITKIGPENPYNTPVFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEIVPLTEEAELELAENREILKEPVHGVYY Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70025 D4T3TCEFV 2008 South Africa C 0 1 333 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTQNPDIVIYQYVDDLLVGSDLEIREHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGTKALTDIVPLTEEAELELAENRKVCKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70026 AZT3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEERIKALTEICEEMEREGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70028 D4T3TCNVP 2008 South Africa C 0 1 324 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRNHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVRELCKLLRGAKALTAIVPLTVEAELELAENREILKEPVHGVYYDPSKD Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70029 D4T3TCEFV 2008 South Africa C 0 1 310 PISPIETVPVKLKPGMDGPKVKQWPLTEEEIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDLIIYQYVDDLLVGSDLEIGQHRAKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPKKDSWTVNDIQKLVGKLNWASQIYSGIKVRQLCKLFRGAKALTDIVPLTEEAELEWAENREIL Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70030 D4T3TCEFV 2008 South Africa C 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKAITAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDVNFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGPHRAKIEELREHLWKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQ Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70031 D4T3TCEFV 2008 South Africa C 0 1 334 PISPIKTVPVNLKPGMDGPKVKQWPLTEEKIRALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFSEVQLGIPHPAGLKKRKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIDIYQYVDDLYVGSDLEIGQHRAKVEQLREHLLKWGLTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPDKASWTVNDIQKLVGKLNWASQIYPGIRVKHLCRLLRGAKTLTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGE Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70032 D4T3TCEFV 2008 South Africa C 0 1 333 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPEMVIYQYMDDLCVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70033 D4T3TCEFV 2008 South Africa C 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQREPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEIVPLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQDNG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70034 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALKEICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRDQNPEMVIYQYMDDLYVGSDLEIGQHRAKIEKLRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCRLLRGAKALTDVVPLTEEAELELAENREILREPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70035 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILAPFRAENPEIVIYQYVDDLLVASDLEIGQHRAKIEELRNHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENRKFRKEPVHGVYYDPSKELIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70036 AZT3TCEFV 2008 South Africa C 0 1 323 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKWKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKYPEIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGFYTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIIPLTDEAELELAENREILKEPVHGVYYDPSK Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70037 D4T3TCNVP 2008 South Africa C 0 1 309 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEKMEKEGKITKIGPENPYNTPVFVIKKKNSTEWRKLTDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMIICQYVDDLYVGSDLEIKQHRAKIEDLRDHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREI Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70038 D4T3TCEFV 2008 South Africa C 0 1 333 PISHIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAQNPEIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVTQLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70039 D4T3TCEFV 2008 South Africa C 0 1 335 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEDMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKQKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLLVGSDLEIGQHRAKIEELRKHLLQWGLTTPDKKHQKEPPFLWMGYELHPDTWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQMCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQGQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70040 D4T3TCEFV 2008 South Africa C 0 1 324 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAXFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKD Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70041 D4T3TCEFV 2008 South Africa C 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFVIKKKGSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYIDDLCVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQ Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70042 AZT3TCNVP 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVICQYVDDLYVGSDLEIGQHREKIEQLREHLLKWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRHLCKLLRGAKALTDIVPLTEEAELELAENREVLKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70043 D4T3TCNVP 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVASDLEIEQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70044 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKNNKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGAYYDPAKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70045 AZT3TCEFV 2008 South Africa C 0 1 323 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKHPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVKHLCKLLRGTKALTDIVPLTEEAELELAENREILKETVHGAYYDPSK Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70046 D4T3TCNVP 2008 South Africa C 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDEGFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTRILEPFRAQNPEIVIYQYVDDLLVGSDLEIGQHRAKIKELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGQ Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70047 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYYSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPSIFQSSMTKILEPFRAKNPELVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70048 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70049 AZT3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIAICEELEKEGKITKIGPENPYNTPVFAIKKKNSNRWRKLMDLRELNKRTQDFWEVQLGIPHPAGLHKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYVDDLYVASDLEIGQHRAKIEELREHLWKWGLYTPDQKHQKEPPLLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIQVRQLCKLLRGAKTLTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70050 AZT3TCEFV 2008 South Africa C 0 1 314 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNSPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYKVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVVSDLEIGQHRAKIGELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVPLTKEAELELAENREILKEPV Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70051 D4T3TCEFV 2008 South Africa C 0 1 335 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKRKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIQVKQLCKLLRGAKALTDIVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70052 D4T3TCEFV 2008 South Africa C 0 1 311 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKTMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILK Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70053 D4T3TCEFV 2008 South Africa C 0 1 333 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPGIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFFTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKHLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70054 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKGNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPS*NNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYSGIKVRQLCKLLRGAKALTEIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70055 D4T3TCEFV 2008 South Africa C 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTEICKEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLYEDFRKYTAFTLPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKHMCRLLRGAKALTDVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGNG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70056 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEKLRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70057 AZT3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRSKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPGIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70058 AZT3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIEKHRAKIEELREHLLKWGLTTPDKKHQKEHPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRHLCKLLRGTKALTDIVPLTEEAELELAENREVLKEPVHGVYYDPSKDLIAEILKPG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70059 AZT3TCEFV 2008 South Africa C 0 1 324 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSNRWRKLVDFRELNKRTQDFWEIQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEQLRQHLLKWGFFTPDEKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGTKALTDVVPLTEEAELELAENREILKEPVHGVYYDPSKD Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70060 AZT3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEDMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELVIYQYVDDLHVGSDLEIEQHRAKIEELREHLLRWGFTTPDEKHQKEPPFHWMGYELHPDKWTVQPIELPEKEGWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70061 D4T3TCEFV 2008 South Africa C 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTEICTELEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLRWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYQGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQ Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70062 D4T3TCNVP 2008 South Africa C 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKRKDGTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYYSIPLDESFRKYTAFTLPSINNAAPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRTKNPEIIIYQYVDDLYVASDLEIGQHRAKVEDLREHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGAYYDPSKDLIAELQKQGQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70063 D4T3TCNVP 2008 South Africa C 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFPIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLELGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILREPVHGVYYDPSKDLIAEIQKQGQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70064 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYYSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRAKNPEMVIYQYVDDLYVGSDLEIEQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70065 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRARNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENRKFLKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70066 AZT3TCNVP 2008 South Africa C 0 1 308 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKITRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSLNNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRNKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPVTLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIIPLTEEAELELAENRE Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70067 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDIIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70068 D4T3TCEFV 2008 South Africa C 0 1 312 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNERPGTRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTQEAELELAENREILKE Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70069 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNESPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70070 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIITLTEEAELELAENREILREPVHGVYYDPSKELIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70071 D4T3TCEFV 2008 South Africa C 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLPKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNAAPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTRNPDIVIYQYVDDLYVGSDLEIGQHRTKVEELRQHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEIVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGE Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70072 AZT3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPEIVIYQYVDDLYVASDLEIGQHRAKIEDLRRHLLKWGFTTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGVKALTDIVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70073 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTQNPEIVIYQYVDDLYVQSDLEIGQHRAKIEELREHLLKWGFITPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTDEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70074 D4T3TCEFV 2008 South Africa C 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEKMEKEGKITKIGPENPYNTPVFAIKKKNSTEWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQDSMTKILEPFRTQNPDMIIYQYVDDLYVGSDLEIGQHRAKIEKLREHLLKWGLTTPDKKYQKEPPLLWMGYELHPDKWTVQPILLPEKDSWTVNDIQKLVGKLNWASQIYPGIQIKQLCRLIRGAKALTDIVQLTEEAELELAENREIIKEPVHGVYYDPSKDLIAEIQKQGHG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70075 AZT3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEIC*EMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFNIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRAKNPEMVIYQYVDDLYVGSDLEIGQHRAKIDELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVTRLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70076 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDLWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKSLTDIIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70078 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVRQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYMDDLYVGSDLEIGEHRAKIEELRDHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDIIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70079 D4T3TCNVP 2008 South Africa C 0 1 333 PISPIEIVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPNIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPINLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVRNLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70080 D4T3TCEFV 2008 South Africa C 0 1 319 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYMDDLYVGSDLEIGQHRAKIEELRDHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYY Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70081 AZT3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSMTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLCVGSDLEIGQHRAKIDELREHLLKWGLTTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEIVPLTEEAELELAENREVXKEPVHGVYYDPSKDLIAELQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70082 AZT3TCEFV 2008 South Africa C 0 1 325 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPSIFQSSMTRILEPFRTQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDVVPLTEEAELELAENREILKEPVHGVYYDPSKDL Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70085 D4T3TCEFV 2008 South Africa C 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTGEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNKTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKKNPDIGIYQYVDDLYVESDLEIEQHRAKIKELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIQVRQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQGNG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70086 AZT3TCEFV 2008 South Africa C 0 1 308 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTAICEEMEKEGKITRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILRPFRAQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENRE Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70087 D4T3TCEFV 2008 South Africa C 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALREICDEMEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKRRRSMTVLDVGDAYFSVPLDENFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRQGNPEIDIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGLTTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYKGIKVKQLCKLLKGAKALTDIVTLTEEAELELAENRKICKEPVHGVYYDPTKDLIAEIQKQGEG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70088 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTKEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRRHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70089 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEMVIYQYMDDLYVGSDLEIGQHRAKVEKLREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70091 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPYRAQNPEMVIYQYMDDLYVGSDLEIGQHRAKVEKLREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70092 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPELVIYQYVDDLYVGSDLEIGQHRAKIEKLREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70093 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLPKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMIIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIIPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70094 D4T3TCEFV 2008 South Africa C 0 1 321 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDP Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70095 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTIQPIQLPEKESWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70096 D4T3TCEFV 2008 South Africa C 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGLPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPDIVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENRKVLKEPVHGVYYDPSKDLIAEIQKQGQ Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70098 D4T3TCEFV 2008 South Africa C 0 1 319 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIKALTEICAEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGXKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAVFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDVVPLTEEAELELAENREILKEPVHGVYY Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70099 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVVELTEEAQLELAENREILKEPVHGVYYDPSKELIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70100 D4T3TCEFV 2008 South Africa C 0 1 334 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTAICDEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFSEVQLGIPHPAGLEKNKSVTVLDVGDAYFSIPLDENFRKYTAFTIPSVNNATPGTRYQYNVLPQGWKGSPAIFQSSMTKILQPFRTKNPDIVIYQYVDDLYVGSDLEIGQHRARVEELRKHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVKNLCKLLRGAKALTDIIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQGQ Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70101 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPELVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPLFWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70102 D4T3TCEFV 2008 South Africa C 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTREKIKALMAICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKRKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNNTPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPDIEIYQYVDDLYVASDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKYLCRLLRGTKALTDIVPLTEEAELELAENREIFKEPVHGVYYDPSKDLIAEIQKQGNG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70103 D4T3TCEFV 2008 South Africa C 0 1 323 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPEIVIYQYMDDLYVGSDLEIEQHREKVEQLREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVRQLCKLLRGAKALTDIVSLTAEAELELAENREILKEPVHGAYYDPSK Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70104 D4T3TCEFV 2008 South Africa C 0 34 335 ITEICKEMEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYSGIKVRQLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQGQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70105 D4T3TCEFV 2008 South Africa C 0 1 319 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALKEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYMDDLYVGSDLEIGQHRAKIEKLRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGAYY Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70106 AZT3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQATMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKVEELRAHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPEKESWTVNDIQKLVGKLNWASQIYPGIQVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70107 D4T3TCNVP 2008 South Africa C 0 1 333 PISPIETIPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLHENFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70108 D4T3TCEFV 2008 South Africa C 0 1 333 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRRSMTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKYPDIDIYQYVDDLYVGSDLEIGQHRARIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPNKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKQPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70109 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEDMEKEGKITKIVPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHREKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70110 AZT3TCEFV 2008 South Africa C 0 1 321 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTEICKEMEKEGKITKIGPDNPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPDLVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLSTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTINDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIIPLTEEAELELAENREILKEPVHGVYYDP Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70111 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKRNKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRARNPEMVIYQYMDDLYVGSDLEIGQHRAKIKELREHLLRWGFTTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKHLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70113 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVNLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGIKKNKSVTILDVGDAYFSVPLDESFRKYTEFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMKKILDPFRARNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDVVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70115 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSLNNETPGIRYQYNVLRQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIRQHRAKIEELRDHLLKWGFYTPDKKHQKEPPFLWMGYELHSDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIRVKNLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70116 D4T3TCEFV 2008 South Africa A 0 1 309 PISPIETVPVTLKPGMDGPRVKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPIFAIKKKDGIKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRSQNPEIIIYQYVDDLYVGSDLEIGQHRAKVEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLKGAKALTDIVALTEEAELELAENREI Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70117 AZT3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTVLDVGDAYFSIPLDESFRKYTAFTIPSINNAAPGTRYQYNVLPQGWKGSPAIFQSSMLKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGKHRAKVEELREHLWKWGLTTPDKKHQKEPPFLWMGYELHPDNWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENRKVCKEQVHGAYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70118 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRARNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPKKDSWTVNDIQKLVGKLNWASQIYPGIKVKQMCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70119 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKAMTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70120 D4T3TCEFV 2008 South Africa C 0 1 324 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPAKD Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70121 D4T3TCEFV 2008 South Africa C 0 1 319 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSSKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEDLREHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYY Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70122 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYVDDLYVGSDLEITQHRAKIEELREHLLRWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQMCKLLRGTKALTDVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70123 D4T3TCEFV 2008 South Africa C 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDVQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGQ Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70124 AZT3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLCVGSDLEIGQHRAKIEELRAHLWKWGFYTPDKKHQKEPPFLWLGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70125 D4T3TCNVP 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKINALKAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLHKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQFSMTKILEPFRAKYPEIIIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGVKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70126 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSITVLDVGDAYFSVPLDENFRKYTAFTIPSTNNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKETQEIVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKEDWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70127 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTVICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIQVKQMCKLLRGAKALTDIVQLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70128 AZT3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALIEICDDMEKEGKITKIGPENPYNTPVFAIKKKNSNRWRKLVDFRELNKRTQEFSEVQLGIPHPGGLEKRKSMTVIDVGDAYFSIPLHEDFRKYTAFTIPSINNATPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYVDDLYVGSDLEIGQHRAKVEKLREHLLKWGLFTPDQKHQKEPPLLWMGYELHPDKWTVQPIQLPNKNSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70129 D4T3TCEFV 2008 South Africa C 0 1 323 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKVEDLRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSK Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70130 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEELEKEGKITKIGPENPYNTPVFVIKKKDGTKWRKLTDFRELNKRTQDFWEVQLGIPHPAGLRQNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFFTPDKKLQKEPPFLWLGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREVFKEPVHGVYYDPSKDLIAELQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70131 AZT3TCEFV 2008 South Africa C 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVASDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70132 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALAAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKNKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHSDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70133 AZT3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAFFSVPLDKEFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRARNPELVIYQYMDDLYVGSDLEMGQHRAKIEELREHLLRWGFTTPDKKHQKEPPLLWMRYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVTQLCRLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70134 AZT3TCEFV 2008 South Africa C 0 1 321 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKIEKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSLTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQASMTKILRPFREQNPDIVIYQYVDDLCVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTDEAELELAENREILKEPVHGVYYDP Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70135 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRRKSMTVLDVGDAYFSVPLDKSFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSRAIFQSSMTKILEPFRKQNPEIDIYQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVTLTEEAELELAENRKVXKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70136 D4T3TCEFV 2008 South Africa C 0 1 334 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALREICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFYTPDKKHQKEPPFHWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQ Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70137 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSMTVLDVGDAYFSVPLDVDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEMVIYQYVDDLYVGSDLEIGQHRAKIDELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70138 D4T3TCEFV 2008 South Africa C 0 1 334 PISPIDTVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPELVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGVKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGE Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70139 AZT3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYVDDLYVSSDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFQWLGYELHPDKWTVQPIKLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRNLCKLLRGAKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70140 D4T3TCEFV 2008 South Africa C 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKLMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNESPGARYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPDIDIYQYMDDLYVGSDLEIEQHRAKIEQLREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKENWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENRRILREPVHGVYYDPSKDLIAEIQKQGEG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70141 D4T3TCNVP 2008 South Africa C 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKRKDGTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYYSIPLDESFRKYTAFTLPSINNAAPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRTKNPEIIIYQYVDDLYVASDLEIGQHRAKVEDLREHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGAYYDPSKDLIAELQKQGQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70142 AZT3TCEFV 2008 South Africa C 0 1 319 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSDKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIIQYMDDLYVGSDLEIGQHRAKIEELRNHLLKWGFFTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYY Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70143 AZT3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICQELEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLDEGFRKYTAITIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLLVGSDLEIGQHRAKVEELREHLWKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKHLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70144 D4T3TCNVP 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIRKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPEMVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70145 D4T3TCEFV 2008 South Africa C 0 1 333 PISSIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEELEKDGKITKIGPENPYNTPIFAIKKKDGTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVMDIGDAYFSIPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPELVIYQYVDDLYVGSDLEIGQHRAKIDELREYLWKWGFYTPDKKYQKEPPIIWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDVVPLTEEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70146 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEELEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTVPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPELDIYQYVDDLYVGSDLEIGQHRAKIKELRDHLWKWGFFTPDEKYQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLIRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70147 D4T3TCEFV 2008 South Africa C 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQTIKLPDKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVPLTKEAELELAENRKVLTEPVHGVYYDPSKELIAEIQKQEHG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70148 D4T3TCEFV 2008 South Africa C 0 1 333 PISSIETVPVKLKPGMDGPMVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70149 D4T3TCEFV 2008 South Africa C 0 1 314 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELRKHLLKWGFTTPDKKHQKEPPFRWMGYELHPDTWTVQTIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVRSLCKLLRGAKALTDIVPLTKEAELELAENREILKEPV Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70150 AZT3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLSEEKLKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEIQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRARNPELVIYQYIDDLYVGSDLELGQHRAKIEELRKHLLKWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPTKELIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70151 D4T3TCEFV 2008 South Africa C 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQASMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRTHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGEG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70152 AZT3TCNVP 2008 South Africa C 0 1 319 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPDNPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDPEFRKYTAFTIPSVNNERPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYVDDLYVASDLEIGKHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTREAELELAENREILKEPVHGVYY Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70153 D4T3TCEFV 2008 South Africa C 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKRKDGTKWRKLIDFRELNKRTQDFCEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLHEGFRKYTAFTIPSINNKTPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPELDIYQYMDDLCVGSDLEIGQHRTKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGYG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70154 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETIPVQLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELEIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGVKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70155 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTILDVGDAYFSVPLDENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKHPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKEDWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70156 AZT3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTKEKIKALTEICDEMEKDGKITKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGLPHPAGLEKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHREKVKELREHLLKWGFYTPEQKHQKEPPFLWMGYELHPDKWTVQPIQLPEKEDWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLIKGTKALTEIVPLTEEAELELAENREVLKEPVHGVYYDPAKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70157 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILKPFREQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLVAEVQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70158 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGVDGPKVKQWPLTEEKIKALTEICEELEKEGKITKIGPENPYNTPIFAIKKKGGTRWRKLMDFRELNKRTQDFWEVQLGIPHPAGLQRSKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLELGQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGVKALTEVVPLTEEAELELAENRKVFKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70159 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALMEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPXIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLRWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEIVTLTEEAELELAENREILKEPVHGAYYDPSKDLIAEVQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70161 D4T3TCNVP 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70162 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPRVRQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNATPGIRYQYNVLPQGWKGSPAIFQASMIKILEPFRTQNPELIIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKHLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70163 AZT3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAANPEIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDIWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDIIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70164 AZT3TCEFV 2008 South Africa C 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLSTPDKKHQKEHPFLWLGYELHPDKWTVQPILLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVTHLCKLLRGTKALTDIVPLXEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGK Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70165 AZT3TCEFV 2008 South Africa C 0 1 333 PISPIATVPVKLKPGMDGPRVKQWPLTEDKIKALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIQVKNLCRLLRGAKALTDIVLLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70166 D4T3TCNVP 2008 South Africa C 0 1 323 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTLPSINNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRTKIKELREHLLKWGFTTPDKKHQEEPPLLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIQVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSK Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70167 D4T3TCEFV 2008 South Africa C 0 1 312 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTVLDVGDAYFSVPLDASFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGHELHPDKWTVQPISLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQRCKLLRGVKALTDIVPLTEEAELELAENREILKE Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70168 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTKEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPELVIYQYVDDLYVASDLEIGQHRAKIEELRDHLLKWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPTKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70169 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYYSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPMGWKGSPAIFQSSMTKILEPFRTKNPELVIYQYIDDLHVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPTKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREVLREPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70170 D4T3TCEFV 2008 South Africa C 0 1 309 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIIPLTEEAELELAENREI Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70171 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIKTVPVQLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPEIDIYQYVDDLLVGSDLEIGQHRAKIEELREHLLQWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70172 D4T3TCEFV 2008 South Africa C 0 1 308 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVSSDLEIGQHRAKIEELRDHLLKWGFFTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLKGTKALTDIVPLTEEAELELAENRE Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70173 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKISKIGPENPYNTPVFAIRKKGSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELIIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70174 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPDIVIYQYVDDLYVASDLEIGQHRAKVEELRDHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLKGVKALTDIVPLTEEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70175 D4T3TCEFV 2008 South Africa C 0 1 317 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKEMEKEGKIEKIGPENPYNTPIFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPELVIYQYVDDLYVGSDLEIEQHRAKIEQLREHLLKWGLTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGV Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70176 AZT3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEELEKEGKITKIGPENPYNTPIFAIKKKGGTRWRKVVDFRELNKRTQDFWEVQLGIPHPAGLPKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVIYQYVDDLYVSSDLEIGQHRAKIEELREHLLKWGLTTPDQKHQKEPPFHWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENRKVLKEPVHGVYYDPSKELIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70177 D4T3TCEFV 2008 South Africa C 0 1 322 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEELEREGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEMVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTANDIQKLVGKLNWASQIYPGIKVKHLCRLLGGTKALTDIVPLTEEAELELAENREILKEPVHGAYYDPS Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70178 D4T3TCEFV 2008 South Africa C 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMEICKEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTVPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIQVRQLCKLLRGAKALTEIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70179 D4T3TCEFV 2008 South Africa C 0 1 333 PISSIETIPVKLKPGMDGPKVKQWPLTEEKINALKAICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIVQHRAKLEELREHLLKWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKTLTDIVPLTEEAELELAENREIRKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70180 D4T3TCEFV 2008 South Africa C 0 1 333 PISSIETIPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTVLDVGDAYFSVPLYEDFRKYTAFTVPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70181 D4T3TCNVP 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYIGSDLELGQHRAKVEELRQHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGVKALTDIVPLTKEAELELAENREILKETVHGAYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70182 D4T3TCEFV 2008 South Africa C 0 1 333 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTQNPDIIIYQYVDDLLVGSDLEIGEHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70183 D4T3TCEFV 2008 South Africa C 0 1 310 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNKTPGIRYQYNVLPQGWKGSPAIFQSSMVKILEPFRAQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLIRGTKALTDIVPLTEEAELELAENREIL Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70184 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILDPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIQVKQLCKLLRGTKALTDIIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70185 D4T3TCEFV 2008 South Africa C 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLAKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPDIVIYQYVDDLYVSSDLEIGQHRAKIDELRNHLLKWGFYTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRCLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70186 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKAITEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKLNPNIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLSTPEKKYQKEHPFLWMGYELHPDKWTVQPIQLPNKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70188 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVKQLCKLLRGAKALTDIVPLTEEAELELAENRKILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70189 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSVNNESPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVQNPDIVIYQYVDDLYVGSDLEIGQHRAKIDELRKHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPTKELIAELQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70190 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILAPFRAENPEIVIYQYVDDLLVASDLEIGQHRAKIEELRNHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENRDFFKEPVHGVYYDPSKELIAEIQNQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70191 D4T3TCEFV 2008 South Africa C 0 1 323 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEREGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNRRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQISMTKILEPFRAQNPELVIYQYMDDLYVGSDLEIGQHRAKIEKLRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSK Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70192 D4T3TCEFV 2008 South Africa C 0 1 319 PISPIETVPVKLKSGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLCVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQMCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYY Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70193 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSIQVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHSDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVTQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70194 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICRRWEKEGKISKIGPENPYNTPVFVIKKKDSNKWRKLTDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIIIYQYVDDLCVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVLGVYYDPSKELIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70195 AZT3TCEFV 2008 South Africa C 0 1 327 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEELEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEIQLGIPHPSGLKXRQSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRAQNPEIIIYQYVDDLLVGSDLEIGQHRAKIKELREHLLRWGLYTPDQKHQKEPPFHWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGAKTLTEIVPLTEEAELELAENREILKEPVHGVYYDPAKELIA Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70196 D4T3TCEFV 2008 South Africa C 0 1 329 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTRILEPFRARNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKEIIAEI Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70197 AZT3TCEFV 2008 South Africa C 0 1 333 PISPIETAPVKLKPGMDXPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILAPFRAKNPEITIYQYVDDLYVSSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQMCKLLRGTKALTDVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70198 D4T3TCEFV 2008 South Africa C 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEVVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKKSWTVNDIQKLVGKLNWASQIYSGIKVKQLCRLLRGAKALTDIVPLTEEAELELAENREILREPVHGVYYDPSKDLIAEIQKQGE Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70199 D4T3TCEFV 2008 South Africa C 0 1 325 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICKEMEEEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKXSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQSTMTKILEPFRAKNPEIVIYQYMDDLYVASDLEIEQHRAKIEELREHLLKWGLTTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVPLTKEAELELAENREILKEPVHGVYYDPSKEL Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70200 D4T3TCEFV 2008 South Africa C 0 1 303 PISHIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTRILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQL*KLLRGAKALTDIVPLTEEAELEL Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70201 AZT3TCEFV 2008 South Africa C 0 1 333 PICPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEELEKDGKITKIGPDNPYNTPIFAIKKKNSDKWRKVVDFRELNKRTQDFWEIQLGIPHPAGLKQNKSVTVLDMGDAYFSVPLDESFRKYTAFTIPSINNRTPGIRYQYNVLPQGWKGSPSIFQASMTKILEPFKKQNPDLEIYQYVDDLYVGSDLEIGQHRAKIKELRDHLWKWGFYTPDKKHQKEPPFLWLGYELHPDKWTVQPICLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKHLCKLLRGAKALTDIVPLTEEAELELAENREIQKEPVHGVYYDPSKELIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70202 AZT3TCEFV 2008 South Africa C 0 1 335 PISTIETVPVKLKPGMDGPRVKQWPLTAEKIKALTEICKEMEKEGKITKIGPENPYNTPIFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAYFSVPLDESFRKYTAFTVPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFSTKNPEIDIYQYVDDLYVGSDLEIEQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLIRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQEHG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70203 D4T3TCNVP 2008 South Africa C 0 1 335 PIRPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPLRTKNPDMVIYQYIDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVTQMCKLLRGAKALTDIVPLTVEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQGDG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70204 D4T3TCEFV 2008 South Africa C 0 1 322 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVIYQYVDDLCVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGTKALTEIVPLTEEAELELAENREILKEPVHGVYYDPS Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70205 D4T3TCEFV 2008 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALRAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPGIVICQYVDDLYVASDLELGQHRAKIEELREHLLKWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIRVRHLCKLLKGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70207 D4T3TCEFV 2008 South Africa C 0 1 308 PISPIPTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEELEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKRKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQDSMTRILEPFRAQNPEIVIYQYVDDLYVASDLEIGQHRAKIEKLREHLLRWGFYTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENRE Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70208 D4T3TCEFV 2008 South Africa C 0 1 326 PISPIETVPVKLKPGTDGPKVKQWPLTREKIEALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQYSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLGWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGTKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLI Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70209 D4T3TCEFV 2008 South Africa C 0 1 304 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICNEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNATPGIKYQYNVLPQGWKGSPAIFQSSMIKILEPFRTKNPDIVIYQYMDDLYVGSDLEIEQHRTKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVRQLCKLLRGAKALTDIVPLTEEAELELA Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70210 AZT3TCEFV 2008 South Africa C 0 1 308 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQREPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENRE Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1748 70211 D4T3TCEFV 2008 South Africa C 0 1 323 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMVKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGVKVRNLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPIK Wallis, CL 2009 19801944 JAIDS Varied HIV drug resistance patterns among patients on failing antiretroviral therapy in the South African national roll-out programme. 1750 70304 D4T3TCNVP 2006 Cameroon CRF02_AG 0 1 430 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKDICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTNNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVRQLAEAVQKIVTESVVIWGKAPKFRLPIQRETWETWWTEYWQATCIPEWEFVNTPPLVKLWYQLE Burda, ST 2010 20029816 J Med Virol HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naive to HAART in Cameroon. 1750 70305 D4T3TCNVP 2006 Cameroon CRF02_AG 0 1 440 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICADMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSVNNETPGTRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPDIVIYQYMDDLYVGSDLEIGQHREKIQELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKIKQLCKLIRGAKALTEVVALTEEAELELAENREILKEPVHGVYYDPAKDLVAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKRRSAHTNDVKQLTEVVQKVTVESIVIWGKTPKFRLPIQKETWEAWWMDYWQATWIPEWEFVNTPPLVKLWYQLEKDPIIGAETF Burda, ST 2010 20029816 J Med Virol HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naive to HAART in Cameroon. 1750 70308 D4T3TCNVP 2006 Cameroon CRF02_AG 0 1 440 PISTIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPAKDLVAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVRQLVEVVQKVAIESIVIWGKTPKFRLPIQKETWETWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKDPIMGAETF Burda, ST 2010 20029816 J Med Virol HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naive to HAART in Cameroon. 1750 70309 D4T3TCNVP 2006 Cameroon CRF02_AG 0 1 440 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICSEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTANPEIVIYQYMDDLYVGSDLEIGQHREKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLSEEAELELAENREILKEPVHGVYYDPTKDLVAEVQKQGQDQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVRQLTEVVQKIATESIIIWGKTPKFRLPIQKETWEAWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKDPIVGAETF Burda, ST 2010 20029816 J Med Virol HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naive to HAART in Cameroon. 1750 70311 D4T3TCNVP 2006 Cameroon CRF02_AG 0 1 440 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICLEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGFKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKTNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKRRSTHTNDVKQLAEVVQKVTTESIVIWGKTPKFRLPIQKETWETWWMEYWQATWIPDWEFVNTPPLVKLWYQLEKDPIAGAETF Burda, ST 2010 20029816 J Med Virol HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naive to HAART in Cameroon. 1750 70317 D4T3TCNVP 2006 Cameroon CRF02_AG 0 1 425 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPAKDLVAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVKQLTEVVQKVALESIVIWGKTPKFKLPIQKETWEAWWMEYWQATWIPEWEFVNTPPLVKL Burda, ST 2010 20029816 J Med Virol HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naive to HAART in Cameroon. 1750 70318 D4T3TCNVP 2006 Cameroon CRF02_AG 0 1 424 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTDICLEMEKEGKISRIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYYSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPMGWKGSPAIFQASMTKILEPFRTKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKYQKDPPLLWMGYELHPDKWTVQHIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLIRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYEPTKDLVAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVKQLTEVVQKVATESIVIWGKTPKFRLPIQKETWETWWMEYWQATWIPEWEFVNTPPLVK Burda, ST 2010 20029816 J Med Virol HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naive to HAART in Cameroon. 1750 70321 D4T3TCNVP 2007 Cameroon D 0 1 440 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICADMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFKKQHPELVICQYVDDLYVGSDLEIGRHREIIEKLREHLLRWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEVVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGESQWSWQIYQEPFKILKTGKYAKMRGAHTNDVKQLTEAVQQIARESIVIWGKTPKFRLPIQKETWETWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIIGAETF Burda, ST 2010 20029816 J Med Virol HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naive to HAART in Cameroon. 1750 70322 D4T3TCNVP 2007 Cameroon CRF02_AG 0 1 440 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKIEKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPEMVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPITLPEKDSGTVNDIQKLVGKLNWASQIYPGIKIKQLCKXXRGAKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQSQWTWQIYQEPFKNLKTGKYAKMRGAHTNDVKQLTEAVQKIATESIVIWGKTPKFRLPIQKETWEAWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGAETF Burda, ST 2010 20029816 J Med Virol HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naive to HAART in Cameroon. 1750 70323 D4T3TCNVP 2007 Cameroon CRF02_AG 0 1 440 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTRILEPFRTKNPEMVIYQYMDDLYVGSDLEIGPHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLKWASQIYPGIKVRQLCKLLRGAKALTDVVTLTEEAELELAENREILKEPVHGVYYDPAKDLVAEIQKQGQDQWTYQIFQEPFKNLKTGKYAKKRSAHTNDVRQLTEVVQKVATESIVIWGKTPKFRLPIQKETWEAWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETF Burda, ST 2010 20029816 J Med Virol HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naive to HAART in Cameroon. 1750 70326 D4T3TCNVP 2007 Cameroon CRF02_AG 0 1 523 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICVEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRSHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQQIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRHLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKRRSAHTNDVKQLTEVVQKIAIESIVIWGKTPKFRLPIQKETWEAWWMEYWQATWIPDWEFVNTPPLVKLWYQLEKDPIVGAETFYVDGAANRETKLGKAGYVTDKGRQKIVSLNETTNQKTELHAIYLALQDSGSEVNIVTDSQYALGIIQAQPDRSESELVNQIIE Burda, ST 2010 20029816 J Med Virol HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naive to HAART in Cameroon. 1750 70327 D4T3TCNVP 2007 Cameroon D 0 1 527 PISPIETVPVKLKXGMDGPKVKQWPLTEEKIKALTDICTQMEEEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPITLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEVVPLTEEAELELAENREILREPVHGVYYDPSKDLIAEIQKQGQGQWTWQIYQEPFKNLKTGKYAKMRGAHTNDVKQLTEAVQKISTESIVIWGKTPKFRLPIQKETWEAWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKDPIVGAETFYVDGAANRETKLGKAGYVTDRGRQKIVPFTDTTNQKTELQAINLALQDSGPEVNIVTDSQYALGIIQAQPDKSESELVTQIIEQLIK Burda, ST 2010 20029816 J Med Virol HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naive to HAART in Cameroon. 1750 70328 D4T3TCNVP 2007 Cameroon CRF02_AG 0 1 440 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALPDICLEMEKEGKISRIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQTSMTKILEPYRTRNPEMVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKXQKEPPFLWMGYELHPDKWTVQHIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPAKDLVAEIQKQGQGQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVKQLTEVVQKVATESIVIWGKTPKFRLPIQKETWETWWMEYWQATWIPDWEFVNTPPLVKLWYQLEKDPIIGAETF Burda, ST 2010 20029816 J Med Virol HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naive to HAART in Cameroon. 1750 70329 D4T3TCNVP 2007 Cameroon CRF02_AG 0 1 440 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKIVDFPELNKRTQDFWEVQLGIPHPAGLKKKKSATVIDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELRQHLLKWGFYTPDEKHQKEHPLLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVRQLCKLLRGAKALTEVVTLTEEAELELAENREILKEPVHGVYYDPVKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYARKRSAHTNDVKQLTEVVQKVATESIVLWGKTPKFRLPIQKETWETWWQEYWQATWIPEWEFVNTPPLVKLWYQLEKDPIEGVETF Burda, ST 2010 20029816 J Med Virol HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naive to HAART in Cameroon. 1750 70332 D4T3TCNVP 2006 Cameroon CRF02_AG 0 1 440 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICKEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRQLNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDPEFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYAGIQVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYEPTKELVAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKRRSAHTNDVKQLTEVVQKVAVESIVIWGKTPKFKLPIQKETWEAWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKDPILGAETF Burda, ST 2010 20029816 J Med Virol HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naive to HAART in Cameroon. 1750 70336 D4T3TCNVP 2006 Cameroon G 0 1 197 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIGQ Burda, ST 2010 20029816 J Med Virol HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naive to HAART in Cameroon. 1750 70340 D4T3TCNVP 2006 Cameroon D 0 1 197 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFKKQNPELVIYQYMDDLYVGSDLEIEQ Burda, ST 2010 20029816 J Med Virol HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naive to HAART in Cameroon. 1750 70347 D4T3TCNVP 2006 Cameroon G 0 1 197 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTDICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGVRYQYNVLPQGWKGSPAIFQASMIKILEPFRTKNPEMVIYQYMDDLYVASDLEIGQ Burda, ST 2010 20029816 J Med Virol HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naive to HAART in Cameroon. 1750 70349 D4T3TCNVP 2007 Cameroon G 0 1 197 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTDICLEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYMDDLYVGSDLEIGQ Burda, ST 2010 20029816 J Med Virol HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naive to HAART in Cameroon. 1750 70350 D4T3TCNVP 2006 Cameroon U 0 1 197 PISPVDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICADMEKEGKISKIGPENPYNTPVFVIKKKDGTKWRKLIDLRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYYSVPLDKSFRKYTAFTIPSINNETPRIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLLVGSDLEIGK Burda, ST 2010 20029816 J Med Virol HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naive to HAART in Cameroon. 1750 70351 D4T3TCNVP 2006 Cameroon G 0 1 197 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICLEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYMDDLYVGSDLELGQ Burda, ST 2010 20029816 J Med Virol HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naive to HAART in Cameroon. 1760 75917 AZT3TCEFV 2007 South Africa C 0 38 247 CRRMEKEGKIEKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRAKNPEIVIYQYVDDLYVGSDLEIEQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Orrell, C 2009 19578237 Antivir Ther HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. 1760 75918 D4T3TCEFV 2006 South Africa C 0 38 247 CEEMEKEGKITKIGPDNPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPTIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIEQHRAKIEQLREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Orrell, C 2009 19578237 Antivir Ther HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. 1760 75919 D4T3TCEFV 2007 South Africa C 0 38 247 CEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIKELREHLLRWGFTTPDKKHQKDPPLLWMGYELHPDKWTVQPIQLP Orrell, C 2009 19578237 Antivir Ther HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. 1760 75920 D4T3TCEFV 2006 South Africa C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGMRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Orrell, C 2009 19578237 Antivir Ther HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. 1760 75921 D4T3TCEFV 2006 South Africa C 0 38 247 CTEIGEEGKITKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKHPDIVIYQYVDDLHVGSDLDIGQHRAKVEELRAHLLKWGFTTPDKKHQKEPPFLWMGHELHPDKWTVQPIQLP Orrell, C 2009 19578237 Antivir Ther HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. 1760 75922 D4T3TCEFV 2007 South Africa C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Orrell, C 2009 19578237 Antivir Ther HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. 1760 75923 D4T3TCEFV 2006 South Africa C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPEIVIYQYMDDLYVGSDLEIGQHRAKVEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Orrell, C 2009 19578237 Antivir Ther HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. 1760 75924 D4T3TCEFV 2005 South Africa A 0 38 247 CMEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIIYQYVDDLYVASDLEIGQHRTKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLP Orrell, C 2009 19578237 Antivir Ther HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. 1760 75925 D4T3TCNVP 2005 South Africa C 0 38 247 CEEMEKEGKITKIGPDNPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPNPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAQNPEIVIYQYMDDLHVGSDLEIGEHRAKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Orrell, C 2009 19578237 Antivir Ther HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. 1760 75926 D4T3TCEFV 2006 South Africa C 0 38 247 CDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDVDFRKYTAFTIPSLNNETPGISYQYNVLPQGWKGSPAIFQSSMTKILAPFRAKNPEIIIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Orrell, C 2009 19578237 Antivir Ther HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. 1760 75927 D4T3TCEFV 2005 South Africa A 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTRILEPFRSQNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELRSHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Orrell, C 2009 19578237 Antivir Ther HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. 1760 75928 D4T3TCEFV 2005 South Africa C 0 38 247 CEDMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLRWGFTTPDQKHQKEPPFLWLGYELHPDKWTVQPIQLP Orrell, C 2009 19578237 Antivir Ther HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. 1760 75929 D4T3TCEFV 2006 South Africa C 0 38 247 CEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDENFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKKNPDIVIYQYVDDLYVGSDLEIGQHREKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Orrell, C 2009 19578237 Antivir Ther HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. 1760 75930 D4T3TCEFV 2007 South Africa C 0 38 247 CTEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRGHLLKWGFTTPDKKHQKEPHFLWMGYELHPDKWTVQPIQLP Orrell, C 2009 19578237 Antivir Ther HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. 1760 75931 D4T3TCEFV 2006 South Africa C 0 38 247 CEEMEKEGKITKIGPENPYNTPIFAIKKKDGKKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEHPFLWLGYELHPDKWTVQPIQLP Orrell, C 2009 19578237 Antivir Ther HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. 1760 75932 D4T3TCEFV 2008 South Africa C 0 38 247 CKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVEFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNESPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPGVVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Orrell, C 2009 19578237 Antivir Ther HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. 1760 75933 D4T3TCEFV 2006 South Africa C 0 38 247 CEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQASMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Orrell, C 2009 19578237 Antivir Ther HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. 1760 75934 D4T3TCEFV 2006 South Africa C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSMNNEAPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIRQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Orrell, C 2009 19578237 Antivir Ther HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. 1760 75935 D4T3TCEFV 2007 South Africa A 0 38 247 CMEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQSKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIIYQYVDDLYVASDLEIGQHRTKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLP Orrell, C 2009 19578237 Antivir Ther HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. 1760 75936 D4T3TCEFV 2004 South Africa C 0 38 247 CEEMEKEGKITKIGPDNPYNTPIFAIKRKGSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAQNPEIVIYQYMDDLHVGSDLEIGEHRAKIEELRSHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Orrell, C 2009 19578237 Antivir Ther HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. 1785 73869 AZT3TCNVP 2004 Russia G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTELEKEGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKQKRSVTVLDVGDAYFSIPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVICQYMDDLYVGSDLEIEQHRAKIEELREHLWKWGFYTPDKKHQKEPPFLWMGYELHPDKWKVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKIKQLCKLIKGTRALTDIVPLTAEAELELAENREILKEPVHGAYYDPSKELIAEVQKQG Knops, E 2010 20430786 J Antimicrob Chemother Evolution of protease inhibitor resistance in the gag and pol genes of HIV subtype G isolates. 1798 77509 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSIPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRAKVEELRAHLLSWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77510 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSTNNETPGTRYQYNVLPQGWKGSPAIFQSSMIKILEPFRIKNPEMVIYQYVDDLLVGSDLEIGQHRAKVEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDRWAVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77511 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDIGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIEICQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKYQKEPPFRWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77512 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDGSKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEVVICQYMDDLYVGSDLEIGQHRAKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77513 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISRIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLNKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRMKNPEMVICQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFFTPEQKHQKEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77514 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKELEEEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFFTPDKKYQKEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77515 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKRKDSSKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAFFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77516 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 239 CKEMEQEGKISKIGPENPYNTPVFAIKKKDGNKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYYSVPLDESFRKYTAFTIPSMNNETPGIRYQYNVLPMGWKGSPGIFQSSMTRILEPFRIKNPEMVICQYMDDLYVGSDLEIEQHRAKIEELRAHLLSWGFYTPDKKHQKEPPFLWMGYELHPDKW Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77517 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPEITIYQYVDDLYVSSDLEIGQHRIKVEELRAHLLSWGFITPDQKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77518 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKSKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPEIIIYQYVDDLYVASDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77519 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEIEEEGKISRIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINIETPGIRYQYNVLPQGWKGSPAIFQHSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77520 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKKNPEIVIYQYVDDLYVSSDLEIGQHRTKINELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPITLP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77521 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CNEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDKSFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKLKNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77522 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNRSVTILDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77523 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVASDLEIGQHRTKVEELRKHLLSWGFSTPDKKYQKEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77524 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CTEMEEEGKISKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKRKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIVQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77525 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILDPFRKKNPEMVIYQYMDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77526 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CNEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEIVICQYMDDLYVASDLEIGQHRAKIEELRAHLSSWGFTTPDKKHQKEPPFHWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77527 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKNSTEWRKLSDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDIVIYQYVDDLYVASDLEIGQHRLKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77528 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRAHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77529 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLLDFRELNKRTQDFWEVQLGIPHPAGLKNNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYMDDLYVASDLEIGQHRVKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77530 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEIIIYQYVDDLYVASDLEIGQHRAKIEELRSHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77531 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CTEMEEKGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVASDLEIGQHREKIEELRAHLLNWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77532 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CREMEEEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPEKKHQKEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77533 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77534 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKTKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEVVVYQYMDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77535 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CREMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77536 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLHESFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLDIGQHRAKVDELRAHLLSWGFTTPDRKYQKEPPFRWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77537 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CNEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRAHLWSWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77538 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLLIGSDLEIGQHRAKIEELRAHLLSWGFYTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77539 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWKVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77540 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEMIIYQYVDDLYVASDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPEKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77541 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKAMEEEGKISKIEPENPYNTPVFVIRNKDKTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDRKHQKEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77542 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMAKILEPFRAKNPEMIICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77543 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77544 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CTEMEEEGKISKIGPENPYNTPIFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWLGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77545 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEAEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILAPFRAKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77546 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEAEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPELVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFYTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77547 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77548 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKLKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFFTPDTKHQKEPPFRWLGYELHPDTWTVQPIVLP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77549 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDGNRWRKVVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKIKNPEMVIYQYVDDLYVGSDLEIGQHRAKIKELRTHLLKWGFTTPDQKHQKEHPFLWLGYELHPDKWTVQPIVLP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77550 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAINKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRIKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDQKHQKEHPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77551 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CREMEAEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPELVIYQYVDDLYVGSDLEIAQHRTKIEELRAHLLSWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIALP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77552 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDQKHQKEHPFHWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77553 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPIFAIKKKGGTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPEMVIFQYVDDLYVGSDLEIGEHRAKIEELRAHLLRWGFFTPDEKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77554 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPTIFQSSMTKILEPFRTKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77555 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKGGTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLHKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQTSMTKILEPFRIKNPEMVIYQYVDDLYVASDLEIGQHRAKIEELRAHLMSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77556 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CNEMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSITVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEVVIYQYVDDLYVASDLEIGQHRAKIEELRAHLLNWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77557 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CTEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRMKIEELRAHLLSWGFTTPDKKHQKEHPFLWMGYELHPDRWTVQPIQLP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77558 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CTELEEDGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYVDDLYVASDLEIGQHRTKIEELRQHLLKWGFYTPDKRHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77559 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CEEMEKDGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIEQHRAKIDELRAHLWTWGFYTPDKKHQKEPPFLWLGYELHPDKWTVKPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77560 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKELEEDGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTRILEPFRIKNPEIIIYQYVDDLYVGSDLEIGQHRTKIEELRAHLWNWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77561 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CREMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLHKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVICQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77562 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNGTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKIKNPEMVIYQYVDDLYVSSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77563 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CREMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQTSMTKILEPFRLKNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLMSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77564 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLFSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77565 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CREMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKTKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77566 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSCMTKILEPFRIKNPEMVIYQYVDDLYVASDLEIGQHRTKIDELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77567 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77568 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKRKDN~KWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEITICQYVDDLYVASDLEIGQHRTKVEELRAHLLSWGFTTPDRKYQKEPPFRWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77569 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIDIYQYVDDLYVASDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77570 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKRKDGTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAFFSVPLDESFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTRILDPFRMKNPEIVIYQYMDDLYVESDLEIGQHRTKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77571 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDIGDAYFSFPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSCMTKILEPFRIKNPEIDICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77572 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKNSTEWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAFFSIPLDENFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIDIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77573 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIEICQYVDDLYVGSDLEIGQHRTKIKELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77574 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMDICQYMDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77575 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CNEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEMVIYQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77576 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEQEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMIICQYVDDLYVGSDLEIGQHRTKIEELRKHLLSWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77577 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKGGTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSINNEQPGLRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIESP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77578 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVSVLDVGDAYFSVPLDESFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLWNWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77579 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CTELEKEGKISKIGPENPYNTPIFAIKKKDGTKWRKLIDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMIICQYVDDLYVGSDLEIGQHRAKIEELRAHLSSWGFYTPDKKYQKEPPFLWMGYELHPNKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77580 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKELEEEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFSTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77581 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKELEEEGKISKIGPENPYNTPVFAIKKKSGTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKYPEMDIYQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFITPDEKHQKEPPLLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77582 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAFFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYMDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDNKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77583 D4T3TCNVP 2007 Thailand CRF01_AE 0 40 247 EMEEEGKISKIGPENPYNTPVFAIKKKDGTRWRKLMDFRELNKRTQDFWEVQLGIPHPAGLQKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKKPDMVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKYQKEPPLLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77584 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPIFAIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRTKNPEMVICQYMDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77585 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPIFAIKRKDGKWWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSLNNETPGIRYQYNVLPMGWKGSAAIFQSSMTKILEPFKKKNPEMVICQYMDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDRKHQKEPPFLWMGYELHPDIWTVQPIVLP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77586 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEKEGKISKIGPENPYNTPIFAIRRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYYSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILELFRIKNPEMVICQYMDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77587 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYYSVPLDESFRKYTAFTIPSLNNGTPGIRYQYNVLPMGWKGSPAIFQNSMTKILEPFKLKNPEMVIYQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77588 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKSKSVTVLDVGDAFYSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPMGWKGSPAIFQSSMIKILEPFKIKNPEMVIYQYVDDLYVASDLEIEQHRMKIEELRAHLLSWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77589 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEKEGKISKIGPENPYNNPVFVIKKKDSTKWRKLIDLRELNRRTQDFWEVQLGIPHPAGLQKTKSVTILDVGDAYYSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTRILEPFKLKNPEMVICQYVDDLYVGSDLEIGQHRTKIEELRAHLMSWGFTTPDEKHQKEPPFLWMGYELHPDRWTVQPIKLP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77590 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CEEMEKEGKISKIGPENPYNTPVFVIKKKDGTKWRKLIDLRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYYSVPLDESFRKYTAFTIPGINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRLKNPEIVICQYIDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77591 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKRKDGIKWRKLMDLRELNKRTQDFWEIQLGIPHPAGLRKNKSVTVLDVGDAYYSIPLDENFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSAAIFQSSMTKILEPFRVKNPDMVICQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGLTTPDKKHQQEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77592 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CEEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYYSVPLDKNFRKYTAFTIPSINNGTPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRIKNPDIEIYQYVDDLYVSSDLEIGQHRAKIEELRAHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77593 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDLRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYYSVPLDKNFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRIKNPELVICQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77594 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPHNTPVFVIKNKDGTKWRKLIDLRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDIGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPMGWKGSPAIFQSTMTKILEPFRIKNPEITICQYMDDLYVGSDLEIGQHRIKVEELRAHLLSWGFTTPDRKHQKEPPFRWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77595 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEKEGKISRIGPENPYNTPVFVIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVLDIGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPELVIYQYVDDLYVGSDLEIGQHRIKVEELRAHLLSWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIDLP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77596 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSTMLKILEPFRIKNPEMVIYQYVDDLYVGSDLEIEQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77597 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPVELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77598 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPTIFQSSMTRILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRTKVEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77599 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CTEMEEEGKISRIGPENPYNTPVFAIKKKDSSKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDIGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77600 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEVVICQYMDDLYVGSDLEIGQHRTKIEELRDHLLKWGFSTPDKKHQKEPPFRWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77601 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTIQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77602 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKELEEEGKISKIGPQNPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPEMDICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGLTTPDKKHQKEPPFHWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77603 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLNKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRINNPEMVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQTEPPFRWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77604 D4T3TCNVP 2007 Thailand CRF01_AE 0 40 247 EMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDMIICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKYQKEPPFRWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77605 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMIICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77606 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFYTPDRKHQKEPPFRWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77607 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CREMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPTIFQSSMTKILEPFRTKNPEMIICQYVDDLYVGSDLEIEQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDIWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77608 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMIICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77609 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRMKNPEIVICQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77610 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKELEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRAQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPDIVIYQYVDDLCIGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77611 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77612 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRRKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77613 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKYQKEPPFLWLGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77614 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSAKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVICQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFRWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77615 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDIGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRMKNPEMIICQYVDDLYVASDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWAVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77616 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVASDLEIGQHRIKIDELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPVTLP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77617 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAINKKNSNRWRKVVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIIICQYVDDLYVASDLEIGQHRTKVEELRAHLLSWGFTTPDQKYQKEPPFLWMGYELHPDKWTVQPIVLP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77618 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDKKYQKEPPFRWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77619 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIIIYQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77620 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 244 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPI Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77621 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CTEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTLLDVGDAYFPVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77622 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CREMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLTKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEVVICQYVDDLYVGSDLEIGQHRIKVEELRAHLLSWGFTTPDKKYQKEPPFRWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77623 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISRIGPENPYNTPIFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRIKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77624 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRTKVEELRAHLLRWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIQLP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77625 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSNRWRKLIDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTRILEPFRIKNPEIVICQYVDDLYIGSDLEIGQHRTKVEELRAHLLNWGFTTPDEKYQKEPPFLWMGYELHPDRWTVQPIQLP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77626 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPTIFQSSMTKILEPFRIKNPEIVICQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFRWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77627 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAINKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSITILDVGDAYFSVPLHESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDQKHQKEPPFRWMGYELHPDRWTVQPIKLP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77628 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKELEEEGKISKIGPENPYNTPIFAIRKKNSNRWRKVVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDVNFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSAMTKILEPFRIKNPEIVIYQYMDDLYVESDLEIGQHRTKIEELRAHLLNWGFFTPEQKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77629 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CEEMEKEGKISKIGPENPYNTPIFAIKKKGGTRWRKIVDFRELNKRTQDFCEIQLGIPHPAGLKKKKSITILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILESFRTKNPEIVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLNWGFFTPDEKYQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77630 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CEEMEKEGKISKIGPENPYNTPIFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQNSMTKILEPFRRKNPEIVICQYVDDLYVASDLEIGQHRAKIEELRAHLLRWGLITPDEKHQKEPPFLWMGYELHPDRWTVQPIQLP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77631 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEAEGKISKIGPENPYNTPIFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDMGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELRAHLLSWAFFTPDEKHQKEPPFHWMGYELHPDKRTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77632 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPIFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDIGDAYFSVPLDESFRKYTAFTIPSTNNETPGTRYQYNVLPQGWKGSPAIFQSSMTRVLEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRAKVEELRAHLLSWGFFTPDQKYQKEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77633 D4T3TCNVP 2007 Thailand CRF01_AE 0 40 247 EMEEEGKISKIGPENPYNTPVFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDIVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFFTPDEKHQKEPPFRWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77634 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 240 CKEMEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDLRAANKSTQDFWEVQLGIPHPAGLKKKKSITVLDVGDGYFLVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMEICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDRWT Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77635 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 241 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLHESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFRWMGYELHPDRWTV Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77636 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 244 CKELEQEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRMKNPEMVIYQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFYTPDKKHQKEPPFLWMGYELHPNKWTVQPI Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77637 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKELEEEGKISKIGPENPYNTPVFAIKKKDSGKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLHKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKVLEPFRTKNPEMVIYQYVDDLYVSSDLEIGQHRAKIEELRAHLLSWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPMRMP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77638 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFTVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRNKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFYTPDKKHQKEPPFLWLGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77639 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLNWGFTTPDNKYQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77640 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIIIIQYVDDLYVGSDLEIGQHRIKIEELRSHLLSWGFTTPDKKHQKEPPFPWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77641 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKELEEAGKISKIGPENPYNTPVFAIKKKNSDKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVIDVGDAYFSIPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYVDDLLVGSDLEIGQHRIKIEELRAHLWSWGFYTPENKHQKEPPFLWMGYELHPDRWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1798 77642 D4T3TCNVP 2007 Thailand CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEVVIVQYVDDLYVGSDLEIGQHRIKIDELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Manosuthi, W 2010 20507208 ARHR Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. 1812 77420 AZT3TCNVP 2004 Uganda D 0 1 242 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKVGPENPYNTPIFAIKKKGSTKWRKLVDFRVLNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYVDDLYVASDLEIGQHRIKIGELREHLLKWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQ Ndembi, N 2010 19938977 J Infect Dis Viral rebound and emergence of drug resistance in the absence of viral load testing: A randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. 1812 77421 AZT3TCNVP 2004 Uganda D 0 1 242 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNSPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSATVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYVDDLYVGSDLEIGQHRMKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQ Ndembi, N 2010 19938977 J Infect Dis Viral rebound and emergence of drug resistance in the absence of viral load testing: A randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. 1812 77428 AZT3TCNVP 2005 Uganda D 0 1 242 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSMNNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDMVIYQYVDDLYVASDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQ Ndembi, N 2010 19938977 J Infect Dis Viral rebound and emergence of drug resistance in the absence of viral load testing: A randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. 1812 77431 AZT3TCNVP 2005 Uganda D 0 1 242 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQ Ndembi, N 2010 19938977 J Infect Dis Viral rebound and emergence of drug resistance in the absence of viral load testing: A randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. 1812 77433 AZT3TCNVP 2005 Uganda A 0 1 242 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHKDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQ Ndembi, N 2010 19938977 J Infect Dis Viral rebound and emergence of drug resistance in the absence of viral load testing: A randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. 1812 77437 AZT3TCNVP 2005 Uganda D 0 1 242 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICTEMEKDGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYVDDLYVASDLEIEQHRIKIEELRGHLLKWGFNTPDKKHQKEPPFLWLGYELHPDKWTVQ Ndembi, N 2010 19938977 J Infect Dis Viral rebound and emergence of drug resistance in the absence of viral load testing: A randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. 1812 77439 AZT3TCNVP 2005 Uganda D 0 1 242 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICREMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQDSMTKILEPFRKQNPDMVIYQYVDDLYVGSDLEIGQHRIKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQ Ndembi, N 2010 19938977 J Infect Dis Viral rebound and emergence of drug resistance in the absence of viral load testing: A randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. 1812 77445 AZT3TCNVP 2005 Uganda A 0 1 242 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRVGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIIYQYVDDLYDASDLEIGQHRTKVDELSDHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVE Ndembi, N 2010 19938977 J Infect Dis Viral rebound and emergence of drug resistance in the absence of viral load testing: A randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. 1812 77448 AZT3TCNVP 2005 Uganda A 0 1 242 PISPIDTVPVKLKPGMDGPKVKQWPLTAEKIKALTEICMEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIIIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQ Ndembi, N 2010 19938977 J Infect Dis Viral rebound and emergence of drug resistance in the absence of viral load testing: A randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. 1812 77452 AZT3TCNVP 2005 Uganda D 0 1 242 PISTIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVICQYVDDLYVASDLEIGQHRAKIEKLREHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQ Ndembi, N 2010 19938977 J Infect Dis Viral rebound and emergence of drug resistance in the absence of viral load testing: A randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. 1812 77454 AZT3TCNVP 2005 Uganda A 0 1 242 PISPIETVPVTLKPGMDGPRIKQWPLTEEKIKALTEICREMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMIIYQYMDDLYVGSDLEIGQHRTKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQ Ndembi, N 2010 19938977 J Infect Dis Viral rebound and emergence of drug resistance in the absence of viral load testing: A randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. 1812 77456 AZT3TCNVP 2005 Uganda D 0 1 242 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKGGKISRIGPDNPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDMVIYQYMDDLYVGSDLEIGQHRIKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQ Ndembi, N 2010 19938977 J Infect Dis Viral rebound and emergence of drug resistance in the absence of viral load testing: A randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. 1812 77458 AZT3TCNVP 2005 Uganda A 0 1 242 PISPIETVPVTLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPEIIIYQYVDDLYVGSDLEIGQHRAKVEELRAHLLRWGFTTPDQKHQKEPPFLWMGYELHPDKWTVQ Ndembi, N 2010 19938977 J Infect Dis Viral rebound and emergence of drug resistance in the absence of viral load testing: A randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. 1812 77463 AZT3TCNVP 2005 Uganda C 0 1 242 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICGEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRTKNPEIVIVQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFITPDKKHQKEPPFLWMGYELHPDKWTVQ Ndembi, N 2010 19938977 J Infect Dis Viral rebound and emergence of drug resistance in the absence of viral load testing: A randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. 1812 77469 AZT3TCNVP 2005 Uganda D 0 1 242 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICMDMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILDPFRKQNPEIVIYQYMDDLCVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQ Ndembi, N 2010 19938977 J Infect Dis Viral rebound and emergence of drug resistance in the absence of viral load testing: A randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. 1812 77475 AZT3TCNVP 2005 Uganda A 0 1 242 PISHIETVPVALKPGMDGPKVKQWPLTEEKIKVLKEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGLRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIIIYQYVDDLYVASDLEIGQHRAKIEELRTHLLSWGLTTPDKKHQKEPPFLWMGYELHPDTWTVQ Ndembi, N 2010 19938977 J Infect Dis Viral rebound and emergence of drug resistance in the absence of viral load testing: A randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. 1812 77480 AZT3TCNVP 2005 Uganda D 0 1 242 PISQIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGFYTPDKKHQKEPPFRWMGYELHPDKWTVQ Ndembi, N 2010 19938977 J Infect Dis Viral rebound and emergence of drug resistance in the absence of viral load testing: A randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. 1812 77481 AZT3TCNVP 2005 Uganda D 0 1 242 PISPIETVPVKLKPGMDGPKVRQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLCEDFRKYTAFTIPSINNETPGMRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQ Ndembi, N 2010 19938977 J Infect Dis Viral rebound and emergence of drug resistance in the absence of viral load testing: A randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. 1812 77484 AZT3TCNVP 2005 Uganda A 0 1 242 PISPIDTVPVRLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISKIGPENPYNTPIFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIIIYQYVDDLYVASDLEIGQHRAKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQ Ndembi, N 2010 19938977 J Infect Dis Viral rebound and emergence of drug resistance in the absence of viral load testing: A randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. 1812 77487 AZT3TCNVP 2005 Uganda A 0 1 242 PISPIETVPVKLKPGMDGPRIKQWPLTEEKIKALTEICADMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIIIYQYMDDLYVGSDLEIGQHRAKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQ Ndembi, N 2010 19938977 J Infect Dis Viral rebound and emergence of drug resistance in the absence of viral load testing: A randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. 1812 77488 AZT3TCNVP 2005 Uganda A 0 1 242 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICGEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLNEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIIYQYMDDLYVGSDLEIGQHRAKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQ Ndembi, N 2010 19938977 J Infect Dis Viral rebound and emergence of drug resistance in the absence of viral load testing: A randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. 1812 77489 AZT3TCNVP 2005 Uganda D 0 1 242 PISPIETVPVKLKPGMDGPKVKQWPLTKEKLKALTEICIDMEKEGKIPRIGPENPYNTPIFALNKKNNTYWRKLVDLKELIKRTQEFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGVRYQYNVLPPGWKGSPAVFQSSMTKILEPFRQQNPEIVIYQYVDDLYVSSDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQ Ndembi, N 2010 19938977 J Infect Dis Viral rebound and emergence of drug resistance in the absence of viral load testing: A randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. 1812 77496 AZT3TCNVP 2005 Uganda A 0 1 242 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQ Ndembi, N 2010 19938977 J Infect Dis Viral rebound and emergence of drug resistance in the absence of viral load testing: A randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. 1812 77499 AZT3TCNVP 2005 Uganda CRF10_CD 0 1 242 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICADMEKEGKITRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEEFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPDIVICQYMDDLYIGSDLEIGQHRRKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQ Ndembi, N 2010 19938977 J Infect Dis Viral rebound and emergence of drug resistance in the absence of viral load testing: A randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. 1812 77500 AZT3TCNVP 2005 Uganda D 0 1 242 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTEICIDMEKEGKISKIGPENPYNTPIFAIKKKGSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKQNPEIVICQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQ Ndembi, N 2010 19938977 J Infect Dis Viral rebound and emergence of drug resistance in the absence of viral load testing: A randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. 1812 77503 AZT3TCNVP 2004 Uganda D 0 1 242 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICREMEEEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGMKYQYQVLPQGWKGSPAIFQSSMTRMLDPFRKQNPEIVIYQYVDDLYVASDLEIGQHRIKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQ Ndembi, N 2010 19938977 J Infect Dis Viral rebound and emergence of drug resistance in the absence of viral load testing: A randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. 1812 77506 AZT3TCNVP 2005 Uganda A 0 1 242 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIRALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPDIVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQ Ndembi, N 2010 19938977 J Infect Dis Viral rebound and emergence of drug resistance in the absence of viral load testing: A randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. 1815 76043 D4T3TCNVP 2006 Kenya A 0 26 230 LTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKRKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPDIIIYQYVDDLWVGSDLDLGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWM Steegen, K 2009 19531211 AIDS Res Ther Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya. 1815 76045 D4T3TCNVP 2006 Kenya A 0 23 230 QWPLTEEKIKALTEICLEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWM Steegen, K 2009 19531211 AIDS Res Ther Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya. 1815 76046 D4T3TCNVP 2006 Kenya D 0 24 233 WPLTEEKIKALTEICADMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRIKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYE Steegen, K 2009 19531211 AIDS Res Ther Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya. 1815 76047 AZT3TCEFV 2006 Kenya C 0 26 230 LTEEKIKALTAICEDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWM Steegen, K 2009 19531211 AIDS Res Ther Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya. 1815 76048 D4T3TCNVP 2006 Kenya A 0 24 229 WPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEEFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPYRSKNPEMIIYQYVDDLLVASDLEIGQHRAKIEELRAHLLSWGLTTPDKKHQKEPPFLW Steegen, K 2009 19531211 AIDS Res Ther Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya. 1815 76049 D4T3TCNVP 2007 Kenya A 0 20 228 KVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKRKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTLPSTNNETPGVRYQYNVLPQGWKGSPAIFQCSMTKILEPFRLKNPDIVICQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFL Steegen, K 2009 19531211 AIDS Res Ther Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya. 1815 76050 D4T3TCNVP 2006 Kenya A 0 21 229 VKQWPLTEEKIKALTEICAEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPRTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLW Steegen, K 2009 19531211 AIDS Res Ther Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya. 1815 76051 D4T3TCEFV 2007 Kenya A 0 20 230 KVKQWPLTEEKIRALTEICMEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVSLNKDFKKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRSKNPEIIIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWM Steegen, K 2009 19531211 AIDS Res Ther Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya. 1815 76052 D4T3TCNVP 2007 Kenya A 0 23 229 QWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHESFKKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRSKNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRTHLLSWGLTTPDKKHQKKPPFLW Steegen, K 2009 19531211 AIDS Res Ther Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya. 1815 76053 D4T3TCNVP 2007 Kenya D 0 21 230 VKQWPLTEEKIKALTEICKEMEEEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILNPFREQNPEMVICQYVDDLYVASDLEIGQHRAKIEELRKHLLKWGFTTPDKKHQKEPPFLWM Steegen, K 2009 19531211 AIDS Res Ther Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya. 1815 76054 AZT3TCEFV 2007 Kenya A 0 23 230 QWPLTEEKIKALTEICKQMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIIIYQYMDDLYVGSDLEIGQHRTKVEELRAHLLSWGFTTPDKKHQKEPPFLWM Steegen, K 2009 19531211 AIDS Res Ther Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya. 1815 76055 D4T3TCEFV 2006 Kenya A 0 24 230 WPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTVPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPYRAKNPEIIIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGLTTPDKKHQKEPPFLWM Steegen, K 2009 19531211 AIDS Res Ther Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya. 1815 76056 D4T3TCEFV 2006 Kenya A 0 23 230 QWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEMVIYQYVDDLYVGSDLEIGQHRTKIEELRTHLLSWGFTTPDKKHQKEPPFLWM Steegen, K 2009 19531211 AIDS Res Ther Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya. 1815 76058 D4T3TCEFV 2006 Kenya A 0 19 234 PKVKQWPLTEEKLKALTEICNEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEEFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPELVIYQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGFFTPDKKHQKEHPFLWMGYEL Steegen, K 2009 19531211 AIDS Res Ther Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya. 1824 76392 AZT3TCNVP 2007 Brazil C 0 1 239 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALQEICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPEIIIYQYMDDLYVGSDLEIGQHREKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKW Rodrigues, R 2010 20334570 ARHR Young pregnant women living with HIV/AIDS in Criciuma, southern Brazil, are infected almost exclusively with HIV type 1 clade C. 1824 76403 AZT3TCEFV 2007 Brazil C 0 1 228 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEREGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPSIFQRSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIRQHRAKIEELREHLLKWGLTTPDKKHQKEPPFL Rodrigues, R 2010 20334570 ARHR Young pregnant women living with HIV/AIDS in Criciuma, southern Brazil, are infected almost exclusively with HIV type 1 clade C. 1824 76404 AZT3TCEFV 2007 Brazil F 0 1 333 PISPINTVPVKLKPGMDGPKVKQWPLTEEKLKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPDIVIYQYIDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVQQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Rodrigues, R 2010 20334570 ARHR Young pregnant women living with HIV/AIDS in Criciuma, southern Brazil, are infected almost exclusively with HIV type 1 clade C. 1824 76409 AZT3TCNVP 2007 Brazil F 0 1 341 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICLEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPYRTKNPDIVIYQYVDDLYVGSDLEIGQHRTKIDELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKTLTDIVPLTAEAELELAENREILKEPVHGAYYDPSKDLVAELQKQGQGQWTYQI Rodrigues, R 2010 20334570 ARHR Young pregnant women living with HIV/AIDS in Criciuma, southern Brazil, are infected almost exclusively with HIV type 1 clade C. 1824 76411 AZT3TCNVP 2007 Brazil C 0 1 234 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRVHLLKWGFTTPDKKHQKEPPFLCMGYEL Rodrigues, R 2010 20334570 ARHR Young pregnant women living with HIV/AIDS in Criciuma, southern Brazil, are infected almost exclusively with HIV type 1 clade C. 1824 76414 AZT3TCEFV 2007 Brazil C 0 1 229 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKAICDEMEREGKIEKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLQKNRSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLW Rodrigues, R 2010 20334570 ARHR Young pregnant women living with HIV/AIDS in Criciuma, southern Brazil, are infected almost exclusively with HIV type 1 clade C. 1824 76417 AZT3TCEFV 2007 Brazil C 0 1 228 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDDMEREGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAQNPEIIIYQYMDDLYVGSDLEIGQHRAKIDELREHLLKWGFTTPDKKHQKEPPFL Rodrigues, R 2010 20334570 ARHR Young pregnant women living with HIV/AIDS in Criciuma, southern Brazil, are infected almost exclusively with HIV type 1 clade C. 1824 76418 AZT3TCEFV 2007 Brazil C 0 1 235 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLAKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELRAHLLKWGFITPDQKHQKEPPLLWMGYELH Rodrigues, R 2010 20334570 ARHR Young pregnant women living with HIV/AIDS in Criciuma, southern Brazil, are infected almost exclusively with HIV type 1 clade C. 1834 76499 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVFYDPSKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76500 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTKEKIEALTEICNEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFCEVQLGIPHPAGLEKKKSVTVIDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYVDDLYVASDLEIGKHRARIEKLRVHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKEAWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAEMELAENREILKEPVHGVYYDSSKELIADVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76501 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALIEICTEMEKEGKISKIGPDNPYNTPVFVIKKKDSNRWRKLTDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTNNPEMVICQYVDDLYVGSDLEIEQHRAKIEELREHLLRWGFSTPDKKYQKEPPFRWMGYELHPDKWTVQSIELPERDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVTLTKEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76502 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISKIGPENPYNTPVFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAKNPEIVICQYVDDLYVGSDLETGQHRAKITELRDHLLRWGFTTPDQKHQKEPPFRWMGYELHPDKWTVQPIQLPDKTVWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLIRGVKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76503 D4T3TCNVP 2007 Nigeria CRF06_cpx 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICREMEEEGKISRIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRTKNPEMEICQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCRLLRGAKALTDIVPLTAEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQGEG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76504 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPRIKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPIFVIKKKDSTKWRKLIDFRELNKRTQDFWEIQLGIPHPAGLKKKKSATVLDVGDAFFSVPLHEEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQTIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVQQLCKLLRGAKALTDVVPLTREAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76505 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICADMEKEGKISRIGPENPYNTPVFAIKKKGGTKWRKLTDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTLPSLNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILKPFRTENPEIIIYQYVDDLYVASDLEIGQHRAKIAELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDNWTVNDIQKLVGKLNWASQIYAGIRTKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76506 D4T3TCNVP 2007 Nigeria G 0 1 334 PISPIATVPVKLKPGMDGPKIKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSTMTKILEPFRAKNPEMEICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQSIKLPEKESWTVNDIQKLVGKLNWASQIYAGIQVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQGR Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76507 D4T3TCNVP 2007 Nigeria CRF01_AE 0 1 334 PISPIETVPVTLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDPNFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRNHLLKWGLTTPDKKYQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENKEILKEPVHGVYYDPSKEIIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76508 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIEIYQYMDDLHVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQAIQLPDKESWTVNDIQKLVGKLNWASQIYSGIKIKQLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76510 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTDMEKEGKISRIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKTSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIMLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTREAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76511 D4T3TCNVP 2007 Nigeria A 0 1 334 PISPIQTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNEKPGVRYQYNVLPQGWKGSPTIFQHSMTKILEPYRSQNPELIICQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76512 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDMADAYYSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREYLLKWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDVVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76513 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKDMEKEGKISRIGPENPYNTPIFAIKKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPTIFQSSMTKILEPYRAKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDQKHQKEPPFRWMGYELHPDKWTVQPIQLPEKENWTVNDIQKLVGKLNWASQIYPGIKVRQLCRLLRGAKALTDIVPLTAEAEMELAENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76515 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKYPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEIVTLTEEAELELAENREILKEPVHGVFYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76516 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNQIPGIRYQYNVLPQGWKGSPAIFQDSMTRILEPFRTKNPEIVIYQYVDDLYVASDLEIGQHRAKVEELREHLLRWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76517 D4T3TCNVP 2007 Nigeria G 0 1 333 PVSPIETLPVKLKPGMDGPRVKQWPLTEEKIIALTEICEDLEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLMDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFAIPLDEDFRKYTAFTIPSRNNQTPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRTKYPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLFTPEQKHQKEPPFHWMGYELHPDKWTVHPIQLPNKDSWTVNDIQKLVGKLNWASQIYPGIKVKHLCRLLRGAKTLTDIVTLTAEAEMELAENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76518 D4T3TCNVP 2007 Nigeria G 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTKEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEMVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQHIELPDKDSWTVNDIQKLVGKLNWASQIYAGIRVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGAYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76519 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIQTVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTDMEKEGKISRVGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLQKKKSATVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTQILEPFRTKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPNKENWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76520 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPTIFQASMTKILEPFRTNNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCRLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76521 D4T3TCNVP 2007 Nigeria G 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICSEMEKEGKISKIGPENPYNTPVFAIKKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKYPEMVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDQKHQKEPPFHWMGYELHPDKWTVQHIELPDKDSWTVNDIQKLVGKLNWASQIYPGVKVKHLCRLLRGAKALTDIVPLTTEAEMELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76522 D4T3TCNVP 2007 Nigeria D 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDGTKWRNLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYYSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILDLFRKQNPELVIVQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGLFTPDKKHQKEPPFLWMGYELHPDKWTVQSIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEVIPLTKEAELELAENREILKEPVHGVYYDPTKELIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76523 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVICQYVDDLYVGSDLEIERHRAKIEELRDHLLRWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPITLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76524 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTELEKEGKISKIGPENPYNTPVFAIKKKNSDKWRKLVDLRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPMGWKGSPAIFQASMTKILEPFRAKNPEIVIVQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFFTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKTKNLCKLLRGAKALTDVVVLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76525 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76526 D4T3TCNVP 2007 Nigeria G 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKDMEKEGKISKIGPENPYNTPIFAIKKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKYPEIVICQYVDDLYVGSDLEIEQHREKIKELREHLLKWGLFTPDQKHQKEPPFRWMGYELHPDKWTVQPIKLPEKDNWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76527 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILQPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWSVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGAYYDPAKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76528 D4T3TCNVP 2007 Nigeria G 0 1 332 PISPIETVPVKLKPGMDGPRVKQWPLTKEKIEALTEICNEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTNNPEIVIYQYVDDLYVASDLEIGQHRAKVEELREHLLKWGFTTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRHLCRLLRGAKALTDIVPLTTEAEMELAENREILKEPVHGVYYDPSKDLIAEVQKQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76529 D4T3TCNVP 2007 Nigeria A 0 1 334 PISPIDTVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMENEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRLKNPEIIIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPDKESWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLIRGAKALTEVVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQEQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76530 D4T3TCNVP 2007 Nigeria D 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRAKNPELVIYQYVDDLYVGSDLEIEQHRAKIEQLREHLMKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGE Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76531 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKAITEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILRPFREENPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDHWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVALTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76532 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQESMTKILEPFRTKYPEIVICQYVDDLYVGSDLEIGQHRAKIKELREHLLRWGFYTPDKKHQTEPPLRWMGYELHPDKWTVQHIELPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEIVPLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76533 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKDMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPYRTRNPEIVIYQYMDDLYVGSDLEIGQHRAKVEELRTHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQSIQLPKKESWTVNDIQKLVGKLNWASQIYPGIKIKQLCKLLRGAKALTDIVQLTEEAELELAENREILKEPVHGAYYDPSKDLIAELQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76534 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICQDMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVIDVGDAYFSIPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPYRTENPEMVIYQYVDDLLVGSDLEIGQHRAKVEKLREHLLRWGLFTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPEKEAWTVNDIQKLVGKLNWASQIYPGVKVRHLCRLLRGAKALTDIVTLTPEAEMELAENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76535 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKDMEKEGKISRIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPEIVIIQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPEQKHQKEPPFLWMGYELHPDKWTVQPIQLPDKEAWTVNDIQKLVGKLNWASQIYPGIKVRHLCRLLRGAKALTDIVPLTAEAEMELAENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76536 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIQTVPVKLKPGMDGPKVKQWPLTEEKIRALTEICNDMEKEGKISRVGPENPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQSSMTQILEPFRTKNPEMVIYQYVDDLYVGSDLELGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKENWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76537 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIKTVPVKLKPGMDGPRVKQWPLTEEKIKALTDICMEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTRNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKIRQLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76538 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALSEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76539 D4T3TCNVP 2007 Nigeria G 0 1 333 PISSIETVPVKLKPGMDGPRVKQWPLTEEKIKAITEICKDMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNRSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHREKVEELREHLLKWGLTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPNKEDWTVNDIQKLVGKLNWASQIYPGIKVKHLCKLLRGAKALTEIVPLTAEAEMELAENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76541 D4T3TCNVP 2007 Nigeria A 0 1 333 PISPIKPVPVKLKPGMDGPKVKQWPLTEEKIKALTEICREMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLHEDFRKYTAFTLPSTNNERPGIRYQYNVLPQGWKGSPAIFQCTMTNILEPFRAQNPELVICQYVDDLYVGSDLEIGQHRTKIEKLREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDVITLTEEAELELAENREILKEPVHGVYYDPSKDLVAELQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76542 D4T3TCNVP 2007 Nigeria G 0 1 333 PICPIEAVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAELEKDGKISKIGPENPYNTPVFAIKKKNSDKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEMVICQYVDDLYVASDLEIGQHRAKIKELRDHLWKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKGSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLSEEAELELAENREILKEPIHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76543 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTELEKEGKISRIGPENPYNTPIFAIKKKDSDKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKNNPEIVICQYVDDLYVGSDLEIGQHRAKVKELRDHLLKWGFYTPDKKHQEEPPFRWMGYELHPDKWTVQPITLPNKENWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVSLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76544 D4T3TCNVP 2007 Nigeria G 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDQDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPELVIYQYVDDLYVGSDLEIGQHRAKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKEIWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTEIVTLTEEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76545 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEDMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSITVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGLTTPDQKYQKEPPFLWMGYELHPDKWTVQPIKLPDKESWTVNDIQKLVGKLNWASQIYSGVRVKNLCKLLRGAKALTDIVTLTVEAEMELAENREILKGPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76546 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTDICADMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIGQHRAKVEELRDHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILREPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76547 D4T3TCNVP 2007 Nigeria A 0 1 334 PISPIETVPVTLKPGMDGPRVKQWPLTEEKIKAITAICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSTNNETPGTRYQYNVLPQGWKGSPAIFQYSMTKILEPFRSKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVTLTEEAELELAENREILKDPVHGVYYDPAKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76548 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRVGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVICQYMDDLYVGSDLETGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76549 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTEICTELEKEGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDHWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76550 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLTKKRSVTVLDVGDAYFSVPLEESFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLYVASDLEIGQHRAKIEELRDHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKEYWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76551 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTEICTEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPGGLKKNRSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNQTPGIRYQYNVLPQGWKGSPAIFQATMTKILEPFRAENPEMVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYKGIQVRQLCKLLRGAKALTDIIPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76552 D4T3TCNVP 2007 Nigeria A 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRLKNPDIVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPVLLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTEVVPLTQEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76553 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEMVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKGLTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76554 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLEKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLETGQHRAKIEELRDHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKENWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76555 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICMEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKRSVTILDVGDAYFSVPLHESFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRDHLLRWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKNLCKLLRGAKALTDIVPLTEEAELELAENREILREPVHGVYYDPSKELIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76556 D4T3TCNVP 2007 Nigeria CRF06_cpx 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIIALKEICAELEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEVVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKEDWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQEHG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76557 D4T3TCNVP 2007 Nigeria G 0 1 334 PISPIETVPVTLKPGMDGPRVKQWPLTEEKIKALTEICMDLEKDGKISKIGPENPYNTPIFAIKKKNSTRWRKLMDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSIPLHESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIVQYVDDLYVASDLEIGQHRAKIDELREYLWKWGFYTPEQKHQKEPPFHWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76558 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTNNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLIRGTKALTDIVTLTEEAELELAENREILKEPVHGVYYDPAKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76559 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKRSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFFTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYSGIKVRQLCKLLRGAKALTDIVQLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76560 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTTEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVASDLEIGQHRAKVEELREHLLKWGFTTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIRIRQLCKLLRGAKALTDIVTLTKEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76561 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKDMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNERPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTRNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76562 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKDMEKEGKISKIGPENPYNTPIFAIKKKNSNRWRKLIDFRELNKRTQDFWEVQLGIPHPGGLKKKRSVTVLDVGDAYFSVPLDEEFRKYTAFTLPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDQKYQKEPPFHWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYAGIKVKHLCKLLRGAKALTDIVPLTAEAEMELAENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76563 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDLEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTIIDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVICQYVDDLYVASDLEIGQHRAKIEELRDHLLRWGFYTPDKKHQKEPPFRWMGYELHPDKWTIQPIQLPNKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76564 D4T3TCNVP 2007 Nigeria CRF06_cpx 0 1 335 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRGKNPDIEICQYVDDLYVGSDLEIGQHRAKVEELREHLSKWGFTTPDKKYQKEPPFLWMGYELHPDKWTMQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTTEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76565 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVASDLEIGQHRAKIEELRDHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76566 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILKPFRTENPEIVICQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76567 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVICQYVDDLYVGSDLELGQHRAKIEELREHLLKWGFTTPDKKLQKDPPFLWMGYELHPDKWTVQPITLPNKDSWTVNDIQRLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76568 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGAYYDPTKDLIAEIQKQGQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76569 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTNNPEMVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76570 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKDICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIIICQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76571 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPDNPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIEQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTEIVPLTKEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76572 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICADMEREGKISKIGPENPYNTPVFVIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNATPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGQHREKIEELRDHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIELPEKDRWTVNDIQKLVGKLNWASQIYAGIRVKQLCKLLRGAKALTDVVTLTEEAELELAENREILKGPVHGAYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76573 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQASMTKILQPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKENWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILREPVHGVYYDPSKDLIAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76574 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTAICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPEMIIIQYVDDLYVGSDLEIEQHRAKIEELREHLLRWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76575 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNDMEKEGKISKIGPENPYNTPIFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTILDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVICQYVDDLYVASDLEIGQHRAKIKELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPSKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76576 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTENPELVIYQYVDDLYVASDLEIGQHRAKIEELRDHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIQVRQLCRLFRGAKALTDVVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76577 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICMEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGVRYQYNVLPQGWKGSPAIFQASMTKILEPFRKDNPEIVIYQYMDDLCVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKDPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76578 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPINTVPVKLKPGVDGPKVKQWPLTEEKLKALTEICMEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKEKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTEIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76579 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTIIDVGDAYFSVPLDETFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPELVICQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPNKESWTVNDIQKLVGKLNWASQIYPGIKVKCLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76580 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEIQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLSTPEQKHQKEPPFRWMGYELHPDKWTVQHIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKNLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPAKDLVAEIQKQGQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76581 D4T3TCNVP 2007 Nigeria G 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIIALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKRSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKYPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFSTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPDKENWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVFYDPSKDLIAEIQKQGQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76582 D4T3TCNVP 2007 Nigeria CRF11_cpx 0 1 333 PISPIDTVPVKLKPGMDGPKVKQWPLTKEKIKALTEICSEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYVDDLYVASDLEIGQHRKKVEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKECWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVTLTAEAELELAENREILKEPVHGVYYDPAKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76583 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 318 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPSIFQASMTKILHPFRTANPEIIIVQYVDDLYVGSDLEIGQHRAKIDELRNHLLRWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDIVTLTEEAELELAENREILKEPVHGVY Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76584 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICMEMEKEGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDCWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREIIKEPVHGAYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76585 D4T3TCNVP 2007 Nigeria G 0 1 333 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPDKRSWTVNDIQKLVGKLNWASQIYSGIQTKQLCKLLRGAKALTDIVPLTEEAELELEENREILRNPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76586 D4T3TCNVP 2007 Nigeria G 0 1 335 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICMEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLLIGSDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVTLTEEAELELAENREILREPVHGVYYDPSKDLIAEVQKQGLG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76587 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTKICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTEWRQLADFRELNKRTQDFWEVQLGIPHPAGLKKKQSVTVIDVGDAYYSVPLDKEFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPELVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGFSTPEKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKIRQLCKLIRGAKALTDVVTLTEEAELELAENREILKEPVHGAYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76588 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTRNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQTIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76589 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPRIKQWPLTKEKIKALTEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPITLPDKDSWTVNDIQKLVGKLNWASQIYPGIRIKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76590 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKDMEKEGKISRIGPENPYNTPIFAIKKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNEVPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPYRTKNPEMVICQYVDDLYVASDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKENWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTVEAEMELAENREILKEPVHGVYYDPSKEVIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76591 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEQDGKISKIGPENPYNTPIFAIKKKNSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKRKSVTILDVGDAYFSIPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRTKYPEIEICQYVDDLYVASDLEIGQHRAKIEELRDYLLKRGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPNKESWTVNDIQKLVGKLNWASQIYQGIKVKQLCKLLRGAKALTEIVPLTKEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76592 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLIDLRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYYSVPLDPSFRKYTAFTLPSVNNETPGIRYQYNVLPMGWKGSPAIFQSSMIKILEPFRTRNPELVICQYIDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKYQKEPPFRWMGYELHPDKWTVQPIQLPNKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76593 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKRSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKEDWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKSLTDIVPLTKEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76594 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRIKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPIFAIKKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGLTTPEQKHQKEPPFHWMGYELHPDKWTVQPIQLPDKKSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILREPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76595 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISRIGPENPYNTPVFAIKRKDGTTWRKLIDLRELNKRTQDFWEIQLGIPHPAGLTKKKSVTVLDVGDAYYSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPMGWKGSPAIFQASMTKILEPFRTKNPEIVICQYMDDLYVASDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQSIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76597 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRIKQWPLTEEKIKALTEICKDMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKRSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYVDDLYVASDLEIGQHRAKIDELRNHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKEVWTVNDIQKLVGKLNWASQIYPGIKVKHLCRLLRGTKALTDIVPLTTEAEMELEENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76598 D4T3TCNVP 2007 Nigeria G 0 1 321 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTILDVGDAYFSVPLHEDFRKYTAFTIPSVNNEKPGIRYQYNVLPQGWKGSPAIFQCSMTKILDPFRRKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKENWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDP Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76599 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNSPIFAIKKKDSAKWRKLIDLRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLDESFRKYTAFTVPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRRKNPELVICQYVDDLYVGSDLEIGQHRAKIEELRSHLLAWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPNKEDWTVNDIQKLVGKLNWASQIYAGIKTRQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76600 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIKTVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRGHLLKWGFSTPDKKHQKEPPFLWMGYELHPDTWTVQPIQLPDKETWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76601 D4T3TCNVP 2007 Nigeria D 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTAMEEEGKISRIGPENPYNTPIFAIKKKDSDKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSIPLDEDFRKYTAFTIPSINNESPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRKQHPELVIYQYMDDLYVGSDLEIGEHRTKIDRLRDHLLKWGLTTPDKKHQKDPPFLWMGYELHPDKWTVQPITLPQKDSWTVNDIQKLVGKLNWASQIYPGIRVRQLCKLLRGTKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQGEG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76602 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKEDWTVNDIQKLVGKLNWASQIYPGIKVKHLCRLLRGAKALTDIVPLTAEAEMELAENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76603 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRAKNPEMVICQYVDDLYVGSDLEIEQHRAKIEELREHLLRWGFYTPDKKHQKEPPFLWMGYELHPDKWTIQPIQLPDKENWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILREPVHGVYYDPSKELIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76604 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICNEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDMVICQYMDDLCVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIITLTEEAELELAENREILKEPVHGVYYDSSKELIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76605 D4T3TCNVP 2007 Nigeria F 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSAKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTIIDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILDPFRAKNPELVICQYVDDLYVGSDLEIVQHRAKVEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKSSWTVNDIQKLVGKLNWASQIYPGIRVKYLCKLLRGAKALTDVVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76606 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPIFAIKRKDG~KWRKLIDLRELNKITQDFWEVQLGIPLPAGLRKNKSVTVLDIGDAYFSVPLYEDFRNYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPYRTKNPEMVIVQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDRKYQKEPPFLWMGYELHPDKWTVQPIQLPNKEDWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKSLTDIVPLTTEAEMELAENREILKEPVHGVYYDPSKDLIAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76607 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVQLKPGMDGPKIKQWPLTEEKIKAITEICAEMEKEGKISKIGPENPYNTPVFAIKRKDN~KWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVICQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPYRKYQKEPPFLWMGYELHPDKWTVQPITLPEKECWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76608 AZT3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICIEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVICQYVDDLYVASDLEIGQHRTKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKNXWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVTLTEEAELELAENREILKEPVHGVYYDPLKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76610 D4T3TCEFV 2007 Nigeria CRF02_AG 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPDKESWTVNDIQKLVGKLNWASQIYPGIKIKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76611 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 335 PISPIETVPVKLKPGMDGPKIKQWPLTKEKIEALTEICLEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSANNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMEIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELEENREILKEPVHGVYYDPSKDLVAEIQKQGQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76612 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKGSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEMVICQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQTIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76613 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKDMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDEKHQKEPPFHWMGYELHPDKWTVQPIQLPDKEHWTVNDIQKLVGKLNWASQIYPGIKVKHLCRLLRGAKALTDIVPLTAEAEMELAENREILKEPVHGVYYDPSKDLIADVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76614 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVICQYVDDLYVGSDLETGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKEDWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76615 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKAITEICTEMEKEGKISKIGPENPYNTPVFAIKRKDS~KWRKLMDLRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQASMTKILEPFRTKNPEIVICQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDRKYQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDVVPLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76616 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIKALTDICNDMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEIVPLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76617 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIIALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKRKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQHSMTKILEPFRTKNPELVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76618 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKAVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIVQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76619 D4T3TCNVP 2007 Nigeria A 0 1 334 PISPIETVPVRLKPGMDGPKIKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPMFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRSKNPEIIIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPDKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVITLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76620 AZT3TCEFV 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPVFAIKKKTSNRWRKIVDFRELNKRTQDFWEVQLGIPHPAGLRKNKSVTILDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTRNPEIVICQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFFTPEEKHQKEPPFHWMGYELHPDKWTVQSITLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLIRGTKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76621 AZT3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSMNNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFFTPDQKHQKEPPFLWMGYELHPDKWTVQPVKLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKHLCKLLRGAKALTDVVTMTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76623 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIRALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLERKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVASDLEIGQHRAKIKELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKESWTVNDIQKLVGKLNWASQIYPGIKVKQMCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76624 D4T3TCNVP 2007 Nigeria G 0 1 332 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICVDMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKQKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGTRYQYNVLPQGWKGSPAIFQSSMLKILEPFRTNNPEMVIYQYVDDLLVGSNLEIEQHRAKIEELRQHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDVVPLTEEAELELAENREILREPVHGVYYDPSKELIAEVQKQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76625 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTRILEPYRKENPEMVIYQYVDDLYVASDLEIGQHRAKIEKLRNHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKENWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKRPVHGVYYDPSKELVAEIHKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76627 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIQLPNKECWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILREPIHGVYYDPSKDLIAEVQRQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76628 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICMEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEKFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTNILKPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDTWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76629 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVICQYIDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIKLPEKENWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76631 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKAVTEICAELEKEGKISKIGPENPYNTPIFAIKRKDG~KWRKLVDFRELNKRTQDFSEVQLGIPHPAGLKKKKSITVLDVGDAYFSIPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSAAIFQSSMIKILEPFRAKNPEMVICQYMDDLYVSSDLEIGQHRAKIEELREHLLKWGLTTPDRKYQKEPPFLWMGYELHPDKWTVQPIQLPDKKSWTVNDIQKLVGKLNWASQVYPGIKVKQLCKLLRGAKALTDIVPLTEEAEWELAENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76632 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTKEKIKALKEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTRNPDIVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76633 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTEICLEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTVLDVGDAYFSVPLHESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKEDWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76634 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKAITDICTEMEKEGKISRIGPENPYNTPVFAIKRKDS~KWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILQPFRTKNPEIVICQYMDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDRKHQKEPPFRWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76636 D4T3TCNVP 2007 Nigeria CRF06_cpx 0 1 335 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICMEMEKEGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEGQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPDMVIYQYIDDLCVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWLGYELHPDKWKVQPIQLPNKESWTVNDIQKLVGKLNGASQIYPGIKVKQLCKLLRGAKALTEIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76637 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVICQYVDDLYVGSDLEIGQHRAKVEELRDHLLKWGFFTPDKKHQKEPPFRWMGYELHPDRWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLKGAKALTDIVTMTEEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76638 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEKEGKISRIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVIDVGDAYFSIPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKVKELREYLWRWGFYTPDKKYQKEPPLLWMGYELHPDKWTVQPIKLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEIVPLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76639 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIATVPVQLKPGMDGPKVKQWPLTEEKIKALTDICLEMEKEGKISKIGPENPYNTPVFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLDKSFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPVQLPNKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76640 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALKEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEVIIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEVQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76641 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIKALTDICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTEDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPELVIYQYVDDLYVASDLEIEQHRAKIGELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTIQTIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDVVPLTEEAELELAENREILKEPVHGVYYDPAKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76642 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIIICQYVDDLYIGSDLEIGQHRAKVEELREHLLKWGFXTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDHWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76644 D4T3TCNVP 2007 Nigeria G 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTILDVGDAYFSVPLAEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTANPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPNKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEVVALTEEAELELAENREILKEPVHGVYYDPSKELIXRVQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76645 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGLDGPRVKQWPLTEEKIKALTDICMEMEKEGKISKIGPENPYNTPIFAIKKKGGTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNQTPGIRYQYNVLPQGWKGSPAIFQAGMTKILEPFRKENPEMVIYQYVDDLYIGSDLEIGQHRAKIEKLREHLLRWGLTTPDQKHQKEPPFLWMGYELHPDKWTVQTIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKHLCRLIRGAKTLTDIVTMTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76646 D4T3TCNVP 2007 Nigeria G 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPEMVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPNKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKELIAEVQKQGLG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76648 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVRLKPGMDGPKVKQWPLTEEKIKALKEICAEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKYPEIIICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76650 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTKEKIKGLIEICTEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEQKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPDIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPEQKHQKEPPFHWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYAGIRIKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76651 D4T3TCNVP 2007 Nigeria A 0 1 334 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKIKKSVTVLDVGDAYFSIPLHESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQDSMTKILEPFRKQNPEFIIYQYVDDLYVASDLEIGQHRAKIDELRAYLWKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVTLTEEAELELAENRELLKDPVHGVYYDPSKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76653 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTDICAEMEKEGKISKIGPENPYNTPVFAIKKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTENPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDQKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDNWTVNDIQKLVGKLNWASQIYAGIKTKQLCKLLRGAKALTDIVPLTEEAELELAENREIQKEPVHGVYYDPTKELVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76654 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTDICAEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIEQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYAGIQVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76655 D4T3TCNVP 2007 Nigeria A 0 1 334 PISPVETVPVKLKPGMDGPKVKQWPLTKEKIEALTAICKELEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQEFWEVQLGIPHPGGLKKKKSVTILDVGDAYFSIPLHEDFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQYSMTKILEPFRTKNPEIIICQYVDDLYVGSDLEIGQHRAKVEELRDHLWKWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKDPVHGVYYDPSKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76656 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIRALTEICNEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPEKESWTVNDIQKLVGKLNWASQIYPGVKVKHLCRLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76657 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTRWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVIYQYVDDLYVGSDLEIGQHRAKIKELREHLLRWGFTTPEQKHQKEPPFLWMGYELHPDKWTVQTIKLPEKESWTVNDIQKLVGKLNWASQIYSGIQTKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76659 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFVIKKKDSTNWRKLTDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMIKILEPFRKENPEIVIYQYIDDLLVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVQLTEEAQLELAENREILREPVHGVYYDPSKDLIAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76660 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALKEICEEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKYPEMVIYQYVDDLYVGSDLEIEQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYEPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76662 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKRKDGTKWRKLADFRELNKRTQDFWEVQLGIPHPAGLQKKRSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETTGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVICQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDEKYQKEPPFRWLGYELHPDKWTVQPIQLPDKERWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILREPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76663 D4T3TCNVP 2007 Nigeria D 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKISRIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRRRNPEMVIYQYVDDLCVGSDLEIGQHRTKIEELREHLLKWGLTTPDQKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEVIPLTQEAELELAENREILKEPVHGVYYDPSKELIAEVQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76664 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 335 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIRKKNSTRWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNATPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIMIYQYVDDLYVASDLEIGQHRAKIEELRDHLLKWGFTTPEQKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76666 D4T3TCNVP 2007 Nigeria CRF06_cpx 0 1 335 PISPIETVPVKLKPGMDGPRIKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSMNNQTPGMRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIQELRDHLLKWGFYTPDKKHQQEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKQPVHGVYYDPSKDLIAELQKQGQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76668 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTAEKIQALTDICAELEEAGKISKIGPENPYNTPVFAIKKKNSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSIPLDQDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIEQHRAKIEELREYLWKWGFYTPDNKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGRLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76669 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTEICMDMEKEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNERPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKYPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLIRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76670 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIKTVPVTLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSITVLDVGDAYFSVPLDENFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRINNPGIVIYQYVDDLCVGSDLEIGQHRAKIEELREHLLRWGFTTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLKGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPAKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76671 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTDICTEMEKEGKISKIGPDNPYNTPVFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELREHLMKWGLTTPDEKHQKEPPFRWMGYELHPDKWTVQSIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVTLTKEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76672 TDF3TCNVP 2007 Nigeria CRF02_AG 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTEICMEMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIMICQYVDDLYVASDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIRVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPAKDLIGEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76673 TDF3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTEICTDMEKEGKISRVGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPSGLEKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTRILDPFRRNNPELVICQYIDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKEHWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDSSKELIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76674 TDF3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTEWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKHLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76675 TDF3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLXKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTRNPEMVICQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDEKHQKEPPFRWMGYELHPDKWTVQAIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76676 TDF3TCNVP 2007 Nigeria D 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICMEMEKEGKISRIGPENPYNTPVFAIKRKDNTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRKQNPEMVICQYIDDLYVGSDLEIGQHRTKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPITLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEVIPLTKEAELELAENREILREPVHGVYYDPSKDLIAEVQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76677 AZT3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEQDGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDPSFRKYTAFTIPSVNNERPGIRYQYNVLPQGWKGSPAIFQASMTRILEPFRKNNPEIVICQYVDDLYVGSDLEIGQHRAKIDELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAQLELAENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76678 TDF3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKRKDNTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVICQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVPMTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76679 TDF3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKEMEEEGKISRIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPYRTKNPEIEICQYVDDLYVGSDLEIGQHRAKVEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPDKENWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76680 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKRKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIEICQYVDDLYVGSDLDIEQHRAKIEELREHLLKWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQSIQLPDKENWTVNDIQKLVGKLNWASQIYPGIKVKHLCRLLRGAKALTDIVPLTTEAEMELAENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76681 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICMEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKYPEMVIYQYVDDLYVGSDLEIGQHRAKIQELREHLLRWGFTTPEQKHQKEPPFLWMGYELHPDTWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKSPVHGVYYEPSKELIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76682 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMEICQYVDDLYVGSDLEIGQHRAKIEELRDHLLRWGFSTPEQKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKTLTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76683 TDF3TCNVP 2007 Nigeria CRF02_AG 0 1 335 PISSVETVPVKLKPGMDGPRVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPIFVIKNKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAFFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEVVICQYVDDLHVASDLEIGQHRAKIKELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76684 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76686 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDKNFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRDHLLRWGFFTPDKKHQKEPPFRWMGYELHPDRWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76687 D4T3TCNVP 2007 Nigeria C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRAQNPGIIICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPNKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVFYDPAKDLIAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76690 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTDICTEMEKEGKLSRIGPDNPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPSIFQESMTKILEPFRKANPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDTWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEIVTLTREAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76691 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLAEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQTSMTKILEPFRTSNPEFVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76692 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTKEKIKALTDICMEMEQEGKISRIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDQEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTRNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLRWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKIKELCKLIRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76693 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVIDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFYTPEEKHQKEPPFHWMGYELHPDKWTVQPIQLPDKESWTVNDVQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76694 D4T3TCNVP 2007 Nigeria G 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTRILEPFRIKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRSHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDAWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76695 D4T3TCNVP 2007 Nigeria G 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRKNNPEMVIYQYVDDLYVGSDLEIGQHRAKVEELRDHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76697 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIIALTEICKDMEKEGKISKIGPENPYNTPIFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVRDAYFSIPLDEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRTKNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWIGYELHPDKWTVQSIKLPDKEVWTVNDIQKLVGKLNWASQIYPGIKVKHLCRLLRGAKALTEVVPLTAEAEMELAENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76699 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICTELEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVASDLEIGQHRAKIEELRDHLLRWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDNWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILRKPVHGVYYDPSKELIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76700 D4T3TCNVP 2007 Nigeria A 0 1 334 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTAICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQNSMTKILEPFRSKNPEIIIYQYVDDLYVASDLEIGQHRTKIEELRAHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKDPVHGVYYDPSKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76701 D4T3TCNVP 2007 Nigeria A 0 1 334 PISPVETVPVALKPGMDGPKVKQWPLTKEKIKALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILDPFRAKNPDIVICQYVDDLYVGSDLEIEQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76702 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPVFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQTSMTKILEPFRAKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRPHLLKWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76703 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISKIGPENPYNTPVFAIKKKGGTRWRKLVDLRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTLQPIELPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76704 TDF3TCEFV 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNGTPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPELEIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQTIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVTMTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76705 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEKEGKISKIGPENPYNTPIFAIKKKNSDRWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVIDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVICQYVDDLYVASDLEIGQHRAKIKELREYLLKWGFFTPEQKHQKEPPFHWMGYELHPDKWTVQPINLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPAKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76706 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIEIVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTENPEIIICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGARALTDIVTLTKEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76707 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNRRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDQDFRKYTAFTIPSLNNQTPGIRYQYNVLPQGWKGSPAIFQTSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLIGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76711 AZT3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKAITEICQEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYIASDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGVKVKHLCRLLRGAKSLTDIVPLTAEAEMELAENREILKEPVHGVYYDPSKELIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76712 AZT3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVQVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNERPGIRYQYNVLPQGWKGSPSIFQASMTKILEPFRTNNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQVYAGIKVKQLCRLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPAKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76713 AZT3TCNVP 2007 Nigeria G 0 1 334 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICLEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPEKELIAEVQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76714 AZT3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTNNPELVIYQYVDDLYVGSDLEIEQHRAKIEELREHLLRWGLYTPDKKHQKEPPFLWMGYELHPDRWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIQVKQLCKLLRGTKALTDIVPLTQEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76715 D4T3TCNVP 2007 Nigeria CRF06_cpx 0 1 334 PISPIEIVPVKLKPGMDGPKVKQWPLTEEKLKALMEICTEMEKEGKISKIGPENPYNTPVFVIKKKDN~KWRKLVDFRELNNRTHDFWEVQLGIPHPAGLKKKKSVTIIDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRVKNPEIVVCQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKYQKEPPLLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIIPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGR Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76716 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKRKDS~KWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVICQYMDDLYVASDLEIGQHREKVEELREHLLRWGFTTPDRKYQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76717 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICADMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKYPEIVICQYVDDLYVGSDLEIGQHREKIEELREHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKTLTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76718 AZT3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISSIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRSKNPEIVIYQYVDDLYVASDLEIGQHRTKIEELRAHLLEWGFFTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVKQLCKLLKGAKALTETVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76720 AZT3TCNVP 2007 Nigeria CRF06_cpx 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEVVIYQYVDDLYVASDLEIGQHRAKIEELREHLWRWGLYTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKENWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGNG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76721 TDF3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIENPEVVICQYMDDLYVGSDLEIGQHRAKIEKLREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76722 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGP*VKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKQSVTILDVGDAYYSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPMGWKGSPAIFQASMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQQIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76723 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVRLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPGGLKKKRSVTVLDVGDAYFSVPLDQSFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILDPFRIKNPELVICQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76724 D4T3TCNVP 2007 Nigeria G 0 1 333 PISSIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTRWRKLVDFRELNKKTQDFWEIQLGIPHPGGLKKKKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSVNNERPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPDIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLSTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDVVPLTAEAEMELAENREILKEPVHGVYYDPSKDLIAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76725 AZT3TCNVP 2007 Nigeria CRF02_AG 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTILDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIEICQYVDDLYVASDLEIGQHRAKIKELREHLLKWGFFTPDEKHQKEPPFHWMGYELHPDKWTVQPIQLPDKEHWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAQALTDIVTMTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76726 D4T3TCNVP 2007 Nigeria A 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDLRELNKRTQDFWEVQLGIPHPAGLPKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNERPGVRYQYNVLPQGWKGSPAIFQASMTKILEPFRSKNPEIIICQYVDDLYVGSDLEIGQHRAKIEELRAHLLTWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDHWTVNDIQKLVGKLNWASQIYGGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKDPVHGVYYDPSKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76727 AZT3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPTIFQASMTKILEPFRTENPEIIICQYVDDLYVGSDLEIGQHRAKIDELRAHLLKWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVSLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76728 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPDNPYNTPIFAIKKKNSNRWRKIVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQESMTRILEPFRMKYPEMVIYQYVDDLYVASDLEIGNHRAKIEELREHLLKWGFSTPDQKHQKEPPFHWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEIVPLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76729 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELRKHLLRWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPINLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76730 D4T3TCNVP 2007 Nigeria CRF06_cpx 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIRALTEICTDMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKENPELMIYQYVDDLCVGSDLEIGQHRAKIEELREHLLKWGLTTPEEKHQKEPPFLWMGYELHPDKWTVQPIQLPNKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVVPLTVEAELELAENREILKEPVHGVYYDPTKDLTAEIQKQGQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76731 AZT3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFCEVQLGIPHPSGLKKKKSATVLDVGDAYFSVPLDEGFRKYTAFTIPSINNATPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPELVIYQYVDDLYVASDLEIGQHRAKVEELRQHLLKWGLFTPDQKYQKEPPLLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPTKDLIAELQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76732 TDF3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPVFAIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPYRTKNPEMVICQYVDDLYVGSDLEIGQHRAKVEELREHLLRWGFTTPDEKHQKEPPFLWMGYELHPDKWTVQHIQLPEKDIWTVNDIQKLVGKLNWASQIYAGIRVKQLCKLLKGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76733 TDF3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRIKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPIFVIKRKDNTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRMKKSVTVLDVGDAFFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSTMIKILDPYRTRNPDMVICQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVQLTEEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76734 TDF3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFVIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEIVICQYVDDLYVSSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76735 TDF3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIRALTEICSEMEKEGKISRIGPENPYNTPVFVIKRKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKKKSATVLDVGDAFFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYAGIKVRQLCRLIRGTKALTEIVPLTEEAELELAENREILKEPVHGVYYDPAKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76736 TDF3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPELEICQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQTEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLKGARALTDIVTLTEEAELELAENREILKAPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76737 AZT3TCNVP 2007 Nigeria CRF06_cpx 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICMEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVPLTAEAELELAENREILKQPVHGVYYDPSKDLIAEIQKQGQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76738 AZT3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLRPGMDGPKVKQWPLTEEKIKALTDICMEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQTSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76739 AZT3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSVNNEKPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIKLPEKDNWTVNDIQKLVGKLNWASQIYAGIRIKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76742 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTRWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDQDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYTGIKVKQLCKLLRGAKALTDVVTLTEEAELELAENKEILKEPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76744 AZT3TCEFV 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICAELEQEGKISKIGPENPYNTPIFAIKKKNSTRWRKLLDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTILDVGDAYFSVPLDKEFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVICQYVDDLYVASDLEIGQHRAKIEELRAHLWKWGFFTPDEKHQKEPPFHWMGYELHPDKWTVQHIELPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76746 TDF3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLSEEKIKALTDICKEMEEEGKISRIGPENPYNTPIFAIKRKDGTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNATPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKEHWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDVVTMTEEAELELAENREILREPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76748 D4T3TCNVP 2007 Nigeria D 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKAITEICMEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEVVICQYVDDLYVGSDLEIGQHRTKIEELRKHLLKWGLTTPDQKYQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEVIPLTKEAELELAENREILREPVHGVYYDPSKDLIAEVQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76750 AZT3TCNVP 2007 Nigeria C 0 1 335 PISPIEAVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTRNPEIIIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFFTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIQVRQLCKLIRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGNG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76751 AZT3TCNVP 2007 Nigeria D 0 1 335 PISTIQTVPVKLKPGMDGPKVKQWPLTKEKIEALTEICLEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSIPLDEDFRKYTAFTIPSTNNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEVVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGLTTPDQKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEIIPLTREAELELAENREILKEPVHGVYYDPSKDLIAEVQKQGQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76754 AZT3TCNVP 2007 Nigeria CRF02_AG 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKNGTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTANPEIVIYQYVDDLYVGSDLEIEQHRAKIEELRGHLLKWGLFTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLIRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76755 TDF3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPYRAKNPEVVIYQYMDDLYVASDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIQIKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPAKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76763 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICMEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLHKKKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSRNNEKPGIRYQYNVLPQGWKGSPAIFQHSMTKILDPFRTKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76765 D4T3TCNVP 2007 Nigeria CRF06_cpx 0 1 335 PISPIKTVPVRLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTRNPEMVICQYVDDLYVGSDLEIGQHRAKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPITLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCRLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQEQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76767 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTEICLEMEKEGKISKIGPENPYNTPVFAIKKKNSSRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNQTPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVICQYVDDLYVASDLEIGQHRAKIKELREHLLKWGFTTPDEKHQKEPPFLWMGYELHPDKWTVQPIKLPDKDCWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76768 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTDICAEMEEEGKISRIGPENPYNTPVFVIRKKDSTKWRKLIDLRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPMGWKGSPAIFQASMTKILAPFRAKYPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDQKYQKEPPFRWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGTKALTDVVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEVQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76769 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTREKIEALTDICTELEKDGKISRIGPDNPYNTPIFAIKKKGSNKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKKKSVTIIDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTENPEMVICQYVDDLYVASDLEIGQHRAKIDELRKYLLKRGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDIVPLTQEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76771 AZT3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAELEKDGKISRIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEIQLGLPHPGGLKKKRSVTVLDVGDAYFSVPLDENFRKYTAFTVPSINNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPYRTNNPEMVICQYVDDLYVASDLEIGQHRAKVEELREHLLKWGLFTPDKKYQKEPPFLWMGYELHPDKWTVQPIKLPDKEVWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76773 AZT3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKELEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRQATVIDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQTSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRQYLLKWGFYTPDKKHQKEPPLLWMGYELHPDKWTVQPIKLPDKESWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76775 TDF3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAFFSVPLDEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKENPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFIWMGYELHPDKWTVQPIQLPEKDRWTVNDIQKLVGKLNWASQIYAGIKIKQLCKLLRGAKALTDIATLTEEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76777 AZT3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDETFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKNNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPEQKHQKEPPFLWMGYELHPDKWTVQSIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEIVPLTEEAELELAENREILREPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76778 AZT3TCNVP 2007 Nigeria G 0 1 333 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNQTPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRKNNPELVIYQYVDDLYVGSDLEIEQHRAKIEELRDHLWRWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKIKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76779 AZT3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKVGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFCEVQLGIPHPAGLEKKRSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNQTPGVRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTRNPEMVIYQYVDDLYVASDLEIGQHRAKIEELREHLLSWGLTTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPDKENWTVNDIQKLVGKLNWASQIYPGIKVRQLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDSSKELIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76782 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTRNPEMVICQYVDDLYIGSDLETGQHRAKIEELREHLLKWGFTTPEKKHQKEPPFLWMGYELHPDKWTIQPIQLPDKESWTVNDIQKLVGKLNWASQIYSGIKIRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76784 D4T3TCNVP 2007 Nigeria B 0 1 335 PISPIKTVPVKLKPGMDGPKVKQWPLTAEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYVDDLYVSSDLEIGQHRTKIEELRQHLLKWGFTTPDEKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76787 AZT3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICADMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPELVIYQYVDDLYVGSDLEIGQHRAKIEQLRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVALTEEAELELAENREILKEPVHGVYYDPTKELVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76788 AZT3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICAEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQSIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVTLTEEAELELAENREILKEPVHGAYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76789 AZT3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTDICTEMEKEGQISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIKELREHLLKWGFITPDKKHQKEPPFLWMGYELHPDKWTVQAIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKNLCKLIRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76793 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKGGTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLXKKKSVTILDVGDAYFSVPLHEDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFFTPEEKHQKEPPFLWMGYELHPDKWTLQPVQLPDKESWTVNDIQKLVGKLNWASQIYPGIRVKQMCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKXIIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76794 TDF3TCNVP 2007 Nigeria G 0 1 333 PISLIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKRSITVLDVGDAFFSVPLDKSFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPEIVICQYVDDLYVASDLEIGQHRAKVEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76796 TDF3TCNVP 2007 Nigeria CRF02_AG 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICADMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVICQYIDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDQKHQKEPPFLWLGYELHPDKWTVQQIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIRVKQLCKLLKGAKALTDIVTLTEEAELELAENREILREPVHGVYYDPPKDLVAEIPKPGPG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76800 TDF3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICQDMEKEGKISKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKRNKSATVLDVGDAFFSIPLDENFRKYTAFTIPRLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYIDDLYVGSDLEIGQHRAKIKELREHLLTWGLTTPDEKHQKEPPLLWMGYELHPDKWTVQPIQLPDKEDWTVNDIQKLVGKLNWASQIYPGIKVKHLCRLLRGAKALTEIVPLTAEAQMELAENREILKEPVHGVYYEPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76801 AZT3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTELEEAGKISRIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILRPFRTENPEIVICQYVDDLYVASDLEIGQHRAKIEELREHLWRWGFYTPENKHQKEPPFLWMGYELHPDKWTVQPIQLPDKENWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76802 D4T3TCNVP 2007 Nigeria CRF01_AE 0 1 333 PISPIHTVPVNLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPVFAIKKKGSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIICQYVDDLYVGSDLEIEQHRTKVEELRAHLLRWGLTTPDEKHQKEPPFRWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLIRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76803 AZT3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICLEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSVTVLDVGDAYFSVPLDPNFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRNKNPDIEICQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFFTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLKGAKALTDIVPLTEEAELELAENREILREPVHGVYYDPSKELIAEIQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76804 AZT3TCNVP 2007 Nigeria CRF06_cpx 0 1 335 PISPIETVPVKLKPGMDGPRIKQWPLTEEKIRALTEICEELEKEGKISKIGPENPYNTPIFAIKKKNSTKWRKIVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRKKNPEMVIYQYVDDLYVASDLEIGKHRAKIEELREHLWKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQAIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKHLCRLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76805 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEIQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILRPFTTENPEIVIYQYVDDLYVGSDLEIGQHRAKIKELREHLLKWGFTTPDQKHQKEPPFLWMGYELHPDTWTVQPIQLPEKDNWTVNDIQKLVGKLNWASQIYAGIRVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76806 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICLEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIDELREHLLRWGFTTPDKKYQKEPPFLWMGYELHPDTWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76809 AZT3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICTELEKEGKISKIGPENPYNTPIFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKRSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPEIVICQYVDDLYVASDLEIGQHRAKVEELREHLLRWGLFTPDEKHQKEPPFHWMGYELHPDKWTVQPIQLPNKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76810 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDKNFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMKKILDPFRTKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76811 D4T3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKGGTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKVATVLDVGDAYFSVPLHEDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPDKKDWTVNDIQKLVGKLNWASQIYPGIKVRHLCRLLRGAKALTEIVPLTAEAEMELAENREILKEPVHGVYYDSEKELIADVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76812 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQDSMTKILKPFRTENPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76813 D4T3TCNVP 2007 Nigeria A 0 1 334 PISPIKTVPVKLKPGMDGPRVKQWPLTEEKIIALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNERPGVRYQYNVLPQGWKGSPAIFQDSMIKILEPYRKQNPEIIIIQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDVVTLTEEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76814 D4T3TCNVP 2007 Nigeria B 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKAIVEICAELEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRVKIEELRQHLLKWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQEHG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76815 AZT3TCNVP 2007 Nigeria G 0 1 333 PISPIETIPVKLKPGMDGPKVKQWPLTGEKIKALTEICAEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDENFRKYTAFTVPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76817 AZT3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICNDMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSATVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKEDWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDIVPLTAEAEMELAENREILKEPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76818 TDF3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISTIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTDICIEMEKEGKISRIGPENPYNTPVFAIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVLDVGDAFFSVPLDEEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTRNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKEHWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLIRGTKALTDIVTMTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76819 AZT3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTEICADMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIKLPDKEDWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILREPVHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76820 AZT3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVALKPGMDGPKVKQWPLTEEKIKALTAICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSINNATPGVRYQYNVLPQGWKGSPAIFQTSMTKILEPYRTKNPEMVIYQYVDDLYVASDLEIGQHRAKIEELRKHLLNWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKEHWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVTLTEEAELELAENREILKESVHGGYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76822 AZT3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRIKQWPLTEEKIKALTEICKDMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVLDVGDAYFSVPLDPDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPDKENWTVNDIQKLVGKLNWASQIYPGIKVRHLCRLLRGAKALTDIVPLTTEAEMELAENREILKEPVHGVYYDPSKDLVAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76824 TDF3TCNVP 2007 Nigeria G 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLRKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILDPFRARNPEIVICQYIDDLYVGSDLEIGQHREKIEELRAHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEVVTLTQEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76825 AZT3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEKDGKISKIGPENPYNTPVFAIKKKDSTKWRKIVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTRILEPFRTRNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLWKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCRLIRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76827 TDF3TCNVP 2007 Nigeria CRF02_AG 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFVIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNSGITIVQYVDDLYVGSDLEIEQHRAKVEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76828 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPRIKQWPLTEEKIKALTEICAELEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNRRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPEIVICQYVDDLYVGSDLEIGQHREKIEELRDHLLKWGLSTPEQKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYAGIQVRQLCKLLRGAKALTDVVTLTEEAELELAENREILKKPVHGVYYDPLKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76831 D4T3TCNVP 2007 Nigeria CRF02_AG 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTDICNEMEKEGKISKIGPDNPYNTPVFVIKKKDSTKWRKLTDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTVPSINNATPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTRNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDVVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76832 AZT3TCNVP 2007 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTELEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIDELRAHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKENWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILREPAHGVYYDPSKDLIAEVQKQG Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76833 AZT3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPINTVPVKLKPGMDGPKVKQWPLTKEKIEALTAICKEMEEEGKISKIGPENPYNTPVFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQTSMTKILEPFRKTNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYPGIRTKQLCKLIRGAKALTDVVTMTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76834 AZT3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTENPEIVIYQYVDDLYVASDLEIGQHRAKIEELRNHLLKWGLTTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCRLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1834 76836 AZT3TCNVP 2007 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLEKKKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPDKDSWTVNDIQKLVGKLNWASQIYPGIRVKQMCKLLRGAKALTDIVTLTEEAELELAENREILREPVHGVYYDPAKDLVAEIQKQGQ Hawkins, CA 2009 19644383 JAIDS Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. 1867 78392 D4T3TCNVP 2006 Cambodia CRF01_AE 0 38 247 CEEMEKEGKISKIGPENPYNTPVFAIKRKDGTRWRKLMDLRELNKRTQDFWEVQLGIPHPAGLQKRKSVTVLDIGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPMGWKGSASIFQSSMTKILEPFKIKNPEMVICQYMDDLYVASDLEIGQHRTKIEELRAHLLNWGLTTPEEKHQKEPPFRWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78393 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CKEMENEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKNKSITVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRAKIDELRAHLLSWGFFTPDKKHQKEPPFLWLGYELHPDKWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78394 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CEEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78395 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKSFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRNNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78396 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDNTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFHWMGYELHPDTWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78397 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78398 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CEDMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRIKIEELRSHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78399 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIIIYQYVDDLYVASDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIKLP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78400 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CEEMEKEGKISKIGPENPYNTPVFAIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPTIFQSSMTKILEPFRTKNPEMVICQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78401 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIIICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDRWTVQPIILP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78402 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPTIFQCSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78403 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CNEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKTLEPFRLKNPEIVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKLQKEPPFLWMGYELHPDKWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78404 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CKEMEKEGKISRIGPENPYNTPVFAIKNKDNTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTLPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHREKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78405 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CNEMEKEGKISKIGPENPYNTPIFAIKKKDSNKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTMPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEMVIYQYVDDLYIGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78406 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKENPEIVIYQYMDDLYVGSDLEIGQHRTKIEQLRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78407 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILDPFRAKNPEIVICQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKYQKEPPFLWLGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78408 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CREMEEEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPVRMKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGLTTPDKKYQKEPPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78409 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78410 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CKEMEEEGKISRIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQNSMAKILEPFRIKNPEMIICQYIDDLYVGSDLEIEQHRTKIEELRAHLLSWGFTTPDRKHQKEPPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78411 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CREMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEIVIYQYMDDWYVGSDLEIGQHRAKIEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDRWTVQPVELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78412 D4T3TCNVP 2006 Cambodia CRF01_AE 0 38 247 CAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAFFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRLKNPELVIIQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78413 D4T3TCNVP 2006 Cambodia CRF01_AE 0 38 247 CNEMEKEGKISKIGPESPYNTPVFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDESFRKYTAFTLPSINNETPGVRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEIVICQYVDDLYIGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFRWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78414 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTRILEPFRLKNPEMVICQYMDDLYVGSDLEIGQHRIKIEELRAHLLNWGFTTPDKKHQKEPPFRWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78415 D4T3TCNVP 2006 Cambodia CRF01_AE 0 38 247 CEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLNWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78416 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CKELEKEGKISKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNQTPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIEQHRAKIEELRGHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPVELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78417 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWGVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILDPFRKSNPELVIYQYVDDLLVGSDLEIGQHRTKIEELRAHLLRWGFTTPDKRHQKEPPFLWMGYELHPDKWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78419 D4T3TCNVP 2006 Cambodia CRF01_AE 0 38 247 CKEMEKEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYMDDLYVGSDLEIGQHRVKIEELRAHLLNWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78420 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKYPEIVICQYVDDLYVGSDLEIGQHRAKIKELREHLLRWGFTTPDKKHQKEPPFRWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78421 D4T3TCNVP 2006 Cambodia CRF01_AE 0 38 247 CKELEKEGKISKIGPENPYNTPIFAIKKKGGTRWRKLTDFRELNKRTQDFWEVQLGIPHPAGLKRKKSITILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIIICQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGLTTPDEKYQKEPPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78423 D4T3TCNVP 2006 Cambodia CRF01_AE 0 38 247 CNEMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDIGDAYFSVPLHESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSTMTRILEPFRIKNPEIDIYQYMDDLCVASDLEIGQHRAKIDELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78425 D4T3TCNVP 2006 Cambodia CRF01_AE 0 38 247 CKEMKEEEKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSTMTKILEPFRTKNPEMVIYQYMDDLYVASDLEIGQHRMKIEELREHLLRWGFSTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78427 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CEEMEKEGKISKIGPENPYNTPVFAIKKKDKTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDNKHQKEPPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78428 D4T3TCNVP 2006 Cambodia CRF01_AE 0 38 247 CNEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRMKNPDMVICQYVDDLYVGSDLEIGQHRIKIDELRAHLLSWGLTTPDKKYQKEPPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78429 D4T3TCNVP 2006 Cambodia CRF01_AE 0 38 247 CEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSIPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78430 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CEEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEMVIYQYVDDLLVGSDLEIGQHRAKIEELRSHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78431 D4T3TCNVP 2006 Cambodia CRF01_AE 0 38 247 CEEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLTKSKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEMDICQYVDDLYVASDLEIGQHRIKIEELRAHLLSWGFFTPEEKHQKEPPFHWMGYELHPDKWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78432 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CKEMEEEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNKTPGIRYQYNVLPQGWKGSPTIFQSSMTRILEPFRIKNPEIVICQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78434 D4T3TCNVP 2006 Cambodia CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMIIYQYMDDLYVGSDLEIEQHRTKIQELRDHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78435 D4T3TCNVP 2006 Cambodia CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMIIYQYMDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIKLP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78436 D4T3TCNVP 2006 Cambodia CRF01_AE 0 38 247 CEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPVELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78437 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEMIIYQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDQKHQKEPPFLWMGYELHPDRWTIQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78438 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CREMEEEGKISRIGPENPYNTPVFAIKKKNSTKWRKLIDFRELNKRTQDFCEVQLGIPHPAGLRKKKSVTVLDVGDAYFSVPLDESFRKYTAFTLPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMAKILEPFRIKNPEMIICQYVDDLYVGSDLEIGQHRIKIDELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78440 D4T3TCNVP 2006 Cambodia CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRLKNPEMIIYQYVDDLYVASDLEIGQHRIKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78441 D4T3TCNVP 2006 Cambodia CRF01_AE 0 38 247 CEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMIIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78442 D4T3TCNVP 2005 Cambodia CRF01_AE 0 38 246 CNEMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRAKNPEIVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLRWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIEL Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78443 D4T3TCNVP 2005 Cambodia CRF01_AE 0 40 247 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMIKILEPFRIKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78445 D4T3TCNVP 2005 Cambodia CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPCNTPVFAIKKKNSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEIVICQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78446 D4T3TCNVP 2006 Cambodia CRF02_AG 0 38 247 CTEMEKEGKISRIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQTSMTKILEPFRTRNPEMVICQYVDDLYVGSDLEIGQHRTKIEELREHLMRWGFSTPDKKYQKEPPFLWMGYELHPDKWTVQTIQLP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78447 AZT3TCNVP 2006 Cambodia CRF01_AE 0 38 247 CKELEEEGKISKIGPENPYNTPIFAIKKKGSNRWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDIGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSLTRILEPFRIKNPEMIICQYVDDLYVGSDLEIGQHRTKIEELRAHLWSWGFFTPDQKHQKEPPFIWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78448 D4T3TCNVP 2007 Cambodia CRF01_AE 0 38 247 CNEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRRKNPEIVIYQYVDDLYVGSDLEIGQHRKIIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDSWTVQPIKLP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78449 D4T3TCNVP 2006 Cambodia B 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKKKDGIKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPDLVIYQYVDDLYVGSDLEIEQHRAKIEELRHHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIMLP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78450 D4T3TCNVP 2006 Cambodia CRF01_AE 0 38 247 CEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMIICQYVDDLYVGSDLEIGQHRMKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78451 D4T3TCNVP 2006 Cambodia CRF01_AE 0 38 247 CTEMEKEGKISRIGPENPYNTPIFAIKKKNSDKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYYSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMLKILEPFRKQNPDIVIYQYVDDLYVSSDLEIEKHRTKIEELRQHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIKLP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78452 D4T3TCNVP 2006 Cambodia CRF01_AE 0 38 247 CKEMEKEGKISKIGPENPYNTPIFAIKRKGGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSAAIFQSSMIKILEPFRRKNPEIVICQYMDDLYVGSDLEIGQHRIKVEELRAHLLSWGFTTPDEKYQKEPPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78453 D4T3TCNVP 2006 Cambodia CRF01_AE 0 38 247 CEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEMVIYQYMDDLYVGSDLEIGQHRRKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78454 D4T3TCNVP 2006 Cambodia CRF01_AE 0 38 247 CEEMEQEGKISKIGPENPYNTPVFAIKKKDSNKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPELVICQYVDDLYVGSDLEIGQHRARIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDSWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78456 D4T3TCNVP 2006 Cambodia CRF01_AE 0 38 247 CKEMEAEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEMVIYQYMDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIALP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78457 D4T3TCNVP 2006 Cambodia CRF01_AE 0 38 247 CKEMEEEGKISKIGPENPYNTPVFVIKNKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRAKVEELRDHLLRWGFTTPDRKHQKEPPFLWMGYELHPDKWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78458 D4T3TCNVP 2006 Cambodia CRF01_AE 0 38 247 CKELEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLWSWGFFTPDKKHQKEHPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78460 D4T3TCNVP 2006 Cambodia CRF01_AE 0 38 247 CEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEVVICQYVDDLYVGSDLEIGQHRIKIEELRAHLLKWGFTTPDKKYQKEPPFRWMGYELHPDRWTVQPIVLP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78461 D4T3TCNVP 2005 Cambodia CRF01_AE 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIIIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78462 D4T3TCNVP 2006 Cambodia CRF01_AE 0 38 247 CEEMEKEGKISKIGPENPYNTPVFAIRKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEMIICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDRWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1867 78464 D4T3TCNVP 2005 Cambodia CRF01_AE 0 38 247 CKELEEAGKISKIGPENPYNTPIFAIKKKNSTKWRKIVDFRELNKRTQDFWEVQLGIPHPGGIEKKKSITILDVGDAYFSIPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQNSMTRILEPFRIKNPEIIIIQYVDDLYVASDLEIGQHRIKVEELRAHLWNWGFYTPDNKHQKEPPFLWMGYELHPDKWTVQPIELP Zolfo, M 2010 20854169 ARHR Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. 1881 79786 D4T3TCNVP 2005 Uganda C 1 1 334 PISPIETVPVKLKLGMDGPKVKQWPLTEEKIEALTAICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVICQYVDDLYVGSDLEIGQHRAKVEELRDHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYPGVKVKHLCKCIRGTKTLTEVVPLTEEAELELAENREILREPVHGVYYDPSKDLIAEIQKQGQ Towler, WI 2010 20455758 ARHR Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda. 1881 79787 D4T3TCNVP 2004 Uganda A 1 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICLEMEKDGKISKIGPENPYNTPIFAIKKKDGNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSIPLDESFRKYTAFTIPSTNNEKPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPYRAKNPEIIIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPDKESWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVTLTEEAELELAENREILKDPVHGVYYDPSKDLIAEIQKQGQ Towler, WI 2010 20455758 ARHR Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda. 1881 79788 D4T3TCNVP 2005 Uganda A 1 1 334 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTLPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPDIIIYQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFSTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCRLLRGTKALTDVVTLTEEAELELAENREILKDPVHGVYYDPSKELIAEIQKQGQ Towler, WI 2010 20455758 ARHR Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda. 1881 79791 D4T3TCNVP 2005 Uganda A 1 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKAITEICKELEKEGKISRIGPENPYNTPIFAIKKKGSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQDRMTKILEPFRLKNPEIIICQYVDDLYVGSDLEIEQHRAKVEELRAHLLSWGLFTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQ Towler, WI 2010 20455758 ARHR Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda. 1881 79795 D4T3TCNVP 2005 Uganda D 1 1 335 PISPIETVPVSLKPGMDGPRVKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYVDDLYVASDLEIKQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEVIPLSEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQG Towler, WI 2010 20455758 ARHR Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda. 1881 79796 D4T3TCNVP 2005 Uganda A 1 1 335 PISPISTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIIYQYVDDLYVASDLEIGQHRAKIKELREHLLSWGFTTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYTGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKDPVHGVYYDPAKDLIVEIQKQGQG Towler, WI 2010 20455758 ARHR Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda. 1881 79799 D4T3TCNVP 2005 Uganda A 1 1 334 PISPIETVPVQLKPGMDGPRVKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPEIIIYQYVDDLYVASDLEIGQHRAKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDVVTLTEEAELELAENREILKNPVHGVYYDPSKDIIAEIQKQGQ Towler, WI 2010 20455758 ARHR Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda. 1885 80178 AZT3TCNVP 2006 France A 0 38 247 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRSQNPEIIIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Rey, D 2009 19036752 AAC High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. 1885 80179 TDF3TCNVP 2006 France B 0 38 247 CTEMEKEGKISRIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNRRTQDFWEVQLGIPHPAGLEKRKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVVCQYIDDLYVASDLEIGKHRTKVEELRQHLLKWGFCTPDKKHQKEPPFLWMGYELHPDKWTVQPITLP Rey, D 2009 19036752 AAC High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. 1885 80180 TDF3TCNVP 2006 France B 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIDICQYVDDLYVASDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIVLP Rey, D 2009 19036752 AAC High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. 1885 80181 TDF3TCNVP 2006 France B 0 38 247 CNEMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVICQYMDDLYVASDLEIGQHRAKIEALRTHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Rey, D 2009 19036752 AAC High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. 1885 80182 TDF3TCNVP 2006 France B 0 38 247 CTEMEKEGKISKIGPENPYNTPVFVIKRKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPEIVICQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Rey, D 2009 19036752 AAC High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. 1885 80183 TDF3TCNVP 2006 France G 0 38 247 CTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYIDDLYVGSDLEIGQHRAKIEELREHLLAWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Rey, D 2009 19036752 AAC High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. 1885 80184 TDF3TCNVP 2006 France B 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDETFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKQNPDIVICQYMDDLYVASDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Rey, D 2009 19036752 AAC High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. 1885 80185 TDF3TCNVP 2006 France C 0 38 247 CEEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIDIYQYMDDLYVASDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFQWMGYELHPDRWTVQPIQLP Rey, D 2009 19036752 AAC High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. 1885 80186 TDF3TCNVP 2006 France A 0 38 247 CNEMEKEGKISKIRPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRAKNPEIVICQYMDDLYVASDLEIEQHRTKIEELRAHLLSWRFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Rey, D 2009 19036752 AAC High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. 1908 81440 AZT3TCEFV 2002 U.S. B 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHREKIEELRQHLLNWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Gulick, RM 2004 15115831 N Engl J Med Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 1908 81497 AZT3TCEFV 2002 U.S. B 0 37 247 VCTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVNFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGNAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Gulick, RM 2004 15115831 N Engl J Med Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 1908 81517 AZT3TCEFV 2002 U.S. B 0 38 247 CTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Gulick, RM 2004 15115831 N Engl J Med Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 1908 81517 AZT3TCEFV 2003 U.S. B 0 1 254 PISPIETVPVKLKTGMDGPKLKRCALTEEKIKALVEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTV Gulick, RM 2004 15115831 N Engl J Med Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 1908 81519 AZT3TCEFV 2003 U.S. B 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQEFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDMVIYQYMDDLYVGSDLEIGQHRTKIEQLRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Gulick, RM 2004 15115831 N Engl J Med Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 1908 81535 AZT3TCEFV 2004 U.S. G 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTNNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Gulick, RM 2004 15115831 N Engl J Med Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 1908 81599 AZT3TCEFV 2002 U.S. B 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAVFQSSMTKILEPFRKENPEIVIYQYMDDLYVGSDLEIGQHRTKIDELRQHLLRWGFTTPDKKHQKEPPSLWMGYELHPDKWTVQPIVLP Gulick, RM 2004 15115831 N Engl J Med Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 1908 81624 AZT3TCEFV 2002 U.S. B 0 38 247 CTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKVEELRQHLFKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Gulick, RM 2004 15115831 N Engl J Med Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 1908 81624 AZT3TCEFV 2002 U.S. B 0 38 247 CTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKVEELRQHLFKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Gulick, RM 2004 15115831 N Engl J Med Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 1908 81629 AZT3TCEFV 2002 U.S. B 0 38 247 CAEMEKEGKISRIGAENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGNAYFSVPLDEEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPELVIYQYMDDLYVASDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPNKWTVQPIELP Gulick, RM 2004 15115831 N Engl J Med Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 1908 81655 AZT3TCEFV 2003 U.S. B 0 38 247 CTEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTRILDPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Gulick, RM 2004 15115831 N Engl J Med Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 1908 81657 AZT3TCEFV 2004 U.S. B 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKKNPDMVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Gulick, RM 2004 15115831 N Engl J Med Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 1908 81668 AZT3TCEFV 2002 U.S. B 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDQNFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPEMVIYQYMDDLYVGSDLEIEQHRAKIEELRQHLLGWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLP Gulick, RM 2004 15115831 N Engl J Med Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 1908 81691 AZT3TCEFV 2003 U.S. B 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNEXPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRKHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Gulick, RM 2004 15115831 N Engl J Med Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 1908 81691 AZT3TCEFV 2003 U.S. B 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLSQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRKHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Gulick, RM 2004 15115831 N Engl J Med Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 1908 81726 AZT3TCEFV 2003 U.S. B 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHREKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Gulick, RM 2004 15115831 N Engl J Med Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 1908 81726 AZT3TCEFV 2003 U.S. B 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHREKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Gulick, RM 2004 15115831 N Engl J Med Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 1908 81736 AZT3TCEFV 2002 U.S. B 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKENPDIVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGLTTPDKKHQKEPPFLWMGY*LHPDKWTVQPIQLP Gulick, RM 2004 15115831 N Engl J Med Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 1908 81741 AZT3TCEFV 2003 U.S. B 0 38 247 CTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKQHSDIDIYQYMDDLYVGSDLEIEQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Gulick, RM 2004 15115831 N Engl J Med Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 1908 81746 AZT3TCEFV 2002 U.S. B 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPELVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Gulick, RM 2004 15115831 N Engl J Med Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 1908 81792 AZT3TCEFV 2002 U.S. B 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRQKIEELRQHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Gulick, RM 2004 15115831 N Engl J Med Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 1908 81801 AZT3TCEFV 2002 U.S. B 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSITVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDLVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Gulick, RM 2004 15115831 N Engl J Med Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 1908 81830 AZT3TCEFV 2002 U.S. B 0 38 247 CTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKKNPELVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Gulick, RM 2004 15115831 N Engl J Med Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 1908 81830 AZT3TCEFV 2002 U.S. B 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKKNPELVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVN Gulick, RM 2004 15115831 N Engl J Med Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 1908 81844 AZT3TCEFV 2002 U.S. B 0 38 247 CADMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDGEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRNKNPDLVIYQYMDDLYVGSDLEIEQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQHIELP Gulick, RM 2004 15115831 N Engl J Med Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. 1911 82465 AZT3TCEFV 2005 South Africa C 0 26 273 LSEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFREQNPEIVIYQYMDDLYVASDLEIGQHRAKIEELRKHLLHWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPG Hoffmann, C 2009 19911963 Clin Infect Dis Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in south Africa. 1913 83499 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLLVGSDLEIKQHREKIEELREHLLKWGFTTPDEKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83500 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGHELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83501 D4T3TCNVP 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPELVIYQYVDDLYVGSDLEIGQHRAKIEKLRDHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83502 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVQLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83503 AZT3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKELEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83504 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILAPFRAQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83505 AZT3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIRALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTRILEPFRAQNPEIVIYQYMDDLYVGSDLEIQQHRAKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83506 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRMRNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRVHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83507 AZT3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPLFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYVDNLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83508 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83509 AZT3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEELEKEGKITKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPDIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKYQKEPPFLWMGHELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83510 AZT3TCNVP 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFITPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83511 AZT3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKYQKDPPFLWMGYELHPDTWTVQPIKLPEKESWTVNDLQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83512 AZT3TCEFV 2008 South Africa C 0 7 258 TVPVTLKPGMDGPKIKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSTMTKILEPFRAQNPEIVIYQYVDDLCVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83513 AZT3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVRQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIEQHRAKIEELREHLLKWGLFTPDEKHQKEHPFLWMGYELHPDKWTVQPIQLPVKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83514 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKNKSVTVLDVGDAYFSIPLDEGFRKYTAFTIPSTNNAAPGTRYQYNVLPQGWKGSPAIFQSSMIKILEPFRTKNPDLVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKNSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83515 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPRVKQWPLTEEKLKALIEICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGLRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELRDHLLKWGFITPDKKYQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83516 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRAHLLKWGFTTPDKKYQKEPPFLWLGYELHPDKWTVQTIQLPEKESWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83517 AZT3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNATPGSRYQYNVLPQGWKGSPAIFQSSMLKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGQHRAKVEELRAHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83518 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKLKALTEICNEMEKEGKITKIGPENPYNTPIFATKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILNPFRAKNPDIVIYQYVDDLYVGSDLEIEQHRAKVEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83519 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83520 AZT3TCEFV 2008 South Africa C 0 6 258 DTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTVPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMVKILEPFRAKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83521 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVASDLELEQHRAKIEELREHLLKWGLTTPDKKHQKEPPLLWMGHELHPDKWTVQSIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83522 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLSEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSATVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPDKECWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83523 AZT3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSTMLKILEPYRTKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83524 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFREQNPEMVIYQYIDDLLVGSDLEIGQHRAKIEKLRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83525 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSAPLDESFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIMQHRAKVEELRDHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83526 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTRNPGIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83527 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPRVRQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRAKYPEIVICQYIDDLYVGSDLEIGQHRAKIEELREHLLKWGLITPDRKHQKEHPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83528 D4T3TCNVP 2008 South Africa C 0 6 258 ETVPVKLNPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEDLRDHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIKLPDQDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83529 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPIKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEAFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIDELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWSVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83530 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAENPEIVIYQYMDDLYVGSDLEITQHRAKIEELRKHLLTWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83531 D4T3TCEFV 2008 South Africa C 0 6 258 DTVPVKLKPGMDGPRVKQWPLTEEKIKALTEICQEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRVHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83532 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVRQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRAGNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEHPFQWMGYELHPDKWTVQPIQLPEKESWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83533 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGKRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPGIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83534 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTRILEPFRARNPEIVIYQYMDGLYVESDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDNWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83535 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSTNNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEVVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83536 D4T3TCNVP 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAENPEIVIYQYMDDLCVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83537 AZT3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLRWGFTTPDQKHQKEPPFLWMGHELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83538 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKWNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDLQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83539 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTTFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83540 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPDNPYNTPVFAIKKKDGTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYVDDLHVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPINLPEKDNWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83541 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIKLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83542 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNATPGVRYQYNVLPQGWKGSPAIFQASMTKILQPFRIKNPDIVIYQYVDDLLVGSDLEIGQHRAKVEELREHLLTWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIHLPDKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83543 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTKEKIQALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKESPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83544 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRTKIDELREHLLKWGFFTPDKKHQKEHPFLWLGYELHPDKWTVQPIKLPEKESWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83545 D4T3TCEFV 2008 South Africa C 0 6 258 DTVPVKLKPGMDGPRIKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPEQDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83546 ABC3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEELEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLWKWGFYTPDKKHQKEPPFLWLGYELHPDKWTVQTIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83547 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPVFAIKKKDSAKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83548 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSINNQTPGVRYQYNVLPQGWKGSPAIFQSSMLKILEPFRAKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRRHLLEWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83549 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83550 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICGEMEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKRKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTQNPDIVIYQYVDDLYVASDLEIKQHRAKIEELRGHLLKWGLTTPDKKHQKEPPFYWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83551 AZT3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83552 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSLTVLDVGDAYFSIPLDENFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRTKNPDIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83553 AZT3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVRQWPLTEEKLKALTEICADMEKEGKITKIGPENPYNTPVFAIRKKDSTKWRKLIDFRELNKRTQDFSEIQLGIPHPAGIEKKKSMTVLDVGDAYFSIPLDEDFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRIKNPDIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83554 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILAPFRARNPEIVIYQYVDDLYVGSDLEIEQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83555 D4T3TCEFV 2008 South Africa C 0 6 258 DTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKNNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKQNPDIVIYQYVDDLYVASDLEIRQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83556 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKYQKEPPFLWLGYEIHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83557 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLNPGMDGPKVKQWPLSEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSMNNQTPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIEQHRAKIKELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83558 AZT3TCNVP 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83559 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQWSMTKILAPFREQNPNIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKYQKEPPFLWMGHELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83560 AZT3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIEQHRAKIEELREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIELPEKDDWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83561 D4T3TCEFV 2008 South Africa C 0 6 258 DTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTKNPEIVIYQYVDDLLVGSDLEIVQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83562 D4T3TCEFV 2008 South Africa C 0 7 258 TVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAKNPEIVIYQYVDDLLVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83563 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVQLKPGMDGPKVKQWPLTEEKIKALTEICDEMEREGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSLNNESPGKRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEVVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83564 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLSEEKIKALTEICEEMEKEGKITRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTILDVGDAYFSVPLDVNFRKYTAFTIPSRNNETPGIRYQ*NVLPQGWKGSPAIFQCSMTKILEPFRTKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPNKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83565 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGTRFQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDLVIYQYVDDLYVGSDLEIGQHRAKIEKLRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83566 D4T3TCNVP 2008 South Africa G 0 6 258 ETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSTMTKILEPFRLKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRNHLLKWGFTTPDKKYQKEPPFLWLGYEIHPDKWTVQPIQLPDKETWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83567 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEDKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTVPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLCVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83568 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83569 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPRVKQWPLTQEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEKLREHLLKWGLTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83570 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGHELHPDKWTVQPIHLPEKDNWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83571 D4T3TCEFV 2008 South Africa C 0 6 258 DTVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIDIYQYVDDLYIGSDLEIGKHREKVEELREHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIMLPDKECWTVNDLQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83572 ABC3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEMVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDRWKVQPITLPEKDNWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83573 D4T3TCEFV 2008 South Africa C 0 6 258 ETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPDNPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSIPLDENFRKYTAFTIPSTNNATPGIRYHYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPDIEIYQYVDDLYVGSDLEIGQHRAKIEELRGHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQ El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83575 AZT3TCNVP 2008 South Africa C 0 1 282 PISPIETVPVKLKPGMDGPKVKQWPLTEDKIKALTAICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEINQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIQVKHLCRL El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83579 D4T3TCNVP 2008 South Africa C 0 1 282 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTTILEPFRVQNPELVIYQYMDDLYVGSDLEIGQHRAKIEKLRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKL El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83580 D4T3TCNVP 2008 South Africa C 0 1 282 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGLHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKL El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83581 D4T3TCEFV 2008 South Africa C 0 1 282 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVASDLEIRQHRAKIEELRRHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKHLCKL El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83587 D4T3TCEFV 2008 South Africa C 0 1 282 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKL El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83588 D4T3TCEFV 2008 South Africa C 0 1 282 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIRILEPFRAQNPEMVIYQYMDDLYVGSDLEIGQHRARVEKLREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVTQLCKL El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83589 D4T3TCEFV 2008 South Africa C 0 1 282 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPELVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIQVKQLCKL El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83591 D4T3TCEFV 2008 South Africa C 0 1 282 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDLVIYQYMDDLYVGSDLEIGQHRAKIDELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKL El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83601 AZT3TCEFV 2008 South Africa B 0 1 282 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKL El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83604 D4T3TCEFV 2008 South Africa C 0 1 282 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSVFQSSMTKILEPFRTKHPDLVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKL El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83608 AZT3TCEFV 2008 South Africa C 0 1 282 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKL El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83612 D4T3TCEFV 2008 South Africa C 0 1 282 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPEIVIYQYMDDLYVASDLELGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKL El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83616 D4T3TCEFV 2008 South Africa C 0 1 282 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKL El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83618 AZT3TCEFV 2008 South Africa C 0 1 282 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKL El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83619 D4T3TCEFV 2008 South Africa C 0 1 282 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIIIYQYMDDLYVGSDLEIGQHREKVEKLREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKL El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83621 D4T3TCEFV 2008 South Africa C 0 1 282 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIMALKAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAHNPDIVIYQYMDDLYVGSDLEIEQHRAKIEELREHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKL El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1913 83626 D4T3TCEFV 2008 South Africa C 0 1 282 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKLTKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPDIVIYQYVDDLYVASDLEIRQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNQDSWTVNDIQKLVGKLNWASQIYPGVKVKQLCKL El-Khatib, Z 2010 20453629 AIDS Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 1918 82737 D4T3TCNVP 2008 Kenya A 0 1 320 PISPIQTVPVKLKPGMDGPRIKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPGIVIYQYMDDLYVGSDLEIGQHRAKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPITLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVPLTKEAELELEENREILKDPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82738 AZT3TCNVP 2008 Kenya A 0 1 320 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIRALKEICAEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMIKILEPFREKNPEIIIYQYVDDLLVGSDLEIGQHRAKIEELRTHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTREAELELEENREILKDPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82739 AZT3TCNVP 2008 Kenya C 0 1 320 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEREGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDASFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQSIQLPEKDNWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82740 D4T3TCNVP 2008 Kenya D 0 1 320 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEVVIYQYVDDLYVGSDLEIGQHRIKIEELREHLLKWGFTTPDKKHQKEPPFRWMGYELHPDTWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYPGIKIKHLCRCIRGAKALTEIVPLTEEAELELAENREILKEPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82741 D4T3TCNVP 2008 Kenya A 0 1 320 PISHIETVPVTLKPGMDGPRIKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPELIIYQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDVVALTEEAELELAENREILKDPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82742 D4T3TCNVP 2008 Kenya A 0 1 320 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRLKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTDVVPLTQEAELELAENREILKDPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82743 AZT3TCNVP 2008 Kenya A 0 1 320 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTQICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVASDLEIGQHRIKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLKGAKALTDTVTLTEEAELELAENREILKDPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82744 ABC3TCNVP 2008 Kenya A 0 1 320 PISPIETVPVKLKPGMDGPKVRQWPLTAEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKGSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRSKNPEIVIYQYMDDLYVASDLEIGQHRAKIDELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIIPLTEEAELELAENREILKEPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82745 AZT3TCEFV 2008 Kenya A 0 1 320 PISSVETVPVALKPGMDGPRIKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPEIIIYQYMDDLYVGSDLEIGQHRTKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKDPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82746 ABC3TCNVP 2008 Kenya A 0 1 320 PISHIETVPVTLKPGMDGPKIKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEGFRKYTAFTIPSINNETPGIRYCYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDVVTLTEEAELELAENREILKDPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82747 AZT3TCNVP 2008 Kenya A 0 1 320 PISPIETVPVTLKPGMDGPKVKQWPLTEEKLKALKEICEEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGLYTPDKKYQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLKGTKALTDIVTLTEEAELELAENREILKDPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82748 D4T3TCEFV 2008 Kenya A 0 1 320 PISPIETVPVKLKPGMDGPRIKQWPLTEEKIKALTEICREMEEEEKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMTRILEPFRARNPELTIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKTLTDIVPLTEEAELELAENREILKDPVHGAYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82749 D4T3TCEFV 2008 Kenya A 0 1 320 PISPIETVPVELKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIIIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVTLTEEAELELAENREILKDPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82751 AZT3TCEFV 2008 Kenya C 0 1 320 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVKNLCKLIRGAKALTDIVTMTEEAELELAENREILKETVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82752 AZT3TCEFV 2008 Kenya A 0 1 320 PISPIETVPVTLKPGMDGPRIKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPEIIIYQYMDDLYVGSDLEIGQHRAKVKELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPSKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVTLTEEAELELAENREILKDPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82753 AZT3TCNVP 2008 Kenya D 0 1 320 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLNWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCLRGTKALTEVVSLTREAELELEENREILKEPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82754 D4T3TCNVP 2008 Kenya A 0 1 320 PISPIETVPVTLKPGMDGPKIKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYKVLPQGWKGSPAIFQSSMTKILKPFKAKNPKIVIYQYVDDLYVGSDLKIGQHKAKVEELKAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIQLPNKDSWTVNDIQKLGGKLNWASQIFPGIQVKQLCKLLKGAKALTNVVVLTEEAKLKLAKNREILKNPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82755 D4T3TCNVP 2008 Kenya A 0 1 320 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICKTMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMIKILEPFRSQNPEIIIYQYMDDLYVGSDLEIGQHRAKVEELRAHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEIVTLTEEAELELAENREILKDPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82756 D4T3TCNVP 2008 Kenya A 0 1 320 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDENFRKYTAFTIPSTNNEIPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIICQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPDKENWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKDPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82757 AZT3TCNVP 2008 Kenya D 0 1 320 PISPIETVPVKLKPGMDGPKVKQWPLTEEKVKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRKKIEQLRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYSGIKVKQLCKCIRGAKALTEVVPLTEEAELELAENREILKEPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82758 D4T3TCNVP 2008 Kenya A 0 1 320 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSITVLDVGDAYFSIPLHEDFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIVLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVTLTEEAELELAENREILKDPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82759 D4T3TCNVP 2008 Kenya D 0 1 320 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKITKIGPENPYNTPIFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLCEDFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYSGIKVRQLCKCIRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82760 AZT3TCNVP 2008 Kenya D 0 1 320 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLHEDFRKYTAFTIPSINNEVPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVICQYVDDLYVGSDLEIGQHRMKIEELREHLLKWGFTTPDKKYQKEPPFRWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKCIKGTKALTEVVPLTEEAELELAENREILKEPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82761 D4T3TCEFV 2008 Kenya A 0 1 320 PISHIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRSKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIILPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVTLTEEAQLELAENREILKDPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82762 AZT3TCNVP 2008 Kenya A 0 1 320 PISPIETVPVKLKAGMDGPRIKQWPLTEEKIKALTEICTELEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPEIIIYQYVDDLYVASDLEIGQHRAKVEELRAHLLSWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKTLTDIVPLTEEAELELAENREILKDPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82763 AZT3TCNVP 2008 Kenya A 0 1 320 PISPIKTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIIIYQYVDDLYVASDLEIGQHRAKVEELRDHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKEHWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVPLTEEAELELAENREILKNPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82764 AZT3TCNVP 2008 Kenya A 0 1 320 PISPVETVPVKLKPGMDGPRIKQWPLTEEKIKALTEICREMEKEGKISKIGPENPYNTPVFAIKKKSSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSATVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMVKILEPFRTQNPEITIYQYMDDLYVGSDLEIGQHRAKVEELRAHLLRWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQTIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82765 AZT3TCNVP 2008 Kenya B 0 1 320 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICGEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQHPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCRLLRGAKTLTDIVPLTKEAELELEENREILKDPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82766 AZT3TCNVP 2008 Kenya A 0 1 320 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICLEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRSKNPEIVIYQYVDDLYVASDLEIEQHRTKIAELRAHLLSWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKETWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKTLTDVVTLTEEAKLELAKNREILKNPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82767 AZT3TCNVP 2008 Kenya A 0 1 320 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIIIYQYMDDLYVGSDLEIGQHRAKVEELRDHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKEHWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVPLTEEAELELAENREILKNPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1918 82768 D4T3TCNVP 2008 Kenya A 0 1 320 PISPIETVPVQLKPGMDGPKVKQWPLTEEKIKALTDICTDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTEVVTLTEEAELELAENREILKEPVHGVYYD Hue, S 2011 21770741 ARHR HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination. 1920 84988 D4T3TCNVP 2008 Central African Republic CRF11_cpx 0 24 231 WPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYMDDLYVGSDFEIGQHREKVEELREHLLRWGFTTPDKKHQKEPPFLWMG Moussa, S 2010 20939688 ARHR First data on HIV-1 resistance mutations to antiretroviral drugs in Central African Republic. 1920 84989 AZT3TCNVP 2008 Central African Republic CRF11_cpx 0 12 244 LKPGMDGPKVKQWPLTEEKIKALTEICADMEKEGKISKIGPENPYNTPVFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPARLKMKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTRNPEMVIYQYVDDLLVASDLEIGQHREKVKKLREHLLKWGFITPDEKHQKEPPFLWMGYELHPDKWTVQTI Moussa, S 2010 20939688 ARHR First data on HIV-1 resistance mutations to antiretroviral drugs in Central African Republic. 1920 84990 AZT3TCEFV 2008 Central African Republic A 0 12 244 LKPGMDGPKVKQWPLTEEKIKALTEICQEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPSIFQSSMTKILEPFRSQNPEIVIYQYMDDLYVGSDLEIEQHRKKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Moussa, S 2010 20939688 ARHR First data on HIV-1 resistance mutations to antiretroviral drugs in Central African Republic. 1920 84991 D4T3TCEFV 2008 Central African Republic A 0 21 233 VKQWPLTEEKIKALTEICLEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVSVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPGIVICQYVDDLYVSSDLEIGQHRAKIEELREHLWKWGFTTPDKKHQKEPPFLWMGYE Moussa, S 2010 20939688 ARHR First data on HIV-1 resistance mutations to antiretroviral drugs in Central African Republic. 1920 84992 D4T3TCNVP 2008 Central African Republic CRF06_cpx 0 23 231 QWPLTEEKIRALTEICADMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMG Moussa, S 2010 20939688 ARHR First data on HIV-1 resistance mutations to antiretroviral drugs in Central African Republic. 1920 84993 D4T3TCNVP 2008 Central African Republic CRF01_AE 0 7 255 TVPVKLKPGMDGPKVKQWPLTEEKIKALTEICREMEEEGKISRIGPENPYNTPVFAIKKKGGTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDENFRKYTAFTIPSTNNEVPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFITPDEKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVN Moussa, S 2010 20939688 ARHR First data on HIV-1 resistance mutations to antiretroviral drugs in Central African Republic. 1920 84994 D4T3TCNVP 2008 Central African Republic G 0 1 244 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICDEVEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRGHLLKWGFTTPEKKHQKEPPFLWMGYELHPDKWTVQPI Moussa, S 2010 20939688 ARHR First data on HIV-1 resistance mutations to antiretroviral drugs in Central African Republic. 1920 85010 D4T3TCNVP 2008 Central African Republic G 0 11 244 KLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLRNNKSITVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVICQYVDDLYVGSDLEIGQHREKVEELRNHLLKWGFTTPDEKHQKEPPFRWMGYELHPDKWTVQTI Moussa, S 2010 20939688 ARHR First data on HIV-1 resistance mutations to antiretroviral drugs in Central African Republic. 1920 85011 D4T3TCNVP 2008 Central African Republic K 0 7 244 TVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKRKDGTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTLPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRCNPEIIIIQYVDDLYVGSDLEIGQHREKVEELRKHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Moussa, S 2010 20939688 ARHR First data on HIV-1 resistance mutations to antiretroviral drugs in Central African Republic. 1920 85012 D4T3TCNVP 2008 Central African Republic A 0 7 255 TVPVKLKPGMDGPKVKQWPLTKEKIEALTEICMEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVICQYVDDLYVASDLEIGQHRAKIEELRAHLLRWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVN Moussa, S 2010 20939688 ARHR First data on HIV-1 resistance mutations to antiretroviral drugs in Central African Republic. 1920 85013 D4T3TCNVP 2008 Central African Republic K 0 11 244 KLKPGMDGPKVKQWPLTEEKIKAITEICLEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDPDFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPELVICQYVDDLYVGSDLEIGQHRQKIEELREHLLKWGFFTPDKKHQKDPPFLWMGYELHPDKWTIQPI Moussa, S 2010 20939688 ARHR First data on HIV-1 resistance mutations to antiretroviral drugs in Central African Republic. 1920 85014 D4T3TCNVP 2008 Central African Republic A 0 12 248 LKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSSKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNERPGIRYQYNVLPQGWKGSPAIFQHSMTKILEPFRSQNPEIVIYQYVDDLYVGSDLEIEQHRTKIEELRAHLLSWGFTTPDKKHQKEPPLFWMGYELHPDKWTVQPIQLPE Moussa, S 2010 20939688 ARHR First data on HIV-1 resistance mutations to antiretroviral drugs in Central African Republic. 1922 83052 D4T3TCEFV 2006 South Africa C 0 1 303 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKRKDG~KWRKLVDFRELNKRTQDFWEVQLGIPHPAGLNKKKSMTVLDVGDAYFSVPLYEDFRKYTAFTIPSMNNETPGIRYQYNVLPMGWKGSPTIFQSSMTKILEPFRTKNPEIVICQYMDDLYVGSDLEIGQHRAKIKELREHLLKWGLTTPDKKHQEEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRHLCKLLRGAKALTAIVPLTEEAELEL Wallis, CL 2010 20890651 Virus Genes Case report of the rare deletion at codon 69 of reverse transcriptase in a South African HIV-1 subtype C infected patient. 1930 83813 AZT3TCNVP 2005 India C 0 1 255 TISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEELEKDGKISKIGPENPYNTPVFAIKKKNSNKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFAIPLDESFRKYTAFTIPSINNETPGIRYQYNVLPLGWKGSPAIFQDSMTKILAPFRAQNPEIVICQYVDDLYVASDLEIGQHRAKIDELRDYLLKRGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPKKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83815 AZT3TCNVP 2005 India C 0 11 255 KLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPDNPYNTPIFAIKKKDSAKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83816 D4T3TCEFV 2005 India C 0 1 255 PISPIEPVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKISKIRPENPYNTPIFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDIGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQHSMTKILEPFRARNPEITIYQYVDDLHVGSDLEIEQHRAKVEELREHLLKWGFITPDKKHQKEPPFQWMGYELHPDKWTVHPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83817 AZT3TCNVP 2005 India C 0 1 255 TISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIHLPEKNSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83818 AZT3TCEFV 2005 India C 0 12 243 LKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTTWRKLVDFRELNKRTQDFWEVQLGIPHPGRLEKKKSVTILDVGDAYFSVPFDESFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHSAKIKELRDHLLRWGFTTPDKQHQKEPPFLWMGYELHPDKWTVQP Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83821 AZT3TCNVP 2005 India C 0 1 255 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICNELEKDGKITKIGPENPYNTPIFAIKKKNSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSIPLDEDFRKYTAFTIPSTNNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLWKWGFYTPNKKYQKEPPFLWMGYELHPDKWTVQPIQLPKKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83829 AZT3TCNVP 2005 India C 0 11 255 KLKPGMDGPKVKQWPLTEEKIKALTEICDELEKDGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDEDFRKYTAFTIPSINNETPGIRYLYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPGIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLWRWGFYTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLPKKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83831 AZT3TCNVP 2005 India C 0 2 247 ISPIETVPVKLKPGMDGPKGKQWPLTEEKIKAFTEICEELEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDTWTVQPIQLP Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83837 D4T3TCNVP 2005 India C 0 1 255 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEELEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVASDLEIGQHRAKIKELREYLLKWGFYTPDEKHQKEPPFHWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83839 D4T3TCNVP 2005 India C 0 11 244 KLKPGMDGPKVKQWPLTEEKIKALTAICKEMEEEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTRILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEKLREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83842 AZT3TCNVP 2005 India C 0 12 255 LKPGMDGPKVKQWPLTEEKIKALTEICNELEKDGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPELIIYQYVDDLLVGSDLEIGQHRAKVAELREYLWKWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83845 AZT3TCNVP 2005 India C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEELEKYGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFAIPLDESFRKYTAFTIPSINNETPGIRYLYNVLPQGWKGSPAIFQDSMTKILAPFRAQNPEIVICQYVDDLYVASDLEIGQHRAKIDELRDYLLKRGFYTPDKKYQKEPPFLWMGHELHPDKWTVQPIQLPKKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83846 D4T3TCNVP 2005 India C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEREGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAQNPEIIIYQYVDDLYVGSDLEIGKHRAKIDELRPHLLKWGFTTPDQKHQKEPPFLWMGYELHPDKWTIQPIQLPENDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83848 AZT3TCNVP 2005 India C 0 1 255 PISPIETVPVKFEPGMDGPKVKQWPLTEEKIKALTEICDELEKDGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTQNPEIVICQYVDDLYVGSDLEIGQHRAKVEELREHLWKWGFYTPDNKHQKEPPFLWMGYELHPDTWTVQPIQLPDKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83849 D4T3TCEFV 2005 India C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRARNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83850 D4T3TCNVP 2005 India C 0 1 255 PISPIETVPVKLKPGMDGPRVKQWPLSEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFKARNPELVIYQYMDDLYVGSDLEIGQHRAKIEESREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83852 D4T3TCNVP 2005 India A 0 1 255 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICTEMKKEGKISKIGPENPYNTPIFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIIYQYMDDLYVASDLEIGKHREKIEELREHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83866 D4T3TCNVP 2005 India C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTAICDEMEKEGKISKIGPENPYNTPIFAIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEQKKSVTVLDVGDAYYSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRIKNPELVICQYVDDLYVASDLEIGQHRAKIEELRKHLLQWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83868 AZT3TCEFV 2005 India C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIEALTAICNEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLYEDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQHSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPRKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83871 AZT3TCNVP 2005 India C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPIFAIKKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTILDVGDAYFSCPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFFTPDQKHQKEPPFHWLGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83872 D4T3TCNVP 2005 India C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRARNPELVIGQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83874 AZT3TCNVP 2005 India C 0 1 255 PISPTDTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQHSMTKILKPFREQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83876 AZT3TCNVP 2005 India C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEELEKEGKITKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQNSMTRILEPFRAQNPEIVICQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFFTPDEKHQKEPPFHWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83877 AZT3TCEFV 2005 India C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83878 D4T3TCNVP 2005 India C 0 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDELEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKQSRSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQDSMTKILEPFRTQNPDIVICQYVDDLYVASDLEIGQHRAKIDELRQHLLRWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVND Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83880 D4T3TCEFV 2005 India C 0 1 255 PISPIETIPVKLNPGMDGPKVKQWPLTEEKIKALMEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSMTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRGHLLKWGFTTPDKKHQKEPPLHWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83881 AZT3TCNVP 2005 India C 0 1 255 PISPTETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLYEDFRKYTAFTIPSRNNEKPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRARNPELVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83882 D4T3TCNVP 2005 India C 0 1 255 PISPIETVPVQLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAQNPEIVICQYVDDLYVGSDLEIGQHRAKIKELRTHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVD Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83885 AZT3TCNVP 2005 India C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNSPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVLDVGDAYFSVPLHEDFRKYTAFTIPSINNKTPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAQNPEMVIYQYVDDLYVGSDLEIGQHRAKIDKLREHLLKWGFYTPDRKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83889 D4T3TCEFV 2005 India C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPEKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83890 AZT3TCNVP 2005 India C 0 1 256 PISPIETIPVKLKPGMDGPRVKQWPLTEEKIKALTEICDELEKDGKITKIGPENPYNTPIFAIKKKNSTKWRKLMDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDIGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPEFVIYQYVDDLYVASDLEIGQHRAKIKELREYLWKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVND Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83893 D4T3TCNVP 2005 India C 0 1 243 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSLNNETPGIRYQYNVLPHGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVSSDLEIGQHRAKIEELREHLLKWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQP Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83894 D4T3TCNVP 2005 India C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKRSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLTWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83896 D4T3TCNVP 2005 India C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKITKIGPENPYNTPVFVIKRKDGIKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYYSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPMGWKGSPAIFQASMIKILDPFRAKNPEIVIVQYIDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83897 D4T3TCNVP 2005 India C 0 11 255 KLKPGMDGPKVKQWPLTEEKIKALTEICEELEKDGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVSVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKVLEPFRAQNPEIIIYQYVDDLYVGSDLEIGQHRAKIKELREYLWKWGFYTPDEKHQEEPPFHWMGYELHPDKWTVQPIELPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83901 D4T3TCNVP 2005 India C 0 1 254 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTEICDELEKEGKITKIGPENPYNTPIFAIKKKNSTKWRKLIDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSIPLHEDFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTV Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83902 D4T3TCNVP 2005 India C 0 11 244 KLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSRNNETPGVRYQYNVLPQGWKGSPAIFQSSMTSILEPFRAQNPEIVIYQYVDDLYVASDLEIGQHRTKIEELRNHLLKWGFTTPDQKHQKEPPFLWMGYELHPDKWTVQPI Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83903 AZT3TCNVP 2005 India C 0 1 255 PISPIETVPVKLKPGMDGPRVKQWPLTKEKIKALTEICDEMEKEGKITRIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILAPFRARNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83905 D4T3TCNVP 2005 India C 0 12 255 LKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLQKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPEIVICQYVDDLYVASDLEIGQHRAKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTIQPIPLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83906 AZT3TCNVP 2005 India C 0 11 237 KLKPGMDGPKVKQWPLTEEKIKALNEICDELEKDGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLSKWGFYTPDKKHQKEPPFLWMGYELHPD Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83907 AZT3TCNVP 2005 India C 0 1 244 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRARNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83909 D4T3TCNVP 2005 India C 0 1 254 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLENKKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTV Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83910 AZT3TCNVP 2005 India C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDELEKEGKISRIGPENPYNTPIFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKYPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83913 AZT3TCNVP 2005 India B 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83916 AZT3TCEFV 2005 India C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTAICDEMEKEGKITKIGPDNPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRERNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83917 D4T3TCNVP 2005 India C 0 14 255 PGMDGPKVKQWPLTEEKIEALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSRNNETPGIEYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPELVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83945 D4T3TCNVP 2006 India C 0 1 232 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDELEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTRILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGY Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83947 D4T3TCNVP 2006 India C 0 12 235 LKPGMDGPKVKQWPLTEEKIKALTEICDELEKEGKISKIGPENPYNTPIFAIKKKNSDRWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVIDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPEIVIVQYVDDLYVGSDLEIGQHRAKVEELREYLLKWGFFTPDWKHQKEPPLLWMGYELH Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83950 D4T3TCNVP 2006 India C 0 1 244 PISPIESVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSAKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLYIGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRANNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83952 D4T3TCEFV 2006 India C 0 1 255 PISPIETIPVKLKPGMDGPRVKQWPLTEEKIKALTAICDEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVEDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83955 D4T3TCNVP 2006 India C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTQNPEMIICQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIELPENDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83956 D4T3TCEFV 2006 India C 0 11 255 KLKPGMDGPRVKQWPLTEEKIKALTEICDEMEKEGKITKIGPEIPYNTPVFAIKKKNSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYVDDLYVGSDLPIGQHRAKIEELREHLLKWGFTTPDRKHQKEHPFLWMGYEIHPDTWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83957 D4T3TCNVP 2006 India C 0 1 255 PISPIETVPVILKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVSVLDMGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRVQNTGIDIYQYMDDLYVGSDLEIGQHRAKIEEIREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83958 D4T3TCNVP 2006 India C 0 1 255 PISPIETVPVKLKPGTDGPRVKQWPLTEEKINALKEICDEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSIPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPEIIIYQYVDDLLVGSDLDIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83959 D4T3TCNVP 2006 India A 0 1 255 PISPIETVPVELKPGMDGPKVKQWPLTEEKIKALTEICTELEKDGKISKIGPENPYNTPIFAIKKKNSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKSKSITVLDVGDAYFSIPLYEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEITIYQYVDDLYVASDLEIGKHRAKIEELRAHLWSWGFYTPDKKHQQEPPYLWMGYELHPDKWTVQPIELPEKESWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83963 AZT3TCNVP 2006 India C 0 11 255 KLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83964 AZT3TCEFV 2006 India C 0 12 255 LKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTRNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKNHQKEPPFLWMGYELHPDKWTVQPIQLPEMDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83966 D4T3TCNVP 2006 India C 0 1 255 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAVFQCSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83973 AZT3TCNVP 2006 India C 0 18 244 GPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKNKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRVQNPEIVIYQYMDDLYVGSDLEIGQHREKIEKLREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83974 D4T3TCNVP 2006 India C 0 2 233 ISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKAICDEMEKEGKITKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAYFSVPLYEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAVFQSSMIKILEPFRAKNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYE Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83977 D4T3TCNVP 2006 India C 0 11 251 ELKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTSILAIKKKDSTMWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRVQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKDPPFLWMGYELHPDKWTVQPIQLPEKDS Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83981 D4T3TCEFV 2006 India C 0 1 241 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTALTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPEIVIYQYMDDLYVGSDLEIGKHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTV Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83982 D4T3TCNVP 2006 India C 0 12 254 LQPGMDSPKIKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTV Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83983 D4T3TCNVP 2006 India C 0 11 244 KLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83984 AZT3TCNVP 2006 India C 0 11 254 KLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSTNNETPGTRYQYNVLPQGWKGSPAIFQSSMTRILEPFRARNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRELLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTV Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83985 AZT3TCNVP 2006 India C 0 1 244 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLYEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83986 D4T3TCNVP 2006 India C 0 11 221 KLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFAVPLDPSFRKYTAFTIPSINNETPGIRYPYNVLPQGWKGSPAILQSSMTKILEPFRKQNPELIIYQYMDDLYVGSDLEIGQHRARIEELRDHLLKWGFTTPDKKH Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83987 AZT3TCNVP 2006 India C 0 1 255 PISPFETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPGIVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83988 D4T3TCEFV 2006 India C 0 12 226 LKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPGIVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLKWGFTTPDKKHQKEPP Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83989 AZT3TCNVP 2006 India C 0 1 255 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPDNPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAQNPDIVIYQYMDDLYVGSDLEIGQHRAKIDELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83990 AZT3TCNVP 2006 India C 0 11 255 KLKPGMEGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKVLEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83991 AZT3TCNVP 2006 India C 0 1 252 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEELEKEGKITKIGPENPYNTPVFAIKKKNSTRWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQNSMTRILEPFRAQNPEIIIGQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFFTPEWKHQKEPPFHWMGYELHPDKWTVQPIQLPENDSW Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83992 AZT3TCNVP 2006 India C 0 1 253 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDELEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWT Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83993 AZT3TCNVP 2006 India C 0 1 244 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIKQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83994 D4T3TCNVP 2006 India C 0 1 255 PISPIETVPVKLKPGMDGPRVKQWPLTGEKIKALTEICGEMEKEGKISKIGPENPYNTPVFAIKRKDGTKWRMLADLRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRTKNPELVICQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83995 D4T3TCNVP 2006 India C 0 8 244 VPVRLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGMITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVICQYIDDLYVASDLEIGQHRAKIKELREHLLEWGFTTPEHKHQKEPPLLWMGYELHPDKWTVQPI Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83996 D4T3TCNVP 2006 India C 0 1 255 PSSPIETVPVILKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTKWRKLVDLRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYYSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTRILEPFRAQNPEIVICQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFYTPDKKYQKEPPFLWMGYELHPDKCTVQPIELPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83997 D4T3TCNVP 2006 India C 0 1 255 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICDELEKDGKISKIGPENPYNTPIFVIKKKNSNKWRKLIDLRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSRNNETPGVRYQYNVLPMGWKGSPAIFQYSMTKILEPFRAKHPEIIICQYVDDLYVGSDLEIGQHRATIDELREHLLKWGLYTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83998 AZT3TCNVP 2006 India C 0 5 255 IETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRERNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 83999 AZT3TCNVP 2006 India C 0 1 255 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKAITAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGKRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84000 AZT3TCNVP 2006 India C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEELEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLYEDFRKYTAFTIPSTNNEKPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEIVICQYVDDLYVGSDLEIGQHRAKIKELREHLLKWGFYTPDEKHQKEPPFHWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84001 D4T3TCNVP 2006 India C 0 14 243 PGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTMILEPFRAQNPEIVICQYMDDLYVGSDLEIGQHRAKIEELRKHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQP Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84020 D4T3TCEFV 2007 India C 0 1 254 SISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEELEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKIVDFRELNKRTQDFWEVQLGLPHPAGLKKSKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRERNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREYLLKWGFYTPDWKHQKEPPFHWMGYELHPDTWTVQPIQLPEKDSWTV Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84022 AZT3TCNVP 2007 India C 0 1 255 SISPNETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEELEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKIVDFRELNKRTQDFWEVQLGLPHPAGLKKSKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRERNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREYLLKWGFFTPDWKHQKEPPFHWMGYELHPDTWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84023 AZT3TCEFV 2007 India C 0 4 255 PMETVPVKLKPGMDGPRVKQWPLTEEKIKALREICDEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGLPHPAGLKQKKSMTVLDVGDAYFSVPLYEEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIIICQYVDDLYVASDLEIGQHRAKIEELREHLSRWGFFTPDWKHQQEPPFHWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84024 AZT3TCEFV 2007 India C 0 2 255 ISPNETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPEMVIYQYMDDLYVGSDLEIGQHRAKIEEIREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84025 D4T3TCNVP 2007 India C 0 2 255 ISPNETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICDELEKDGKISKIGPENPYNTPIFAIKKKNSTKWRKVVDFRELNKRTQDFCEVQLGIPHPGGLKKNKSVTVLDVGDAYFSIPLHEDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVQNPEIVICQYVDDLYVGSDLEIKQHRAKIEELREHLWKWGFYTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84029 D4T3TCNVP 2007 India C 0 1 247 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYMDDLCVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIELP Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84030 AZT3TCNVP 2007 India C 0 8 248 VPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTNILEPFRAQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRGHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPE Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84031 D4T3TCNVP 2007 India C 0 7 248 TVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDIGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTNILEPFRAKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPE Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84032 D4T3TCNVP 2007 India C 0 1 248 PNSPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEDMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILVPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPE Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84033 AZT3TCNVP 2007 India C 0 7 248 TVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLRKNKSVTVLDVGDAYFSVPLDESFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPGIVIYQYVDDLYVGSDLEIGQHREKIEELREHLLKWGFTTPDKKHQKEHPFTWMGYELHPDKWTVQPIELPE Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84035 D4T3TCNVP 2007 India C 0 8 255 VPVKLKPGMDGPRVKQWPLTEEKIKALTEICDELEREGKISKIGPENPYNTPIFAIKKKNSDKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEEFRKYTAFTIPSVNNETPGIRYQYNVLPMGWKGSPAIFQASMTKILEPFRAKNPEIIIYQYVDDLLVGSDLEIGQHRVKIEELREHLLKWGLYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84037 AZT3TCNVP 2007 India C 0 1 255 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPDNPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTRILEPFRKRNPELVIYQYMDDLYVGSDLEIGKHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84038 D4T3TCNVP 2007 India C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIEALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKISEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQRIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84039 AZT3TCNVP 2007 India C 0 1 254 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLYEEFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTQNPEIVICQYVDDLYVGSDLEIGQHRAKIEDLREHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTV Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84040 AZT3TCNVP 2007 India C 0 8 254 VPVKLKPGMDGPKVKQWPLTEEKIKALTEICDELEKEGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTRNPGIVIYQYVDDLLVGSDLEIEQHRAKIEELREHLSKWGFYTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTV Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84041 D4T3TCNVP 2007 India C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKISKIGPENPYNTPIFAIKKKNSDRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTQNPELVIYQYVDDLYVGSDLEIGQHRAKIEELRTHLLKWGFITPDEKHQKEPPFLWMGYELHPDTWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84042 D4T3TCNVP 2007 India C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTRILEPFRARNPEMVIYQYMDDLYVGSDLEIEQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84046 D4T3TCEFV 2007 India C 0 2 255 ISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRSHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84047 D4T3TCEFV 2007 India C 0 4 255 PIETVPDKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPEIVICQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84049 D4T3TCNVP 2007 India C 0 8 250 VPVKLKPGMDGPRVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPELVIYQYVDDLYVGSDLEIGQHRAKIEELRVHLLKWGLTTPDRKHQKEPPFLWMGYELHPDKWTVQPIQLPEKD Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84050 D4T3TCNVP 2007 India C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTAICEEMEKEGKITRIGPENPYNTPIFVIKKKDSSKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLSKSKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILAPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84052 D4T3TCNVP 2007 India C 0 8 254 VPVKLKPGMDGPKVKQWPLTEEKIKALTEICQEMEKEGKITRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVICQYVDDLYVGSDLEIGQHRAKVEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTV Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84053 D4T3TCNVP 2007 India C 0 7 255 TVPVKLKPGMDGPKVKQWPLTEEKIQALTEICNELEKEGKITKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQASMIKILEPFRARNPELVIVQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84055 AZT3TCNVP 2008 India C 0 2 255 ISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEELEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFYTPDEKHQKEPPFHWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84056 AZT3TCNVP 2008 India C 0 1 254 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPIFAIKKKGSDRWRKLVDFRELNKRTQDFWEVQLGIPHPSGLTKNKSVTILDVGDAYFSCPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKVLEPFRTQNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPEQKHQTEPPFHWLGYELHPDKWTVHPIQLPDKDSWTV Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84057 D4T3TCNVP 2008 India C 0 1 254 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTV Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84060 AZT3TCEFV 2008 India C 0 2 254 ISPIETVPVKLKPGMDGPKVKQWPLTEEKIIALTEICNEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEEFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTV Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84061 D4T3TCEFV 2008 India C 0 1 255 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLCEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTRNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84062 AZT3TCEFV 2008 India C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPEIVIYQYVDDLLVGSDLELGQHRAKIEELREHLLKWGLTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84064 D4T3TCNVP 2008 India C 0 8 255 VPVKLKPGMDGPKVKQWPLTEENIKALTEICNELEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTIIDVGDAYFSVPLDEYFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIIIVQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPEKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84067 AZT3TCEFV 2008 India C 0 1 255 SISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICNEMEKEGQITKIGPENPYNTPIFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKNNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVASDLEIGQHREKIEELRQHLLRWGFVTPDQKHQKEHPFHWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84068 D4T3TCNVP 2008 India C 0 1 255 SISPIETVPVKLKPGMDGPKVKQWPLTEEKIRVLTEICDEMEKEGKITKIGPENPYNTPVFVIKKKGSDRWRKLIDLRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQYSMTKILEPFRAKNPELIICQYIDDLYVGSDLEIKQHRAKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1930 84069 D4T3TCNVP 2008 India C 0 8 255 VPVKLKPGMDGPKVKQWPLTEEKIKALTEMCNEMEKEGKITKIGPENPYNTPIFAIKKKDG~KWRKLTDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEEFRKYTAFTIPSINNETPGVRYQYNVLPMGWKGSPAIFQSSMTKILEPFRAQNPEIIIYQYVDDLLIGSDLEIGQHRAKVEELRGHLLKWGLTTPDKKHQKEPPFQWMGYELHPDKWTVQPIQLPEKDSWTVN Deshpande, A 2009 19534630 ARHR Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. 1932 85475 D4T3TCEFV 2008 South Africa C 0 1 196 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILAPFRAQNPEIVIYQYMDDLYVGSDLEIG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85476 D4T3TCNVP 2008 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSFPLNESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMMKILEPFRAKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85477 D4T3TCNVP 2008 South Africa C 0 1 253 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWT van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85478 D4T3TCEFV 2008 South Africa C 0 1 259 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICQEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDQDFRKYTAFTIPSVNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85479 D4T3TCEFV 2008 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICDEMEKEGKITKIGPDNPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYIGSDLEIGEHRAKIEELREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85480 D4T3TCNVP 2008 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKESWTVNDIQK van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85481 D4T3TCEFV 2008 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTAICEDMEKEGKISKIGPENPYNTPVFAIKKKGSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPEIVIYQYVDDLYVASDLEIGQHRTKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQK van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85482 AZT3TCNVP 2008 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRANNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85483 D4T3TCNVP 2008 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAQNPGIVICQYVDDLYVGSDLEIGLHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85484 D4T3TCNVP 2008 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYVDDLYVGSDLEIEQHRAKIEELREHLLKWGLTTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85485 D4T3TCEFV 2008 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMEICEEMEKEGKITKIGPENPYNTPVFAIKKKGSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQRKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNDTPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPDIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFFTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPDKDSWTVN van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85486 D4T3TCEFV 2008 South Africa C 0 1 258 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRARNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIQLPTKESWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85487 D4T3TCEFV 2008 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQTSMTKILEPFRVKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85488 D4T3TCNVP 2008 South Africa B 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQK van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85489 D4T3TCEFV 2008 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALVAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPRIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPILLPEKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85490 D4T3TCNVP 2008 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIEQHREKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85491 D4T3TCEFV 2008 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRAKNPEIVIYQYMDDLCVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85492 D4T3TCNVP 2008 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85493 D4T3TCEFV 2008 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85494 D4T3TCNVP 2008 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTAICEEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85495 D4T3TCEFV 2008 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85496 D4T3TCNVP 2008 South Africa C 0 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTEICEEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTQNPEIVICQYVDDLYVGSDLEIGPHRAKVEELRKHLLAWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVND van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85497 D4T3TCNVP 2008 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILQPFRTENPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPINLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85498 D4T3TCEFV 2008 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDMDIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPILLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85499 D4T3TCNVP 2008 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPTIFQSSMTKILEPFRAQNPDIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85500 D4T3TCNVP 2008 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQFSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85501 D4T3TCEFV 2008 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85502 AZT3TCNVP 2007 South Africa C 0 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRNKNPNIVICQYVDDLYVGSDLEIEQHRAKIEELREHLLRWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVND van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85503 AZT3TCNVP 2007 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIEALMAICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTRWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNQMPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFREKNPEVVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85504 D4T3TCNVP 2008 South Africa C 0 1 260 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKL van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85505 D4T3TCEFV 2008 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDANFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85506 AZT3TCNVP 2008 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVRNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTIQPIKLPEKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85507 AZT3TCEFV 2008 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEREGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPELVIYQYMDDLYVGSDLEIMQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85508 D4T3TCEFV 2007 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPSIFQCSMKKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85509 D4T3TCEFV 2008 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICAEMEKEGKITKIGPENPYNTPMFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTILDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85510 D4T3TCNVP 2008 South Africa B 0 1 261 PISPIETVPVKFKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGLRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKHNPDLVIYQYVDDLYVGSDLEIGEHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLV van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85511 D4T3TCNVP 2008 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGKRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPDLVIYQYVDDLYVGSDLEIGQHREKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPILLPEKDSWTVNDIQK van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85512 D4T3TCEFV 2008 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAQNPEIVIYQYIDDLYVGSDLEIGPHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPILLPEKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85513 D4T3TCEFV 2008 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPELVIYQYVDDLYVGSDLEIGQHRAKIEDLRDHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTMQPIQLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85514 D4T3TCNVP 2008 South Africa C 0 1 262 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85515 D4T3TCNVP 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYCYNVLPQGWKGSPAIVQASMTKILEPFRTQNPEIVIYQYVDDLRVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPTQLPEKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85516 D4T3TCNVP 2008 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDMVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIVLPEKESWTVNDIQK van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85517 D4T3TCEFV 2008 South Africa C 0 1 241 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLQKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRTQNPEIVIYQYIDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTV van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85518 D4T3TCNVP 2008 South Africa C 0 1 259 PISSIETVPVQLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDGTKWRKLVDFREVNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNKTPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPDIVIYQYVDDLYVASDLEIGQHRAKIEKLRDHLLKWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDIQK van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85519 D4T3TCEFV 2008 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85520 D4T3TCNVP 2008 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPNIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85521 D4T3TCEFV 2008 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHREKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85522 AZT3TCNVP 2008 South Africa C 0 1 260 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTKGRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKL van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85523 D4T3TCNVP 2008 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITRIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRTQNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85524 D4T3TCNVP 2008 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLHEDFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85525 D4T3TCEFV 2008 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPSIFQSSMTRILEPFRAENPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85526 D4T3TCEFV 2008 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPELVIYQYVDDLYVGSDLEIGRHRAKIEELRQHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85527 D4T3TCNVP 2008 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85528 D4T3TCNVP 2008 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTVPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIIQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDQKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85529 D4T3TCNVP 2008 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLELGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85530 D4T3TCEFV 2008 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIIALTEICKEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILQPFRAQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKNSWTVNDIQK van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85531 AZT3TCNVP 2008 South Africa C 0 1 262 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSTMIKILEPFRARNPEMVIVQYIDDLYVGSDLEIEQHRAKIKELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85532 D4T3TCNVP 2008 South Africa C 0 1 258 PISPIETVPVQLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTRILEPFRAKNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85533 D4T3TCNVP 2008 South Africa B 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDMVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPDKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85534 D4T3TCNVP 2008 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85535 D4T3TCEFV 2007 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPTKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85536 D4T3TCNVP 2008 South Africa C 0 1 262 PISSIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSAKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQHSMTRILEPFRAKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85537 D4T3TCEFV 2008 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYVDDLYVGSDLEIGQHRTKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85538 D4T3TCNVP 2008 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85539 D4T3TCNVP 2008 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLNKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRVENPEIVIYQYVDDLLVGSDLEIGQHRAKIEELRKHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85540 D4T3TCNVP 2008 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQK van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85541 D4T3TCEFV 2008 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLEKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPGIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85542 AZT3TCEFV 2008 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILGPFRKQNPEIDIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFRWLGYELHPDKWTVQPIQLPEKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85543 D4T3TCEFV 2008 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPIFVIRKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARHPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85544 D4T3TCEFV 2008 South Africa F 0 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQHSMTKILEPFRAKNPEIVIYQYMDDLLVGSDLEIGQHRTKIEELREHLLKWGLTTPDKKYQKEPPFHWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85545 D4T3TCEFV 2008 South Africa C 0 1 259 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKRKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAGNPEIVIYQYMDDLCVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQK van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85546 AZT3TCNVP 2009 South Africa C 0 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIAICEEMEKEGKITKIGPENPYNTPVFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRTHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVND van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85547 D4T3TCNVP 2009 South Africa C 0 1 257 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIRALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAQNPDIVICQYVDDLYVGSDLEIVQHRAKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85548 D4T3TCEFV 2008 South Africa C 0 59 240 PVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTRILEPFRAKNPEIIIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWT van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85549 D4T3TCNVP 2008 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQEFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMAKILEPFRAKNPEIVITQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85550 D4T3TCEFV 2008 South Africa B 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGMRYQYNVLPQGWKGSPAIFQYSMTKILEPFRKKNPDIVIYQYMDDLYIASDLEIGQHRTKIEELRRHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQK van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85551 AZT3TCNVP 2009 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDGGDAYFSVPLDESFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHREKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQPPEKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85552 D4T3TCNVP 2008 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTILDVGDAYFSVPLDEGFREYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85553 D4T3TCEFV 2009 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMAICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMAKILEPFRAKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85554 AZT3TCEFV 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEVIIYQYVDDLYVGSDLEIEQHRAKIDKLREHLLKWGFTTPDKKYQKEPPLRWMGYELHPDKWTVQPIQLPEKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85555 D4T3TCEFV 2009 South Africa C 0 1 252 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPDNPYNTPIFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNSAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKYQKEPPFLWLGYELHPDKWTVQPIQLPDKESW van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85556 D4T3TCNVP 2009 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIQLPEKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85557 D4T3TCNVP 2009 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYMDDLYVGSDLEIGQHREKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85558 AZT3TCEFV 2009 South Africa C 0 1 260 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEELEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPDIDIYQYVDDLYVASDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPEKDSWTVNDIQSL van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85559 D4T3TCNVP 2009 South Africa C 0 16 258 MDGPKVKQWPLTEEKIKALTAICDEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPTVFQSSMTKILEPFRAQNPDIVICQYVDDLYVGSDLEIGKHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85560 D4T3TCNVP 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDELEKEGKISKIGPENPYNTPVFAIKRKNSTKWRKLVDFRELNKRTQDFSEVQLGIPHPAGLKKKRSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFREQNPDIVIYQYMDDLCVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85561 AZT3TCNVP 2009 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPYRTQNPELVICQYVDDLYVASDLEIGQHRAKIEELRKHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIRLPEKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85562 D4T3TCNVP 2009 South Africa C 0 1 262 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIIIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85563 D4T3TCEFV 2009 South Africa C 0 1 257 PISPIEAVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLNESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTRILEPFRAKNPEIVIYQYMDDLYVGSDLEIEQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85564 D4T3TCNVP 2007 South Africa D 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGPHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85565 D4T3TCEFV 2009 South Africa B 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPSIFQSTMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRIKIEELRKHLLGWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLV van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85566 D4T3TCNVP 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKINALKAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPTKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85567 AZT3TCEFV 2009 South Africa B 0 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALVEICTEMEREGKISKIGPENPYNTPVFAIKKKNSDRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNEVPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFREQNPDMVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLKWGLFTPDQKHQKEHPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85568 D4T3TCEFV 2009 South Africa C 0 1 254 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPDLVIYQYVDDLYVGSDLEIGQHRAKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTV van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85569 D4T3TCEFV 2009 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEELEKEGKISKIGPENPYNTPVFAIKKKESTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKNKSMTVIDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVICQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFHWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85570 D4T3TCEFV 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKRSMTVLDVGDAYFSVPLDENFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85571 D4T3TCEFV 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPDIVIYQYMDDLYVGSDLEIEQHRRKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85572 D4T3TCNVP 2007 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRTKNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85573 D4T3TCNVP 2009 South Africa C 0 1 261 PISPIETVPVKLKPGTDGPKVKQWPLTKEKIEALIEICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSTMTKILEPFRVKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQSLV van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85574 D4T3TCNVP 2009 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEELEKEGKITKIGPENPYNTPVFAIKRKDGTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAYFSVPLDENFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPDLDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQK van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85575 AZT3TCEFV 2009 South Africa C 0 1 257 PISPIETVSVKLKPGMDGPKVKQWPLSEEKIKALTEICKEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELKKHLLKWGFTTPDKKHQKKPPFLWMGYELHPDKGTVQPIQLPKKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85576 D4T3TCNVP 2009 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEELEKEGKITKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAENPEIVICQYVDDLYVGSDLELGQHRAKVEELREHLLKWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85577 TDF3TCEFV 2009 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85578 D4T3TCNVP 2009 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPYRAKNPEIDIYQYMDDLYVGSDLEIGQHRAKIEELREHLWKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85579 AZT3TCNVP 2009 South Africa C 0 1 247 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPSIFQTSMTKILEPFRTQNPEIVICQYMDDLYVGSDLEIAQHRAKIEELREHLLKWGFTTPDKKYQKEPPFRWMGYELHPDKWTVQPIQLP van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85580 D4T3TCEFV 2009 South Africa C 0 1 252 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSTMIKILEPFRAQNPDLVIYQYMDDLYVGSDLEIGQHRAKIENLREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSW van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85581 D4T3TCEFV 2009 South Africa C 0 1 258 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTQILEPFRAKNPEIVIYQYMDDLHVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85582 D4T3TCNVP 2009 South Africa C 0 1 257 PISPIETVPVQLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKRKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVICQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85583 D4T3TCNVP 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85584 D4T3TCEFV 2009 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRTHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85585 D4T3TCNVP 2009 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLIEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKRKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIDICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85586 D4T3TCNVP 2009 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKAITAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85587 D4T3TCNVP 2009 South Africa C 0 1 252 PISPINTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKTSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNRTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSW van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85588 D4T3TCNVP 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELRKHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPKKESWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85589 D4T3TCNVP 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIEALKAICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLPKSKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNESPGLRYQYNVLPQGWKGSPAIFQHSMTKILEPFRTQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85590 D4T3TCEFV 2009 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKYPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85591 D4T3TCEFV 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPGIVIYQYMDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPLHWMGYELHPDKWTVQPIQLPEKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85592 TDF3TCEFV 2009 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85593 D4T3TCNVP 2009 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPDIIICQYIDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPFRWMGYELHPDKWTVQPIQLAEKDSWTVNDIQK van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85594 D4T3TCEFV 2009 South Africa B 0 1 254 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVSVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRTKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTV van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85595 D4T3TCEFV 2009 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGEHRAKIEELRNHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85596 D4T3TCEFV 2009 South Africa C 0 1 260 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKNSWTVNDIQKL van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85597 AZT3TCEFV 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPELVIYQYMDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85598 AZT3TCNVP 2009 South Africa B 0 1 260 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALVEICAEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTVPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKL van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85599 D4T3TCEFV 2009 South Africa C 0 1 260 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTEICKEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYIDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKL van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85600 D4T3TCNVP 2009 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICREMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYVDDLYVGSDLEIGQHRAKIDELREHLLKWGFTTPDNKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85601 AZT3TCNVP 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85602 D4T3TCEFV 2009 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITRIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYVDDLYVGSDLEIGQHRAKIDELREHLLKWGFTTPDNKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85603 D4T3TCEFV 2009 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRGHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85604 AZT3TCNVP 2009 South Africa C 0 1 257 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIRALTAICEEMEKEGKITRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPEIVICQYMDDLYVGSDLEIMQHRAKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85605 AZT3TCEFV 2007 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTAICEEMEKERKITKIGPENPYNTPVFAIKRKDSTKWRELVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYVDDLYVGSGLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85606 D4T3TCNVP 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPNIVIYQYVDDLYVASDLEIEQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPINLPEKSSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85608 D4T3TCNVP 2009 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDENFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYVDDLYVGSDLEIGQHRAKIEKLREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85609 D4T3TCNVP 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGMPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAXNPELVIYQYVDDLYVGSDLDIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85610 D4T3TCEFV 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAENPEIDIYQYVDDLLVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIQLPEKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85611 AZT3TCEFV 2009 South Africa B 0 1 255 PISPIETVPVKLKPGMDGPKVRQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIEQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVN van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85612 D4T3TCEFV 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85613 D4T3TCEFV 2007 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTMICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRTQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKDPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85614 AZT3TCEFV 2009 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQTSMIKILEPFRAKNPEIVIYQYMDDLYVGSDLEIEQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85615 AZT3TCNVP 2009 South Africa A 0 1 238 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPSIFQSSMIKILEPFRSKNPDLVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85616 D4T3TCNVP 2010 South Africa C 0 1 257 PISPIETVPVQLKPGMDGPKVKQWPLTEEKIKALKAICEEMEKEGKITKIGPENPYNTPVFVIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSMTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRRKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85617 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPDIVIYQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIELPDKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85618 TDF3TCNVP 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85619 D4T3TCNVP 2010 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGEHRAKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85620 D4T3TCEFV 2007 South Africa C 0 1 231 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSNKWRKLADFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILKPFKAKNPKIVIYQYVDDLYVGSDLKIGQHKAKIKKLKAHLLKWGFTTPNKKHQKEPPFLWMG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85621 AZT3TCEFV 2007 South Africa B 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85622 D4T3TCEFV 2007 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85623 D4T3TCNVP 2007 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNGTPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85624 D4T3TCNVP 2007 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPRIKQWPLTDEKINALKAICEEMEKEEKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMIKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85625 D4T3TCEFV 2007 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMEICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQXLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85626 D4T3TCEFV 2007 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAKKQSSMIKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHREKIEQLRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85627 D4T3TCEFV 2007 South Africa C 0 77 262 FRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLNENFKKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYMDDLHVGSDLEIGQHREKIEELRAHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85628 D4T3TCEFV 2007 South Africa C 0 1 249 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRAQNPDIIIYQYVDDLWVGSDLEIGQHREKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEK van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85629 D4T3TCNVP 2007 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYVDDLCVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFFWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85630 D4T3TCNVP 2006 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTKNPEMVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85631 D4T3TCEFV 2007 South Africa C 0 1 259 PISPVETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIKQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85632 D4T3TCEFV 2007 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMSVLDVGDAYFSVPLDEEFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVASDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85633 D4T3TCEFV 2007 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPMLWMGYELHPDKWTVQPIVLPDKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85634 D4T3TCEFV 2007 South Africa C 0 1 258 PISPIETTPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILDPFRAKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85635 AZT3TCNVP 2007 South Africa C 0 1 258 PISPIETVSVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKDGTTWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPNIVIYQYVDDLYVGSDLEIGQHRAKVEELRVHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQ van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85636 D4T3TCNVP 2007 South Africa C 0 1 191 PISSIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRAQNPGIVIYQYMDDLYVAS van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85637 D4T3TCEFV 2007 South Africa C 0 1 251 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDS van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85638 D4T3TCEFV 2007 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTILDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85639 D4T3TCNVP 2008 South Africa C 0 1 256 PISPIETVPVKLKPGMDGPRVKQWPLTEEKLKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVND van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85640 AZT3TCEFV 2008 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSSKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYVDDLYVGSDLEIGQHRAKVEKLREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1932 85641 D4T3TCEFV 2008 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEREGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMIKILEPFRTQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFHWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG van Zyl, GU 2011 21837793 J Med Virol Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. 1939 84406 D4T3TCEFV 2005 U.S. B 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVDICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKENPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVIPLTAEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQGLGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKITTESIVIWGKTPKFRLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIIGAETFYVDGAANRETKLGKAGYVTDRGRQKVVSLTDTTNQKTELQAIHLALQDSGLEVNIVTDSQYALGIIQAQPDKSESDLVNQIIEQLIKKEKVYLAWVPAHKGIGGNEQVDKLVSTGIRRVL Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84421 TDF3TCEFV 2004 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVKICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSNLEIGQHRVKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGYDQWTYQIYQEPFKNLKTGKYAKRRGAHTNDVKQLTEAVQKIATESIVIWGKTPKFKLPIQKETWEA Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84426 AZT3TCEFV 2003 U.S. B 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVVPLTKEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGHGQWTYQIYQEPFKNLKTGKYAKMKGAHTNDVRQLVEAVQKITLESIVIWGKTPKFKLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLETEPIVGAETFYVDGAANRETKLGKAGYVTDRGRQKVVPLTDTTNQKTELQAIHLALQDSGLEVNIVTDSQYALGIIQAQPDKSESELVSQIIEQLIQKEKVYLAWVPAHKGIGGNEQVDKLVSSGIRKVL Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84436 AZT3TCEFV 2005 U.S. B 0 1 388 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIIIYQYMDDLYVGSDLEIGQHREKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPNKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVVPLTEEAELELAENREILREPVHGVYYDPSKDLIAEIQKQGLGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKITTESIVIWGKIPK Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84462 AZT3TCEFV 2003 U.S. B 0 1 560 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRKQNPDIVIYQYMDDLYVGSDLEIEQHRIKIEELRDHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLIRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQGQWTYQIYQEPHKNLKTGKYAKMRGTHTNDVKQLTEAVQKVATESIVIWGKIPKFRLPIQKDTWDVWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTDRGRQKVVSLTDTTNQKTELQAIYLALQDSGSEVNIVTDSQYALGIIQSQPDKSESELVNQIIEQLINKEKIYLAWVPAHKGIGGNEQVDKLVSNGIRRVL Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84481 AZT3TCEFV 2003 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVASDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVRQLCKLLRGTKALTEVIPLTEEAELELAENREILKETVHGGYYDPSKDLIAEIQKQEQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKIATESIVIWGRTPKFRLPIQKETWEA Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84482 D4T3TCEFV 2004 U.S. B 0 1 560 PISPIDTIPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLRKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPDIVIYQYMDDLYVGSDLEIEQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTINDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGQGQWTYQIYQEPFKNLRTGKYARTRGTHTNDVRQLTEAVQKIARESIVIWGKTPKFKLPIQKETWETWWIDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGAETFYVDGAANRESKLGKAGYVTDKGRQKVVNLTDTTNQQTELQAVYLALQDSELEVNIVTDSQYVLGIIQAQPDQSDSALVSQIIEQLIKKEKVYLAWVPAHKGIGGNEQVDKLVSSGIRKVL Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84483 D4T3TCEFV 2004 U.S. B 0 1 560 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRKQNPDMVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIALPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKSLTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIVEIQKQGQDQWTYQIYQEPFKTLKTGKYARTRGTHTNDVKQLAEAVQKITTESIVIWGKTPKFRLPIQKETWDTWWSEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIIEAETFYVDGAANRETKEGKAGYVTDRGRQKIISLTDTTNQKTELQAIYLALQDSGLEVNIVTDSQYALGIIQAQPDRSESELVCQIIEQLIKKEKVYLAWVPAHKGIGGNEQIDKLVSKGIRRVL Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84484 TDF3TCEFV 2003 U.S. B 0 1 560 PISPIETVPVRLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPSIFQCSMTKILDPFRKQNPDIVIYQYMDDLYVGSDLEIEQHRTKVEELRQHLMRWGLCTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVIPLTREAELELAENREILKEPVHGAYYDPSKELIAEIQKQEHGQWSYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKIALESIVIWGKTPKFRLPIQKETWEAWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIIGAETFYVDGAANRETKLGKAGYVTNRGRQKVISLTDTTNQKTELQAIHLALQDSDSEVNIVTDSQYALGIIQAQPDKSESELVNLIIEQLIKKEKVYLAWVPAHKGIGGNEQVDKLVSSGIRKVL Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84512 AZT3TCEFV 2005 U.S. B 0 1 560 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGEHRIKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRHLCKLLRGAKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGTHTNDVRQLTEAVQKITTESIVIWGKTPKFKLPIQKETWDTWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKDPIVGAETFYVDGAANRETKLGKAGYVTDKGRQKVVSLTDTTNQKTELQAIHLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVSQIIEQLINKEKVYLAWVPAHKGIGGNEQVDKLVSAGIRKVL Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84529 AZT3TCEFV 2004 U.S. B 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPITLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYAKMRGAHTNDVKQLTEAVQKVATESIVIWGKTPKFRLPIQKETWEAWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIMGAETFYVDGAANRETKIGKAGYVTDRGKQKVVSLADTTNQKTELQAINLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVSQIIEQLIKKEKVYLAWVPAHKGIGGNEQVDKLVSTGIRKVL Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84535 AZT3TCEFV 2004 U.S. B 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQASMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPITLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQGEGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKIATESIVIWGKTPKFRLPIQKETWEAWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKDPIIGAETFYVDGAANRETKLGKAGYVTDRGRQKAVPLTDTTNQKTELQAIYLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKEKVYLAWVPAHKGIGGNEQVDKLVSAGIRKVL Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1939 84538 D4T3TCEFV 2003 U.S. B 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKKNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTEVVPLTAEAELELAENREILKTPVHGVYYDPSKDLIAEIQKQGQEQWTYQIYQEPFKNLKTGKYAKVRGAHTNDVKQLTEAVQKIATESIVIWGKTPKFKLPIQKETWEAWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGAETFYVDGAANRETKLGRAGYVTDRGRQKVVSLADTTNQKTELQAIYLALQDSGSEVNIVTDSQYALGIIHAQPDRSESEIVNQIIEQLIKKEKIYLAWVPAHKGIGGNEQVDKLVSSGIRKVL Riddler, SA 2008 18480202 N Engl J Med Class-sparing regimens for initial treatment of HIV-1 infection. 1951 85249 D4T3TCEFV 2008 South Africa C 0 1 321 PISPIETVPVKLKTGKYAPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDP Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85250 AZT3TCEFV 2008 South Africa C 0 1 303 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTILDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFFTPDEKHQTEPPLRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELEL Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85251 D4T3TCEFV 2008 South Africa C 0 1 325 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDL Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85252 D4T3TCEFV 2008 South Africa C 0 1 327 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDLVIYQYVDDLYVGSDLEIGQHRAKIEELRTHLLKWGFTTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDLQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDVVPITEEAELELAENRD~LKEPVHGVFYDPSKDLIA Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85253 AZT3TCEFV 2008 South Africa C 0 1 328 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNSPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYKVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVVSDLEIGQHRAKIGELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAE Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85255 D4T3TCEFV 2008 South Africa C 0 1 312 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNERPGTRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTQEAELELAENREILKE Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85256 D4T3TCNVP 2008 South Africa C 0 1 323 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTLPSINNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRTKIKELREHLLKWGFTTPDKKHQEEPPLLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIQVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSK Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85258 D4T3TCEFV 2008 South Africa C 0 1 305 PISAIETVPVKLKPGMDGPKIKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVASDLEIGKHREKIEELRKHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTDIVPLTEEAELELAD Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85259 D4T3TCEFV 2008 South Africa C 0 1 308 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTNNPEMVIYQYVDDLYVGSDLEIGQHRAKVEELRIHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGTKALTEVVTLTEEAELELAENRE Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85260 D4T3TCEFV 2008 South Africa C 0 1 303 PISHIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTRILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQL*KLLRGAKALTDIVPLTEEAELEL Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85261 AZT3TCEFV 2008 South Africa C 0 1 323 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPEIVIYQYVDDLYVGSDLEIGQHRAKVEQLREHLLRWGFTTPDKKHQKEHPFLWMRYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRELCKLLRGAKALTDIVPLTEEAELELAENKEILKEPVHGVYYDPSK Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85262 D4T3TCEFV 2008 South Africa C 0 1 324 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRKLNKRTQDFWEVQLGIPHPAGXKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAVFQSSMIKILEPFRTKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENKEILKEPVHGAYYDPSKD Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85263 AZT3TCEFV 2008 South Africa C 0 1 324 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSNRWRKLVDFRELNKRTQDFWEIQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEQLRQHLLKWGFFTPDEKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGTKALTDVVPLTEEAELELAENREILKEPVHGVYYDPSKD Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85264 AZT3TCEFV 2008 South Africa C 0 1 323 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKWKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKYPEIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGFYTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIIPLTDEAELELAENREILKEPVHGVYYDPSK Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85265 D4T3TCEFV 2008 South Africa C 0 1 321 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKIEKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSLTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQASMTKILRPFREQNPDIVIYQYVDDLCVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTDEAELELAENREILKEPVHGVYYDP Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85266 D4T3TCEFV 2008 South Africa C 0 1 308 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVKHLCKLLRGAKALTDIVTLTEEAELELAENRE Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85269 D4T3TCEFV 2008 South Africa C 0 1 317 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKEMEKEGKIEKIGPENPYNTPIFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPELVIYQYVDDLYVGSDLEIEQHRAKIEQLREHLLKWGLTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGV Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85271 D4T3TCEFV 2008 South Africa K 0 1 321 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTELEKEGKISRIGPENPYNNPVFAIKKKDGTKWRKISDFRELNKRTQDFWEVQLGIPHPAGLEKRKSVTILDVGDAYFSIPLDESFRKYTAFTIPSINNEVPGIRYQYNVLPQGWKGSPAIFQDSMTKILEPFRTKNPEMVICQYVDDLYVASDLEIGQHRAKIDELREHLWKWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIKLPEKDDWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKSLTEVVPLTAEAELELAENREILKEPVHGVYYDP Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85272 TDF3TCEFV 2008 South Africa C 0 1 330 PISPVETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEELEKEGKITKIGPENPYNTPIFAIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPEIVIYQYMDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTQEAELELAENREILKEPVHGVYYDPSKDLIAEIQ Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85273 D4T3TCEFV 2008 South Africa C 0 1 324 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAXFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKD Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85274 D4T3TCEFV 2008 South Africa C 0 1 319 PISSIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICEELEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTRILEPFRTQNPEIVIYQYVDDLYVASNLEIGQHRAKIEELREHLWKWGFYTPDKKHQKEPPFFWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYY Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85275 D4T3TCEFV 2008 South Africa C 0 1 310 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNKTPGIRYQYNVLPQGWKGSPAIFQSSMVKILEPFRAQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLIRGTKALTDIVPLTEEAELELAENREIL Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85276 D4T3TCEFV 2008 South Africa C 0 1 290 PISPIEAVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTLPSTNNAAPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQSIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLKGAKALT Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85277 D4T3TCEFV 2008 South Africa C 0 1 322 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEELEREGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEMVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTANDIQKLVGKLNWASQIYPGIKVKHLCRLLGGTKALTDIVPLTEEAELELAENREILKEPVHGAYYDPS Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85278 D4T3TCEFV 2008 South Africa C 0 1 322 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYIGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPS Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85279 D4T3TCEFV 2008 South Africa C 0 1 353 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELRKHLLKWGFTTPDKKHQKEPPFRWMGYELHPDTWTVQTIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVRSLCKLLRGAKALTDIVPLTQEAELELAENRKICKKPGHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKILKTGK Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85280 D4T3TCEFV 2008 South Africa C 0 1 328 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRAQNPELVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDVQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAK Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85281 AZT3TCNVP 2008 South Africa C 0 1 320 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALMEICDELEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIIPLTEEAELELAENREILKQPVHGVYYD Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85282 D4T3TCEFV 2008 South Africa C 0 1 319 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSSKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEDLREHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYY Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85283 D4T3TCNVP 2008 South Africa C 0 1 325 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALMAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAEIREXLKEPVHGVYYDPSKDL Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85284 TDF3TCEFV 2008 South Africa C 0 1 305 PISPIKTVPVKLKPGMDGPRVKQWPLTEEKIRALKEICEEMEKEGKITKIGPENPYNTPVFAIKRKDSTEWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRSKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPELVIYQYVDDLYVGSDLEIGQHRAKIEKLRDHLLKWGFTTPDQKHQKEPPFRWMGYELHPDKWTVQPIQLPEKENWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAE Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85285 D4T3TCEFV 2008 South Africa C 0 1 326 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFVIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAFFSVPLDENFRKYTAFTIPSINNETPGKRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYVDDLYVGSDLEIGPHRAKIEELREHLLRWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELEENREILKEPVHGVYYDPSKDLI Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85287 D4T3TCEFV 2008 South Africa C 0 1 306 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAEN Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85288 AZT3TCEFV 2008 South Africa C 0 1 320 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALMEICDELEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIIPLTEEAELELAENREILKQPVHGVYYD Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1951 85291 AZT3TCEFV 2008 South Africa C 0 1 326 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLIRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLI Sigaloff, KC 2011 21819219 ARHR Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. 1952 85292 AZT3TCNVP 2007 Zambia C 0 1 323 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIIICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFFTPEEKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSK Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85293 D4T3TCEFV 2007 Zambia C 0 1 330 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQXFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQXFPGIKVRQLCKLIRGVKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDRIAEIQ Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85295 AZT3TCEFV 2007 Zambia C 0 1 322 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNRSVTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYVDDLLVGSDLEIGQHRAKVEELRDHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVRQLCKLLRGAKALTDIVPLTEEAELELAFXREILREPVHGVXHDPS Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85296 TDFFTCEFV 2007 Zambia C 0 1 316 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVSVLDVGDAYFSVPLDEDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPELVICQYVDDLYVASDLEIGQHREKVEKLREHLLRWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLIRGAKTLTDVVPLTEEAELELAENREILKEPAGG Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85297 D4T3TCNVP 2007 Zambia C 0 1 323 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIRAITEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFFTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDVVPLTEEAELELAENRVXLKEPVHGVYYDPSK Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85298 AZT3TCEFV 2007 Zambia C 0 1 309 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIEALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSRNNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYVDDLYVGSDLEIGQHRAKIVELREHLLKWGFYTPDKKHQQEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREI Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85299 D4T3TCNVP 2007 Zambia C 0 1 323 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNATPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIIIYQYMDDLYVASDLEIGQHRAKVEELQNHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLKGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSK Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85300 AZT3TCNVP 2007 Zambia C 0 1 319 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTAICEEMEKEGKITRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELXXRTQDFWEVXLGIXHPAGLKRNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNEKPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFSTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVRQLCKLLRGTKALTDIVPLTEXAELELAENREILKEPIHGVYY Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85301 TDFFTCEFV 2007 Zambia A 0 1 304 PISPIETVPVKLNPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTEWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPDIVIYQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELEWA Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85302 AZT3TCNVP 2007 Zambia C 0 1 331 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEELEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQSKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIIIYQYVDDLYVGSELEIKQHREKVEELRDHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTMQPIQLPEQDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDVVPLTEEAELELAENREILREPVHGAYYDPSKDLIAEIQK Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85304 D4T3TCNVP 2007 Zambia C 0 1 332 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALKEICEEMEKEGKITRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNEIPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKKYPDIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFFTPDKKHQKEPPFLWMGYELHPDKWTMQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAXIQKQ Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85305 AZT3TCEFV 2007 Zambia C 0 1 331 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAEYREILKEPVHGVYDDPSKEXITEIDK Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85306 AZT3TCEFV 2007 South Africa C 0 1 316 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFVIKKKNGTEWRKLIDLRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAFYSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQASMTKILEPFRTKNPDLVICQYIDDLYVASDLEIGQHRAKIEELREHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIQVKQLCKLLRGAKALTDIVPLTKEAELELAENREILKGPVQG Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85308 D4T3TCEFV 2007 South Africa C 0 1 331 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSNKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAYLLKWGFFTPDKKYQKEPPFLWLGYEIHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGVKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQK Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85309 D4T3TCEFV 2007 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEDFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSELEIGQHRAKVEELREHLIKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPVQLPEKDSWTVNDIQKLVGKLNWASQIYPGVRVKNLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDXIAEIXKQG Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85310 AZT3TCNVP 2007 South Africa C 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRTQNPEIVICQYVDDLYVASDLEIGQHRAKIEELRKHLLRWGLTTPDQKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKELIAELQKQGQ Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85311 D4T3TCNVP 2007 Zambia C 0 1 335 PISPIKTIPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITRIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFCEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSLNNETPGVRYQYNVLPQGWKGSPAIFQDSMTRILKPFRTQNPELIICQYVDDLYVASDLEIGQHRAKVKDLRNYLWKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYPGIRVKQLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELVAEIQKQGEG Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85312 TDFFTCEFV 2008 Zambia C 0 1 329 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFVIKRKDNTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIDIYQYVDDLYVASDLEIKQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKEDWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEI Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85313 TDFFTCEFV 2008 Zambia C 0 1 324 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTEICDELEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSLTVIDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIIIYQYVDDLLVGSDLEIGQHRAKIEELREYLLKWGFFTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKD Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85314 D4T3TCNVP 2008 Zambia C 0 1 330 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTVICEEMEKEGKITRIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNEVPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQHPEVVIYQYMDDLYVGSDLEIGQHRETIEKLRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAETR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85315 AZT3TCNVP 2007 Zambia C 0 1 324 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYTGIKVKQLCKLLRGTKALTDVVPLTEEAELELAENREILNKPAQGVYYDPSKD Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85316 D4T3TCNVP 2007 Zambia C 0 1 309 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKAIMEICDELEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVICQYVDDLYVGSDLEIGQHRAKIEELRDHLSKWGFYTPEKKHQKEPPFRWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLIRGTKALTEIVPLTAEAELELAENREI Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85319 TDFFTCNVP 2008 Uganda A 0 1 311 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSGRWRKLMDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTILDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIIICQYVDDLYVGSDLEIGQHRTKVEELRAHLLSWGFITPDEKHQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDVVTLTEEAELELAENREILK Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85320 AZT3TCEFV 2008 Uganda A 0 1 310 PVSPIETVPVKLKPGMDGPRIKQWPLTEEKIKALTEICEEMEKDGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKKTQDFWEVQLGIPHPGGLKKNKSITVLDVGDAYFSIPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQTSMTKILKPFRSQNPGIVIYQYVDDLYVGSDLEIGQHRAKVEELRAHLWKWGFYTPDNKHQQEPPFHWLGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVVTLTEEAELELAENREIL Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85321 D4T3TCEFV 2008 Uganda A 0 1 309 PISSIETVPVTLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPDLVIYQYVDDLYVGSDLEIGQHRAKVEELRAHLLKWGFTTPDRKHQKEHPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKSLTDVVPLTEEAELELAENREI Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85322 AZT3TCEFV 2008 Uganda D 0 1 310 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMIKILEPFRKQNPEMVIYQYMDDLYVGSDLEIGQHRIKIEKLREHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCIRGAKALTEVVPLTEEAELELAENREIL Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85323 AZT3TCNVP 2008 Uganda D 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKINALIEICAELEKEGKITKIGPENPYNTPIFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIIIYQYVDDLYVASDLEIGQHRTKIEELREHLWKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYGGIKVKQLCKCLKGAKSLTEVVPLTKEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85324 AZT3TCEFV 2008 Uganda D 0 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPVKLPEKENWTVNDIQKLVGKLNWASQIYPGIKVKQLCRCIRGTKALTEIVPLTEEAELELAE Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85326 AZT3TCNVP 2008 Uganda D 0 1 308 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDLEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKKQNPEMVICQYVDDLYIGSDLEIGQHRTKIEELRAHLLSWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDIWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCIRGAKALTEVVPLTEEAELELAENRE Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85327 TDFFTCEFV 2008 Uganda D 0 1 299 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFVIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMIIYQYVDDLCVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIHLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCLRGAKTLTEVIPLTEEA Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85329 AZT3TCNVP 2008 Uganda A 0 1 307 PISPIETVPVTLKPGMDGPRVKQWPLTKEKIEALTEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPEIIICQYVDDLYVGSDLETGQHRAKIEELRAHLLSWGLSTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPDKESWTVNDIQKLVGKLNWASQIYSGIKVRQLCKLIRGTKALTEVVPMTEEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85330 D4T3TCNVP 2008 Uganda A 0 1 309 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQHSMTKILEPFRSKNPEIIICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYTGIKVKQLCKLLRGAKALTDIVPLTKEAELELAENREI Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85331 AZT3TCEFV 2008 Uganda A 0 1 307 PISPIETVPVTLKPGMDGPRIKQWPLTEEKIKALTEICSEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTILDVGDAYFSVPLDQNFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPEIIICQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDIVTLTEEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85332 AZT3TCNVP 2008 Uganda A 0 1 308 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKITRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIIIYQYMDDLYVASDLEIGEHRTKIEELREHLLNWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIRVKQLCKLLRGTKALTDIVTLTEEAELELAENRE Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85333 D4T3TCEFV 2008 South Africa C 0 1 299 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKELEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPDIVIYQYVDDLYVQSDLEIGQHRAKIEELREHLWKWGFYTPDEKHQKEPPFLWMGYELHPDKWTVQPINLPEKESWTVNDIQKLVGKLNWASQNYPGIQXKNLCRLLRGTKALTDIVXLTEEA Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85334 D4T3TCEFV 2007 South Africa C 0 1 323 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEDMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYVDDLYVGSDLEIGQHREKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSK Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85335 TDFFTCEFV 2008 South Africa C 0 1 326 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAFFSVPLDEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLV Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85336 D4T3TCEFV 2008 South Africa C 0 1 308 PISPIETVPVKLKPGMDGPKVRQWPLSEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPSIFQSTMIKILEPFRTKNPEIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENRE Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85337 D4T3TCEFV 2007 South Africa C 0 1 332 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAXIKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPGIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQ Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85338 D4T3TCEFV 2008 South Africa C 0 1 311 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTXFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYVDDLHVGSDLEIGQHRAKVEELRKHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENRKVSK Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85339 D4T3TCEFV 2008 South Africa C 0 1 301 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDLVIYQYVDDLYVGSDLEIGQHRAKIKELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKIRQLCKLLRGTKALTDIVPLTEEAEL Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85341 D4T3TCEFV 2007 South Africa C 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPINLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85342 D4T3TCEFV 2007 South Africa C 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAYFSVPLDADFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIIIYQYMDDLYVGSDLEIEQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIRLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVRNLCKLIRGTKALTDIVPLTEEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85343 D4T3TCEFV 2007 South Africa C 0 1 324 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFQWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKIRQLCKLIRGAKALTDIVPLTEEAELELAENREILKEPVHGVFYDPSKD Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85344 AZT3TCNVP 2007 South Africa C 0 1 326 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEELEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIQNPGIVIYQYVDDLYVASDLEIGEHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELI Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85345 D4T3TCEFV 2007 South Africa C 0 1 324 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLRWGFTTPDKKHQKEHPLLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIRVRNLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKD Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85346 TDFFTCEFV 2007 South Africa C 0 1 324 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKRKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEIVIYQYMDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVRQICKLLRGAKALTDIVPLTEEAELELAENREXLKQPVHGAYYDPSKD Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85347 AZT3TCEFV 2007 South Africa C 0 1 328 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEELEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLMDLRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELVIYQYVDDLYVGSDLEIGQHRAKIDELREHLLKWGFYTPDKKHQKEHPFRWMGYELHPNTWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGTKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAE Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85349 AZT3TCEFV 2008 South Africa C 0 1 317 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIDIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENRXILKEPVHGV Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85350 D4T3TCEFV 2008 Kenya A 0 1 308 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLPRSRSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEMIIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDQKHQKEPPFHWMGYELHPDKWTVQPITLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVALTEEAELELAENRE Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85351 AZT3TCNVP 2008 Kenya A 0 1 343 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFFTPDEKHQKEPPFLWMGYELHPDKWTVQPIXLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVTLTEEAELELAENREILRDPVHGVFYDPSKDLIAEIQKQGQDQWTYQIYQ Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85352 AZT3TCEFV 2008 Kenya A 0 1 317 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICLEMEKEGKISKIGPENPYNTPVFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPDIVIYQYVDDLYVGSDLEIGPHRAKIEELRTHLLNWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVKQLCKLLRGTKALTDVVTLTEEAELELAENREILRNPVHGV Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85353 D4T3TCEFV 2008 Kenya A 0 1 328 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICREMEEEGKISKIGPENPYNTPVFVIKRKHGTKWRKLIDFRELNKRTQDFXEIQLGIPHPAGLEQKKSVTVLDVGDAYWSVPLDEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSAAIFQSSMTKILEPFRSQNPEIFICQYMDDLYVSSDLEIGQHRTKIEELRAHLLRWGFTTPDEKHQKEPPFLWMGYELHPDKWTVQPIELPNKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENKEILKEPVHGVYYDPSKDLIAE Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85354 D4T3TCNVP 2008 Kenya D 0 1 327 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVICQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCLRGTKALTEVVPLTQEAELELSENREILREPVHLVYYDPSKDLIA Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85355 TDFFTCNVP 2008 Uganda A 0 1 298 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEEEGKISKIGPENPYNTPIFAIKKKNSTRWRKIVDFRELNKRTQDFWEVQLGLPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEMVIYQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDQKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVTLTEE Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85356 AZT3TCNVP 2008 Uganda D 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYVDDLYVASDLEIGQHRRKIVELREHLLKWGFTTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVKRLCRLLRGTKALTDIVTMTEEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85357 AZT3TCNVP 2008 Uganda A 0 1 308 PISPIDTIPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQNSMLKILEPFRKRNPELTIYQYVDDLYVGSDLEIGQHRAKIEELREHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVPLTEEAELELAENRE Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85358 AZT3TCNVP 2008 Uganda A 0 1 317 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAELEKEGKISRIGPENPYNTPIFAIKKKNSDRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEMIIYQYVDDLYVASDLEIGQHRAKIEELRAHLLRWGLFTPDQKHQKEPPFHWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTKEAELELAENREILRDPVHGV Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85359 AZT3TCNVP 2008 Uganda A 0 1 307 PVSPIETVPVKLKPGMDGPRIKQWPLTEEKIKALTEICKEMEKEGQISKVGPDNPYNTPVFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIIIYQYVDDLYVASDLEIGQHRKKIEELRAHLLKWGLFTPDQKHQKEPPFHWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVTLTEEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85360 AZT3TCNVP 2008 Uganda D 0 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPSGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNATPGTRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPEMIIYQYVDDLYVASDLEIGQHRRKIEELREHLLKWGFFTPDQKHQKEPPFHWMGYELHPDNWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCIRGAKALTEVVPLTAEAELELAE Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85361 TDFFTCEFV 2008 Uganda A 0 1 307 PISPIETVPVTLKPGMDGPRIKQWPLTEEKIKALTEICKEMEQEGKISKIGPENPYNTPVFVIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSITVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIIIYQYVDDLYVASDLEIGQHRTKVEELRAHLLSWGFTTPDNKYQKEPPFLWMGYELHPDKWTVQPITLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85362 AZT3TCEFV 2008 Uganda D 0 1 306 PISPIDTIPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPDNPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPELVIYQYMDDLYVGSDLEIGQHRAKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCLRGAKALTEVVPLTEEAELELAEN Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85363 TDFFTCNVP 2008 Uganda A 0 1 306 PISPIKTVPVTLKPGMDGPRVKQWPLTEEKIKALTEICKEMEKEGKISKMGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIIICQYVDDLYVGSDLEIGQHRAKVEELRAHLLSWGFTTPDEKHQKEPPFHWMGYELHPDKWTVQHIELPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVTLTEEAELELAEN Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85364 AZT3TCNVP 2008 Uganda D 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNELEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIIIYQYVDDLLVGSDLEIGQHRAKIEELRGHLLKWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKCIRGAKALTEIVPLTEEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85365 AZT3TCEFV 2008 Uganda A 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPIFAIKRKDGTTWRKLIDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDIGDAFYSVPLDESFRKYTAFTLPSTNNETPGIRYQYNVLPMGWKGSPAIFQSTMIKILEPFRSKNPEIIICQYVDDLYVASDLEIGQHRTKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKESWTVNDIQKLVGKLNWASQIYAGIRVKQLCKLLRGAKALTDVITLTEEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85366 D4T3TCNVP 2008 Uganda CRF01_AE 0 1 309 PISPIETVPVTLKPGMDGPRIKQWPLTEEKIKALIEICNEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSLNNATPGVRYQYNVLPQGWKGSPAIFQSSMIKILEPFRSKNPEIIIYQYVDDLYVGSDLEIGQHRAKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREI Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85367 D4T3TCNVP 2008 Uganda A 0 1 303 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIQALTEICLEMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYYSIPLDESFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPSIFQSSMTKILEPFRSKYPDIIIYQYVDDLYVASDLEIGQHRARIEELRDHLLRWGFFTPDKKHQKEPPFLWMGYELHPDRWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVTLTEEAELEL Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85368 D4T3TCNVP 2008 Uganda CRF01_AE 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTEICTELEQEGKISKIGPENPYNTPIFAIKKKNSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSIPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQDSMTKILEPFRKQNPEMIIYQYVDDLYVASDLEIGQHRAKIEELRAHLWNWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEIVTLTEEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85369 AZT3TCNVP 2008 Uganda A 0 1 307 PISPIETVPVTLKPGMDGPRIKQWPLTEEKIKALTEICLEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPDIIIYQYMDDLYVGSDLEIGQHRAKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPDKDNWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVTLTEEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85370 AZT3TCNVP 2008 South Africa C 0 1 355 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRVKNPEIVICQYVDDLYVGSDLEIGQHRAKIKELREHLLKWGLTTPDKKHQKEPPFHWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGNEQWTYQIYQEPFKNLKTGKYA Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85371 D4T3TCEFV 2008 South Africa C 0 1 326 PISHIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRMRNPDIVIYQYVDDLRVGSDLEIGQHRAKIEELREHLLKWGLTTPDQKHQKEPPFLWMGYELHPDKWTVQPIILPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLAEEAELELAENREILKEPVHGVYYDPSKELI Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85372 TDFFTCEFV 2008 South Africa C 0 1 309 PISSIETIPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRQNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVICQYVDDLYVASDLEIGQHRAKIEKLREHLLKWGFTTPDKKHQKEHPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEIVPLTEEAELELAENREI Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85373 AZT3TCNVP 2008 South Africa C 0 1 326 PICPIETVPVKLKPGMDGPRVKQWPLAKEKIKALREICEELEKDGKISRIGPENPYNTPIFAIKKKNSDKWRKLMDFRELNKRTQDFWEVQLGIPHPGGLEKKRSVTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNGEPGTRYQYNVLPQGWKGSPSIFQSSMTKILEPFKRQNPDIVIYQYVDDLYVASDLEIGQHRAKIKELRDHLWEWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLI Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85374 D4T3TCEFV 2008 South Africa C 0 1 328 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAE Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85376 AZT3TCEFV 2008 South Africa C 0 1 308 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKNSNRWRKLVDFRELNKRTQDFCEVQLGIPYPGGLKKNKSVTILDVGDAYFSIPLDEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPELVIYQYVDDLYVGSDLEIGQHRERIDKLREHLLKWGLFTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENRE Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85377 AZT3TCEFV 2008 South Africa C 0 1 323 PISPIETVPVKLKPGMDGPRVKQWPLTKEKIKALTEICEELEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLMDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRANNPEMVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGLYTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENRXILKDPVHGVYYDPSK Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85378 D4T3TCNVP 2008 Kenya A 0 1 304 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICADMEKEGKISKIGPENPYNTPIFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIICQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGLITPDEKHQKEPPFHWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVTLTEEAELELA Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85379 D4T3TCEFV 2008 Kenya D 0 1 324 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTEICADMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLIRGTKALTEIVPLTAEAELELAENREILKEPVHGVLYDPSKD Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85380 AZT3TCEFV 2008 Kenya A 0 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKRKDGTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYYSVPLHEDFRKYTAFTLPSTNNETPGVRYQYNVLPMGWKGSPAIFQCSMTKILEPFKLKNPDIVICQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKHLCRLLRGAKALTEVVTLTEEAELELAE Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85381 D4T3TCNVP 2008 Kenya D 0 1 331 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNEAPGVRYQYNVLPQGWKGSPAIFQSSMAKILEPFRNQNPEMVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKTLTDIIPLTDEAELELAENRDXLKEPVHGVYYDPSKELIAKYRK Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85382 D4T3TCNVP 2008 Kenya A 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIIIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDIVTLTEEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85383 AZT3TCEFV 2008 Kenya C 0 1 345 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSSKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEDFRKYTAFTLPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFYTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGNDQWTYQIYQEP Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85384 AZT3TCEFV 2008 Kenya D 0 1 345 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPIFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKKNPEMVIYQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDQKHQKEHPFHWMGYELHPDRWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCIRGTKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQEHDQWTYQIYQEP Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85385 TDFFTCEFV 2008 Zambia C 0 1 328 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKRKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVESDLEIGQHRAKIEELRDHLLKWGFTTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLIRGTKALTEIVPLTKEAELELAENRVFLKEPVHGVYYDPYKDIIAE Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85387 D4T3TCEFV 2008 South Africa C 0 1 345 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQSSMVKILEPFRAKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYQGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQGNDQWTYQIYQEP Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85389 AZT3TCNVP 2008 Uganda A 0 1 276 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLQKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPEIIICQYVDDLYVGSDLEIGQHRKKVEELRAHLLNWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKEDWTVNDIQKLVGKLNWASQIYAGIKV Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85390 D4T3TCNVP 2008 Uganda A 0 1 307 PISPIKTVPVTLKPGMDGPRIKQWPLTKEKIEALTEICADMEKEGKISKVGPENPYNTPVFAIKKKDSTRWRKIADFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSIPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPEIIIYQYVDDLYVSSDLEIGQHRAKIKELRAHLLKWGFITPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVTLTEEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85391 TDFFTCNVP 2008 Uganda A 0 1 307 PISPIETVPVTLKPGMDGPKVKQWPLTEEKLKALTEICKEMEKEGKISKIGPENPYNTPIFAIKKKGSDRWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELRAHLLKWGFTTPDQKHQKEPPFLWMGYELHPDNWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDVITMTEEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85392 AZT3TCNVP 2008 Uganda D 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIIALTEICTELEKEGKISRIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSIPLHKDFRKYTAFTIPSTNNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYVDDLYVGSDLEIEQHRIKIEELREHLLKWGFYTPEKKHQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYPGIKIRQLCKCIRGTKALTEVVPLTEEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85393 AZT3TCNVP 2008 Uganda A 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGRISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRSKNPEIIIYQYMDDLYVGSDLEIGQHREKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIQVRQLCKLLRGTKALTEVVTLTEEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85394 AZT3TCNVP 2008 Uganda D 0 1 307 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPIFAIKKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPELVICQYVDDLYVGSDLELGQHRTKIEELREHLLKWGFTTPEQKHQKEPPFRWMGYELHPDKWTVQSIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCRCIRGAKALTEVVALTAEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85395 AZT3TCNVP 2008 Uganda G 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDELEKDGKITKIGPENPYNTPIFAIKKKNSDKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTNNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIRVRNLCKLLRGAKALTDIVPLTEEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85396 D4T3TCNVP 2008 Uganda D 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPEMVICQYVDDLYVGSDLEIGQHRTKIKELREHLLRWGFTTPDQKHQKEPPFRWMGYELHPDKWTVQPIQLPVQESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDVIPLTEEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85397 D4T3TCNVP 2008 Uganda A 0 1 311 PISPIETVPVTLKPGMDGPKIKQWPLTEEKIKALTDICAELEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPDIIICQYVDDLYVGSDLEIGQHRAKVEELRAHLLSWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDVVTLTDEAELELAENREILK Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85398 D4T3TCNVP 2008 Uganda D 0 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSARWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPYRKQNPEMIICQYVDDLYVGSDLEIGQHRIKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYAGIKIRQLCKCLRGAKALTEVVPLTAEAELELAE Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85399 AZT3TCEFV 2008 Uganda D 0 1 307 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPELVIYQYVDDLYVGSDLEIGLHRRKIEELREHLWKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKCIRGAKALTEVVTLTEEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85400 D4T3TCNVP 2008 Uganda A 0 1 310 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYMDDLYVGSDLEIGQHRAKIEELREHLLSWGLTTPDKKYQKEPPFLWMGYELHPDRWTVQAIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGTKALTDVVTLTEEAELELAENREII Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85401 AZT3TCNVP 2008 Uganda A 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSRNPEIIIYQYVDDLYVASDLEIGQHRAKIEELRAHLWKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKSLTEVVTMTREAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85402 AZT3TCNVP 2008 Uganda A 0 1 302 PISPIETVPVTLKPGMDGPRIKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPDIIICQYVDDLYVGSDLEIGQHRAKVEELRAHLLSWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVTLTEEAELE Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85403 AZT3TCNVP 2008 Uganda D 0 1 308 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRRKIEELREHLWKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPDKESWTVNDIQKLVGKLNWASQIYSGIKVKQLCKCIRGAKTLTEVVPLTEEAELELAENRE Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85404 AZT3TCNVP 2008 Uganda D 0 1 308 PISPIETVPVKLKPGMDGPKVKQWPLTAEKLKALTEICSEMEKEGKISRIGPENPYNTPIFAIKKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRQNPEMVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIELPEKENWTVNDIQKLVGKLNWASQIYSGIKVKQLCRLLKGAKSLTEVVPLTEEAELELAENRE Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85405 AZT3TCNVP 2008 Uganda D 0 1 299 PISPIETVPVKLKPGMDGPRVKQWPLTKEKIEALTEICTELEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSIPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEVIPLTAEA Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85406 D4T3TCNVP 2008 Uganda D 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIKALTEICTELEKEGKVSKIGPENPYNTPIFAI*NRDSTKWRK*VDFRELNKITQDFWEVHLGIPHPAGLKKNKSITVLDVGDAYFSVPLDENFRKYTAFTIPSTNNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRIKIEELRKHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCIRGAKALTEVVPLTEEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85407 AZT3TCNVP 2008 Uganda A 0 1 311 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIIIVQYVDDLYVGSDLEIGQHRTKIEELREHLWKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPINLPEKESWTVNDIQKLVGKLNWASQIYPGIQVRQLCKLLRGAKALTEVVPMTKEAELELAENREILK Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85408 D4T3TCNVP 2008 Uganda D 0 1 314 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTEICAEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSIPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRSKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCIRGTKALTEVVPLSEEAELELAENREILKEPV Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85409 AZT3TCEFV 2008 Uganda A 0 1 309 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILAPFRAKNPDIIIYQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFFTPDQKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREI Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85410 AZT3TCNVP 2008 Uganda D 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIIALTEICSELEKEGKISKIGPENPYNTPIFAIRKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPEMVIYQYVDDLYVASDLEIGQHRIKIEELREHLLKWGFTTPDEKHQKEPPFLWMGYELHPEKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKIRQLCKCIRGAKALTEVVPLTEEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85411 TDFFTCNVP 2008 Uganda C 0 1 311 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKISRVGPDNPYNTPVFAIKKKDSTEWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVICQYVDDLYVASDLEIGKHRAKIEELREHLLRWGLTTPDKKYQKEPPFRWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGVQVKQLCKLLRGAKALTDIVPLTEEAELELAENREILK Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85412 AZT3TCEFV 2008 Uganda D 0 1 310 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTEICMELEQEGKISRIGPENPYNTPIFAIKKKNSDRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVICQYVDDLYVASDLEIGQHRIKIEELREYLWKWGFFTPDKKYQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKCIRGTKALTEVVPLTEEAELELAENREIL Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85413 AZT3TCNVP 2008 Uganda A 0 1 324 PISPVETVPVTLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKNKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRSKNPEIIIVQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGLYTPDKKYQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLKGTKALTDVVTLTEEAELELAENKEILKDPVHGVYYDPSKD Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85414 AZT3TCNVP 2008 Uganda D 0 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICSEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRKQNPEMVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCRCLRGAKTLTEIVQLTEEAELELAE Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85415 AZT3TCNVP 2008 Uganda D 0 1 307 PISTVETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICSEMEKEGKISRIGPENPYNTPIFAIKKKDSNKWRKLIDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDEEFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMIKILEPFRKQNPEMVIYQYMDDLYVGSDLEIGQHRTKIEKLREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPVKLPEKESWTVNDIQKLVGKLNWASQIYPGVKVKQLCRLLRGAKALTEVIPLTEEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85416 AZT3TCEFV 2008 Uganda A 0 1 307 PISPIETVPVTLKPGMDGPRIKQWPLTEEKIKALTEICTELEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPEITIYQYVDDLLVGSDLEIGQHRAKVEELRAHLLSWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDVVTLTEEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85417 D4T3TCNVP 2008 Uganda D 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKAITEICLEMEKEGKISKIGPENPYNTPIFAIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPITLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEVIPLTKEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85423 D4T3TCNVP 2009 Nigeria CRF02_AG 0 1 322 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTDICTELEKEGKISKIGPENPYNTPIFAIKKKDSAKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAANPEIVICQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDNWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLIRGAKALTDIVILTEEAELELAENREILKEPVHGVFYDPT Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85424 D4T3TCNVP 2009 Nigeria CRF06_cpx 0 1 319 PISPIETVPVKLKPGMDGPRIKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKRNPEMVICQYVDDLYVGSDLEIGQHRAKIKELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTMQPIQLPDQDSWTVNDIQKLVGKLNWASQIYPGIKVKHLCKLLRGAKALTEVVPLTAEAELELAENREILKEPVHGVYY Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85425 AZT3TCNVP 2008 Nigeria CRF02_AG 0 1 324 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDKKFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEVEICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVKQLCKLLRGAKTLTDKVTLTKEAELELAENREILKQPVHGVYYDPTKD Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85426 AZT3TCEFV 2008 Nigeria CRF02_AG 0 1 330 PISPIETVPVKLKPGMDGPRVRQWPLTEEKIKALTEICADLEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKIVDFRELNKRTQDFWEVQLGLPHPGGLKKNKSVTVLDVGDAYFSVPLDPEFRKYTAFTIPSLNNETPGVRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLWKWGFYTPDKKHQKEHPFLWMGYELHPDKWTVQPIKLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQ Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85427 AZT3TCNVP 2008 Nigeria CRF02_AG 0 1 355 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICADLEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNERPGVRYQYNVLPQGWKGSPAIFQTSMTKILEPFRKNNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRELLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLIRGAKALTEVVALTEEAELELAENREIFREPVHGVYYDPTKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYA Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85428 AZT3TCNVP 2008 Nigeria G 0 1 327 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLDANFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKNNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKENWTVNDIQKLVGKLNWASQIYSGIKVKQLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKEIMA Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85429 AZT3TCNVP 2008 Nigeria G 0 3 311 SPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPEMVIYQYVDDLYVASDLELGQHRAKIEELREHLLTWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEIVTLTKEAELELAENREILR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85430 AZT3TCEFV 2008 Nigeria CRF02_AG 0 1 269 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIKELREHLLKWGLTTPDKKHQTEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQ Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85431 TDFFTCNVP 2008 Nigeria CRF02_AG 0 1 330 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTDICMEMEKEGKISKIGPENPYNTPIFAIKRKDNTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDQDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRNKNPEIVICQYVDDLYVASDLEIGQHRAKIKELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQ Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85432 D4T3TCNVP 2008 Nigeria CRF02_AG 0 1 313 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTENPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVILTEEAELELAENREILKEP Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85433 AZT3TCEFV 2008 Nigeria G 0 1 330 PISPIETVPVKLKPGMDGPRIKQWPLTEEKIKALTEICKDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFSEVQLGIPHPAGLKKNRSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELVIYQYVDDLHVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIRVKHLCRLLRGAKALTDIVPLTAEAEMELAENREILKEPVHGVYYDPSKELIAEVQ Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85434 AZT3TCNVP 2008 Nigeria CRF02_AG 0 1 306 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICTEMENEGKISRIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQTSMTKILEPFRTENPEIVICQYVDDLYVGSDLEIGQHRAKIEELRNHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYAGIKVRQLCRLLRGAKALTDIVPLTEEAELELAEN Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85435 D4T3TCEFV 2009 Kenya A 0 1 326 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKYNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRSQNPELVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRCLRGVKALTEIVTLTEEAELELAENREILKEPVHGVYYDPSKDLI Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85436 TDFFTCNVP 2009 Kenya D 0 1 342 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICAELEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSIPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRAKVKELRKHLWKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEIVTLTEEAELELAENREILKDPVHGVFYDPSKDLTAEIQKQGQDQWTYQIY Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85437 D4T3TCNVP 2009 Kenya A 0 1 324 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDMGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRSKNPEIIIYQYMDDLYVGSDLEIGQHRTKVEELRAHLLSWGLTTPDKKHQKEPPFHWMGYELHPDKWTVQPIVLPEKENWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVTLTEEAELELAENREILKNPVHGVYYDPSKD Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85438 D4T3TCNVP 2009 Kenya A 0 1 324 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICAEMEREGKISKIGPENPYNTPIFAIKKKNSNRWRKLVDFRELNKRTQDFWEIQLGLPHPAGLKKNKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQDSMTKILAPFRSKYPEITIYQYVDDLYVGSDLEIGQHRERIKELRAHLLSWGFTTPDQKYQKEPPFHWMGYELHPDTWTVQPIILPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVTLTEEAELELAENREILKNPVHGVYYDPSKD Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85439 D4T3TCEFV 2009 Kenya A 0 1 323 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIIIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDVVTLTEEAELELAENREILKEPVHGVYYDPSK Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85443 AZT3TCNVP 2009 Nigeria G 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAELEKEGKISKIGPENPYNTPIFAIKKKGSDRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKQKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMEICQYVDDLYVGSDLEIGQHRAKIEELRNHLLRWGFFTPEQKHQKEPPFHWLGYELHPDKWTVHPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85444 D4T3TCNVP 2009 Nigeria CRF02_AG 0 1 324 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICTEMEKEGKISRIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKTSVTIIDVGDAYFSVPLHEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQTSMTQILEPFRKRNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIVLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGAKALTDVVTLTREAELELAENREILKQPVHGVYYDPTKD Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85445 TDFFTCEFV 2009 Nigeria G 0 1 308 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPVFAIKKKGSTEWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILDPFRAKNPELVIYQYVDDLYVGSDLEIEQHRAKIEKLREHLLRWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPVQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTKEAELELAENRE Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85446 D4T3TCNVP 2009 Nigeria G 0 1 330 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICREMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRTKYPDIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKQPVHGVYYDPSKELIAEIQ Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85447 D4T3TCNVP 2009 Nigeria G 0 1 328 PISTIETVPVKLKPGMDGPKVKQWPLTEEKIRALTEICIEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKRNPEMVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKENWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAE Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85448 AZT3TCNVP 2009 Nigeria G 0 1 343 PISPIETVPVKLKPGMDGPKIKQWPLTGEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPITLPDKEDWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILREPVHGVYYDPSKPLIAEVQKQGPDQWTYQIYQ Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85449 D4T3TCNVP 2009 Nigeria G 0 1 343 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTAMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSVNNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIKELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVTLTEEAELELAENREILREPVHGVYYDPSKDLIAEIQKQGLDQWTYQIYQ Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85450 AZT3TCNVP 2009 Nigeria G 0 1 345 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTDICAEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTRNPEMVIYQYVDDLYVASDLEIEQHRAKIEELREHLLKWGFTTPDRKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIRVRQLCKLLRGAKALTDIVTLTEEAELELAENREILREPAHGVYYDPSKDLIAEIQKQGLDQWTYQIYQEP Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85451 D4T3TCNVP 2009 Nigeria G 0 1 343 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRARNPEIVICQYVDDLYVASDLEIGQHRAKVEELRNHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPNKEDWTVNDIQKLVGKLNWASQIYPGIQVRQLCKLLRGAKALTDIVPLTKEAELELAENREILKEPVHGVYYDSSKELIAEVQKQGEDQWTYQIYQ Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85452 TDFFTCNVP 2009 Nigeria CRF02_AG 0 1 323 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTEWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPFRWMGYELHPDKWTVQPIELPDKDSWTVNDIQKLVGKLNWASQIYAGIRIKQLCKLLRGAKALTDTVVLTEEAELELAENREILKEPAHGVYDDPTK Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85453 AZT3TCNVP 2009 Nigeria CRF02_AG 0 1 246 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMDICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPRVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQL Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85454 AZT3TCNVP 2009 Nigeria CRF02_AG 0 1 332 PISTIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSATVLDVGDAYFSVPLDEEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILRPFREANPEIVIYQYVDDLYVGSDLEIGQHRAKIEQLREHLLKWGLSTPDKKYQKEPPFLWLGYELHPDKWTVQPIKLPEKDDWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQ Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85455 AZT3TCEFV 2009 Nigeria G 0 1 316 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNELEKGGKXTKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTRNPEMVIYQYVDDLLIGSDLEIGQHRAKIKELRDHLWKWGFYTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKQPVHG Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85456 D4T3TCNVP 2009 Nigeria G 0 1 311 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFVIKKKDSNKWRKLIDLRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYYSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPMGWKGSPAIFQYSMTKILEPFRTKNPEMVICQYVDDLYVASDLEIGQHRAKIEELRNHLLKWGLTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIIPLTEEAELELAENREILK Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85457 D4T3TCEFV 2008 South Africa C 0 1 330 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWLGYELHPDTWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQ Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85458 D4T3TCNVP 2008 South Africa C 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLYEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPDIVICQYVDDLYVASDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85459 D4T3TCEFV 2008 South Africa C 0 1 326 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKIXKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDRKHQKEPPLLWMGYELHPDKWTVQPIQLPEKEDWTVNDIQKLVGKLNWASQIYAGIKVRELCKLLRGTKALTDIVPLTREAELELAENRVLXKEPVHGVYYDPSKDLI Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85460 AZT3TCEFV 2008 South Africa C 0 1 316 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKIEKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHG Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85461 AZT3TCEFV 2008 South Africa C 0 1 323 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQCMDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREXLKEPVHGVYYDPSK Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85462 D4T3TCEFV 2008 South Africa C 0 1 304 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKVGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNESPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYVDDLYVASDLEIGQHRAKIEELRDHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELA Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85463 D4T3TCEFV 2008 South Africa C 0 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRXLNRRTQDFWEVQLGIPHPSGXKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNEKPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYVDDLYVGSDLEIGQHRAKIKELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGTKALTEIVPLTEEAELELAD Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85464 TDFFTCNVP 2008 South Africa C 0 1 343 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFVIKRKDGTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEVVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENKEILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQ Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85465 TDFFTCNVP 2008 South Africa C 0 1 303 PISPIETVPVKLKPGVDGPKVKQWPLTEEKIKALTAICEEMEKEGKISRIGPENPYNTPVFAIKRKDNTEWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKNSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPEIEIYQYVDDLYVSSDLEIKQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPNKWTVQPIKLPDKESWTVNDIQKLVGKLNWASQIYPGIRVKHLCKLLRGTKALTDVVPLTEEAELEL Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85466 D4T3TCEFV 2008 South Africa C 0 1 326 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICEEMEKEGKITKIGPDNPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKRKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYVDDLCVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFQWMGYELHPDKWTVQPIHLPEKDNWTVNDIQKLVGKLNWASQIYPGIRVRHLCKLLRGAKALTDIVPLTEEAELELAENREXQKEPVHGVYYDPSKELI Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85467 D4T3TCEFV 2008 South Africa C 0 1 329 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALMAICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEI Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85468 D4T3TCEFV 2008 South Africa C 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICSEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIREHRAKIDELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKEDWTVNDIQKLVGKLNWASQIYPGIKVTQLCKLIRGTKALTEIVPLTEEAELELAENR Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85469 D4T3TCEFV 2008 South Africa C 0 1 324 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKD Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85470 AZT3TCEFV 2008 South Africa C 0 1 299 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNATPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRHHLFKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPEIKVRQLCKLLRKTKALTDIVPLTEEA Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85471 D4T3TCNVP 2008 South Africa C 0 1 321 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPDNPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVLDVGDAYFSVPLDEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSTMTKILEPFRTQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDQKHQKEYPFLWMGYELHPDKWTVQPIVLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQMCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDP Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85472 D4T3TCEFV 2008 South Africa C 0 1 277 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRSKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWSVNDIQKLVGKLNWASQIYPGIKVK Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1952 85473 D4T3TCEFV 2008 South Africa C 0 1 313 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLSEEAELELAENREILKEP Sigaloff, KC 2011 21694603 JAIDS Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. 1956 86268 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 262 KVKQWPLTKEKIEALTEICNEMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRMKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVG Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86269 AZT3TCNVP 2008 Thailand CRF01_AE 0 20 262 KVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVICQYVDDLYIGSDLEIGQHRTKIEELRAHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVG Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86270 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 262 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLRKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQFSMTKILQPFRAKNPEIIICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFFTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVG Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86271 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 262 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKGGTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDIGDAYFSVPLHESFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDIQICQYVDDLYVGSDLEIGQHREKIKELRAHLLSWGFFTPDKKHQEEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVG Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86272 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 262 KVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNQTPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRSKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLWSWGFYTPDKKHQKEPPFLWMGYELHPDTWTVQPIELPEKDSWTVNDIQKLVG Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86274 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 259 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAFFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEMVIYQYVDDLLVGSDLEIGQHRTKIEELRAHLLSWGFFTPDKKHQKEPPFLWMGYELHPDKWKVQPIELPEKDSWTVNDIQK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86275 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 263 RVKQWPLTEEKIKALTEICKELEEAGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELRAHLWSWGFYTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86276 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 263 RLKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRMKNPEIVICQYVDDLYVGSDLEIGQHRRKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86277 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 244 KVKQWPLTEEKIKAITEICKELEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRMKNPDIIICQYVDDLYVGSDLEIGQHRTKVEELRAHLLSWGFYTPDKKYQKEPPFLWMGYELHPDRWTVQPI Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86278 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIRALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLMDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRTKIEELRQHLWSWGFFTPDKKHQKEPPFLWMGHELHPDRWTVQPIELPEKDSWTVNDIQKLLGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86279 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 264 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIDICQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKL Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86281 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICKEMEAEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86282 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICKEMEEEGKISRIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEMVICQYVDDLYVGSDLEIGQHREKIEELRTHLWKWGFYTPDKKHQKEPPFLWMGYELHPDRWTVQPIVLPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86284 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 257 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEIVIYQYVDDLYVASDLEIGQHRTKIEELRTHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDI Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86286 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 263 KVKQWPLTKEKIEALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMIIYQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFITPDQKHQKEPPFLWMGYELHPDRWTVQPIELPEKDHWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86287 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 244 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELVICQYMDDLYVGSDLEIGQHRIKVEELRAHLLSWGFTTPDKKHQKEPPFRWMGYELHPDRWTVQPI Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86288 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 244 RVKQWPLTEEKLKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDGTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPDMVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPI Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86289 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 244 RVKQWPLTEEKIKALTEICREMEEEGKISKIGPENPYNTPIFAINKKNSTRWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKKNPEMVIYQYVDDLYVGSDLEIGQHRAKIDELRAHLLRWGFTTPDQKHQKEPPFLWMGYELHPDRWTVQPI Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86291 D4T3TCEFV 2008 Thailand CRF01_AE 0 20 232 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDMVIYQYVDDLLVGSDLEIGQHRTKIEELRAHLMSWGFTTPDKKHQKEPPFLWMGY Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86292 D4T3TCNVP 2008 Thailand CRF01_AE 0 30 244 KIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLRWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPI Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86293 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 256 RVKQWPLTEEKIKALTEICKEMEEEGKISRIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRIKNPEIIICQYVDDLYVGYDLEIGQHRTKIEELRAHLLSWGFYTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVND Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86294 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 265 KVKQWPLTEEKLKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSNKWRKLTDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIIIIQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGKLN Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86295 TDF3TCEFV 2008 Thailand CRF01_AE 0 20 265 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRIKNPEIIICQYMDDLYVSSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQNLVGKLN Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86296 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 265 KVKQWPLTKEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVASDLEIGQHRAKIDELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPDQDSWTVNDIQKLVGKLN Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86298 D4T3TCNVP 2008 Thailand B 0 20 265 KVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDLDICQYVDDLYVGSDLEIGKHRTKIEELRQHLLRWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPILLPEKDSWTVNDIQKLVGKLN Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86302 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 258 KVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEVVICQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPERDSWTVNDIQ Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86303 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 266 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKRKDS~KWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDIGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIDICQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGKLNW Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86304 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 258 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKRKDGTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVASDLEIGQHRIKIEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPVKDNWTVNDIQ Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86305 AZT3TCEFV 2008 Thailand B 0 20 255 KVKQWPLTEEKINALVEICTEMEKEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDLLIYQYVDDLYVGSDLEIGQHRTKIEELREHLWKWGFYTPDKKHQKEPPFLWMGYELHPDTWTVQPIELPEKDSWTVN Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86306 D4T3TCNVP 2008 Thailand B 0 20 263 KVKQWPLTEEKIKALMEICAEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVSVLDVGDAYYSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRKQNPDIVICQYIDDLYVASDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86307 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 237 KVKQWPLTEEKIKALTENCKEMEEGRKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLPKNKSVTVLDVGDAYYSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRIKNPGMVIYQYVDDLYVGSDLEIGQHRGKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPD Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86308 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 264 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKRNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPVELPEKDSWTVNDIQKLVGKL Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86309 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRIKNPEMVICQYVDDLYVGSDFEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86310 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 255 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEMIICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPEQKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVN Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86311 D4T3TCNVP 2008 Thailand B 0 20 259 RVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVICQYMDDLYVGSDLEIEQHRIKIEELRQHLLGWGFTTPDKKHQKEPPFLWMGYELPPDKWTVQPIVLPEKDSWTVNDIQK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86312 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFVIKKKNSTKWRKLIDLRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNQTPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRTKNPEIIIYQYVDDLYVASDLEIGQHRTKVEELRAHLLSWGFTTPDEKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLMGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86313 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 240 KVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKYPDMIIYQYVDDLLVGSDLEIGQHRERIKELRDHLWSWGFYTPDKKYQKEPPFLWMGYELHPDRWT Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86315 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICEELEEERKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYIDDLLVGSDLEIEQHRAKIEELRAHLWSWGFFTPERKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86316 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPTIFQSSMTKILEPFRRKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDEKHQKEPPFLWMGYELHPDSWTVQPIKLPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86318 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86319 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 263 RVKQWPLTEEKIKALTEICKEMEEEGKISRIGPENPYNTPIFAIKKKNSTRWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDQKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86321 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALMEICKEMEEEGKISKIGPENPYNTPVFAIKKKDGTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDIVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLWSWGFYTPDKKHQKEHPFLWLGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86322 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 261 KIKQWPLAEEKIKALTEICNEMEKEGKISKMGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLNWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLV Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86324 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTKICEEMEKEGKISKIGPENPYNTPVFAIKQKD~~KWRKLVDFRELNKRTQDFWEIQLGIPHPSGLKKKKSVTILDVGDAYFSVPLDENFRKYTAFTLPSINNETPGVRYQYNVLPMGWKGSPAIFQSSMTKILEPFRAKNPEMVICQYIDDLYVGSDLEIGQHRIKVEELRAHLLSWGLTTPDRKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86326 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKGGTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEMIIYQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86328 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGTRYQYNVLPQGWKGSPAIFQNSMTKILEPFRIKNPDMVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKGSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86333 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICKEMEEEGKISRIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDMIIIQYVDDLYVGSDLEIGQHRTKVEELRAHLLSWGLTTPDQKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86334 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86336 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 256 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIVQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFFTPDKKHQKEPPFLWMGYELHPDRWTVQPIVLPDKDSWTVND Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86337 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 255 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMIIYQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVN Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86338 D4T3TCNVP 2008 Thailand B 0 20 259 KVKQWPLTEEKIKALVEICTELEKDGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDIGDAYFSVPLDEKFRKYTAFTIPSVNNETPGVRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVICQYVDDLYVGSDLEIGQHRIKVEELRQHLSRWGFYTPDKKCQKEPPFRWMGYELHPDKWTVQPIVLPEKDSWTVNDIQK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86340 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 259 RVKQWPLTEEKIKVLRDICKEMEEEGKISRIGPENPYNTPVFVIKNKNRNTWRKLMDFRELNKRTQDFWEIQLGLPHPAGLAKKKSATVLDVGDAYFSIPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQDSMTKILEPFRTKNPEMIIYQYMDDLYVGSDLEIGQHRAKVDELRAHLLKWGLTTPDRKHQKGPPFLWMGYELHPDRWTVKPIELPERDSWTVNDIQK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86343 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 259 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNSPVFAIKKKDSTKWRKLIDLRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRLKNPEIVICQYVDDLYVGSDLEIGQHREKIEELRAHLLSWGFFTPDKKHQKEPPFRWMGYELHPDRWTVQPIELPEKDSWTVNDIQK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86344 D4T3TCNVP 2008 Thailand B 0 20 260 KVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSIPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKL Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86345 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 259 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLRWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86346 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 256 KVKQWPLTEEKLKALMEICKELEEAGKISKIGPENPYNTPVFVIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPDIIICQYVDDLYVGSDLEIGQHRTKVEELRAHLLSWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVND Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86347 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 259 RVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRIKIEELRAHLLRWGFTTPEEKHQKEPPFLWMGYELHPDKWTVQPIALPEKDSWTVNDIQK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86348 AZT3TCEFV 2008 Thailand CRF01_AE 0 20 254 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDKWTV Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86350 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 254 RVKQWPLTEEKLKALIEICREMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTV Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86353 D4T3TCNVP 2008 Thailand B 0 20 263 KVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYVDDLYVASDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86354 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSATVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFYTPDKKHQKEPPFLWMGYELHPDRWTVQPIKLPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86355 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQTSMTKILEPFRIKNPEMVIVQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFFTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86357 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 254 KVKQWPLTEEKIKALTEICREMEEEGKISKIGPENPYNTPIFAIKKKGGTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEMIICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDEKYQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTV Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86360 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 255 RVKQWPLTEEKIKALTEICEAMEKEGKISKIGPENPYNTPVFAIKKKNSNRWRKLIDLRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYYSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPMGWKGSPAIFQSSMIKILEPFKIKNPEMVICHYVDDLYVGSDLEIGQHRAKVEELRAHLLKWGLTTPDEKYQKEPPFHWMGYELHPDKWTVQPIELPEKDSWTVN Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86362 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 254 RVKQWPLTEEKIKAITEICKEMEEEGKISKIGPENPYNTPVFAIKRKDGTTWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSAAIFQSSMTKILEPFKIKNPELVICQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGLTTPDKKHQQEPPFRWMEYELHPDKWTVQPIELPEKDSWTV Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86366 D4T3TCNVP 2008 Thailand CRF01_AE 0 28 255 EEKIKALTEICKELEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMTICQYVDDLYVGSDLEIEQHRAKIEELRAHLWSWGFFTPDKKYQKEPPFLWMGYELHPDRWKVQPIELPEKDSWTVN Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86368 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPVFAIKKKDNTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLVKKKSVTILDVGDAYFTVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIKLPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86369 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKGGNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEVVICQYVDDLYVGSDLEIGQHRAKVEELRAHLLSWGFFTPDEKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86370 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86371 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDIVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIKLPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86372 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALREICEEMEKEGKISKIGPENPYNTPVFAIKKRDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86374 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 263 RVKQWPLTKEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIIIYQYVDDLYVASDLEIKQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86375 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 263 KIKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMIICQYMDDLYVASDLEIGQHRTKIEELRKHLLSWGFTTPDKKHQKEPPFRWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86376 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 263 KVKQWPLTKEKIKALTEICQEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVASDLEIGQHRARIEELRVHLLSWGLTTPDKKHQKEPPFLWMGYELHPDRWTVQPIKLPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86379 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 254 KVKQWPLTKEKIEALTEICKEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTV Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86380 AZT3TCNVP 2009 Thailand CRF01_AE 0 20 255 KVKQWPLTEEKIKALTKICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESLRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVN Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86381 AZT3TCNVP 2009 Thailand CRF01_AE 0 20 263 RVKQWPLTEEKIKALTEICKEMEQEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFSEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIIIYQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86382 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 254 KVKQWPLSEEKLKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVSVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIIICQYVDDLYVGSDLEIGQHRKKVEELRAHLLSWGFDTPDKKHQKEPPFRWMGYELHPDKWTVQPIELPEKDSWTV Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86383 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 259 KVKQWPLTEEKIKALMEICKEMEEEGKISRIGPENPYNTPVFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86385 D4T3TCNVP 2009 Thailand B 0 20 259 KVKQWPLTEEKIKALVEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86386 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 254 RVKQWPLTEEKLKALTEICEEMEKEGKISKIGPENPYNTPIFAIKKKGGTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSITVLDVGDAYYSVPLDESFRKYTAFTIPSINNATPGIRYQYNVLPMGWKGSPAIFQYSMTKILEPFKMKNPEMVIYQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGLTTPDQKHQQGPTYLWMGYELHPDRWTVQPIELPEKDSWTV Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86388 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 259 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKNSDRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPEFIIYQYVDDLYVASDLEIEQHRIKIEELRAHLLSWGFITPEQKHQKEPPFHWMGYELHPDRWTVQPIELPEKDSWTVNDIQK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86389 AZT3TCEFV 2009 Thailand CRF01_AE 0 20 255 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIEMPEKDSWTVN Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86390 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 259 KVKQWPLTEEKLKALTEICKEMEEEGKISRIGPENPYNTPVFVIKKKDSTKWRKLTDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDIGDAYFSVPLDENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEMIIIQYVDDLYVGSDLEIEQHRMKIKELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86391 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 259 KVKQWPLTEEKIKALMEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKRNPEIIIYQYVDDLYVGSDLEIGEHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86392 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 259 KVKQWPLTEEKIKALTEICKEMEEEGKISRIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKGNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSCMTKVLDPFRIKNPEMVIYQYVDDLYVGSDLEIEQHRAKIEELRAHLWSWGFYTPDKKHQKEPPFLWLGYELHPDKWTVQPIELPEKDSWTVNDIQK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86393 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 240 KVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPIFAIKKKNSTKWRKFVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRLKNTEMVIYQYVDDLYVGSDLEIGQHREKIEELRAHLLKWGFFTPDKKHQKEPPFLWMGYELHPDRWT Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86396 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 262 KVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDKDFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKVLEPFRVKNPELTICQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFFTPDKKHQKEPPFRWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVG Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86397 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRIKNPEMVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86398 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 259 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYYSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPMEWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRAKVEELRAHLLSWGLTTPDQKYQKEPPLLWMGYELHPDRWTVQPIELPEKDSWTVNDIQK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86399 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICKEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEMTIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPERDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86400 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGLTTPDKKYQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86401 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 261 KVKQWPLTEEKIKALTKICKEMEEEGKISKIGPENPYNTPVFAIKNKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGLTTPDRKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLV Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86402 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 263 RVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTRILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDQKHQKEPPFHWMGYELHPDRWKVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86403 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 255 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIRKKDSSKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIIICQYVDDLYIGSDLEIGQHRAKVEELRPHLLRWGFTTPDKKYQKEPPFHWMGYELHPDRWTVQPIELPEKDSWTVN Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86404 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 255 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKKNPEMVIYQYVDDLYVASDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPERDSWTVN Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86405 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRKKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86406 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 262 RVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEIIIYQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDQKHQKEPPFQWMGYELHPDRWTVQPIQLPEKDSWTVNDIQKLVG Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86407 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 262 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVG Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86408 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIVQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86410 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 263 KIKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKNSTRWRKLMDLRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMIIYQYVDDLLVGSDLEIGQHRTKVEELRAHLLSWGFTTPDQKYQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86411 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 262 KVKQWPLTKEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKYPEIVIYQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDQKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVG Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86412 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 223 RVKQWPLTEEKIKALTEICKEMEEEGKISRIGPENPYNTPVFAIKKKNSTRWRKLTDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTVLDIGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPELEICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86413 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 262 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILDPFRIKNPDLVICQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVG Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86418 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 262 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKNNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVG Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86419 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 262 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTILDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEMVICQYMDDLYVGSDLEIGQHRIKIEELRAHLMSWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVG Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86420 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPIFAIKKKNSTRWRKIVDFRELNKRTQDFWEVQLGIPHPGGLHKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVASDLEIEQHRLKIDELRAHLLSWGFFTPDQKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86421 D4T3TCEFV 2009 Thailand B 0 20 262 KVKQWPLTEEKLKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIEQHRTKIEDLRQHLLAWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVG Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86424 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 255 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFYTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVN Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86425 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 255 KVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPIFAIKKKDGTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQHSMTRILEPFRIKNPELVICQYVDDLYVGSDLEIGQHRAKIEELRAHLWSWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVN Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86426 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 255 RVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYMDDLYVGSDLEIGQHRKKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEQDSWTVN Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86427 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICKEMEEEGKISRIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVSSDLEIGQHRAKIEELRAHLLSWGFFTPDQKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86428 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 259 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDQKHQKEPPFRWMGYELHPDRWTVQPIELPEKDSWTVNDIQK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86429 AZT3TCNVP 2009 Thailand B 0 20 239 KVKQWPLTKEKIKALVEICAEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKKTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRQHLLKWGLFTPDQKHQKEPPFLWMGYELHPDKW Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86430 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 255 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIIICQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVN Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86432 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICKELEEDGKISKIGPDNPYNTPVFAIRKKNSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSIPLHESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVASDLEIGQHRTKIEELRAHLWNWGFYTPEKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86433 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 255 KVKQWPLTEEKIKALTEICREMEEEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQAKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNGTPGIRYQYNVLPQGWKGSPTIFQSSMTKILEPFRTKNPEMIICQYVDDLYVGSDLEIGQHRIKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVN Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86434 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 255 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVADAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIDICQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDNKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVN Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86436 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 255 KVKQWPLTEEKIKALTEICKEMEEEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVICQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVN Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86437 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 255 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRMKNPEMVIYQYVDDLYVASDLEIGQHREKIKELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVN Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86438 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 255 KVKQWPLTEEKIKALTEICKELEEDGKISKIGPENPYNTPVFVIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSIPLDESFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRIKNPEIIIVQYVDDLYVGSDLEIGQHRIKIDELRAHLSKWGFYTPDKKYQKEPPFLWMGYELHPDRWTVQPIKLPEKDSWTVN Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86439 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 255 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEVLICQYVDDLYVGSDLEIEQHRTKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVN Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86441 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 254 KVKQWALTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRTKVEELRAHLLNWGFTTPDQKYQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTV Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86442 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIEALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIVQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFRWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86443 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 250 KVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIDIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKD Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86444 D4T3TCNVP 2008 Thailand CRF01_AE 0 20 254 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEMVIYQYVDDLYVGSDLEIGQHREKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDSWTVQPIELPEKDSWTV Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86445 D4T3TCEFV 2009 Thailand CRF01_AE 0 20 262 KVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTRILEPYRIKNPEMVIYQYVDDLYVGSDLEIGQHREKIEELRAHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVG Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86448 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 262 KVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPVFAIKKKDSNKWRKLMDFRELNKRTQDFWEIQLGIPHPAGLEKKKSVTIIDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIVQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFFTPEKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVG Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86449 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 262 RVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIVIYQYMDDLYVGSDLEIEQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPITLPEKDSWTVNDIQKLVG Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86450 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 262 KVKQWPLTEEKIKALTDICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFSEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVG Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86452 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVASDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPERDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86454 D4T3TCEFV 2009 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQQNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTRILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRTKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86455 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 262 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVASDLEIGQHRIKIDELRAHLLSWGFTTPDEKYQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVG Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86456 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 259 KVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTRWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYVDDLYVGSDLEIGQHRAKIKELRDHLLSWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPITLPEKDSWTVNDIQK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86457 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 262 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLLVGSDLEITQHRTKIEELKAHLLTWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVG Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86458 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 262 KVKQWPLTEEKIKALTEICKELEEAGKISKIGPENPYNTPVFAIKKKGGTKWRKVTDFRELNRRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSIPLDENFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQTSMTKILEPFRIKNPEMVICQYVDDLYVGSDLEIEQHRAKIKELRAHLWNWGFYTPEDKYQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVG Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86459 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 262 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIRKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRMKNPEIIICQYVDDLYVGSDLEIGQHRSKIEELRAHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIELPERDSWTVNDIQKLVG Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86462 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 263 RVKQWPLTEEKIKAITEICKEMEEEGKISKIGPENPYNTPIFAIKRKDG~KWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSITVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKIKNPEMVICQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDRKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86463 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 263 RVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKDSNRWRKLMDLRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPTIFQSSMTKILEPFRARNPEIIIIQYVDDLYVGSDLEIGQHRTKIKELREHLLRWGFTTPEQKHQKEPPFRWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86465 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDIGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMIIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86467 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYYSVPLDESFRKYTAFTIPSTNNETPGVRYQYNVLPMGWKGSPAIFQSSMTKILEPFRIKNPEMVIIQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86468 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICKEMEEEGKISRIGPENPYNTPVFVIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEEKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86469 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKALTEICKEMEAEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRAKVEELRAHLLRWGFTTPDEKYQKEPPFLWLGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86470 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 263 KVKQWPLTEEKIKAITEICKELEEEGKISKIGPENPYNTPVFAIKKKDSDKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEMIIVQYVDDLYVGSDLEIGQHRTKIKELRAHLLSWGLFTPDKKHQEEPPFRWMGYELHPDRWTVQPIELPDKDHWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86473 D4T3TCNVP 2009 Thailand B 0 20 263 KVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPDIVICQYVDDLYVGSDLEIGQHRAKIEELRQHLLRWGFTTPDKKYQKEPPFLWMGYELHPNKWTVQPIVLPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86474 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 263 RVKQWPLTEEKIKALTEICKEMEEEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIIICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86477 AZT3TCNVP 2009 Thailand CRF01_AE 0 20 263 KVKQWPLTKEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVSSDLEIGQHRAKIEELRQHLLKWGFFTPDQKHQKEPPFLWMGYELHPDKWTVQPIELPEQDSWTVNDIQKLVGK Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86480 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 262 KVKQWPLTKEKIKALTEICKEMEEEGKISRIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEIVIYQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVG Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1956 86481 D4T3TCNVP 2009 Thailand CRF01_AE 0 20 262 KVKQWPLTAEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDGSKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPEMIIYQYVDDLYVASDLEIGQHRRKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVG Bunupuradah, T 2011 22024527 Antivir Ther Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. 1970 90257 D4T3TCEFV 2008 South Africa C 1 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKAITAICEDMEKEGKISKIGPENPYNTPIFAIKRKDNN~WRQLMDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYMDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDRKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQG Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90258 AZT3TCNVP 2008 South Africa C 1 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPIFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVICQYVDDLYVGSDLEIGQHRAKIDELREHLLKWGFFTPDEKHQKEPPFHWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYEPSKELIAEIQKQGQ Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90261 D4T3TCEFV 2008 South Africa C 1 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLRWGFTTPDQKYQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKTLTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90262 D4T3TCEFV 2008 South Africa C 1 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKIKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGQ Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90263 D4T3TCEFV 2008 South Africa C 1 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALKEICEEMEKEGKITKIGPENPYNSPIFAIKKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSAPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRTRNPEIVIYQYVDDLCVGSDLEIGQHRAKVEELRSHLLQWGFTTPDKKHQKEPPFHWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEIVPLTKEAELELAENREILKEPVHGVYYDSSKELIAEIQKQGE Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90264 D4T3TCEFV 2008 South Africa C 1 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPGIIIYQYMDDLYVGSDLEIGQHREKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90265 D4T3TCEFV 2008 South Africa C 1 1 333 PISPIETVPVKLKPGMDGPRVKQWPLSEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKRKDN~KWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPEIVIYQYMDDLYVGSDLELEQHRAKIEELREHLLKWGLTTPDRKHQQEPPLRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLIRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQG Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90267 AZT3TCNVP 2008 South Africa C 1 1 335 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKITKIGPENPYNTPIFAIKKKSGNRWRKLVDFRELNKRTQDFWEIQLGIPHPGGLKKNKSVTVLDVGDAYFSIPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKVEELRAHLLKWGLITPEEKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEIVALTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQGEG Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90268 D4T3TCEFV 2008 South Africa C 1 1 333 PISHIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEELEQDGKITKIGPENPYNTPIFAIKKKNSTKWRKVVDFRELNKRTQDFWEVQLGIPHPSGLKRSKSMTVLDVGDAYFSIPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPGMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFYTPDNKHQEEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90269 D4T3TCEFV 2008 South Africa C 1 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGMKKNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELRAHLLKWGLTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90270 D4T3TCEFV 2008 South Africa C 1 1 335 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDGNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKSKKSMTVLDVGDAYYSVPLDEDFRKYTAFTIPSVNNEAPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLCVASDLEIGQHRAKVEELRQHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGEG Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90271 D4T3TCEFV 2008 South Africa C 1 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIDELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90273 AZT3TCNVP 2008 South Africa C 1 1 333 PISSIETVPVKLKPGMDGPRVKQWPLTEEKIKALKEICDEMEKEGKITKIGPENPYNTPIFAIKKKSSNRWRKLVDFRELNKRTQDFWEIQLGIPHPAGLTKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQNSMTRILEPFRVKNPEIVICQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFVTPDEKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLKGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQG Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90274 D4T3TCEFV 2008 South Africa C 1 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKAVTAICEEMEKEGKITKIGPENPYNTPIFAIKRKDG~RWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNEEPGIRYQYNVLPMGWKGSPSIFQSSMTKILEPFRAQNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGQ Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90275 D4T3TCEFV 2008 South Africa C 1 1 335 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYVDDLYVGSDLEIEQHRAKVEELREHLLKWGLTTPDKKHQKEHPFIWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILREPVHGVYYDPSKDLIAEIQKQGQG Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90276 D4T3TCEFV 2008 South Africa C 1 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILAPFRAKNPELVIYQYVDDLYVGSDLELGQHRAKIEELREHLLKWGFTTPDKKYQKEHPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGE Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90277 D4T3TCEFV 2008 South Africa C 1 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIKALTEICEELEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSVNNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELDIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGLYTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90278 D4T3TCEFV 2008 South Africa C 1 1 334 PISTIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEELEKEGKISKIGPENPYNTPIFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKVEELREHLLKWGLTTPDRKHQKEPPFLWMGYELHPDKWTVQPIQLPDKSSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEQVHGVYYDPSKDLIAEIQKQGE Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90279 AZT3TCEFV 2008 South Africa C 1 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEELEKEGKITKIGPENPYNTPIFAIKKKNSNRWRKLMDLRELNKRTQDFWEVQLGIPHPSGLKKKKSMTVIDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSTMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFYTPEEKHQKEPPLHWMGYELHPDKWTVQTIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQG Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90280 D4T3TCEFV 2008 South Africa C 1 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLAKRRSMTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNSTPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRMKNPDIDIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGLTTPDEKHQKEPPLLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRNLCKLLRGAKALTDIVPLTEEAELELAENREILKETVHGAYYDPSKDLIAEIQKQG Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90281 D4T3TCEFV 2008 South Africa C 1 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKNKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILRPFRERNPELDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDRKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQG Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90282 D4T3TCEFV 2008 South Africa C 1 1 333 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90284 D4T3TCEFV 2008 South Africa C 1 1 333 PISSIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKITKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPYRAKNPEMVIYQYVDDLYVGSDLEIEQHRAKIDELREHLLKWGLTTPDQKHQKEPPFHWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90285 D4T3TCEFV 2008 South Africa C 1 1 335 PISPIETAPVKLKPGMDGPKVKQWPLTKEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLEKKKSVTVLDVGDAYFSIPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIRILEPFRAKNPEIVICQYVDDLYVSSDLEIGQHRAKIEELREHLSRWGLITPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIQVKQLCRLLRGAKALTDIIPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGDG Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90287 D4T3TCEFV 2008 South Africa C 1 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEELEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFCEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEITQHRAKIEELREHLWKWGFYTPDKKHQKEHPFLWMGYELHPDKWKVQPIQLPEKESWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90289 D4T3TCEFV 2008 South Africa C 1 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKGSTRWRKLIDFRELNKRTQDFWEVQLGIPHPAGLIKKKSMTVLDVGDAYFSVPLDENFRKYTAFTLPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVICQYVDDLYVGSDLEIGQHREKIKELREHLLKWGLTTPDQKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90293 D4T3TCEFV 2009 South Africa C 1 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITRIGPDNPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQDSMTRILRPFREKNPEIVIYQYVDDLYVGSDLEIEQHRAKIEELREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVFYDPSKDLIAEIQKQG Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90295 D4T3TCEFV 2009 South Africa C 1 1 333 PISSIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDQKHQKEPPFLWMGYELHPDKWTLQPINLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPAKELIAEIQKQG Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1970 90297 D4T3TCEFV 2009 South Africa C 1 1 335 PISPIETVPVRLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPDNPYNTPIFAIKKKGGTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKENKSMTVLDVGDAYFSIPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPEIVIYQYVDDLLVGSDLEIEQHRAKIEELREHLLKWGLTTPDQKHQKEPPFHWMGYELHPDKWTVHPIQLPEKDSWTVNDIQKLVGKLNWASQIYQGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQEHG Green, TN 2011 21819257 ARHR Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in south Africa. 1976 92378 AZT3TCNVP 2004 Cambodia CRF01_AE 0 16 239 MDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSAMTKILEPFRRKNPEIVICQYVDDLYVGSDLEIGQHRTKIEELRGHLLSWGFFTPDQKHQKEPPFLWMGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92379 AZT3TCNVP 2004 Cambodia CRF01_AE 0 16 239 MDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLPKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLRNPELIIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFITPDKKHQKEPPFLWMGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92380 AZT3TCNVP 2005 Cambodia CRF01_AE 0 16 239 MDGPKVKQWPLTKEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFNTPDQKHQKEPPFLWMGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92381 AZT3TCNVP 2004 Cambodia CRF01_AE 0 16 239 MDGPKVKQWPLTAEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLMDFRELNKRTQDFWEVQLGIPHPGGLQKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRIKIEELRAHLWSWGFFTPDEKHQKEPPFLWMGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92382 AZT3TCNVP 2005 Cambodia CRF01_AE 0 16 239 MDGPKVKQWPLTEEKIKALKEICEEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPDIIIYQYVDDLYVASDLEIGQHRTKIEELREHLLRWGLFTPDQKHQKEPPFLWMGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92383 AZT3TCEFV 2005 Cambodia CRF01_AE 0 16 239 MDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFFTPEEKHQKEPPFLWMGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92384 D4T3TCEFV 2005 Cambodia CRF01_AE 0 16 239 MDGPRVKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQTSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRSHLLSWGFTTPDQKHQKEHPFRWMGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92386 AZT3TCNVP 2005 Cambodia CRF01_AE 0 16 239 MDGPKVKQWPLTAEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSITILDVGDAYFSVPLDESFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRIKNPEMVICQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFFTPDEKHQKEPPFLWMGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92387 D4T3TCEFV 2005 Cambodia CRF01_AE 0 16 237 MDGPKVKQWPLTEEKLKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNGTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRSHLLSWGFYTPDKKHQKEHPFLWMGYELHPD Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92388 AZT3TCNVP 2004 Cambodia CRF01_AE 0 16 239 MDGPKVKQWPLTAEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLPKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIIIYQYVDDLYVASDLEIGQHRAKIEELRAHLWSWGFFTPDKKHQKEPPFLWMGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92390 AZT3TCNVP 2005 Cambodia CRF01_AE 0 16 239 MDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLLDLRELNKRTQEFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPDMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFYTPDKKHQKEPPFLWLGYELHPDKW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92391 AZT3TCNVP 2006 Cambodia CRF01_AE 0 16 239 MDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92392 AZT3TCNVP 2004 Cambodia CRF01_AE 0 16 239 MDGPKVKQWPLTEEKIKAITEICEELEKEGKISKIGPENPYNTPVFAIKKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEMVICQYVDDLYVASDLEIGQHRAKIDELRDHLLKWGFFTPDQKYQKEPPFRWMGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92393 AZT3TCEFV 2005 Cambodia CRF01_AE 0 16 239 MDGPKVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPIFAIKKKNSTRWRKIVDFRELNKRTQDFWEVQLGIPHPGGLPKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVIYQYVDDLYVGSDLEIGQHRAKIDELRAHLLSWGFFTPDQKHQKEPPFLWMGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92394 AZT3TCNVP 2006 Cambodia CRF01_AE 0 26 239 LTEEKIKALTEICKELEEEGKISKIGPENPYNTPVFAIKKKNSTRWRKLIDFRELNKRTQDFSEVQLGIPHPGGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKRNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFFTPDEKHQKEPPFLWLGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92395 AZT3TCNVP 2006 Cambodia CRF01_AE 0 16 239 MDGPKVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFFTPDKKHQKEPPFLWMGYELHPDKW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92396 AZT3TCEFV 2004 Cambodia CRF01_AE 0 16 239 MDGPKVKQWPLTEEKMKALTEICEELEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKNKSITILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMIIYQYVDDLYVGSDLEIGQHRAKIEELRAHLWNWGFYTPDKKHQKEPPFLWLGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92397 AZT3TCNVP 2005 Cambodia CRF01_AE 0 16 239 MDGPKVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPIFAIKKKNSTRWRKIVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKYPDIVIYQYVDDLYVASDLEIGEHRTKIEELRAHLLNWGFFTPEQKHQKEPPFLWMGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92398 D4T3TCNVP 2005 Cambodia B 0 16 238 MDGPKVKQWPLTEEKIKALVEICTFLEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSIPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVICQYVDDLYVGSDLEIEQHRTKIEELRNHLWKWGFYTPDNKHQKEPPFLWMGYELHPDK Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92399 AZT3TCEFV 2005 Cambodia CRF01_AE 0 16 239 MDGPKVKQWPLTEEKIKALTEICNELEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVQSDLEIGQHRIKIEELRAHLLSWGFFTPDQKYQKEPPFLWMGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92401 AZT3TCEFV 2004 Cambodia CRF01_AE 0 16 239 MDGPKVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLWSWGFYTPDKKHQKEHPFLWMGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92402 D4T3TCEFV 2006 Cambodia CRF01_AE 0 16 239 MDGPKVKQWPLTEEKIKALTEICEELEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKIVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRTKNPEMIIYQYVDDLYVSSDLEIEQHRTKIKELRAYLLSWGFFTPDQKHQQEPPYHWMGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92405 D4T3TCEFV 2005 Cambodia CRF01_AE 0 16 239 MDGPKVKQWPLTKEKIKALTEICEEMEKEGKISKIGPENPYNNPVFVIKKKDSTNWRKLIDLRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDIGDAYYSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSLTKILEPFRIKNPEIVICQYVDDLYVASDLEIEQHRTKIEELRGHLLSWGFTTPDKKHQKEHPFLWMGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92407 AZT3TCEFV 2006 Cambodia CRF01_AE 0 16 239 MDGPKVKQWPLTKEKIKALTEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDIGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIIIYQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92408 AZT3TCEFV 2004 Cambodia CRF01_AE 0 16 239 MDGPKIKQWPLAEEEIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92409 AZT3TCNVP 2004 Cambodia CRF01_AE 0 16 239 IDCPRVKQWPLAEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRIKNPEMIICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFFTPDKKHQKEPPFRWMGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92410 AZT3TCNVP 2005 Cambodia CRF01_AE 0 16 239 MDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSMNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPELVIYQYVDDLLVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92411 AZT3TCEFV 2004 Cambodia CRF01_AE 0 23 239 QWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92412 AZT3TCEFV 2005 Cambodia CRF01_AE 0 16 239 MDGPKVKQWPLTKEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92413 D4T3TCEFV 2005 Cambodia CRF01_AE 0 16 239 MDGPKVKQWPLTEEKLKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSITVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92414 D4T3TCEFV 2005 Cambodia CRF01_AE 0 16 239 MDGPRVKQWPLTEEKIKALTEICKELEKEGKISKIGPENPYNTPVFAIKKKDSNKWRKVVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSITVLDIGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIIICQYVDDLYVSSDLEIGQHRAKIEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92416 AZT3TCNVP 2005 Cambodia CRF01_AE 0 16 239 MDGPKVKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDRW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92417 AZT3TCEFV 2005 Cambodia B 0 16 239 MDGPKVKQWPLTEEKINALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSNRWRKLVDFRVLNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIEQHRTKVEELRHHLLKWGFTTPDKKHQKEPPFRWMGYELHPDKW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1976 92418 AZT3TCEFV 2004 Cambodia CRF01_AE 0 16 239 MDGPKIKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLQKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEMVIYQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPERW Ferradini, L 2011 21439074 J Int AIDS Soc High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. 1977 91435 D4T3TCNVP 2010 Central African Republic A 1 1 334 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDTWTVQPIQLPNKECWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKSLTDVVPMTREAELELAENREILKDPVHGVYYDPSKDLIAEIQKQGQ Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91436 D4T3TCNVP 2010 Central African Republic CRF11_cpx 1 1 333 PVSPVDTVPVKLKPGMDGPKVKQWPLTEEKIKALMEICTEMEKEGKISKIGPENPYNTPVFAIQKKGGNRWRKLSDFRELNKRTQDFWEVQLGIPHPAGLHKKKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTHNPEIVICQYVDDLYVASDLEIGQHRKKVEELRKHLLKWGLVTPDEKHQQEPPFHWMGYELHPDKWTVQPIQLPDKECWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLIRGTKALTEIVTLTAEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91437 D4T3TCNVP 2010 Central African Republic CRF11_cpx 1 1 333 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTRWRKISDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKYPEIVICQYVDDLYVGSDLEIGQHREKVEELRNHLLKWGFTTPEEKHQKEPPFRWMGYELHPDKWTVQTIQLPDKESWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGTKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLTAEIQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91438 D4T3TCNVP 2010 Central African Republic A 1 1 334 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISRIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLYEGFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPSIFQSSMTKILEPFRARNPEIIICQYVDDLYVASDLEIGQHRTKIEELRNHLLKWGFFTPDKKHQKEPPFRWMGYELHPDRWTVQPIKLPENDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLIRGAKALTATVTMTEEAELELAENREILKEPVHGAYYDPSKDLVAEIQKQGQ Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91439 D4T3TCNVP 2010 Central African Republic C 1 1 333 PISPIEPVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAQNPEIVICQYVDDLYVGSDLEIKQHREKIEELREHLLKWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYKGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91440 D4T3TCNVP 2010 Central African Republic CRF01_AE 1 1 333 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLHEGFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIICQYVDDLYVASDLEIEQHRAKIEELRAHLLRWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91441 D4T3TCNVP 2010 Central African Republic CRF11_cpx 1 1 333 PISSIDTVPVQLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILDPFRKQNPELVIYQYMDDLYVGSDLEIEQHREKVERLREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPDKECWSVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91442 D4T3TCNVP 2010 Central African Republic H 1 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEREGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVSVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIGYVYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRDKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPVKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEIVPLTKEAELELAENREILREPIHGAYYDPSKDLIAEIQKQGQ Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91443 D4T3TCNVP 2010 Central African Republic A 1 1 334 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKRNKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPEIVICQYVDDLYVGSDLEIEQHRAKIEELRAHLLSWGFTTPDNKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRHLCRLLRGAKALTDVVPLTEEAELELAENREILKNPVHGVYYDPSKDLIAEIQKQEQ Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91444 D4T3TCNVP 2010 Central African Republic A 1 1 334 PISPIETVPVTLKTGMDGPKVKQWPLTEEKLKALTEICNEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEIQLGIPHPAGLKKKNSVTVLDVGDAYFSVPLHESFRKYTAFTLPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRSKNPEIVICQYVDDLYVGSDLEIEQHRAKIEELRAHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDVVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQ Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91445 D4T3TCNVP 2010 Central African Republic A 1 1 333 PISPIDTVPVTLKPGMDGPRVKQWPLTEEKIKALTEICREMEEEGKISKIGPENPYNTPVFAIKRKHGDKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSMNNETPGVRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPELVICQYMDDLYVASDLEIGQHRAKIEKLRAHLLSWGLTTPDGKHQKEPPFRWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTKEAELELEENREILKETVHGVYYDPSKDLIAEVQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91446 D4T3TCNVP 2010 Central African Republic A 1 1 333 PISPIETVPVTLKPGMDGPKIKQWPLTEEKIKAITEICEEMEKEGKISKIGPENPYNTPVFAIKRKDN~NWRKLVDFRELNRRTQDFWEIQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPEIVICQYMDDLYVASDLEIEQHRTKIEQLRDHLLRWGLTTPDRKYQKEPPFLWMGYELHPDKWTVQPIQLPEKEGWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLIRGTKALTDVVTFTKEAELELAENREILKDPVHGVYYDPSKDLIAEIQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91447 D4T3TCNVP 2010 Central African Republic A 1 1 334 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVSVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMIICQYMDDLYVASDLEIEQHRAKIEELRAHLLSWGLTTPDKKHQKEPPFRWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDVVPLTEEAELELAENREILRNPVHGVYYDPSKDLVAEIQKQGQ Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91448 D4T3TCNVP 2010 Central African Republic CRF02_AG 1 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICADMEKEGKISKIGPENPYSTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNSEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVTLTKEAELELAENREILKEPVHGVYYDPGKDLIAEIQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91449 D4T3TCNVP 2010 Central African Republic G 1 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIKALTEICNDMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGGAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIIIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKEDWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLIRGTKALTEIVPLTTEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQ Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91450 D4T3TCNVP 2010 Central African Republic A 1 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPEIVIYQYVDDLYVGSDLEIGQHRAKIDELRNHLLKWGFTTPDKKYQKEPPFLWMGYELHPDTWTVQSIQLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVVPLTKEAELELAENREILKTPVHGVYYDPSKDLVAEIQKQGQ Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91451 D4T3TCNVP 2010 Central African Republic CRF01_AE 1 1 333 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRRKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQHSMTKILEPFRLKNPGIDIYQYMDDLYVGSDLEIEEHRTKIDELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTEVVPLTKEAELELAENREILKDPVYGVYYDPSKELIADIQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91452 D4T3TCNVP 2010 Central African Republic CRF11_cpx 1 1 333 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSIPLDPDFRKYTAFTIPSMNNESPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYMGSDLEIGQHREKVEELRQHLLKWGLTTPDKKHQKEPPFLWMGYELHPDTWTVQPIQLPDKECWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDVVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91453 D4T3TCNVP 2010 Central African Republic CRF02_AG 1 1 334 PISSIETIPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSIPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPKIIICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPVRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTAIVPMTVEAEMELAENREILKEPVHGVYYDPSKDLIAELQKQGQ Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91454 D4T3TCNVP 2010 Central African Republic A 1 1 333 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPMFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVICQYVDDLYVGSDLEIGEHRAKIEELRDHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKELCKLIRGTKALTEVVPLTREAELELAENKEILKDPVHGVYYDPAKDLIAEIQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91455 AZT3TCEFV 2010 Central African Republic CRF01_AE 1 1 333 PISPVDTVPVKLKPGMDGPRVKQWPLTEEKIKALTEICXEMEKEGKISRIGPENPYNTPVFAIKKKNSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKNNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGTRYQYNVLPQGWKGSPAIFQGSMPKILEPFRTKNPELVICQYVDDLYVASDLEIGEHRKKVEELRXHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPNKDCWTVNDIQKLVGKLNWASQIYPGIKVKELCKLIRGTKALTDIVPLTREAELELAENKEILKDPVHGVYYDPAKDLIAEVQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91456 D4T3TCNVP 2010 Central African Republic D 1 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPIFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRTKIKELREHLLKWGFTTPDNKHQKEPPYRWLGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYAGIKVRQLCKCIRGAKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQ Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91457 D4T3TCNVP 2010 Central African Republic A 1 1 333 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKISKIGPENPYNTPVFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSATVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEMVICQYVDDLYVGSDLEIEQHRKKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKHLCKLLRGAKALTDVVPLTEEAELELAENREILKEPVHGVYYDSSKDLLAEIQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91458 D4T3TCNVP 2010 Central African Republic CRF11_cpx 1 1 333 PISPIDTVPVTLKPGMEGPKVKQWPLTEEKIKALTEICIEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFREPNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDKSFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRNENPDIVICQYVDDLYVGSDLEIGQHRKKVEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPDKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDVVPLTAEAELELAENREILKEPVHGVYYDPAKDLIAEVQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91459 D4T3TCNVP 2010 Central African Republic F 1 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTEEKLKALTEICLEMEKEGKISRIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSTNNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVICQYVDDLYVGSDLEIGQHRTKIEELRDHLLKWGLITPDKKYQKEPPSLWMGYELHPDKWKVQSIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKTKQLCKLLRGTKALTDIVPLTTEAELELAENREILKEPVHGAYYDPSKEIIAEIQKQGQ Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91460 D4T3TCNVP 2010 Central African Republic A 1 1 332 PISPIETVPVALKPGMDGPKVKQWPLTEEKIKALTEICREMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQHSMTKILEPFRSQNPDIVIYQYVDDLYVGSDLEIEQHRTKIEELRAHLVRWGFTTPDKKHQKEPPFLWMGYELHPEKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEIVPLTEEAELELAENREILKNPVHGVFYDPSKELIAEIQKQ Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91461 D4T3TCNVP 2010 Central African Republic CRF11_cpx 1 1 333 PISPVDTVPVKLKPGMDGPRVKQWPLTEEKIKALTEICVDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKKSVTVLDVGDAYFSIPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTNNPEIVICQYVDDLYVGSDLEIGQHREKVEELREHLLKWGLTTPDKKHQKEPPFHWMGYELHPDKWTVQPIQLPDKECWTVNDIQKLVGKLNWASQIYPGIKIRQLCKLIRGTKALTEIVPLTPEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91462 D4T3TCEFV 2010 Central African Republic A 1 1 333 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPIFAIKKKDSSKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPELVIYQYVDDLYVGSDLEIEQHREKIEELRAHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDIWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEVVPLTKEAELELAENREILKDPVHGVYYDPSKDLIAEIQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91463 D4T3TCNVP 2010 Central African Republic A 1 1 334 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICREMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLHKDFRKYTAFTIPSINNETPGIRYCYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIEQHRKKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDVIPLTKEAELELAENREILKDPVHGVFYDPSKDLIAEIQKQGH Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91464 D4T3TCNVP 2010 Central African Republic A 1 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTEICREMEEEGKISKIGPENPYNTPVFVIKKKDGTKWRKLIDFRELDKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYYSVPLHEDFRKYTAFTIPSTNNETPGVRYQYNVLPMGWKGSPAIFQSSMTKILEPFRAKNPEIVICQYVDDLYVGSDLEIEQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGTKALTDVVPLTEEAELELAENREILKNPVHGVYYDPSKELIAEIQKQGQ Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91465 D4T3TCNVP 2010 Central African Republic G 1 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNDMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKRSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPEKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGTKALTDIVPLTAEAELELAENREILKNPVHGAYYDSSKELIAEVQKQGE Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91466 D4T3TCNVP 2010 Central African Republic CRF11_cpx 1 1 334 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTDICREMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKSFRKYTAFTIPSTNNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHREKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPDKESWTVNDIQKLVGKLNWASQIYSGIRVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQ Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91467 D4T3TCNVP 2010 Central African Republic A 1 1 334 PISPVDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMELEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNQTPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPELIIYQYVDDLYVGSDLEIGQHRRKIEELRAHLLSWGFTTPDKKHQKGPPFLWMGYELHPDSWTVQPIQLPEKESWTVNDIQKLVGKLN*ASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKNPVHGVYYDPSKDLVAEIQKQGQ Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91468 D4T3TCNVP 2010 Central African Republic A 1 1 334 PISPINTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRMKNPEIVICHYVDDLYVGSDLEIGLHREKVEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIQVRQLCKLLRGTKALTEVVPLTEEAELELAENREILKNPVHGVFYDPSKDLIAEIQKQGQ Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91469 D4T3TCEFV 2010 Central African Republic A 1 1 334 PISPIDTVPVTLKPGMDGPRVKQWPLTKEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILGPYRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKYQKEHPFLWLGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGKLNWAIQIYPGIQVRQLCKFLRGAKGLTDIVVLIEEAELELAENREILKNPVHGVYYDPSKDLIAEIQKQGQ Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91470 D4T3TCNVP 2010 Central African Republic G 1 1 333 PISTIETVPVKLKPGMDGPKVKQWPLTEEKIKAITEICNDMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTILDVGDAYFSIPLDEEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILKTFRTQNPDIVICQYVDDLYVGSDLEIEQHREKIEELRKHLLKWGLTTPDEKYQKEPPFLWMGYELHPDKWTVQPIQLPEQDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLIRGAKALTEVVPLTREAELELAENREILKEPVHGAYYDPSKDLIAEIQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91471 D4T3TCNVP 2010 Central African Republic CRF11_cpx 1 1 314 PISPIDTIPVKLKPGMDGPKVKQWPLTKEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNQTPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRKKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPDKESWTVNDIQKLVGKLNWASQIYAGIKVKELCKLIRGTKALTDIVPLTAEAELELAENREILKEPV Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91472 D4T3TCNVP 2010 Central African Republic CRF01_AE 1 1 333 PISPIETVPVKLNPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSTMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPVELPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCRLLRGAKALTDIVTLTEEAEMELAENREILKTPVHGVYYDPSKELIAEIQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91473 D4T3TCNVP 2010 Central African Republic A 1 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRTHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIQVKQLCKLLRGTKALTDIVPLTVEAEMELAENREILKNPVHGAYYDPSKELIAELQKQGQ Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91474 D4T3TCNVP 2010 Central African Republic A 1 1 334 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVSVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMIICQYMDDLYVASDLEIEQHRAKIEELRAHLLSWGLTTPDKKHQKEPPFRWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDVVPLTEEAELELAENREILRNPVHGVYYDPSKDLVAEIQKQGQ Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91475 D4T3TCNVP 2010 Central African Republic CRF11_cpx 1 1 333 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPVFAIKKKDST*WRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQGSMLKILEPFRTKYPEIVIYQYVDDLYVASDLEIGQHREKVEELREQLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91476 AZT3TCEFV 2010 Central African Republic CRF11_cpx 1 1 333 PISPVDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSATVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYKVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHREKVEELRKHLLSWGLTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPDKENWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGAYYDPSKELIAEVQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91478 D4T3TCNVP 2010 Central African Republic CRF11_cpx 1 1 318 PISPVDTVPVKLKPGMDGPRVKQWPLTKEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNQTPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKQNPEMVIYQYVDDLYVGSDLEIGQHREKIEELRSHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKEDWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVY Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91479 D4T3TCNVP 2010 Central African Republic D 1 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICADMEKEGKISRIGPENPYNTPIFAIKRKDSAKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLYEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKHNPEIVICQYMDDLYVASDLEIGQHRAKIKELREHLLKWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQHIELPEKESWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLIRGTKALTEVVPLTEEAELELAENREILKETVHGVYYDPSKDLIAEIQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91480 D4T3TCNVP 2010 Central African Republic A 1 1 334 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPTIFQSSMTKILEPFRSQNPEIVICQYVDDLYVGSDLEIGQHRAKIKELRDHLLRWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQ Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91481 D4T3TCNVP 2010 Central African Republic CRF13_cpx 1 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSAKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPEIVIYQYMDDLYVGSDLEIGQHRKKVEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIRIRQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPEKELIAEIQKQGE Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91482 D4T3TCNVP 2010 Central African Republic K 1 1 334 PISPIETVPVKLKPGMDGPKVKQWPLSKEKIKALTEICAEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLSDFRELNKRTQDFWEVQLGIPHPAGLEKKRSVTVLDVGDAYFSIPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTRNPELIIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTAEAELELAENREILKEQVHGVYYDPSKDLIAEVQKQGQ Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91483 D4T3TCNVP 2010 Central African Republic CRF11_cpx 1 1 333 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICADMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLTKKKSITVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVSSDLEIGQHREKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKECWTVNDIQKLVGKLNWASQIYPGIRVKYLCKLLRGTKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKEIIAEVQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91484 D4T3TCNVP 2010 Central African Republic CRF11_cpx 1 1 333 PISPVDTIPVKLKPGMDGPKVKQWPLTKEKIKALTEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFREPNKRTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHREKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPNKESWTVNDIQKLVGKLNWASQIYSGIRVKQLCRLLRGTKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91485 D4T3TCNVP 2010 Central African Republic A 1 1 333 PISPIKTVPVTLKPGMDGPKVKQWPLTKEKIKALTEICDEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQFSMQKILEPFRSKNPEIVIYQYVDDLYVGSDLEIEQHRTKIEELRAHLLRWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDVIPLTDEAELELAENREILKEPVHGVYYDSSKELIAEIQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91486 D4T3TCNVP 2010 Central African Republic CRF11_cpx 1 1 333 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYMDDLYVGSDLEIGQHREKVEELRKHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKECWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGTKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLVAEVQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91487 D4T3TCEFV 2010 Central African Republic CRF11_cpx 1 1 333 PISPIETVPVKLNPGMDGPKVKQWPVTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLERKKSMTVLDVGDAYFSVPLHEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLLVASDLEIGKHREKVEDLRKHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLSAEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91488 D4T3TCNVP 2010 Central African Republic A 1 41 240 LEKERKISKIGPENPYNTPVFAIKKKNSTKWRKIVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVIDVGDAYFSIPLHESFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQDSMTKILKPFRTKNPEIIIYQYVDDLYVASDLEISQHRTKVKELREYLWSWGFYTPDKKYQKEPPFLWMGYELHPDKWT Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91489 D4T3TCNVP 2010 Central African Republic D 1 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPAFAIKKKDSTKWRKLVDLRELNKRTQDLWEAQLGIPHPAGLRKKKSVTVLDVGDAYFSVPLDETFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKKNTDIIICQYVDDLYVGSDLEIEQHRAKIEELREHLLRWGFTTPDKKHQKEPPFRWMGYELHPEKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGVRVKYLCRLLRGTKALTDIVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQGQ Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91490 D4T3TCNVP 2010 Central African Republic CRF11_cpx 1 1 333 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICADMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPEVIIYQYVDDLYVASDLEIGQHREMIEKLRKHLLEWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKECWTVNDIQKLVGKLNWASQIYPGIRTKQLCRLLRGTKALTDIVTLTAEAELELAENRELLKEPVHGVYYDPSKDLIAEVQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91491 D4T3TCNVP 2010 Central African Republic CRF11_cpx 1 1 333 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICADMEKEGKISKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKTKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTQNPEVVICQYMDDLYVGSDLEIGQHREKIEELRNHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKECWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQG Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91492 D4T3TCNVP 2010 Central African Republic A 1 1 332 PISPIETVPVTLKPGMDGPRVKQWPLTEEKIKALTEICADMEKEGKISKIGPENPYNTPVFAIKKKDSNNWRKISDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPELVIVQYVDDLYVGSDLEIEQHRTKIEELRAHLLSWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNEIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKSLTDVVPFTKEAELELAENREILKDPVHGVYYDPSKELIAEIQKQ Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1977 91493 D4T3TCNVP 2010 Central African Republic G 1 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNDMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRTKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELRNHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPINLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCRLLRGTKALTDIVPLTAEAELELAENREILKNPVHGVYYDPSKDLIAEIQKQGE Charpentier, C 2011 21599597 ARHR Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: A cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. 1983 91026 AZT3TCNVP 1998 Spain B 0 1 399 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALLEICTELEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKQKKSVTVLDVGDAYFSIPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKKQNPDIVIYQYMDDLYVASDLEIGQHRTKIKELRQHLWDWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGTKALTEVVPLTKEAELELAENREILKEPVHGVYYDPSKGLIAEIQKQGEGQWTYQIYQEPFKNLKTGKYARMRSAHTNDVKQLTEAVQKITTESIVIWGKAPKFRLPIQKETWE Podzamczer, D 2002 12212928 Antivir Ther A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). 1983 91033 AZT3TCNVP 1999 Spain B 0 1 399 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTEVIPLTAEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGTHTNDVKQLTEAVQKISTESIVIWGKTPKFKLPIQRETWE Podzamczer, D 2002 12212928 Antivir Ther A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). 1983 91035 AZT3TCNVP 1999 Spain B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQCSMTKILDPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGQGQWTYQIYQEQFKNLKTGKYARMRGAHTNDVKQLTEAVQKIATESIVIWGKTPKFRLPIQKETWEA Podzamczer, D 2002 12212928 Antivir Ther A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). 1983 91046 AZT3TCNVP 1999 Spain B 0 1 399 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEICQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKDLVAELQKQGQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKIAQEGIVIWGKIPKFKLPIQKETWE Podzamczer, D 2002 12212928 Antivir Ther A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). 1983 91061 AZT3TCNVP 1999 Spain B 0 1 399 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVIPLTKEAELELAENREILKEPVHGAYYDPSKDLIAELQKQGQGQWTYQIYQEPFKNLKTGKYARVRSAHTNDVKQLTEAVQKITTESIVIWGKTPKFKLPIQKETWE Podzamczer, D 2002 12212928 Antivir Ther A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). 1983 91063 AZT3TCNVP 1999 Spain B 0 1 399 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTQILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRRHLLKWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTEIVPLTREAELELAENREILKEPVHGVYYDPSKDLIAEIQKQEQCQWTYQIYQEPFKNLKTGKYARMKSAHTNDVKQLTEVVQKITTESIVIWGKTPKFRLPIQKETWE Podzamczer, D 2002 12212928 Antivir Ther A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). 1983 91064 AZT3TCNVP 1999 Spain B 0 1 399 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVICQYMDDLYVGSDLEIGQHRDKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPVVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVIPLTTEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARTRGAHTNDVKQLTEAVQKIATESIVIWGKTPKFRLPIQKETWE Podzamczer, D 2002 12212928 Antivir Ther A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). 1983 91087 AZT3TCNVP 1999 Spain B 0 1 399 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTGFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRKQNPDIVICQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIRVKQLCKLLRGTKALTEVVQLTEEAELELAENREILKESVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYAKMRGAHTNDVRQLTEAVQKITTESIVIWGRIPKFKLPIQKETWE Podzamczer, D 2002 12212928 Antivir Ther A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). 1983 91096 AZT3TCNVP 1999 Spain B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKRKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGTKALTEVVPLTEEAELELAENREILREPVHGVYYDPSKDLIAEIQKQEQGQWTYQIYQEPFKNLKTGKYAKIRGAHTNEVKQLTEAVQKIATESIVIWGKTPKFRLPIQKETWEA Podzamczer, D 2002 12212928 Antivir Ther A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). 1987 91494 AZT3TCNVP 2007 Mali CRF02_AG 1 1 243 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTDICAEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRSKNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQP Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91495 AZT3TCNVP 2007 Mali CRF02_AG 1 1 243 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNERPGIRYQYNVLPQGWKGSPAIFQASMTKILQPFRDKYPEIVICQYVDDLYVGSDLEIGQHRAKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQP Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91496 AZT3TCNVP 2007 Mali CRF02_AG 1 1 243 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICLEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPQIVIYQYVDDLYIGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQP Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91497 AZT3TCNVP 2007 Mali D 1 1 243 PISPIETVPVKLKPGMDGPKVNQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRNKNPEMIIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQP Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91498 AZT3TCNVP 2007 Mali CRF01_AE 1 1 243 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNATPGVRYQYNVLPQGWKGSPAIFQYSMTKILEPFRSKNPEIVIYQYMDDLYVGSDLEIGQHRIKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQP Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91499 AZT3TCNVP 2007 Mali CRF02_AG 1 1 243 PISPIETVPVKLKPGMDGPKVKQWPLTREKIEALTDICNEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSVNNERPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQP Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91500 AZT3TCNVP 2007 Mali CRF02_AG 1 1 243 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNQTPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQP Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91501 AZT3TCNVP 2007 Mali CRF02_AG 1 1 243 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPIFAIRKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKEKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPELVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQP Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91502 AZT3TCNVP 2007 Mali CRF02_AG 1 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLHENFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILKPFRTENPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQ Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91503 AZT3TCNVP 2007 Mali CRF02_AG 1 1 243 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTIQP Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91504 AZT3TCNVP 2007 Mali CRF02_AG 1 1 239 PISPIETVPVKLKPGMDGPRVNQWPLTEEKIKALTDICMEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILELFKAENPEMVICQYVDDLYVGSDLEIGQHRARIEKLREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKW Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91505 AZT3TCNVP 2007 Mali CRF02_AG 1 1 243 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTDICLEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILQPFRTENPEIVIYQYVDDLYVASDLEIGQHRAKIKELREHLLKWGFTTPDKRHQKEPPFLWMGYELHPDKWTVQP Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91506 AZT3TCNVP 2007 Mali CRF01_AE 1 1 240 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICKEMEEEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSTTVLDVGDAYFSVPLDPNFRKYTAFTIPSVNNAAPGVRYQYNVLPQGWKGSPAIFQHSMTKILEPFRSHNPELMIYQYMDDLYVGSDLQIGQHRIKIEELRAHLLRWGFPTPDKKHQKEPPFLWMGYELHPDKWT Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91507 AZT3TCNVP 2007 Mali K 1 1 253 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVASDLELGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPDKESWT Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91508 AZT3TCNVP 2007 Mali CRF02_AG 1 1 252 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPEVVIYQYVDDLYVGSDLEIEQHRAKIEGLREHFLRWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSW Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91509 AZT3TCNVP 2007 Mali CRF02_AG 1 1 252 PISPIETVPVKLKPGMDAQKVKQWPLTEEKIKALTEICADMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTRNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSW Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91510 AZT3TCNVP 2007 Mali CRF02_AG 1 1 249 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEEEGKISRIGPENPYHTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLRKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVVCQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHRKEPPFLWMGYELHPDKWTVQPIQLPEK Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91511 AZT3TCNVP 2007 Mali CRF06_cpx 1 1 255 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICMEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKKNPEVVIYQYMDDLYVGSDLEIGQHRAKVEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVN Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91512 AZT3TCNVP 2007 Mali CRF02_AG 1 1 254 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKDICAEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDTEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTENPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTV Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91513 AZT3TCNVP 2007 Mali CRF02_AG 1 1 254 PISPIETVPVKLKPGMDGPKVKQWPWTEEKIKALTEICTDMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEIVICQYVDDLYVASDLEIGQHRTKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTV Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91514 AZT3TCNVP 2007 Mali CRF06_cpx 1 1 254 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKVKNPEMVICQYMDDLYVGSDLEIGQHRAEIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKTSWTV Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91515 AZT3TCNVP 2007 Mali CRF02_AG 1 1 252 PISPIETVPVKLKPGMDGPKGKQWPWTEEKIKALTDICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSVNNATPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTNNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLWTWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSW Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91516 AZT3TCNVP 2007 Mali C 1 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHKSFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYMDDLYVGSDLEIGEHRAKIEELRDHLFKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQ Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91517 AZT3TCNVP 2007 Mali CRF02_AG 1 1 255 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICREMEKEGKISKIGPENPYNTPIFAIKKKGSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSGTVLDVGDAYFSVPLNKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYMDDLYVGSDLELGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQAIQLPDKDSWTVN Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91518 AZT3TCNVP 2007 Mali G 1 1 244 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIKALTEICKEMEEEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQASMTKILDPFRTKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91519 AZT3TCNVP 2007 Mali CRF02_AG 1 1 204 PISPIEIVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMDKKEKISKIGPENPYNTPVFAIKKNDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSATVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKENPEIVIYQYVDDLYVGSDLEIGQHRAKIEE Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91520 AZT3TCNVP 2008 Mali CRF02_AG 1 16 257 MDGPKVKQWPLTEEKLKALTSICAEMESEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKGNPDIVIYQYIDDLYVGSDLEIGQHREKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91521 AZT3TCNVP 2008 Mali CRF02_AG 1 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDSWTVNDIQ Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91522 AZT3TCNVP 2008 Mali CRF02_AG 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDI Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1987 91523 AZT3TCNVP 2008 Mali A 1 1 258 PISPVETVPVTLKPGMDGPKVKQWPLTEEKIKALTTICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQYSMTKILEPFRAQNPEIIIYQYVDDLLVGSDLDIGQHRTKVEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Germanaud, D 2010 19933171 AAC Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali 1988 90246 AZT3TCNVP 2007 Cameroon CRF02_AG 0 1 320 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICMEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKENPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLAWGFFTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYD Aghokeng, AF 2011 21270223 J Clin Microbiol High failure rate of the ViroSeq HIV-1 genotyping system for drug resistance testing in Cameroon, a country with broad HIV-1 genetic diversity 1988 90247 D4T3TCNVP 2007 Cameroon CRF02_AG 0 1 320 PISPIETVPVKLKPGMDGPRVKQWPLTKEKIEALKEICTEMEKEGKISRIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLAKKKSATVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTNNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKTLTDIVTLTEEAELELAENREILKEPVHGVYYD Aghokeng, AF 2011 21270223 J Clin Microbiol High failure rate of the ViroSeq HIV-1 genotyping system for drug resistance testing in Cameroon, a country with broad HIV-1 genetic diversity 1988 91687 D4T3TCNVP 2007 Cameroon CRF01_AE 0 1 320 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALREICAEMEKEGKISKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLRWGLTTPDKKYQKEPPFHWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIQTKQLCRLIRGTKALTDIVPLTEEAELELAENKEILKNPVHGVYYD Aghokeng, AF 2011 21270223 J Clin Microbiol High failure rate of the ViroSeq HIV-1 genotyping system for drug resistance testing in Cameroon, a country with broad HIV-1 genetic diversity 1988 91689 D4T3TCNVP 2007 Cameroon A 0 1 320 PISPIETVPVALKPGMDGPKVKQWPLTEEKIKALTEICREMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILDPFRTKNPELVIYQYVDDLYVGSDLEIEQHRAKIEQLRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVPLTEEAELELAENREILKDPVHGVYYD Aghokeng, AF 2011 21270223 J Clin Microbiol High failure rate of the ViroSeq HIV-1 genotyping system for drug resistance testing in Cameroon, a country with broad HIV-1 genetic diversity 1988 91690 D4T3TCNVP 2007 Cameroon CRF02_AG 0 1 320 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIRALTEICNEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSVNNEVPGIRYQYNVLPQGWKGSPAIFQASMTRILEPFRTSNPEIVICQYIDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPNKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYD Aghokeng, AF 2011 21270223 J Clin Microbiol High failure rate of the ViroSeq HIV-1 genotyping system for drug resistance testing in Cameroon, a country with broad HIV-1 genetic diversity 1988 91691 D4T3TCNVP 2007 Cameroon CRF02_AG 0 1 320 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICLEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFPWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDVVPLTEEAELELAENREILKDPVHGAYYD Aghokeng, AF 2011 21270223 J Clin Microbiol High failure rate of the ViroSeq HIV-1 genotyping system for drug resistance testing in Cameroon, a country with broad HIV-1 genetic diversity 1988 91692 D4T3TCNVP 2007 Cameroon A 0 1 320 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPELIIYQYMDDLYVASDLEIGQHRAKIEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPILLPNKNSWTVNDIQKLVGKLNWASQIYPGIRVKQLCKLIRGTKALTEVVTLTEEAELELAENREILKDPVHGVYYD Aghokeng, AF 2011 21270223 J Clin Microbiol High failure rate of the ViroSeq HIV-1 genotyping system for drug resistance testing in Cameroon, a country with broad HIV-1 genetic diversity 1988 91694 D4T3TCNVP 2007 Cameroon D 0 1 320 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICLEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVICQYVDDLYVGSDLEIGQHRTKIEELREHLLRWGFTTPDKKYQKEPPFLWLGYELHPDKWTMQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKTLTEVIPLTKEAELELAENREILKEPVHGVYYD Aghokeng, AF 2011 21270223 J Clin Microbiol High failure rate of the ViroSeq HIV-1 genotyping system for drug resistance testing in Cameroon, a country with broad HIV-1 genetic diversity 1988 91698 D4T3TCNVP 2007 Cameroon CRF02_AG 0 1 320 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRAKVEELRGHLLTWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVTLTEEAELELAENREILREPVHGVYYD Aghokeng, AF 2011 21270223 J Clin Microbiol High failure rate of the ViroSeq HIV-1 genotyping system for drug resistance testing in Cameroon, a country with broad HIV-1 genetic diversity 1988 91701 D4T3TCNVP 2007 Cameroon CRF02_AG 0 1 320 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMENEGKISRIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQDSMTKILEPFRIKNPDIIICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQTIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYD Aghokeng, AF 2011 21270223 J Clin Microbiol High failure rate of the ViroSeq HIV-1 genotyping system for drug resistance testing in Cameroon, a country with broad HIV-1 genetic diversity 1988 91704 D4T3TCNVP 2007 Cameroon CRF02_AG 0 1 320 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPVFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSATVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTENPEIVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIQVRQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYD Aghokeng, AF 2011 21270223 J Clin Microbiol High failure rate of the ViroSeq HIV-1 genotyping system for drug resistance testing in Cameroon, a country with broad HIV-1 genetic diversity 1988 91705 D4T3TCNVP 2007 Cameroon CRF02_AG 0 1 320 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICXDMEREGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYD Aghokeng, AF 2011 21270223 J Clin Microbiol High failure rate of the ViroSeq HIV-1 genotyping system for drug resistance testing in Cameroon, a country with broad HIV-1 genetic diversity 1988 91706 D4T3TCNVP 2007 Cameroon CRF02_AG 0 1 320 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPYRTKNPEMVICQYMDDLYVGSDLEIGQHRVKIDGLRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIQVRQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYD Aghokeng, AF 2011 21270223 J Clin Microbiol High failure rate of the ViroSeq HIV-1 genotyping system for drug resistance testing in Cameroon, a country with broad HIV-1 genetic diversity 1988 91708 D4T3TCNVP 2007 Cameroon CRF02_AG 0 1 320 PISPVDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICSEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRVKNPEMVIYQYMDDLYVGSDLEIGQHRAKVEELRPHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYD Aghokeng, AF 2011 21270223 J Clin Microbiol High failure rate of the ViroSeq HIV-1 genotyping system for drug resistance testing in Cameroon, a country with broad HIV-1 genetic diversity 1993 92165 D4T3TCEFV 2002 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRKQNPDIVIYQYIDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEIIPLTREAEIELAENREILKEPVHGAYYDPAKDLIVEIQKQGQGQWTYQFYQEPFKNLKTGKYARTRGAHTNDVKQLTEAVQKIATESIVIWGKTPKFKLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92166 D4T3TCEFV 2001 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRIKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVIPLTEEAELELAENREILREPVHGVYYDPSKDLVAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVRQLTEAVQKIAQESIVIWGKTPKFRLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92167 D4T3TCEFV 2001 U.S. F 0 1 400 PISPIETVPVNLRPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILDPFRAKNPDIDIYQYMDDLYVGSDLEIGEHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENKEILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPLKNLKTGKYAKMRSAHTNDVKQLAEAVQKIALESIVIWGKTPKFRLPILKETWDA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92168 D4T3TCEFV 2003 U.S. F 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGVRYQYNVLPQGWKGSPAIFQHSMTKILDPFRAKNPNIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDIWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTEVVPLTREAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGLGQWTYQFYQEPFKNLKTGKYARMRGAHTNDVKQLTEVVQKIALESIIIWGKTPKFRLPILKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92169 D4T3TCEFV 2001 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDGEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPYRKQNPEVVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKIATESIVIWGKIPKFKLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92170 D4T3TCEFV 2003 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKHNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRRHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIILPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVVPLTAEAELELAENREILKEPVHGVYYDPSKELIAEIQKQEQGQWTYQIYQEPFKNLKTGKYARIRGAHTNDVKQLTEAVQKIATESIVIWGKIPKFRLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92171 D4T3TCEFV 2001 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDMVIYQYMDDLYVGSDLEIEQHRTKIEKLRQHLLGWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTEVVPLTKEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGWGQWTYQIYQEPFKNLKTGKYARMRGTHTNDIKQLTEAVQKITTESIVIWGKTPKFKLPIQKETWET Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92172 D4T3TCEFV 2003 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQRNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRIKIEELRQHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIILPDKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGTKSLTEVVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGLGQWTYQIYQEPYKNLKTGKYARMKGAHTNDVRQLTEAVQKIATESIVIWGKIPKFRLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92173 D4T3TCEFV 2003 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYAGIKIKQLCKLIRGTKALTEVVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGEGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKIATESIVIWGKIPKFKLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92174 D4T3TCEFV 2002 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALLEICTEMESEGKISRVGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPDLVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLKGAKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMKGAHTNDVKQLTEAVQKIATESIVIWGKTPRFKLPIQKETWGA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92175 D4T3TCEFV 2002 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGKHRTKVEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTEVIPLTKEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVRQLTEAVQKIATESIVIWGKAPKFKLPILKETWDA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92176 D4T3TCEFV 2003 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQASMTKVLEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVITLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGEGQWTFQIYQEPFKNLKTGKYAKMRGAHTNDVKQLAEAVQRVAIESIVIWGKTPRFKLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92177 D4T3TCEFV 2001 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILKPFREQNPEMVIYQYMDDLYVGSDLEIGQHRAKIEKLRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQTIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVIPLTAEAEMELAENREILKEPVHGVYYDPSKDLVAEIQKQDNGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKIALESIVIWGKIPKFRLPMQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92178 D4T3TCEFV 2001 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLEKKKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSINNATPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKHLCKLLRGAKALTEVISLTKEAELELAENREILKEPVHGVYYDPTKDLIAELQKQGQGQWTYQIYQEPFKNLKTGKYGRMRGAHTNDVKQLTEAVQKIVTESIVIWGKTPKFKLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92179 D4T3TCEFV 2001 U.S. B 0 1 400 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKKTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPDIIIYQYIDDLYVSSDLEIEQHRTKIEELREHLFKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVVTLTREAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKIATESIVIWGKTPKFKLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92180 D4T3TCEFV 2003 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPEMVIYQYMDDLYVGSDLEIEQHRTKIEELREHLLAWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLIRGAKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGDGQWSYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTGAVHKIATESIVIWGKTPKFRLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92181 D4T3TCEFV 2002 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVVYQYMDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVVPLTEEAQLELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKIATESIVIWGKTPKFRLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92182 D4T3TCEFV 2001 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQEFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRTKVEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKDLIVEIQKQGQGQWTYQIYQEPFKILKTGKYARTRGAHTNDVKQLTEAVQKIATESIVIWGKTPKFRLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92183 D4T3TCEFV 2001 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNRKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVVYQYMDDLYVGSDLEIGQHRAKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTEVIPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQDQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKIATESIVIWGKTPKFRLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92184 D4T3TCEFV 2003 U.S. B 0 1 400 PISPIDTVPVKLKPGMDGPRVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDMVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVIPLTAEAELELAENREILKEPVHGVYYDPSKELIAEVQKQELGQWTYQIYQEPFKILKTGKYARVRGTHTNDVKQLIEAVQKIATECIVIWGKTPKFKLPIQKETWGT Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92185 D4T3TCEFV 2001 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELKEHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVISLTKEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQELGQWTYQIYQEPFKNLKTGKYAKMRGAHTNDVKQLTEAVQKIATESIVIWGKTPKFRLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92186 D4T3TCEFV 2003 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDIDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRTKVEELRQHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTMQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVIPLTAEAEIELAENREILKEPVHGVYYDPSKDLIAELQKQGQGQWTYQIYQEPFKILKTGKYARMRGAHTNDIKQLTEAVQKISTESIIIWGKTPKFRLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92187 D4T3TCEFV 2003 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLAEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLRKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRIKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDLQKLIGKLNWASQIYAGIKVKQLYKLLRGAKALTEVVPLTEEAELELAENREILKEPVHGAYYDPSKDLTAEIQKQGLGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKIALESIVIWGKTPKFKLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92188 D4T3TCEFV 2003 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARTRGAHTNDVKQLTEAVQKIATESIVIWGKTPKFRLPINKETWES Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92189 D4T3TCEFV 2001 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALEEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYIGSDLEIGQHRTKVEKLREHLLRWGFTTPDKKHQKEPPFPWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVIPLTKEAEMELAENREILREPVHGAYYDPSKELIAEIQKQGEGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVRQLTEAVQKIATESIVIWGKTPKFRLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92190 D4T3TCEFV 2003 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKKTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGEHRTKIEELREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKNLCKLLRGAKALTEVIPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKIATESIVIWGRTPKFRLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92191 D4T3TCEFV 2001 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFREQNPDIVIYQYVDDLYVGSDLEIGRHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQSQWTYQIYQEPFKILKTGKYARTKGAHTNDVKQLTEAVQKIATEGIVIWGRTPKFRLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92192 D4T3TCEFV 2001 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRKQNPDMVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVVPLTAEAQLELAENREILKEPVHGVYYDPSKDLVAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMKGAHTNDVKQLTEAVQKIATESIVIWGKTPKFKLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92193 D4T3TCEFV 2003 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIEQHRTKVEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLIRGTKALTEVVPLSEEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGTHTNDVKQLTEAVQKIATESIVIWGKTPKFKLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92194 D4T3TCEFV 2003 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGVKALTEVVPLTREAELELAENREILKEPVHGVYYDPSKDLIAELQKQGQGQWTYQIYQEPFKNLKTGKYARMKGAHTNDVKQLTEAVQKIATESIVIWGKIPKFKLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92195 D4T3TCEFV 2002 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSIPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIDIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWSYQIYQEPFKNLKTGKYARMRGAHTNDVRQLTEAVQKIATESIVIWGKTPKFRLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92196 D4T3TCEFV 2000 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLIRGTKALTEVIPLTKEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQGGGQWTYQIYQEPYKNLKTGKYARTRGTHTNDVKQLTEAVQKIATESIVIWGKTPKFRLPIQKETWES Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92197 D4T3TCEFV 2001 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIQALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVIPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRSAHTNDVKQLTEAVQKIATESIVIWGKTPKFKLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92198 D4T3TCEFV 2003 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMEICIEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLKGAKALTEVIPLSKEAELELAENREILKEPVHGVYYDPSKELVAELQKQGQGQWTYQIYQEPFKNLKTGKYARVRGAHTNDVKQLTEAVQKIATESIVIWGKTPKFKLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92199 D4T3TCEFV 2002 U.S. B 0 1 400 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALLEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYMDDLYVASDLEIGQHRLKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPITLPEKESWTVNDIQKLVGKLNWASQIYAGVKVKQLCKLLKGAKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKVALECIVIWGKTPKFRLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92200 D4T3TCEFV 2003 U.S. B 0 1 400 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLEKNRSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRTKIDELRAHLLGWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVVPLTEEAQLELAENREILKEPVHGVYYDPTKELIAELQKQGQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKIATESIIIWGKTPKFKLPIQKETWGS Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92201 D4T3TCEFV 2002 U.S. B 0 1 400 PISPIETVPVRLKPGMDGPRVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVVYQYVDDLYVGSDLDIGKHREKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLIRGTKALTEVITLTKEAELELAENREILKEPVHGVYYDPSKDLIAELQKQELGQWTYQIYQEPFKNLKTGKYARIKGAHTNDVKQLVEAVQRIATESIVIWGKTPKFRLPIQRETWDA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92202 D4T3TCEFV 2003 U.S. A 0 1 400 PISPIETVPVALKPGMDGPRVKQWPLTEEKIKALTEICSEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPGIIIYQYMDDLYVGSDLEIGQHRTKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGARSLTDIVTLTEEAELELAENREILKDPVHGVYYDPSKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYARKRSAHTNDVKQLAEVIQKVVLESIVIWGKTPKFKLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92203 D4T3TCEFV 2003 U.S. D 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPELVIYQYMDDLYVGSDLEIGQHRTKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPDKESWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLKGAKALTEVVPLTNEAELELAENREILKEPVHGVYYDPLKDLIAELQKQGQGQWTYQIYQEPFKNLKTGKYARMRGTHTNDVKQLTEAVQKISTESIVIWGKIPKFRLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92204 D4T3TCEFV 2003 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQNFWEVQLGIPHPAGLQKNKSVTILDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVVPLTNEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQGLGQWTYQIYQEPFKNLKTGKYARMRGTHTNDVKQLIEVVQKIAVESIVIWGKTPKFKLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92205 D4T3TCEFV 2003 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKDPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGDGQWTYQIYQEQFKNLKTGKYARIKGAHTNDVKQLTEAVQKIATESIVIWGKIPKFRLPIQKETWDA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92206 D4T3TCEFV 2001 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPNKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKSLTEVVPLTAEAELELAENREILREPVHGAYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARARGVHTNDVKQLTEAVQKITTESIVIWGKTPKFRLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92207 D4T3TCEFV 2003 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKSLTEVVPLTKEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQGHGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKIATESIVIWGKTPKFRLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92208 D4T3TCEFV 2001 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSRNNETPGMRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGPKALTEVIPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWSYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKIATESIVIWGKTPKFKLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92209 D4T3TCEFV 2003 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDMVIYQYVDDLYVGSDLEIGQHRVKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGPKALTEVIPLTREAELELAENREILKEPVHGVYYDPSKELIAELQKQEDGQWTYQIYQDPFKNLKTGKYARMRGTHTNDIKQLADAVQKIASESIVIWGKTPKFKLPIQKDTWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92210 D4T3TCEFV 2003 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILDPFRQQNPDIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGHELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGYGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKIATESIVIWGKVPKFKLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92211 D4T3TCEFV 2003 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIRVKQLCKLLRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPCKNLKTGKYARMRGTHTNDVKQLTEAVQKIATESIVIWGKTPKFKLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92212 D4T3TCEFV 2003 U.S. B 0 1 400 PISPIETVSVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDGAKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAHFSVPLAKNFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPELVIYQYMDDLYVGSDLEIGQHRTKIEELRKHLLGWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIVEIQKQGQDQWTYQIYQEPFKNLKTGKYAKTRGAHTNDVKQLTEAVQKIATESIVIWGKIPKFKLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1993 92213 D4T3TCEFV 2003 U.S. B 0 1 400 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSTNNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRIKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQGQCQWTYQIYQEPFKILKTGKYARTRGAHTNDVKQLTEAVQKIATESIIIWGKIPKFKLPIQKETWEA Margot, NA 2006 16925730 HIV Med Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 1994 92214 D4T3TCNVP 2003 Thailand CRF01_AE 0 31 225 IKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNQTPGVRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEP Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92215 D4T3TCNVP 2003 Thailand CRF01_AE 0 36 240 EICKKMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVADAYFSVPLHESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRRKNPDIVIYQYMDDLYVGSDLEIGQHRTKVEELRAHLLSWGFTTPDEKHQKEPPFLWMGYELHPDKWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92216 D4T3TCNVP 2009 Thailand CRF01_AE 0 22 240 KQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRKKNPEIVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLNWGFTTPDKKLQKEPPFLWMGYELHPDSWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92217 D4T3TCNVP 2005 Thailand CRF01_AE 0 40 230 EMEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIVICQYVDDLYVSSDLEIEQHRTKIEELRAHLLSWGFTTPDKKPQKEPPFLWM Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92218 D4T3TCNVP 2004 Thailand CRF01_AE 0 24 240 WPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKIKNPEMVICQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92219 D4T3TCNVP 2003 Thailand CRF01_AE 0 40 240 ELEEEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLQKKKSVTVLDVGDAYFSIPLDENFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVICQYVDDLYVASDLEIGQHRTKIEELRAHLYSWGFYTPDEKHQKEPPFHWMGYELHPDKWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92220 D4T3TCNVP 2004 Thailand CRF01_AE 0 13 240 RPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92221 D4T3TCNVP 2003 Thailand CRF01_AE 0 37 240 ICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFSTPDKKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92223 D4T3TCNVP 2003 Thailand CRF01_AE 0 41 239 MEEEGKILKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIIIYQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRW Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92224 D4T3TCNVP 2004 Thailand CRF01_AE 0 2 240 ISPIDTVPVTLKPGMDGPKVRQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKLQKEPPFLWMGYELHPDKWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92225 D4T3TCNVP 2004 Thailand CRF01_AE 0 26 240 LTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92227 TDF3TCNVP 2010 Thailand CRF01_AE 0 32 240 KALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIIIYQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGLFTPDKKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92228 AZT3TCEFV 2003 Thailand CRF01_AE 0 40 239 ELEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLPKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDIVIYQYVDDLYVGSDLEIGQHRTKVEELRAHLWSWGFYTPDKKHQKEPPFLWMGYELHPDKW Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92229 D4T3TCNVP 2007 Thailand CRF01_AE 0 33 240 ALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRRKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRNHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92230 D4T3TCEFV 2004 Thailand CRF01_AE 0 26 240 LTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVGSGLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWLGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92231 D4T3TCNVP 2004 Thailand CRF01_AE 0 36 237 EICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEMVICQYVDDLYVGSDLEIAQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPD Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92232 D4T3TCNVP 2006 Thailand CRF01_AE 0 30 240 KIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRTKVEELRAHLLSWGFTTPDQKHQKEPPFLWMGYELHPDKWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92233 D4T3TCNVP 2004 Thailand CRF01_AE 0 24 240 WPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMIIYQYVDDLYVGSDLEIGQHRMKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDSWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92234 AZT3TCEFV 2003 Thailand CRF01_AE 0 4 240 PMDTIPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92235 AZT3TCNVP 2007 Thailand CRF01_AE 0 31 240 LKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIIICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMEYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92236 AZT3TCNVP 2007 Thailand CRF01_AE 0 31 240 IKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRRKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMDIYQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92237 D4T3TCNVP 2003 Thailand CRF01_AE 0 31 240 IKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKYQKEPPFRWMGYELHPDKWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92238 D4T3TCNVP 2003 Thailand CRF01_AE 0 12 240 IKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKILKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIVICQYMDDLYVGSDLEIGQHRTKIEELRAHLLSGGFTTPDKKLQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92239 D4T3TCNVP 2003 Thailand B 0 40 224 EMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKE Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92240 AZT3TCNVP 2006 Thailand CRF01_AE 0 31 240 IKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNERPGVRYQYNVLPQGWKGSPAIFQDSMTKILEPFRTKNPEILICQYVDDLYVGSDLEIGQHRTKVEELRKHLLSWGFTTPDKKYQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92241 D4T3TCNVP 2004 Thailand CRF01_AE 0 40 240 EMEEEGKISKIGPENPYNTPVFAIKKKDSAKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDMVIYQYVDDLYVASDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92242 D4T3TCNVP 2004 Thailand CRF01_AE 0 38 238 CKEMEEEGKISKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPTIFQSSMTKILEPFRIKNPEMVICQYMDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92243 D4T3TCEFV 2003 Thailand CRF01_AE 0 27 240 TEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVSVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMIIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92244 D4T3TCNVP 2004 Thailand CRF01_AE 0 3 240 SPIDTVPVTLKPGMDGPRVNLWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHLKELPFFWMGYELHPGRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92245 AZT3TCNVP 2009 Thailand CRF01_AE 0 31 240 IKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVSVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFYTPDEKHQKEPPFLWMGYELHPDKWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92246 D4T3TCNVP 2007 Thailand CRF01_AE 0 31 240 IKALTEICKEMEEEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDIVICQYVDDLYVGSDLEIGQHRAKIEELRAHLFSWGFTTPDKKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92247 D4T3TCNVP 2006 Thailand CRF01_AE 0 36 240 EICKEMEEEGKISKIGPENPYNTPIFAIKKKGGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPELVICQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDNKHQKEPPFLWMGYELHPDKWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92248 AZT3TCNVP 2008 Thailand B 0 35 240 VEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKVEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92249 D4T3TCNVP 2004 Thailand CRF01_AE 0 36 238 EICKEMEEEGKISRIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDR Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92250 AZT3TCNVP 2007 Thailand CRF01_AE 0 31 240 IKALTEICNEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIEQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92251 D4T3TCNVP 2004 Thailand CRF01_AE 0 8 240 VPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEVVIYQYVDDLYVASDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92252 D4T3TCNVP 2003 Thailand CRF01_AE 0 36 239 EICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPDIVICQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRW Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92253 AZT3TCNVP 2006 Thailand CRF01_AE 0 30 240 KIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRVKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92254 D4T3TCEFV 2006 Thailand CRF01_AE 0 41 240 MEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIIICQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92255 D4T3TCNVP 2004 Thailand CRF01_AE 0 41 240 MEEEGKISKIGPENPYNTPVFAIKRKNNTTWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIIICQYVDDLYVASDLEIEQHRAKVDELRAHLLSWGLTTPDQKYQKEPPFLWMGYELHPDKWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92256 D4T3TCNVP 2003 Thailand CRF01_AE 0 3 240 SPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIEQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92257 D4T3TCNVP 2004 Thailand CRF01_AE 0 47 239 ISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHLKEPPFLWMGYELHPDRW Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92258 AZT3TCEFV 2003 Thailand CRF01_AE 0 14 240 PGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVIYQYVDDLYVGSDLEIGQHRAKIDELRAHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92260 D4T3TCNVP 2003 Thailand CRF01_AE 0 7 240 TVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSTNNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92261 D4T3TCNVP 2005 Thailand CRF01_AE 0 36 240 EICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEMVIYQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDRKHQKEPPFLWMGYELHPDKWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92262 D4T3TCNVP 2004 Thailand CRF01_AE 0 38 240 CKEMEEEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVICQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFRWMGYELHPDKWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92263 D4T3TCNVP 2003 Thailand CRF01_AE 0 40 237 EMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVASDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPD Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92264 D4T3TCNVP 2005 Thailand CRF01_AE 0 34 240 LTEICKEMEEEGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEMVIYQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92265 D4T3TCNVP 2004 Thailand CRF01_AE 0 27 240 TEEKIKALTEICKEMEEEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPEMVICQYVDDLYVASDLEIGQHRTKIEELRAHLFSWGFTTPDKKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92266 D4T3TCNVP 2003 Thailand CRF01_AE 0 12 240 LKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQTSMTKILEPFRIKNPEMIIYQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWLGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92267 D4T3TCNVP 2003 Thailand CRF01_AE 0 40 240 EMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLQKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVICQYIDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92268 AZT3TCEFV 2009 Thailand CRF01_AE 0 40 240 EMEEEGKISKIGPENPYNTPVFAIKKKNSNRWRKLVDFRELNKRTQDFCEVQLGIPHPAGLHKKKSMTVLDVGDAYFSVPLHDSFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVASDLEIGQHRTKIEELRAHLMSWGLTTPDQKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92269 D4T3TCNVP 2004 Thailand CRF01_AE 0 8 240 LPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLQKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEIVIYQYVDDLYVASDLEIGQHRTKIDELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92270 AZT3TCNVP 2007 Thailand CRF01_AE 0 31 240 IKALTEICKEMEEEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRMKNPEIVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92271 D4T3TCNVP 2003 Thailand CRF01_AE 0 38 240 CKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEKFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEIVIYQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92272 D4T3TCNVP 2006 Thailand C 0 30 240 KIRALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLEKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRARNPEMVIYQYVDDLYVASDLEIMQHRAKIKELRNHLLQWGLTTPDKKHQKEPPFLWMGYELHPDKWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92273 D4T3TCNVP 2003 Thailand CRF01_AE 0 38 236 CKEMEEEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDIVIYQYMDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHP Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92274 D4T3TCNVP 2004 Thailand CRF01_AE 0 40 240 EMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIIICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92275 D4T3TCEFV 2005 Thailand B 0 9 240 PVKLKPGMDGPKVKQWPLTEEKINALIEICTEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEIQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIIIYQYVDDLYVGSDLEIEQHRTKVEQLREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92276 AZT3TCEFV 2005 Thailand CRF01_AE 0 5 240 IDTVPVSLKPGMDGPKVKQWPLTEGKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKYQKEPPFLGMGYKLLPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92277 AZT3TCNVP 2008 Thailand CRF01_AE 0 36 240 EICKEMEEEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLHKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92278 D4T3TCNVP 2003 Thailand CRF01_AE 0 5 240 MDTVPVSLRPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISRIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKKSVTILDVGDAYFSVPLDENFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEVIICQYVDDLYVGPDLEIGQHRIKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92279 D4T3TCNVP 2004 Thailand CRF01_AE 0 37 237 ICKEMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLLVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFRWMGYELHPD Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92280 D4T3TCNVP 2004 Thailand CRF01_AE 0 6 240 DTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLLVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92281 D4T3TCNVP 2004 Thailand CRF01_AE 0 26 239 LTEEKIKALTEICKEMEEEGKISRIGPENPYNTPVFAIKKKDSSKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIDICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKW Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92282 D4T3TCNVP 2005 Thailand CRF01_AE 0 3 240 SPMDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRRKIEELRAHLLSWGFTTPDKKHQKEPPFLWLGYELHPDKWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92284 AZT3TCNVP 2008 Thailand CRF01_AE 0 31 240 IKALTEICKEMEEEGKISRIGPENPYNTPVFAIRKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEMVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDQKHQKEPPFRWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92285 AZT3TCEFV 2006 Thailand CRF01_AE 0 31 240 IKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYMDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFNWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92286 D4T3TCNVP 2004 Thailand CRF01_AE 0 6 240 DTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKILKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRIKNPDVVICQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92287 D4T3TCNVP 2003 Thailand CRF01_AE 0 37 240 ICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKRKRSVTVLDVGDAYFSVPLDESFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQTSMTKILEPFRIKNPDIVICQYVDDLYVGSDLEIGQHRAKIEELRTHLLRWGFTTPDKKYQKEPPFRWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92288 D4T3TCNVP 2003 Thailand CRF01_AE 0 32 240 KALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIIIYQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92289 D4T3TCNVP 2003 Thailand CRF01_AE 0 39 240 TEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKKNPEMVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92290 D4T3TCNVP 2003 Thailand CRF01_AE 0 37 235 ICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRIKVEELRAHLLSWGFTTPDNKHQKEPPFLWMGYELH Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92291 TDF3TCNVP 2007 Thailand CRF01_AE 0 31 240 IKALTEICKAMEAEGKISKIGPENPYNTPVFVIKNKDGTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKRKKSVTILDVGDAFFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFKIKNPEIVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92292 D4T3TCNVP 2005 Thailand CRF01_AE 0 31 240 IKALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKGGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDEKHQKEPPFLWMGYELHPDKWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92293 AZT3TCNVP 2007 Thailand CRF01_AE 0 31 240 IKALTEICAEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIIIYQYVDDLYVASDLEIGQHRIKIEELRAHLLSWGFFTPDNKHQKEPPFLWLGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92294 AZT3TCEFV 2007 Thailand CRF01_AE 0 31 240 IKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFRWMGYELHPDSWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92295 AZT3TCEFV 2008 Thailand CRF01_AE 0 31 240 IKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIIIYQYVDDLYVGSDLEIEQHRTKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92296 D4T3TCNVP 2007 Thailand CRF01_AE 0 31 240 IKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDEKFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEMVIYQYVDDLYVGSDLEIGPHRAKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92297 AZT3TCEFV 2007 Thailand CRF01_AE 0 31 240 IKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEHPFRWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92298 AZT3TCEFV 2006 Thailand CRF01_AE 0 31 240 IKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQDRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92299 AZT3TCEFV 2006 Thailand CRF01_AE 0 31 240 IKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFITPDEKHQKEPPFLWMGYELHPDKWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92300 AZT3TCNVP 2006 Thailand CRF01_AE 0 37 240 ICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMIIYQYVDDLYVASDLEIGQHRAKIKELRAHLLSWGFFTPDEKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92301 D4T3TCNVP 2005 Thailand CRF01_AE 0 31 240 IKALTEICKEMEEEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYYSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPMGWKGSPAIFQCSMTKILEPFKIKNPEIVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWT Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92302 AZT3TCEFV 2005 Thailand CRF01_AE 0 38 233 CKEMEEDGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSITVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPELVIYQYVDDLYVGSDLEIGQHRIKIEELRAHLWSWGFYTPDKKHQKEPPFRWLGYE Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92303 TDFFTCEFV 2010 Thailand CRF01_AE 0 1 334 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLMGKLNWASQIYGGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKTPVHGVYYDPSKDLVAEVQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92304 AZT3TCNVP 2008 Thailand CRF01_AE 0 1 334 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALPEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPGTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLLVGSDLEIGQHRKKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILNTPVHGVYYDPSKDLVAEVQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92305 TDFFTCEFV 2007 Thailand CRF01_AE 0 1 334 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSITVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLIRGTKALTDIVPLTEEAELELAENREILRTPVHGVYYDPSKDLVAEVQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92306 TDFFTCEFV 2009 Thailand CRF01_AE 0 1 334 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIIIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEHPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKNPVHGVYYDPSKDLIAEVQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92307 D4T3TCNVP 2003 Thailand CRF01_AE 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEMVIYQYVDDLYVGSDLEIEQHRIKIEELRAHLLSWGFFTPDKKHQKEPPFLWLGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKTLTDIVPLTEEAELELAENREILKTPVHGVYYDPSKDLVAEVQKQGQG Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92308 D4T3TCEFV 2007 Thailand CRF01_AE 0 1 334 PISPVETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQHSMTKILEPFRIKNPEIIIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPERDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILQTPVHGVYYDPSKDLVAEVQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92309 AZT3TCEFV 2006 Thailand CRF01_AE 0 1 334 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSATVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRMKNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEHPFLWMGYELHPDRWTVQPVELPEKDSWTVNDIQKLVGKLNWASQIYAGIKIKQLCKLLRGAKALTDIVPLTAEAELELEENREILKTPVHGVYYDPSKDLVAEVQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92310 TDFFTCNVP 2006 Thailand CRF01_AE 0 1 334 PISPIDTVPVKLKPGMDGPKVKQWPLSEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDIGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKTTVHGVYYDPSKDLVAEVQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92311 TDFFTCEFV 2007 Thailand CRF01_AE 0 1 334 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVPLTEEAELELAENREILKTPVHGVYYDPAKDLVAEVQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92312 TDFFTCEFV 2007 Thailand CRF01_AE 0 1 334 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEVVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVPLTEEAELELAENREILKTPVHGVYYDPSKDLVAEVQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92313 AZT3TCNVP 2006 Thailand CRF01_AE 0 1 334 PISPIDTVPVTLKPGMDGPKVKQWPLTKEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFRWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILSTPVHGVYYDPSKDLVAEVQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92314 TDFFTCEFV 2007 Thailand CRF01_AE 0 1 334 PISPIDTVPVSLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTEWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIDIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPLLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDVVPLTEEAELELAENREILKNPVHGVYYDPSKDIVAEVQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92315 TDFFTCNVP 2006 Thailand CRF01_AE 0 1 334 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAFFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIIQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKTPVHGVYYDPSKDLIAEVQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92316 AZT3TCNVP 2006 Thailand CRF01_AE 0 1 334 PISPIDTVPVSLKPGMDGPKVKQWPLTKEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEMVIYQYVDDLYVASDLEIEQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPVELPEKDSWTVNDIQKLVGKLNWASQIYPGIRIKQLCKLLRGAKALTDIVPLTGEAELELAENREILKTPVHGVFYDPSKDLVAEVQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92317 AZT3TCNVP 2006 Thailand CRF01_AE 0 1 334 PISPINTVPVTLKPGMDGPKVKQWPLTEEKLKALTEICREMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKNKSATVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIIIYQYVDDLYVASDLEIGQHRKKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVPLTAEAEFELAENREILKTPVHGVYYDPSRDLVAEVQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92318 AZT3TCNVP 2006 Thailand CRF01_AE 0 1 334 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLXKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKIKQLCRLLRGTKALTDIVPLTEEAELELAENREILKTPVHGAYYDPSKDLVAEVQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92319 D4T3TCNVP 2003 Thailand CRF01_AE 0 1 334 PISPIDTVPVKLKPGMDGPKIKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPYRRKNPEMVICQYVDDLYVASDLEIGQHRIKIEELRAHLMSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEIVQLTEEAELELAENREILKTPVHGVYYDPSKDLVAEVQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92320 TDFFTCEFV 2007 Thailand CRF01_AE 0 1 334 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKDGTKWRKIVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTRALTDIVPLTEEAELELAENREILKNPVHGVYYDPSKDLVAEVQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92321 AZT3TCNVP 2007 Thailand CRF01_AE 0 1 334 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISRIGPENPYNTPVFAIKKKDGTKWRKLMDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQNSMVKILEPFRVKNPEIIICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDRWTVQPIELPERDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVPLTEEAELELAENREILKTPVHGVYYDPSKDLVAEVQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92322 TDFFTCEFV 2008 Thailand CRF01_AE 0 1 334 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDIGDAYFSVPLDKDFRKYTAFTIPSINNGTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPELTIYQYVDDLYVGSDLEIGQHRIKVEELRAHLLRWGFTTPDKKHQKEPPFLWMGHELHPDSWTVQPIELPERDCWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVIQLTEEAELELAENREILKTPVHGVYYDPSKDLVAEVQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92323 D4T3TCNVP 2007 Thailand CRF01_AE 0 1 334 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISRIGPENPYNTPIFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIIIYQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKTPVHGVYYDPSKDLVAEVQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92324 TDFFTCNVP 2007 Thailand CRF01_AE 0 1 334 PISPINTIPVSLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVICQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIQVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKTPVHGTYYDPSKDLVAEVQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92325 AZT3TCNVP 2006 Thailand CRF01_AE 0 1 335 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKLKALTEICREMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMIICQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYGGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKTPVHGAYYDPSKDLVAEIQKQGQG Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92326 TDFFTCEFV 2007 Thailand CRF01_AE 0 1 334 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRIKIEELRAHLLNWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKTPVHGTYYDPSKDLVAEVQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92327 D4T3TCNVP 2006 Thailand CRF01_AE 0 1 334 PISPIDTIPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYIDDLLVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGVKVKQLCKLLRGAKALTEVVTLTEEAELELAENREILKTPVHGAYYDPSKDLVAEVQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92328 TDFFTCNVP 2008 Thailand CRF01_AE 0 1 334 PISPIDTIPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKRKDSSKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRIKNPEIFICQYMDDLYVGSDLEIEQHRTKVEELRAHLLSWGFTTPDRKYQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKIKQLCKLLRGTKALTDIVPLTAEAELELAENREILKTPVHGVYYDPSKDLVAEVQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92329 AZT3TCNVP 2009 Thailand CRF01_AE 0 1 334 PISPIETIPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSLPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIVICQYMDDLYVGSDLEIGQHRTKIEELRAHLLKWGFTTPDEKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILRTPVHGVYYDPSKDLVAEVQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92330 TDFFTCNVP 2007 Thailand CRF01_AE 0 1 334 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTILDVGDAFFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIALPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILRTPVHGVYYDPSKDLVAEVQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92331 AZT3TCEFV 2008 Thailand CRF01_AE 0 1 334 PISPIDTVPVTLKPGMDGPKVKQWPLTKEKIKALTEICNEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGLTTPDKKYQKEPPFRWMGYELHPDRWTLQPIELPEKDSWTVNDIQKLVGKLNWASQIYGGIKVKQLCKLLRGAKALTEVVPLTEEAELELAENREILKTPVHGVYYDPSKDLVAEVQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92332 TDFFTCEFV 2008 Thailand CRF01_AE 0 1 334 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPERDCWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVPLTEEAELELAENREILRTPVHGVYYDPSKDLVAEIQKQGQ Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92333 TDFFTCNVP 2007 Thailand B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPDLVICQYIDDLYVGSDLEIGQHRTKVEELRRHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVIPLTEEAELELAENREILREPVHGAYYDPSKDLIAEIQKQGRG Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1994 92334 TDFFTCNVP 2007 Thailand B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALVEICTEMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKKSITVLDVGDAFFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILESFRKQNPDIVICQYVDDLYVGSDLEIGQHRVKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKELCKLLRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGLG Ngo-Giang-Huong, N 2011 22132100 PLoS ONE Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: A bayesian analysis. 1997 75701 TDFFTCEFV 2010 U.S. B 0 1 327 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISRIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKKKSVTILDVGDAYFSVPLDKEFRKYTAFTLPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRKQNPDLVICQYIDDLYVGSDLEIGQHRAKIEELRQHLLRWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQTIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTKEAELELAENREILKEPVHGAYYDPSKDLIA Melikian, GL 2012 22330916 AAC Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility. 2011 94931 AZT3TCNVP 2009 Uganda A 0 1 305 PISPIETVPVTLKPRMDGPRIKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNATPGIRYCYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPGIIIYQYVDDLYVASDLEIGQHRAKVEELRAHLLSWGFTTPDKKHQKEPPFRWLGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEIVTLTEEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94933 AZT3TCEFV 2007 Uganda D 0 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTREKIKALTEICTDMEKEGKISRIGPENPYNTPIFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPEIVIYQYVDDLYVGSDLDIGQHRIKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLQEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKCLRGTKALTEVVPLTQEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94934 AZT3TCNVP 2008 Uganda D 0 1 305 PISPIETVPVKLKPGMDGPKIKQWPLTKEKIEALTEICKEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNRRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDADFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVASDLEIGQHRIKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIRVKQLCKCLRGTKALTEVVPLTAEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94935 AZT3TCNVP 2007 Uganda D 0 1 305 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPEMVIYQYVDDLYVASDLEIGQHRLKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKECWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCIRGTKALTEVVPLTEEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94936 D4T3TCNVP 2008 Uganda D 0 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDLWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKCLRGTKALTEVVPLTKEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94937 AZT3TCEFV 2007 Uganda D 0 1 305 PISPIETVPVKLNPGMDGPKVKQWPLTEEKIRALIEICTDMEKEGKISRIGPENPYNSPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMIIYQYVDDLYVSSDLEIGQHRTKIEKLREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDLQKLVGKLNWASQIYPGIKVRQLCKCLRGAKALTEIVPLTEEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94938 AZT3TCEFV 2008 Uganda D 0 1 305 PISPIDTIPVSLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKDGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILESFRKQNPEIVIYQYMDDLYVGSDLDIGQHRTKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIRVRNLCKCIRGTKALTEVVPLTEEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94939 AZT3TCNVP 2006 Uganda D 0 1 305 PISKIETIPVKLKPGMDGPKVKQWPLTEEKIKALIEICTELEKEEKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPELVIYQYIDDLYVGSDLEIGQHRIKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYQGIKIKQLCKCIRGAKALTEVVPLTEEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94940 AZT3TCNVP 2008 Uganda D 0 1 305 PISPIETVPVELKPGMDGPKVKQWPLTEEKIKALTEICTELEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEPFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQDSMTKILEPFRKQNPEMVIYQYVDDLYVGSDLEIGQHRMKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEVVPLTREAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94941 D4T3TCNVP 2007 Uganda D 0 1 305 PISPIETVPVKLRPGMDDPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMAICQYVDDLYVGSDLEIGQHRMKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIILPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCIRGVKALTEVVPLTEEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94942 AZT3TCNVP 2005 Uganda D 0 1 305 PISPIEAVPVKLKPGMDGPKIKQWPLTEEKIKALTEICMEMEKEGKISKIGPENPYNTPIFAIKKKDSAKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLCEDFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIEICQYVDDLYVGSDLEIGQHRAKIKELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCLRGAKALTEVVPLTEEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94943 AZT3TCNVP 2007 Uganda D 0 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKAITEICTDMEKEGKISRIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTILDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPEMVICQYVDDLYVGSDLEIEQHRIKIEKLRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYAGIKVRQLCKCIRGIKSLTEVVPLTAEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94944 AZT3TCNVP 2006 Uganda D 0 1 305 PISTITTVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRKQNPELVIYQYMDDLYVGSDLEIGQHRIKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCLRGAKALTEVVPLTEEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94945 D4T3TCEFV 2006 Uganda C 0 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRKYLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIILPEKESWTVNDIQKLVEKLNWASQIYPGIKVRQLCKCLRGTKALTEVIPLTVEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94946 AZT3TCNVP 2007 Uganda A 0 1 305 PISPIDTVPVTLKPGMDGPRIKQWPLTEEKIKALTEICTDMEKEGKISRVGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRSQNPEIIIYQYVDDLLVGSDLEIGQHRAKVEELRAHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVVTLTEEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94947 AZT3TCEFV 2007 Uganda D 0 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGEHRAKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGTKALTEVVALTEEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94948 D4T3TCNVP 2008 Uganda D 0 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNRRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVICQYVDDLYVGSDLEIGQHRIKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKCLRGVKALTEVVPLTQEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94949 AZT3TCEFV 2007 Uganda A 0 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEMVIYQYMDDLHVASDLEIGQHRAKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCRCIRGAKALTEIVPLTEEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94950 AZT3TCEFV 2008 Uganda D 0 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICSDMEKEGKISRIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIDICQYVDDLYVGSDLEIGQHRIKIKELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQSIKLPDKDSWTVNDIQKLVGKLNWASQIYPGIRVKQLCKCIRGTKGLTEVVPLTEEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94951 AZT3TCEFV 2007 Uganda D 0 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDEAFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPEMVIYQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCIGGAKALTEVVPLTEEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94952 D4T3TCNVP 2009 Uganda D 0 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICSEMEKEGKISRIGPENPYNTPVFAIKKKDGNKWRKLVDFRELNKRTQEFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIIICQYVDDLYVGSDLEIGQHRIKIEELRXHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPINLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCLRGAKTLTEVIPLTEEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94953 D4T3TCNVP 2008 Uganda A 0 1 305 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRRYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRSQNPEIIIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYSGIKIRQLCKCIRGTKALTEVVPLTEEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94955 AZT3TCNVP 2008 Uganda D 0 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKLTRIGPENPYNTPIFAIKKKGGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRKQNPELIICQYVDDLYVGSDLEIGQHRTKIEELREHLWKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYPGIKVRHLCKCLRGTKALTEVIPLTEEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94956 AZT3TCEFV 2007 Uganda D 0 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRQNPEMVIYQYVDDLYVGSDLEIGQHRIKIEELREHLLKWGFXTPDKKHQKEHPFLWMGYELHPDKWTVQTIELPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCIRGTKALTEVVPLTKEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94958 AZT3TCNVP 2008 Uganda D 0 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVICQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYSGIKVKQLCKCLRGAKALTEVVPLTAEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94960 AZT3TCNVP 2007 Uganda A 0 1 305 PISPIETVPVKLKLGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPVFAIEKKDSTKWRKLVDFRELNKRTQDLWEIQLGIPRPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRSQNPDIIIYQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFSTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDVITLTEEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94961 D4T3TCNVP 2007 Uganda A 0 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTEICTDMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDVVTLTEEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94962 AZT3TCNVP 2005 Uganda D 0 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLCEDFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYMDDLYVGSDLEIGQHRRKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQAINLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCIRGAKALTEVVPLTEEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94964 AZT3TCNVP 2008 Uganda A 0 1 305 PISPIETVPVKLKPGMDGPRVKQWPLTEGKIKALSEICAEMEKEGKITRIGPENPYNTPIFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRSKNPDIIIYQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKEHWTVNDIQKIVGKLNWASQIYSGIKVKQLCKLLRGTKALTDIVTLTEEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94965 D4T3TCNVP 2007 Uganda CRF01_AE 0 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIIIYQYVDDLYVASDLEIGQHRAKIEELRDHLLKWGFFTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTDIVPLTEEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94966 AZT3TCNVP 2005 Uganda D 0 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDGTKWRRLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYVDDLYVGSDLEIGQHRIKIEELRGHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTAQPIKLPEKESRTVNDIQKLVGKLNWASQIYPGIKVKQLCKCIKGTKALTEVVPLTEEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94967 AZT3TCNVP 2008 Uganda D 0 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRTGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTVPSINNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRKQNPEMVIYQYVDDLYVASDLEIGQHRIKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCLRGAKALTEVVPLTGEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2011 94968 AZT3TCEFV 2005 Uganda A 0 1 305 PISPIETVPVTLKPGMDGPKIKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSSAIFQSSMTKILEPFRLQNPGIIIIQYVDDLYVGSDLEIGQHRTKVEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEIITMTEEAELELAE Reynolds, SJ 2012 22443282 ARHR Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. 2012 95009 AZT3TCNVP 2009 Cameroon D 1 1 372 PISPIKPVAVQLKPGMDGPKIKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLMDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNGTPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFKKQNPELTIYSYVDDLYVGSDLEIGQHRAKIEKLREHLLKWGLSTPDKKHQKEPPFLWMGYELHPEKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKIKQLCRLIRGAKALTEVIPLTKEAELELAENREILREPVHGVYYDPSKELIAEIQKQGESQWSWQIYQEPFKNLKTGKYAKMKSAHTNDVKQLTETV Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95010 AZT3TCNVP 2009 Cameroon CRF02_AG 1 1 296 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTELEKEEKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGLFTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLIGASQIYAGIKVKQLCKLLRGAKALTDIVTLT Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95011 AZT3TCNVP 2009 Cameroon G 1 1 316 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTDLEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTILDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKENPEIVIYQYVDDLYVGSDLEIGQHRAKIKELRAHLLKWGFTTPDKKHQTEPPFLWMGYELHPDKWTMQPIQLPDKENWTVNDIQKLVGKLNWASQIYPGIKVRHLCKLLRGAKALTDVVPLTAEAEMELAENREILREPVHG Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95012 AZT3TCNVP 2009 Cameroon CRF02_AG 1 1 356 PISPMKRPQIKLKPGRDGPKVKQWPLTEEKIKALRRICLEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLHKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQGSMTKILEPFRKENPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELEENREILKEPVHGVYYDPTKDLVAEIQKQGQDQWTYQIYQEPFKNLKTGKYAR Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95013 D4T3TCNVP 2010 Cameroon CRF02_AG 1 1 340 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLVKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVICQYVDDLYVASDLEIGQHRAKIEELRTHLLEWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPNKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTMTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGEGQWTYQ Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95014 AZT3TCNVP 2009 Cameroon CRF13_cpx 1 1 265 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLRKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQDSMTKILKPFRTQNPEIVICQYVDDLYVGSDLEIGKHREKIEELREHLLRWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDEDSWTVNDIQKLVGKLN Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95016 AZT3TCNVP 2009 Cameroon A 1 1 303 PISPIDTVPVTLKPGMDGPKVKQWPLTEGKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNGTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQHSMTKILEPFRSKNPEIVIYQYVDELYVGSDLEIEQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVVPLTKEAELEL Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95017 AZT3TCNVP 2009 Cameroon CRF02_AG 1 1 266 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICMEMEKEGKISRIGPENPYNTPVFAIKKKNSDRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRSHLLRWGFFTPDQKHQKEPPFHWLGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNW Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95018 AZT3TCEFV 2010 Cameroon A 1 1 320 PISPIETVPVALKPGMDGPKVKQWPLTEEKIKALTEICMEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIEQHRTKIEELRAHLLSWGFYTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDVVPLTEEAELELAENREILKEPVHGVYYD Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95019 D4T3TCNVP 2009 Cameroon CRF02_AG 1 1 341 PISSIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTELEEEGKISKIGPENPYNTPIFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGVRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIKELRAHLLKWGFYTPDKKYQEEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKTLTDIVTMTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGQDQWTYQI Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95020 AZT3TCNVP 2009 Cameroon A 1 1 340 PISPIETVPVKLKPGMDGPRVKQWPLTKEKIKALTEICSDLEKDGKITRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPDIIICQYVDDLYVASDLEIGQHRAKIDELRNYLWKWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDVVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQDQWTYQ Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95021 D4T3TCNVP 2009 Cameroon D 1 1 339 PISPIETIPVKLRPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKEKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEVVIYQYVDDLLVGSDLEIGQHRTKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPINLPKKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEVIPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQGQEQWTY Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95022 AZT3TCNVP 2009 Cameroon CRF02_AG 1 1 339 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIKALTDICTELEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTENPEMVIYQYVDDLLVGSDLEIGQHRAKVEKLREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVKNLCKLIRGTKALTEIVPLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQDQWTY Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95023 AZT3TCEFV 2009 Cameroon CRF02_AG 1 1 339 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIRKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDVDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYAGIQVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGQDQWTY Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95024 AZT3TCNVP 2009 Cameroon CRF11_cpx 1 1 373 PISPVDTVPVKLKPGMDGPKVKQWPLTKEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDPNFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPELVIYQYVDDLYVASDLEIGQHREKVEELREHLLKWGFSTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKTKQLCKLIRGTKALTDIVPLTAEAEMELAENREILKEPVHGVYYDPSKDLIAEVQTQGLDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDVRQLTEVVQ Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95025 AZT3TCNVP 2009 Cameroon CRF02_AG 1 1 331 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALQDICAEMEQEGQISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVASDLEIGQHRTKIEELREHLLKWGLSTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPAKDLVAEIQK Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95026 AZT3TCEFV 2009 Cameroon CRF02_AG 1 1 303 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTDICMEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNATPGTRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEVVIYQYMDDLYVGSDLEIGQHREKIQELRDHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTEIVTLTEEAELEL Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95028 AZT3TCNVP 2010 Cameroon CRF02_AG 1 1 338 PISPIETVPVKLKPGMDGPKVKQWPLTREKIEALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILAPFRAENPEIVIYQYVDDLYVGSDLEIEQHRAKIEELREHLWKWGFYTPDKKHQKEPPFHWLGYELHPDKWTVQAIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGQGQWT Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95029 AZT3TCNVP 2010 Cameroon CRF02_AG 1 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPGGLKKNKSVTILDVGDAYFSVPLDETFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIQIKQLCKLLRGAKALTDIVTLTEEAKLELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95030 D4T3TCNVP 2009 Cameroon F 1 1 323 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLTWGFTTPDNKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIRVRHLCKLLRGAKALTDVVPLTPEAELELAENREIIKEPVHGVYYDPSK Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95031 AZT3TCNVP 2009 Cameroon CRF02_AG 1 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICLEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQQIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGQG Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95032 D4T3TCNVP 2009 Cameroon CRF02_AG 1 1 299 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIGQHREKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEA Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95033 D4T3TCNVP 2009 Cameroon CRF02_AG 1 1 339 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICMEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKRNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQTSMTKILEPFRTNNPEIVIYQYVDDLYVGSDLEIEQHREKIQELREHLLKWGFYTPDKKHQTEPPFLWMGYELHPDKWTVQPIELPEKDNWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEIVTLTEEAELELAENREILKEPVHGVYYDPAKDLVAEIQKQGQDQWTY Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95034 AZT3TCNVP 2009 Cameroon CRF02_AG 1 1 339 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPSGLKKNKSVTVLDGGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFYTPDKKHQKEPPFLWLGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIRVKQLCKLIRGAKALTEVVTLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGQDQWTY Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95035 D4T3TCEFV 2009 Cameroon CRF02_AG 1 1 339 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPVQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGQDQWTY Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95036 AZT3TCNVP 2009 Cameroon CRF02_AG 1 1 340 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIKALTDICSEMEQEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDKKFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKVEDLRGHLLNWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTMTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQDQWTYQ Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95037 AZT3TCNVP 2009 Cameroon A 1 1 320 PISPIETVPVTLKPGMDGPRVKQWPLTEEKIKALTEICAELEKDGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKNKSVTVLDVGDAYFSIPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRTQNPEIVIYQYVDDLYVASDLEIGQHRKKIEELRAHLWSWGFYTPDNKHQKEPPFLWMGYELHPDKWTVQPILLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGTKTLTEVVAMTEEAELELAENREILKDPVHGVYYD Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95038 D4T3TCEFV 2009 Cameroon A 1 1 331 PISPVETVPVALKPGMDGPRVKQWPLTKEKIEALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLPKSKSVTVLDGGDAYFSVPLYEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILDPFRAKNPEIVIYQYVDDLYVGSNLEIEQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKECWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVPLTEEAELELAENREILKDPVHGAYYDPSKELIAEIQK Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95039 AZT3TCNVP 2009 Cameroon CRF02_AG 1 1 324 AISPIETVPVTLKPGMDGPKVKQWPLTEEKLKALTEICKEMEEDGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNGTPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIIIYQYVDDLYVGSDLEIGQHRAKVEELRAHLTKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPAKD Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95040 D4T3TCNVP 2009 Cameroon A 1 1 314 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEKDGKISKIGPENPYNTPIFAIRKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNYETPGIRYPYNVLPQGWKGSPAIFQNAMTKILEPFRKKNPEIVIY*YVDDLYVGSDLEIEQHRAKIKDLRDYLWKWGFYTPDKKYQKEPPFLWMGYELHPAKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDVVPLTEGAELELAENRKILKEPV Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95041 AZT3TCNVP 2009 Cameroon CRF02_AG 1 1 380 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRRSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNERPGVRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGLFTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDTWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVALTEEAELELAENREILKEPVHGVYYDPAKDLVAEIQKQGEGQWTYQIYQEPFKILKTGKYAKKGSAHTNDVRQLTQVVQKVSTESI Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95042 AZT3TCNVP 2009 Cameroon CRF02_AG 1 1 328 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKAITEICAEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVGSDLDIGQHREKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPAKDLIAE Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95043 AZT3TCNVP 2010 Cameroon CRF02_AG 1 1 315 PISPIETVPVKLKPGMDGPKVKQWPLTEDKIKALTDICLEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKYPEIVIYQYVDDLLVGSDLEIGQHRAKIEELRGHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIRVKHLCKLLRGAKTLTEVVTLTREAELELAENREILQEPVH Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95044 D4T3TCNVP 2010 Cameroon F 1 1 352 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICDEMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSINNQTPGVRYQYNVLPQGWKGSPAIFQSSMTKILDPFRAKNPELVICQYVDDLYVASDLEIGQHRTKIEELREHLLRWGFFTPDKKHQKEPPFLWMGYELHPDKWTIQAIQLPDEDSWTVNDIQKLVGKLNWASQIYPGIRVKHLCKLLRGAKALTDVVTLTAEAELEMAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPHKNLKTG Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95046 D4T3TCNVP 2010 Cameroon CRF02_AG 1 1 323 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPHGWKRSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIDELRYHLLTWGFYTPDKKHQKEPPFLWMGYELHPDTWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGSKALTDVVTLTEEAELELAENREILKEPVHGVYYDPAK Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95047 AZT3TCNVP 2010 Cameroon CRF02_AG 1 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTDICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKRSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPILLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVPLTEEAELELAENREILKEPVHGVYYDPAKDLVAEIQKQG Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2012 95048 AZT3TCNVP 2010 Cameroon CRF02_AG 1 1 339 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISRIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYVYNVLPQGWKGSPAIFQDSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGQDQWTY Fokam, J 2011 21817951 Pediatr Infect Dis J Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. 2013 95053 D4T3TCNVP 2009 Malawi C 0 1 319 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDEGFRKYTAFTIPNVNNEAPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKYPDIIICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIIPLTAEAELELEENREILKEPVHGVYY Luebbert, J 2012 22573849 Clin Infect Dis Virological failure and drug resistance in patients on antiretroviral therapy after treatment interruption in Lilongwe, Malawi. 2013 95065 D4T3TCNVP 2009 Malawi C 0 1 319 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYHYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIIICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYY Luebbert, J 2012 22573849 Clin Infect Dis Virological failure and drug resistance in patients on antiretroviral therapy after treatment interruption in Lilongwe, Malawi. 2013 95078 D4T3TCNVP 2009 Malawi C 0 1 319 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPELVIYQYMDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQMCKLLRGAKALTDVIPLTEEAELELAENREILKEPVHGVYY Luebbert, J 2012 22573849 Clin Infect Dis Virological failure and drug resistance in patients on antiretroviral therapy after treatment interruption in Lilongwe, Malawi. 2016 95155 D4T3TCNVP 2008 Togo K 0 1 436 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICADMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPEKKHQKEPPFLWMGYELHPDKWTMQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIQVRQLCKLLRGAKALTDVVPLTAEAELELAENREILKEPVHGAYYDPSKDLVAEIQKQGQGQWTYQIYQEPHKNLKTGKYARIKSTHTNDVKQLTEAVQKIAQESIVIWGKTPKFRLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLETEPIAG Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95156 D4T3TCNVP 2008 Togo CRF02_AG 0 1 433 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEKEGKISRVGPENPFNTPIFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPSIFQESMTKILEPFRTKYPEIVICQYVDDLYVGSDLEIGQHREKIEELRGHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPINLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDVVTLTEEAELELAENREILKESVHGVYYDPTKDLIAEIQKQGQDQWTYQIYQEPFKILKTGKYAKRRSAHTNDVKQLTEVVQKAAIESIVIWGKTPKFRLPIQKETWETWWMDYWQATWIPEWEFVNTPPLVKLWYQLEKDP Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95157 D4T3TCNVP 2008 Togo CRF02_AG 0 1 434 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEREGKISKIGPENPYNTPVFAIKRKDS~KWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTENPEIVICQYMDDLYVSSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKRRSAHTNDVKQLTEVVQKVSMESIVIWGKTPKFRLPIQKETWEAWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKDPI Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95158 D4T3TCNVP 2008 Togo CRF02_AG 0 1 444 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEIVICQYMDDLYVGSDLEIGQHRAKIEELREHLLNWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVKQLTEVVQKVATEGIVIWGKTPKFRLPIQKETWETWWMEYWQATYIPEWEFVNTPPLVKLWYQLEKDPIIGAETFYVDG Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95159 D4T3TCNVP 2008 Togo CRF02_AG 0 1 432 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDNWTVQPITLPEKESWTVNDIQKLVGKLNWASQIYAGIRIKQLCKLLRGAKALTDVVTLTEEAELELAENREILKEPVYGVYYDPAKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVKQLVEVVQKAATESIVIWGKTPKFRLPIQKETWEAWWMDYWQATWIPEWEFVNTPPLVKLWYQLEKD Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95160 D4T3TCNVP 2008 Togo CRF02_AG 0 1 433 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILDPFRAKNPEIVIYQYVDDLYVASDLEIEQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGVKALTDVITLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVRQLVEVVQKVATESIVIWGKTPKFRLPIQRETWETWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKDP Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95161 D4T3TCNVP 2008 Togo CRF02_AG 0 1 434 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEKEGKISRVGPENPYNTPIFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPSIFQASMTKILEPFRTKYPEIVICQYVDDLYVGSDLEIGQHREKIEELRGHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPINLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDVVTLTEEAELELAENREILKESVHGVYYDPTKDLIAEIQKQGQDQWTYQIYQEPFKILKTGKYAKRRSAHTNDVKQLTEVVQKAAIESIVIWGKTPKFRLPIQKETWETWWMDYWQATWIPEWEFVNTPPLVKLWYQLEKDPI Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95162 D4T3TCNVP 2008 Togo CRF02_AG 0 1 434 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHKDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPTIFQASMTKILEPFRSKNPDLIIVQYVDDLYVGSDLEIEQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPAKDLVAEIQKQGQDQWTYQIYQEPFKNLKTGKYARKRSAHTNDVRQLVEVVQKVITESIVIWGKTPKFKLPIQKETWEAWWMEYWQATCIPDWEFVNTPPLVKLWYQLEKDPM Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95163 D4T3TCNVP 2008 Togo CRF02_AG 0 1 434 PISPIETVPVKLKPGKDGPKVKQWPLTEEKKKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRGHLLNWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVVTLTEEAELELAENREILKDPVHGVYYDPSKDLVAEIQKQGMDQWTYQIYQEPFKNLKTGKYARRRTAHTNDIKQLVEVVQKVVTESIVIWGKAPKFKLPIQKETWETWWMEYWQATYIPEWEFVNTPPLVKLWYQLEKDPI Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95164 D4T3TCNVP 2008 Togo K 0 1 435 PISPIETVPVKLKPGMDGPKIKQWPLTEEKLRALTEICEDMEKEGKISKIGPENPYNTPVFIIKKKDGNKWRKLIDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDIGDAYYSVPLDENFRKYTAFTIPSINNERPGIRYQYNVLPMGWKGSPAIFQASMIKILEPFRKRNPEMVICQYIDDLYVASDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTEIVPLTAEAELELAENREILKEPMHGVYYDPAKDLIAEIQKQGQDQWTYQIYQEPHKNLKTGKYARTKSAHTNDVKQLTEAVQKIAIESIVIWGKTPKFRLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLETEPIV Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95165 D4T3TCNVP 2008 Togo CRF02_AG 0 1 435 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTRNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVTLTEEAELELAENREILREPVHGVYYDPTKELIAEIQKQGQDQWTYQIYQEPFKILKTGKYAKKRSAHTNDVKQLVEVVHKVAVESIVIWGKTPKFRLPIQRDTWEAWWREYWQATWIPEWEFVNTPPLVKLWYQLEKDPII Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95166 D4T3TCNVP 2008 Togo CRF02_AG 0 1 429 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIHKKGSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTIIDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILQPFRTKYPEIVICQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGLFTPDEKYQKEPPFHWMGYELHPDKWTVQPIELPDKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLIRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKELVAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKRRSAHTNDVKQLTEVVQKVTIESIVIWGKTPKFRLPIQKETWETWWMEYWQATWIPEWEFVNTPPLVKLWYQL Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95167 D4T3TCNVP 2008 Togo CRF02_AG 0 1 446 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALADICTEMEKEGKISKIGPENPYNTPVFAINKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTNNPDIVICQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKNLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPTKELIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKRRSAHTNDVKQLTEVVQKIAVESIVIWGKTPKFRLPIQKETWEAWWLEYWQATWIPEWEFVNTPPLVKLWYQLEKDPIIGAETFYVDGAA Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95168 D4T3TCNVP 2008 Togo CRF02_AG 0 1 434 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTILDVGDAYFSVPLDKEFRKYTAFTLPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKDNPKIVIYQYVDDLYVASDLEIGQHRAKIEELREHLMKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKRRSTHTNDIKQLTEVVQKVGTEGIVIWGKTPKFRLPIQRETWEAWCMEYWQATWIPEWEFVNTPPLVKLWYQLEKDPI Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95169 D4T3TCNVP 2008 Togo CRF02_AG 0 1 435 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKLATVLDVGDAYFSVPLYEEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTENPGIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQSIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYAKRKSAHTNDVRQLVEVVQKVATEGIVIWGKTPKFRLPIQKETWEAWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKDPIL Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95170 D4T3TCNVP 2008 Togo CRF02_AG 0 1 443 PISPIKTVPVKLKPGMDGPRVKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPIFAIKKKDSSKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKENPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRNHLLKWGLTTPDKKHQKEPPFLWMGYELHPDTWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVPLTEEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGEGQWTYQIYQEPFKNLKTGKYARKKSAHTNDVRQLVEVVQKVTTESIVIWGKAPKFKLPIQKETWETWWTEYWQATFIPEWEVVNTPPLVKLWYQLEKDPIMGAETFYVD Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95171 D4T3TCNVP 2008 Togo CRF02_AG 0 1 434 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKGSDRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVICQYVDDLYVASDLEIGQHRAKIKELREHLLKWGFTTPDQKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVRQLTEVVQKVSVESIVIWGKTPKFRLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKDPI Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95172 D4T3TCNVP 2008 Togo CRF02_AG 0 1 438 PISPIETVPVKLKPGMDGPRIKQWPLTKEKIKALTEICQEMEKEGKISRIGPENPYNTPIFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEMEICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVTLTKEAELELAENREILKDPVHGVYYDPSKDLVAEIQKQGQDQWTYQIYQEPFKNLKTGKYARKRSAHTNDVRQLAEVVQKVATESIVIWGKTPKFKLPIQKETWDTWWMEYWQATYIPEWEFVNTPPLVKLWYQLEKEPIPGAE Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95173 D4T3TCNVP 2008 Togo CRF02_AG 0 1 434 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICGEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAQNPEIVICQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYAKKGSAHTNDVKQLTGAVQKVARESIIIWGKTPKFRLPIQKETWDAWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKDPI Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95174 D4T3TCNVP 2008 Togo CRF02_AG 0 1 436 PISPIETVPVKLKPGMDGPKVKQWPLTEEKKKALTEICTEMEKEGKISKIGPENPYNTPIFAIKRKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNESPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYMDDLCVGSDLEIGEHRAKIEQLREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKIKQLCKLIRGAKALTDVVPLTQEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGDDQWTYQIYQEPFKNLKTGKYAKRRSAHTNDVKQLTEVVQKVAMESIVIWGKTPKFRLPIQKETWEAWWMDYWQATWIPEWEFVNTPPLVKLWYQLEKDPIIG Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95175 D4T3TCNVP 2008 Togo G 0 1 433 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKDMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDASFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDCWTVNDIQKLVGKLNWASQIYPGVKVKQLCKLLRGAKALTDIVPLTPEAEMELAENREILREPVHGVYYDPSKELIAEVQKQGLDQWTYQIYQEPYKNLKTGKYAKRGSTHTNEVKQLVEVVQKIATEGIVIWGKVPKFKLPIRKETWEVWWTEYWQATWIPEWEFVNTPPLVKLWYQLETEP Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95176 D4T3TCNVP 2008 Togo CRF02_AG 0 1 433 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKKPPFLWMGYELHPDKWTVQPIQLPKKDSWTVNDVQKLVGKLNWASQIYAGIKVKQLCKLLGGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQNQGQDQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVRQLTEVVQKVTLECIIIWGKTPKFRLPIQKDTWEAWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKDP Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95177 D4T3TCNVP 2008 Togo K 0 1 433 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPHKNLKTGKYARTKSAHTNDVKQLTEAVQKVAQESIVIWGKTPKFRLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLETEP Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95178 D4T3TCNVP 2008 Togo CRF02_AG 0 1 434 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKISKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKAVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPTIFQASMTKILEPFRAKNPEMVIVQYVDDLYIGSDLEIGQHRAKIEELRAHLLEWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKNLCRLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVKQLTEVVQKVAMESIVIWGKTPRFRLPIQKETWETWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKDPI Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95179 D4T3TCNVP 2008 Togo K 0 1 438 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKNFRKYTAFTLPSLNNETPGVRYQYNVLPQGWKGSPAIFQASMTKILEPFRKRNPEVVIYQYVDDLYVGSDLEIGQHRAKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYSGIKVRELCKLIRGTKALTEIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGRGQWTYQIYQEPHKNLKTGKYAKIKSAHTNDVRQLTEAVQKIALESIVIWGKTPKFRLPIQKETWETWWTEYWQATWIPEWEFVNTSPLVKLWYQLETEPIARAE Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95180 D4T3TCNVP 2008 Togo CRF02_AG 0 1 435 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSATVLDVGDAYFSVPLDEEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQQSMTKILEPFRTKNPEIIIYQYVDDLYVGSDLEIEQHRAKIEELRAHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVKQLCKLLRGAKALTDIVALTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVKQLTEVVQKVASESIVIWGKTPKFRLPIQKETWETWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKDPII Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95181 D4T3TCNVP 2008 Togo CRF02_AG 0 1 443 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALKEICTEMEKEGKISKIGPENPYNTPIFAIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEIVICQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKRRSAHTNDVKQLAEVVQKVTTESIVIWGKAPKFRLPIQRDTWETWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKDPIAGAETFYVD Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95182 D4T3TCNVP 2008 Togo CRF02_AG 0 1 434 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAVFQASMTKILEPFRTKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKHLCKLLRGAKTLTDIITLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKRRSAHTNDVKQLTEVVQKVAVESIVIWGKTPKFRLPIQKETWEAWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKDPI Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95183 D4T3TCNVP 2008 Togo CRF02_AG 0 1 434 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTNICEEMEKEGKISKIGPENPFNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYMDDLYVASDLEIGQHRAKIEELREHLLTWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKNSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPAKDLVAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVKQLTEVVQKVAVESIVIWGKTPKFRLPIQKETWEAWWMEYWQATWIPEWGFVNTPPLVKLWYQLEKDPI Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95184 D4T3TCNVP 2008 Togo CRF02_AG 0 1 435 PISPIETVPVKLKPGMDGPKVKQWPLTEEKKKALTEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKRKKSVTVLDVEDAYFSVPLHEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPTIFQASMTKILEPFRAKNPEMVIVQYVDDLYIGSDLEIGQHRAKIEELRAHLLEWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQRPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKNLCRLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVKQLTEVVQKVAMESIVIWGKTPRFRLPIQKETWETWWMEYWQATWIPE*EFVNTPPLVKLWYQLEKDPII Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95185 D4T3TCNVP 2008 Togo CRF02_AG 0 1 438 PISSVETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTRILEPFRTQNPEIVIYQYVDDLLVGSDLEIGQHRAKVEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDCWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGAKALTEVVTLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVKQLTEVVQKVATEGIVIWGKTPKFKLPIQKETWDTWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKDPIXGAE Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95186 D4T3TCNVP 2008 Togo G 0 1 438 PISPIETVPVKLKPGMDGPRIKQWPLTEEKIKALTEICKDMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVICQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIIPLTAEAEMELEENREILKEPVHGVYYDPSKELIAEVQKQGLDQWTYQIYQEPYKNLKTGKYAKKGSAHTNDVKQLTEAVQKIATESIVIWGKIPKFKLPIRKETWEVWWTEYWQATWIPDWEFINTPPLVKLWYQLETEPILGAE Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95187 D4T3TCNVP 2008 Togo CRF02_AG 0 1 392 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEEFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQASMTKILEPFRRKNPEIVICQYMDDLYVASDLEIGQHRAKVEELREHLWRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVKQLTEVVQKVATESIVIWGKTPKFRLP Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95188 D4T3TCNVP 2008 Togo K 0 1 434 PISPIDTVPVKLKPGMDGPKIKQWPLSEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEAQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPGIVICQYMDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDVVSLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGSGQWTYQIYQEPHKNLKTGKYARMKSAHTNDVKQLTEAVQKIALESIVIWGKTPKFRLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLETEPI Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95189 D4T3TCNVP 2008 Togo K 0 1 358 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEELEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRRKNPELVICQYIDDLYVGSDLEIGQHRAKIEELRNHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPVQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTAEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQGQWTYQIYQEPHKNLKTGKYARMR Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95190 D4T3TCNVP 2008 Togo CRF02_AG 0 1 443 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQASMTRILEPFRTRNPEIVIYQYVDDLYVGSDLEIEQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIQVRQLCKLLRGAKALTDIVTMTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQGQWTYQIYQEPFKNLKTGKYAKRRSAHTNDVKQLIEVVQKAAVESIVIWGKTPKFRLPIQKETWEAWWMEYWQATWIPEWKFVNTPPLVKLWYQLEKDPIAGAETFYVD Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95191 D4T3TCNVP 2008 Togo CRF02_AG 0 1 443 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVIDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQTIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVIPLTEEAELELAENREILKEPVHGVYYDPAKDLVAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKRRSAHTNDVKQLTEVVQKVSTESIVIWGKTPKFRLPIQKETWETWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKDPIVGAETFYVD Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95192 D4T3TCNVP 2008 Togo CRF02_AG 0 1 444 PISTIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPELVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQTIKLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTVEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQDQWTYQIYQEPYKNLKTGKYAKRRSAHTNDVKQLTEAVQKIARECIVIWGKTPKFRLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKDPIIGAETFYVDG Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95193 D4T3TCNVP 2008 Togo K 0 1 443 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTEICNDMEKEGKISKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTIIDVGDAYFSVPLDPEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPEKKHQKEPPFLWMGYELHPDKWTMQPIQLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEQHKNLKTGKYAREKSAHTNDVKQLTEAVQKIALECIVIWGKTPKFRLPIQKETWETWWTNYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGAETFYVD Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95194 D4T3TCNVP 2008 Togo CRF02_AG 0 1 434 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRARNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPVQLPEKDSWTVNDIQKLVGKLNWASQIYPGIQVRQLCKLLRGAKALTDIVTLTEEAELELAENKEILKEPVHGVYYDPTKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVRQLTEAVQKVATESIIIWGKTPKFRLPIQKETWDTWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKDPI Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95195 D4T3TCNVP 2008 Togo G 0 1 433 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSVNNEIPGIRYQYNVLPQGWKGSPAICQTSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDCWTVNDIQKLVGKLNWASQIYPGVKVKQLCKLLRGAKALTDIVPLTPEAEMELAENREILREPVHGVYYDPSKELIAEVQKQGLDQWTYQIYQEPYKNLKTGKYAKRGSTHTNEVKQLVEVVQKIATEAIVIWGKVPKFKLPIRKETWEVWWTEYWQATWIPEWEFVNTPPLVKLWYQLETEP Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95196 D4T3TCNVP 2008 Togo CRF02_AG 0 1 434 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICLEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRRHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQAIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKRRSAHTNDVRQLVEVVQKVSTESIVIWGKTPKFRLPIQKETWETWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKDPI Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95197 D4T3TCNVP 2008 Togo CRF02_AG 0 1 443 PISPIETVPVKLKPGMDGPRVKQWPLTKEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKGSDRWRKLVDFKELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVICQYVDDLYVASDLEIGQHRAKIKELREHLLKWGLTTPDQKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVRQLTEVVQKVSVESIVIWGKTPKFRLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKDPITGAETFYVD Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95198 D4T3TCNVP 2008 Togo CRF02_AG 0 1 434 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICGEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWKKLVDFRELNKRTQDFCEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAQNPEIVICQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPTKELIAEIQKQGQGQWTYQIYQEPFKNLKTGKYAKKGSAHTNDVKQLTGAVQKVARECIVIWGKTPKFRLPIQKETWDAWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKDPI Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95199 D4T3TCNVP 2008 Togo CRF02_AG 0 1 434 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSVNNETPGVRYQYNVLPQGWKGSPAIFQASMTKILEPFRTRNPELVVYQYMDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKIKELCKLLRGAKALTEVVPLTKEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGEGQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVRQLTEVVQKVATESIVIWGKTPKFRLPIQKETWEAWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKDPI Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2016 95200 D4T3TCNVP 2008 Togo CRF02_AG 0 1 445 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSVNNEIPGIRYQYNVLPQGWKGSPAVFQASMTKILEPFRTNNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQDQWTYQIYQEPFKHLKTGKYAKRRSAHTNDVKQLTEVVQKVATESIVIWGKTPKFKLPIQKETWEAWWMEYWQATWIPEWEFVNTPPLVKLWYQLEKDPIAGAETFYVDGA Dagnra, AY 2011 21663632 J Int AIDS Soc High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. 2023 99463 D4T3TCEFV 2009 Zimbabwe C 0 1 324 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNAAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPDMVIYQYVDDLLVASDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIRVRNLCKLIRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKD Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99464 AZT3TCNVP 2009 Zimbabwe C 0 1 326 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALMAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLI Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99465 AZT3TCEFV 2009 Zimbabwe C 0 1 330 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEELEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIEQHRAKIEELREHLLKWGFFTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPEKEDWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENGEILKEPVHGVYYDPSKDXIAEIQ Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99466 AZT3TCNVP 2009 Zimbabwe C 0 1 306 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIQALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVASDLEIGQHRAKVEQLRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTIQPIQLPEKEDWTVNDIQKLVGKLNWASQIYPGVKVKYLCRLLRGAKALTDIVPLTEEAELELAEN Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99467 AZT3TCNVP 2009 Zimbabwe C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNATPGIRYQYNVLPQGRKGSPAIFQSSMTKILEPFRAQNPELVIYQYVDDLYVASDLEIGQHRAKIDKLREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEIVPLTEEAELELAENREILKEPVHGAYYDPTKDLIAELQKQG Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99468 AZT3TCNVP 2009 Zimbabwe C 0 1 320 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPDIVIYQYVDDLLVGSDLEIGQHRAKIKELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIIPLTEEAELELAXNREILKEPVHGVYYD Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99469 AZT3TCNVP 2009 Zimbabwe C 0 1 304 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYMDDLYVGSDLEIGQHRAKIDELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDVVPLTEEAELELA Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99470 AZT3TCNVP 2009 Zimbabwe C 0 1 330 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEDLREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQ Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99471 D4T3TCNVP 2009 Zimbabwe C 0 1 308 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTQNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAETEK Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99472 AZT3TCNVP 2009 Zimbabwe C 0 1 331 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPEKESWTVNDIQKLVGKLNWASQIYPGIRVKHLCKLLRGTKALTDIVPLTEEAELELAENRKVXQEPVHGVYYDPSKELIAKIQK Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99473 AZT3TCNVP 2009 Zimbabwe C 0 1 318 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKITRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNKTPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPELVIYQYVDDLYVGSDLELGQHRAKIEELREHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIVLPDKEDWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEIVPLTKEAELELAENREILKEPVHGAY Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99474 TDF3TCNVP 2009 Zimbabwe C 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIRRKDNTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAFFSVPLDKNFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIDELRKHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENR Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99475 AZT3TCEFV 2008 Kenya A 0 1 307 PISPIDTVPVKLKPGMDXPRVKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIIIYQYVDDLYVGSDLEIGQHRAKVEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDTWTVQPIKLPEKENWTVNDIQKLVGKLNWASQIYAGIQVKQLCRLLRGAKALTDIVTLTEEAELELAENR Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99476 AZT3TCEFV 2008 Kenya A 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEREGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLYEEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENR Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99477 AZT3TCNVP 2008 Kenya B 0 1 307 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPGIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENR Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99478 AZT3TCNVP 2008 Kenya A 0 1 309 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSTNNATPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRSKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGTKALTDIVTLTEEAELELAENREI Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99479 AZT3TCEFV 2008 Kenya A 0 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMEICKDMEKEGKISKVGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWLGYELHPDKWTVQPIKLPEKDSWTVNDIQKLIGKLNWASQIYPGIQVKQLCRLLRGAKALTDIVTLTKEAELELEE Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99480 AZT3TCNVP 2008 Kenya C 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIIPLTEEAELELAENR Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99481 AZT3TCNVP 2008 Kenya A 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLPEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRSKNPEIIIYQYMDDLYVGSDLEIGQHRTKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKEHWTVNDIQKLVGKLNWASQIYPGIKVKHLCRLLRGAKALTDIVPLTEEAELELAENR Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99482 AZT3TCEFV 2008 Kenya CRF01_AE 0 1 309 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICLEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPEMIIYQYMDDLYVGSDLEIEQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIILPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTREAELELAENREI Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99483 D4T3TCNVP 2008 Kenya A 0 1 302 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICADMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIIYQYMDDLYVGSDLEIGQHRTKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKEHWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELE Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99484 AZT3TCNVP 2008 Kenya D 0 1 298 PISPISTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYMDDLYVGSDLEIGQHRTKIEELRKHLLAWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCLRGAKALTEVIPLTAE Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99485 AZT3TCNVP 2008 Kenya A 0 1 306 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIIYQYMDDLYVGSDLEIEQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDHWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAEN Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99486 AZT3TCNVP 2008 Kenya CRF01_AE 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEVIIYQYVDDLYVGSDLEIGQHRAKVEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVVTLTEEAELELAENR Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99487 AZT3TCNVP 2008 Kenya A 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLPEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRSKNPEIIIYQYMDDLYVGSDLEIGQHRTKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKEHWTVNDIQKLVGKLNWASQIYPGIKVKHLCRLLRGAKALTDIVPLTEEAELELAENR Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99488 AZT3TCNVP 2008 Kenya D 0 1 317 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEKEGKISKIGPENPYNNPIFAIKKKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKTRQLCKCIRGTKALTEVIPLTEEAELELAENREILKEPVHGV Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99489 AZT3TCEFV 2008 Kenya A 0 1 323 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPEIIIYQYVDDLYVGSDLEIGQHRTKVEELRAHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTIQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVTLTEEAELELAENREILKDPVHGVYYDPSK Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99490 AZT3TCNVP 2008 Kenya A 0 1 308 PISPIETVPVKLKPGMDGPRIKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDHWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDIVPLTEEAELELAENRE Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99491 AZT3TCNVP 2008 Kenya C 0 1 314 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQASMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGHELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPV Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99492 D4T3TCNVP 2008 Kenya A 0 1 323 PISPIETVPVKLKPGMDGPKVKQWPLTVEKIKALTDICTEIEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYGGLRRYTAFTIPRTNNETPGIRYQYNVLSQGWKGSPAIFQCSMTKILETLRSKNRELIIYQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLIGKLNWASQIYGGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKNPVHGVYYDPSK Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99493 AZT3TCEFV 2008 Kenya D 0 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKKQNPEMVICQYVDDLYIGSDLEIGQHRSKIEELRAHLLSWGFITPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDIWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCIRGAKALTEVVPLTEEAELELAE Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99494 AZT3TCEFV 2008 Kenya A 0 1 312 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIEALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIIICQYVDDLYVGSDLEVGQHREKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYGGIKVKQLCRLLRGAKALTDIVPLTEEAELELAENREILKD Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99495 D4T3TCNVP 2008 Kenya D 0 1 316 PISPISTVPVKLKPGMDGPKVKQWPLTVEKIKALTEICREMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLNKYISVTVLDVGNAYFSVPLHEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPTIFQSSMTKILEPFRKQNPEIVICQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLIRGTKALTDIVPLTKEAELELEENREILKNPVHG Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99496 AZT3TCNVP 2008 Kenya A 0 1 310 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPELIIYQYVDDLYVGSDLEIEQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPVVLPEKESWTVNDIQKLVGKLNWASQIYARIKVKQLCRLLRGAKALTEVVTLTKEAELELAENREIL Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99497 ABC3TCNVP 2009 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLQKSKSVTILDVGDAFFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTKEAELELEENREILKEPVHGVYYDSSKELIAEIQKQG Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99498 TDFFTCNVP 2009 Nigeria G 0 1 332 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRNHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKSLTDIVPLTKEAELELAENRXVLKEPVHGVYYDPSKDLIADIQRK Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99499 AZT3TCNVP 2009 Nigeria CRF01_AE 0 1 325 PISPINTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQHSMTKILEPFRSQNPEIIIYQYMDDLYIGSDLEIGQHREKVEELRAHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENRXILKEPVHGVYYDPSKDL Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99500 AZT3TCNVP 2009 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPIPAGLQKKKSVTVLDVGDPYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYPGIKIRQLCKLIRGAKALTDIVVLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99501 TDFFTCNVP 2009 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNALPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVISQYMDDLYVGSDLEIGQHRAKVEELRDHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILREPVHGVYYDPSKDLIAEVQKQG Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99502 AZT3TCNVP 2009 Nigeria G 0 1 324 PISPIETVPVKLKPGMDGPKIKQWPLSEEKIKALTEICQEMEKEGKISRVGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFSEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSKNNKTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKENPEIEIYQYVDDLCVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYSGIKVRQLCKLLRGAKALTEIVPLTAEAELELAENRXILREPVHGVYYDSSKD Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99503 AZT3TCEFV 2009 Nigeria CRF02_AG 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEVVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQSIKLPEKDIWTVNDVQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQG Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99504 TDFFTCNVP 2009 Nigeria G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPIFAIKKKDSNEWRKLVDFRELNKRTQDFWEVQLGIPHPGGLRKKKSVTVLDVGDAFFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPYRTRNPEMVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPDKEQWTVNDIQKLVGKLNWASQIYPGIKVKHLCKLLRGAKALTDIVTLTVEAEMELAENREILKEPVHGVYYDPSKELIAEVQKQG Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99505 AZT3TCNVP 2009 Nigeria G 0 1 317 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKENWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGV Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99506 AZT3TCNVP 2009 Nigeria G 0 1 327 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICLEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRTKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRDHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIA Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99507 TDFFTCNVP 2009 Nigeria G 0 1 328 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKDMEKEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRTSNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKEHWTVNDIQKLVGKLNWASQIYSGIKVRNLCKLIRGAKALTDIVPLTAEAEMELAENREILKEPVHGVYYDPSKELIAE Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99508 AZT3TCNVP 2009 Nigeria G 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKNNPEIVICQYVDDLYVGSDLEIGQHREKIEELRNHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKENWTVNDIQRLVGKLNWASQIYPGIKVRHLCKLLRGAKALTDIVPLTTEAEMELAENREILKEPVHGVYYDPAKELIAEVQKQGQ Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99509 AZT3TCNVP 2009 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTEEKINALKEICTEMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPDIVICQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFYTPDKKYQKEPPFLWLGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILREPVHGVYYDPTKDLVAEIQKQGQ Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99510 ABC3TCNVP 2009 Nigeria CRF02_AG 0 1 327 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKEKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYMDDLYVGSDLELGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIRVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYNPAKELIA Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99511 AZT3TCNVP 2009 Nigeria CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDNWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKTLTDIVPLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGQ Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99512 AZT3TCNVP 2009 Nigeria G 0 1 331 PISPIETVPVKLKPGMDGPKIKQWPLTEEKLKALTEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEIQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRKKNPEMTICQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYAGIKVKHLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKEIIAEVQK Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99513 TDFFTCEFV 2008 South Africa C 0 1 331 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIEQHRAKIENLREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEQVHGVYYDPSKDLIAEIQK Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99514 TDFFTCEFV 2008 South Africa C 0 1 324 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIRALTEICEEMEREGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFREQNPEIVIYQYVDDLYVGSDLEIEQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKD Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99515 TDFFTCEFV 2008 South Africa C 0 1 331 PISPIETVPVKLKPGMDGPKVKQWPLTEETIKALTAICEDMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHREKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQK Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99516 TDFFTCEFV 2008 South Africa C 0 1 331 PISPIETVPVKLKPGMDGPRVKQWPLTKEKIEALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSMTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPELVIYQYVDDLYVASDFEIGKHREKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGVKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQK Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99517 TDFFTCEFV 2008 South Africa C 0 1 330 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIQVKNLCKLLRGAKGLTDIVQLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQ Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99518 TDFFTCEFV 2008 South Africa C 0 1 330 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFVIKRKDNTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTILDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILKPFREQNPEMDIYQYVDDLYVGSDLEIGQHRAKIKELREHLLKWGFTTPDKKHQEEPPLLWMGYELHPDKWTVQPIHLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLKGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQ Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99519 AZT3TCEFV 2008 South Africa C 0 1 330 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKRDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQ Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99520 TDFFTCEFV 2008 South Africa C 0 1 331 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKITKIGPENPYNTPIFAIRKKDSTKWRKILDFRELNKRTQDFWEVQLGIPHPAGLKKKKSLTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRMKNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGHELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTAVVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQK Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99521 TDFFTCEFV 2008 South Africa C 0 1 308 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPNIVIYQYMDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENRK Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99522 D4T3TCEFV 2008 South Africa C 0 1 329 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKAMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYVDDLYVGSDLEIGQHRAKVEELRKHLLEWGFTTPDKKYQKEPPLLWMGYELHPDKWTVQSIKLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEI Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99523 TDFFTCNVP 2008 South Africa C 0 1 317 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKRKDNTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSVNNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIVICQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRHLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGV Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99524 TDFFTCEFV 2008 South Africa C 0 1 330 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSNKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQTSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPLLWMGYELHPNKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQ Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99525 D4T3TCNVP 2008 South Africa C 0 1 306 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTILDVGDAYFSVPLYEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILAPFRAKNPEIVICQYVDDLYVGSDLEIEQHRAKIEELREHLLRWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYQGIKVKQLCKLLRGTKALTDIVPLTEEAELELAEN Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99526 D4T3TCEFV 2008 South Africa C 0 1 308 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRHLCKLLRGAKALTDIVPLTEEAELELAENRK Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99527 D4T3TCNVP 2008 South Africa C 0 1 331 PISPIKTIPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKIEKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYMDDLYVGSDLEIGQHREKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEVVPLTEEAELELAENREILREPVHGVYYDPSKDLIAEIQK Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99528 D4T3TCEFV 2008 South Africa C 0 1 324 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKEIWTVNDIQKLVGKLNWASQIYQGIKVKQLCKLLRGAKALTDIISLTEEAELELAENREIIKEPVHGVYYDPSKD Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99529 TDFFTCEFV 2008 South Africa C 0 1 330 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFREQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILREPVHGVYYDPSKDXIAEIQ Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99530 AZT3TCEFV 2008 South Africa C 0 1 328 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILAPFRARNPEVVIYQYVDDLYVGSDLEIKEHRAKIEELRAHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAE Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99531 D4T3TCEFV 2008 South Africa C 0 1 324 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALKAICEEMEKEGKIEKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTTILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENRVILKEPVHGVYYDPSKD Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99532 D4T3TCEFV 2008 South Africa C 0 1 331 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYMDDLYVGSDLEIGQHREKIEDLRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQSIVLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDVVPLTEEAELELAENREILKEPVHGAYYDPSKDLIVEIQK Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99533 D4T3TCNVP 2008 South Africa C 0 1 330 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRERNPKIVICQYMDDLYVGSDLEIGQHRAKIEELRDHLLRWGFITPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQ Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99534 D4T3TCEFV 2008 South Africa C 0 1 330 PISSIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPELVIYQYMDDLYVGSDLEITQHRARVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQMCKLLRGAKALTDIIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQ Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99535 D4T3TCEFV 2008 South Africa C 0 1 331 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICKEMEEEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAFFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTGNPELVIYQYMDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENRVXLKEPVHGVYYDPSKDLIAEIQK Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99536 D4T3TCEFV 2008 South Africa C 0 1 313 PISPIETIPVRLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSCMTKILEPFRTRNPNLVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKEDWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGTRALTEIVTLTEEAELELAENREILKEP Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99537 D4T3TCEFV 2008 South Africa C 0 1 240 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPDIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHRKEPPLLWMGYELHPDKWT Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99538 D4T3TCEFV 2008 South Africa C 0 1 328 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPEMVIYQYMDDLYVGSDLEIGQHREKIEELREHLLKWGFTTPDKKHQKEPPFHWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVPLTKEAELELAENREILKEPVHGVYYDPSKELIAK Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99539 TDFFTCEFV 2008 Uganda A 0 1 313 PISPIDTVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKEMENEGKISKIGPENPYNTPIFAIKRKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEITIYQYVDDLYVESDLEIGKHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDVVPLTTEAELELAENREIIKEP Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99540 AZT3TCEFV 2008 Uganda D 0 1 305 PISPIDTVPVKLKPGMDGPRIKQWPLTGEKIEALTEICREMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVVPLTEEAELELAE Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99541 AZT3TCNVP 2008 Uganda D 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNQTPGTRYQYNVLPQGWKGSPAIFQSSMKKILDPFRKQNPEMIIYQYVDDLYVGSDLEIKQHRIKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCLRGAKGLTEVVPLTEEAELELAENR Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99542 AZT3TCEFV 2008 Uganda CRF01_AE 0 1 307 PISPIETVPVTLKPGMDGPRVKQWPLTEEKIKALTEICKDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIIYQYMDDLYVGSDLEIGQHRAKVEELRAHLLGWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVPLTEEAELELAENR Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99543 AZT3TCNVP 2008 Uganda A 0 1 289 PISPISTVPVKLNPGMDGPKVNQWPLPEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIVIYQYVDDLYVGSDLETGQHRTKIEELRAHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPDKESWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGTKAL Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99544 AZT3TCNVP 2008 Uganda A 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEQEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKESWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTEIVTLTEEAELELAENR Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99545 AZT3TCEFV 2008 Uganda D 0 1 309 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICADMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPYRKQNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCIRGTKALTEVVPLTEEAELELAENREI Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99546 AZT3TCNVP 2008 Uganda A 0 1 307 PISPIETVPVTLKPGMDGPRVKQWPLTEEKIKALTEICREMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELRAHLLKWGLFTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGARALTEVVTLTEEAELELAENR Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99547 AZT3TCEFV 2008 Uganda D 0 1 315 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEKEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQCSMTKILEPFRQQNPELVIYQYMDDLYVGSDLEIGQHRMKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIHLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKCLRGTKTLTEVVSLTEEAELELAENREILKEPVH Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99548 AZT3TCEFV 2008 Uganda A 0 1 309 PISPIETVPVALKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSSKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPEIIIYQYMDDLYVGSDLEIKQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDIVTLTEEAELELAENREI Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99549 AZT3TCNVP 2008 Uganda D 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKITRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKNSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNEAPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKQNPEMVIYQYVDDLLVGSDLEIGQHRIKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPNKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIRVRQLCKCIRGTKALTEVVPLTEEAELELAENR Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99550 AZT3TCEFV 2008 Uganda A 0 1 302 PISPIETVPVTLKPGMDGPRVKQWPLTEEKIKALTEICKDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPEVIIYQYMDDLYVGSDLEIGQHRAKVEELRAHLLGWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCRLLRGAKALTDIVPLTEEAELE Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99551 TDFFTCNVP 2008 Uganda D 0 1 307 PISPINTIPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKRKDGTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTILDVGDAYYSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQNSMTKILEPFRKQNPEMVICQYIDDLYVGSDLEIGQHREKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIILPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKCIRGTKALTEVVPLTKEAELELAENR Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99552 TDFFTCNVP 2008 Uganda A 0 1 309 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEREGRISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIIYQYMDDLYVASDLEIGQHREKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREI Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99553 AZT3TCNVP 2008 Uganda A 0 1 307 PISPIDTVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSRNPELVIYQYVDDLYVGSDLEIGQHRTKVEELRKHLLSWGLTTPDKKHQKEPPFLWLGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENR Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99554 AZT3TCNVP 2008 Uganda D 0 1 307 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLYEEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILDPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRTKIEELRRHLLEWGFTTPDKKHQKEHPFRWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCIRGAKALTEVVPLTEEAELELAENR Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99555 TDFFTCEFV 2008 Uganda D 0 1 308 PISPIKTVPVTLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPIFAIKKKGSSEWRKLVDFRELNKRTQDFWEVQLGIPHPAGIRKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPEIIIYQYVDDLYVGSDLEIGQHRIKVEELRAHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIELPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCIRGTKALTEVVPLTEEAELELAENRE Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99556 AZT3TCNVP 2008 Uganda A 0 1 309 PISPIDTVPVKLKPGMDGPRVKQWPLTEEKIKALTEICADMEREGRISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQEFWEVQLGIPHPGGLKKEKSVPVLDVGDAFFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRLKNPEIIIYQYMDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTIQPIELPEKESWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREI Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99557 AZT3TCNVP 2008 Uganda CRF01_AE 0 1 311 PISPIETVPVTLKPGMDGPRVKQWPLTEEKIKALTEICKDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIIIYQYMDDLYVGSDLEIGQHRAKVEELRAHLLGWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNNIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVPLTEEAELELAENREILK Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99558 AZT3TCEFV 2008 Uganda A 0 1 307 PISPIETVPVTLKPGMDGPRIKQWPLTEEKIKALTEICLEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPDIIIYQYVDDLYVGSDLEIGQHRKKVEELRAHLLSWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIELPDKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDVVTLTEEAELELAENR Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99559 TDFFTCEFV 2008 Uganda A 0 1 319 PISPISTVPVKLKPGMDGPRIKQWPLTEEKIKALTEICKEMENEGKISKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEITIYQYVDDLYVESDLEIGKHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKERWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDVVPLTTEAELELAENREIIKEPVHGVYY Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99560 TDFFTCEFV 2008 Uganda D 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEREGKISKIGPENPYNTPIFAIKKKNSTEWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYVDDLYVQSDLEIGQHRAKIEQLREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKECWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLIRGVKALTEVVPLTEEAELELAENR Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99561 TDFFTCEFV 2008 Uganda A 0 1 315 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRKLNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIIIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEVIPLTKEAELELAENREILKDPVH Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99562 AZT3TCEFV 2008 Uganda A 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDIIIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEVVTLTEEAELELAENR Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99563 TDFFTCEFV 2008 Uganda D 0 1 306 PISPIETVPVQLKPGMDGPKVKQWPLTAEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKRKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAFFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVQSDLEIGQHRKKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPDKEDWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCIRGAKALTEIIPLTAEAELELAEN Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99564 TDFFTCNVP 2008 Uganda D 0 1 313 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRKLNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRIKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCIRGTKALTEVVPLTEEAELELAENREILKEP Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99565 AZT3TCEFV 2008 Uganda CRF01_AE 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIIIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQSIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLIRGTKALTEVVALTEEAELELAENR Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99566 TDFFTCEFV 2008 Uganda A 0 1 313 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIIIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKDP Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99567 TDFFTCEFV 2008 Uganda CRF01_AE 0 1 308 PISPIETVPVTLKPGMDGPRIKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIIYQYMDDLYVGSDLEIGQHRAKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDVVPLTEEAELELAENRE Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99568 AZT3TCEFV 2008 Uganda CRF01_AE 0 1 316 PISPIETVPVTLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRSKNPEMIIYQYVDDLYVGSDLEIGQHRTKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKDTVHG Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99569 AZT3TCNVP 2008 Uganda D 0 1 309 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKAITEICNELEKDGKISRIGPENPYNTPIFAIKKKGGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPEMVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYSGIKVRQLCKLLRGAKALTEVVPLTEEAELELAENREI Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99570 AZT3TCNVP 2008 Uganda D 0 1 312 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKKNPEMVIYQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPITLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCIRGAKALTEVVPLTAEAELELAENREILKE Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99571 TDFFTCEFV 2008 Uganda CRF01_AE 0 1 310 PISPIETVPVTLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGQISKIGPENPYNTPVFAIKRKDGTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLRKNRSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMLKILEPFRSKNPEIIICQYVDDLYVASDLEIGEHRAKVEELRAHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEIVPLTEEAELELAENREIL Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99572 TDFFTCEFV 2008 Uganda CRF01_AE 0 1 307 PISPIETVPVTLKPGMDGPRVKQWPLTAEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELIIYQYMDDLYVGSDLEIGQHRTKVEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVALTEEAELELAENR Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99573 TDF3TCNVP 2008 Uganda D 0 1 313 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYVDDLYVSSDLAIEQHRIKIEELREHLLKWGFYTPDKKHQKEPPFQWMGYELHPDKWTIQPVVLPEKDIWTVNDIQKLVGKLNWASQIYPGIRVKHLCKCIRGTKGLTEVVPLTEEAELELAENREILKEP Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99574 AZT3TCNVP 2008 Uganda A 0 1 301 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLLDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFFTPDEKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDIVTLTEEAEL Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99575 AZT3TCEFV 2008 Uganda D 0 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEEFRKYTAFTIPSTNNEAPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKHNPEIVIYQYMDDLYVGSDLEIGQHRIKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPINLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKCLRGTKALTEVIPLTEEAELELAE Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99576 AZT3TCNVP 2008 Uganda A 0 1 311 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDVVPLTREAELELEENREILK Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99577 AZT3TCNVP 2008 Zambia C 0 1 331 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKKTQDFWEVQLGIPHPAGLKKRKSVTVLDVGDAYFSVPLDKDFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIDICQYVDDLYVGSDLEIGQHRAKIEELRDHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELEENREILKEPVHGVYYDPSKDLIAEIQK Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99578 AZT3TCNVP 2008 Zambia C 0 1 299 PISPIKTVPVKLKPGMDGPKVKQWPLTKEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKFVDFRELNKKTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVFYQYVDDLYVASDLEIGQHREKIKELRTHLLKGGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPKKDSWTVNDIQKLVGKLNWASQIYPGIKVRQFCKFIRGTKALTEIVPLTEEA Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99579 AZT3TCNVP 2008 Zambia C 0 1 326 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILNPFREQNPEIVICQYVDDLYVGSDLEIGQHRAKIEKLREHLLRWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYKGIKVRQLCKLIRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELI Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99580 TDFFTCEFV 2008 Zambia C 0 1 331 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKIVDFRELNKRTQDFSEIQLGIPHPAGLKKNKSVTILDVGDAFFSVPLDESFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRTKNPDLVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEHPFLWMGYELHPDKWTIQPIVLPEKEDWTVNDIQKLVGKLNWASQIYQGIRVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQK Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99581 TDFFTCEFV 2008 Zambia C 0 1 328 PISPIATVPVKLKPGMDGPRVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLKWGFTTPDKKHQKEPPFLWMGYELHPEKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAD Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99582 AZT3TCNVP 2008 Zambia C 0 1 331 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPELVIYQYMDDLYVGSDLEIGQHRAKIEQLRDHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQK Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99583 AZT3TCNVP 2008 Zambia C 0 1 329 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVSSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTVEAELELAENREILKEPVHGVYYDPSKDLVAEI Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99584 TDFFTCEFV 2008 Zambia C 0 1 326 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICNEMEQEGKITKIGPDNPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSIPLDENFRKYTAFTIPSTNNATPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYMDDLYVGSDLEIEQHRAKIEELRERLLKWGLTTPDKKHQKEPPFRWLGYELHPDKWTVQAIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLM Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99585 AZT3TCNVP 2008 Zambia C 0 1 308 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRSKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENRK Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99586 D4T3TCNVP 2008 Zambia C 0 1 319 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKRKDGTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPEIVICQYMDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIQVKHLCRLLRGTKALTDVVPLTEEAELELAENRDXLKEPVHGVYY Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99587 D4T3TCNVP 2008 Zambia C 0 1 313 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNAAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQAIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVRHLCKLLRGAKALTDIVPLTEEAELELAENRXLLKEP Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99588 TDFFTCEFV 2008 Zambia C 0 1 327 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRASNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRTHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGTKALTEVVPLTEEAELELAENREILKEPVHGAYYDPTKDLIA Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99589 TDFFTCEFV 2008 Zambia C 0 1 330 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGQITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRVHLLKWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPVVLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKETVHGVYYDPSKDLIAEIQ Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99590 TDFFTCNVP 2008 Zambia C 0 1 331 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALKEICDEMEKEGKISKIGPENPYNTPVFAIKRKDNTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKRKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVICQYVDDLYVASDLEIGQHRAKIEELRKHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQK Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99591 TDFFTCNVP 2008 Zambia C 0 1 333 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALIAICEEMEKEGKITKIGPENPYNTPVFVIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKEAWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQG Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99592 TDFFTCNVP 2008 Zambia C 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPDIDIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAETREILKEPVHGAYYDPSKDLIAEIQKPG Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99593 TDFFTCEFV 2008 Zambia C 0 1 309 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIIPLTEEAELELAENREI Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99594 ABC3TCEFV 2008 Zambia C 0 1 331 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELVIYQYVDDLLVGSDLEIVQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQK Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99595 TDFFTCEFV 2008 Zambia C 0 1 329 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEI Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99596 ABC3TCEFV 2008 Zambia C 0 1 331 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIEALMAICEEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFREQNPEIVICQYMDDLYVGSDLEIGQHRAKIKELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKEDWTVNDIQKLVGKLNWASQIYKGIKVRQLCKLLRGAKALTDIGPLTEEAELELAEXREILKEPVHGVYYDPSKDLIAEIQK Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99597 TDFFTCEFV 2008 Zambia C 0 1 355 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICEEMEKEGKITKIGPENPYNTPVFAIKRKDGTKWRKLADFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPDIVIYQYVDDLYVESDLEIRQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYQGIKVKQLCKLIRGTKALTDIVPLTEEAELELAENRKVCKEPVHGVYYDPSKDLIAEIQKQGDDQWTYQIYQEPFKNLKTGKYA Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99598 TDFFTCEFV 2008 Zambia C 0 1 307 PISPIETIPVKLKPGMDGPKVKQWPLTEEKLKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQHSMTKILEPFRTRNPEIEIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPILLPEQESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENR Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99599 TDFFTCEFV 2008 Zambia C 0 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELVICQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENR Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99600 AZT3TCEFV 2008 Zambia C 0 1 331 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPEKDSWTVNDIQKLVGKLNWASQIYPGVRVRHLCRLLRGTKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQK Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99601 TDFFTCEFV 2008 Zambia C 0 1 327 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKENWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIA Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99602 TDFFTCEFV 2008 Zambia C 0 1 324 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSMTILDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPELVIYQYVDDLYVASDLEIEQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYSGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKD Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99603 TDFFTCNVP 2008 Zambia C 0 1 331 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDNWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQK Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2023 99604 TDFFTCEFV 2008 Zambia C 0 1 326 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGVKVRNLCKLLRGTKALTDIVPLTEEAELELAENREILREPVHGVYYDPSKDLI Hamers, RL 2012 22474222 Clin Infect Dis Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. 2024 99607 AZT3TCEFV 2008 Morocco B 0 8 244 VPVKLKPGMDGPRVKQWPLTEEKIKALVEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLRKEKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHLDKWTVQPI El Annaz, H 2012 21919803 ARHR Drug resistance mutations in HIV type 1 isolates from patients failing antiretroviral therapy in Morocco. 2024 99624 AZT3TCEFV 2009 Morocco B 0 9 249 PVKLKPGMDGPKVKQWPLTEEKLRALMEICAEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKNNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKNNPGIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLKRGFITPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEK El Annaz, H 2012 21919803 ARHR Drug resistance mutations in HIV type 1 isolates from patients failing antiretroviral therapy in Morocco. 2024 99627 AZT3TCEFV 2008 Morocco B 0 1 250 SISPIETVPVKLKPGMDGPKVKQWPLTEGKIKALVEICTEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLEKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIAIYQYMDDLYIGSDLELGQHRAKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLQEKD El Annaz, H 2012 21919803 ARHR Drug resistance mutations in HIV type 1 isolates from patients failing antiretroviral therapy in Morocco. 2024 99634 AZT3TCEFV 2009 Morocco B 0 11 204 KLKPGMDGPKVKQWPLSEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYGSVPLDEDFRKYTAFTIPSTNNETPGVRYHYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIDIYQYVDDLYVGSDLEIGQHRAKIEE El Annaz, H 2012 21919803 ARHR Drug resistance mutations in HIV type 1 isolates from patients failing antiretroviral therapy in Morocco. 2024 99636 AZT3TCEFV 2009 Morocco B 0 8 249 VPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGPHRTKIEELRQHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVRPIVLPEK El Annaz, H 2012 21919803 ARHR Drug resistance mutations in HIV type 1 isolates from patients failing antiretroviral therapy in Morocco. 2024 99640 AZT3TCEFV 2008 Morocco CRF02_AG 0 9 250 PVKYKPGMDGPRVRQWPLTEEKIKALTDICTDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILGPFRAENPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKD El Annaz, H 2012 21919803 ARHR Drug resistance mutations in HIV type 1 isolates from patients failing antiretroviral therapy in Morocco. 2024 99641 AZT3TCEFV 2007 Morocco B 0 1 255 YISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYIDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN El Annaz, H 2012 21919803 ARHR Drug resistance mutations in HIV type 1 isolates from patients failing antiretroviral therapy in Morocco. 2024 99649 AZT3TCEFV 2008 Morocco B 0 9 247 PVKLKPGMDGPKVKQWPLTEEKIKALKEICTELEKEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIIIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLQWGFDTPDKKHHKEPPFLWMGYELHPDKWTVQPIVLP El Annaz, H 2012 21919803 ARHR Drug resistance mutations in HIV type 1 isolates from patients failing antiretroviral therapy in Morocco. 2031 101809 D4T3TCEFV 2006 South Africa C 0 1 560 PISPIKTVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVGQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDVKQLTEAVQKIAMESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPMAGVETFYVDGAANRETKIGKAGYVTDRGRQKVVTLTETTNQKTELQAIRLALQDSGSEVNIVTDSQYALGILQAQPDRSESEIVNQIIEELIKKERVYLTWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101810 D4T3TCEFV 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEREGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIKQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYQGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILRNPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVRQLTEAVQKIAMESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGAETFYVDGAANRETKTGKAGYVTDKGRQKIVTLNETTNQKAELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLINKERIYLSWVPAHKGIGGNEQIDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101811 D4T3TCNVP 2006 South Africa C 0 1 560 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRTKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRHMCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKIALESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGAETFYVDGAANRETKMGKAGYVTDKGRQKIVTLTETTNQKAELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESEIVNQIIEQLINKERIYLSWVPAHKGIGGNEQVDKLVSNGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101812 D4T3TCEFV 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIKELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKEDWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGEDQWTYQIYQEPFKILKTGKYAKRRTTHTNDVKQLTGAVQKIAQECIVIWGKTPKFRLPIQKETWETWWTNYWQATWIPEWEFVNTPPLVKLWYQLEKEPILGAETFYVDGAANRETRVGKAGYVTDRGRQKVISLTETTNQKTELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLINKERVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101813 D4T3TCEFV 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQTSMTKILDPFREQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGVKVKYLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDVRQLTEAVQKIALESVVIWGKTPRFRLPIQKETWDIWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPLIGVETFYVDGAANRETKIGKAGYVTDRGRQKVVTLTETTNQKTELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDNSESELVNQIIEQLIQKERVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101814 D4T3TCNVP 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIRIRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKILKTGKYAKMRSAHTNDVKQLVEAVHKIAQESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKMGKAGYVTDRGKQKIVSMTETTNQKTELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKERVYLSWVPAHKGIGGNEQVDKLVSNGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101815 D4T3TCEFV 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKITKIGPENPYNTPVFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQHPEIVIYQYVDDLYVGSDLEIGQHRATIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQDPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKIGLESIVIWGKTPKFRLPIQKETWEIWWTNYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGVETFYVDGAANRETKIGKAGYVTDRGRQKIVHLTETTNQKTELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNEIIEQLIKKDKVYLSWVPAHKGIGGNEQVDKLVSNGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101816 D4T3TCEFV 2007 South Africa C 0 1 560 PISPIETVPVTLKPGMDGPKVKQWPLSEEKIKALTEICTEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHREKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLIRGTKALTDIVPLTEEAELELAENREILREPVHGVYYDPSKDLIAEVQKQGNDQWTYQIYQEPFKNLKTGKYAKRRSAHTNDVKQLTEAVQKIASESIVIWGKTPKFRLPIQKETWEAWWTDYWQATWIPDWEFINTPPLVKLWYQLEKEPIAGVETFYVDGASNRDTKIGKAGYVTDRGRQKVVSLTETTNQKTELQAIQLALQDSGPEVNIVTDSQYALGIIQAQPDKSESEIVNQIVEQLIRKERVYLSWVPAHKGIGGNEQVDKLVSNGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101817 D4T3TCEFV 2006 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICGEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELRTHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVSLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGDDQWTYQIYQEPFKILKTGKYAKRRTAHTNDVKQLTEAVQKIAQECIVIWGKTPKFRLPIQKETWEIWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGAETFYVDGAANRETKMGKAGYVTDRGRQKIVSQSETTNQKTELQAILIALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKERVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101818 D4T3TCEFV 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDLVIYQYMDDLYVGSDLTIGQHREKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRHLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGDGQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKIAMESIVIWGKTPKFRLPIQKETWEAWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPILGAETFYVDGASNRETKAGKAGYVTDRGRQKVVTLTETTNQKSELQAIQLALQDSGPEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKERIYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101819 D4T3TCNVP 2008 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAKNPEIVICQYVDDLYVGSDLEIGQHRAKVEDLREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPTKDLIAELQKQGDDQWTYQIYQEPFKILKTGKYAKRRTAHTNDVKQLTEAVQKIAMESIVIWGKTPKFRLPIQKETWETWWTNYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGVETFYVDGAANRDTKLGKAGYVTDRGRQKIISITETTNQKTELQAIQLALQDSGPEVNIVTDSQYALGIIQAQPDKSESELVNQIIEELIKKERVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101820 D4T3TCNVP 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPINLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGEDQWTYQIYQEPFKILKTGKYAKRRTAHTNDVRQLTEAVQKISMESIVIWGRTPKFRLPIQKETWEAWWIDYWQATWIPEWEFVNTPPLVKLWYQLEKEPLAGVETFYVDGAANRETKIGKAGYVTDRGRQKVITINETTNQKTELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKERVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101821 D4T3TCNVP 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMLKILEPFRAQNPEVVICQYVDDLYVGSDLEIGQHRAKIEKLREHLLKWGFTTPEKKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGEDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDIKQLAEAVQKIATESIVIWGKTPKFRLPIQKETWEIWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGVETFYVDGAANRDTKMGKAGYVTDRGRQKVVTLTETTNQKTELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESEIVNQIIEQLVKKERVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101822 D4T3TCEFV 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLCVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDVKQLTEAVQKIAMESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKVGKAGYVTDRGRQKAITLAETTNQKTELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEELIKKERVYLSWVPAHKGIGGNEQVDKLVSKGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101823 D4T3TCEFV 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIEQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKENWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGNDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDIKQLTEAVQKISMESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKIGKAGYVTDKGRQKIVTLNETTNQKAELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVSQIIEQLIKKERVYLSWVPAHKGIGGNEQVDKLVSNGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101824 D4T3TCEFV 2008 South Africa C 0 1 560 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSCPLDEEFRKYTAFTIPSTNNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEIVPLTEEAELELAENREILREPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKILKTGKYAKTRTAHTNDVRQLIEAVQKIAQESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIPGAETFYVDGAANRETKIGKAGYVTDRGRQKIVSLNETTNQKTELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEELIKKERIYLSWVPAHKGIGGNEQVDKLVSRGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101825 D4T3TCNVP 2007 South Africa C 0 1 560 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALKEICEDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPDIVIYQYMDDLYVASDLNIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQTCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGAYYDPSKDLIAEVQKQGHDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLAETVQKIALESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAEAETFYVDGAANRETKLGKAGYVTDRGRQKIVSLNETTNQKAELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLINKDRIYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101826 D4T3TCNVP 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDLVIYQYVDDLYVGSDLEIEQHRAKIKELREHLLRWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGDDQWTYQIYQEPFKILKTGKYAKRRTAHTNDVKQLTEAVQKISLESIVIWGKIPKFRLPIQKETWEIWWTDYWQAT*IPEWEFVNTPPLVKLWYQLEKEPIAEAETFYVDGAANRETKIGKAGYVTDRGRQKIVTISETTNQKTELQAIQLALQDSGPEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIQKERVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101827 D4T3TCEFV 2005 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPRVKQWPLTGEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQG*KGSPAIFQSSMTKILEPFRKKNPDIVIYQYVDDLYVASDLEIGQHRAKIEELRQHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIRVRHLCKLLRGTKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGHDQWTYQIYQEPFKILKTGKYAKMRTAHTNDVKQLTEAVQKIALESIVIWGKTPKFRLPIQKNIWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRDTKLGKAGYVTDKGRQKIVALNETTNQKAELQAIQLALQDSGPEVNIVTDSQYALGIIQAQPDKSDSEIVTQIIEQLITKERVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101828 D4T3TCEFV 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKIALESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEYVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKIGKAGYVTDRGRQKIISLTETTNQKTELQAIKLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIRKDRVYLSWVPAHKGIGGNEQVDKLVSNGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101829 D4T3TCNVP 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKRSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRANNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILREPVHGVYYDPSKELIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKIAIESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGAETFYVDGAANRDTKIGKAGYITDRGRQKIISLTETTNQKTELKAIYLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVSQIIEQLINKERVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101830 D4T3TCNVP 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGDDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKVALESIVIWGKTPKFKLPIQKETWDIWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGAETFYVDGAAHRETKKGKAGYVTDRGRQKIVSLSETTNQKTELQAIQLALQDSGTEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKERVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101831 D4T3TCEFV 2008 South Africa C 0 1 560 PISPIETVPVRLKPGMDGPKVKQWPLTEEKIKALTAICNEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQTSMTKILEPFRTQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGDDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKISQESIVIWGKTPKFRLPIQKETWEIWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTDRGRQKIVSLTETTNQKTELQAIQLALQDSGPEVNVVTDSQYALGIIQAQPDKSESEIVNQIIEQLIKKERVYLSWVPAHKGIGGNEQVDKLVSNGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101832 D4T3TCNVP 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTLPSTNNATPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYPGIQVKHLCKLLRGAKALTDIVSLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKILKTGKYAKMRTAHTNDVRQLAEAVQKIALESIVIWGKTPKFRLPIQKEAWGTWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAAIRETKIGKAGYVTDRGRQKVISLSETTNQKAELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLINKERIYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101833 D4T3TCEFV 2006 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDRWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGEGQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKIALESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKDPIVGAETFYVDGAANRETKKGKAGYVTDRGRQKIVPLTETTNQKAELQAILLALQDSEVKVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLINKERIYMSWVPAHKGIGGNEQVDKLVSNGIRRVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101834 D4T3TCNVP 2006 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDIVICQYVDDLYVGSDLEIGQHREKIGELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKECWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGVKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGDDQWTYQIYQEPFKILKTGKYAKRRTTHTNDIKQLTDAVQKISMESIVIWGRTPKFRLPIQKETWDMWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKDPMTGVETFYVDGAANRETKIGRAGYVTDRGRQKVVTLTETTNQKTELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKERVYLSWVPAHKGIGGNEQVDKLVSNGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101835 D4T3TCEFV 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIMQHRAKIEDLREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKIALECIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGAETFYVDGAANRETKQGKAGYVTDRGRQKIVPLTETTNQKAELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESEIVNQIIEQLINKERIYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101836 D4T3TCNVP 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEQVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKILKTGKYAKMRTAHTNDVKQLTEAVQKIARESIVIWGKTPKFRLPIQKETWETWWTNYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGAETFYVDGAANRETKMGKAGYVTDRGRQKVVPLTETTNQKAELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLINKEKIYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101837 D4T3TCEFV 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREIIKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKHLKTGKYAKMRTAHTNDVKQLTEAVQKITLESIVIWGKAPKFRLPIQKETWETWWTNYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETRIGKAGYVTDRGRQKIVSLSETTNQKAELQAIQLALQDSGSEVNVVTDSQHALGIIQAQPDKSESEIVNQIIEQLINKERIYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101838 D4T3TCNVP 2006 South Africa C 0 1 560 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLTKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTANPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKILKTGKYAKMRTAHTNDVKQLIEAVQKIAMESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGAETFYVDGAANRETKLGKAGYVTNKGRQKIVSLTETTNQKAELQAIQLALQDSGLEVNIVTDSQYALGIIQAQPDKSESEIVNQIIEQLINKERVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101839 D4T3TCNVP 2008 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYVDDLYVGSDLEIGQHRVKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTIQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGCDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDIKQLTEAVQKIALESIVIWGKTPKFRLPIQKETWERWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAEAETFYVDGAANRETKLGKAGYVTDRGRQKIITITETTNQKTELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKEKVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101840 D4T3TCEFV 2008 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMVKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGDDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDVKQLTEVVQKISMECIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEYVNTPPLVKLWYQLEKEPIPGAETFYVDGAANRETKLGKAGYVTDKGRQKSVSLKETTNQKTELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIELLIKKEKVYLSWVPAHKGIGGNEQVDKLVSKGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101841 D4T3TCEFV 2008 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICADMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKIALESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKDPIAGAETFYVDGGANRDTKLGKAGYVTDRGRQKIISLPKTTNQKAELHAIQLALQDSGSEVNIVTDSQYALGIIQALPDKSESELVNQIIEQLINKERIYLSWVPAHKGIGGNEQVDKLVSKGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101842 D4T3TCEFV 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKISKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTRILEPFRTQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKIALESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGVETFYVDGAANRETKLGKAGYVTDRGRQKVVSLTETTNQKTELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEELIKKERVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101843 D4T3TCEFV 2006 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNSTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIDIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIHLPEKESWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGYDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLAEAVQKIALESIVIWGKIPKFRLPIQKETWEIWWTDYWQATWIPDWEFVNTPPLVKLWYQLEKEPIAGAETFYVDGAANRETKLGKAGYVTDRGRQKVVSLSETTNQKTELQAIQIALQDSGSEVNIITDSQYALGIIQAQPDKSESELVNQIIELLIKKERVYLSWVPAHKGIGGNEQVDKLVSKGIRRVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101844 D4T3TCEFV 2008 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSVNNATPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRRKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKYQKEPPFQWLGYEIHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIRVKHMCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGNDQWTYQIYQEPFKNLKTGKYAKMRSAHTNDIKQLTEVVQKIAMESIVIWGKTPKFRLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIPGAETFYVDGASNRETKVGKAGYVTDKGRQKVITLTETTNQKSELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESDLVNQIIEQLINKERIYLSWVPAHKGIGGNEQVDKLVSNGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101845 D4T3TCNVP 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLNKNKSXTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRAKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAEFELAENREILKEPVHGAYYDPSKDLIAEIQKQGDDQWTYQIYQEPFKNLKTGKYGKMRTAHTNDVKQLTEAVQKIALESIVIWGKTPKFRLPIQKETWEIWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGAETFYVDGAANRDTKIGKAGYVTDRGRQKVVSLSETTNQKTELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKERVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101846 D4T3TCNVP 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQASMTIILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDNWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVRNLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKILKTGKYAKRRTAHTNDVKQLTEAVQKIAMESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKQGKAGYVTDRGRQKSICLNETTNQKTELQAIQLALQDSGSEVNIVTDSQYALGIIQAHPDKSESELVNQIIEQLIKKERVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101847 D4T3TCNVP 2008 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKITRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRNHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTLQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILREPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKTLKTGKYAKMRTAHTNDVKQLTEAVQKIASESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGVETFYVDGAASRDTKVGKAGYVTDRGRQKVITISETTNQKTELQAIQLALQDSGSEVNIVTDSQYALGIIQALPDKSESELVNQIIEQLIKKERVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101848 D4T3TCNVP 2008 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVLAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKMRSAHTNDVKQLTEAVQKIALECIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGAETFYVDGAANRETKMGKAGYVTDRGRQKVVSITETTNQKTELQAIQLALQDSGLEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIQKERVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101849 D4T3TCEFV 2008 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLENNKSVTVLDVGDAYFSVPLDEGFRKYTAFTLPSMNNETPGIRYQYNVLPQGWKGSPAIFQASMTRILEPFRAQNPEMVIYQYVDDLYVASDLEIGQHRAKIEELRRHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGDDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDIKQLTEAVQKIAQESIVIWGKTPKFRLPIQKETWEIWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGAETFYVDGAANRETKMGKAGYVTDRGRQKITSLSETTNQKAELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSDSEIVNQIIEQLIKKEKVYLSWVPAHKGIGGNEQIDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101850 D4T3TCNVP 2006 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKNNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRNHLLKWGLTTPDKKHQKEPPFLWLGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYPGIQVRHLCKLLRGTKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGDGQWTYQIYQEPFRNLKTGKYAKMRTAHTNDVKQLTEAVQKITLESIVIWGKTPKFRLPIQKETWETWWTDYWQATCIPEWEFVNTPPLVKLWYQLEKEPIAGAETFYVDGAANRDTKMGKAGYVTDKGRQKIVTLNETTNQKAELQAIQLALQDSGLEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLINKERIYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101851 D4T3TCNVP 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAQALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGEDQWTYQIYQEPFKILKTGKYAKRRTAHTNDVKQLTEAVQKICRESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPMAGVETFYVDGAANRETKVGKAGYVTDRGRQKVITLNETTNQKTELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESEIVNQIIEELIKKERVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101852 D4T3TCEFV 2006 South Africa C 0 1 560 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRRHLLEWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGENQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKIALESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKDPIAGAETFYVDGAANRETKMGKAGYVTDRGRQKVVTISETTNQKTELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKERVYLSWVPAHKGIGGNEQVDKLVSNGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101853 D4T3TCEFV 2006 South Africa C 0 1 560 PISPIETIPVKLKPGMDGPKVKQWPLTKEKIEALTAICKEMEKEGKITKIGPDNPYNTPIFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFREKNPGIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGDDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKISMECIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGAETFYVDGAANRETKIGKAGYVTDKGRQKVVSISETTNQKTELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKERVYLSWVPAHKGIGGNEQVDKLVSRGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101854 D4T3TCEFV 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPYRIKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGYDQWTYQIYQEPFKNLKTGKYAKMKTTHTNDVKQLTEAVQKIALESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKDPIAEAETFYVDGAANRETKLGKAGYVTDRGRQKIVSLNETTNQKAELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLINKERVYLTWVPAHKGIGGNEQVDKLVSRGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101855 D4T3TCEFV 2008 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPDIVIYQYMDDLYVGSDLEIGQHREKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKRRTTHTNDVKQLTEAVQKIALESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLETEPMAGIETFYVDGAANRETKMGRAGYVTDRGRQRVINLTETTNQKAELQAIQLALQDSGLEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIQKEKVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101856 D4T3TCEFV 2006 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPDIVIYQYVDDLYVSSDLEIGQHREKIKELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKRRSAHTNDVKQLTEAVQKIATESIVIWGKVPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGAETFYVDGAANRDTKLGKAGYVTDRGRQKIVSLTETTNQKTELHAIYLALQDSGSEVNIVTDSQYALGIIQAQPDKSESEIVNKIIEQLIRKERVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101857 D4T3TCEFV 2008 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRARNPEIVIYQYVDDLYVGSDLEIEQHRAKIEELREHLLKWGFTTPDKKHQKEHPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGDDQWTYQIFQEPFKNLKTGKYTKRRAAHTNDVKQLTEAVQKIAMESIVTWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGVETFYVDGAANRETKLGRAGYVTDRGRQKVVPLTETTNQKAELQAIQLALQDSGLEANIVTDSQYALGIIQVQPDKSESELVNQIIEQLINKERVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101858 D4T3TCEFV 2008 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSTNNEKPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGHDQWTYQIYQEPFKILKTGKYAKMRTAHTNDVKQLTEAVQKIALESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGAETFYVDGAANRETKMGKAGYVTDRGRQKIVSLNETTNQKAELQAIQLALQDSGLEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLINKERIYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101859 D4T3TCEFV 2008 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKAITEICDEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDPDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLHVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEHPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIIPLTEEAELELAENREVLKEPVHGAYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKVKAAHTNDVRQLAEAVQKITMESIVIWGKAPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKDPIIGAETFYVDGAANRETKIGKAGYITDRGRQKIVSLNETTNQKAELQAIQLALQDSEAEVNIVTDSQYALGIIQAQPDKSESEIVNQIIEQLINKERVYLSWVPAHKGIGGNEQVDKLVSTGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101860 D4T3TCEFV 2008 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFVIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPSIFQASMTKILEPFRTENPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLKGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGDDQWTYQIYQDPFKNLKTGKYAKMRSAHTNDVKQLIEAVQKIALESIVIWGKTPKFRLPIQKETWEIWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIQGVETFYVDGAANRETKMGKAGYVTDRGRQKIIQLTETTNQKTELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKERVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101861 D4T3TCEFV 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLHVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKIALESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKDPIAGAETFYVDGAANRETKIGKAGYVTDQGRQKIITLNETTNQKAELQAIQLALQDSGLEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLINKERVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101862 D4T3TCEFV 2006 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSRNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVASDLEIEQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGHELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLIRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKSRSAHTNDVKQLTEAVQKIARESIIIWGRTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKDPIAGVETYYVDGAANRETKIGKAGYVTDKGRQKIITLNETTNQKAELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIQKERIYLSWVPAHKGIGGNEQVDKLVSKGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101863 D4T3TCEFV 2007 South Africa C 0 1 560 PISPIETVPVKLKPGTDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDEKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGDDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKIALESIVIWGKTPKFRLPIQKETWEIWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKDPIAGAETFYVDGASHRETKKGKAGYVTDRGRQKIINLSETTNQKAELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKERVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101864 D4T3TCNVP 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQYSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIQVKQMCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDSSKELVAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVRQLTEVVQKISVESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPDWEFVNTPPLVKLWYQLEKEPIAGAETFYVDGAANRETKIGKAGYVTDRGRQKVVPLTETTNQKTELQAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIRKERVYLSWVPAHKGIGGNEQVDKLVSNGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101865 D4T3TCEFV 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDIIPLTEEAELELAENREILREPVHGVYYDPSKELIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDVKQLTEAVQKIATESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGVETFYVDGAANRETKIGRAGYVTDRGRQKIITLNETTNQKTELQAIHLALQDSGSKVNIVTDSQYALGILQAQPDKSESELVNQIIEQLIKKEKIYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101866 D4T3TCEFV 2006 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQCSMLKILEPFRAKNPEIVIYQYVDDLYVGSDLEIEQHRAKIEELREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKKKSTHTNDVKQLTDAVQKIAMESIVIWGKTPKFRLPIQKETWDTWWSDYWQATWIPEWEFVNTPPLVKLWYQLEKDPIVGVETFYVDGAANRETKLGKAGYVTDKGRQKVVSLTDTTNQKTELQAIKLALQDSGAEVNIVTDSQYALGIIQAQPDNSESELVNQIIEQLIKKERVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101867 D4T3TCEFV 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPRVRQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSTMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGVKVKHLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGDDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDVKQLTEAVQKIALESIVIWGKTPKFRLPIQKETWEIWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGVETFYVDGAASRETKMGRAGYVTDRGRQKVVSLSETTNQKTELHAIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVSQIIEQLIKKERVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101868 D4T3TCEFV 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTLPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIDIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDNWTVNDIQKLVGKLNWASQIYSGIQVRQLCKLLKGAKALTDIVPLTEEAELELAENREILKEQVHGVYYDPSKDLIAEIQKQGHGQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKIAMESIVIWGKTPKFRLPIQKETWETWWSDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGAETFYVDGAANRETKTGKAGYVTDKGRQKIVSLNETTNQKAELQAIQLALQDSGLEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLVNKERIYLAWVPAHKGIGGNEQVDKLVSKGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101869 D4T3TCEFV 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKGSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRTKNPEIVIYQYVDDLYVQSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDIKQLTEAVQKIATESIVIWGRIPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTDRGKQKVVSITETTNQKTELQAIHLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKERVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101870 D4T3TCNVP 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDIKQLTEAVQKIATESIVIWGRIPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIIGAETFYVDGAANRETKLGKAGYVTDRGKQKVISITETTNQKTELQAIYLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIQKEKVYLSWVPAHKGIGGNEQVDKLVSSGIRKVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2031 101871 D4T3TCEFV 2007 South Africa C 0 1 560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTVPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKQPVHGVYYDPSKELIAEIQKQGNDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLIEAVQKIAVESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAGVETFYVDGAANRETKLGKAGYVTDKGRQKVVSLAETTNQKTELQAIWLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVSQIIEELIKKERVYLSWVPAHKGIGGNEQVDKLVSNGIRRVL Brehm, JH 2012 22618567 Clin Infect Dis Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. 2086 111935 D4T3TCNVP 2006 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSITVLDVGDAYFSVPLHESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKYQKEPPFLWLGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111936 D4T3TCNVP 2006 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYIDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111937 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKLKALTEICEEMEKEGKISKIGPENPYNTPVFAIQNKDRTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTLPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMIICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111938 D4T3TCNVP 2006 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPTIFQCSMTKILEPFRMKNPEIVICQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111939 D4T3TCNVP 2006 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPELVICQYVDDLYVGSDLEIGQHRTKIEELRDHLLKWGLTTPDKKHQKEPPFHWMGYELHPDKW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111940 D4T3TCNVP 2006 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICMEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKNKSITILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEMTIYQYVDDLYVGSDLEIGQHRTKIEELRSHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111941 D4T3TCNVP 2006 Cambodia CRF01_AE 1 24 239 WPLTKEKIEALTEICNEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVGSDLEIEQHRTKIEELRGHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111942 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNQTPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEIIIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDTW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111943 D4T3TCNVP 2008 Cambodia CRF01_AE 1 25 239 PLTEEKIKALTKICKEMEEEGKISKIGPENPYNTPVFTIKNKDGTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPTIFQSSMIKILEPFRTKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGLTTPDRKHQKEPPFLWMGYELHPDKW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111944 D4T3TCNVP 2006 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRSHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111945 D4T3TCNVP 2009 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIYKKNSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMIIYQYVDDLYVSSDLEIGQHRAKIDELRAHLWSWGFFTPDKKHQKEPPFLWMGYELHPDKW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111946 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTAFCEELEKEGKISKIGPENPYNTPVFAIKRKDGTTWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSISVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPDIVICQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGLTTPDKKYQKEPPFLWMGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111947 D4T3TCNVP 2006 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRTKIEELREHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111948 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKLKALTEICKEMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEMVICQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111949 D4T3TCNVP 2007 Cambodia CRF01_AE 1 24 239 WPLTEEKLKALTEICKEMEEEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRRKNPELVICQYVDDLYIGSDLEIGQHRTKIEELRAHLLSWGFSTPDKKHQKEPPFLWMGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111950 D4T3TCNVP 2005 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICKEMEEEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFFTPDKKHQKEPPFRWMGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111951 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111952 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRRKIEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111953 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTILDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIIICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFFTPDKKHQKEPPFLWMGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111954 D4T3TCNVP 2008 Cambodia B 1 24 239 WPLTEEKIKALTEICREMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIEQHRTKIEELRHHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111955 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIEQHRRKIEELRAHLLRWGFTTPDKKYQKEPPFLWMGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111956 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKIKVLTEICKEMEEEGKISKIGPENPYNTPIFAIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYYSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSCMTKILEPFKIKNPELVICQYMDDLYVGSDLEIGQHRRKIEELRAYLLSWGFTTPDKKYQKEPPFLWMGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111957 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKIKVLTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYYSVPLDESFRKYTAFTIPSINNQTPGIRYQYNVLPMGWKGSPAIFQCSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111958 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLMDLRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYYSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPTIFQSSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111959 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEIIICQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFITPDKKHQKEPPFLWMGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111960 D4T3TCNVP 2007 Cambodia CRF01_AE 1 24 239 WP*TEEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQQKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEMIIYQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111961 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEMVIYQYVDDLYVASDLEIGQHRIKIKELRDHLLRWGFTTPDKKHQKEPPFLWMGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111962 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFFTPDEKHQKEPPFHWMGYELHPDKW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111963 D4T3TCNVP 2009 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICKEMEEEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRQKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNEIPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMIICQYVDDLYVGSDLEIGQHRAKIEELRGHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111964 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111965 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICNELEQDGKISKIGPENPYNTPVFAIKKKNSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLAKKKSITVLDVGDAYFSIPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQDSMTKILEPFRRKNPEMIICQYVDDLYVASDLEIGQHRTKIEELRAHLWNWGFYTPDKKHQKEPPFLWMGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111966 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKLKALKEICEEMEKEGKISKIGPENPYNTPVFVIKKKDGTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYYSVPLDEDFRKYTAFTIPSINNGTPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRIKNPDMIIYQYVDDLYVASDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111967 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111968 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTQICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDENFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFRWMGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111969 D4T3TCNVP 2009 Cambodia CRF01_AE 1 24 239 WPLTKEKIQALTEICKEMEEDGKISKIGPENPYNTPVFAIRKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSIPLDEGFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRRKYPDIVIYQYVDDLYVASDLEIGQHRTKIEELRAHLSNWGFYTPDKKHQKEPPFLWMGYELHPDKW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111970 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTRNPEMVIYQYVDDLYVASDLEIRQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFRWMGYELHPDKW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111971 D4T3TCNVP 2009 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICNELEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDESFRKYTAFTLPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRVKNPEIVICQYVDDLYVASDLEIGQHRAKIEELRSHLLSWGLITPDKKYQKEPPFLWMGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111972 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKLKALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRTKIEELRSHLLSWGFYTPDKKHQKEFPFLWMGYELHPDKW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111973 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICNEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111974 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICKKMEEEGQISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEDLRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111975 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKLKALTEICTEMEKEGKISKIGPENPYNTPVFVIKKKDSAKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLQRKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAKNPEIMICQYVDDLYVGSDLEIGQHRTKIEELREHLLRWGFTTPEKKHQKEPPFLWMGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111976 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIKELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111977 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKKNPEIVIVQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111978 D4T3TCNVP 2009 Cambodia CRF01_AE 1 24 239 WPLTEEKLKALTEICKEMEEEGKISKIGPENPYNTPVFVIKKKESTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDIGDAYFSVPLHEDFRKYXAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPELIICQYIDDLYVGSDLEIGQHRTKIEELRAHLWNWGFFTPDKKHQKEPPFHWMGYELHPDKW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111979 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKHSNRWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIIICQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFITPDEKHQKEPPFLWMGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111980 D4T3TCNVP 2007 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111981 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTAEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111982 D4T3TCNVP 2009 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKILDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGLTTPDKKYQKEPPFLWMGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111983 D4T3TCNVP 2008 Cambodia CRF01_AE 1 24 239 WPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTLPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKENPEIIIYQYVDDLYVASDLEIGQHRTKIEELRAHLLRWGFTTPDKKYQKEPPFLWMGYELHPDKW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111984 D4T3TCNVP 2009 Cambodia CRF01_AE 1 24 239 WPLTKEKIKALTEICKEMEEEGKISKIGPENPYNTPVFVIKKKNSTKWRKLIDLRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYYSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQASMTKILEPFRKENPEMVIYQYVDDLYVASDLEIGQHRTKIEKLRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2086 111985 D4T3TCNVP 2009 Cambodia CRF01_AE 1 24 239 WPLTEEKLKALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKGSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRMKNPEMVICQYVDDLYVASDLEIGQHRTKIEELRAHLLNWGFTTPDKKHQKEPPFLWMGYELHPDRW Coetzer, M 2013 23506238 ARHR Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-Line antiretroviral therapy by WHO 2010 guidelines. 2122 115220 TDF3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVRQWPLTEEKIKALTEICKEMEKEGQITKIGPENPYNTPIFAIKRKDNTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSTMTKILEPFRARNPEIVIYQYVDDLYVGSDLEIGQHREKIEELREHLLKWGFTTPDQKYQKEPPFLWLGYEIHPDKWTVQPIQLPEKESWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115221 D4T3TCEFV 2010 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRVKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115223 D4T3TCEFV 2007 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIRQHRAKIEELREHLLKWGFTTPDKKHQKEPPLLWLGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115224 D4T3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSMTVLDVGDAYFSVPLDETFRKYTAFTIPSLNNATPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPDIVIYQYVDDLYVGSDLEIGQHRAKIEDLREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115226 D4T3TCEFV 2007 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLNPNFRKYTAFPIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILKPFRARNPKLVIYQYVDDLYVGSDLEIGQHRAKIDELRNHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115227 D4T3TCEFV 2012 South Africa C 0 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKRKDS~KWRKLMDFRELNKRTQEFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPELVICQYMDDLYVASDLEIGQHRAKIEDLREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115228 D4T3TCEFV 2009 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFREQNPELVIYQYMDDLYVASDLEIGQHRAKIEKLRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115230 D4T3TCEFV 2012 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115231 TDF3TCNVP 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMAICEEMEKEGKITKIGPENPYNTPVFVIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115233 D4T3TCEFV 2012 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFATKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSMTILDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEVVIYQYVDDLYVGSDLEIGQHRAKIEKLREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115234 D4T3TCEFV 2011 South Africa C 0 1 252 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEVVIYQYVDDLYVGSDLEIGQHRAKIEKLRDHLLKWGFTTPDKKHQKEPPFLWMGHELHPDKWTVQPIQLPEKDSW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115235 D4T3TCNVP 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALMAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVICQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKYQKEPPFRWMGYELHPDKWTVQPIQLPEKESWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115236 D4T3TCNVP 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSTMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115240 TDF3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICDEMEKEGKITKIGPENPYNTPIFAIKRKDN~KWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPDIVICQYMDDLYVTSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115241 D4T3TCEFV 2009 South Africa C 1 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSINNERPGIRYHYNVLPQGWKGSPAIFQSSMTRILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115242 ABC3TCEFV 2011 South Africa C 0 1 219 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKRSKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQTSMTKILEPFRAQNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLGWGFTTPDK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115243 D4T3TCEFV 2006 South Africa C 0 1 263 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTRILEPFRAKNPEIVIYQYVDDLYVGSDLEIMQHRAKVEELRQHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115246 AZT3TCEFV 2009 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQREPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115247 D4T3TCEFV 2009 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSAKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPSIFQSSMTKILEPFRARNPELVIYQYVDDLYVGSDLEIMQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115249 D4T3TCEFV 2012 South Africa C 1 1 256 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPDLVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115252 AZT3TCNVP 2006 South Africa C 1 1 344 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEHFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFRWLGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIQVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGHDQWTYQIYKE Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115253 D4T3TCEFV 2012 South Africa C 0 1 260 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDGTEWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEEFRKYTAFTIPSVNNQTPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYVDDLYVESDLEIGQHRAKIEELRGHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKL Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115254 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115255 D4T3TCNVP 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTREKIEALKAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSTMTKILEPFRAQNPEMVICQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115258 D4T3TCNVP 2008 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMAKILEPFRTRNPDLIICQYMDDLYVGSDLELGQHRAKIEELREHLLKWGSTTPDNKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115259 D4T3TCEFV 2010 South Africa C 1 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115261 D4T3TCEFV 2009 South Africa C 1 1 257 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALMAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPEIIIYQYMDDLYVGSDLEIGQHRAKVEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115262 TDF3TCEFV 2011 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEMVIYQYIDDLYVQSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115263 D4T3TCNVP 2010 South Africa C 0 1 250 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKITKIGPENPYNTPVFAIKKKDGAKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFFTPDKKYQKEPPLLWLGYELHPDKWTVQPIQLPTKD Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115264 D4T3TCEFV 2006 South Africa C 0 1 345 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQRNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAXIEELRDHLLKWGFTTPDKKXQKEHPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEP Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115267 D4T3TCEFV 2007 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQASMTKILEPFRSKNPEIIIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPDKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115269 D4T3TCEFV 2010 South Africa C 1 1 160 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSCPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGW*GSPAIF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115272 TDF3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFVIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLIKKKSMTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLEWGFTTPDKKYQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115273 D4T3TCEFV 2007 South Africa C 1 1 247 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRNHLLKWGFYTPDKKHQKEHPFLWLGYELHPDKWTVQPIQLP Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115274 TDF3TCEFV 2011 South Africa C 0 1 223 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLDIKQHRAKIEELRAHLLKWGFTTPDKKHQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115275 TDF3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVQLKPGMDGPKVKQWPLTEETIKALTEICEEMEKEGKITKLGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPDIVIYQYMDDLYVGSDLEIGQHRAKIDDLRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115279 TDF3TCEFV 2012 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKINALKAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQRLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115280 ABC3TCEFV 2011 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIQALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNRRTQDFWEVQLGIPHPAGIKKRKSVTVLDVGDAFFSVPLDESFRKYTAFTIPSVNNKTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPGIDIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDKKYQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115283 D4T3TCEFV 2010 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSLNNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSRNPNMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEHPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115284 D4T3TCNVP 2010 South Africa C 0 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWKVQPIELPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115285 AZT3TCNVP 2011 South Africa C 1 1 225 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEP Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115288 TDF3TCNVP 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICDEMEKEGKISKIGPENPYNTPVFAIKRKDNTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVICQYVDDLYVGSDLEIGQHRAKIEELRHHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115289 D4T3TCEFV 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAANPEIIIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115291 TDF3TCEFV 2012 South Africa C 0 1 261 PISSIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPFNTPVFAIKKRNSTEWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRSQNPEIVICQYVDDLYVASDLEIGQHRAKIEELRNHLLKWGFTTPDKKHQKEPPFHWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115292 D4T3TCEFV 2008 South Africa C 1 1 239 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDTW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115293 D4T3TCNVP 2007 South Africa C 1 1 262 PISPIKTVPVKLKPGMDGPRVKQWPLTKEKIEALTAICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLTKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFHWMGYELHPDRWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115296 TDF3TCEFV 2011 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPGIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115297 D4T3TCEFV 2010 South Africa C 1 1 258 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIRALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEMVIYQYVDDLLVGSDLEIGQHRAKIEELREHLFRWGFTTPDKKHQKEPPFHWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115299 D4T3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQEWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIEQHRAKIEELRKHLLAWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115300 ABC3TCEFV 2010 South Africa C 1 1 258 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNASPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPDIVIYQYVDDLYVGSDLEIGKHRAKVEELRAHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115301 D4T3TCNVP 2012 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSATVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPGIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115302 D4T3TCEFV 2011 South Africa C 0 1 257 PISPIKTVPVKLKPGMDGPKVKQWPLTKEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIKELREHLLKWGFTTPDQKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115303 AZT3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTDICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLWKWGFYTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115304 D4T3TCEFV 2011 South Africa C 0 1 262 PISPIDTVPVTLKPGMDGPKVKQWPLTKEKIEALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLMDLRELNKRTQDFWEVQLGIPHPAGLEKSKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115305 TDF3TCNVP 2011 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVRQWPLTEEKIKALTEICEEMEKEGKITKIGPDNPYNTPVFAIKKKNSTNWRKLVDFRELNKRTQDFWEVQLGIPHPAGLPKNKSVTVLDVGDAYYSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRIQNPELIIYQYVDDLYVGSDLEIEQHRAKIEKLRDHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPKKDSWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115306 D4T3TCEFV 2008 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDLVIYQYVDDLYVGSDLEIGQHREKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115308 D4T3TCEFV 2010 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTVICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNRRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115309 D4T3TCEFV 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKRKNSPKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKKKSMTVLDVGDAFFSVPLDENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPEIVIYQYMDDLCVGSDLEIGQHRAKIEELREHLLRWGFTTPEKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115310 TDF3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRARNPEIIIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPDKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115311 D4T3TCEFV 2011 South Africa C 1 1 258 PISPIEPVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFKELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVESDLEIVQHRAKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115313 TDF3TCEFV 2012 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPDNPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIDIYQYVDDLYVGSDLEIGQHRAKIDELRNHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115314 D4T3TCEFV 2011 South Africa C 1 1 257 PISPIEIVPVKLKPGMDGPKVKQWPLTEEKIKALLAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTTQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115315 TDF3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115322 D4T3TCEFV 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLKWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115324 D4T3TCEFV 2008 South Africa C 0 1 261 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLCVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115326 D4T3TCEFV 2010 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115327 D4T3TCEFV 2009 South Africa C 0 1 256 PISPIEPVPVKLKPGMDGPRVKQWPLTEEKIRALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKINELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115329 D4T3TCEFV 2007 South Africa C 1 1 332 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPVFAIKRKGGTEWRKLVDFRELNKRTQDFSEVQLGIPHPAGLEKKKSMTVIDVGDAYFSVPLDESFRKYTAFTIPSLNNQTPGVRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPELVICQYVDDLYVASDLEIGQHRAKIEKLRDHLLKWGLTTPDRKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115331 AZT3TCEFV 2009 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRGHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115334 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEKLRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115335 AZT3TCNVP 2010 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKIKELREHLLKWGFSTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115336 D4T3TCEFV 2010 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRRHLLQWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115338 D4T3TCEFV 2011 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGEHRTKVEELRGHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115339 TDF3TCEFV 2011 South Africa C 0 1 248 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPIFALKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSMPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVICQYMDDLYVGSDLEIGQHRAKVEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPE Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115341 D4T3TCEFV 2010 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQDSMLKILKPFRAQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQAIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115342 D4T3TCEFV 2007 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKRKDSNKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYIDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115343 TDF3TCNVP 2011 South Africa C 0 1 260 PISPIETVPVKLKPGMDGPKVKQWPLTEDKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKRKDNTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEITICQYVDDLYVASDLEIGQHRAKIEELRAHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPVKESWTVNDIQKL Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115344 ABC3TCEFV 2009 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPSGIKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFNWMGYELHPDKWTVQPIMLPDKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115345 ABC3TCEFV 2010 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFVIKRKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKRSKSMTVLDVGDAFFSVPLDEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPICLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115346 D4T3TCEFV 2009 South Africa C 0 1 252 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRTKNPGIVIYQYVDDLYVGSDLEIGQHREKIEELRKHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115347 D4T3TCEFV 2012 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICGEMEKEGKISKIGPENPYNTPVFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSMTVLDVGDAYFSVPLDESFKKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPDIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115349 D4T3TCEFV 2010 South Africa C 1 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNKTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVQSDLEIGQHRAKIEELREHLLRWGFTTPDNKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115354 TDF3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIDIYQYVDDLYVGSDLEIGQHRAKIKELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115355 AZT3TCNVP 2010 South Africa C 0 1 124 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDEGF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115356 TDF3TCEFV 2011 South Africa C 0 1 223 PISTIETVPVKLKPGMDGPKVKQWPLTEEKIKALMAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIEQHRAKVEELREHLLKWGFTTPDKKHQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115357 D4T3TCEFV 2011 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICDEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFSEVQLGIPHPAGLKQKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNKTPGIRYQYNVLPQGWKGSPAIFQHSMTKILEPFRTKNPNIVIYQYVDDLYVGSNLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKKPPFLWMGYELHPDKWAVQPIHLPEKESWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115358 D4T3TCEFV 2008 South Africa C 1 1 223 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKRKDGTKWRKIVDFRELNKRTQDFCEIQLGIPHPAGLRKNKSMTVLDVGDAFFSIPLDESFRKYTAFTIPSINNEKPGTRYQYNVLPQGWKGSPAIFQASMIKILEPFRAKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEQLREHLLKWGLTTPDKKHQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115359 TDF3TCEFV 2011 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIRKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRTQNPDIVIYQYIDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115361 TDF3TCNVP 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKRKDNTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKRKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTQNPEIDICQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115362 D4T3TCEFV 2008 South Africa C 1 1 257 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGHHRAKIEELRNHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQTIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115363 D4T3TCEFV 2011 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIVLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115365 D4T3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKNSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115366 D4T3TCEFV 2011 South Africa C 0 1 252 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAENPEIVIYQYVDDLYIGSDLEIGQHRAKIEELREHLLKWGFTTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115367 D4T3TCEFV 2008 South Africa C 0 1 258 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPSGLQKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTLPSINNGTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYVDDLYVGSDLEIGQHRIKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115368 D4T3TCEFV 2009 South Africa C 1 1 255 PISPITTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRVHLLKWGFTTPDKKHQKEPPFHWMGYELHPDKWTVQPIQLPEKDSWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115369 TDF3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICDEMEKEGKISKIGPENPYNTPIFAIKKKGSTEWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAFFSVPLDESFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYMDDLYVESDLEIRQHRAKIEELREHLLRWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115371 D4T3TCEFV 2011 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115372 AZT3TCEFV 2006 South Africa C 1 1 342 PISPIDTIPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRTQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIMLPEKENWTVNDIQKLVGKLNWASQIYPGIKVRHLCKLLRGAKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIY Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115373 D4T3TCEFV 2010 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKGSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPELVIYQYVDDLYVGSDLEIEQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115374 D4T3TCEFV 2007 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRANNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115376 ABC3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGPHREKIEELREHLLKWGFTTPDKKYQKEHPFLWMGYELHPDKWTVQPIQLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115379 TDF3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPYREKNPEIVIYQYMDDLYVGSDLEIKEHRAKIKELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115380 TDF3TCEFV 2010 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115381 AZT3TCEFV 2007 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFTIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFREQNPDIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115385 ABC3TCEFV 2012 South Africa C 0 1 262 PISSIETVPVKLKPGMDGPKVKQWPLSEEKIKALTEICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPEIDIYQYVDDLYVGSDLEIGQHRAKIKELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115387 D4T3TCEFV 2012 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEDMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKVVDFRELNRRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILDPFRKENPEIGIYQYVDDLYVDSDLEIGQHRAKVEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115388 TDF3TCEFV 2011 South Africa C 0 1 262 PISPIETVPVTLKPGMDGPRVKQWPLTEEKIKALKEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPDIVIYQYVDDLYVGSDLEIGQHREKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115389 ABC3TCEFV 2011 South Africa C 1 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITRIGPENPYNTPVFVIKRKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAFFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCIMTKILEPFRAQNPEIVIYQYVDDLCVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115390 D4T3TCNVP 2011 South Africa C 0 1 259 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPEMVIYQYVDDLWVGSDLQIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115391 D4T3TCEFV 2011 South Africa C 1 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLLVASDLEIGQHRAKIEELRKHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115392 TDF3TCEFV 2011 South Africa C 0 1 256 PISPIETVPVKLKAGMDGPKVRQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKRKDGTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115394 TDF3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRTQNPDIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115395 AZT3TCEFV 2009 South Africa C 0 1 260 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIKELRKHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKL Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115399 AZT3TCEFV 2009 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNELEKEGKITKIGPENPYNTPVFVIKKKNSNRWRKLTDFRELNKRTQDFWEVQLGIPHPAGLKKNRSMTVLDVGDAYFSVPLDENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLWKWGFYTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115400 D4T3TCEFV 2010 South Africa C 1 1 238 PISPVETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNEAPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYVDDLYVGSDLEIGQHRAKVAELREHLLKWGLTTPDKKHQKEPPLLWMGYELHPDK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115402 D4T3TCEFV 2011 South Africa C 0 1 262 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMTRILEPFRARNPELVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115403 D4T3TCEFV 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTIQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115404 D4T3TCNVP 2012 South Africa C 0 1 262 PISPIETVPVQLKPGMDGPKVKQWPLTKEKIKALTEICEELEKDGKITKIGPENPYNTPIFAIKKKDSDKWRKLVDFRELNKRTQDFFEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEMVIYQYVDDLYVGSDLEIGQHRAKIDELRAHLSKWGFYTPDKKHQTDPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115405 D4T3TCEFV 2008 South Africa B 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSIPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDLVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115408 AZT3TCEFV 2007 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSLNNKTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGPHRAKIDELRAHLLKRGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115409 TDF3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTEICEEMEKEGKITKIGPDNPYNTPIFAIKKKGSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVIYQYVDDLYVGSDLEIEQHRAKIEELRAHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115413 D4T3TCEFV 2012 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKEMEKEGKITKIGPDNPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTRILEPFRANNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115414 D4T3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEMVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTIQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115415 D4T3TCEFV 2011 South Africa C 0 1 251 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSIMRRILDPFRAQNPEMAICQYVDDLYVGSDLEIEQHRAKIEKLREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIELPEKES Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115416 D4T3TCEFV 2006 South Africa C 1 1 341 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKITKIGPENPYNSPVFAIKKKNSTRWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQGSMTKILEPFRAKNPEIVIYQYIDDLYVQSDLEIGQHRAKIVELRKHLLQWGLTTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGDDQWTYQI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115417 D4T3TCEFV 2010 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115419 D4T3TCNVP 2012 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPTIFQSSMTKILEPFRAKNPELIICQYVDDLYVGSDLEIGQHRAKIEDLRAHLLKWGLTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115420 TDF3TCEFV 2011 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115423 TDF3TCEFV 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTKEKLEALTAICEEMEKEGKISKIGPENPYNTPVFAIKRKDGTKWRKLVDFRELNKRTQDFSEVQLGIPHPAGLKRKKSMTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSTMTKILEPFRKQNPDIDICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115424 D4T3TCEFV 2010 South Africa C 1 1 252 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRQHLLAWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115425 D4T3TCEFV 2010 South Africa C 0 1 252 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGKRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPDIVIYQYIDDLHVGSDLEITQHREKVEELRQHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115426 ABC3TCEFV 2011 South Africa C 0 1 258 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEEFRKYTAFTIPSINNETPGVRFQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115428 AZT3TCEFV 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAELKRKKSMTVLNVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTQNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLRWGLFTPDQKHQKEPPFHWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115429 D4T3TCEFV 2006 South Africa C 0 1 341 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKAITEICNKMEKEGQISKIGPDNPYNTPVFAIKRKDKF~WRKLMDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAQNPEIIIYQYVDDLYVGSDLEIGQHRAKVKELREHLLKWGLTTPDRKHQEEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGTKALTEIVPLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGHDQWTYQI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115432 D4T3TCNVP 2009 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVICQYVDDLYVGSDLEIRQHRAKVEELREHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115433 D4T3TCEFV 2010 South Africa C 1 1 257 PISPIETVPVQLKPGMDGPRVKQWPLTEEKIKALTEICEEMEREGQITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTILDVGDAYFSIPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELVIYQYVDDLYVGSDLEIGQHRAKIKELREHLLKWGFTTPEHKHQKEPPLLWMGYELHPDKWTVQPIQLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115434 AZT3TCEFV 2010 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDLEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLWKWGFYTPDKKHQKEHPFQWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115435 ABC3TCEFV 2011 South Africa C 1 1 252 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGKRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYMDDLYVESDLELGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115436 AZT3TCEFV 2009 South Africa C 0 1 260 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKL Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115438 D4T3TCEFV 2007 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTREKIEALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115443 D4T3TCEFV 2008 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115444 D4T3TCEFV 2007 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSAKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPEMTIYQYVDDLYVGSDLEIGQHRAKIGELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115448 ABC3TCEFV 2011 South Africa C 0 1 260 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYYSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKL Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115450 D4T3TCEFV 2009 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEKLREHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115451 TDF3TCEFV 2011 South Africa C 0 1 260 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNEVPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRKENPDLVICQYIDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKYQKEPPFLWMGYELHPNKWTVQPIQLPEKESWTVNDIQKL Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115454 TDF3TCNVP 2012 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKKWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTQWRKLVDFRELNKRTQDFWEIQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQTIELPDKESWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115455 D4T3TCEFV 2010 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKVGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIIIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115456 D4T3TCEFV 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICDEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPINLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115457 D4T3TCEFV 2008 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPDNPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLCVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115458 AZT3TCNVP 2011 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKRKKSMTVLDVGDAYFSIPLDESFRKYTAFTIPSMNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115459 D4T3TCEFV 2012 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGKRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDVVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115461 D4T3TCEFV 2010 South Africa C 1 1 257 PISHIETVPVELKPGMDGPKVKQWPLTEEKIKALTAICEEMDKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNATPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPGIVIYQYMDDLYVGSDLEIGQHRAKVEELREHLLGWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115463 D4T3TCEFV 2011 South Africa C 1 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICKEMEEEGKITKIGPENPYNTPIFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIDIYQYVDDLYVGSDLEIGQHRAKIEELRGHLLKWGLTTPDKKLQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115464 TDF3TCEFV 2011 South Africa C 0 1 233 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTRILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLRWGFTTPDKKHLKEPPFLWMGYE Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115465 D4T3TCEFV 2011 South Africa C 0 1 258 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115466 D4T3TCEFV 2011 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKIIKIGPDNPYNTPVFVIKKKDSTKWRKLVDFKELNKRTQDFWEVQLGIPHPAGLKKSKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELRSHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEQDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115467 D4T3TCEFV 2008 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNRRTQDFWEVQLGIPHPSGLEKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQASMTRILEPFRTRNPELVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLGWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115468 D4T3TCEFV 2009 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLSEEKLKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGLTTPDKKHQKEHPFRWMGYELHPDKWTVQPIQLPTKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115469 D4T3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILAPFRAQNPEMVIYQYVDDLLVGSDLEIGQHRAKIEKLREHLLKWGFTTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115470 AZT3TCNVP 2009 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVQNPEIVIYQYVDDLYVASDLEIGPHRAKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115471 D4T3TCEFV 2008 South Africa C 1 1 221 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEHFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAQNPEVVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKH Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115472 D4T3TCEFV 2012 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115473 TDF3TCEFV 2012 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVRQWPLTEEKIKALTEICKEMEKEGKITRIGPENPYNTPVFVIKRKDRTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLQKKKSMTVLDVGDAYFSIPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILQPFRTRNPDIVIYQYVDDLYVASDLEIGQHRAKVEELRNLLLKWGLTTPDEKHHKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115474 D4T3TCEFV 2011 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRTQNPGIVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTIQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115475 ABC3TCEFV 2012 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRNHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115476 D4T3TCEFV 2012 South Africa C 0 1 166 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSMTVLGVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMLK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115477 D4T3TCEFV 2010 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSMNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYVDDLLVGSDLEIGQHREKIEELRKHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115479 D4T3TCEFV 2010 South Africa C 1 1 257 PISSIETVPVQLKPGMDGPKVKQWPLTKEKIEALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLYEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIIIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTAQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115480 D4T3TCEFV 2011 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKEMEKEGKITRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRRSMTVLDVGDAYFSVPLDEGFRKYTAFTVPSINNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIDIYQYVDDLYVGSDLEIGKHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115482 D4T3TCEFV 2008 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTQNPEIVIYQYVDDLYVASDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115483 D4T3TCEFV 2009 South Africa C 0 1 248 PISSIETVPVKLKSGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRSKSMTVLDVGDAYFSIPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFREQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPLRWMGYELHPDKWTVQPIVLPE Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115484 D4T3TCEFV 2009 South Africa C 1 1 257 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115485 D4T3TCEFV 2008 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNEVPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRTKIDELREHLLKWGFFTPDKKHQKEHPFLWLGYELHPDKWTVQPIKLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115486 D4T3TCEFV 2012 South Africa C 0 1 262 PISPIDTVPVKLKPGMDGPKVKQWPLSEEKIKPLTKFCKKMEKEGKFTKIGPENPYNTPLFAIKKKNSDRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKIDELRNHLLKWGFTTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115487 D4T3TCEFV 2007 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVSSDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115489 AZT3TCNVP 2007 South Africa C 0 1 262 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFCEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGSRYQYNVLPQGWKGSPAIFQSSMKKILDPFRARNPELVICQYVDDLYVGSDLEIGQHRAKIKELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115490 TDF3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNSPVFAIKRKNGTEWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAFFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIIIYQYMDDLCVGSDLEIGQHRAKIEQLRAHLLKWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQTIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115491 D4T3TCEFV 2009 South Africa C 1 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMAKILEPFRAKNPEIVIYQYVDDLYVGSDLEIEQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPNKWTVQPIQLPEKDSWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115494 TDF3TCNVP 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVICQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKESWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115496 D4T3TCEFV 2007 South Africa C 1 1 258 PISPIKTVPVKLKPGMDGPKVKQWPLTKEKIKALTEICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEKLRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115498 D4T3TCEFV 2009 South Africa C 0 1 262 PISPIETVPVKLNPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKRNKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPEIVIYQYVDDLYVGSDLEKMQHRAKVEELREHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115501 AZT3TCEFV 2009 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPRVKQWPLTAEKIKALTEICADMEKEGQITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKNRKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPDIDIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGLFTPDQKHQKEPPFHWLGYELHPDKWTVQPIQLPEKESWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115502 TDF3TCNVP 2011 South Africa C 0 1 257 PISSIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFVIKRKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKRKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIDICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115503 ABC3TCEFV 2012 South Africa C 1 1 256 PISPIDTVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAVFQSTMIKILEPFRTQNPNIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115504 D4T3TCNVP 2010 South Africa F 1 1 257 PISPIETVPVKLKPGMDGPRIKQWPLTEEKIKALTEICIELEKDGKISRIGPENPYNTPIFAIKKKNSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTIIDVGDAYFSIPLDPDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRSKYPEIVICQYVDDLYVASDLEIGQHREKIKELRDYLWKWGFYTPENKYQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115505 D4T3TCEFV 2007 South Africa C 0 1 257 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPNLNIYQYVDDLYVGSDLKIGQHKAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPILLPKKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115506 AZT3TCEFV 2008 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEMVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDRWKVQPITLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115507 D4T3TCEFV 2008 South Africa C 1 1 161 PISPIETTPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPEIFQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115508 D4T3TCEFV 2011 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALREICEEMEKEGKITKIGPENPYNTPIFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMKRILDPFRTQNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115509 D4T3TCEFV 2012 South Africa C 1 1 241 PISSIKTVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEDMEREGKITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSMTVLDVGDAYFSIPLDENFGKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRVKNPELVIYQYVDDLYVGSDLEIEQHRAKIEELREHLLKWGLTTPDEKHQKEPPFRWMGYELHPDKWTV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115510 D4T3TCEFV 2008 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICDEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQGSMTKILEPFRAKNPDLVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115511 D4T3TCEFV 2009 South Africa K 0 1 237 PISPIETVPVKLKPGMDGPKVRQWPLTEEKIKALTEICGEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDEDFRKYTAFTIPSTNNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYMDDLYVGSDLEIGQPRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPD Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115512 D4T3TCEFV 2010 South Africa C 0 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTGEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEMVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115513 D4T3TCEFV 2010 South Africa C 1 1 257 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDMVIYQYVDDLYVGSDLEIGQHRAKIEELRTHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115514 D4T3TCEFV 2008 South Africa C 0 1 240 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVNFRELNKKTQNFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWT Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115515 ABC3TCEFV 2009 South Africa C 1 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEGMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFCEVQLGIPHPAGIKKNKSVTVLDVGDAYFSIPLDEGFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIEQHRAKVEELRALLLKWGLTTPDNKHQEEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115516 D4T3TCEFV 2009 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKNNKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRARNPEIVIYQYVDDLYVASDLEIGQHRAKIKELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLCKKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115518 D4T3TCEFV 2012 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVRNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115521 D4T3TCEFV 2009 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRRKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDNWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115523 TDF3TCEFV 2010 South Africa C 0 1 258 PISPIETVPVKLKAGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGEAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIDIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115524 D4T3TCEFV 2012 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEELEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMVRILEPFRAKNPEIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115525 D4T3TCNVP 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICEELDKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSIPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKYPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115526 D4T3TCEFV 2010 South Africa C 1 1 261 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLPKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGKRYQYNVLPQGWKGSPSIFQSSMTKILEPFRTQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115527 ABC3TCEFV 2009 South Africa C 1 1 251 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKRKDGTKWRKVIDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAFFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPDIVICQYMDDLYVTSDLEIGQHRAKIEELREHLLKWGLTTPDNKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDS Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115529 D4T3TCEFV 2012 South Africa C 1 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHREKIEELRAHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115532 D4T3TCEFV 2010 South Africa C 1 1 258 PISPIKTVPVKLKPGMDGPKVKQWPLTGEKLKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKGSTKWRKLVDFRELNKRTQDFSEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELRSHLLTWGLTTPDKKHQKEPPILWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115533 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVQLKPGMDGPKVKQWPLSEEKIKALTEICQEMEKEGKITKIGPENPYNTPIFAIKKKDGNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSVTVLDVGDAYFSVPLYEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPDMDIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGFITPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115535 D4T3TCEFV 2010 South Africa C 0 1 252 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115536 D4T3TCEFV 2012 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLQKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYVDDLYVGSDLEIEQHRAKIEQLRDHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115540 D4T3TCEFV 2010 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYVDDLYVGSDLEIGKHRAKIEELRNHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPTKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115541 D4T3TCEFV 2010 South Africa C 1 1 258 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQASMTKILEPFRTRNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDTWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115543 AZT3TCEFV 2009 South Africa C 0 1 253 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFKKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKXSWT Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115545 D4T3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNSPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFREQNPEIVIYQYVDDLYVGSDLEIGHHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115548 D4T3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPTIFQSSMTKILEPFRTQNPEIDIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115549 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLSAEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQHSMTKILEPFRTRNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELRDHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115551 D4T3TCEFV 2009 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDLVIYQYIDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIHLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115552 D4T3TCEFV 2010 South Africa C 1 1 256 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALREICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPDIVIYQYVDDLYVSSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIQLPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115553 D4T3TCEFV 2009 South Africa C 1 1 254 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115555 D4T3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115558 AZT3TCEFV 2008 South Africa C 0 1 248 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQHSMTKILEPFRTQNPEIDIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPE Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115562 D4T3TCNVP 2012 South Africa C 0 1 256 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALREICEEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEFVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115563 D4T3TCEFV 2012 South Africa C 0 55 261 PYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIMLPEKESWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115565 TDF3TCEFV 2011 South Africa C 0 1 258 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALMEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115569 AZT3TCNVP 2011 South Africa C 0 1 257 PISSIETVPVQLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPDIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115573 D4T3TCEFV 2008 South Africa C 1 1 257 PISPIKTVPVKLKPGMDGPKVKQWPLSGEKIKALTEICKEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115575 TDF3TCEFV 2010 South Africa C 0 1 257 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115576 D4T3TCEFV 2009 South Africa C 0 1 262 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPDIVIYQYVDDLYVASDLEIRQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPNKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115578 ABC3TCEFV 2011 South Africa C 1 1 258 PISPIETVPVRLKPGMDGPKVKQWPLTKEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPVKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115580 TDF3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKINALKAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLLVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIQLPTKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115581 D4T3TCEFV 2009 South Africa C 1 1 240 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKGSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEDFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWT Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115587 D4T3TCEFV 2008 South Africa C 0 1 257 PISPIETVPVQLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115588 D4T3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRNHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115589 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEKKIKALTEICEEMEKEGKITKIGPDNPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRNHLLKWGFTTPDQKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115591 TDF3TCEFV 2010 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPGIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115592 D4T3TCEFV 2009 South Africa C 1 1 259 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPELVIYQYVDDLYVSSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115594 TDF3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNDMEKEGKITRIGPENPYNTPIFAIKRKGSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNAEPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVVSDLEIGQHREKIEELRDHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115595 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115596 D4T3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVRLKPGMDGPKVKQWPLTEEKIKALTEICEQMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRRHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIHLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115597 AZT3TCEFV 2011 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKVGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115598 D4T3TCEFV 2010 South Africa C 0 1 252 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPDMIIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115600 TDF3TCEFV 2011 South Africa C 0 1 257 PISPIEPVPVKLKPGMDGPKVKQWPLTEEKIKALTEICGEMEKEGKITKIGPDNPYNTPIFAIKKKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPELEIYQYVDDLYVGSDLEIGQHRAKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPQKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115603 AZT3TCNVP 2007 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVRQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKNRSATVLDVGDAYFSVPLDESFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDQKYQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115604 D4T3TCEFV 2010 South Africa C 1 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLLVGSDLEIKQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115609 D4T3TCEFV 2011 South Africa C 0 1 261 PISSIKTVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIEQHRAKVAELREHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115610 D4T3TCEFV 2010 South Africa C 0 1 254 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRRHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115611 TDF3TCEFV 2011 South Africa C 0 1 256 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLCVGSDLEIGQHRTKIEELRNHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115616 TDF3TCEFV 2011 South Africa C 0 1 258 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIRALTAICEEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIIICQYIDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115617 D4T3TCEFV 2012 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALKEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEEFRKYTAFTIPSLNNEAPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEITQHRAKIEELREHLLRWGFTTPDKKYQKDPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115619 ABC3TCEFV 2009 South Africa C 1 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRKHLLTWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115620 TDF3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVICQYMDDLYVSSDLEIEQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115621 D4T3TCEFV 2008 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115622 D4T3TCEFV 2011 South Africa C 1 1 251 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIKLPEKDS Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115623 AZT3TCEFV 2007 South Africa C 0 1 341 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNKTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGNDQWTYQI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115624 D4T3TCEFV 2007 South Africa C 1 1 257 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRNHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115625 D4T3TCNVP 2012 South Africa C 0 1 260 PISPIETIPVKLKPGMDGPKIKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQDSMTRILEPFRAKNPELVICQYVDDLYVGSDLEIGQHREKIEDLRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIQL~QKDSWTVNDIQKL Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115626 D4T3TCEFV 2007 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFVIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSRNNETPGVRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPELVIYQYMDDLCVGSDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115627 D4T3TCEFV 2007 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDDMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNRRTQDFWEIQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSLNNASPGVRYQYNVLPQGWKGSPAIFQYSMTKILEPFRAKNPEMEIYQYVDDLYVGSDLEIGQHRAKIEELRRHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115628 D4T3TCEFV 2011 South Africa C 0 1 254 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRTHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKESWTV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115629 TDF3TCEFV 2010 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPEIVIYQYMDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115631 AZT3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115632 D4T3TCEFV 2010 South Africa C 1 1 239 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQRKSMTVLDVGDAYFSVPLDEGFRKYTAFTIHSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYVDDLYVASNLEIGQHRAKIQELREHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115636 TDF3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDEKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115637 AZT3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLWKWGFYTPDEKHQKEPPFLWLGYELHPDKWTVQTIRLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115640 D4T3TCEFV 2011 South Africa C 0 1 252 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTEICKEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIKLPEKDSW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115641 TDF3TCEFV 2011 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTILDVGDAYFSVPLHESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLKWGFTTPDKKHQKEHPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115644 TDF3TCEFV 2011 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSLTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLCVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115647 D4T3TCEFV 2009 South Africa C 0 1 258 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAYFSVPLDEDFRKYTAFTVPSLNNATPGVRYQYNVLPQGWKGSPAIFQSSMVKILEPFRAKNPEIDIYQYVDDLYVGSDLEIGQHRAKVEELRTHLLKWGLTTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115648 AZT3TCEFV 2012 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGLPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGVRFQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLLVGSDLEIGQHREKIEELRAHLLKWGFYTPDEKHQKEPPFLWMGYELHPDKWTVQPINLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115651 D4T3TCNVP 2009 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPRRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAENPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115653 D4T3TCEFV 2009 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVQSDLEIGQHREKIEELKEHLLRWGFYTPDNKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115654 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKVLTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSIPLDESFRKYTAFTIPSINNSSPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRTQNPDIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115655 TDF3TCEFV 2012 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLTKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIGIYQYMDDLYVESDLEIGQHRAIVERLRDHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115656 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFREKNPELVIYQYMDDLYVGSDLEIGQHRAKVEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115657 D4T3TCEFV 2010 South Africa C 1 1 257 PISSIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDKNFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115658 D4T3TCEFV 2007 South Africa C 1 1 218 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPD Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115661 AZT3TCEFV 2010 South Africa C 0 1 122 PISPIETVPVKLKAGMDGPRVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVSLDK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115662 D4T3TCEFV 2006 South Africa C 1 1 341 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPELVIYQYVDDLHVGSDLEIGQHRAKIEELREHLLKWGFSTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRELCKLLRGAKALTDIIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGNDQWTYQI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115664 D4T3TCEFV 2009 South Africa C 0 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTTNPDIVIYQYVDDLHVGSDLPIEQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115665 AZT3TCEFV 2010 South Africa C 0 1 257 PISPIDTVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKRKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWLGYELHPDKWTVQPIELPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115666 D4T3TCEFV 2009 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSAKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYYSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRTQNPEIVICQYVDDLYVASDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115667 D4T3TCEFV 2009 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILKPFREKYPEITIYQYIDDLYVGSDLEIGQHRATIEELRDHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115668 D4T3TCEFV 2009 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115670 D4T3TCEFV 2011 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEREGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQSIMIKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPILLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115671 D4T3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKMGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDQKHQKEPPFLWMGYELHPDKWIVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115673 D4T3TCEFV 2010 South Africa C 0 1 214 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIKQHRAKIEELRDHLLKWGF Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115674 TDF3TCEFV 2011 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRARNPEIVIYQYMDDLYVGSDLEIEQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115676 AZT3TCEFV 2006 South Africa C 0 1 341 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEELEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKIVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPTINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYVDDLYVGSDLEIGQHRARIEKLRDHLLKWGFTTPDKKLQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQGNDQWTYQI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115678 D4T3TCEFV 2006 South Africa C 1 1 341 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115679 TDF3TCNVP 2012 South Africa C 0 1 253 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPDNPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPELVICQYVDDLYVASDLEIGQHRARIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWT Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115680 D4T3TCEFV 2009 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115684 D4T3TCEFV 2011 South Africa C 0 1 257 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSINNEKPGIRYQYNVFPQGWKGSPAIFQSSMTKILEPFRARNPEMVIYQYVDDLYVGSDLEIGQHRANIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDTWTVQPIQLPDKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115686 AZT3TCEFV 2008 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRERNPDIVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGLTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPDKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115687 TDF3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115689 AZT3TCEFV 2010 South Africa C 0 1 252 PISPIETIPVKLKPGMDGPKVKQWPLTKEKLKALTAICDEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115692 TDF3TCEFV 2009 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLERKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRTQNPEIVICQYMDDLYVGSDLEIGQHRAKVEELRAHLLKWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIKLPEKESWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115693 AZT3TCEFV 2008 South Africa C 0 1 257 PISSIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKEMEEEGKITKIGPENPYNTPVFVIKKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIDIYQYVDDLYVGSDLEIGQHREKVKQLREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115694 D4T3TCEFV 2009 South Africa C 1 1 256 PISPIDTVPVKLKPGMDGPKVKQWPLTKEKIKALTVICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRKHLIQWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115695 D4T3TCEFV 2009 South Africa C 1 1 252 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSMNNATPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAANPGIDLYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPDKESW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115696 TDF3TCEFV 2011 South Africa C 0 1 258 PISPIETIPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNRRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNATPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIIIYQYIDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEHPFLWMGHELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115697 D4T3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPYRAKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115699 D4T3TCEFV 2009 South Africa C 1 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPLLWLGYELHPDKWTVQPIQLPNKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115700 TDF3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVICQYVDDLYIASDLEIGQHRAKIEELRAHLLKWGFTTPDEKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115701 D4T3TCEFV 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLERRKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115704 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPNINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPDIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIVLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115706 TDF3TCEFV 2011 South Africa C 0 1 262 PISHIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQCSMTKILEPFRRKNPDIDIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLHWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPILLPEKESWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115707 D4T3TCEFV 2011 South Africa C 0 1 257 PISPIETAPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGTRFQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDLVIYQYVDDLYVGSDLEIGQHRAKIEKLRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115708 AZT3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTAICEELEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSMTVIDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLCVGSDLEIRQHRAKIEELRAHLLRWGFYTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115709 D4T3TCEFV 2012 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTAICEEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNEAPGKRYQYNVLPQGWKGSPAIFQCSMTRILDPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKVEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115711 D4T3TCEFV 2010 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115712 D4T3TCEFV 2010 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEDLRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115713 D4T3TCEFV 2008 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTAEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPGIEICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115715 D4T3TCEFV 2009 South Africa C 0 1 257 PISPISTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRTQNPDLVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115716 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115717 D4T3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEMVIYQYMDDLHVGSDLEIGQHRAKIEELRQHLLTWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115718 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFSEVQLGIPHPAGLKQKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNKTPGIRYQYNVLPQGWKGSPAIFQHSMTKILEPFRTKNPNIVIYQYVDDLYVGSNLEIGQHRAKIEELREHLLKWGLTTPDKKHQKKPPFLWMGYELHPDKWAVQPIHLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115719 TDF3TCEFV 2010 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPIFAIKRKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEIVICQYVDDLLVGSDLEIGQHRAKIEELREHLLRWGFTTPEQKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115722 D4T3TCEFV 2006 South Africa C 0 1 343 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYVDDLDVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115724 D4T3TCEFV 2010 South Africa C 1 1 239 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPDIVIYQYVDDLYVGSDLAIGEHRAKIEELRAHLLKWGFTTPDKKHQKEHPFLWLGYELHPDKW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115725 D4T3TCEFV 2011 South Africa C 1 1 257 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115727 D4T3TCNVP 2009 South Africa C 0 1 258 PISPIETIKVKLKPGMDGPKVKQWPLTEEKLKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSTMTKILEPFRAQNPGIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115728 D4T3TCNVP 2012 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITRIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRARNPEIVIYQYVDDLWVGSDLEIKQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPDKESWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115729 D4T3TCEFV 2009 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKIKQWPLSEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFFTPDKNHQKEPPLLWLGYELHPDKWTVQPIQLPEKDSWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115730 TDF3TCEFV 2009 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEGFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115731 D4T3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYVDDLYVGSDLEIGPHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115732 D4T3TCEFV 2006 South Africa C 1 1 341 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHREKIEELRNHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGNDQWTYQI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115736 AZT3TCNVP 2009 South Africa C 1 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTAICEDMEREGKITRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115737 ABC3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMVKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115738 D4T3TCNVP 2009 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKKKSATVLDVGDAYFSVPLDESFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRARNPDLVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115743 TDF3TCEFV 2011 South Africa C 0 1 260 PISPIKTVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFVIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNEVPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPELVIYQYVDDLYVGSDLEIKQHREKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKL Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115744 AZT3TCEFV 2012 South Africa C 0 61 242 FAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSIPLDEDFRKYTAFTIPSLNNAAPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRASNPDIVIYQYVDDLYVGSDLELGQHRAKVEELRKHLLKWGLSTPDKKHQKXPPPLXMGYELHPDKWTVQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115745 D4T3TCEFV 2010 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRSKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPELVIYQYVDDLYVGSDLEIGQHRAKIDELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115746 D4T3TCEFV 2007 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEDLRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115747 TDF3TCEFV 2011 South Africa C 0 1 254 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICQEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPELVIYQYMDDLYVGSDLEIGQHRAKIEDLRAHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115748 AZT3TCNVP 2012 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKGSNRWRKLIDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDESFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYVDDLYVASDLEIGQHRAKVEELRDHLLKWGFITPDEKHQKEPPFHWMGYELHPDKWTVQPVKLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115751 D4T3TCEFV 2008 South Africa C 1 1 259 PISTIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAKNPEIDIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLKWGFTTPDKKHQKEPPLRWLGYELHPDKWTVQPIQLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115752 ABC3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICKELEEEGKITKIGPENPYNTPIFAIKKKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAFFSVPLDENFRKYTAFTIPSINNETPGIKYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLGIEQHRAKIEELRQHLLKWGLTTPDKKYQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115753 D4T3TCEFV 2011 South Africa C 0 1 262 PISPIETVPVKXKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEXKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYVDDLYVGSDLEIGQHRAKVEELRKHLLRWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115756 D4T3TCEFV 2011 South Africa C 0 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTEICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115757 D4T3TCEFV 2007 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEDMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPELVIYQYVDDLYVGSDLELGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115758 D4T3TCEFV 2006 South Africa C 0 1 341 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLGWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115763 D4T3TCEFV 2010 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSIPLDENFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFKKENPDIVIYQYVDDLYVGSDLEIGQHRAKIEKLREHLLKWGLTTPDRKHQKEPPFRWMGYELHPDKWTVQPIQLPDKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115766 ABC3TCEFV 2009 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPRVKQWPLTEEKINALKAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNGTPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTQNPEIDIYQYVDDLYVGSDLEIGQHRAKVEELREHLLRWGLTTPDKKHQKEPPFLWMGHELHPDKWTVQPIQLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115767 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQHIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115768 AZT3TCEFV 2011 South Africa C 0 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKQKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNRAPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGLTTPDKKHQKDPPFLWMGYELHPDKWTVQPIQLPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115769 D4T3TCNVP 2010 South Africa C 0 1 256 PISPIETIPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTVPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115771 D4T3TCEFV 2010 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTILDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDIVIYQYVDDLYVGSDFEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115772 ABC3TCEFV 2011 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICAEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVIYQYVDDLLVGSDLELGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115773 AZT3TCEFV 2008 South Africa C 0 1 262 PISPIETVPVQLKPGMDGPKVRQWPLTEEKIKALTEICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEVVIYQYMDDLYVGSDLEIGQHRAKIEKLREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115775 ABC3TCEFV 2011 South Africa C 1 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGLPHPAGLEKKKSVTVLDVGDAYYSVPLDEEFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVSSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115776 D4T3TCEFV 2009 South Africa C 0 1 259 PISPIETVPVKLKPGVDGPKVKQWPLSEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNATPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKDNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115778 D4T3TCEFV 2008 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTEWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNEKPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115784 D4T3TCEFV 2010 South Africa C 0 1 258 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLQWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115786 TDF3TCEFV 2011 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAFFSVPLNEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115787 D4T3TCEFV 2009 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLTKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115790 TDF3TCEFV 2011 South Africa C 0 1 257 PISSIETVPVQLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFVIKRKDNTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLYEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115792 D4T3TCEFV 2009 South Africa C 1 1 260 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAKNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKL Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115793 D4T3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIMQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDTWTVQPIKLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115794 TDF3TCEFV 2011 South Africa C 0 1 262 PISTIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLPKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115796 D4T3TCNVP 2011 South Africa C 0 1 210 PISPIETVPVKLKPGMDGPKVKQWPLTTEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLAKKKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSTNNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKENPDIVIYQYVDDLYVASDLEIGQHRAKIEELREHLL Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115798 AZT3TCEFV 2009 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTEICEDMEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSTMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHREKIEELREHLLKWGFYTPDQKHQKEHPFLWMGYELHPDTWTVQPIMLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115799 ABC3TCEFV 2011 South Africa C 1 1 247 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKISEPFRTKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDTWTVQPIQLP Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115800 D4T3TCEFV 2009 South Africa C 1 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDGNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFQWMGYELHPDKWTVQPINLPEKESWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115802 AZT3TCNVP 2009 South Africa C 1 1 259 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKGFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRGHLLRWGFITPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPEKNSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115803 D4T3TCEFV 2007 South Africa C 1 1 230 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGITKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPNIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFQWM Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115805 TDF3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLNKKKSMTVLDVGDAFFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVICQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115806 D4T3TCEFV 2009 South Africa C 1 1 241 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALVEICEEMEKEGKISKIGPENPYNTPVFAIKKKNGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEQNKTVTVLDVGDAYFSVPLYEDFRKYTAFTIPNLNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRQHLLKWGFTTPEEKHQKEPPFLWMGYELHPDKWTV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115808 D4T3TCEFV 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPYRAKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115811 TDF3TCNVP 2011 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMAICEEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVICQYIDDLYVGSDLEIGQHRAKVEELRTHLLKWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115812 D4T3TCEFV 2008 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEREGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLLVGSDLEIGKHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115815 D4T3TCEFV 2010 South Africa C 0 1 254 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITRIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNRRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILKPFREQNPGIVIYQYVDDLYVASDLEIGQHRAKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115817 ABC3TCEFV 2010 South Africa C 0 1 252 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGIKKNRSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNKTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPELVIYQYVDDLYVGSDLEITQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115818 D4T3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTQNPNIVIYQYVDDLYVGSDLEIGQHRAKTEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPSKESWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115820 AZT3TCNVP 2009 South Africa C 1 1 252 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIEQHRAKIEKLREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLTEKESW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115821 D4T3TCEFV 2011 South Africa C 0 1 261 PISSIETIPVKLKPGMDGPKVKQWPLTEEKIKAITEICNEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLQKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLLVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115822 AZT3TCNVP 2012 South Africa C 0 1 261 PISPIKTVPVQLKPGMDGPKVKQWPLTKEKIKALTEICAEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEMVIYQYVDDLYVASDLEIGQHRAKIEELRDHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115824 TDF3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVRQWPLTEEKIKALVEICEEMEKEGKISKIGPENPYNTPIFAIKKKSSNRWRKLVDFRELNKRTQDFWEVQLGLPHPAGLQKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIIIYQYVDDLCVASDLEIGQHRAKVEELREHLLKWGFVTPDQKHQKEPPFLWMGYELHPDKWTVQTIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115827 TDF3TCEFV 2012 South Africa C 0 1 260 PISPIETVPVKLKPGMDGPRVRQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFVIKKKDGTEWRKLSDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSRNNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFREQNPGMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLRWGLTTPDRKHQKEHPFIWMGYELHPDTWTMQPIQLPEKDSWTVNDIQKL Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115832 D4T3TCEFV 2010 South Africa D 1 1 258 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYVDDLYVGSDLEIGQHRLKIEELRKHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115833 AZT3TCEFV 2010 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEDMEKEGKISKIGPENPYNTPIFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPYRRKNPDIIICQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGLSTPDQKHQKEPPLLWMGYELHPDKWTVQPIVLPEKDSWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115835 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIKTVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSMNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRANNPELVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTIQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115836 D4T3TCEFV 2011 South Africa C 1 1 244 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVASDLEIKQHREKIEELRRHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115838 ABC3TCEFV 2011 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKISKIGPEDPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPDIVIYQYVDDLYVGSDLEIGQHRAKVEELRQHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115839 D4T3TCEFV 2009 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDLVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115840 AZT3TCEFV 2012 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTIILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115848 D4T3TCEFV 2009 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKRRSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRQNPDIVIYQYVDDLYVGSDLEMGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPILLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115855 D4T3TCEFV 2012 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKIEKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAFFSVPLDKSFRKYTAFTIPSINNQTPGIRYQYNVPPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYVDDLYVGSDLEIGRHRAKIEELRKHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115856 D4T3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFREQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115857 D4T3TCEFV 2011 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVASDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115860 D4T3TCEFV 2010 South Africa C 0 1 258 PISPIETIPVKLKPGMDGPRVKQWPLTKEKIEALTEICKEMEKEGKITKIGPDNPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPELIIYQYVDDLYVGSDLEIGQHRAKIKELREHLLKWGLTTPDQKHQEEPPFHWMGYELHPDKWTMQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115862 D4T3TCEFV 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115863 D4T3TCEFV 2006 South Africa C 1 1 345 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIKQHRAKIEELREHLLKWGFFTPDKKHQKDPPLRWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGVKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQDQWTYQIYKEP Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115864 D4T3TCEFV 2007 South Africa CRF01_AE 1 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTAEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKRKDN~KWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSAAIFQSSMTKILEPFRSKNPEIIICQYMDDLYVSSDLEIGQHRTKIEELRAHLLRWGLTTPDRKHQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115866 TDF3TCEFV 2012 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTQNPEIVIYQYMDDLYVGSDLEIGQHRAKVEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115870 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEEKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIKQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115871 TDF3TCEFV 2011 South Africa A 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIIIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIILPEKESWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115872 TDF3TCEFV 2010 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKRKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVASDLEIGQHRVKIEELREHLLRWGFTTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115873 D4T3TCEFV 2007 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNSPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115874 D4T3TCEFV 2011 South Africa C 1 1 258 PISTIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYIDDLHIGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115875 D4T3TCEFV 2010 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPELVIYQYVDDLYVGSDLEIEQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115876 TDF3TCEFV 2011 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLEKKKSMTVLDVGDAYFSIPLDEDFRKYTAFTIPSINNAAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRANNPDIIIYQYMDDLYVGSDLELGQHRAKIEKLREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKESWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115877 D4T3TCNVP 2006 South Africa C 0 1 343 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSTMIKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGPDQWTYQIYQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115878 ABC3TCEFV 2009 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTVICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIDIYQYVDDLLVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115880 D4T3TCEFV 2011 South Africa C 0 1 258 PISTIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPDIDIYQYVDDLYVGSDLEIKQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115881 D4T3TCEFV 2010 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICKEMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGLPHPAGLQKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYVDDLYVASDLEIGQHRAKIEELRQHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115882 D4T3TCEFV 2007 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRSHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPVQLPEKNSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115883 D4T3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRARNPEIVIYQYVDDLCVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115885 D4T3TCEFV 2011 South Africa C 0 1 252 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPDIVIYQYVDDLYVGSDLELGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115888 D4T3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIEALIAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELIIYQYVDDLLVGSDLEIGQHRAKVEKLRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115889 AZT3TCEFV 2010 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTEICKEMEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLNKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELRGHLLKWGFTTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115890 AZT3TCEFV 2008 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEQLREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115892 TDF3TCEFV 2012 South Africa C 0 1 261 PISPIETIPVKLKPGMDGPKVKQWPLTEEKLKALTEICEDMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNRRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAFFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIDIYQYIDDLYVGSDLEIGQHRAKIEELRMHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115893 D4T3TCEFV 2010 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPRIKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115894 AZT3TCNVP 2011 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMIKILEPFRAQNPEIVIYQYVDDLLVGSDLEIGQHRAKIKELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115895 D4T3TCEFV 2007 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEGMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDIVIYQYMDDLYVSSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115896 D4T3TCEFV 2010 South Africa C 0 1 255 PISPIKTVPVKLKPGMDGPRVKQWPLSEEKIKALTDICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYMDDLYVGSDLEIGQHREKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115897 AZT3TCEFV 2010 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTKICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYVDDLCVGSDLEIKQHREKIEQLREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115899 D4T3TCEFV 2009 South Africa C 0 1 260 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLPKNKSVTVLDVGDAYFSVPLDEAFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIDELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKL Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115902 TDF3TCEFV 2009 South Africa C 0 1 256 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNGTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDLVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFFTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPDKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115904 D4T3TCEFV 2010 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPEIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPKKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115906 D4T3TCEFV 2007 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNRSVTVLDVGDAYFSVPLDENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPTKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115909 TDF3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPFFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTILDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQHSMTKILGPFRAKNPEIVICQYVDDLYVASDLEITQHRAKIKELRXHLLTWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115910 D4T3TCEFV 2008 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGKHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115911 TDF3TCEFV 2011 South Africa C 0 1 262 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELVIYQYVDDLYVASDLELGQHRAKVEELRDHLLKWGFTTPDKKHQKEPPFLWMGXELHPDKWTAQPIQLQTKDSWTVNXIQKIVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115912 ABC3TCEFV 2011 South Africa C 0 1 261 PISSIETIPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEREGKITKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSIPLDEEFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115913 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIDTVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELRAHLLKWGFTTPDKKHQKEPPFRWMGYELHPNKWTVQPIELPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115914 D4T3TCEFV 2011 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKSKSMTILDVGDAYFSVPLDEGFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTRILEPFRAKNPDIVIYQYVDDLYVGSDLEIVQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYKLHPDKWTIQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115915 TDF3TCEFV 2010 South Africa C 0 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTAICDEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEMVIYQYIDDLYIGSDLEIGQHRAKIEKLREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115917 D4T3TCEFV 2008 South Africa C 1 1 250 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPXPAGXKKNKSVTVLDXGDAYFSVPLDENFRKYTAFTLPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKD Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115919 ABC3TCEFV 2012 South Africa C 1 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPSGLEKKKSVTVLDVGDAFFSVPLDESFRKYTAFTIPSINNATPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPNIVIYQYVDDLYVCSDLEIGQHRAKIEELRDHLLKWGFATPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115921 TDF3TCEFV 2011 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEMVIYQYMDDLYVGSDLEIGQHRAKIEKLRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115923 D4T3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDLVIYQYVDDLCVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115924 AZT3TCNVP 2008 South Africa C 0 1 252 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIRALKAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115926 D4T3TCEFV 2007 South Africa C 0 1 252 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDGTKWRKLMDLRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYYSVPLDEDFRKYTAFTIPSLNNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRTKNPEVVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115927 D4T3TCEFV 2009 South Africa C 1 1 255 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGIKKKRSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNKTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLFVGSDLEITQHRAKIKELREHLLKWGLTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115929 TDF3TCEFV 2011 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNSPIFAIKKKDSTEWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPEIVIYQYIDDLYVGSDLEIGQHRAKVEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115931 D4T3TCNVP 2009 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIRQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115933 AZT3TCNVP 2008 South Africa CRF01_AE 1 1 261 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSIPLDKNFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIVICQYVDDLYVGSDLEIGQHRTKVEELRNHLLGWGLTTPDKKHQKEPPFRWMGYELHPDTWTVQPIQLPDKDSWTVNDIQNLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115935 D4T3TCEFV 2008 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPSIFQSTMLKILEPFRKQNPDIIIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPITLPDKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115936 ABC3TCEFV 2011 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNELPQGWKGSPAIFQSSMTKILEPFRAQNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLAWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115937 D4T3TCEFV 2008 South Africa C 1 1 258 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALKEICEEMEREGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPFLWLGYEIHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115938 D4T3TCEFV 2009 South Africa C 0 1 257 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSITVLDVGDAYFSVPLDEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELRNHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115940 D4T3TCEFV 2012 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTAICEEMEKEGKITRIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPXKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115942 D4T3TCEFV 2009 South Africa C 1 1 253 PISPIETVKVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKIEKIGPENPYNTPVFAIKKKDSTKWRKLGDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDAGDAYFSVPLDEGFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWT Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115943 TDF3TCEFV 2011 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115944 D4T3TCEFV 2007 South Africa C 1 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTIQPIQLPQKDSWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115946 D4T3TCEFV 2008 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICGEMEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKRKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTQNPDIVIYQYVDDLYVASDLEIKQHRAKIEELRGHLLKWGLTTPDKKHQKEPPFYWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115948 D4T3TCEFV 2007 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTLPSLNNETPGIRYQYNVLPQGWKGSPAIFQSTMTKILEPFRANNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIHLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115949 D4T3TCEFV 2007 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115950 TDF3TCEFV 2011 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPIFAIKRKDNTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAFFSVPLDKDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIDIYQYVDDLYVGSDLEIEQHRAKVEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115951 D4T3TCEFV 2011 South Africa C 0 1 251 PISPIKTVPVKLKPGMDGPRVKQWPLTEEKIKALTEICNELEKEGKITKIGPENPYNTPIFAIKKKNSNRWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQDSMTRILEPFRVKNPEIVIYQYVDDLYVQSDLPIEQHRAKIEELRAHLLRWGFTTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDS Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115953 TDF3TCNVP 2012 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVICQYIDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIVLPEKESWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115954 D4T3TCEFV 2010 South Africa C 0 1 252 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLEKRKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPDIVIYQYVDDLYVSSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115955 AZT3TCNVP 2008 South Africa C 0 1 262 PISPIETVPVQLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEGFRKYTAFTIPSTNNASPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAQNPEIIIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFTWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115956 D4T3TCEFV 2010 South Africa C 0 1 216 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSIPLDENFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRMKNPDIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGLTT Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115958 D4T3TCEFV 2008 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALKEICEEMEREGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115959 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKVGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYMDDLYVGSDLEIEQHRAKIEKLRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115960 AZT3TCEFV 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIEQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115961 TDF3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTKICEEMEKEGKITKIGPENPYNTPIFAIRRKDGTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKKKSMTVLDVGDAFFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPDLDIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKESWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115965 D4T3TCEFV 2009 South Africa C 1 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSLNNGTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115966 D4T3TCEFV 2009 South Africa C 1 1 257 PISPIETVPVKLKPGVDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFVIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLSMNKSRTVLDVGDAYFSVPLDEGFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRMKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115967 D4T3TCEFV 2008 South Africa C 1 1 262 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICNEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVIDVGDAYFSVPLDEEFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVESDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115968 D4T3TCEFV 2009 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALMAICEEMEKEGKITKIGPDNPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPELVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115969 ABC3TCEFV 2011 South Africa C 1 1 258 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPKKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115970 TDF3TCEFV 2011 South Africa C 0 1 216 PISSIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTRILEPFKTQNPDIVIYQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGFTT Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115972 D4T3TCEFV 2009 South Africa C 0 1 258 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115973 D4T3TCEFV 2006 South Africa C 0 1 345 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALRAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNEAPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEMVIYQYVDDLYVGSDLEIGKHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQMYPGIKVRQLCRLLRGAKALTDIIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQDQWTYQIYQEP Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115974 AZT3TCEFV 2009 South Africa C 0 1 254 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPGIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115976 D4T3TCEFV 2007 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICGEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLELGQHRAKVEELRQHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPKKESWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115977 D4T3TCEFV 2008 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDGDFRKYTAFTIPSVNNETPGKRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPGIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115978 D4T3TCEFV 2007 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYIDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFRWLGYELHPDKWTVQPIELPEKESWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115979 D4T3TCEFV 2010 South Africa K 1 1 233 PISPIETVPVKLKPGMDGPKVRQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSITVLDVGDAYFSIPLDEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLLVGSDLEIGQHRTKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYE Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115982 AZT3TCNVP 2010 South Africa C 0 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRSHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115984 D4T3TCEFV 2007 South Africa C 0 1 258 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSRNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115985 D4T3TCEFV 2010 South Africa C 0 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKVMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRARIEELREHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115987 AZT3TCEFV 2007 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPRIKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVSSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEQDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115990 D4T3TCEFV 2009 South Africa C 1 1 253 PISPIETVPVKLKPGMDGPRIKQWPLTEEKIKALTAICKEMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPDIDIYQYVDDLYVGSDLDIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWT Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115991 D4T3TCEFV 2009 South Africa C 1 1 251 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDS Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115992 TDF3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSMTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGHELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115993 TDF3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAFFSVPLDENFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIQNPDLVICQYMDDLYVGSDLEIGQHRAKIEELRNHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPTKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115995 D4T3TCEFV 2011 South Africa C 0 1 258 PISSIKTIPVKLKPGMDGPRVKQWPLTEEKIKALTENCEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPEQDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 115999 D4T3TCEFV 2007 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKEKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRKQNPDIVIYQYVDDLYVGSDLEIEQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116001 AZT3TCEFV 2009 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPNIDIYQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116002 TDF3TCNVP 2011 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICDEMEKEGKITKIGPENPYNTPVFVIKRKDNTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNEVPGIRYQYNVLPQGWKGSPAIFQASMTRILEPFRTQNPDIVICQYVDDLYVASDLEIGQHRAKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116003 D4T3TCEFV 2007 South Africa C 0 1 341 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIEQHRAKIEELRKHLLAWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIQVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGDDQWTYQI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116004 ABC3TCEFV 2011 South Africa C 0 1 249 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIIALTAICEEMEKEGKITKIGPDNPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTVLDVGDAFFSIPLDENFRKYTAFTIPSINNTTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTANPDIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116006 D4T3TCNVP 2011 South Africa C 0 1 254 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALKAICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPSGLKGNKSVTILDVGDAYFSIPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPYRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPDKESWTV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116007 TDF3TCEFV 2011 South Africa C 0 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICDEMEKEGKITKIGPENPYNTPVFVIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAKNPELVICQYVDDLYVSSDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116009 D4T3TCEFV 2010 South Africa C 1 1 252 PISPIETVPVKLKPGMDGPRVKQWPLTGEKIKALTAICEEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116012 AZT3TCEFV 2007 South Africa C 0 1 257 PISTIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQGSMTKILEPFRTQNPDIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWLGYELHPDKWTVQPIKLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116013 D4T3TCEFV 2010 South Africa C 0 1 252 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEREGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQTSMTRILEPFRTQNPDLVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEHPFLWMGYELHPDTWTVQPIKLPEKDSW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116014 D4T3TCEFV 2010 South Africa C 1 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNATPGTRYQYNVLPQGWKGSPAIFQSSMIKILQPFRTKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPDKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116022 D4T3TCEFV 2007 South Africa C 0 1 120 PISPIETVPVQLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPL Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116027 D4T3TCEFV 2008 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICQEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116032 AZT3TCEFV 2010 South Africa C 0 1 261 PIIPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKEKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116035 D4T3TCEFV 2012 South Africa C 0 1 209 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSDKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSIPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPEIVIYQYVDDLYVGSDLEIEQHRAKIVELRDHL Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116040 D4T3TCEFV 2006 South Africa C 0 1 341 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYIDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLKGAKALTDIVPLTEEAELELAENKEILKEPVHGVYYDPSKELIAEIQKQGHDQWTYQI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116041 ABC3TCEFV 2010 South Africa C 0 1 252 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPELVIYQYMDDLYVGSDLEIGQHRAKIEELRDHLLRWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKESW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116042 D4T3TCEFV 2007 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLPKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPEIVIYQYVDDLYVGSDLEITQHRAKIEELRQHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116043 AZT3TCEFV 2008 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPEIVIYQYVDDLYVESDLEIGQHRAKIEELREHLLRWGFTTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116044 TDF3TCEFV 2011 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICADMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLIKKKSATVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSAAIFQASMTKILEPFRTKNPDIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDEKHQKELPCRWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116045 D4T3TCEFV 2008 South Africa C 0 1 257 PISPISTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAKNPEIVIYQYMDDLLVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116046 TDF3TCNVP 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTEEKINALKAICEEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNRSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPEIVICQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPEKKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116047 D4T3TCEFV 2011 South Africa C 1 1 252 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCTMTKILEPFRAKNPEIVIYQYVDDLHVGSNLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116048 D4T3TCEFV 2008 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116050 D4T3TCEFV 2010 South Africa C 1 1 252 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEELEKEGKITKIGPENPYNTPIFAIKKKDSNRWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPEIIIYQYVDDLLVGSDLEIGQHRAKIEELRAHLLKWGLTTPDQKHQKEPPFHWMGYELHPDKWTVQPIQLPEKDSW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116052 D4T3TCEFV 2009 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPVFVIKKKDSAKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNEAPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPELVIYQYVDDLYVGSDLEIGQHRAKIEQLREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116055 D4T3TCEFV 2009 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLNKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEDLRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116056 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116058 D4T3TCEFV 2011 South Africa C 0 1 258 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKNSATWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIIIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIHLPEKESWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116062 TDF3TCEFV 2012 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIEALTAICEEMEKEGKISKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSLTVLDVGDAFFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAQNPDIVICQYVDDLYVASDLELGQHRAKVEELRAHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPILLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116063 D4T3TCEFV 2007 South Africa C 1 1 259 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALKDICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPVQLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116064 D4T3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICQEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116065 D4T3TCNVP 2008 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICADMEKEGKITRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNEAPGIRYQYNVLPQG*KGSPAIFQSSMTKILEPFRAKNPDILICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116066 AZT3TCNVP 2010 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPRVKQWPLTDEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRTQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116067 D4T3TCEFV 2010 South Africa C 1 1 256 PISTIETVPVKLKPGMDGPKVKQWPLSEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDEGFRKYTAFTIPSINNEQPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPGIIIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116068 D4T3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKITKIGPENLYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLAIEQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116070 TDF3TCEFV 2012 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPDNPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPELVIYQYVDDLYVASDLEIGQHRAKIEELRDHLLKWGLTTPDKKHQKESPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116071 D4T3TCEFV 2009 South Africa C 1 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116073 D4T3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFREFNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPEKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116075 D4T3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVRQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMPKILEPFRTKNPDIDIYQYVDDLYVGSDLEIGQHRAKVEELREHLLRWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPITLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116077 D4T3TCEFV 2007 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKQNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116078 ABC3TCEFV 2011 South Africa C 1 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAFFSVPLDEDFRKFTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRMKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116080 AZT3TCEFV 2009 South Africa C 0 1 257 PISSIETVPVKLKPGMDGPKVKQWPLTKEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPELVIYQYVDDLLVGSDLEIGQHRAKIEELRDHLLKWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116081 D4T3TCEFV 2011 South Africa C 0 1 252 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKRKDNTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116083 D4T3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPTVKQWPLTEEKIKALMEICAEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNATPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPDIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116084 D4T3TCEFV 2010 South Africa C 0 1 251 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHREKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDS Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116085 ABC3TCEFV 2011 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSTMIKILEPFRTKNPEMVIYQYMDDLYVGSDLEIEQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116087 D4T3TCNVP 2010 South Africa A 0 1 234 PISPIKTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYMDDLYVGSDLEIGQHRTKVEELRNHLLKWGLTTPDKKHQKEPPFLWMGYEL Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116088 D4T3TCNVP 2010 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNESPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116089 D4T3TCEFV 2009 South Africa C 1 1 260 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYMDDLYVGSDLEIEQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKL Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116090 TDF3TCEFV 2011 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKRKDNTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRTQNPDIDIYQYVDDLYVGSDLEIKQHRAKIEELRKHLLQWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116091 D4T3TCEFV 2007 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116092 D4T3TCEFV 2011 South Africa C 0 1 252 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIDIYQYVDDLYVASDLEIEQHRAKIEELREHLLKWGLITPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPEKESW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116093 TDF3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLYEDFRKYTAFTIPSINNEKPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKRNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116094 TDF3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116095 D4T3TCEFV 2012 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDASFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPELVIYQYVDDLYVASDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116097 D4T3TCEFV 2009 South Africa C 1 1 259 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116099 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTAICEEMEKEGKITKIGPENPYNTPAFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLNKNRSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILAPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116105 D4T3TCEFV 2009 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFREKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116107 D4T3TCEFV 2008 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKIKQWPSTEKKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFSEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKKNPELVIYQYVDDLYVASDLEIGQHRAKIEDLREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116108 TDF3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKNKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTQNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116110 TDF3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVRLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRARNPELVIYQYVDDLYVGSDLEIGQHREKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116113 D4T3TCNVP 2008 South Africa C 0 1 258 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFREQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEKLREHLLKWGLTTPDKKHQKEPPFHWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116114 D4T3TCEFV 2011 South Africa C 0 1 262 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRRHLLQWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116115 TDF3TCEFV 2009 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIIIYQYIDDLYVGSDLEIGQHRTKVEELRKHLLKWGFTTPDEKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116116 AZT3TCEFV 2008 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDELEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLRWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116117 D4T3TCEFV 2010 South Africa C 0 1 258 PISSIETVSVKLKPGMDGPKVKQWPLTEEKIKALKAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116119 TDF3TCEFV 2011 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSDRWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGVRYQYNVLPQGWKGSPAIFQYSMTKILEPFRTQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDQKHQKEHPFRWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116120 TDF3TCEFV 2010 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPRVKQWPLSEEKIKALTAICEDMEKEGKITKIGPENPYNTSIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTILDVGDAYFSVPLDENFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIDIYQYVDDLYVGSDLEIGQHRAKIKELREHLLKWGLTTPDKKHQTEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116121 D4T3TCEFV 2012 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPIFAIRKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIDIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLQWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116123 D4T3TCEFV 2008 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLQWGLTTPDKKHQKGPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116125 D4T3TCEFV 2007 South Africa C 1 1 342 PISPITTVPVRLKPGMDGPKVKQWPLTEEKIRALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKHLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGEGQWTYQIY Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116127 TDF3TCNVP 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEELEKEGKITRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQDSMTKILRPFREQNPEMVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFFTPDKKHQKEPPLLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116128 TDF3TCEFV 2011 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPYRTKNPDIVIYQYMDDLYVGSDLEIGQHRAKIDELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPNKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116130 D4T3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWVVQLGIPHPAGLKKKNSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEVVIYQYMDDLYVGSDLEIGQHREKIEQLREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQAIKLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116133 D4T3TCEFV 2008 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPEIDIYQYVDDLYVGSDLEIGKHREKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKTSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116134 D4T3TCEFV 2012 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVNFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRARNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLRWGFYTPDRKHQKEHPFLWMGYELHPDTWTVQPIQLPEKESWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116135 D4T3TCEFV 2011 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTAICDEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAKNPELVIYQYVDDLYVGSDLEITQHRAKIKELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116137 D4T3TCEFV 2009 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALIEICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLPKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116139 D4T3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPRVKQWPLSEEKIKALTAICEEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVQNPDIVIYQYVDDLHVASDLEIGQHREKIEELREHLLRWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116142 AZT3TCNVP 2012 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPSIFQSTMTRILEPFRTRNPDIIIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116145 D4T3TCEFV 2009 South Africa C 1 1 237 PISPIETVPVKLKPGMDGPRIKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSVNNATPGIRYQYNVLPQGWKGSPAIFQGSMTKILQPFRMKNPDIVIYQYVDDLYVGSDLEIGQHRAKVEELRQHLLKWGLTTPDKKHQKEPPFLWMGYELHPD Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116146 D4T3TCEFV 2012 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRSKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILQPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116148 D4T3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116150 AZT3TCNVP 2012 South Africa C 0 1 261 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVASDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116151 D4T3TCEFV 2008 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRMKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116154 D4T3TCEFV 2007 South Africa C 1 1 217 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTVPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRQQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTP Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116155 D4T3TCEFV 2011 South Africa C 0 1 258 PISSIETVPVKLKPGMDGPRIKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIAELREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116156 D4T3TCNVP 2009 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAELEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNEVPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFFTPDKKHQKEPPFRWMGYELHPDKWTVHPIQLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116157 D4T3TCEFV 2010 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMARILEPFRKQNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116159 AZT3TCEFV 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEELEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLMDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPSIFQYSMTKILEPFRTKNPELIIYQYVDDLYVGSDLEIEQHRAKIKELREHLLKWGFFTPEEKHQKEPPFHWMGYELHPDNWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116160 D4T3TCEFV 2011 South Africa C 1 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPIFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFITPDEKHQKEHPFLWMGYELHPDTWTVQTIQLPEKDSWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116161 D4T3TCEFV 2012 South Africa C 1 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLLVGSDLEIGQHRAKIGELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDNWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116162 ABC3TCEFV 2009 South Africa C 1 1 253 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALREICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAFFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWT Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116163 TDF3TCNVP 2012 South Africa C 0 1 233 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIKQHRAKVEELRRHLLKWGFTTPDKKHQKEPPFLWMGYE Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116165 TDF3TCEFV 2010 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFVIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFREQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLTWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116167 AZT3TCNVP 2009 South Africa C 0 1 238 PISHIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSIPLDPSFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMLKILEPFRKQNPEIVIYQYVDDLFVGSDLEIGQHRAKIEELREHLLKWGLTTPDQKHQKEPPFLWMGYELHPDK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116170 D4T3TCEFV 2010 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPELVIYQYMDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116171 D4T3TCEFV 2006 South Africa C 1 1 341 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALKAICEEMEKEGKISKIGPENPYNTPIFAIKKKNSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDKNFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLYVASDLEIGHHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGVKALTDIVPLTEEAELELAENREILKEPVHGAYYDPSKELIAEIQKQGNDQWTYQI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116172 AZT3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICREMEKEGKITKIGPDNPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQHSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116173 D4T3TCEFV 2007 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTAICEEMEKEGKITKIGPENPYNTPVFAIKRKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIDIYQYVDDLYVGSDLEIGEHRAKIEELRKHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKNSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116174 D4T3TCEFV 2008 South Africa C 1 1 225 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFSEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRAKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEP Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116175 TDF3TCNVP 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKRKDS~KWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAFFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIGIYQYMDDLYVESDLEIGQHRAKIKELRKHLLEWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116176 D4T3TCEFV 2010 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELRAHLLKWGFTTPDRKHQKEPPLRWMGYELHPDKWTVQPIQLPXKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116180 D4T3TCNVP 2010 South Africa C 0 1 252 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVICQYVDDLYVGSDLEIGQHRAKIEDLRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116181 D4T3TCEFV 2009 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDELEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116184 D4T3TCEFV 2008 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLHESFRKYTAFTIPSMNNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116185 ABC3TCEFV 2012 South Africa C 0 1 240 PISPIETVPVRLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAFFSVPLDEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWT Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116186 D4T3TCEFV 2011 South Africa C 0 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRRKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPEIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDRKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116188 D4T3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPRVKQWPLTEEKLKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFSEIQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDRKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116190 TDF3TCEFV 2009 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSLTVLDVGDAYFSVPLDEDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYIDDLCVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116191 D4T3TCEFV 2007 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVRQWPLTEEKIKALTEICNEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNESPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLRWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKSSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116192 TDF3TCEFV 2012 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLLVGSDLEIGQHREKIEELKEHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116193 D4T3TCEFV 2007 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTEICEEMEREGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYVDDLYVGSDLQIEQHRAKIEQLREHLLKWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPKKSSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116194 AZT3TCEFV 2007 South Africa C 0 1 252 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKYPDIVIYQYVDDLYVGSDLEIEQHREKIEELRTHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116195 D4T3TCEFV 2011 South Africa C 0 1 244 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPGIVIYQYVDDLYVGSDLEIGQHREKVEELRAHLLKWGFTTPDRKHQKEHPFHWMGYELHPDKWTIQPI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116196 ABC3TCEFV 2012 South Africa A 1 63 262 IKKKDSTKWRKVVDFRELNKRTQDFSEIQLGIPHPAGIKQNKSVTILDVGDAFFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQNTMIKILEPFRTKNPEIIIYQYVDDLYVGSDLEIGQHRAKVEELRAHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTAQPIELPEKESWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116198 ABC3TCEFV 2010 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116200 D4T3TCEFV 2011 South Africa C 0 1 257 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYVDDLCVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116201 D4T3TCEFV 2007 South Africa C 0 1 257 PISPIETIPVKLKPGMDGPRVKQWPLTEEKIKALKEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEVVIYQYVDDLYVGSDLEIGQHRAMIERLRDHLLKWGFTTPDKKYQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116202 D4T3TCNVP 2009 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116203 D4T3TCEFV 2008 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKNNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRLKNPELVIYQYVDDLLVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116204 TDF3TCEFV 2012 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRSKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRANNPEIVIYQYIDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116205 D4T3TCEFV 2010 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTEICEEMEKEGKIEKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRVHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116206 TDF3TCEFV 2012 South Africa C 0 1 261 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPDNPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKRRKSMTVLDVGDAYFSIPLDEDFRKYTAFTIPSINNAAPGIRYQYNVLPQGWKGSPAIFQSSLTKILEPFRAKNPEIDIYQYVDDLYVGSDLEIGQHRAKVEELRELLLQWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116209 TDF3TCEFV 2011 South Africa C 0 1 254 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTRILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116211 D4T3TCEFV 2009 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICSEMEKEGKIEKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIEQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116213 D4T3TCEFV 2012 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQSKSMTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116215 AZT3TCEFV 2008 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICDEMEKEGKITKIGPENPYNTPIFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLPKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIIIYQYVDDLYVGSDLEIGQHRAKVEELRKHLLKWGFYTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116216 TDF3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEELEKEGKISKIGPENPYNTPIFAIKRKDGTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKRKSVTILDVGDAYYSVPLDESFRKYTAFTLPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRAKYPEIVIYQYVDDLYVASDLEIGQHREKIEELREHLLKWGLYTPDKKYQKEPPLLWMGYELHPDRWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116218 D4T3TCNVP 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116219 ABC3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAFFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRPKNPELDIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116220 D4T3TCEFV 2009 South Africa C 1 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRTQNPDIDIYQYVDDLYVGSDLEIGQHREKIEELRAHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116221 D4T3TCEFV 2009 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116222 D4T3TCEFV 2007 South Africa C 1 1 341 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLERNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPEIVIYQYVDDLLVGSNLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIQVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116223 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICVEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIHLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116224 AZT3TCEFV 2009 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLAEDFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIKQHRAKVEELREHLLKWGLVTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116225 D4T3TCEFV 2008 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKNKSITVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLITPDKKYQKEPPLLWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116228 TDF3TCEFV 2012 South Africa C 0 63 261 IKKKDSXKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSLNNGTPGIRYQYNVLPQGWKGSPAIFQASMTKILAPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116229 D4T3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLGVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILKPFRAQNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPITLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116233 D4T3TCEFV 2007 South Africa C 1 1 257 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALKAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYMDDLYVGSDLEIGRHREKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPKKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116234 D4T3TCEFV 2010 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKRKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRKQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116236 ABC3TCEFV 2010 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVIDVGDAFFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPEIVIYQYVDDLYVASDLEIKQHREKVEELRVHLLEWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQRLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116237 D4T3TCEFV 2010 South Africa C 1 1 257 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILRPFRANNPEIVICQYMDDLYVGSDLEIGQHRAKVEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116238 D4T3TCEFV 2011 South Africa C 0 1 251 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEELEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTIQPIQLPEKDS Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116239 AZT3TCEFV 2008 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDGNKWKKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSTMTKILQPFRARNPKMVIYQYMDDLYVGSDLEIGQHREKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116240 D4T3TCEFV 2008 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYMDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116242 AZT3TCEFV 2009 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLHEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIDIYQYMDDLLVGSDLEIGQHRAKIEDLKAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116244 D4T3TCEFV 2010 South Africa C 1 1 259 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRVKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116245 TDF3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIEALTAICEEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSMTVPDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKSNPDIVICQYMDDLYVASDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116247 D4T3TCEFV 2007 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIIIYQYVDDLCVGSDLEIGKHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPTKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116248 D4T3TCEFV 2010 South Africa C 0 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEVVIYQYVDDLLVGSDLEIGQHRAKIEKLREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116249 D4T3TCEFV 2007 South Africa C 1 1 262 PISPIETIPVKLKPGMDGPKVKQWPLTKEKIEALKEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDETFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116250 D4T3TCEFV 2008 South Africa C 0 1 251 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEEKITKIGPENPYNTPIFAIKKKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDS Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116251 AZT3TCEFV 2010 South Africa C 0 1 234 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTMICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQASMTRILAPFRAQNPDIVIYQYMDDLYVGSDLEIGQHRVKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYEL Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116252 D4T3TCEFV 2011 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEKLREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQAIKLPEKDSWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116253 D4T3TCNVP 2009 South Africa C 0 1 257 PISTIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICNEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRNHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116255 D4T3TCEFV 2010 South Africa C 1 1 262 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTEICKDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116256 D4T3TCEFV 2008 South Africa C 1 1 260 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYVDDLYVQSDLKIEQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPDKESWTVNDIQKL Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116258 D4T3TCEFV 2007 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116259 D4T3TCEFV 2010 South Africa C 0 1 256 PVSHIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTNWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAYFSIPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDRKHQKEPPLLWMGYELHPDKWTVQPIQLPDKESWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116260 D4T3TCEFV 2012 South Africa C 0 1 210 PISHIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKNRKSMTVLDVGDAYFSIPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPELDIYQYVDDLYVGSDLEIGQHRAKIEELRAHLL Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116261 D4T3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENLYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIEQHRAKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKKSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116262 TDF3TCEFV 2012 South Africa C 0 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALREICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTQWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGLRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIIIYQYVDDLYIASDLEIGEHRAKVEELRAHLLKWGLTTPDRKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116263 AZT3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKRKALLEICEEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116265 D4T3TCEFV 2011 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALIEICADMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNEKPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFHWMGYELHPDKWTVQPIQLPDKDSWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116266 D4T3TCEFV 2010 South Africa C 0 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGQITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPEIVIYQYVDDLYVGSDLEIGQHREKIEELREHLLKWGFTTPDKKYQKEPPFLWLGYEIHPDKWTVQPIQLPEKESWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116267 D4T3TCEFV 2011 South Africa C 1 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALMEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFFTPDKKHQQEPPLRWMGYELHPDKWTVQPIQLPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116268 D4T3TCNVP 2011 South Africa C 0 1 260 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAQNPEIIIYQYVDDLLVGSDLEIRQHRAKVEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKL Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116273 D4T3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPRVKQWPLSEEKIKALTAICEEMEKERKITKIGPENPYNTPVFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIDIYQYVDDLYVASDLEIGQHRAKIKELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPITLPEKESWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116276 D4T3TCEFV 2006 South Africa C 1 1 344 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICDEMEREGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSMNNEAPGIRYQYNVLPQGWKGSPAIFQSTMTKILEHFRAQNPELVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQMYPGVKVKHLCRLLRGAKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGHDQWTYQIYQE Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116282 D4T3TCEFV 2011 South Africa C 1 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116284 TDF3TCEFV 2011 South Africa C 0 1 262 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQHSMTRILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116285 D4T3TCEFV 2012 South Africa C 0 62 262 AIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116286 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTREKIEALTEICEEMEKEGKITKIGPDNPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELIIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116287 D4T3TCEFV 2011 South Africa C 0 1 258 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRTRNPDIEIYQYVDDLYVGSDLAIEQHRAKIEELREHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116288 D4T3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQRSMTKILEPFRARNPEIVIYQYVDDLYVGSDLEIGPHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116290 D4T3TCEFV 2007 South Africa C 1 1 257 PISPIKTVPVKLKPGMDGPKVKQWPLAEEKIKALTEICNEMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLEKRKSMTVLDVGDAFFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEMVIYQYVDDLYVGSDLEIGPHRAKIEKLRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116291 D4T3TCEFV 2011 South Africa C 0 1 261 PISPIDPIPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPGIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116293 AZT3TCNVP 2009 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTRILEPFRASNPGIVIYQYMDDLYVGSDLEIEQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116295 D4T3TCEFV 2011 South Africa C 1 1 251 PISPIETVPVKLKPGMDGPKVKQWTLTEKKIKALTAICEEMEKEEKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDAEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIRQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDTWTVQPIQLPNKDS Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116298 D4T3TCEFV 2007 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQHPELIIYQYMDDLYVGSDLEIGQHRAKIEKLRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116299 D4T3TCEFV 2010 South Africa C 1 1 242 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116301 TDF3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGQITKIGPENPYNTPVFAIKRKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAFFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIDICQYMDDLYVSSDLEIGQHRAKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116302 D4T3TCNVP 2010 South Africa C 0 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICEEMEKEGKIEKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFKKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLDIKQHRAKIKELREHLLKWGFTTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116304 D4T3TCEFV 2008 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNSPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKEKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYVDDLYVASDLEIGIHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116307 TDF3TCEFV 2011 South Africa C 0 1 254 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKNSTEWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAYFSVPLYEDFRKYTAFTIPSMNNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKENPEIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116308 D4T3TCEFV 2010 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKIQKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116310 D4T3TCEFV 2007 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKAICEEMEKEGKITKIGPDNPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDNWTVQPIQLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116312 ABC3TCEFV 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGIKQNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116314 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116315 TDF3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKRNALMAICEEMEKEGKISKIGPENPYNTPVFVIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIDELRTHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116318 D4T3TCEFV 2010 South Africa C 0 1 259 PISPVETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSTMTKILEPFRAKNPEIVIYQYVDDLYVASDLELKQHRAKIEELRKHLLEWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116319 D4T3TCEFV 2007 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSTMTKILEPFRTKNPDIVIYQYMDDLYAGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116320 D4T3TCEFV 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKEKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKQNPDIVIYQYVDDLLVGSDLEIGQHRAKIEELRKHLLEWGLTTPDKKHQKEPPFLWMGHELHPNKWTIQPIVLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116321 D4T3TCEFV 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRAKNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGHELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116323 AZT3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRKKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116324 D4T3TCEFV 2007 South Africa C 0 1 262 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPNIIIYQYVDDLLVGSDLEIGQHRAKVEELRVHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116325 D4T3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKRKDS~KWRKLVDFRELNKRTQDFCEVQLGIPHPSGIKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIEQHRAKIKELRDHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116326 D4T3TCEFV 2009 South Africa C 1 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPDNPYNTPVFAIKKKNSSKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILAPFRTKNPEIVIYQYMDDLYVASDLEIGQHRAKIEELREHLWKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116332 D4T3TCEFV 2009 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116333 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYIDDLYVGSDLEIGQHRAKIEKLRDHLLKWGFTTPDKKHQKEPPFRWLGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116334 D4T3TCEFV 2010 South Africa C 1 1 255 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALKEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116336 TDF3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAHNPELVIYQYMDDLYVGSDLEIEQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPITLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116340 D4T3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPINLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116342 D4T3TCEFV 2011 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSPKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAANPEIVIYQYMDDLHVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116344 AZT3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIKQHRAKVEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116345 D4T3TCEFV 2012 South Africa C 1 1 261 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRGHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116346 TDF3TCEFV 2011 South Africa C 0 1 231 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFVIKRKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAFFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIRQHRAKIEELRNHLLKWGLTTPDKKHQKEPPFLWMG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116347 D4T3TCEFV 2007 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQHIELPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116348 D4T3TCEFV 2007 South Africa C 0 1 341 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDIWTVNDIQKLVGKLNWASQIYPGIRVKNLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGHDQWTYQI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116349 D4T3TCEFV 2011 South Africa C 0 1 258 PISSIDTIPVKLKPGMDGPRVKQWPLTEEKLKALTAICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLTDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116350 D4T3TCEFV 2007 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAYFSVPLHESFRKYTAFTIPSINNERPGTRYQYNVLPQGWKGSPAIFHSSMTKILEPFRTQNPEIDIYQYVDDLYVGSDLKIEQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116351 D4T3TCEFV 2009 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKAITAICEELEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRAQNPQIIIYQYVDDLLVGSDLEIGQHRAKIEELRDHLLKWGFYTPDKKHQKEPPFLWMGYELHPERWTVQPIQLPTKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116353 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGVRYQYNVLPQGWKGSPSVFQVSMTKILKPFRTQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116355 D4T3TCEFV 2010 South Africa C 1 1 256 PISPIETVPVKLKPGMDGPKIKQWPLSEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIRRKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKRNKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116357 TDF3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRARNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPCLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116359 D4T3TCEFV 2011 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116360 D4T3TCEFV 2010 South Africa C 1 1 257 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELIIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDRWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116361 AZT3TCEFV 2007 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPLHWLGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116366 D4T3TCEFV 2007 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILDPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116367 TDF3TCEFV 2012 South Africa C 0 1 260 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALVAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSITVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRARNPEMIIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKL Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116372 D4T3TCEFV 2010 South Africa C 1 1 236 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLCVGSDLEIEQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHP Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116373 AZT3TCEFV 2007 South Africa C 0 1 262 PISPIDTVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKGSNRWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKRKRSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNATPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYVDDLYVDSDLEIGQHRAKIEELRQHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116374 ABC3TCEFV 2011 South Africa C 1 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPEIVIYQYVDDLYVGSDLEIEQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116375 D4T3TCEFV 2010 South Africa C 0 1 251 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDKDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIDIYQYVDDLYVGSDLEIGQHRAKIEELRGHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDS Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116377 D4T3TCEFV 2011 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTKEKIEALKAICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFCEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLYVASDLELGQHRAKIEELREHLLKWGFTTPDEKHQKEPPLLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116378 ABC3TCEFV 2010 South Africa C 1 1 241 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSTMTKILEPFRTKNPEIVIYQYVDDLYVQSDLEIGQHRAKIEELRAHLLKWGFTTPDNKHQKEPPFLWMGYELHPDKWTV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116379 D4T3TCEFV 2008 South Africa C 0 1 239 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSMPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRTKVEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116380 D4T3TCEFV 2006 South Africa C 0 1 342 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVRNLCKLLRGAKALTDIIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIY Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116381 D4T3TCEFV 2007 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKINALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEQDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116383 D4T3TCEFV 2011 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116386 D4T3TCEFV 2011 South Africa C 1 1 258 PISPIETVPVRLKPGMDGPRIKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116387 ABC3TCEFV 2010 South Africa C 0 1 262 PISSIETVPVKLKPGMDGPKVKQWPLTAEKIKALTEICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPSGIKKNKSMTVLDVGDAFFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116388 D4T3TCEFV 2008 South Africa C 1 1 258 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFVIKRKGSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLTKRKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPDIVIYQYMDDLYVESDLEIGQHRAKIEELRAHLLKWGFTTPDNKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116389 TDF3TCNVP 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTTEKIEALTAICEEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAFFSVPLDESFRKYTAFTIPSRNNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116390 TDF3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILQPFRTNNPDIVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLRWGLTTPDEKHQKEPPFLWMGYELHPDKWTVQTIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116391 D4T3TCEFV 2007 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRANNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116392 TDF3TCNVP 2011 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFVIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPDIVIIQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116393 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEITQHRAKIEELRQHLLKWGFTTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116395 D4T3TCEFV 2010 South Africa C 1 1 257 PISPIETVPVRLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLTDFRELNKRTQDFSEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116396 TDF3TCEFV 2012 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIKALTEICEDMEKEGKITKIGPENPYNTPIFAIRKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRTKNPEIVIYQYVDDLYVGSDLEIEQHRAKVEELREHLLKWGFITPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116402 D4T3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRAHLLRWGLTTPDRKHQKKPPLLWMGYELHPDKWTVQPIQLPEKESWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116403 D4T3TCEFV 2008 South Africa C 0 1 244 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLDENFKKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYVDDLYVASDLEIGQHRSKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQTI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116406 D4T3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDGGDAYFSVPLDESFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTLQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116408 D4T3TCEFV 2008 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICAEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116409 D4T3TCEFV 2009 South Africa C 0 1 253 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIDIYQYVDDLYVGSDLEIKQHRKKIEDLRAHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWT Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116410 D4T3TCEFV 2010 South Africa C 1 1 257 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILDPFRAKNPELDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116412 D4T3TCNVP 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDETFRKYTAFTIPSTNNTAPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTRNPDIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116418 TDF3TCEFV 2010 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICAEMEKEGKIEKIGPENPYNTPIFALKRKDG~KWRKLVDFRELNKRTQDFSEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSAAIFQCSMTKILEPFRKENPEMVIYQYMDDLCVGSDLEIGQHRAKIEELREHLLKWGLTTPDRKHQEKPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116419 D4T3TCEFV 2009 South Africa C 1 1 261 PISSIETVPVQLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116420 AZT3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMIKILEPFRTKNPDIVIYQYMDDLYVGSDLEIGQHRAKVEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116423 ABC3TCEFV 2007 South Africa C 1 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPIFAIKRKGSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKKKSMTVLDVGDAFFSVPLDENFRKYTAFTIPNINNETPGIKY*YNVLPQGWKGSPAIFQSSMTKILKPFRTKNPKMVICQYMDDLYVSSDLKLGQHKAKIKELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPKKDSWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116425 D4T3TCEFV 2011 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116426 D4T3TCEFV 2008 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMEICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKRKKSMTVLDVGDAYFSVPLDKDFRKYTAFTVPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVASDLEIGQHRAKIGELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116427 D4T3TCEFV 2010 South Africa C 1 1 257 PISPIETVPVKLKAGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYMDDLYVASDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116428 D4T3TCEFV 2007 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLFVGSDLEIGQHRAKIEELREHLLKWGFTTPDRKHQKEPPLLWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116429 D4T3TCEFV 2011 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICDEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116430 ABC3TCEFV 2011 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKDKQWPLTEEKIKALTEICEXMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGIKRNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPEIVIYQYVDDLYVGSDLEIVQHRAKIKELREHLLRWGFTTPDKKHQTEPPFLWMGYELHPDKWTVQPIMLPEKESWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116431 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTIQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116433 D4T3TCEFV 2011 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIRALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLCVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116434 TDF3TCEFV 2012 South Africa C 0 1 262 PVSPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKISKIGPENPYISLIFAIKRKDGTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSIPLDEGFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116435 TDF3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKIKQWPLTKEKIKALTAICEDMEKEGKISKIGPENPYNTPIFAIKKKDSTEWRKLMDFRELNKRTQDFCEIQLGIPHPAGLEKKKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAQNPEMVICQYVDDLYVASDLEIEQHRAKIEKLREHLLRWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116436 D4T3TCNVP 2009 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICGEMEKEGKITKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116437 D4T3TCEFV 2010 South Africa C 0 1 257 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICKEMEEEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116438 D4T3TCEFV 2009 South Africa C 1 1 259 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTKNPEIVIYQYVDDLYVGSDLEIEQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116439 D4T3TCEFV 2011 South Africa A 0 1 258 PISHIETVPVKLKPGMDGPRIKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRSQNPEIIIYQYVDDLYVGSDLEIGQHRAKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKESWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116440 D4T3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKVEQLREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116443 D4T3TCEFV 2011 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116444 TDF3TCNVP 2011 South Africa C 0 1 251 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLQKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKNS Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116446 AZT3TCNVP 2011 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIEQHRAKIEELRDHLLKWGFTTPDKKYQKEPPLLWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116447 AZT3TCEFV 2008 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRIKIEELRKHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116449 TDF3TCEFV 2010 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPVFVIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPDIDIYQYIDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQTIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116450 D4T3TCEFV 2010 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLDEGFRKYTAFTLPSTNNEIPGLRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPELVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116453 D4T3TCEFV 2010 South Africa C 1 1 252 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRRKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELDIYQYVDDLYVGSDLEIEQHRAKIEDLRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116457 AZT3TCNVP 2009 South Africa C 1 1 261 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNGTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYVDDLYVGSDLEIGQHRARIEKLRDHLLKWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116458 TDF3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLSDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTNNPDIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116459 D4T3TCEFV 2009 South Africa C 1 1 255 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116460 D4T3TCEFV 2010 South Africa C 1 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTRILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRSHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116462 D4T3TCEFV 2012 South Africa C 0 59 261 PVKAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQDSMTKILRPFREQNPEIDIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116464 AZT3TCEFV 2008 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKRKNSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPDIVIYQYVDDLYVGSDLEIEQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116469 AZT3TCEFV 2008 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRTRNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRGHLLKWGFTTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116471 ABC3TCEFV 2009 South Africa C 0 1 252 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGIKKNRSVTVLDVGDAFFSVPLDESFRKYTAFTIPSTNNAAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPNIVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGLTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPDKDSW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116472 D4T3TCEFV 2007 South Africa C 0 1 258 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRRHLLAWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116473 D4T3TCEFV 2010 South Africa C 0 1 249 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116476 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGWDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRSKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPDIVIYQYVDDLYVGSDLEIGQHREKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116477 D4T3TCEFV 2009 South Africa C 0 1 258 PISSIETIPVKLKPGMDGPRVKQWPLTKEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLNKNRSVTILDVGDAYFSVPLFEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPDIVIYQYVDDLYVGSDLEIGQHRAKIQELRDHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116480 D4T3TCEFV 2007 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKIKQWPLSEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKGSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNESPGTRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEMVIYQYMDDLRVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116481 D4T3TCEFV 2010 South Africa C 1 1 257 PISPIEAVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116484 D4T3TCEFV 2009 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGRITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEQLRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTIQPIQLPDKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116485 D4T3TCEFV 2007 South Africa C 1 1 341 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTEICEELEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSMTVIDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPEMVIYQYVDDLYVASDLEIEQHRAKIEELREHLLKWGFFTPDKKYQKEPPILWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGNDQWTYQI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116486 TDF3TCEFV 2011 South Africa C 0 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSELEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116487 D4T3TCEFV 2009 South Africa C 1 1 247 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAXNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116489 D4T3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPELVIYQYVDDLYVGSDLEIEQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116490 TDF3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAFFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAKFQSSMIKILEPFRAKNPEIVICQYMDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116492 D4T3TCEFV 2007 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLAEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLPKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMXYXLHPDKWTVQPIQLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116493 D4T3TCEFV 2007 South Africa C 0 1 342 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDIIPLTEEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQGHDQWTYQIY Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116494 TDF3TCEFV 2012 South Africa C 0 1 260 PISPIETVPVKLKPGMDGPRVKQWPLTKEKIEALTAICEEMEKEGQITKIGPENPYNTPIFAIKRKDGTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAFFSVPLDKDFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYMDDLYVESDLEIEQHRAKIEELRAHLLRWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKL Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116495 D4T3TCEFV 2009 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPALFQDSMTRILRPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGLFTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116496 D4T3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLTDFRELNKRTQDFWEVQLGIPHPGGLQKNKSVTVMDVGDAYFSVPLDESFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRKQNPDIVICQYVDDLYVASDLEIGQHRAKIEELREHLLKWGLTTPDKKYQKEPPFHWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116497 D4T3TCEFV 2012 South Africa B 1 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKNSDRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKVEELRQHLLKWGLFTPDQKHQKEPPFHWMGYELHPDKWTVQTIELPEKESWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116498 D4T3TCEFV 2010 South Africa C 1 1 256 PISPIEAIPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLHEDFRKYTAFTIPSVNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHREKIKELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116501 D4T3TCEFV 2010 South Africa C 0 1 237 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILQPFRTKNPEIEIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGLFTPDKKHQKEPPFLWMGYELHPD Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116505 ABC3TCEFV 2011 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICAEMEKEGKITKIGPENPYNTPVFAIKKKDSSKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116506 TDF3TCEFV 2011 South Africa C 0 1 259 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFVIKRKDNTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAFFSVPLDEDFRKYTAFTIPSINNGTPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPEMDIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFQWMGYELHPDKWTVQPIQLPDKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116507 AZT3TCEFV 2007 South Africa C 0 1 221 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSITVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMIKILEPFRTQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKH Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116509 TDF3TCEFV 2011 South Africa C 0 1 256 PISPIETVPVRLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPEMDIYQYVDDLYVGSDLEIGQHREKIEELRAHLLRWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116510 TDF3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTREKIEALTAICEEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTRNPDIVICQYMDDLYVSSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116511 D4T3TCEFV 2011 South Africa C 0 1 255 PISPIDTVPVKLKPGMDGPKIRQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSTMIKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116512 D4T3TCNVP 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKYPEIDICQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116514 D4T3TCEFV 2010 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSLNNATPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDMVIYQYVDDLYVGSDLEIGQHRAKIEELRVHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116515 TDF3TCEFV 2010 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTRILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELREHLFKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116518 ABC3TCEFV 2011 South Africa C 1 1 262 PISPIETVPVKLKPGMDGPKVKQWPLHREKIKALTAICEEMEKKKKISKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVSIIDVGDAYFSVPLDPSFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFREKNPELTIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPNKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116520 TDF3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDADFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMIKILQPFRTKNPDLVIYQYMDDLYVGSDLEIGQHRAKVEELREHLLKWGLTTPDKKHQREPPFLWMGYELHPDKWTVQTIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116522 TDF3TCEFV 2012 South Africa C 0 1 244 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKRSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRTQNPDIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116524 TDF3TCEFV 2010 South Africa C 0 1 252 PISPIETVPVKLKPGMDGPKVKQWPLSEEKRKALIEICTEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELELYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116526 D4T3TCEFV 2011 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILAPFRAKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116529 D4T3TCEFV 2010 South Africa C 1 1 257 PISPIEPVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMIKILEPFRKQNPDIVIYQYVDDLLVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116530 D4T3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDLVIYQYVDDLYVGSDLEIGQHRAKIDELRAHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116531 D4T3TCEFV 2007 South Africa C 1 1 259 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALKEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHREKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116532 D4T3TCEFV 2010 South Africa C 1 1 257 PISSIETVPVKLKPGMDGPKIKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKRKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIDIYQYVDDLYVGSDLEIGQHREKVEELRRHLLKWGFTTPDEKHQKEPPLLWMGYELHPDKWTVQPIKLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116534 D4T3TCNVP 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116535 AZT3TCNVP 2011 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDEKHQKEPPFFWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116538 D4T3TCEFV 2011 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTILDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILGPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKESWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116541 D4T3TCEFV 2007 South Africa C 1 1 341 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLTKNKSVTILDVGDAYFSVPLDEGFRRYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILKPFRTQNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPEKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILREPVHGVYYDPSKDLIAEIQKQGQDQWTYQI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116545 D4T3TCEFV 2007 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNKTPGLRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDLVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116546 ABC3TCEFV 2011 South Africa C 0 1 256 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALMEICNEMEREGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEMVIYQYVDDLYVGSDLEIGQHRERIEKLREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116547 D4T3TCEFV 2010 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPELVIYQYVDDLYVASDLEIGQHRAKIEELRERLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116549 AZT3TCNVP 2012 South Africa C 1 1 230 PISSIDTVPVKLKPGMDGPKIKQWPLTKEKIKALTEICEEMEKEGKITRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQDSMTKILKPFRAKNPEIVICQYVDDLYVASDLEIKQHRAKIEELREHLLKWGFFTPDKKHQKEPPFLWM Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116550 D4T3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALREICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIEQHRAKIEELREHLLRWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116551 D4T3TCEFV 2011 South Africa C 0 1 261 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIKLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116553 D4T3TCEFV 2011 South Africa C 0 1 254 PISSIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRDHLLKWGLTTPDKKHQKEPPFRWMGYELHPDKWTVQPIKLPEKDSWTV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116554 TDF3TCEFV 2011 South Africa C 0 1 255 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTEWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIDIYQYVDDLYVASDLEIGQHRAKIKELREHLLRWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIELPEKDSWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116557 D4T3TCEFV 2010 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116558 D4T3TCEFV 2010 South Africa C 0 1 256 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTAICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116559 D4T3TCEFV 2007 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPKVRQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116561 TDF3TCEFV 2012 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTQWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVIDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIEIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116562 D4T3TCNVP 2007 South Africa C 1 1 250 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICEEKEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELRNHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKD Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116565 AZT3TCEFV 2010 South Africa C 1 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKGGTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSINNEKPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELRAHLLRWGFTTPDQKYQKEPPFLWMGYELHPDSWTVQPIQLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116567 D4T3TCEFV 2009 South Africa C 1 1 258 PISPIETVPVKLKPGMDGPRVKQWPLSEEKIRALTEICKEMEEEGKITKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIDIYQYVDDLYVGSDLEIGQHRAKIEELRSHLLKWGFTTPDKKHQQEPPLLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116571 D4T3TCEFV 2009 South Africa C 1 1 252 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICREMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLTKNKSMTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKNSW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116572 TDF3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMEICSEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRRKSMTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIDIYQYVDDLYVGSDLEIGQHRVKIKELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116576 D4T3TCEFV 2012 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSLNNGTPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116577 TDF3TCEFV 2010 South Africa C 0 1 256 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYMDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKESPFLWMGYELHPDKWTVQPIQLPEKESWTVND Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116578 D4T3TCEFV 2008 South Africa C 1 1 252 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNSPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLNENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILKPFRTQNPDIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPLRWMGYELHPDKWTVQPIVLPEKXSW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116579 D4T3TCEFV 2009 South Africa C 0 1 259 PISPIETVPVKLKPGMDGPRIKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLQKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIDIYQYVDDLYVGSDLEIGQHRKKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116581 ABC3TCEFV 2008 South Africa C 1 1 259 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAFFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAQNPEIVIYQYVDDLYVGSDLEIKQHRAKVEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPDKESWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116582 D4T3TCEFV 2011 South Africa C 0 1 258 PISSIATVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRVKNPEIVIYQYVDDLYVGSDLELGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116583 D4T3TCEFV 2009 South Africa C 0 1 254 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQVAXTKILEPFRAQNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDQKYQKEPPFRWLGYEIHPDKWTVQPIQLPEKDSWTV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116586 D4T3TCEFV 2011 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICAEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELRKHLLQWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQQIQLPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116587 AZT3TCNVP 2007 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNELPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLSTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDRDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116588 D4T3TCEFV 2007 South Africa C 0 1 341 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTEICNEMEKEGKISKVGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPSIFQSSMTKILEPFRKQNPEIDIYQYMDDLYVASDLEIRQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGVKVKQMCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGNDQWTYQI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116589 D4T3TCEFV 2010 South Africa C 1 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPTKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116590 D4T3TCEFV 2009 South Africa C 0 1 254 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSMNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116593 D4T3TCEFV 2010 South Africa C 1 1 259 PISPIKTVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKSNKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELVIYQYVDDLYVGSDLEIMQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116594 D4T3TCEFV 2009 South Africa C 1 1 252 PISPIETVPVKLKPGTDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPINLPDKESW Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116595 D4T3TCEFV 2010 South Africa C 1 1 261 PISHIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPELVIYQYVDDLYVGSDLEIGQHRAKIEKLRDHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116597 D4T3TCEFV 2009 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEELEKEGKITKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKVMTVLDVGDAYFSVPLDENFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELIIYQYMDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKYQKEPPLLWMGYELHPDKWTVQSIELPEKESWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116601 D4T3TCEFV 2011 South Africa C 0 1 234 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYEL Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116602 TDF3TCEFV 2011 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKGSDRWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEITQHRAKIEELREHLLKWGFTTPDQKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116603 AZT3TCEFV 2007 South Africa C 0 1 342 PISPIETVPVKLKPGMDGPKVKQWPLTEEKTKALTAICEEMEKEGKITKIGPENPYNSPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLAIEQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDNWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGVKVKHLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGAYYDPSKDIIAEIQKQGNDQWTYQIY Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116604 D4T3TCEFV 2007 South Africa C 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRGHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDI Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116606 TDF3TCEFV 2011 South Africa C 0 1 255 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALMEICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVN Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116607 D4T3TCEFV 2009 South Africa C 0 1 262 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVG Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116608 TDF3TCNVP 2012 South Africa C 0 1 261 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116609 TDF3TCEFV 2011 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIDELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116611 D4T3TCEFV 2009 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNEIPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIEQHRAKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPVKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116613 D4T3TCEFV 2011 South Africa C 0 1 254 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEDMEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTV Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2122 116614 D4T3TCEFV 2008 South Africa C 0 1 258 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGPHRAKIEELREHLLKWGFSTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Van Zyl, GU 2013 23840622 PLoS ONE Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. 2130 118733 ABC3TCEFV 2006 U.S. B 0 1 299 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDREFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIIIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGTKALTEVVPLTEEA Mollan, K 2012 23148287 J Infect Dis HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. 2130 118748 ABC3TCEFV 2006 U.S. B 0 1 299 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRHHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKSLTEVVPLTEEA Mollan, K 2012 23148287 J Infect Dis HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. 2130 118785 TDFFTCEFV 2009 U.S. B 0 1 236 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPDLVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHP Mollan, K 2012 23148287 J Infect Dis HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. 2130 118824 ABC3TCEFV 2007 U.S. B 0 1 232 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKRKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGPRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIEQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGX Mollan, K 2012 23148287 J Infect Dis HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. 2130 118829 ABC3TCEFV 2006 U.S. B 0 1 299 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALLEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVIPLTKEA Mollan, K 2012 23148287 J Infect Dis HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. 2130 118841 ABC3TCEFV 2009 U.S. B 0 1 299 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILDPFRKQNPDIVIYQYMDDLYVGSDLEIVQHRAKVEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKSLTEVIPLTEEA Mollan, K 2012 23148287 J Infect Dis HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. 2130 118847 ABC3TCEFV 2007 U.S. B 0 1 302 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALMEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDMVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIRVKYLCKLLRGTKALTEVVPLTEEAELE Mollan, K 2012 23148287 J Infect Dis HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. 2130 118851 TDFFTCEFV 2006 U.S. B 0 1 301 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLLDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGMRYQYNVLPQGWKGSPAIFQSTMTKILDPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDNWTVNDIQKLVGKLNWASQIYPGIKVKHLCRLLRGTKSLTEVIPLTKEAEL Mollan, K 2012 23148287 J Infect Dis HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. 2130 118903 TDFFTCEFV 2006 U.S. B 0 1 300 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIEQHRAKIDELRQHLLKWGFSTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVIQLTEEAE Mollan, K 2012 23148287 J Infect Dis HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. 2130 118919 ABC3TCEFV 2006 U.S. B 0 1 236 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHP Mollan, K 2012 23148287 J Infect Dis HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. 2130 118922 ABC3TCEFV 2006 U.S. B 0 1 301 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIDIYQYMDDLYVGSDLEIEQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIFSGIKVRQLCKLLRGTKALTEVIPLTREAEL Mollan, K 2012 23148287 J Infect Dis HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. 2130 118984 ABC3TCEFV 2006 U.S. B 0 1 257 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDGNKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSINNETPGIRFQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRRHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDI Mollan, K 2012 23148287 J Infect Dis HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. 2140 120054 TDF3TCEFV 2011 South Africa C 0 1 333 PISSIETIPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILREPVHGVYYDPSKDLIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120055 TDF3TCEFV 2011 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKRKNSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKRRKSATVLDVGDAFFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVIYQYMDDLYVESDLEIGQHRAKIEELRAHLLKWGFTTPDEKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKTRQLCKLLRGVKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120056 D4T3TCNVP 2011 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIQALTAICKEMEEEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKTKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDVQKLVGKLNWASQIYPGIRVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120057 TDF3TCEFV 2010 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKRKDNTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRMQNPEIVIYQYMDDLLVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120058 TDF3TCEFV 2010 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKDGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPDIVIYQYMDDLCVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120059 TDF3TCNVP 2010 South Africa C 0 1 333 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAFFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMKKILEPFRARNPELDICQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120061 TDF3TCEFV 2010 South Africa C 0 1 333 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKISKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDPEFRKYTAFTIPSINNETPGRRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELVIYQYMDDLCVGSDLEIEQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILREPVHGVYYDPSKDLIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120062 TDF3TCEFV 2011 South Africa C 0 1 333 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKRKDGTTWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMIKILEPFRAKNPEIVIYQYMDDLNVGSDLEIGQHRAKVEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRNLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120063 TDF3TCEFV 2011 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKIKQWPLSEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIDICQYMDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKEDWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120064 TDF3TCEFV 2011 South Africa C 0 1 332 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVICQYMDDLYVGSDLEIEQHRAKIEELRAHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQ Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120066 D4T3TCEFV 2010 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEELEKEGKITKIGPENPYNTPIFAIKRKDGTKWRKVTDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAFFSVPLHEDFRKYTAFTIPSVNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYMDDLYVESDLEIGQHRAKIEELREHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIRTKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120068 TDF3TCEFV 2011 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICEEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAFFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYMDDLYVSSDLEIKQHREKVEKLRDHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLKGTKALTDVIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120069 TDF3TCEFV 2011 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALREICDEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKSKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIIPLTEEAELELAENREILKEPVHGVFYDPSKDLIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120070 TDF3TCEFV 2010 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEQMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSMNNEAPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120071 TDF3TCEFV 2010 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTEWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKVKELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIQVKNLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120072 TDF3TCEFV 2011 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPIFAIKRKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAFFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYMDDLYVESDLEIGQHRAKIEELRNHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120073 TDF3TCEFV 2011 South Africa C 0 1 333 PISTIETVPVKLKPGMDGPRVKQWPLTEEKIKALTTICEEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSIPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGVKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120074 TDF3TCEFV 2011 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYMDDLYVGSDLEIEQHRAKIEKLREHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120075 TDF3TCEFV 2011 South Africa C 0 1 333 PISTIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICKEMEEEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSIPLDEDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVRQLCKLLRGAKALTDIVSLTEEAELELAENREILKEPVHGAYYDPSKELIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120076 TDF3TCEFV 2010 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKRKDS~KWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNKTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYMDDLYVESDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLKGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120077 TDF3TCEFV 2011 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYIDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120078 TDF3TCEFV 2010 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYMDDLYVESDLEIEQHRAKIEELRKHLLAWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120079 TDF3TCEFV 2011 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPELVIYQYVDDLYVGSDLEIGQHRAKIEELRRHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120080 TDF3TCEFV 2011 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120081 TDF3TCEFV 2011 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYMDDLLVGSDLEIEQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQICKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120082 TDF3TCEFV 2010 South Africa C 0 1 333 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKGSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGVRYQYNVLPQGWKGSPAIFQCSMTKILEPFRARNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120084 TDF3TCEFV 2011 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICKEMEEEGKITKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKQRKSVTILDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKKNPEIEICQYIDDLYIGSDLEIGQHRAKIEELRQHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKSLTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120085 TDF3TCEFV 2011 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMVKILEPFRAKNPELVICQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKYQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120086 TDF3TCEFV 2010 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIDICQYMDDLYVGSDLEIGQHRVKIEELRTHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPIHGAYYDPSKDLIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120087 TDF3TCEFV 2011 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTVICEEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIAICQYMDDLYVASDLEIGQHRAKVEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIQVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120088 D4T3TCEFV 2011 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYMDDLYVGSDLEIEQHRARIEKLRDHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVKELCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIADVQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120089 TDF3TCEFV 2010 South Africa C 0 1 333 PICPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAFFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEMVIYQYMDDLYVESDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKEDWTVNDIQKLVGKLNWASQIYPGIQVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120090 TDF3TCEFV 2011 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKEMEEEGKITKIGPENPYNTPIFAIKRKDNTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAFFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRARNPELDIYQYVDDLYVGSDLEIGQHRAKIEELRTHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2140 120091 TDF3TCEFV 2010 South Africa C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQG Sunpath, H 2013 22739389 AIDS High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. 2147 121164 D4T3TCNVP 2005 Thailand B 1 38 234 CTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKRYPDIVICQYVDDLYVGSDLEIGEHREKIEELREHLLKWGFYTPDKKYQKEPPFLWMGYEL Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121165 D4T3TCNVP 2006 Thailand CRF01_AE 1 31 240 IKALTEICKEMEEEGKISKIGPENPYNSPVFVIKKKDGNKWRKLIDVRELNKRTQDFWEVQLGIPHPGGLEKKKSITVLDVGDAYYSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQYSMTKILEPFRIKNPEMVIYQYVDDLYVASDLEIAQHRTKIEELRAHLLSWGMTTPDKKHQKDPPFLWMGYELHPDKWT Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121166 D4T3TCNVP 2004 Thailand CRF01_AE 1 24 240 WPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWT Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121167 D4T3TCNVP 2004 Thailand CRF01_AE 1 21 255 VKQWPLTEEKIKALTEICQEMGKERKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPTIFQSSMTRILEPFKIKNPEMIICQYVDDLYVGSDLEIEQHRAKIDELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVN Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121168 D4T3TCNVP 2005 Thailand CRF01_AE 1 40 239 DMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLIDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTLPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPNKKYQREPPFLWMEYELHPDRW Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121170 D4T3TCNVP 2004 Thailand CRF01_AE 1 21 255 VKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSDKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVASDLEIGQHRIKIEELRAHLWSWGFFTPDKKHQKEPPFLWMGYELHPDRWTVQPINLPEKDSWTVN Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121171 D4T3TCNVP 2004 Thailand CRF01_AE 1 21 248 VKQWPLTEEKIKALTEICKELEEAGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDIGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSTMIKILEPFRTKNPELVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFYTPDKKYQKEPPFLWMGYELHPDRWTVQPIKLPE Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121172 D4T3TCNVP 2006 Thailand CRF01_AE 1 20 255 KVKQWPLTKEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIVQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFFTPDQKHQKEPPFLWMGYELHPDKWKVQPIELPEKDSWTVN Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121173 AZT3TCNVP 2006 Thailand CRF01_AE 1 20 258 KVKQWPLTEEKIKALTEICKEMEAEGKISKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFKIKNPEMVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFYTPDNKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQ Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121174 D4T3TCEFV 2003 Thailand CRF01_AE 1 24 240 WPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPIFAIKKKNSTKWRKLLDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTILDVGDAYFSIPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIEQHRTRIEELRAHLWSWGFYTPDKKHQKEPPFLWMGYELHPDKWT Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121175 AZT3TCNVP 2006 Thailand CRF01_AE 1 20 258 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKGGTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIIIYQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFFTPDEKHQKEPPFLWMGYELHLDRWTVQPIELPEKDSWTVNDIQ Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121176 D4T3TCNVP 2006 Thailand CRF01_AE 1 20 254 KVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPIFAIKKKNSDRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQDSMTKILEPFRKKNPEMIIVQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFFTPEQKHQKEPPFHWMGYELHPERWTVQPIQLPEKDSWTV Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121177 D4T3TCNVP 2005 Thailand CRF01_AE 1 20 258 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSSKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQ Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121178 D4T3TCEFV 2005 Thailand CRF01_AE 1 3 240 SPIDTVPVKLKPGMDGPKVKQWPLTEEKIRALTEICEEMEKEGKISKIGPENPYNTPIFAIKKKDGTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIVIYQYMDDLLVGSDLEIGQHRAKVEELRAHLLSWGFNTPDKKHQKEPPFLWMGYELHPDKWT Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121179 D4T3TCNVP 2005 Thailand CRF01_AE 1 2 240 ISPIDTVPVTLKPGMDGPRVKQWPLTEEKIKAITEICKEMEEEGKISKIGPENPYNTPVFAIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDIGDAYFSVPLHKDFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIVICQYMDDLYVASDLEIGQHRTKVEELRAHLSSWGLTTPDRKHQKEPPFRWMGYELHPDKWT Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121180 D4T3TCNVP 2005 Thailand CRF01_AE 1 19 254 PKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKGSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCCMTKILEPFRIKNPDIVIYQYMDDLYVQSDLEIGQHRAKIEELRAHLLSWGFTTPDEKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTV Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121181 D4T3TCNVP 2004 Thailand CRF01_AE 1 20 258 KVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVVVQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFFTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121182 AZT3TCNVP 2006 Thailand CRF01_AE 1 20 258 RVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTRWRKLIDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKVEELRAHLLKWGFITPDEKYQKEPPFLWLGYELHPDKWTVQPIELPEKDSWTVNDIQ Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121183 D4T3TCNVP 2007 Thailand CRF01_AE 1 20 244 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKYPEIVIYQYVDDLLVGSDLEIEQHRAKIEELRAHLWSWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPI Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121185 AZT3TCNVP 2006 Thailand CRF01_AE 1 20 258 KVKQWPLTKEKIEALTEICKELEEAGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGLPHPAGLEKKKSMTVLDIGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIIIYQYVDDLYVASDLEIGQHRTKIEELRAHLWNWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQ Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121186 D4T3TCNVP 2007 Thailand CRF01_AE 1 38 241 CKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEMVIYQYVDDLYIGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTV Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121187 D4T3TCNVP 2006 Thailand CRF01_AE 1 21 232 VKQWPLTEEKIKALTEICKEMEEERKISKIGPENPYNTPVFVIRKKESSKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVIDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQYSMTRILEPFRIKNPEIVIYQYVDDLLVGSDLEIGQHRAKVEELRAHLWSWGFFTPDKKHQKEPPFHWMGY Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121188 D4T3TCNVP 2004 Thailand CRF01_AE 1 9 240 PVKLKPGMDGPKVKLWPLTEEKIKALTEICKEMEQEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRKENPDMVIYQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWT Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121189 D4T3TCNVP 2005 Thailand CRF01_AE 1 32 240 KALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEIIICQYVDDLYVGSDLEIEQHRTKVEELRAHLLSWGFFTPDKKHQKEPPFLWMGYELHPDKWT Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121191 D4T3TCNVP 2004 Thailand CRF01_AE 1 20 258 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYYSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFKIKNPELVICQYVDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQ Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121192 D4T3TCNVP 2004 Thailand B 1 38 240 CTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVSVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVICQYMDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWT Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121193 D4T3TCNVP 2004 Thailand CRF01_AE 1 21 255 VKQWPLTEEKLKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVN Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121194 D4T3TCNVP 2004 Thailand CRF01_AE 1 13 240 KPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKTKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRLKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKYQKEPPFLWLGYELHPDRWT Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121195 AZT3TCNVP 2003 Thailand CRF01_AE 1 21 256 VKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKIKNPELIIYQYVDDLLVASDLEIGQHRTKIEELRAHLLSWGFFTPDEKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVND Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121196 D4T3TCNVP 2005 Thailand CRF01_AE 1 20 258 KVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTVLDVGDAYYSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFKLKNPELTIYQYVDDLLVGSDLEIGQHRIKVEELRAHLLSWGFTTPDKKHQKEPPFHWMGYELHPDKWTVQPIELPEKESWTVNDIQ Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121197 AZT3TCNVP 2004 Thailand CRF01_AE 1 3 240 SPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDIVIYQYVDDLYVSSDLEIGQHRTKIEELRAHLLSWGFFTPDKKHQKEPPFLWMGYDFHPDRWT Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121198 D4T3TCNVP 2006 Thailand CRF01_AE 1 40 231 EMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVICQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGLYTPDQKHQKEPPFRWMG Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121199 D4T3TCNVP 2006 Thailand CRF01_AE 1 20 259 KVKQWPLTEEKIKALTEICKEMEEEGKISRIGPENPYNTPIFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQK Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121200 D4T3TCNVP 2006 Thailand CRF01_AE 1 20 258 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNSPVFAIKKKDSTRWRKLIDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPTIFQSSMTKILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGLTTPDKKHQKEPPFHWMGYELHPDKWTVQPIELPEKDSWTVNDIQ Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121201 D4T3TCNVP 2006 Thailand CRF01_AE 1 36 240 EICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKIKNPEMVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWT Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121202 D4T3TCNVP 2005 Thailand CRF01_AE 1 20 258 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMIKILEPFRTKNPEMVIYQYMDDLYVASDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQ Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121203 D4T3TCNVP 2004 Thailand CRF01_AE 1 9 240 PVTLKPGMDGPKVKQWPLTEEKIIALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIIICQYVDDLYVGSDLEIGQHRTKIEELRAHLLNWGFTTPDKKHQKEPPFLWMGYELHPDRWT Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121204 D4T3TCNVP 2004 Thailand CRF01_AE 1 7 240 TIPVKLKPGMDGPRVKQWPLTEEKIKALTDICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILGPFRIKNPDIVICQYIDDLYVGSDLEIGQHRAKVEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKWT Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121205 AZT3TCNVP 2003 Thailand CRF01_AE 1 3 240 SPIDTVPVTLKPGMDGPKVKLWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWT Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121206 AZT3TCNVP 2004 Thailand CRF01_AE 1 22 253 KQWPLTAEKIKALTEICQEIEKISKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIQELRDHLLKWGFFTPDEKHQKEPPFLWMGYELHRDSWTVQPIQLPEKDSWT Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121207 D4T3TCNVP 2004 Thailand CRF01_AE 1 40 232 EMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHREKIEELRAHLLSWGFTTPDKKHQKEPPFRWMGY Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121208 D4T3TCNVP 2006 Thailand CRF01_AE 1 20 258 KVKQWPLTEEKIKALTEICKELEEEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIIICQYVDDLYVGSDLEIGQHRTKIEELRAHLWSWGFYTPDKKYQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQ Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121209 D4T3TCNVP 2005 Thailand CRF01_AE 1 30 240 KIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDIGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIIICQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGLTTPDKKHQKEPPFRWMGYELHPDRWT Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121210 D4T3TCNVP 2004 Thailand CRF01_AE 1 12 240 LKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPDIVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDNKHQKEPPFRWMGYELHPDKWT Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121211 D4T3TCNVP 2004 Thailand CRF01_AE 1 24 231 WPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWKKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMG Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121212 D4T3TCNVP 2004 Thailand CRF01_AE 1 21 250 VKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKD Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121213 D4T3TCNVP 2005 Thailand CRF01_AE 1 32 239 KALTEICKEMEEEGKISKIGPENPYNTPVFVIKKKNSTKWRKLIDLRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYYSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTRILEPFRIKNPEIVICQYVDDLYVASDLEIGQHRIKVEELRDHLLRWGFTTPDKKYQKEPPFLWMGYELHPDKW Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121214 D4T3TCNVP 2005 Thailand CRF01_AE 1 20 258 KVKQWPLTEEKIKALTEICKEMEEEGKISRIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLRKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKIKNPELVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQ Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121215 D4T3TCNVP 2006 Thailand CRF01_AE 1 20 258 RVKQWPLTEEKIKAITEICRELEEEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDIGDAYFSVPLDPSFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKVLEPFRTKNPEIVICQYVDDLYVGSDLEIEQHRAKIEELRAHLLSWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQ Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121216 D4T3TCNVP 2006 Thailand CRF01_AE 1 32 240 KALIEICKELEEEGKISRIGPENPYNTPVFAIKKKNGNKWRKITDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEMVIYQYVDDLLVGSDLEIGQHRTKIKELRAHLWSWGFYTPDKKHQEEPPFLWMGYELHPDKWT Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121217 D4T3TCNVP 2007 Thailand CRF01_AE 1 20 259 RVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRRKNPEMVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQK Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121218 D4T3TCEFV 2005 Thailand CRF01_AE 1 36 240 EICKEMEEEGKISKIGPENPYNTPVFVIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKTVTVLDVGDAYYSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPMGWKGSPAIFQSSMIKILEPFKIKNPDIVIYHYVDDLLVGSDLEIEQHRAKIEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDRWT Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121219 D4T3TCNVP 2005 Thailand CRF01_AE 1 37 241 ICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTV Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121220 D4T3TCNVP 2007 Thailand CRF01_AE 1 20 258 KVKQWPLTEEKIIALTEICKELEAEGKISRIGPENPYNTPLFAIKKKDSTKWRKLMDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQDSMTRILEPFRIKNPEMIICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGLFTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQ Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121221 D4T3TCNVP 2004 Thailand CRF01_AE 1 37 239 ICKEMEEEGKISRIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNGAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRW Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121222 D4T3TCNVP 2005 Thailand CRF01_AE 1 3 240 SPIDTVPVTLKPGMDGPRVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFVIKKKDGTKWRKLTDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSTMTKILEPFRLKNPELIICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFYTPDKKYQKEPPFLWMGYELHPDKWT Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121223 D4T3TCNVP 2004 Thailand CRF01_AE 1 21 255 VKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVSSDLEIRQHRTKVEELRAHLLSWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVN Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121224 AZT3TCNVP 2006 Thailand CRF01_AE 1 25 248 PLTEEKIKALTEICKELEEEGKISRIGPENPYNTPIFAIKKKNSTRWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFFTPDQKYQKEPPFLWMGYELHPDRWTVQPIELPE Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121225 D4T3TCNVP 2006 Thailand CRF01_AE 1 20 259 KVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEIVIYQYVDDLYVASDLEIGQHRRKIEELRAHLLSWGFFTPDQKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQK Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121226 D4T3TCNVP 2005 Thailand CRF01_AE 1 2 240 ISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVICQYVDDLYVGSDLEIGQHRLKIEELRAHLLSWGFTTPDKKYQKEPPFRWMGYELHPDRWT Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121227 D4T3TCNVP 2004 Thailand CRF01_AE 1 31 240 IKALTEICKEMEEEGKISRIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVASDLEIGQHRTKIEELRAHLLNWGFTTPDKKHQKEPPFLWMGYELHPDRWT Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121228 D4T3TCNVP 2006 Thailand CRF01_AE 1 20 258 KVKQWPLTEEKIKALTEICKELEEDGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLAQKKSVTVLDVGDAYFSIPLHESFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRAHLWNWGFYTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQ Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121229 AZT3TCNVP 2006 Thailand CRF01_AE 1 20 258 KVKQWPLTEEKLKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRIKIEELRAHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQ Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121230 D4T3TCEFV 2005 Thailand CRF01_AE 1 31 240 IKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIEIYQYVDDLYVGSDLEIGQHRTKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWT Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121231 D4T3TCNVP 2004 Thailand CRF01_AE 1 21 253 VKQWPLTKEKIKALTEICKEMEEEGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRARNPEITIYQYVDDLYIASDLEIGQHRIKIEELRAHLLSWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWT Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121234 D4T3TCEFV 2005 Thailand CRF01_AE 1 31 240 IKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEMVIYQYVDDLYIGSDLEIGQHRKKIEELRTHLLSWGFYTPDKKYQKEPPFLWLGYEIHPDRWT Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2147 121235 D4T3TCNVP 2004 Thailand CRF01_AE 1 20 253 KVKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYYSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQCSMTKILEPFRKQNPDIVICQYIDDLYVGSDLEIGQHRAKIEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWT Puthanakit, T 2010 20345882 HIV Med HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. 2161 124788 AZT3TCNVP 2008 Rwanda A 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVPLTEEAELELAENREILKDPVHGVYYDPSKDLIAEIQKQGQ Rusine, J 2013 23950859 PLoS ONE Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda. 2161 124789 AZT3TCNVP 2010 Rwanda A 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTAEKIKALTEICLEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVTLTREAELELAENREILKDPVHGVYYDPSKDLIAEIQKQGQ Rusine, J 2013 23950859 PLoS ONE Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda. 2161 124790 AZT3TCNVP 2009 Rwanda A 0 1 334 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIRKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLQKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPEIIIYQYVDDLYVASDLEIGQHRKKVEELRAHLLSWGFTTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGTKALTEVVTLTEEAELELAENREILKDPVHGVYYDPSKDLIAEIQKQGQ Rusine, J 2013 23950859 PLoS ONE Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda. 2161 124791 AZT3TCNVP 2010 Rwanda C 0 1 333 PISPIKTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLEESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRLKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIQLPDKDSWTVNDVQKLVGKLNWASQIYPGVQVRNLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQG Rusine, J 2013 23950859 PLoS ONE Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda. 2161 124792 AZT3TCNVP 2009 Rwanda C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKDGKIEKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVPLTEEAELELAENREILKGPVHGVYYDPSKDLIAEVQKQG Rusine, J 2013 23950859 PLoS ONE Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda. 2161 124793 AZT3TCNVP 2010 Rwanda A 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICMEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSTNNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPDIIIYQYVDDLYVASDLEIGQHRVKVEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDVVTLTEEAELELAENREILKDPVHGAYYDPSKELIAEIQKQGQG Rusine, J 2013 23950859 PLoS ONE Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda. 2161 124794 AZT3TCNVP 2009 Rwanda A 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICNEMEKDGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNATPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPDIIIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKDPVHGVYYDPSKDLIAEIQKQGQ Rusine, J 2013 23950859 PLoS ONE Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda. 2161 124795 AZT3TCNVP 2009 Rwanda A 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRSKNPEIIICQYMDDLYVASDLEIGQHRVKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDVVTLTEEAELELAENREILKEPVHGAYYDPSKELIAEIQKQGQ Rusine, J 2013 23950859 PLoS ONE Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda. 2161 124796 AZT3TCNVP 2009 Rwanda A 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKITRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNRRTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIIIYQYMDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQGQ Rusine, J 2013 23950859 PLoS ONE Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda. 2161 124797 AZT3TCNVP 2007 Rwanda A 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIIIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTEXVTLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Rusine, J 2013 23950859 PLoS ONE Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda. 2161 124798 AZT3TCNVP 2010 Rwanda CRF01_AE 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKLSRVGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKNNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNQTPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIIYQYVDDLYVGSDLDIGQHRAKIEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVVTLTEEAELELAENREILKDPVHGVYYDPSKDLTAEIQKQGQ Rusine, J 2013 23950859 PLoS ONE Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda. 2162 124904 AZT3TCNVP 2010 Ghana CRF02_AG 0 1 266 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALKDICAEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRNKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQSITLPDQDSWTVNDIQKLVGKLNW Nii-Trebi, NI 2013 23977189 PLoS ONE HIV-1 drug-resistance surveillance among treatment-experienced and -naive patients after the implementation of antiretroviral therapy in Ghana. 2162 124905 AZT3TCNVP 2010 Ghana CRF02_AG 0 1 266 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLYEEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKYPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDTWTVQPIQLPDKDSWTVNDIQKLIGKLNW Nii-Trebi, NI 2013 23977189 PLoS ONE HIV-1 drug-resistance surveillance among treatment-experienced and -naive patients after the implementation of antiretroviral therapy in Ghana. 2162 124906 AZT3TCEFV 2009 Ghana D 0 1 266 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICLEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRNKNPEIVIYQYVDDLYVGSDLELEQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNW Nii-Trebi, NI 2013 23977189 PLoS ONE HIV-1 drug-resistance surveillance among treatment-experienced and -naive patients after the implementation of antiretroviral therapy in Ghana. 2162 124907 D4T3TCEFV 2010 Ghana CRF02_AG 0 1 266 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTNNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGHELHPDKWTVQPIQLPTKDSWTVNDIQKLVGKLNW Nii-Trebi, NI 2013 23977189 PLoS ONE HIV-1 drug-resistance surveillance among treatment-experienced and -naive patients after the implementation of antiretroviral therapy in Ghana. 2162 124909 AZT3TCEFV 2010 Ghana CRF02_AG 0 1 266 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKDICTEMEKEGKISKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSATVLDVGDAYFSVPLDETFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVICQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPVQLPEKDSWTVNDIQKLVGKLNW Nii-Trebi, NI 2013 23977189 PLoS ONE HIV-1 drug-resistance surveillance among treatment-experienced and -naive patients after the implementation of antiretroviral therapy in Ghana. 2162 124910 AZT3TCNVP 2009 Ghana CRF01_AE 0 1 266 PISPIKTVPVTLKPGMDGPKVKQWPLTEEKIKALTAICKEMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNEKPGVRYQYNVLPQGWKGSPAIFQYSMTKILEPYRAQNPEIIIYQYVDDLYVASDLEIGQHRAKIEELRAHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPHKDSWTVNDIQKLVGKLNW Nii-Trebi, NI 2013 23977189 PLoS ONE HIV-1 drug-resistance surveillance among treatment-experienced and -naive patients after the implementation of antiretroviral therapy in Ghana. 2162 124911 D4T3TCEFV 2010 Ghana CRF02_AG 0 1 266 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICTEMEKEGKISKIGPENPYNTPIFAIKKKGGTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPDMVIYQYVDDLYVGSDLEIGEHRKRIEELREHLLRWGFVTPDEKHQKEHPFLWMGYELHPDKWTIQPITLPNKDSWTVNDIQKLVGKLNW Nii-Trebi, NI 2013 23977189 PLoS ONE HIV-1 drug-resistance surveillance among treatment-experienced and -naive patients after the implementation of antiretroviral therapy in Ghana. 2162 124912 AZT3TCNVP 2009 Ghana CRF02_AG 0 1 266 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTELEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQDSMTRILEPFRTENPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNW Nii-Trebi, NI 2013 23977189 PLoS ONE HIV-1 drug-resistance surveillance among treatment-experienced and -naive patients after the implementation of antiretroviral therapy in Ghana. 2162 124917 AZT3TCEFV 2010 Ghana CRF02_AG 0 1 266 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQASMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNW Nii-Trebi, NI 2013 23977189 PLoS ONE HIV-1 drug-resistance surveillance among treatment-experienced and -naive patients after the implementation of antiretroviral therapy in Ghana. 2162 124918 AZT3TCNVP 2010 Ghana CRF02_AG 0 1 266 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIEALTAICKEMEAEGKISKIGPENPYNTPIFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTIIDVGDAYFSVPLHEDFRKYTAFTIPSRNNERPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGLFTPDQKHQKEPPFHWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNW Nii-Trebi, NI 2013 23977189 PLoS ONE HIV-1 drug-resistance surveillance among treatment-experienced and -naive patients after the implementation of antiretroviral therapy in Ghana. 2162 124919 D4T3TCEFV 2009 Ghana CRF02_AG 0 1 266 PISPIETVPVKLNPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSITILDVGDAYFSVPLDPDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMIKILDPFRARNPELVIYQYVDDLYVSSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNW Nii-Trebi, NI 2013 23977189 PLoS ONE HIV-1 drug-resistance surveillance among treatment-experienced and -naive patients after the implementation of antiretroviral therapy in Ghana. 2162 124928 AZT3TCEFV 2010 Ghana G 0 1 266 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKELEEDGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGLPHPGGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIIIYQYVDDLYIASDLEIGQHRAKIEELREYLWKWGFYTPDNKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNW Nii-Trebi, NI 2013 23977189 PLoS ONE HIV-1 drug-resistance surveillance among treatment-experienced and -naive patients after the implementation of antiretroviral therapy in Ghana. 2162 124933 D4T3TCEFV 2009 Ghana G 0 1 266 PISPIGTVPVKLKPGMDGPKVKQWPLTEEKIKALKEICTELEKEGKISKIGPDNPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRMKNPEMEIYQYMDDLYVGSDLELGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPVKESWTVNDIQKLVGKLNW Nii-Trebi, NI 2013 23977189 PLoS ONE HIV-1 drug-resistance surveillance among treatment-experienced and -naive patients after the implementation of antiretroviral therapy in Ghana. 2162 124937 AZT3TCEFV 2009 Ghana CRF02_AG 0 1 266 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRSQNPEIIIYQYMDDLYVGSDLEIEQHRTKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNW Nii-Trebi, NI 2013 23977189 PLoS ONE HIV-1 drug-resistance surveillance among treatment-experienced and -naive patients after the implementation of antiretroviral therapy in Ghana. 2162 124938 D4T3TCEFV 2010 Ghana CRF01_AE 0 1 266 PISPIETIPVTLKPGMDGPKVKQWPLTEEKIKALTAICKEMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQHSMTKILEPYRAQNPDMIIYQYMDDLLVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPHKDSWTVNDIQKLVGKLNW Nii-Trebi, NI 2013 23977189 PLoS ONE HIV-1 drug-resistance surveillance among treatment-experienced and -naive patients after the implementation of antiretroviral therapy in Ghana. 2162 124940 AZT3TCNVP 2010 Ghana CRF02_AG 0 1 266 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQTSMTKILEPFRMKNPEMVIYQYVDDLYVGSDLEIGQHRAKIDELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDTWTVQTIQLPEKDSWTVNDIQKLVGKLNW Nii-Trebi, NI 2013 23977189 PLoS ONE HIV-1 drug-resistance surveillance among treatment-experienced and -naive patients after the implementation of antiretroviral therapy in Ghana. 2162 124942 AZT3TCNVP 2009 Ghana CRF02_AG 0 1 266 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDPEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILQPFRDKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWLGYELHPDKWTVQPIQLPSKDPWTVNDIQKLVGKLNW Nii-Trebi, NI 2013 23977189 PLoS ONE HIV-1 drug-resistance surveillance among treatment-experienced and -naive patients after the implementation of antiretroviral therapy in Ghana. 2167 126069 AZT3TCEFV 2006 Republic Of Georgia A 0 35 246 LNFCKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSTMTKILEPFRLKNPEIVIYQYVDDLYVGSDLEIGQHRTKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIML Dvali, N 2012 22585715 J Med Virol Characterization of HIV-1 subtypes and drug resistance mutations among individuals infected with HIV in Georgia. 2167 126071 D4T3TCEFV 2006 Republic Of Georgia A 0 30 247 QIGCTLNFCNEMEKEGKISKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPDIVIYQYMDDLYVSSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Dvali, N 2012 22585715 J Med Virol Characterization of HIV-1 subtypes and drug resistance mutations among individuals infected with HIV in Georgia. 2167 126072 AZT3TCEFV 2006 Republic Of Georgia B 0 30 247 QIGCTLNFGTEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRTKIEELRDHLLRWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Dvali, N 2012 22585715 J Med Virol Characterization of HIV-1 subtypes and drug resistance mutations among individuals infected with HIV in Georgia. 2167 126073 AZT3TCNVP 2008 Republic Of Georgia A 0 35 247 LNFCKEMEEEGKISKVGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRLKNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Dvali, N 2012 22585715 J Med Virol Characterization of HIV-1 subtypes and drug resistance mutations among individuals infected with HIV in Georgia. 2167 126074 AZT3TCEFV 2006 Republic Of Georgia A 0 35 247 LNFCMEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSRNPEIIIYQYVDDLYVSSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Dvali, N 2012 22585715 J Med Virol Characterization of HIV-1 subtypes and drug resistance mutations among individuals infected with HIV in Georgia. 2167 126075 AZT3TCNVP 2007 Republic Of Georgia A 0 30 247 QIGCTLNFCKELEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPXIEIYQYVDDLYIGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLP Dvali, N 2012 22585715 J Med Virol Characterization of HIV-1 subtypes and drug resistance mutations among individuals infected with HIV in Georgia. 2167 126076 D4T3TCEFV 2006 Republic Of Georgia A 0 35 247 LNFCNEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFITPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Dvali, N 2012 22585715 J Med Virol Characterization of HIV-1 subtypes and drug resistance mutations among individuals infected with HIV in Georgia. 2167 126078 AZT3TCNVP 2007 Republic Of Georgia A 0 35 247 LNFCMEMEKEGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIVIYQYVDDLYVSSDLEIGQHRAKIEELRPHLLSWGLTTPDKKHQKEPPFLWMGYELHPEKWTVQPIVLP Dvali, N 2012 22585715 J Med Virol Characterization of HIV-1 subtypes and drug resistance mutations among individuals infected with HIV in Georgia. 2167 126079 AZT3TCEFV 2007 Republic Of Georgia A 0 35 247 LNFCKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSITILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRLKNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPITLP Dvali, N 2012 22585715 J Med Virol Characterization of HIV-1 subtypes and drug resistance mutations among individuals infected with HIV in Georgia. 2167 126082 AZT3TCEFV 2007 Republic Of Georgia A 0 35 247 LNFCMEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIVIYQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLP Dvali, N 2012 22585715 J Med Virol Characterization of HIV-1 subtypes and drug resistance mutations among individuals infected with HIV in Georgia. 2167 126083 D4T3TCNVP 2008 Republic Of Georgia A 0 30 247 QIGCTLNFCKEMEKEGKISKIGPENPYNTPVFVIKRKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRLKNPDIVICQYIDDLYVSSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLP Dvali, N 2012 22585715 J Med Virol Characterization of HIV-1 subtypes and drug resistance mutations among individuals infected with HIV in Georgia. 2167 126084 AZT3TCNVP 2007 Republic Of Georgia A 0 30 247 QIGCTLNFCSEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPDIVIYQYVDDLYVSSDLEIGQHRTKIEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Dvali, N 2012 22585715 J Med Virol Characterization of HIV-1 subtypes and drug resistance mutations among individuals infected with HIV in Georgia. 2167 126085 AZT3TCNVP 2007 Republic Of Georgia A 0 30 247 QIGCTLNFCREMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVLDVGDAYFSVPLDENFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLP Dvali, N 2012 22585715 J Med Virol Characterization of HIV-1 subtypes and drug resistance mutations among individuals infected with HIV in Georgia. 2167 126086 AZT3TCEFV 2006 Republic Of Georgia A 0 30 246 QIGCTLNFCREMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEV*LGIPHPAGLKKKKSITVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRLKNPEIIIYQYVDDLYVSSDLEIGQHRTKVEELRAHLLSWGFYTPDQKHQKEPPFRWLGYELHPDKWTVQPIML Dvali, N 2012 22585715 J Med Virol Characterization of HIV-1 subtypes and drug resistance mutations among individuals infected with HIV in Georgia. 2167 126087 D4T3TCNVP 2006 Republic Of Georgia A 0 30 247 QIGCTLNFCKYMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPGIIICQYMDDLYVGSDLEIGEHRTKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKWTIQPIMLP Dvali, N 2012 22585715 J Med Virol Characterization of HIV-1 subtypes and drug resistance mutations among individuals infected with HIV in Georgia. 2167 126088 AZT3TCEFV 2008 Republic Of Georgia A 0 30 247 QIGCTLNFCKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPDIEIYQYVDDLYVSSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLP Dvali, N 2012 22585715 J Med Virol Characterization of HIV-1 subtypes and drug resistance mutations among individuals infected with HIV in Georgia. 2167 126089 AZT3TCEFV 2007 Republic Of Georgia B 0 30 247 QIGCTLNFCTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLSWGFYTPDKKHQKEPPFLWLGYELHPDKWTVQPIVLP Dvali, N 2012 22585715 J Med Virol Characterization of HIV-1 subtypes and drug resistance mutations among individuals infected with HIV in Georgia. 2167 126090 AZT3TCNVP 2007 Republic Of Georgia A 0 30 247 QIGCTLNFCKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRLKNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPITLP Dvali, N 2012 22585715 J Med Virol Characterization of HIV-1 subtypes and drug resistance mutations among individuals infected with HIV in Georgia. 2167 126091 D4T3TCEFV 2007 Republic Of Georgia A 0 35 247 LNFCNEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPGIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDRKHQKEPPFLWMGYELHPDKWTVQPIMLP Dvali, N 2012 22585715 J Med Virol Characterization of HIV-1 subtypes and drug resistance mutations among individuals infected with HIV in Georgia. 2167 126092 AZT3TCEFV 2007 Republic Of Georgia A 0 35 247 LNFCRELEEEGKISRIGPENPYNTPVFAIKKKNSTRWRKILDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIIYQYVDDLYVSSDLEIGKHRAKVEELRAHLWRWGFYTPDEKHQKEPPFLWMGYELHPDKWTVQPIMLP Dvali, N 2012 22585715 J Med Virol Characterization of HIV-1 subtypes and drug resistance mutations among individuals infected with HIV in Georgia. 2167 126093 AZT3TCNVP 2006 Republic Of Georgia A 0 35 247 LNFCMEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDASFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGLTTPDKKHQKEPPFRWMGYELHPDKWTVQPIMLP Dvali, N 2012 22585715 J Med Virol Characterization of HIV-1 subtypes and drug resistance mutations among individuals infected with HIV in Georgia. 2167 126094 AZT3TCEFV 2006 Republic Of Georgia A 0 35 247 LNFCMEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIVIYQYVDDLYVSSDLEIGQHRTKIEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Dvali, N 2012 22585715 J Med Virol Characterization of HIV-1 subtypes and drug resistance mutations among individuals infected with HIV in Georgia. 2169 126189 AZT3TCNVP 2004 Kenya A 0 1 244 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126191 AZT3TCNVP 2006 Kenya D 0 1 244 PISPIDTVPVKLKPGMDGPKIKQWPLTEEKIKALTEICLDMEKEGKISRIGPENPYNTPIFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVICQYVDDLYVGSDLEIGQHRIKIKELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126192 AZT3TCNVP 2005 Kenya A 0 1 244 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNEMPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIIIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126193 AZT3TCNVP 2005 Kenya A 0 1 244 PISPIETVPVTLKPGMDGPRVKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRSQNPEIIIYQYVDDLYVGSDLEIGQHRAKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126194 AZT3TCNVP 2005 Kenya A 0 1 244 PISPIETVPVTLKPGMDGPRIKQWPLTEEKIKALTEICMEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPDLIIYQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFSTPDEKHQKEPPFLWMGYELHPDTWTVQPI Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126197 AZT3TCNVP 2005 Kenya D 0 1 244 PISPIKAVPVQLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPELVIYQYMDDLYVGSDLEIEQHRTKIEKLRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126198 AZT3TCNVP 2005 Kenya A 0 1 244 PISPIETVPVKLKPGMDGPKVKQWPLTGEKIKALTEICTDMEKEGKISRIGPDNPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIRQHRVKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126200 AZT3TCNVP 2006 Kenya D 0 1 244 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYMDDLYVGSDLEIGQHRIKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126201 AZT3TCNVP 2005 Kenya A 0 1 244 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPELVIYQYMDDLYVGSDLEIGQHRTKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126202 AZT3TCNVP 2007 Kenya A 0 1 244 PISPIETVPVKLKPGMDGPKIKQWPLSEEKIKALTEICADMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEMVIYQYVDDLYVASDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126206 AZT3TCNVP 2005 Kenya A 0 1 244 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIIIYQYVDDLLVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126208 AZT3TCNVP 2005 Kenya A 0 1 244 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRDHLLKWGFTTPDKKHQKDPPFLWMGYELHPDKWTVQPI Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126209 AZT3TCNVP 2005 Kenya A 0 1 244 PISPITTVPVKLKPGMDGPKVKQWPLTAEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLFEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVICQYVDDLYVASDLEIGQHRTKIQELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126210 AZT3TCNVP 2004 Kenya A 0 1 244 PISQIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRSKNPEIIIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126212 AZT3TCNVP 2004 Kenya A 0 1 244 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRSKNPEIIIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126213 AZT3TCNVP 2007 Kenya A 0 1 244 PISPIETVPVTLKPGMDGPRIKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDKNFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPGITIYQYMDDLYVGSDLEIGQHRAKVEELRAHLLNWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126214 AZT3TCNVP 2005 Kenya A 0 1 244 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126215 AZT3TCNVP 2004 Kenya C 0 1 244 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICAEMEKEGKIEKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIIIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126216 AZT3TCNVP 2006 Kenya A 0 1 244 PISTIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICMEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAVFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGKHRAKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126218 AZT3TCNVP 2005 Kenya A 0 1 244 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEEFRKYTAFTIPSTNNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEVVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126219 AZT3TCNVP 2007 Kenya C 0 1 244 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLADFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126220 AZT3TCNVP 2005 Kenya D 0 1 244 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAVFQSSMTKILEPFRKQNPEMVIYQYMDDLYVGSDLEIRQHRRKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126223 AZT3TCNVP 2006 Kenya D 0 1 244 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPV Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126224 AZT3TCNVP 2004 Kenya A 0 1 244 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTEICLEMEKEGKISKIGPENPYNTPVFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLHEDFRKYTAFTIPSINNATPGVRYQYNVLPQGWKGSPAIFQSSMMKILEPFRNKNPEIIIIQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126225 AZT3TCNVP 2005 Kenya A 0 1 243 PISPIEAVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTDMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIIIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQP Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126227 AZT3TCNVP 2005 Kenya C 0 1 244 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKRSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126228 AZT3TCNVP 2005 Kenya A 0 1 244 PISPIETVPVALKPGMDGPKVKQWPLTAEKIKALTEICIEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPDIIIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2169 126229 AZT3TCNVP 2005 Kenya A 0 1 244 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMIKILEPFRSKNPEIIIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Inzaule, S 2013 23224100 J Clin Microbiol Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. 2170 126230 TDFFTCEFV 2009 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSLNNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKESWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126231 TDFFTCEFV 2008 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPRVRQWPLTEEKIKALTEICKDMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSVNNESPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFREKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126232 TDFFTCEFV 2009 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPRVRQWPLTEEKIKALTEICKDMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESVRKYTAFTIPSVNNESPGIRYQYNVLPQGWKGSPAIFQSSMTKILGPFREKNPEIVICQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126233 TDFFTCNVP 2010 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKRKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPELVIYQYVDDLYVASDLEIGQHRAKIEELRKHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126234 TDFFTCEFV 2009 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRNHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126235 TDFFTCEFV 2009 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKNNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPVQLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126236 TDF3TCEFV 2009 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126237 TDF3TCEFV 2010 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMAICEEMEKEGQITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126238 TDFFTCEFV 2008 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPDKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126239 TDF3TCNVP 2010 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYIDDLYVGSDLEIGPHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDNWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126240 TDF3TCEFV 2010 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICSEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126241 TDF3TCEFV 2010 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMAICEEMEKEGQITKIGPENPYNTPVFAIKKKDSTQWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPDIVICQYVDDLYVASDLEIGQHRAKIEELRKHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126242 TDFFTCEFV 2010 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILDPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126243 TDFFTCEFV 2008 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126244 TDFFTCEFV 2008 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPRVRQWPLTEEKIKALTEICKDMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNESPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFREKNPEIVICQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126245 TDFFTCEFV 2010 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPDKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126246 TDF3TCEFV 2010 South Africa C 0 1 255 PISHIETIPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDLCEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126247 TDF3TCNVP 2010 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVIYQYMDDLYVGSDLEIGKHREKIEELRQHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126248 TDFFTCEFV 2009 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIQNPEIVIYQYMDDLYVGSDLEIVQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126249 TDFFTCEFV 2010 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMIKILEPFRRQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126250 TDF3TCNVP 2008 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAVFQSSMTKILEPFRTQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126251 TDFFTCNVP 2010 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEELEKDGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVICQYMDDLYVGSDLEIGQHRAKIEELREHLWKWGFYTPDKKHQKEYPFQWMGYELHPDKWTVQPIQLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126252 TDFFTCEFV 2009 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126253 TDF3TCNVP 2009 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNEIPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRTHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126254 TDFFTCEFV 2009 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNAVPGIRYQYNVLPQGWKGSPAIFQWSMTKILEPFRAQNPEIIIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126255 TDF3TCNVP 2010 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYIDDLYVGSDLEIGPHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDNWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126256 TDF3TCEFV 2009 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNRRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIDIYQYMDDLYVGSDLEIGQHRAKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126258 TDF3TCEFV 2010 South Africa C 0 1 255 PISPIETVPVKLKPGIDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNRRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIDIYQYVDDLYVGSDLEIGQHRAKITELREHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126259 TDFFTCEFV 2009 South Africa C 0 1 255 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKNNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126260 TDFFTCEFV 2010 South Africa C 0 1 255 PISPIETIPVKLKPEMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126261 TDF3TCEFV 2008 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126262 TDFFTCEFV 2009 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNATPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYMDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126263 TDF3TCNVP 2010 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPRVKQWPLTDEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTRWRKLVDFRELNRRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNAIPGIRYQYNVLPQGWKGSPAIFQASMTKILKPFRDQNPDIVIYQYVDDLYVGSDLEIGQHREKIEELREHLLKWGLTTPDQKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126264 TDF3TCNVP 2010 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTEWRKLVDFRELNKRTQDFCEVQLGIPHPGGLTKKKSVTILDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPGLVICQYVDDLYVGSDLEIGQHRAKIQELRDHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126265 TDF3TCNVP 2010 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEKLREHLLRWGFTTPDKKHQREPPFLWMGYELHPDKWTVQPILLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126266 TDFFTCEFV 2010 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIEHHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQAIQLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126267 TDF3TCNVP 2010 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPTIFQSSMTKILEPFRARNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126268 TDFFTCEFV 2010 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEQLRAHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126270 TDFFTCEFV 2009 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALIEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEIQLGIPHPAGIKKNKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMVKILGPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKVEKLREHLLKWGLTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126271 TDFFTCNVP 2009 South Africa C 0 1 255 PISSIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126272 TDF3TCNVP 2010 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQEFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYENFKKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTQNPDLVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126273 TDFFTCEFV 2009 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNRRTQDFWEVQLGIPHPSGLKKNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126274 TDFFTCEFV 2010 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITRIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIDIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFQWMGYELHPDKWTVQPICLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126275 TDF3TCNVP 2010 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVIYQYMDDLYVGSDLEIGQHRAKIDELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126276 TDFFTCEFV 2010 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPSIFQCSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEKLREHLLMWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPDKDIWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126277 TDFFTCEFV 2009 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNKDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLQWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126278 TDF3TCNVP 2010 South Africa C 0 1 255 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPGLVIYQYMDDLYVGSDLEIGQHRAKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126279 TDF3TCNVP 2009 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRRYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAQNPEIVIYQYMDDLYVGSDLEIGQHRAKIKELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126280 TDFFTCEFV 2010 South Africa C 0 1 255 PISSIETVPVKLKPGMDGPRVKQWPLTEEKIQALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDEGFRKYTAFTIPSINNETPGIRYEYNVLPQGWKGSPAIFQSSMIKILEPFRTKNPEIVIYQYMDDLYVGSDLEIEQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDNWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2170 126281 TDFFTCEFV 2008 South Africa C 0 1 255 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRKQNPNLVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVN Hoffmann, CJ 2013 23751421 Antivir Ther Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. 2176 127852 AZT3TCNVP 2008 Senegal CRF02_AG 1 1 238 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTDICMEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNKTPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYMDDLYVASDLEIGQHREKIEKLREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Kebe, K 2013 22860571 ARHR High rate of antiretroviral drug resistance mutations in HIV type 1 infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines. 2176 127855 AZT3TCNVP 2008 Senegal D 1 1 267 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRFGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQHSMIKILEPFRTKNPELVICQYVDDLYVASDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPITLPEKESWTVNDIQKLVGKLNWA Kebe, K 2013 22860571 ARHR High rate of antiretroviral drug resistance mutations in HIV type 1 infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines. 2176 127856 AZT3TCEFV 2009 Senegal CRF02_AG 1 1 275 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYVDDLLVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIK Kebe, K 2013 22860571 ARHR High rate of antiretroviral drug resistance mutations in HIV type 1 infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines. 2176 127862 AZT3TCNVP 2008 Senegal CRF02_AG 1 1 275 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICAEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFFTPDEKHQKEPPFLWMGYELHPDTWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIK Kebe, K 2013 22860571 ARHR High rate of antiretroviral drug resistance mutations in HIV type 1 infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines. 2176 127872 AZT3TCNVP 2010 Senegal CRF02_AG 1 1 238 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICLEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPSIFQASMLKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLRWGFYTPDKKHQKEPPFLWMGYELHPDK Kebe, K 2013 22860571 ARHR High rate of antiretroviral drug resistance mutations in HIV type 1 infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines. 2176 127878 D4T3TCNVP 2008 Senegal CRF02_AG 1 1 271 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPITLPEKDSWTVNDIQKLVGKLNWASQIY Kebe, K 2013 22860571 ARHR High rate of antiretroviral drug resistance mutations in HIV type 1 infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines. 2176 127879 AZT3TCNVP 2010 Senegal CRF02_AG 1 1 238 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRRHLLEWGFTTPDKKHQKEPPFLWMGYELHPDK Kebe, K 2013 22860571 ARHR High rate of antiretroviral drug resistance mutations in HIV type 1 infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines. 2176 127881 AZT3TCEFV 2010 Senegal CRF02_AG 1 1 238 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICLEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDK Kebe, K 2013 22860571 ARHR High rate of antiretroviral drug resistance mutations in HIV type 1 infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines. 2176 127882 AZT3TCNVP 2010 Senegal CRF02_AG 1 1 238 PIIPMETVPVKLKPGMDGPKIKQWPLTEEKIKALTDFCAELEKEGKISRIGSENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLEKKKSVTILDVGDAYFSVPLEENFRKYTAFTIPSVNNETPGVRYQYNVLPQGWKGSPAIFQTSMTKIL*PFRTQNPEMVICQYVDDLYVGSDLEIGQHRTKIEELRAHLLKWGFSTPDKKHQKEPPFRWMGYELHPDK Kebe, K 2013 22860571 ARHR High rate of antiretroviral drug resistance mutations in HIV type 1 infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines. 2176 127883 AZT3TCNVP 2009 Senegal CRF02_AG 1 1 334 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRRHLLEWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVKQLCRLIRGTKALTDVVTLTKEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Kebe, K 2013 22860571 ARHR High rate of antiretroviral drug resistance mutations in HIV type 1 infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines. 2176 127884 AZT3TCNVP 2007 Senegal CRF02_AG 1 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICAELEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTLPSLNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVICQ*VDDLYVGSDLEIGQHRAKIEELREHLWRWGFFTPDKKYQKEPPFLWMGYELHPDKWTVQPIKLPEQDSWTVNDIQKLVGKLNWASQIYPGIRVKQLCKLLKGAKALTDIVALTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQG Kebe, K 2013 22860571 ARHR High rate of antiretroviral drug resistance mutations in HIV type 1 infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines. 2176 127889 AZT3TCNVP 2008 Senegal G 1 1 275 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQSIKLPDKDSWTVNDIQKLVGKLNWASQIYAGIK Kebe, K 2013 22860571 ARHR High rate of antiretroviral drug resistance mutations in HIV type 1 infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines. 2176 127891 AZT3TCNVP 2009 Senegal CRF02_AG 1 1 238 PISPIETVPVRLKPGMDGPKVKQWPLSEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLDPEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRQKNPEIIIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDK Kebe, K 2013 22860571 ARHR High rate of antiretroviral drug resistance mutations in HIV type 1 infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines. 2176 127895 D4T3TCNVP 2008 Senegal CRF02_AG 1 1 271 PISPIETVPVKLKPGMDGPRIKQWPLSEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAINKKDSTKWRKLVDFRELKKRTQDFWEVQLGIPHPAGLKKNKSATVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIY Kebe, K 2013 22860571 ARHR High rate of antiretroviral drug resistance mutations in HIV type 1 infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines. 2187 131428 AZT3TCEFV 2012 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNKTPGIRYQYNVLPQGWKGSPSIFQCSMTKILEPFRSRNPELVIYQYVDDLYVSSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131430 AZT3TCEFV 2010 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGKISKIGPENPYNTPVFVIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPDIVIYQYVDDLYISSDLEIGQHRTKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131432 AZT3TCNVP 2012 Russia B 0 1 251 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGEISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYMDDLYVASDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131433 AZT3TCEFV 2011 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQXSMTKILEPFRVKNPEIVIYQYMDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131434 AZT3TCNVP 2010 Russia A 0 1 251 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTDICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIVIYQYMDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPITLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131436 AZT3TCNVP 2011 Russia A 1 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFKSKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIXLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131437 AZT3TCEFV 2013 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKFLEPFRLKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEHPFLWMGYELHPDTWTVQPVMLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131439 ABC3TCNVP 2012 Russia CRF02_AG 1 1 251 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTDMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRRKNPEIVICQYIDDLYVGSDLEIGQHRAKVEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131441 AZT3TCEFV 2013 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTDICNEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILDPFRAKNPEIIIYQYMDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131442 AZT3TCNVP 2010 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNRRTQDFWEVQLGIPHPAGLEKKKSITVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRLKNPEIVIYQYVDDLYVTSDLEIGQHREKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131443 AZT3TCEFV 2011 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGKISKIGPENPYNTPVFVIKKKDSSKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRSKNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLNWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131444 AZT3TCEFV 2011 Russia A 0 1 251 PISPIETVPVTLKPGMDGPRVKQWPLTEEKIKALIEICEEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRLKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131447 AZT3TCNVP 2011 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIEICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMIKILEPFRAKNPDIVIYQYVDDLYVSSDLEIKQHRAKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131448 AZT3TCNVP 2010 Russia A 1 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGKISRIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRLKNPEIVIYQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKDPPFLWMGYELHPDKWTVQPIMLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131449 AZT3TCEFV 2012 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICNEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNRRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRVKNPEVVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131450 AZT3TCEFV 2010 Russia A 0 1 251 PISPIETVPVTLKPGMDWPKVKPWPLTEGKIKALIEICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKFLEPFRNKNPDIVIFQYVDDLYVGSDLEIGQHRTKIEELRQHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131452 AZT3TCEFV 2011 Russia A 0 1 251 PISPIKTVPVTLKPGMDGPKVKQWPLTGEKIKALIEICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIIIYQYVDDLYVSSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131453 AZT3TCEFV 2010 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEEEGKISRIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTRILEPFRIKNPEIVIYQYVDDLYVSSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131455 AZT3TCNVP 2010 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKKKSITVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRLKNPDIVIYQYVDDLYVSSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131458 AZT3TCEFV 2012 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTDICNEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTRILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKDPPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131460 AZT3TCEFV 2010 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNRRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRLKNPEIVIYQYMDDLYVGSDLEIGKHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131471 D4T3TCEFV 2013 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTDICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPDIVIYQYVDDLYVSSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131474 AZT3TCNVP 2010 Russia A 1 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGKISKIGPENPYNTPVFVIKKKNSTRWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIVICQYVDDLYVGSDLEIGQHRIKVEELRAHLLSWGFITPDEKHQKEPPFRWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131475 AZT3TCEFV 2013 Russia CRF02_AG 0 1 251 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRRKNPEIVIYQYMDDLYVGSDLDIGQHRAKIEELRVHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131476 AZT3TCEFV 2010 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTDICKEMEKEGKISRIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSITVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDIVIYQYVDDLYVSSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131483 AZT3TCEFV 2010 Russia A 1 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGKISRIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTRILEPFRLKNPDIVIYQYVDDLYVSSDLEIGQHRAKIEDLRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131484 ABC3TCEFV 2012 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTDICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRLKNPGVVIYQYVDDLYVASDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131489 AZT3TCNVP 2011 Russia A 1 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKNNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131491 AZT3TCEFV 2010 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRLKNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131493 AZT3TCEFV 2013 Russia CRF02_AG 0 1 251 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTDMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTILDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRRNNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLNWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131499 AZT3TCNVP 2011 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTKEKIKALTDICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIVICQYVDDLYVASDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131500 ABC3TCEFV 2012 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRLKNPDIVIYQYVDDLYVSSDLEIGQHRTKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131503 AZT3TCEFV 2013 Russia A 0 1 251 PISPIKTVPVTLKPGMDGPKVKQWPLTEEKIKALTDICMEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTQILEPFRSKNPEIVIYQYMDDLYVSSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131504 AZT3TCEFV 2011 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICEEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPSIFQSSMIKILDPFRSKNPELVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131508 AZT3TCEFV 2011 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKLKALIEICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLIDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRLKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRADLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131509 ABC3TCEFV 2012 Russia CRF02_AG 0 1 251 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRRKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLNWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131511 AZT3TCEFV 2011 Russia A 1 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTRILEPFREKNPEVVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131513 ABC3TCNVP 2013 Russia A 1 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTDICSEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAFFSVPLDKNFKKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEMIIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKNS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131514 AZT3TCEFV 2011 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICTEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPDIVIYQYVDDLYVSSDLEIGQHRTKIEELRAHLLSWGFSTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131522 AZT3TCEFV 2010 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTDICKELEKEGKISRIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEIVIYQYVDDLYVSSDLEIGQHRTKIEELRAHLWSWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131524 AZT3TCEFV 2010 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQASMTKILEPFRLKNPEIVIYQYMDDLYVGSDLEIGQHRTKIDELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131528 AZT3TCEFV 2013 Russia A 0 1 190 PISPIETVSVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGKISRIGPGNPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSINNKTPGIRYQYNVLPQGWKGSPAIFQNSMTKILDPFRSKNPEIVIYQYVDDLYVG Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131530 AZT3TCEFV 2011 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIEICEEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPELVIYQYMDDLYVGSDLEIEQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131532 AZT3TCEFV 2011 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQCSMTKILEPFRIKNPELVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPITLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131534 D4T3TCNVP 2010 Russia A 1 1 250 PISPIETVPVTLRPGVDGAKVRQWPLTEEKIKALIDICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNGTPGIRYQYNVLPQGWKGSPSIFQSSMIKILEPFRSKNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKD Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131535 AZT3TCEFV 2013 Russia A 0 1 251 PISPIKTVPVTLKPGMDGPKVKQWPLTEEKIKALTDICNEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRLKNPEIVIYQYVDDLYVSSDLEIERHRAKIEELRAHLLSWGFYTPDQKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131537 AZT3TCEFV 2012 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGKISKIGPKNPYNTPVFVIKKKDSTKWRKLVDFRELNRRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRSKNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131538 AZT3TCEFV 2011 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALMDICQEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRVKNPEIIIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKYQKEHPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131539 ABC3TCEFV 2013 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICNEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKVVDFRELNKRTQDFWEIQLGIPHPAGLHKKKSVTVLDVGDAFFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPELDIYQYVDDLYVSSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131540 AZT3TCEFV 2012 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWKKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSITVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVSSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131545 AZT3TCEFV 2011 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSVTVLDVGDAYFSIPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTRILEPFRIKNPEIVIYQYVDDLYVSSDLEIGQHRAKIEELRAHLLSWGFSTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131546 D4T3TCEFV 2011 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTDICNELXKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSIPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLQNPDIIIYQYVDDLYVSSDLEIGQHRTKIEELRAHLWSWGFXTPDQKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131551 AZT3TCEFV 2012 Russia CRF02_AG 0 1 251 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRRKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLNWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131553 AZT3TCEFV 2011 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKISKVGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPQIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131555 AZT3TCEFV 2012 Russia A 0 1 251 PISPIETVPVKLKPGMDGPKVKQWPLTGEKIKALIEICTEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEIVIYQYVDDLYVGSDLEIEQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131556 AZT3TCEFV 2010 Russia A 0 1 251 PISPIETVPVKLKPEMDGPKVKPMPLTEEKIKALVDICTEMEKEGKISKVGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKKNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKXPPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131560 AZT3TCEFV 2010 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTKEKIEALIEICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRIQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIVIYQYVDDLYVSSDLEIGQHRAKIDELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDI Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131564 AZT3TCEFV 2013 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTDICKEMEKEGKISKIGPENPYNTPIFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRSKNPEIVIYQYVDDLYVSSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131566 ABC3TCEFV 2013 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALMDICKEMEKEGKISKIGPENPYNNPVFVIKKKDSTKWRKITDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAFFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRSKNPDIVICQYVDDLYVSSDLEIGQHRAKIEELRAHLLSWGFTTPDNKHQKEPPFLWMGHELHPDKWTVQPIMLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131567 ABC3TCEFV 2012 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICTEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRLKNPDIVIYQYVDDLYVSSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131573 AZT3TCEFV 2012 Russia CRF02_AG 0 1 251 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILDPYRRKNPELVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131578 D4T3TCNVP 2012 Russia A 1 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGKISRIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNRRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKSFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRVRNPEIVICQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131583 AZT3TCNVP 2011 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPGGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRSKNPEVIIYQYVDDLYVASDLEIGQHRAKIEELRAHLLSWGFXTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131584 D4T3TCEFV 2011 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRVKNPELVIYQYVDDLYVSSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131586 AZT3TCNVP 2013 Russia CRF02_AG 0 1 250 PISPIESVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPRINNEKPGIRYQYNVLPQGWKGSPAIFQASMTKILDPFRRKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLNWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKD Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131588 AZT3TCEFV 2010 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIELCKEMEKEGKISRIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGFKKKKSVTVLDVGDAYFSVPIDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRLKNPDIVIYQYVDDLYVSSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131590 AZT3TCEFV 2013 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVNKWPLTEEKIKALRDICKEMEREGKISKIGPENPYNTPVFVIKKKNSTKWRKLVDFRELNRRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRSKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131591 AZT3TCEFV 2010 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKKKSITVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRSKNPEIVIYQYVDDLYVSSDLEIGQHRAKIEELRAHLLRWGFTTPDQKHQKEPPFLWMGYELHPDKWTVQPITLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131593 AZT3TCEFV 2012 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIEICKEMEKEGKISKVGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGMQYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMQKILEPFRSKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131594 AZT3TCEFV 2010 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVRNPGIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131598 AZT3TCEFV 2012 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTDICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKKNPDIVIYQYVDDLYVSSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131599 AZT3TCEFV 2011 Russia A 0 1 251 PISPVETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQCSMTKILEPFRLKNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131600 AZT3TCEFV 2011 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALRDICKEMEKEGKISKTGPENPYNTPVFVIKKKNSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKQNPEIVIYQYMDDLYVSSDLEIGQHRTKIEELRQHLLSWGFTTPDEKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131602 AZT3TCNVP 2013 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPSIFQNSMTKILEPFRLKNPEVVIYQYVDDLYVSSDLEIGQHRTKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131604 AZT3TCNVP 2012 Russia CRF02_AG 0 1 251 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKDICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKKNPEIIIYQYVDDLYVGSDLEIAQHRAKIEELRAHLLNWGFTTPDKKHQKEPPFLWMGYELHPEKWTVQPIQLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131609 ABC3TCNVP 2012 Russia CRF02_AG 1 1 251 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTDMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRRKNPEIVICQYMDDLYVGSDLEIGQHRAKVEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131612 AZT3TCNVP 2012 Russia A 1 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRLKNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131614 AZT3TCEFV 2010 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGQISKIGPENPYNTPVFVIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSTMTKILEPFRSKNPEIIIYQYMDHLYVSSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131615 AZT3TCEFV 2010 Russia A 0 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALIDICKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRSKNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2187 131616 AZT3TCNVP 2010 Russia A 1 1 251 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALLDICTEMEKEGKISRIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNGTPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRSKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPITLPDKDS Kolomeets, AN 2014 25259833 AIDS A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. 2188 131620 TDF3TCNVP 2005 Luxembourg CRF01_AE 0 40 238 EMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLDIEQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDR Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131621 TDFFTCEFV 2007 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIEQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131622 TDFFTCEFV 2009 Germany B 0 40 238 EMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQVWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131623 TDFFTCNVP 2010 Portugal A 0 40 238 DMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIIIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLTWGFTTPDKKHQKEPPFLWMGYELHPDT Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131624 TDFFTCEFV 2009 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKRKGSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKAVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVESDLEIEQHRTKIEELRQHLLKWGFTTPDEKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131625 TDFFTCNVP 2005 Germany B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGEHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131626 TDFFTCEFV 2009 Portugal G 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGTRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIEIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGLTTPDKKHQKEHPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131627 TDF3TCNVP 2004 Portugal G 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIENPEIVICQYIDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWLGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131628 TDFFTCEFV 2008 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLQWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131629 TDF3TCEFV 2007 Luxembourg CRF02_AG 0 40 238 EMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTRNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131630 TDFFTCEFV 2009 Portugal G 0 40 238 DMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYMDDLYVGSDLEIEQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131631 TDFFTCEFV 2010 Portugal G 0 40 238 EMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPDIVLYQYVDDLYVGSDLEIGQHRAKVEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131632 TDF3TCEFV 2003 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIDIYQYIDDLYVGSDLEIREHRAKIEDLRQHLLQWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131633 TDFFTCEFV 2006 Italy B 0 40 238 EMEKEGQISKIGPENPYNTPVFVIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEQKKSITVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVSSDLEIGQHRAKIEELRQHLLKWGFSTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131634 TDFFTCNVP 2006 Germany B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKLDELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131635 TDFFTCEFV 2005 Germany B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTQNPDIVIYQYMDDLYVGSDLEIGQHRSKIEELRGHLLRWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131636 TDFFTCEFV 2009 Sweden C 0 38 241 CREMEEEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIIIYQYMDDLYVGSDLEIEQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTV Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131637 TDF3TCEFV 2003 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPEIGICQYVDDLYVASDLEIGQHRAKIEELRDHLLKWGFTTPDNKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131638 TDF3TCEFV 2004 Portugal C 0 40 238 EMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYVDDLCVGSDLKIEQHRAKIEGLREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131639 TDFFTCEFV 2008 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKGSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKRKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVESDLEIEQHRTKIEELRQHLLKWGFTTPDEKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131640 TDFFTCEFV 2007 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIEQHRAKIEELREHLLKWGLTTPDTKHQKEPPFRWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131641 TDFFTCNVP 2009 Portugal G 0 40 238 EMEREGKISKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAFFSVPLDESFRKYTAFTIPSTNNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELVICQYVDDLYVGSDLEIGQHRAKIEELRQHLLSWGFTTPDEKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131642 TDF3TCEFV 2005 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131643 TDF3TCEFV 2005 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDNKHQKEHPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131644 TDFFTCNVP 2010 Portugal G 0 40 238 DMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPGGLKKKRSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRAKNPELEICQYVDDLYVGSDLEIGQHRAKIEELRNHLLKWGFTTPDNKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131645 TDFFTCEFV 2008 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTSIFAIKKKDSTKWRKLLDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVSSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131646 TDFFTCEFV 2010 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSIPLDKEFRKYTAFTIPSINNKTPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGLTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131647 TDFFTCEFV 2010 Portugal G 0 40 238 EMEKEGKISRIGPENPYNTPIFAIKKKDSTTWRKIVDFRELNKRTQDFWEIQLGIPHPSGLEKKKSVTVLDVGDAFFSVPLYEDFRKYTAFTIPSINNGTPGTRYQYNVLPQGWKGSPAIFQNSMTKILEPFRKANPEMQIYQYVDDLYVSSDLEKGQHRAKIEELRQHLLRWGFTTPDKKHQKEHPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131648 TDF3TCEFV 2005 Italy CRF02_AG 0 40 238 EMEKEGKISKIGPENPYNTPVFAIRKKNSTRWRKIVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQASMTRILEPFRTRNPEMGIYQYVDDLYVGSDLEIEQHRAKIKELREHLLRWGLFTPDQKHQKEPPFHWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131649 TDFFTCNVP 2010 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDLVIYQYVDDLYVGSDLEIGQHRVKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131650 TDFFTCNVP 2006 Portugal G 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDSTEWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPEMVICQYVDDLYIASDLEIGEHRAKVKELRKHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131651 TDFFTCEFV 2007 Italy B 0 40 237 EMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPD Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131652 TDFFTCEFV 2010 Portugal G 0 40 238 DMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPSGIKKNKSVTILDVGDAYFSVPLDREFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131653 TDFFTCEFV 2009 Portugal CRF02_AG 0 40 238 EMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131654 TDFFTCEFV 2009 Portugal G 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPSGIKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLNWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131655 TDF3TCEFV 2007 Italy B 0 39 245 TEMEKEGKISRVGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGVKKNKSVTVLDVGDAFFSVPLDKEFRKYTAFTIPSINNETPGIRDQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLRWGFTTPDKKHQKDPPFLWMGYELHPDKWTVQPIV Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131656 TDF3TCEFV 2005 Portugal G 0 40 238 DMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131657 TDFFTCEFV 2007 Portugal G 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131658 TDF3TCEFV 2006 Portugal CRF02_AG 0 40 238 DMEKEGKISRIGPENPYNTPVFAIKRRDGTTWRKLVDFRELNKRTQDFWQIQLGIPHPAGLQKKKSVTVLDVGDAFFSVPLDEDFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILDPFRRKNPEIVICQYMDDLYVVSDLEIGQHRAKIEELRGHLLKWGFTTPDKKYQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131659 TDFFTCEFV 2008 Sweden CRF01_AE 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDR Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131660 TDFFTCEFV 2009 Luxembourg CRF02_AG 0 40 238 EMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131661 TDFFTCEFV 2008 Portugal CRF01_AE 0 40 238 EMEQEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYMDDLHVSSDLEIGQHRTKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131662 TDF3TCEFV 2005 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131663 TDF3TCEFV 2007 Italy CRF02_AG 0 40 238 EMEKEGKISKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPYRTKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131664 TDFFTCEFV 2009 Sweden C 0 40 238 EMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILKPFKAQNPKIDIYQYVDDLYVGSDLEIKEHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGHELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131665 TDFFTCEFV 2010 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKGSTEWRKLVDFRELNKKTQDFWEIQLGIPHPAGLKNNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVASDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131666 TDFFTCNVP 2008 Italy CRF02_AG 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKENPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131667 TDFFTCEFV 2007 Germany B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKVEELRTHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131668 TDFFTCEFV 2010 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIEQHRAKIEELRKHLLAWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131669 TDF3TCEFV 2004 Portugal G 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKRKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPSGIKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPGIVIYQYIDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131670 TDF3TCNVP 2008 Belgium C 0 40 238 EMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPNIVIYQYVDDLYVGSDLEIGQHRTKIKELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131671 TDF3TCEFV 2005 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQCSMAKILEPFRKQNPDIVIYQYVDDLYVSSDLEIGQHRTKIEELRQHLLKWGFITPDKKHQKEPPFLWMGYELHPNK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131672 TDFFTCNVP 2007 Italy B 0 40 238 EMEKEGKITKIGPENPYNTPVFVIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKQSVTVLDVGDAYFSVPLDPEFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDMVIVQYVDDLYVGSDLEIGQHRTKIEELRQHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131673 TDFFTCEFV 2007 Spain CRF02_AG 0 40 234 EMEKEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTSNPEVVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYEL Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131674 TDF3TCEFV 2004 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIDIYQYMDDLYVGSDLEIGQHRRKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131675 TDF3TCEFV 2005 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRVKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131676 TDF3TCEFV 2004 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFVIKRKDGTTWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKRKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIEICQYVDDLLVGSDLEIGQHRTKIEELRQHLLGWGFTTPDKKYQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131677 TDFFTCEFV 2010 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFVIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVICQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGFSTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131678 TDF3TCNVP 2005 Portugal G 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131679 TDFFTCEFV 2008 Portugal C 0 40 238 EMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDLVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFRWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131680 TDFFTCEFV 2008 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYIGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131681 TDFFTCEFV 2009 Italy B 0 39 245 TEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIV Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131682 TDFFTCEFV 2010 Sweden CRF01_AE 0 40 238 EMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPEMVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDR Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131683 TDFFTCEFV 2009 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKHNPDMVIYQYVDDLCVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131684 TDFFTCEFV 2006 Sweden A 0 40 237 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLHEEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEMIIYQYVDDLYVGSDLEIGQHRAKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPD Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131685 TDFFTCEFV 2008 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNATPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGKHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131686 TDFFTCEFV 2010 Sweden CRF01_AE 0 40 238 EMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYPAFPIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131687 TDFFTCEFV 2008 Portugal B 0 40 238 EMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLRKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRKQNPDLVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131688 TDFFTCEFV 2005 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRAKVEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131689 TDF3TCNVP 2004 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVICQYIDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131690 TDFFTCNVP 2009 Portugal G 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPSGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRRKNPDIVIYQYVDDLYIASDLQKEQHRAKIKELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131691 TDFFTCEFV 2009 Portugal G 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKGSTQWRKILDFRELNKRTQDFWEVQLGIPHPSGLEKKKSITVLDVGDAYFSVPLDKNFRKYTAFTIPSVNNATPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIVICQYVDDLYVSSDLEIGQHRAKIEELREHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131692 TDFFTCEFV 2010 Portugal B 0 40 237 EMEKEGKISKIGPENPYNTPIFAIKRKGSTEWRKLVDFRELNKRTQDFWEVQLGIPHPGGIKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRRKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLRWGFCTPDKKHQKEPPFLWMGYELHPD Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131693 TDFFTCEFV 2006 Portugal G 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131694 TDFFTCEFV 2006 Portugal G 0 40 238 EMEREGKISKIGPENPYNTPIFAIRRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGIKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRGHLLSWGLTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131695 TDFFTCEFV 2007 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131696 TDF3TCEFV 2006 Italy B 0 40 238 EMEKEGKISKVGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDEEFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYMDDLYVGSNLEIGQHRAKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131697 TDF3TCNVP 2005 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRSKIEELRKHLLKWGLTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131698 TDFFTCEFV 2007 Germany A 0 40 238 DMEKKGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPTTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPEIIIYQYMDDLYVGSDLEIGQHRAKVEELRTHLLRWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131699 TDFFTCEFV 2010 Italy B 0 40 238 EMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILKPFREQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131700 TDFFTCNVP 2008 Germany CRF01_AE 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIIIYQYIDDLYVSSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131701 TDFFTCEFV 2008 Portugal G 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVPRQGWTGSPATFETSMTKILEPFRMKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEHPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131702 TDF3TCEFV 2004 Portugal G 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPSGIKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131703 TDF3TCEFV 2004 Italy B 0 40 238 EMEKEGKIEKIGPENPYNTPVFAIKRKDSSKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVQSDLEIGKHRAKIEELRQHLFRWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131704 TDFFTCEFV 2010 Portugal G 0 40 238 EMEREGKISKIGPENPYNTPIFAIKKKDSTEWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIEIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGLTTPDKKHQKEPPFRWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131705 TDFFTCEFV 2007 Spain B 0 40 238 EMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTKEFWEVQLGIPHPAGLKKKKSVTVLDVGDTFFSVP*DKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIEQHRTKVEELRQHLLRWGFTTPEKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131706 TDFFTCEFV 2007 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGTRYQYNVLPQGWKGSPAIFQHSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIEQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131707 TDFFTCEFV 2008 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGIKKRKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKVLEPFRKQNPDIDIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131708 TDFFTCEFV 2009 Luxembourg B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPNLVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131709 TDFFTCEFV 2008 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGIKRNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLRWGFTTPDNKHQKEPPFRWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131710 TDFFTCEFV 2010 Portugal G 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIEQHRAKIEELRGHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131711 TDFFTCNVP 2009 Germany B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTILDVGDAYFSVPLHEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAVFQSSMTKILEPFRKQNPEIVICQYVDDLYVGSDLEIGQHRTKVEELRQHLLSWGFTTPDKKYQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131712 TDFFTCEFV 2009 Germany A 0 40 238 EMEKEGKISKIGPDNPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQHSMTKILEPFRLRNPELIIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEHPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131713 TDF3TCEFV 2006 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKQNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDMVIYQYMDDLYVGSNLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131714 TDFFTCEFV 2009 Portugal G 0 40 238 EMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRMKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131715 TDFFTCEFV 2009 Sweden C 0 40 238 DMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDETFRKYTAFTIPSRNNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRANNPEVVIYQYMDDLYIGSDLEIGQHRAKIEELRDHLLRWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131716 TDF3TCEFV 2005 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKRNPEIVIYQYMDDLYVGSDLELGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131717 TDFFTCEFV 2010 Portugal B 0 40 238 ELENEGKISKIGPENPYNTPVFAIKKKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIEIYQYVDDLYVGSDLEIGTHREKIEELRQHLLRWGFCTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131718 TDFFTCEFV 2008 Portugal C 0 40 238 EMEKEGKITKIGPENPYNTPIFAIKRKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVCSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131719 TDF3TCEFV 2006 Italy G 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131720 TDF3TCNVP 2004 Portugal G 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLEKKKSATVLDVGDAYFSVPLDESFRKYTAFTIPSTNNKTPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFKIKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELRGHLLSWGFTTPDKKHQKEPPLLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131721 TDFFTCNVP 2009 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDLWEVQLGIPHPAGLKKKKSVTIMDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKYQKEPPFRWIGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131722 TDF3TCEFV 2005 Italy B 0 40 236 EMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAFFSVPLDQDFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQASMTKILEPFRKQNPEIVIYQYMDDLYVESDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHP Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131723 TDF3TCNVP 2004 Italy B 0 40 237 EMEKEGKISRIGPENPYNTPVFVIKRKDSTRWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIDICQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPD Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131724 TDF3TCEFV 2003 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRIKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131725 TDFFTCEFV 2010 Italy B 0 40 238 EMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIEQHRAKIEELRQHLLQWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131726 TDFFTCEFV 2009 Portugal B 0 40 238 EMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSITVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYVDDLYVASDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131727 TDFFTCEFV 2010 Portugal G 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLNWGFTTPDKKHQKEHPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131728 TDFFTCEFV 2010 Portugal G 0 40 238 EMEREGKISKIGPENPYNTPIFAIKKKDSTEWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLNWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131729 TDFFTCEFV 2006 Portugal G 0 40 238 DMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPYRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIDELRQHLLSWGFTTPDKKHQKEPPFLWMGHELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131730 TDF3TCNVP 2005 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSSKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILGPFRKQNPDIVICQYVDDLYVASDLEIGQHRTKIEELRQHLLKWGLTTPDQKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131731 TDFFTCEFV 2008 Germany B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131732 TDFFTCEFV 2006 Portugal G 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKIVDFRELNKRTQDFWEIQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFKRDNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEHPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131733 TDF3TCEFV 2007 Belgium CRF02_AG 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTRNPGIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131734 TDFFTCEFV 2009 Portugal G 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEHPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131735 TDFFTCEFV 2006 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDGNEWRKIVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKKNPDMDIYQYVDDLLVGSDLEIEQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131736 TDF3TCEFV 2005 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPDMVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131737 TDFFTCEFV 2007 Portugal C 0 40 238 DMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDADFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEVVIYQYMDDLYVGSDLEIGQHRAKVEELRKHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131738 TDFFTCEFV 2009 Portugal B 0 40 238 ELEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGLPHPAGLTKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVICQYVDDLYVSSDLEIGQHRTKIEELRQHLLRWGFSTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131739 TDFFTCEFV 2009 Italy F 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILDPFRTQNPDIVIYQYMDDLYVGSDLEIGQHREKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131740 TDF3TCEFV 2006 Sweden C 0 40 238 EMEKEGKISRVGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIDIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131741 TDFFTCEFV 2005 Portugal B 0 40 238 ELEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLFRWGFYTPDKKHQKEPPFRWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131742 TDFFTCEFV 2008 Italy B 0 40 237 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPEMVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPD Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131743 TDFFTCNVP 2010 Portugal B 0 40 238 EMEKEGKISKVGPENPYNTPIFVIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPDIVICQYVDDLYVGSDLEIEQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131744 TDF3TCEFV 2005 Portugal B 0 40 238 EMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILRPFREQNPDIVIYQYMDDLYISSDLEIGQHRTKIEELRQHLLKWGLTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131745 TDF3TCEFV 2003 Portugal B 0 40 238 EMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSIPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIDIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLQWGLTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131746 TDFFTCEFV 2007 Portugal C 0 40 238 EMEKEGKISKIGPENPYNTPVFVIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSATVLDIGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEHPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131747 TDFFTCEFV 2008 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQHSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131748 TDFFTCEFV 2010 Portugal G 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHREKIEELRKHLLSWGFTTPDKKHQKEHPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131749 TDFFTCEFV 2009 Portugal G 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDSNEWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIEIYQYVDDLLVGSDLEIGQHRAKIEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131750 TDFFTCNVP 2010 Luxembourg CRF02_AG 0 40 238 EMEKEGKITRIGPENPYNTPVFAIKNKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVLDVGDAFFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVICQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131751 TDFFTCEFV 2007 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDNTKWRKLVDFRELNKRTQDFWEIQLRIPHPAGLKKKKSVTVLDVGDAYFSVPLDVDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRKQNPDLVIYQYMDDLYVGSDLEIGLHRTKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131753 TDFFTCEFV 2009 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDPEFRKYTAFTIPSMNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVASDLEIGQHRTKIEELRQHLLGWGFTTPDKKHQKEPPFRWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131754 TDFFTCEFV 2009 Portugal G 0 40 238 EMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRMKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLSWGLTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131755 TDF3TCEFV 2008 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKIVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTILDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPEIFICQYVDDLYVASDLEIGQHRAKIEELRQHLLRWGFYTPDQKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131756 TDF3TCEFV 2007 Portugal CRF02_AG 0 40 238 EMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIEQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131757 TDFFTCEFV 2010 Portugal G 0 40 238 EMEKEGKISKIGPENPYNTPVFAIRRKDNTTWRKLVDFRELNKRTQDFWEVQLGIPHPSGIKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTNNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131758 TDFFTCEFV 2006 Germany CRF02_AG 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKRNKSVTVLDVGDAYFSVPLDPAFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKNNPEIVIYQYVDDLLVGSDLEIGQHRTKIKELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131759 TDF3TCEFV 2005 Portugal G 0 40 238 EMEREGKISKIGPENPYNTPIFAIKRKDRTKWRKVMDFRELNKRTQDFWEVQLGIPHPSGIKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDEKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131760 TDFFTCEFV 2008 Portugal G 0 40 238 EMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMEIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131761 TDFFTCEFV 2009 Portugal CRF02_AG 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKRKDSTEWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEMVIYQYVDDLYVGSDLEIEQHRAKIEQLREHLLRWGFTTPDKKHQKEPPFLWLGYEIHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131762 TDFFTCEFV 2010 Portugal G 0 40 238 EMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131763 TDFFTCEFV 2010 Portugal B 0 40 238 EMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131764 TDFFTCEFV 2007 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIEQHRTKIEELRQHLLRWGFTTPDKKHQKEHPFRWMGYELHPEK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131765 TDFFTCEFV 2007 Italy B 0 40 238 EMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131766 TDF3TCEFV 2005 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTQILEPFRKQNPELVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131767 TDFFTCEFV 2007 Portugal G 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPSGIKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPELVIYQYVDDLYIGSDLEIGQHREKIEDLRKHLLRWGFTTPDEKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131768 TDFFTCEFV 2007 Portugal G 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLQKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEMVIYQYMDDLYVGSDLEKRQHRAKIEELRQHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131769 TDFFTCEFV 2009 Portugal G 0 40 238 DMEREGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRTKNPEIEIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131770 TDFFTCEFV 2007 Portugal B 0 40 238 EMEKEGKISRVGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNEQPGLRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIEQHRTKVEELRQHLLGWGLTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131771 TDF3TCEFV 2004 Portugal CRF02_AG 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVGSDLELGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131772 TDF3TCEFV 2005 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYYSIPLDKEFRKYTAFTIPSKNNETPGIRYQYNVLPMGWKGSPAIFQSSMTRILEPFREQNPGIVVCQYMDDLYVGSDLEIEQHRAKIEELRQHLLKWGLTTPDKKHQKEPPFRWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131773 TDFFTCEFV 2007 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYIDDLYVGSDLEIGQHRIKVEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131774 TDF3TCEFV 2007 Italy B 0 39 244 TEMEKEGKISKIGPENPYNTPVFAIKRKDSTEWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVSSDLEIGKHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131775 TDFFTCEFV 2010 Portugal G 0 40 238 EMEREEKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQNFWEIQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFKKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKIKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131776 TDFFTCNVP 2009 Sweden B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAFFSVPLDENFRKYTAFTIPSINNETPGIRYQSHVLPQGWKGSPAIFQSSMTKILQPFRRKNPGIVVIQYVDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131777 TDFFTCEFV 2008 Portugal G 0 40 238 DMEKEGKISKIGPENPYNTPIFAIKKKGSTEWRKLVDFRELNKRTQDFWEVQLGIPHPRGIPKNKSITVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKNNPDIVIYQYVDDLYVGSDLEIGQHRAKIKELRKHLLSWGLTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131778 TDFFTCEFV 2009 Portugal CRF02_AG 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKRKGGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDQDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRRKNPEIVIYQYIDDLYVQSDLEIGQHRAKIEELREHLLKWGFSTPDNKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131779 TDFFTCEFV 2009 Portugal G 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDSTEWRKMVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEHPFRWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131780 TDF3TCEFV 2005 Italy C 0 40 238 DMEKEGKITKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIDICQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQEEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131781 TDF3TCEFV 2005 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131782 TDFFTCNVP 2007 Portugal G 0 40 238 DMEREGKISKIGPENPYNTPIFAIKRKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKYQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131783 TDF3TCEFV 2004 Italy F 0 38 246 CTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRDLNKRTQEFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILDPFRAKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQL Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131784 TDF3TCEFV 2005 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131785 TDFFTCEFV 2007 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLLDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRQHLLAWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131786 TDFFTCNVP 2009 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIEQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131787 TDF3TCNVP 2004 Italy B 0 39 244 TEMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVICQYVDDLYVASDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131788 TDFFTCEFV 2007 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKKQNPDLVIYQYVDDLLIGSDLEIEQHRTKIEELRQHLLGWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131789 TDFFTCEFV 2010 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFFTPDKKHQKEPPFLWLGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131790 TDFFTCEFV 2007 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIHKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKKNPEIVIYQYVDDLYVGSDLEIEQHRTKIKELRQHLLRWGFTTPEQKHQTEPPFHWMGYEIHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131791 TDFFTCEFV 2009 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFVIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIEQHRTKVEQLRKHLLKWGFTTPDKKHQKEHPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131792 TDFFTCEFV 2009 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSITVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVASDLEIGQHRAKIEELRQHLFRWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131793 TDF3TCEFV 2005 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPDIVIYQYMDDLYVESDLEIEQHRTKIEELRQHLFRWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131794 TDFFTCEFV 2008 Portugal CRF02_AG 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131795 TDFFTCEFV 2009 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131796 TDFFTCEFV 2007 Portugal G 0 40 238 DMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEEFRKHLLRWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131797 TDFFTCEFV 2010 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKGSTKWRKLMDFRELNKRTQEFCEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRKQNPDIVIYQYIDDLYVGSDLEIEQHRTKIEELRQHLLKWGLTTPDKKHQKDPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131798 TDF3TCEFV 2004 Italy B 0 40 238 EMEKEGKISRIGPENPYNTPVFAIKNKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGIKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPSIFQHSMTKILEPFRKQNPDIIIYQYMDDLHVGSDLEIGQHRAKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131799 TDFFTCNVP 2005 Portugal G 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDSTEWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAFFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGLTTPDEKYQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131800 TDFFTCEFV 2010 Portugal CRF02_AG 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRQNNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131801 TDF3TCEFV 2006 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRNQNPDIVIYQYIDDLYVASDLEIEQHRAKIEELRHHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131802 TDF3TCEFV 2004 Portugal C 0 40 238 EMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTRILEPFRAKNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131803 TDFFTCNVP 2010 Germany B 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLQKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSRMTRILGPFRKQNPDIIVCQYMDDLYVGSDLEIGEHRTKIEELRQHLLKWGFTTPDKKYQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131804 TDFFTCEFV 2008 Germany CRF01_AE 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKXFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSTMTRILEPFRSRNPEMVVYQYMDDLYVGSDLEIGQHREKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131805 TDF3TCEFV 2009 Israel C 0 38 246 CEEMEKEGKISKIGPENPYNTPVFVIKRKDNTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRSQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQL Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131806 TDFFTCNVP 2006 Italy C 0 40 238 EMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLHEDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAQNPEIVICQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131807 TDFFTCEFV 2007 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131808 TDF3TCEFV 2008 Portugal G 0 40 238 DMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVVYQYMDDLYVGSDLEIEQHRAKIDELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131809 TDF3TCEFV 2003 Italy B 0 40 238 EMEKEGKISKVGPENPYNTPVFAIKRKDSTKWRKLMDFRELNKKTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDMVIYQYMDDLYVESDLEIEQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131810 TDFFTCEFV 2010 Portugal B 0 40 238 EMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDTDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPNIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131811 TDFFTCEFV 2006 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSITVLDVGDAFFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVICQYVDDLYVSSDLEIGQHRTKVEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131812 TDFFTCEFV 2010 Portugal CRF01_AE 0 40 238 EMEQEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDPSFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQYSMTKILEPFRSKNPEIVIYQYMDDLYVGSDLEIGQHRAKIDELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131813 TDFFTCNVP 2010 Portugal G 0 40 238 DMEREGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQNFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRTKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131814 TDFFTCEFV 2008 Portugal G 0 40 238 DMEKEGKISKIGPENPYNTPIFAIKKKDSTEWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131815 TDFFTCEFV 2009 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSNLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131816 TDF3TCEFV 2007 Israel C 0 38 246 CAEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYMDDLYVESDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQL Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131817 TDFFTCEFV 2010 Portugal G 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIEIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131818 TDFFTCEFV 2007 Italy B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIEKHRIKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131819 TDFFTCEFV 2010 Portugal B 0 40 238 ELEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLLDFRELNKRTQDFWEVQLGIPHPGGLRKNKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPDIVICQYVDDLYVASDLEIGQHRSKIEELRQHLLRWGLFTPDEKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131820 TDFFTCEFV 2007 Germany B 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131821 TDFFTCEFV 2010 Sweden CRF01_AE 0 40 238 EMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPEMVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131822 TDFFTCNVP 2008 Portugal G 0 40 238 EMEKEGKISKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLEKKKSITVLDVGDAYFSVPLDETFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRSRNPEIVICQYVDDLYVASDLEKEQHRAKIEELRQHLLSWGFTTPDKKHQKEPPFLWLGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131823 TDFFTCEFV 2007 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTQWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGSRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDMVIYQYVDDLYIGSDLEIGQHRAKIEELRQHLLRWGFTTPDRKHQKEHPFRWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2188 131824 TDFFTCEFV 2010 Portugal B 0 40 238 EMEKEGKISKIGPENPYNTPVFAIKKKDSTQWRKLLDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRRQNPDIVIYQYVDDLYVASDLEIGQHRTKIEELRQHLLKWGLTTPDKKHQKEHPFRWMGYELHPDK Theys, K 2013 23183438 AAC HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. 2189 134680 AZT3TCEFV 2007 Portugal B 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIEQHRIKIDELRQHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEIITLTREAELELAENREILKEPVHGVYYDPSKDLIAELQKQGK Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134681 AZT3TCEFV 2003 Portugal B 0 1 314 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALVEICTEMEKEGKISKIGPENPYNTPVFVIRKKDSTKWRKLIDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSIPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIEQHRTKIEELRQHLLKWGLTTPDKKHQKEPPFRWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLKGTKALTEIIPLTKEAELELAENREILKEPV Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134682 AZT3TCEFV 2008 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134683 AZT3TCNVP 2007 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICAELEKEGKISKIGPENPYNTPVFAIKKKDSNRWRKLVDFRELNKKTQDFWEVQLGIPHPSGLKKKKSATVLDVGDAYFSIPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKRNPDIVIYQYVDDLYVGSDLEIEQHRTKIEELRQHLLEWGLSTPDQKHQKEHPFLWMGYELHPDKWTVRPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVVALTREAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134684 AZT3TCNVP 2007 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKINQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134685 AZT3TCEFV 2003 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPKIEIYQYMDDLYVGSDLEIGQHREKVEELRKHLLSWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGTYYDPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134686 D4T3TCEFV 2004 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKNNTEWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSVTVLDVGDAYFSVPLDPEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIDIYQYVDDLLVGSDLKIGRHRTKIEELRQHLLSWGFTTPDKKHQKEPPFQWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYTGIKVKQLCKLLRGAKALTEVIPLTEEAEMELAENREILREPVHGVYYDPSKDLIAELQKQGEG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134687 TDFFTCEFV 2009 Portugal CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGTRYQYNVLSQGWKGSPSIFQASMTKILEPFRKGNPDLVIYQYMDDLYVGSDLEIGQHRAKIEKLREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPQKDSWTVNDIQKLVGKLNWASQIYPGIRVKQLCKLLRGAKTLTDIVTLTEEAELELAENREILKAPVHGVYYDPTKDLIAEIQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134688 AZT3TCEFV 2014 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTLDFWEVQLGIPHPAGLQKNKSITVLDVGDAYFSVPLDPDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRAKVEELRQHLLRWGFTTPDKKHQKDPPFRWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEVVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134689 D4T3TCEFV 2006 Portugal D 0 1 335 PISPIATVPVQLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLYEDFRKYTAFTIPSVNNETPGTRYQYNVLPQGWKGSPAIFQSSMIKILDPFRKQNPELVIYQYVDDLYVGSDLEIEQHRAKIEKLREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQTITLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTEVIPLTKEAELELAENREILKEPVHGVYYDPSKDLIAELQKQDRG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134690 AZT3TCEFV 2008 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRRKNPEIVIYQYMDDLYVGSDLEIEQHRVKIEELRQHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKENWTVNDIQKLVGKLNWASQIYPGIQVRQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQGSG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134691 AZT3TCEFV 2002 Portugal B 0 1 315 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEIQLGIPHPAGLQNNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGMRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPELIIYQYMDDLYVASDLEIGQHRAKIEELREHLLKWGFFTPDQKHQKEPPFLWMGYELHPDTWTVQPITLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVVPLTREAELELAENREILKEPVQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134692 AZT3TCNVP 2006 Portugal B 0 1 333 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLKGAKALTDVIPLSKEAELELAENREILKEPVHGVYYDPLKDLIVEIQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134693 ABC3TCNVP 2014 Portugal CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAFFSVPLDKDFRKYTAFTIPSLNNETPGTRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKKPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEIVPLSKEAELELAENREILKDPVHGVYYDPSKDLVAEIQKQGH Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134694 AZT3TCNVP 2007 Portugal CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKNPEIVIYQYMDDLCVGSDLEIGQHRAKIEELREHLLNWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVALTEEAELELAENREILKEPVHGTYYDPTKDLVAEIQEQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134695 TDFFTCEFV 2008 Portugal G 0 1 334 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIRALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTRNPEMVIYQYMDDLYVSSDLEIGKHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEIVPLTVEAELELAENREILKEPVHGAYYDPSKDLVAEIQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134696 AZT3TCEFV 2006 Portugal B 0 1 335 PISPIETVPVKLRPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLGWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134697 AZT3TCEFV 2009 Portugal CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIEQHRTKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKIKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134698 TDFFTCEFV 2009 Portugal CRF02_AG 0 1 335 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIRALKEICEEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEMEICQYIDDLYISSDLEIGKHREKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKIKQLCKLLRGAKTLTQIVPLTKEAELELAENREILKEPVHGVYYDPSKDLVAELQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134699 TDFFTCEFV 2006 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSITVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGKHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGEG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134700 AZT3TCEFV 2006 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKLSKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELRRHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTIEAELELAENREILKEPVHGVYYEPSKELIAEVQKQGPG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134701 AZT3TCEFV 2007 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLNWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134702 AZT3TCEFV 2006 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLNKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLLVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVIPLTKEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGEG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134703 D4T3TCNVP 2005 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIEQHRAKIEDLRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQHIELPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGTKALTDVIPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134704 TDFFTCEFV 2007 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIALPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQEQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134705 AZT3TCNVP 2007 Portugal B 0 1 335 PISPIETVPVKLRPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVICQYVDDLYVGSDLEIGQHRVKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPERDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEVIPLTKEAELELAENREILREPVHGVYYDPSKDLIAEIQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134706 AZT3TCNVP 2007 Portugal A 0 1 334 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIRKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSTMTKILEPFRSKNPEIIIYQYVDDLYVASDLEIGQHRAKIEELRAHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134707 AZT3TCEFV 2008 Portugal G 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEIVIYQYVDDLCVGSDLEKEQHRAKIEELRQHLLNWGFTTPDKKHQKDPPFLWMGYELHPDKWTVQPIQLPTKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKELIAEVQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134708 AZT3TCEFV 2002 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLCVGSDLEIGQHRTKVEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTIQPIVLPEKDSWTVNDLQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEIVPLTAEAEMELAENREILKEPVHGVYYDPSKDLIVEIQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134709 D4T3TCNVP 2010 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALMEICTEMEKEGKISQIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPSIFQCSMTKILEPFRKQNPDIVICQYVDDLYVGSDLEIEQHRTKIEELRQHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIELPDRDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEIVPLTREAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGEG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134710 AZT3TCNVP 2006 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTKEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKRNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKVAELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGAYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134711 AZT3TCNVP 2009 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRRDNPEIVICQYVDDLYVASDLEIGQHRTKIEKLRQHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDVVPLTAEAEMELAENREILKEPVHGVYYDPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134712 AZT3TCEFV 2006 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTREKIKALIEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLEKKKSITVLDVGDAYFSVPLDKDFRKYTAFTIPSINNESPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVICQYVDDLYVASDLDIGEHRTKIEELRQHLLKWGFTTPDKKHQKDPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEIVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134713 AZT3TCEFV 2005 Portugal F 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSITILDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILDPFRAKNPDLVIYQYVDDLYIGSDLEIGQHRIKIDELRAYLLKWGFYTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKDCWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLKGAKALTDIVTLTTEAELELAENREILKEPVHGVYYDPTKDLIAELQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134714 AZT3TCEFV 2006 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVSSDLEIGQHRAKIEELREHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLSTEAELELAENREILKEPVHGVYYDPSKELIAELQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134715 D4T3TCEFV 2014 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKIKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134716 TDFFTCEFV 2006 Portugal G 0 1 335 PISPIETVPVSLKPGMDGPKVKQWPLTEEKIRALTEICAEMEKEGKISKIGPDNPYNTPIFAIKKKNSTTWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGVRYQYNVLPQGWKGSPAIFQASMTKILEPFRTRNPEMVICQYMDDLYISSDLEIEKHRAKIEELREHLLKWGFTTPDNKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLIRGTKALTEVVPLTAEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134717 AZT3TCEFV 2005 Portugal CRF01_AE 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIIALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEHPFHWMGYELHPDKWTVQPINLPDKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCRLLRGAKALTEIVPLTEEAELELAENREILKTPVHGVYYDPSKDLVAELQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134718 ABC3TCEFV 2009 Portugal G 0 1 333 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLEKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVASDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134719 AZT3TCEFV 2008 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEREGKISKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPSGIKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFSTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVQGVYYDPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134720 D4T3TCEFV 2004 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSITVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLKWGFATPDKKHQKEPPFLWLGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVVTLTKEAELELAENREILREPVHGVYYDPSKDLIAEIQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134721 AZT3TCNVP 2009 Portugal G 0 1 321 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRRDNPEIVICQYMDDLYVGSDLEIGQHRTKIEKLRQHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDVVPLTAEAEMELAENREILKEPVHGVYYGP Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134722 AZT3TCEFV 2007 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIIALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKTKSITVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPEIVIYQYVDDLHIGSDLEIGQHRAKVEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYEPSKELVAEVQKQGPG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134723 AZT3TCEFV 2009 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIEQHRIKIEELRHHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLIRGTKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134724 AZT3TCEFV 2006 Portugal CRF02_AG 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKRSITVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTRNPEMVIYQYMDDLYVSSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKTLTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134725 D4T3TCEFV 2005 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEIIPLTKEAELELAENREILKEPVHGVYYDPSKDLMAEIQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134726 AZT3TCEFV 2008 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEHPFLWLGYELHPDKWTVQPIILPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134727 TDFFTCEFV 2008 Portugal CRF02_AG 0 1 322 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIRALTEICADMEKEGKISRIGPDNPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKGNPEMVIYQYMDDLYVSSDLEIGQHRAKIEKLREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQTIQLPDKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLIRGTKALTEVVPLTAEAELELAENREILKEPVHGVYYDPS Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134728 AZT3TCEFV 2010 Portugal B 0 1 335 PISPIETIPVKLKPGMDGPKVKQWPLTKEKIQALVEICTELEKDGKISKIGPENPYNTPVFAINKKNSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSIPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLLMGSDLEIGQHRAKIEELRQYLWKWGFYTPDKKHQKDPPFLWMGYELHPDRWTVQPIELPEKDHWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKTLTDVIPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134729 AZT3TCEFV 2002 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLDIGQHRAKIEELRKHLLSWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134730 AZT3TCEFV 2006 Portugal B 0 1 335 PISPIKTVPVRLKPGMDGPKVKQWPLTEEKLKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIDIYQYVDDLYVGSDLEIGQHRAKIEELRQHLFKWGFYTPDKKHQKEPPLLWLGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEIVPLTREAELELAENREILKEPVHGVYYDPSKDLIAEIQKQELG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134731 D4T3TCNVP 2010 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLWVGSDLAIEQHRTKIEELRQHLLRWGFYTPDKKHQKEPPFQWMGYELHPDNWTVQPITLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEIIPLTREAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGYG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134732 AZT3TCEFV 2006 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSITVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRAKVEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIQVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134733 D4T3TCNVP 2004 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDIVICQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134734 AZT3TCNVP 2006 Portugal C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134735 AZT3TCEFV 2006 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPNIVIYQYVDDLLVGSDLEIGQHRAKIEELRKHLLSWGFTTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134736 AZT3TCEFV 2009 Portugal G 0 1 333 PISPIKTVPVKLKPGMDGPRVKQWPLTAEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQDSMTRILEPFRTKNPEIEIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTTEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134737 AZT3TCEFV 2005 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPEVVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKERWTVNDIQKLVGKLNWASQIYPGIKVEQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134738 ABC3TCEFV 2006 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPSGIKKNKSVTVLDVGDAFFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEIVIYQYVDDLYVGSDLELGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQELG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134739 AZT3TCNVP 2004 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTTEAELELAENREILKEPVHGVYYEPSKELIAEVQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134740 D4T3TCNVP 2007 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPVQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134741 AZT3TCNVP 2014 Portugal C 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPNMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIXLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVRNLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQNQEHG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134742 TDFFTCEFV 2009 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDMVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVVPLTAEAELELAENREILKEPVHGVYYDPAKELIAELQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134743 AZT3TCEFV 2005 Portugal B 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTEEKLKALMEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDADFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLKWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVVPLTKEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134744 AZT3TCNVP 2004 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKKTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIIIYQYVDDLYVASDLEIEQHRIKIEELRQHLLTWGFTTPDQKHQKEPPFLWMGYELHPDKWTVQHIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKHLCKLLRGTKALTEVITLTREAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134745 AZT3TCEFV 2008 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134746 AZT3TCNVP 2005 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPDRDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEVIPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGEG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134747 AZT3TCNVP 2007 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIKALTEICMEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPDIEIYQYMDDLYVGSDLEIGQHRAKVEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDVIQLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134748 TDFFTCEFV 2010 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICLEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKGLTDIVPLTTEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134749 TDFFTCEFV 2005 Portugal CRF02_AG 0 1 335 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIRALTEICTEMENEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYIDDLYVSSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDLQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGEG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134750 AZT3TCEFV 2008 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKYPDIVIYQYVDDLYVGSDLEIGQHREKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKEHWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREVLKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134751 TDFFTCEFV 2004 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALIEICTEMEKEGKISKIGPANPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQASLTKILEPFRKQNPDIEIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLGWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVVPLTKEAEIELAENREILREPVHGVYYDPSKDLIAELQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134752 D4T3TCEFV 2004 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDREFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIEQHRTKIEELRQHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEIIPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134753 AZT3TCEFV 2005 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDVVPLTAEAEMELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134754 AZT3TCEFV 2005 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKENPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKYQKEPPFLWLGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134755 AZT3TCEFV 2005 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134756 AZT3TCEFV 2007 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSLNNERPGIRYQYNVLPQGWKGSPAIFQFSMTKILEPFRLKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIQLPDKECWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVFYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134757 TDF3TCEFV 2005 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGIKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKIKQLCKLIRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134758 AZT3TCEFV 2006 Portugal C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134759 AZT3TCEFV 2005 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIEIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAEMELAENREILKEPVHGVYYDPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134760 AZT3TCEFV 2006 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHREKIEELRQHLLKWGFTTPDKKHQKEHPFLWMGYELHPDTWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGTKALTEVVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134761 AZT3TCNVP 2006 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRVGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRIRNPEIVICQYVDDLYVGSDLEIGQHRTKIDELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPITLPDKESWTVNDIQKLVGKLNWASQIYPGIQVRQLCKLLRGAKALTEIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134762 AZT3TCEFV 2008 Portugal B 0 1 335 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKQNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRAKIDELRQHLLRWGFTTPDQKHQKEHPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134763 AZT3TCNVP 2004 Portugal G 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGTKALTDIVPLTAEAELELAENREILKDPVHGVYYDPSKDLIAEVQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134764 AZT3TCEFV 2007 Portugal G 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTEICSEMEREGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRNKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPAKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELEENREILKEPVHGVYYDPSKELIAEVQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134765 AZT3TCEFV 2004 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLLVGSDLEIEQHRTKIEELRQHLLKWGLTTPDQKHQKEPPFHWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVVPLTREAELELAENREILKEPVHGVYYDPSKDLIAELQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134766 ABC3TCNVP 2005 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISRIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRTHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134767 TDFFTCEFV 2008 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKVNQWPLTEEKIKALTEICNDMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKSFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFREKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLRWGLTTPDKKHQKDPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIIPLTAEAELELAENREILREPVHGVYYEPSKDLIAEVQKQGPG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134768 AZT3TCNVP 2007 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICADMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQGPG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134769 AZT3TCNVP 2010 Portugal CRF02_AG 0 1 335 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICADMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIENPEMVIYQYVDDLYVSSDLEIGQHRAKIEKLREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEIVPLTVEAELELEENREILKEPVHGVYYDPSKDLVAEIQKQGEG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134770 ABC3TCEFV 2009 Portugal B 0 1 321 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKRKNGTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAFFSVPLDENFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVESDLEIGQHRTKIEELRQHLLKWGFTTPDEKHQKEPPFLWMGYELHPDKWTVQPIELPVKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKSLTEVIPLTKEAELELAENREILKEPVHGVYYDP Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134771 AZT3TCNVP 2004 Portugal G 0 1 333 PISPIETVPVKLRPGMDGPKVKQWPLTKEKIKALTEICLEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKNSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134772 AZT3TCNVP 2004 Portugal G 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKNNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRKHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDVVPLTAEAEMELAENREILKEPVHGVYYDPSKELIAEVQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134773 AZT3TCEFV 2007 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRIKNPDIEIYQYVDDLYVGSDLEIGQHRAKVEELRKHLLSWGFFTPDKKYQKEHPFLWLGYELHPDTWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTTEAELELAENREILKEPVHGVYYDPSKELIAEVQKQGPG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134774 AZT3TCNVP 2005 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTDICSDMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYMDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCRLLRGAKALTDIVPLTKEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134775 D4T3TCEFV 2006 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLHQEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEIVPLTAEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134776 AZT3TCEFV 2003 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGLTTPDKKHQKEPPFLWMGYELHPDNWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134777 AZT3TCEFV 2007 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEREGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIEQHRAKIGELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134778 AZT3TCNVP 2007 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDPSFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134779 AZT3TCNVP 2002 Portugal G 0 1 334 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQSIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKGLTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGK Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134780 AZT3TCNVP 2008 Portugal C 0 1 335 PISPIETVPVSLNPGMDGPKVKQWPLTEEKIKALKAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILKPFREQYPEIVIYQYMDDLYVGSDLEIGQHRAKIEKLRDHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVRQLCKLLRGAKALTDIVPLTEEAELELAENRGILKEPVHGVYYDPSKELIAELQKQGYG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134781 D4T3TCEFV 2010 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIIALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQNSMTRILEPFRKENPEIEICQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134782 AZT3TCNVP 2009 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICMEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLQIEQHRAKIEELRQHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAEMELAENREILKEPVHGVYYEPSKELIAEVQKQGPG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134783 AZT3TCEFV 2006 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKVGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLQNNKSVTILDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVASDLEIEQHRTKIEELRQHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPVELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVVPLTREAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134784 AZT3TCEFV 2004 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNRRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLLVGSDLEIGQHRTKIEELRPHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVIPLTKEAELELAENREILREPVHGVYYDPSKDLIAELQKQEQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134785 AZT3TCNVP 2002 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALVEICTEMEKEGKISKIGPENPYNNPVFVIKKKDSTKWRKLIDLRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAFYSVPLDEEFRKYTAFTIPSRNNETPGIRYQYNVLPMGWKGSPAIFQCAMTKILEPFRKQNPDIVICQYVDDLYVGSDLEIEQHRTKIKELRQHLLKWGFTTPDEKHQTEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEIVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134786 AZT3TCEFV 2004 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISRVGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPGMVIYQYMDDLLVGSDLDIEQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGHELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTRALTEIIPLTREAELELAENREILREPVHGVYYDPSKDLIAEIQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134787 AZT3TCEFV 2004 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLRWGLTTPDKKHQKEHPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVIPLTEEAELELAENREILKETVHGVYYDPTKDLIAEIQKQGEG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134788 AZT3TCEFV 2005 Portugal CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISRVGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDNDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIRIKQLCKLIRGAKALTDVVTLTEEAELELAENREILKEPVHGAYYDPTKDLVAEIQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134789 ABC3TCNVP 2007 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAFFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVASDLEIGQHREKIEELRKHLLSWGFTTPDNKYQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAEMELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134790 AZT3TCEFV 2006 Portugal CRF02_AG 0 1 335 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIRALTEICTEMEKEGKISRIGPDNPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVSSDLEIGKHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEVVPLTTEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQEQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134791 AZT3TCEFV 2007 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPVQDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIALTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134792 ABC3TCEFV 2010 Portugal CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDREFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRVKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPAKDLVAEIQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134793 AZT3TCEFV 2005 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTKEKIEALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPSGLKQNKSVTVLDVGDAYFSVPLDESFRKYTAFTLPSVNNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRVKIEELRKHLLSWGLTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134794 ABC3TCEFV 2010 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEVVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKECWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDVVPLTAEAELELAENREILKEPVHGVYYEPAKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134795 TDFFTCEFV 2008 Portugal CRF02_AG 0 1 335 PISPIETVPVKLKPGMDGPRIKQWPLTREKIEALTEICADMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPELEIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTTEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134796 TDFFTCNVP 2010 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICAEMENEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNERPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYMDDLYVASDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKKSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKELVAEVQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134797 AZT3TCEFV 2005 Portugal F 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLAWGFTTPDKKHQKEHPFLWMGYELHPDTWTVQQIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDIVPLTVEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134798 AZT3TCEFV 2008 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEIIPLTKEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134799 D4T3TCNVP 2006 Portugal G 0 1 333 PISPIETAPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKLSKIGPENPYNTPVFAIKKKDSTEWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRNNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPVKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELEENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134800 ABC3TCEFV 2009 Portugal B 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLHEDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRNQNPEIVIYQYMDDLYVGSDLEIGQHRVKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKENWTVNDIQKLVGKLNWASQIYSGIKVKQLCRLLKGAKALTEIVPLTREAELELAENREILKEPVHGAYYDPSKDLIAEIQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134801 AZT3TCEFV 2005 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPRIKQWPLTEEKIKALTEICTEMEKEGKISKIGPDNPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRKKNPEIVIYQYMDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPKIKVKQLCRLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134802 AZT3TCEFV 2003 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICSEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPILLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134803 D4T3TCNVP 2006 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALVEICTEMEKEGKISKIGPENPYNTPVFVIKKKGGNRWRKLTDFRELNKRTQDFWEVQLGIPHPAGLHKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDMIICQYVDDLYVASDLEIGQHRTKIEELRQHLLRWGLTTPDEKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVIPLTAEAELELAENREIFKEPVHGVYYDPSKDLTAELQKQGNG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134804 AZT3TCNVP 2014 Portugal C 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPNMIICQYMDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIRVRNLCKLLRGAKALTDIVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQEHG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134805 D4T3TCNVP 2005 Portugal B 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFREQNPDIVICQYVDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDQKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134806 AZT3TCEFV 2008 Portugal CRF02_AG 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIKALTEICAELEKEGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRKHLLKWGFYTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVALTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134807 AZT3TCEFV 2007 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDLVIYQYVDDLYVGSDLEIGQHRAKIDELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKSLTEVIPLTAEAELELAENREILKEPVHGVYYDPSKDLVAELQKQENG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134808 AZT3TCNVP 2006 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYIGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134809 AZT3TCNVP 2004 Portugal G 0 1 306 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTDMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIQNPEMVICQYMDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKYQKEPPFRWMGYELHPDKWTVQPIQLPNKESWTVNDIQKLVGKLNWASQIYPGIKTKQLCKLLRGAKALTDIVPLTAEAELELEEN Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134810 AZT3TCEFV 2006 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIEQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPEKWTVQPITLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVIPLTAEAELELAENREILKEPVHGVFYDPSKDLIAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134811 AZT3TCEFV 2002 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKRKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134812 ABC3TCNVP 2010 Portugal B 0 1 329 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPEIDICQYVDDLYIASDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEVVQLTAEAELELAENREIIKEPVHGVYYDPSKDLVAEI Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134813 AZT3TCEFV 2002 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPSGLQKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLIRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134814 AZT3TCNVP 2004 Portugal C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDENFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPIHGVYYDPSKDLIAEIQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134815 ABC3TCEFV 2009 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPSGIKKNKSVTVLDVGDAYFSVPLDENFRRYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRRKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKGLTEIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134816 AZT3TCNVP 2010 Portugal C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEIVPLTTEAELELAENREILKEPVHGVFYDPSKDLIAEIQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134817 D4T3TCEFV 2002 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKMKKSITVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLLVGSDLEIGQHRIKIEELRQHLLRWGFYTPDKKHQKEPPFLWMGYELHPEKWTVQPITLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134818 AZT3TCNVP 2003 Portugal G 0 1 335 PISPIETVPVKLRPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAEMELAENREILKEPVHGVYYDPSKELIAEVQKQGPG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134819 AZT3TCEFV 2004 Portugal CRF02_AG 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICIELEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQRNKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEIVIYQYVDDLYIGSDLEIGQHRAKIEELRGYLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134820 AZT3TCEFV 2009 Portugal K 0 1 334 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIRVKHLCRLLRGAKALTDIVPLTAEAELELAENREILREPVHGVYYDPSKDLIAEIQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134821 AZT3TCEFV 2002 Portugal C 0 1 311 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITRIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPSIFQSTMTKILAPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLTWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIQLTDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILK Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134822 AZT3TCEFV 2003 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELRKHLLSWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTTEAELELAENREILKDPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134823 AZT3TCNVP 2005 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPDIIIYQYVDDLYVGSDLEIEQHRAKIEELRQHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYSGIKIRQLCKLLRGAKALTEVVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134824 AZT3TCEFV 2007 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICADMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134825 TDFFTCNVP 2009 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRMKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134826 AZT3TCEFV 2005 Portugal CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTEMETEGKISRVGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDNDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYAGIRIKQLCKLIRGAKALTDVVTMTEEAELELAENREILKEPVHGAYYDPTKDLVAEIQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134827 AZT3TCEFV 2006 Portugal CRF02_AG 0 1 335 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIRALTEICTEMEKEGKISRIGPDNPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYVDDLYVSSDLEIGKHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEVVPLTTEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQEQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134828 AZT3TCNVP 2007 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEIQLGIPHPSGLEKKKSATVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDLVIYQYVDDLYVGSDLEIEQHRTKIEELRQHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPINLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEIVPLTKEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGEG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134829 AZT3TCEFV 2005 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRSKIEELRQHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQEQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134830 TDFFTCEFV 2014 Portugal CRF01_AE 0 1 335 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTAICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQHSMTKILEPFRLQNPEIIIYQYMDDLYVGSDLEIGQHRTKVEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGAYYDPSKDLVAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134831 AZT3TCNVP 2008 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKAIVEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYVDDLYVGSDLEIEQHRIKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLIRGTKALTEVVQLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQEHG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134832 AZT3TCNVP 2014 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGEHRIKVEELRQHLLKWGFSTPDKKHQKEPPFRWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGEG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134833 AZT3TCNVP 2008 Portugal CRF02_AG 0 1 334 PISSIETVPVNLKPGMDGPKIKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGAYYDPTKDLVAEIQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134834 AZT3TCNVP 2010 Portugal H 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSISVLDVGDAYFSVPLDESFRKYTAFTIPSTNNERPGVRYQYNVLPQGWKGSPAIFQSSMTKILAPFRAQNPEMVIYQYVDDLYVGSDLEIGQHREKIEELRTHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPVKLPEKESWTVNDIQKLVGKLNWASQIYSGIKVKQLCRLLKGAKALTDIVTLTEEAEMELAENREILKEPVHGVFYDPSKDLIAEIQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134835 AZT3TCEFV 2006 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHREKIEALRQHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKDLTAELQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134836 AZT3TCEFV 2006 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDKSFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIGIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134837 AZT3TCNVP 2007 Portugal CRF02_AG 0 1 335 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIIALTEICKEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYMDDLYVGSDLEIEQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVIPLTAEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGEG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134838 D4T3TCNVP 2010 Portugal G 0 1 333 PISPIETVPVELKPGMDGPKVKQWPLTEEKIKALTEICSEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSMNNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELEENREILKEPVHGVYYDPSKDLIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134839 AZT3TCNVP 2009 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALAEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVASDLEIEKHRIKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEIVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134840 AZT3TCEFV 2007 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDLVIYQYMDDLYVGSDLEIGQHRAKIDELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKSLTEVIPLTAEAELELAENREILKEPVHGVYYDPSKDLVAELQKQENG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134841 AZT3TCEFV 2009 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIEIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDNKHQKEPPFLWLGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLIRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134842 AZT3TCEFV 2010 Portugal CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALRDICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVVTLTEEAQLELAENREILREPVHGVYYDSTKDLIAEIQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134843 TDFFTCNVP 2010 Portugal CRF02_AG 0 1 335 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKNSTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRKENPEMVIYQYVDDLYVSSDLELGQHRAKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGAYYDPSKDLVAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134844 AZT3TCEFV 2008 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEREGKISKIGPENPYNTPIFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPELVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIALTKEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134845 AZT3TCEFV 2006 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTEICTDMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRTKNPEIEIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELVAEVQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134846 AZT3TCNVP 2009 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGTKALTEVIPLTREAELELAENREILKEPVHGVYYDPSKDLIAEVQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134847 AZT3TCEFV 2008 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQHNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLNWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKPVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELESAENREILREPVHGVYYDPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134848 D4T3TCEFV 2006 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNEAPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQEKG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134849 TDFFTCNVP 2010 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRQQNQDIVIVQYVDDLYVGSDLEIGQHRAKIKELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134850 AZT3TCEFV 2005 Portugal B 0 1 335 PISPVETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIEIYQYVDDLLIGSDLEIGQHRTKIEELRQHLLKWGFTTPEKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKTLTEIVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134851 D4T3TCEFV 2003 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDMVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEIIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134852 TDFFTCNVP 2010 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMEICAEMEKEGKIEKIGPENPYNTPIFVIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLQKKKSITVLDVGDAFFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVICQYVDDLYVASDLEIGQHRAKIEELRQHLFKWGFDTPDKKHQKEPPFLWMGYELHPDKWTVQPINLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLIKGTKALTEVIALTKEAELELAENREILKQPVHGVYYDPSKDLIAELQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134853 AZT3TCEFV 2009 Portugal G 0 1 334 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTADAELELAENREILKEPVHGVYYEPSKELIAEVQKQGR Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134854 AZT3TCNVP 2007 Portugal CRF02_AG 0 1 334 PISPIKTVPVKLKPGTDGPKVKQWPLTEEKIKALMDICAEMEKEGKITRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKSKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILDPFRIKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTEVVALTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134855 AZT3TCNVP 2010 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTELEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVICQYVDDLYVASDLEIGQHKIKIEELRQHLLRWGFFTPDQKHQKEPPFLWMGYELHPDRWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134856 AZT3TCEFV 2007 Portugal CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTDICAEMEKEGQISKIGPENPYNTPVFAIKKKGGDRWRKLVDFRELNKRTQDFWEIQLGIPHPAGLQKRKSVTVIDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIEICQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKGLTDIVALTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134857 AZT3TCEFV 2007 Portugal C 0 1 332 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKVEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGAYYDPSKDLVAEVQKQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134858 TDFFTCEFV 2007 Portugal K 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTEICNDMEKEGKISRIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRRKNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTEVVPLTAEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134859 D4T3TCEFV 2004 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTLPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFYTPDKKHQKEHPFIWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134860 AZT3TCEFV 2004 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALIEICTEMEKEGKISKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPEMVICQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVVPLTREAELELAENREILREPVHGVYYDPSKDLIAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134861 AZT3TCEFV 2006 Portugal C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICMEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIRVKHLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134862 AZT3TCNVP 2006 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALKKICTELEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMLKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALSDIVPLTVEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134863 TDF3TCEFV 2004 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSDKWRKLVDFRELNKRTQDFWEIQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPELVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVIALTKEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134864 AZT3TCNVP 2006 Portugal CRF02_AG 0 1 335 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICAEMEKEGKISKIGPDNPYNTPIFAIKKKTSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITILDVGDAYFSVPLYEDFRKYTAFTIPSVNNERPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRIKYPEIVICQYVDDLYVGSDLEIREHRAKIEELREHLLKWGFSTPEQKHQKEPPFHWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTEVVPLTAEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134865 D4T3TCNVP 2004 Portugal C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTQNPEIIIYQYVDDLYVASDLEIGQHRAKIKELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134866 AZT3TCNVP 2005 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDVVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134867 AZT3TCEFV 2006 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEIVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134868 AZT3TCNVP 2003 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRAKIKELRAHLLSWGFYTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134869 AZT3TCEFV 2007 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNRSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPDIVIYQYVDDLYVGSDLEIEQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEIVPLTEEAELELAENREILREPVHGVYYDPSKELIAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134870 AZT3TCEFV 2010 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVRQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIEQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTETVSLTREAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGEG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134871 ABC3TCEFV 2010 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGTKALTEIIPLTKEAELELAENREILKVPVHGVYYDPSKDLIAEIQKQELG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134872 AZT3TCNVP 2004 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQNSMTRILEPFRKQNPDIVICQYVDDLYVASDLEIGQHRTKIEELRDHLLRWGFFTPDEKHQKEPPFHWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRHLCKLLRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134873 AZT3TCNVP 2010 Portugal G 0 1 328 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICADMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTNNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTAEAEMELTENREILKEPVHGVYYDASKELIAD Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134874 AZT3TCEFV 2005 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEREGKISKIGPENPYNTPIFAIRKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYVDDLYVGSDLEIGQHRAKVEELRKHLLSWGFYTPDEKHQKEHPFLWMGYELHPDKWTVQPIQLPDKENWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKTLTEIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134875 AZT3TCEFV 2005 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIEKHRAKIEELRKHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDVIPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134876 D4T3TCEFV 2006 Portugal G 0 1 320 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEKGQHRAKIEELRQHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPNKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYD Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134877 D4T3TCNVP 2006 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKAITEICAELEREGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSATVIDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKNNPDIIIYQYVDDLYVGSDLEKEQHRAKVEELRQHLLSWGFYTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTAEAELELEENREILKEPVHGVYYDPSKELIAEVQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134878 AZT3TCEFV 2005 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPILLPNKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134879 AZT3TCEFV 2014 Portugal G 0 1 333 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTEICKDMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQDTMTRILEPFRRKNPEMIIYQYMDDLYVGSALEISRHRATIENLRDHLLKWGFTTPDKKHHKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTTEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134880 AZT3TCNVP 2009 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTDICTEMEREGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPDIVIYQYVDDLYVGSDLEIGHHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQGPG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134881 AZT3TCEFV 2009 Portugal C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTAICKDMEKEGKITKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPGIVIVQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREIIKESVHGAYYDPSKDLIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134882 AZT3TCNVP 2006 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSVNNEKPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVICQYVDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVVPLTAEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134883 TDF3TCEFV 2006 Portugal B 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFVIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKHNPDIVICQYMDDLYIASDLEIEQHRTKIKELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDVIPLTDEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGE Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134884 D4T3TCEFV 2006 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFYTPDEKHQKEPPFLWMGYELHPDTWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELEENREILKEPVHGVYYDPSKDLIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134885 AZT3TCEFV 2007 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIEQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEIVPLSREAELELAENREILKEPVHGRYYDPSKDLIAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134886 AZT3TCEFV 2008 Portugal C 0 1 333 PISPIETVSVKLKPGMDGPKVKQWPLTEEKVKALMEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSMTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIKELREHLLKWGFTTPDQKHQKEPPLLWMGYELHPDKWTVQPIKLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGAYYDPLKDLIAEIQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134887 AZT3TCEFV 2006 Portugal C 0 1 314 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICEEMEKEGKITKIGPENPYNTPIFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPV Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134888 AZT3TCEFV 2004 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRRYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRMKNPEVVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGLTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134889 AZT3TCEFV 2005 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRHHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTEVIPLTKEAEMELAENREILKEPVHGVYYDPSKDLIAELQKQEQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134890 AZT3TCEFV 2008 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPSIFQSSMLKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELRKHLLSWGFTTPEKKHQKEPPFLWMGYELHPDTWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134891 AZT3TCEFV 2009 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRRNPEIVIYQYVDDLYVGSDLEKGQHRAKIEELRQHLLSWGLTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPVKESWTVNDIQKLVGKLNWASQIYPGIQVRQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEIQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134892 AZT3TCEFV 2007 Portugal CRF02_AG 0 2 334 ISPIETVPVNLKPGMDGPKVKQWPLTEEKIKALPDICPDMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQGSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVVLTEEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134893 AZT3TCEFV 2008 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPNIVIYQYMDDLYVGSDLEIEQHRTKVEELRQHLLGWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134894 AZT3TCEFV 2004 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSKNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPEIEIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFSTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILREPVHGVYYDPSKDLIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134895 AZT3TCEFV 2005 Portugal B 0 1 335 PISPIETIPVTLKPGMDGPKVKQWPLTKEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRIKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKSLTEVIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134896 TDFFTCEFV 2009 Portugal CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIRALTEICTEMEKEGKISKIGPDNPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLNQKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVICQYVDDLYVSSDLEIGEHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEVVPLTAEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQEQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134897 ABC3TCNVP 2010 Portugal B 0 1 334 PISPIETVPVKLKPGMDGPKVRQWPLSEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAFFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPTIFQSTMTKILEPFRKQNPDIVICQYVDDLYVGSDLEIGQHRTKIDELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGTKALTEVVALTKEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134898 ABC3TCEFV 2010 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSITVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGVRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGTKALTEIIPLTKEAELELAENREILKVPVHGVYYDPSKDLIAEIQKQELG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134899 AZT3TCNVP 2006 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALVDICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIEQHRTKIEELRRHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEIVPLTREAELELAENREILKEPAHGVYYDPSKDLIAELQKQEQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134900 AZT3TCNVP 2009 Portugal CRF02_AG 0 1 334 PISPIETVPVQLKPGMDGPKVKQWPLTEEKIKALTEICTDMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIGQHREKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDVVTLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134901 AZT3TCNVP 2014 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEIVPLTAEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134902 TDFFTCEFV 2007 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRHHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEIVPLTKEAELELAENREILREPVHGVYYDPSKDLIAEIQKQELG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134903 AZT3TCEFV 2005 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRKQNPEIVIYQYMDDLYVGSDLEIEQHRTKIEELRQHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134904 TDFFTCEFV 2009 Portugal G 0 1 333 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPELEIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLSWGLTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKIKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134905 AZT3TCNVP 2009 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLQWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGTKALTEVIPLTREAELELAENREILKEPVHGVYYDPSKDLIAEVQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134906 D4T3TCEFV 2004 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKAIVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLLDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWSVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEIIPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134907 D4T3TCEFV 2006 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTELEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLEKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVSSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKSLTEVIPLTKEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134908 AZT3TCEFV 2004 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPSMVIYQYVDDLYVGSDLEIEQHRTKIDELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVVPLTAEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQDHG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134909 AZT3TCNVP 2004 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEVIICQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134910 TDFFTCEFV 2008 Portugal CRF02_AG 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICTDMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEIIIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVALTEEAELELAENREILREPVHGVYYDPPKDLVAEIQNQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134911 AZT3TCEFV 2005 Portugal G 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTELEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLSWGFYTPDKKYQKEPPFRWLGYEIHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLIRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYEPSKELVAEVQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134912 AZT3TCNVP 2009 Portugal C 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALIAICEEMEKEGKITRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMAKILEPFRTKHPDIVICQYVDDLYVGSDLEIGQHRAKVEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQMCKLLRGAKALTDIVPLTEEAELELAENREILREPVHGAYYDPSKDLIAEIQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134913 AZT3TCEFV 2010 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMEICTDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILDPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKSLTEIVPLTTEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQELG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134914 ABC3TCNVP 2010 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICREMETEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPSGLKRKKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSMNNETPGVRYQYNVLPQGWKGSPTIFQSSMIKILEPFRTNNPELVICQYVDDLYIGSDLELGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKENWTVNDIQKLVGKLNWASQIYPGIQIRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134915 ABC3TCNVP 2008 Portugal C 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTEWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTILDVGDAFFSVPLDEGFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVICQYVDDLYVGSDLEIGQHRAKIEKLRDHLLKWGFTTPDKKYQKEPPFRWMGYELHPDKWTVQTIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIRVKHLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134916 AZT3TCEFV 2008 Portugal F 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSVNNEAPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTKNPEIVIYQYVDDLHVGSDLEIEQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGHELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENKEILKEPVHGVYYDPSKDLIAEIQKQGHG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134917 AZT3TCNVP 2009 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICREMEREGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLHKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRLKNPDIVIYQYVDDLWVGSDLELGQHRAKIEELRKHLLSWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILREPVHGVYYDPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134918 AZT3TCNVP 2004 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKERWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134919 ABC3TCNVP 2010 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKAIMEICTEMEKEGKISKIGPENPYNTPIFAIKKKDGTKWRKVVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVICQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVVTLTEEAELELAENREILREPVHGVYYDPTKDLIAELQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134920 AZT3TCEFV 2005 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYVDDLYVGSDLEIGEHRLKIEELRQHLLRWGFTTPDKKHQKEHPFLWMGYELHPDTWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKSLTEVIPLTKEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134921 AZT3TCEFV 2006 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFRSSMTKILEPFRKQNPDIVIYQYVDDLYVSSDLEIGQHRAKIEELREHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEIIPLTKEAELELAENREILKEPVHGVYYDPSKELIAELQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134922 TDF3TCEFV 2004 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDIEIYQYVDDLYVGSDLEIGLHRAKIEELRKHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134923 AZT3TCNVP 2007 Portugal CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPSIFQASMTKILEPFRNKNPGIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIRVKQLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134924 ABC3TCNVP 2004 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAFFSVPLDKDFRKYTAFTIPSTNNEAPGIRYQYNVLPQGWKGSPAIFQSSMAKILEPFRKQNPDIVICQYVDDLYVGSDLEIGQHRTKIEELRQYLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEIVPLTREAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134925 AZT3TCEFV 2008 Portugal CRF02_AG 0 1 334 PISPVETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTILDVGDAYFSVPLDEGFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFKQKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVVPLTEEAELELAENREILKEPVHGVYYDPAKDLVAEIQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134926 AZT3TCNVP 2006 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALKEICTELEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMLKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLQWGFFTPDKKHQKEPPFLWMGYELHPDNWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALSDIVPLTVEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGVG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134927 AZT3TCNVP 2010 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICADMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTNNPEIVIYQYMDDLYVGSDLEIGQHREKIEELRKHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTAEAEMELAENREILKEPVHGVYYDASKELIAEVQKQEPG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134928 D4T3TCNVP 2005 Portugal A 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICKEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKENWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGAKALTDIVTMTEEAEVELAENREILKDPVHGVYYDPSKDLVSEIQKHGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134929 D4T3TCEFV 2007 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYITPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIEQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPITLPEQDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKSLTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134930 ABC3TCEFV 2010 Portugal CRF02_AG 0 1 334 PISPIETVSVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSLTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMVIYQYMDDLCVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQAIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVALTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134931 AZT3TCEFV 2009 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTELEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLAEDFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSSAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELIQHLWRWGFSTPDKKHQKEPPFRWMGYELHPDTWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGTKALTEVVPLSVEAELELAENREILKEPVHGVYYDPTKDLIAELQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134932 TDFFTCNVP 2010 Portugal A 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICREMEKEGKISKIGPEIPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVICQYMDDLCVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKNPVHGVYYDPSKDLTAEIQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134933 AZT3TCEFV 2006 Portugal CRF02_AG 0 1 335 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIRALTEICTEMEKEGKISKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLEKKKSVTVLDVGDAFFSVPLNENFKKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTKNPEMVIYQYMDDLYVSSDLEIGKHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEIVPLTAEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134934 AZT3TCEFV 2007 Portugal G 0 1 333 PISPIETVPVKLKPGMNGPRVKQWPLTKEKIKALVEICTEMEKEGKISKIGPENPYNAPVFAIKKKDRTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIF*SSMTKILEPFRTKNSEIVIYQYVDDLYVGSDLEIGQHRAKVEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKGLTDIVPLTTEAELELAENREILKEPVHGVYYDPSQELVAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134935 AZT3TCNVP 2004 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDERFRKYTAFTIPSTNNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKDPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134936 D4T3TCEFV 2006 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLLDFRELNKRTQDFWEVQLGIPHPAGLKNNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPEIVIYQYVDDLYVASDLEIEQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEIVPLTREAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134937 AZT3TCEFV 2005 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIEIYQYVDDLLVGSDLEIGQHRTKIEELRGHLLAWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPITLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRNLCKLLRGAKALTDIVPLTAEAELELAENKEILKEPVHGVYYEPSKELIAEVQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134938 AZT3TCNVP 2004 Portugal G 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICMEMEKEGKISKIGPENPYNTPIFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNERPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGLATPDQKHQKEPPFHWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDVIPLTEEAELELAENREILREPVHGVYYDPSKELIAEVQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134939 AZT3TCNVP 2004 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLHKKKSATVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDLVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKESWTVNDIQKLVGKLNWASQIYPGIRVRELCKLIRGAKALTEVVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134940 AZT3TCNVP 2004 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNKTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPELVVYQYMDDLYVGSDLEIGQHRAKVEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134941 D4T3TCEFV 2004 Portugal K 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPGIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTMQPIQLPDKESWTVNDIQKLVGKLNWASQIYSGIKVRQLCKLLRGAKALTDVIPLTAEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQ Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2189 134942 TDFFTCEFV 2009 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALREICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTNWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSITVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWLGYEIHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEIIPLTREAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGLG Theys, K 2013 23027713 J Antimicrob Chemother Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. 2190 134943 TDFFTCEFV 2011 Sweden CRF01_AE 0 1 330 PISPIKTVPVTLKPGMDGPRVKQWPLTEEKLKALTEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSQNPEMVIYQYVDDLYVGSDLEIGQHRAKVEELRAHLLSWGLTTPDKKHQKEPPFHWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYAGIQIKQLCKLLRGAKALTDIVTLTEEAELELAENREILKNPVHGVYYDPSKDLIAELQ Theys, K 2013 unpublished EuResist network data set 2190 134944 TDFFTCEFV 2010 Sweden D 0 32 235 KALTEICSEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEGFRKYTAFTIPSTNNETPGIRFQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPEIAIYQYMDDLYVGSDLEIGQHRIKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELH Theys, K 2013 unpublished EuResist network data set 2190 134945 TDFFTCEFV 2011 Sweden CRF01_AE 0 1 330 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICREMEEEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDIGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPYRLKNPEIVIYQYMDDLYVGSDLEIGQHRIKIEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKIPVHGVYYDPSKDLIAEIQ Theys, K 2013 unpublished EuResist network data set 2190 134946 TDFFTCEFV 2012 Italy B 0 30 247 QIGCTLNFCAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVSLDENFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQCSMIKILEPFRKQNPDIVIYQYMDDLYVGSDLEIEQHRAKVENLRQHLLQ*GFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Theys, K 2013 unpublished EuResist network data set 2190 134947 TDFFTCEFV 2012 Luxembourg G 0 1 345 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGQISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKRKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIEIYQYVDDLYVASDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQGPGQWTYQIYQEP Theys, K 2013 unpublished EuResist network data set 2190 134948 TDFFTCNVP 2012 Germany B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMENEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQXSMTKILDPFRTENPEIVIYQYMDDLYVGSDLEIGQHRAKIENLREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKQNWTVNDIQKLVGKLNWASQIYPGIRIRQLCKLLRGAKALTEVITLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQGEG Theys, K 2013 unpublished EuResist network data set 2190 134949 TDF3TCEFV 2010 Belgium CRF02_AG 0 1 341 PISPIKTVPVSLKPGMDGPRVKQWPLTAEKIQALTEICNEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYMDDLYVGSDLEIGQHRVKVEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQHITLPDKENWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGAKALTDVVPLTKEAELELAENREILKEPVHGVYYDPEKELIAELQKQGQDQWTYQI Theys, K 2013 unpublished EuResist network data set 2190 134951 TDFFTCNVP 2011 Portugal G 0 1 320 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICMEMEKEGKISRIGPENPYNTPIFVIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPEIVICQYVDDLYVGSDLEIGQHRVKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDIVTLTAEAELELAENREILKEPVHGVYYE Theys, K 2013 unpublished EuResist network data set 2190 134952 TDFFTCEFV 2011 Italy B 0 30 247 QIGCTLNFCTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPDIVIYQYMDDLYVGSDLEIEQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Theys, K 2013 unpublished EuResist network data set 2190 134953 TDFFTCEFV 2012 Italy CRF01_AE 0 30 247 QIGCTLNFCREMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQCSMTKILEPFRLKNPEIVIYQYVDDLYVGSDLEIGQHRKRIEELRAHLLSWGFTTPEKKHQKEPPFLWMGYELHPDKWTVQPIMLP Theys, K 2013 unpublished EuResist network data set 2190 134954 TDFFTCEFV 2011 Italy B 0 35 247 LNFCTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTILDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIEQHRTKIEELRQHLLGWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Theys, K 2013 unpublished EuResist network data set 2190 134956 TDFFTCEFV 2012 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGIEKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPDIVIYQYVDDLYVGSDLEIRQHRKKVEELRQHLLRWGFTTPDEKHQKEPPFLWMGYELHPDKWTVQPIELPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQG Theys, K 2013 unpublished EuResist network data set 2190 134957 TDFFTCEFV 2011 Italy G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICADMEKKEKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDIVIYQYMDDLYVGSDLETGQHRAKIEELRDHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Theys, K 2013 unpublished EuResist network data set 2190 134959 TDF3TCEFV 2004 Germany B 0 1 335 PISPIETVPVKLKPGMDGPRVRQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDIWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLIRGAKALTEVITLTQEAELELAENREILKEPVHGVYYDPTKELIAEIQKQGQG Theys, K 2013 unpublished EuResist network data set 2190 134960 TDF3TCEFV 2005 Portugal B 0 1 335 PISPIETIPVKLKPGMDGPKVKQWPLTREKIKALVEICTEMEKEGQISKIGPENPYNTPVFVIKRKDNTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIEIYQYVDDLYVGSDLEIGQHRAKVEELRKHLLHWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGLG Theys, K 2013 unpublished EuResist network data set 2190 134961 TDFFTCEFV 2013 Germany C 0 1 300 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRIQDFWEVQLGIPHPAGLKKRRSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIRQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPDKESWTVNDVQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTKEAE Theys, K 2013 unpublished EuResist network data set 2190 134962 TDFFTCNVP 2013 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSPKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMAKILEPFRIKNPEIVICQYMDDLYVGSDLEIGQHREKIKELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQGPG Theys, K 2013 unpublished EuResist network data set 2190 134963 TDFFTCEFV 2012 Italy B 0 30 247 QIGCTLNFCTEMEKEGKISKIGPENPYNTPVFAIKKKGSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEAFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVSSDLEIEQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP Theys, K 2013 unpublished EuResist network data set 2190 134964 TDFFTCEFV 2009 Portugal B 0 1 335 PISLIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPSGIKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEIVPLTREAELELAENREILKEPVHGVYYDPSKELIAEIQKQGLG Theys, K 2013 unpublished EuResist network data set 2190 134965 TDFFTCNVP 2013 Belgium CRF02_AG 0 1 344 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTDICLEMEKEGKISKIGPENPYNTPVFAIKRKDSTK*RKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSATVLDVGDAFFSVPLDKDFRKYTAFTIPSVNNKTPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTENPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKNSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQDQWTYQIYQE Theys, K 2013 unpublished EuResist network data set 2190 134967 TDFFTCEFV 2008 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIQALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRDLNKRTQDFWEIQLGIPHPSGLKQKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRQNPDMIIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVVQLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQG Theys, K 2013 unpublished EuResist network data set 2190 134968 TDFFTCNVP 2010 Italy B 0 30 247 QIGCTLNFCTDMEKEGKISRIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSITILDVGDAYFSVPLDEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFKTKNPEMVICQYVDDLYVGSDLELGQHRAKIEELRKHLLSWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLP Theys, K 2013 unpublished EuResist network data set 2190 134969 TDFFTCEFV 2011 Italy B 0 1 345 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKDFKKYTAFTIPSINNETPGIRYQFNVLPQGWKGSPAIFQCSMTKILEPFRKQKPNVVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQGQWTYQIYQEP Theys, K 2013 unpublished EuResist network data set 2190 134970 TDFFTCEFV 2011 Portugal B 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPSIFQSSMIKILEPFRKQNPDIDIYQYVDDLYVGSDLEIGQHRTKVEELRQHLLKWGLTTPDKKHQKEPPLLWMGHELHPDKWTVQPINLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEIVPLTREAEIELAENREILKEPVHGVYYDPSKDLIAELQKQGQ Theys, K 2013 unpublished EuResist network data set 2190 134971 TDFFTCEFV 2013 Portugal F 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICMEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRMKNPDIVIYQYMDDLYVGSDLEIGQHREKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIQVRNLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGQG Theys, K 2013 unpublished EuResist network data set 2190 134972 TDFFTCEFV 2012 Sweden B 0 1 330 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMEICTEMEKEGKISKIGPENPYNTPVFAIKKKGSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVQSDLEIGQHRTKIEELREHLLKWGFTTPDNKHQKEPPFLWMGYELHPDKWTVQPITLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEVIPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQ Theys, K 2013 unpublished EuResist network data set 2190 134973 TDFFTCNVP 2012 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICADMEREGKISKIGPENPYNTPIFAIKRKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVTQLCKLLRGAKALTDIVPLTADAELELAENREILKEPVHGVYYEPSKELIAEVQKQGLG Theys, K 2013 unpublished EuResist network data set 2190 134974 TDFFTCNVP 2010 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQEFCEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQYSMTKILEPFRKQNPNIVIIQYVDDLYVGSDLEIGQHRTKIEELRQHLLKWGLTTPDEKHQKDPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGTKSLTEVVPLTKEAELELAENREILREPVHGVYYDPSKDLIAELQKQGQG Theys, K 2013 unpublished EuResist network data set 2190 134975 TDFFTCEFV 2013 Germany CRF01_AE 0 1 325 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVDICEEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAVFQSSMTKILEPFRVKNPEIVIYQYMDDLYVGSDLEIGQHRAKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTIQPIMLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDL Theys, K 2013 unpublished EuResist network data set 2190 134977 TDFFTCEFV 2010 Belgium C 0 1 341 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEDMEKEGKLSRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRRYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMIKILEPFRTKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQI Theys, K 2013 unpublished EuResist network data set 2190 134978 TDFFTCEFV 2010 Italy B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKITALIEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDREFRKYTAFTIPSRNNETPGVRYQYNVLPQGWKGSPAVFQSSMTRILEPFRKQNPDLVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLGWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGTKALTEVIPLTKEAELELAENREILKEPVHGAYYDPSKDLIAEIQKLGQG Theys, K 2013 unpublished EuResist network data set 2190 134979 TDFFTCNVP 2013 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRVKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIQVRQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Theys, K 2013 unpublished EuResist network data set 2190 134980 TDFFTCEFV 2009 Portugal B 0 1 335 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIDIYQYVDDLLVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGTKALTEIVPLTREAEIELAENREILKEPVHGVYYDPSKDLVAEIQKQGLG Theys, K 2013 unpublished EuResist network data set 2190 134981 TDFFTCEFV 2012 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTDMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDKNFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEVEQHRAKIEELRKHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTTEAELELAENREILKEPVHGAYYEPSKELIAEVQKQGLG Theys, K 2013 unpublished EuResist network data set 2190 134982 TDFFTCNVP 2010 Italy B 0 30 247 QIGCTLNFCTEMEKEGKISKIGPENPYNTPVFAIKRKNSTKWRKLVDFRELNKKTQDFWEIQLGIPHPAGLKKKKSATVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFREQNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIVLP Theys, K 2013 unpublished EuResist network data set 2190 134983 TDFFTCEFV 2008 Italy A 0 1 324 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRSKNPEIIIYQYMDDLYVGSDLEIGQHRAKIDELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTEIVTLTEEAELELAENREILKDPVHGVYYDPAKD Theys, K 2013 unpublished EuResist network data set 2190 134986 TDFFTCEFV 2011 Portugal B 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISRVGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKQNPDIVIYQYVDDLYVGSDLEIEQHRTKIEELRQHLLKWGFTTPDKKHQKEHPFLWMGYELHPDTWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTREAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Theys, K 2013 unpublished EuResist network data set 2190 134987 TDFFTCEFV 2007 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKSLTEIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQEKG Theys, K 2013 unpublished EuResist network data set 2190 134988 TDFFTCNVP 2010 Portugal G 0 1 325 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKGSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQQKRSITVLDVGDAYFSVPLDEDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKYPDIVICQYVDDLYVASDLEIGQHRERIEELRNHLLKWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLIRGTKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKEL Theys, K 2013 unpublished EuResist network data set 2190 134989 TDFFTCEFV 2010 Italy B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKILDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGEHRTKIEELRQHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTIQPIMLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVRQLCRLLRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGLG Theys, K 2013 unpublished EuResist network data set 2190 134990 TDFFTCEFV 2013 Portugal B 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNATPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRKQNPDMVIYQYMDDLYVGSDLEIGEHRTKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGE Theys, K 2013 unpublished EuResist network data set 2190 134991 TDFFTCNVP 2010 Germany B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKDGKISKIGPENPYNTPVFAIKKKGSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKKNPEIVICQYIDDLCVGSDLEIEQHRTKVEELRKHLLVWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKEIIAEIQKQGQG Theys, K 2013 unpublished EuResist network data set 2190 134992 TDFFTCEFV 2013 Luxembourg G 0 1 341 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAFFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYMDDLCVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTTEAELELAENREILKEPVHGVYYEPSKELIAEVQKQGQDQWTYQI Theys, K 2013 unpublished EuResist network data set 2190 134993 TDFFTCEFV 2011 Luxembourg B 0 1 341 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALLEICTEMEKEGKISKIGPENPYNTPVFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKNKSVTILDVGDAYFSVPLYEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPITLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQI Theys, K 2013 unpublished EuResist network data set 2190 134994 TDFFTCEFV 2013 Portugal G 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDPSFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKIKQLCKLIRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQGQ Theys, K 2013 unpublished EuResist network data set 2190 134996 TDFFTCEFV 2012 Sweden A 0 1 343 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKITKIGPENPYNTPIFAIKRKGSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKHPDIVIYQYMDDLYVESDLEIGQHRAKIEELRAHLLSWGFTTPDQKHQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTATVTLTEEAELELAENREILKDPVHGVYYDPSKDLIAEIQKQGQDQWTYQIYQ Theys, K 2013 unpublished EuResist network data set 2190 134997 TDFFTCEFV 2013 Sweden C 0 1 330 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICDEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYCYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIITLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQ Theys, K 2013 unpublished EuResist network data set 2190 134998 TDFFTCEFV 2011 Portugal C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNATPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIRVRQLCKLLRGAKALTDIVPLTKEAELELAENREILKEPVHGVYYDPSKELIAEIQKQG Theys, K 2013 unpublished EuResist network data set 2190 134999 TDFFTCEFV 2011 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRMKNPEIVIYQYMDDLCVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Theys, K 2013 unpublished EuResist network data set 2190 135000 TDFFTCEFV 2012 Sweden CRF01_AE 0 1 327 PISPIDTIPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSLNNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIAQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKTPVHGVYYDPSKDLIA Theys, K 2013 unpublished EuResist network data set 2190 135001 TDFFTCEFV 2011 Sweden K 0 1 328 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYMDDLYVGSDLEIGQHRVKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGTKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAE Theys, K 2013 unpublished EuResist network data set 2190 135002 TDFFTCEFV 2008 Germany A 0 1 334 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTDICNEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKXFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSTMTRILEPFRSRNPEMVVYQYMDDLYVGSDLEIGQHREKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQ Theys, K 2013 unpublished EuResist network data set 2190 135003 TDFFTCEFV 2011 Sweden CRF01_AE 0 1 328 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKNNPEIVIYQYMDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKIKQLCKLLRGAKALTEIVPLTEEAELELAENREILKTPVHGVYYDPSKDLIAE Theys, K 2013 unpublished EuResist network data set 2190 135004 TDFFTCEFV 2009 Sweden A 0 1 334 PISPIETVPVTLKPGMDGPRIKQWPLTEEKIKALTEICMEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRT*DFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFGKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIIIYQYMDDLYVGSDLEIGQHRTKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKESWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTEVVTLTEEAELELAENREILRNPVHGVYYDPSKDLTAEIQKQGQ Theys, K 2013 unpublished EuResist network data set 2190 135005 TDFFTCEFV 2011 Sweden A 0 1 327 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICMEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPYRSKNPEIIIYQYMDDLYVGSDLEIGQHRAKVEELRNHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYGGIKVRQLCKLLRGAKALTDIVVLTEEAELELAENREILKEPVHGAYYDPSKDLIA Theys, K 2013 unpublished EuResist network data set 2190 135006 TDFFTCEFV 2009 Belgium C 0 1 341 PISPIETVPVKLKPGMDGPKVRQWPLTEEKIEALKAICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSRNNEAPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPDIVIYQYMDDLYVGSDLEIGQHRVKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPINLPEKENWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGEDQWTYQI Theys, K 2013 unpublished EuResist network data set 2190 135007 TDFFTCEFV 2010 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPIFAIKNKDNTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYMDDLLVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTTEAELELAENREILREPVHGVYYEPSKELIAEVQKQG Theys, K 2013 unpublished EuResist network data set 2190 135008 TDFFTCEFV 2011 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILDPFRRKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIQVRQLCKLLRGTKALTDIVPLTTEAELELAENREILKEPVHGVYYDPSKELIAEVQKQGLG Theys, K 2013 unpublished EuResist network data set 2190 135009 TDFFTCEFV 2013 Italy B 0 1 244 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKHGTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLQQKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNSELVIYQYVDDLYVASDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Theys, K 2013 unpublished EuResist network data set 2190 135010 TDFFTCEFV 2011 Italy G 0 30 247 QIGCTLNFCTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDETFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRVKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQAIQLP Theys, K 2013 unpublished EuResist network data set 2190 135011 TDFFTCNVP 2011 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISRIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPNIVICQYVDDLYVGSDLEIGQHRTKIEELRQHLLRWGFITPDEKHQKEPPFLWMGYELHPDNWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGPG Theys, K 2013 unpublished EuResist network data set 2190 135012 TDFFTCNVP 2013 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQGLG Theys, K 2013 unpublished EuResist network data set 2190 135013 TDFFTCEFV 2011 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPSGLKKKKSITVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPKIVIYQYMDDLYAGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYSGIQVRQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQGQG Theys, K 2013 unpublished EuResist network data set 2190 135014 TDFFTCEFV 2012 Sweden B 0 1 328 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGTRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLGWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAE Theys, K 2013 unpublished EuResist network data set 2190 135015 TDFFTCNVP 2013 Portugal C 0 1 333 PISPINTVPVKLKPGMDGPKVKQWPLSEEKIKALKEICEEMEKEGKITKIGPENPYNTPVFAIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYIDDLLVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPILLPDKDSWTVNDIQKLVGKLNWASQIYSGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENKEILKEPVHGVYYDPSKDLIAEIQKQG Theys, K 2013 unpublished EuResist network data set 2190 135016 TDFFTCEFV 2009 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLNKKKSMTVLDVGDAFFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVASDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVVPLTKEAELELAENREILKEPVHGVYYDPSKDLTAEIQKQGLG Theys, K 2013 unpublished EuResist network data set 2190 135017 TDFFTCNVP 2009 Germany B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYIDDLYVSSDLEIGQHRAKIKELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPNKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQG Theys, K 2013 unpublished EuResist network data set 2190 135018 TDFFTCNVP 2009 Luxembourg B 0 1 341 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDQDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTEVISLTAEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGQGQWTYQI Theys, K 2013 unpublished EuResist network data set 2190 135019 TDFFTCEFV 2012 Sweden B 0 1 326 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMIKILDPFRKQNPDLVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGTKSLTEIIPLTEEAELELAENREILKTPVHGVYYDPSKDLI Theys, K 2013 unpublished EuResist network data set 2190 135020 TDFFTCEFV 2011 Sweden A 0 1 327 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTDICREMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRSKNPEIVIYQYMDDLYVGSDLEIGQHRIKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIA Theys, K 2013 unpublished EuResist network data set 2190 135021 TDFFTCEFV 2011 Sweden CRF01_AE 0 1 327 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICRVMELEGQISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIIIYQYMDDLYVGSDLEIGQHRAKIEKLRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDVVTMTEEAELELAENREILRDPVHGVYYDPSKDLIA Theys, K 2013 unpublished EuResist network data set 2190 135022 TDFFTCEFV 2007 Italy F 0 37 247 LCAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILDSFRAKNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Theys, K 2013 unpublished EuResist network data set 2190 135023 TDFFTCEFV 2011 Sweden D 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFKELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQASMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIEQHRIKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDSSKELIAEIQKQGEG Theys, K 2013 unpublished EuResist network data set 2190 135026 TDFFTCEFV 2012 Sweden B 0 1 330 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGIKKNKSVTILDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIILPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVVPLTTEAELELAENREILKEPVHGVYYDPSKDLIAEIQ Theys, K 2013 unpublished EuResist network data set 2190 135027 TDFFTCNVP 2009 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIKALTEICMEMEKEGKISKIGPENPYNTPVFAIKRKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVICQYVDDLYVGSDLEIGQHRIKIEELRRHLLGWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQELG Theys, K 2013 unpublished EuResist network data set 2190 135028 TDFFTCEFV 2013 Italy B 0 1 342 PISPIETVPVRLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDLWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPNIVIYQYMDDLYVGSDLEIEQHRIKVEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGLGQWTYQIY Theys, K 2013 unpublished EuResist network data set 2190 135029 TDFFTCEFV 2011 Sweden K 0 1 335 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICTEMENEGKISRIGPDNPYNTPIFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDKDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILDPFRMKNPEIEICQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDVVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQEHG Theys, K 2013 unpublished EuResist network data set 2190 135030 TDFFTCEFV 2013 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSMNNATPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLELGQHRTKIEELRKHLLAWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCRLLRGTKALTEVVTLTKEAELELAENREILREPVHGVYYDPTKDLIAEIQKQGQG Theys, K 2013 unpublished EuResist network data set 2190 135031 TDFFTCEFV 2006 Italy F 0 30 247 QIGCTLNFCTDMEKEGKISKIGPENPYNTPVFVIKRKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSLNNETPGVRYQYNVLPQGWKGSPAIFQHSMTKILEPFRTKNPDIDICQYVDDLLVGSDLELEQHRAKIEELRAHLLTWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Theys, K 2013 unpublished EuResist network data set 2190 135032 TDF3TCNVP 2005 Sweden C 0 1 221 PISPIETVPVKLKPGMDGPKVK*WPSAEEIIKALTAICDEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVICQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKH Theys, K 2013 unpublished EuResist network data set 2190 135035 TDFFTCEFV 2009 Italy K 0 35 247 LNFCNDMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEKFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPVQLP Theys, K 2013 unpublished EuResist network data set 2190 135036 TDFFTCEFV 2010 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEREGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRRRNPEIVIYQYMDDLYVGSDLEIEQHRAKIEELRQHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKELIAEVQKQG Theys, K 2013 unpublished EuResist network data set 2190 135037 TDFFTCNVP 2010 Portugal G 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICMEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKRSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEMEIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLIVEVQKQGQ Theys, K 2013 unpublished EuResist network data set 2190 135039 TDFFTCEFV 2010 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQG Theys, K 2013 unpublished EuResist network data set 2190 135041 TDFFTCEFV 2007 Italy B 0 30 247 QIGCTLNFCTEMEKEGKISKIGPENPYNTPVFAIKKKDSNRWRKVVDFRELNKKTQDFWEVQLGIPHPAGLPKNKSVTVLDVGDAFFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGPHRAKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLP Theys, K 2013 unpublished EuResist network data set 2190 135042 TDFFTCNVP 2007 Italy B 0 30 247 QIGCTLNFCTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPGKNYETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIEKHRTKVEELRQHLLGWGFTTPDKKHQKEPSSLWMGYELHPDKWTVQPVVLP Theys, K 2013 unpublished EuResist network data set 2190 135043 TDFFTCEFV 2010 Luxembourg G 0 1 341 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKGLTDIVPLTTEAELELAENREILKEPVHGVYYEPAKELIAEVQKQGPDQWTYQI Theys, K 2013 unpublished EuResist network data set 2190 135044 TDFFTCEFV 2013 Belgium C 0 1 313 PISPIETVPVQLKPGMDGPKVKQWPLTEEKIKALTEICEDMEKEGRISKIGPENPYNTPVFAIKKKDNTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPEIVIYQYMDDLYIASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDNWTVQPIQLPEKKSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEP Theys, K 2013 unpublished EuResist network data set 2190 135045 TDFFTCEFV 2012 Italy C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFVIKRKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRTKNPELDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Theys, K 2013 unpublished EuResist network data set 2190 135046 TDFFTCEFV 2013 Portugal B 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKMNKSVTILDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMKRILEPFRKHNPDIVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDNWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGTKALTEVVPLTAEAELELAENREILREPVHGVYYDPSKDLIAEIQKQGQ Theys, K 2013 unpublished EuResist network data set 2190 135047 TDF3TCEFV 2005 Portugal A 0 1 334 PISPVETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSTMTKILEPFRAKNPEIIIYQYMDDLYVSSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPESKVKHLCRLLRGAKALTDVVTMTEEAELELAENREILRDPVHGVYYDPSKDLIAEIQKQGQ Theys, K 2013 unpublished EuResist network data set 2190 135048 TDFFTCEFV 2013 Portugal CRF02_AG 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKGSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSLNNETPGIRYEYNVLPQGWKGSPAIFQASMTKILEPFRRKNPEIEICQYIDDLYVASDLEIGQHRTKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQG Theys, K 2013 unpublished EuResist network data set 2190 135049 TDF3TCEFV 2010 Sweden C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDIGDAYFSVPLYEEFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPDLIIYQYMDDLYVGSDLEIGQHRTKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKGLTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Theys, K 2013 unpublished EuResist network data set 2190 135050 TDFFTCEFV 2012 Luxembourg B 0 1 345 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGTRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVVYQYMDDLYVGSDLEIGQHRAKIEELRQHLLTWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTREAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGDGQWTYQIYQEP Theys, K 2013 unpublished EuResist network data set 2190 135051 TDFFTCEFV 2011 Portugal G 0 1 335 PISPIETVPVKLKPGMDGPKIKQWPLTKEKIRALTEICTEMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTRNPEMVICQYVDDLYVSSDLELGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIRVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGYG Theys, K 2013 unpublished EuResist network data set 2190 135052 TDFFTCNVP 2011 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFVIKNKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKQKKSVTVLDVGDAFFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKGNPDMVICQYMDDLYVGSDLEIGQHRTKVEELRQHLLGWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGTKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGQG Theys, K 2013 unpublished EuResist network data set 2190 135053 TDFFTCEFV 2013 Germany B 0 1 300 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKKTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKHLCKLLRGTKALTEVIPLTKEAE Theys, K 2013 unpublished EuResist network data set 2190 135054 TDFFTCEFV 2011 Germany B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDF*EVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPEIVIYQYMDDLYVGSDLEIGQHRIKVEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPITLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEVVPLSREAEIELAENREILREPVHGVYYDPSKDLIAEVQKQGEG Theys, K 2013 unpublished EuResist network data set 2190 135056 TDFFTCEFV 2012 Italy B 0 30 247 QIGCTLNFCTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIIIYQYVDDLYVSSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Theys, K 2013 unpublished EuResist network data set 2190 135057 TDFFTCEFV 2012 Sweden A 0 1 327 PISPIETVPVTLKPGMDGPKVKQWPLTEEKIKALTDICNEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKDLIA Theys, K 2013 unpublished EuResist network data set 2190 135058 TDFFTCEFV 2008 Portugal B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSLNNETPGTRYQYNVLPQGWKGSPAIFQCSMTKILDPFRKQNPELVIYQYIDDLLVGSDLEIEQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASHIYPRIKVRQLCKLLRGTKALTEIIPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQELG Theys, K 2013 unpublished EuResist network data set 2190 135059 TDF3TCEFV 2006 Luxembourg B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIILPDKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGTKALTDVVPLTAEAELELAENKEILKEPVHGVYYDPSKDLIAEIQKQGQG Theys, K 2013 unpublished EuResist network data set 2190 135060 TDFFTCNVP 2012 Portugal G 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMTRILEPFRIKNPEIVICQYVDDLYVGSDLEIGQHRAKIEELRKHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPAKELIAEVQKQG Theys, K 2013 unpublished EuResist network data set 2190 135062 TDFFTCEFV 2013 Germany C 0 1 301 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVLLHEDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQFSMTKILEPFRSRNPELVIYQYMDDLYVGSDLEIELHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQFCKLLRGAKALTDIVPLTKEAEL Theys, K 2013 unpublished EuResist network data set 2190 135064 TDFFTCEFV 2012 Portugal CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKAITDICTDMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAKNPEIVIYQYMDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVTLTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQGQ Theys, K 2013 unpublished EuResist network data set 2190 135065 TDF3TCEFV 2006 Italy B 0 30 247 QIGCTLNFCTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVIYQYMDDLYVGSDLGIEQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Theys, K 2013 unpublished EuResist network data set 2190 135066 TDFFTCEFV 2012 Sweden B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKGSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYIDDLYVGSDLEIGQHRTKIEELRQHLLTWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDSWTVNDLQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDIIAEIQKQEQG Theys, K 2013 unpublished EuResist network data set 2190 135067 TDF3TCEFV 2004 Germany B 0 1 332 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDADFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLQWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKSLTEVVPLTKEAELELEENREILKEPVHGAYYDPTKDLIAEIQKQ Theys, K 2013 unpublished EuResist network data set 2190 135069 TDFFTCEFV 2012 Sweden CRF01_AE 0 1 330 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIEQHRTKVEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEVVPLTEEAELELAENREILKTPVHGVYYDPSKDLIAEIQ Theys, K 2013 unpublished EuResist network data set 2190 135070 TDFFTCEFV 2012 Italy B 0 30 247 QIGCTLNFCTEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLKKKESITVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPDIVIYQYMDDLYVGSDLEIGKHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Theys, K 2013 unpublished EuResist network data set 2190 135071 TDF3TCNVP 2011 Portugal G 0 1 332 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPIFAIKKKGSTEWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKVEELRKHLLSWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYEPSKELIAEVQKQ Theys, K 2013 unpublished EuResist network data set 2190 135072 TDFFTCEFV 2013 Belgium A 0 1 342 PISPIETVPVQLKPGMDGPRVKQWPLTEEKIKALTEICTDMEKEGKISRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIIIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKENWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKDPVHGVYYDPSKDLIAEIQKQGQDQWTYQIY Theys, K 2013 unpublished EuResist network data set 2190 135073 TDFFTCEFV 2011 Portugal CRF02_AG 0 1 334 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIDICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSITVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTRNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKANWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDIVALTEEAELELAENREILKEPVHGVYYDPTKDLVAEIQKQEQ Theys, K 2013 unpublished EuResist network data set 2190 135074 TDFFTCEFV 2013 Germany B 0 1 301 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQYPDMVIYQYMDDLYVGSDLEIEQHRMKIEDLRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKSLTEVVPLTKEAEL Theys, K 2013 unpublished EuResist network data set 2190 135075 TDFFTCEFV 2009 Italy B 0 1 324 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGMRYQYNVLPQGWKGSPAIFQSSMTKI*DPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIVLPDKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVVQLTEEAELELAENREILKEPVHGVYYDPSKD Theys, K 2013 unpublished EuResist network data set 2190 135076 TDFFTCEFV 2011 Sweden CRF01_AE 0 1 334 PISPIDTVPVTLKPGMDGPKVKQWPLTEEKIKALTEICKEMEEEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIELPEKDCWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKTPVHGVYYDPSKDLIVEVQKQGQ Theys, K 2013 unpublished EuResist network data set 2190 135077 TDFFTCEFV 2010 Portugal F 0 1 335 PISPIETVPVKLKPGMDGPKVRQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDKDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQGSMTKILDPFRAKNPEVVIYQYMDDLYVGSDLEIGQHRTKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKIKQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGAYYDPSKDLIAELQKQGQG Theys, K 2013 unpublished EuResist network data set 2190 135078 TDF3TCEFV 2009 Italy B 0 1 335 PISPIETVPVQLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKGSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSINNRTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVESDLEIGQHRAKIEELRQHLLHWGFTTPDNKYQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYAGIKTKQLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVHGAYYDPSKELIAEIQKQGLG Theys, K 2013 unpublished EuResist network data set 2190 135079 TDFFTCEFV 2010 Germany B 0 1 301 PISPIETVPVRLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIDIYQYMDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGTKTLTEIVPLTKEAEL Theys, K 2013 unpublished EuResist network data set 2190 135080 TDFFTCEFV 2011 Luxembourg B 0 1 341 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGVRYQYNVLPQGWKGSPAIFQSSMIKILEPFRKQNPDMDIYQYMDDLYVGSDLEIGEHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKSLTEVIPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQI Theys, K 2013 unpublished EuResist network data set 2190 135081 TDFFTCEFV 2009 Germany B 0 1 335 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGEHRTKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDNWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEIIPLTEEAELELAENREILKEPVHGVYYDPSKDLVAELQKQGQG Theys, K 2013 unpublished EuResist network data set 2190 135082 TDFFTCNVP 2011 Portugal C 0 1 333 PIRPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDENFRKYTAFTIPSVNNAVPGIRYQYNVLPQGWKGSPAIFQNSMTKILEPFRTKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIRVKNLCKILRGAKALTDIVPLTEEAELELAENREILKEPVHGAYYDPSKDLIAEVQKQG Theys, K 2013 unpublished EuResist network data set 2190 135083 TDFFTCEFV 2012 Luxembourg B 0 1 345 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRTKIDELRQHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGPKALTEVVPLTKEAELELAENREILREPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEP Theys, K 2013 unpublished EuResist network data set 2190 135085 TDFFTCNVP 2012 Luxembourg CRF02_AG 0 1 345 PISHIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLNKNKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIMIYQYVDDLYVGSDLEIGQHRTKIEELREHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVTLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQGQWTYQIYQEP Theys, K 2013 unpublished EuResist network data set 2190 135087 TDFFTCEFV 2009 Italy C 0 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTQICAEMEKKGKIPKMGPENPYTTPLFAIKKKDSIKWRKLVDFRDLNKRTQDFWEVHLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKESPSIFQASMTKILEPFRTKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGTKALTDIVPLTAEAELELAENREILREPVHGVYYDPSKDLIAEIQKQG Theys, K 2013 unpublished EuResist network data set 2191 135088 D4T3TCEFV 2012 South Africa C 1 1 345 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVTQLCKLLRGAKALTDIIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGDDQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135091 D4T3TCEFV 2012 South Africa C 1 1 345 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKYQKEPPFLWLGYEIHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQDQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135098 ABC3TCEFV 2010 South Africa C 1 1 302 PISHIETVPVKLKPGMDGPKVKQWPLTEEKIKALMEICEEMEKEGKISKIGPDNPYNTPVFAIRKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKQSKSMTVLDVGDAFFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQDSMTKILEPFRTKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIKLPEKDSWTVNDLQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELE Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135101 D4T3TCEFV 2012 South Africa C 1 1 434 PISPIETVPVKLKPGMDGPKVKQWPLSEEKLKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRARNPDIVIYQYIDDLYVGSDLEIEQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPNKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTEIVPLTEEAELELAENREILKEPVHGAYYDPSKELIAEIQKQGNDQWTYQIYQEPFKILKTGKYAKMRTAHTNDVKQLTEAVQKIAIESIVIWGKTPKFRLPIQKETWETWWTNYWQATWIPEWEFVNTPPLVKLWYQLETEPI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135103 D4T3TCNVP 2012 South Africa C 1 1 343 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRKQNPNIEICQYVDDLYVGSDLEIGQHRAKIEELRKHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKHLCKLLRGAKALTDIIPLTEEAELELAENREILKEPVHGIYYDPSKDLIAEIQKQGQDQWTYQIYQ Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135104 D4T3TCEFV 2012 South Africa C 1 1 411 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIKALTEICDELEKEGKITKIGPENPYNTPIFAIKKKNSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLPKSKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIIIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFFTPEKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKMRSAHTNDVKQLTEAVQKIAMECIVIWGKTPKFRLPIQKETWELWWTEYWQATWI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135106 D4T3TCNVP 2010 South Africa C 1 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTLPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPELIIYQYVDDLCVGSDLEIGQHRAKIEELREHLWKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENR Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135107 D4T3TCEFV 2011 South Africa C 1 1 318 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEIQLGIPHPAGLQKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKYQKEPPFLWMGYEIHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGTKALTDIVTLTEEAELELAENRXVLKEPVHGVY Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135108 ABC3TCEFV 2012 South Africa C 1 1 434 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGNDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDVKQLTEAVQKIAQESIVIWGKTPKFRLPIQKETWELWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135109 D4T3TCEFV 2011 South Africa C 1 1 342 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIKELREHLLKWGLTTPDQKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGNDQWTYQIY Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135111 D4T3TCEFV 2012 South Africa C 1 1 397 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLPRNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILAPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKRRSAHTNDVKQLAEAVQRIALESIVIWGKTPRFRLPIQKET Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135112 D4T3TCEFV 2010 South Africa C 1 1 305 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALIEICEDMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDPDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIEQHRAKIEELRDHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPTKDNWTVNDIQKLVGKLNWASQIYPGIQTRNMCKLLRGTKALTDIVPLTEEAELELAE Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135113 D4T3TCEFV 2010 South Africa C 1 1 318 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNSPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSAPLDENFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQCNMTKILEPFRAQNPELVIYQYVDDLCVGSDLEIGQHRAKIEKLREHLLRWGFTTPDKKYQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENXEILKESVHGAY Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135114 D4T3TCEFV 2012 South Africa C 1 1 343 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAFFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPGIVIYQYVDDLYVGSDLEIGQHRAKIKELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYQGIKVKQLCKLLRGAKALTDIVQLTKEAELELAENREILKEPVHGAYYDPSKDLIAELQKQGHDQWTYQIYQ Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135115 D4T3TCEFV 2010 South Africa C 1 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTEICKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLMWGFTTPDKKHQKEHPFLWMGYELHPDTWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRHLCKLLRGSKALTDIVPLTEEAELELAENR Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135116 D4T3TCEFV 2010 South Africa C 1 1 331 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSIPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIIIYQYVDDLCVGSDLEIKQHRAKIEQLREHLLKWGLTTPDQKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDVVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIKK Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135117 D4T3TCEFV 2010 South Africa C 1 1 328 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNASPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIIIYQYVDDLCVGSDLEIGQHRAKIEELREHLLKWGLTTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPDKEDWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENLEILKEPVHGVLYDHQKQMITE Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135118 D4T3TCEFV 2012 South Africa C 1 1 421 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTVPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKYQKEPPLLWMGYELHPDRWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTDIIPLTKEAELELAENREILREPAHGVYYDPSKELIAEIQKQGDDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDVKQLTEVVQKIALESIVIWGKTPKFRLPIQKETWEIWWTDYWQATWIPEWEFVNTPP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135120 D4T3TCNVP 2011 South Africa C 1 1 438 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEELEKEGKISKIGPENPYNTPVFVIKKKDGIKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKEKKSMTVLDVGDAYYSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRTQNPELIIYQYVDDLYVASDLEIGQHRAKVEELREHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLKGAKALTDIVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGDDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDIRQLTEAVQKIAMESIVIWGRTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPMTGAE Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135122 D4T3TCNVP 2010 South Africa C 1 1 332 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPIFAIKRKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNATPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRKQNPDIEICQYIDDLYVASDLEIGQHRAKIEQLREHLLKWGLTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRHLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAELQRR Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135125 D4T3TCEFV 2012 South Africa C 1 1 427 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKTVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTQNPDIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDRWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGTKALTDIVLLTEEAELELAENREILKEQVHGVYYDPSKELIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKIAMESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPDWEFVNTPPLVKLWY Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135126 ABC3TCEFV 2012 South Africa C 1 1 345 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLGWGFTTPDKKHQKEHPFLWMGYELHPDTWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQDQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135127 D4T3TCNVP 2009 South Africa C 1 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLTDFRELNKRTQDFCEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNATPGIRYQYNVLPMGWKGSPAIFQSSMTIILEPFRAKNPELIIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIQVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIKAEG Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135128 D4T3TCEFV 2012 South Africa C 1 1 345 PISPIKTIPVKLKPGMDGPRVKQWPLSKEKIKALTAICDEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNRRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLLVGSDLEIGQHRTKIEELRQHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEQDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTEIVPLTREAELELAENREILKEPVNGVYYDPSKDLIAEIQKQGDDQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135129 D4T3TCEFV 2011 South Africa C 1 1 329 PISTIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGLPHPAGLEKKKSMTVLDVGDAYFSIPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGLTTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135132 D4T3TCEFV 2011 South Africa C 1 1 319 PISPIETVPVKLKPGMDGPRVKQWPLSEEKIKALTEICAEMEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLMDLRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYYSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILDPFRAKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPEQKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVFY Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135134 D4T3TCEFV 2011 South Africa C 1 1 325 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALMEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRNHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDL Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135135 D4T3TCEFV 2012 South Africa C 1 1 423 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIIIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGTYYDPSKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDVKQLTEAVQKIAMESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLV Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135140 D4T3TCEFV 2010 South Africa C 1 1 308 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEELEKEGKITKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVIDVGDAYFSVPLDEDFRKYTAFTIPSINNEKPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRERNPGIEIYQYVDDLYVASDLEIGQHREKIKELREYLLKWGFFTPDKKHQQEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENRE Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135141 D4T3TCEFV 2012 South Africa C 1 1 434 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFVIKRKDNTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLCVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDVQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTNIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDVKQLTEAIQKIAQECIVIWGKTPRFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135143 D4T3TCEFV 2011 South Africa C 1 1 303 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNDMEKEGKITRIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKSKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTKEAELEL Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135146 D4T3TCEFV 2011 South Africa C 1 1 324 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFSEVQLGIPHPAGLKRNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKD Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135147 ABC3TCEFV 2012 South Africa C 1 1 345 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGLGQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135149 ABC3TCEFV 2012 South Africa C 1 1 343 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTAICDEMEKEGKISKIGPENPYNTPVFVIKKKNSDKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAFYSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILQHFKAQNPGIVIYQYVDDLYVSSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVFYDPAKDLIAEIQKQGNDQWTYQIYQ Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135150 D4T3TCEFV 2012 South Africa C 1 1 423 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKEMEEEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRANNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGNDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKISLESIVIWGKTPKFRLPIQKETWEIWWTDYWQATWIPEWEFVNTPPLV Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135151 ABC3TCEFV 2011 South Africa C 1 1 333 PISPINTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKRKNG~KWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAFFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVQSDLEIGQHRAKIEELREHLLKWGFTTPDEKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIIPLTKEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQG Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135152 D4T3TCEFV 2012 South Africa C 1 1 345 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNEKPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDVVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135153 D4T3TCEFV 2012 South Africa C 1 1 434 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRNHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGQDQWTYQIYQEPFKNLRTGKYAKMRGAHTNDVKQLTEAVQKISQECIVIWGKTPKFRLPMLKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135155 D4T3TCNVP 2010 South Africa C 1 1 328 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQCTMTKILEPFRVKNPEIVIYQYVDDLCVGSDLEIGQHRAKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCRLLRGTKALTDIVPLTREAELELAENREILKEPVHGVYYDPSKDLIAE Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135156 D4T3TCEFV 2011 South Africa C 1 1 305 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQFSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDTWTVQAIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVKHLCKLLRGAKALTEVVPLTEEAELELAE Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135158 D4T3TCEFV 2012 South Africa C 1 1 303 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGHELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVTLTEEAELEL Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135159 D4T3TCEFV 2010 South Africa C 1 1 324 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEDMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTIQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKE Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135160 D4T3TCEFV 2011 South Africa C 1 1 345 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSIPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKYQKEPPFLWMGHELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIQVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGMSQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135162 D4T3TCEFV 2010 South Africa C 1 1 307 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTAICEEMEKEGKISKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPDIVIYQYVDDLYVGSDLEIGQHRAKIDELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIIPLTEEAELELAENR Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135166 D4T3TCEFV 2009 South Africa C 1 1 271 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKMEPENPYNTPVFALLKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKRNKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSLNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPGIVIYQYVDDLYVGSDLEIGQHRAKVEELRNHLLKWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKFVGKLNWASQIY Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135169 ABC3TCEFV 2011 South Africa C 1 1 341 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAFFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLAWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGTKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDIIAEIQKQSHDQWTYQI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135170 D4T3TCEFV 2009 South Africa C 1 1 324 PISPIETVPVKLKPGMDGPKIRQWPLTEEKIKALTEICEEMEKEGKISKIGPDNPYNTPIFAIKRKDGIKWRMLADFRELNKRTQDFSEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSAAIFQSSMIKILEPFRTQNPDIVICQYMDDLYVASDLEIGQHRAKIEELRDHLLKWGLTTPDEKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGVQCKQLCKLLRGTKALTDIVPLTKEAELELAENREILKEPVHGVYYDPSKD Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135171 ABC3TCEFV 2012 South Africa C 1 1 345 PISPIETVPVKLKPGMDGPKVKQWPLSKEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNGLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIKEHRAKIEELRAHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGVKVKNLCKLLRGTKALTDVVQLTEEAELELAENREIIKEPVHGVYYDPSKDLIAEIQKQGNDQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135172 ABC3TCEFV 2012 South Africa C 1 1 426 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEQEGKISKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLPQNRSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPAHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKIALESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLW Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135174 D4T3TCEFV 2012 South Africa C 1 1 433 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKQNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPELVIYQYVDDLYVGSDLEIGQHRAKIEKLREHLLKWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQAIELPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEQFKILKTGKYAKKRTAHTNDVRQLTEAVQKISQESIVIWGKIPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKDP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135175 D4T3TCEFV 2011 South Africa C 1 1 322 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREIAKEPVHGVYYDPS Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135176 D4T3TCEFV 2011 South Africa C 1 1 343 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTEICKDMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLPQSKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYVDDLYVGSDLEIKQHREKIKELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIIPLTEEAELELAENREILREPVHGVYYDPSKDLIAEIQKQGLDQWTYQIYQ Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135177 ABC3TCEFV 2012 South Africa C 1 1 434 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKRKDGTKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAFFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIDICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGYDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDVKQLAEAVQKIALESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFINTPPLVKLWYQLETEPI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135178 D4T3TCEFV 2012 South Africa C 1 1 418 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEELEKEGKITRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPHMDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPAKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKIATESIVIWGKSPKFRLPIQKETWETWWTDYWQATWIPEWEFVN Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135180 D4T3TCEFV 2012 South Africa C 1 1 419 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDTWTVQPIELPEKEDWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVRLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDIRQLTEAVQKISMECIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNT Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135181 D4T3TCEFV 2010 South Africa C 1 1 324 PISPIETVPVKLKPGTDGPRVKQWPLTEEKIKALMAICEEMEKEGKISKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRTQNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKNLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKE Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135183 D4T3TCEFV 2011 South Africa C 1 1 345 PISPIETVPVNLKPGMDGPKVKQWPLTKEKIEALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKETVHGAYYDPSKDLIAEIQKQGDDQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135184 D4T3TCEFV 2012 South Africa C 1 1 433 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTRWRKLVDFRELNKRTQDFCEVQLGIPHPAGLNNNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDLIIYQYVDDLLVGSDLEIGQHRAKVKELREHLLKWGLTTPDQKHQKEPPLLWMGYELHPDKWTVQPIVLPEQDSWTVNDIQKLVGKLNWASQIYPGIQVRQLCKLLRGTKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGCGQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLAEAVQKVARESIVIWGKTPKFRLPIQKETWELWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135185 D4T3TCEFV 2011 South Africa C 1 1 295 PISPIETVPVRLKPGMDGPKVKQWPLTKEKIEALTAICDEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRMVADFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPL Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135188 D4T3TCEFV 2009 South Africa C 1 1 341 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEELEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDKEFRKYTAFTIPSVNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIDIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGLTTPDEKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAEFELAENREILKEPVHGVYYDPSKDLIAELQKQGDDQWTYQI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135192 D4T3TCEFV 2011 South Africa C 1 1 345 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTAICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQCSMTKILEPFRTKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLAEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGVKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGQGQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135194 D4T3TCEFV 2012 South Africa C 1 1 411 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILDPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIRVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGTYYDPSKDLIAEIQKQGNDQWTYQIYQEPFKNLKTGKYARMRAAHTNDVKQLTEAVQKVCMESIVIWGKIPKFRLPIQKETWETWWTDYWQATWI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135196 D4T3TCEFV 2011 South Africa C 1 1 342 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPDNPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSMTILDVGDAYFSVPLYEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFFTPDKKHQKEPPLRWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDSSKELIAEIQKQGQDQWTYQIY Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135197 D4T3TCEFV 2011 South Africa C 1 1 308 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKRKDGTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAFYSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVESDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIIPLTEEAELELAENRE Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135198 ABC3TCEFV 2011 South Africa C 1 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNRSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPEMVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQMCKLLRGTKALTDVVPLTEEAELELAENREILKEPVHGAYYDPSKELIAEIQKQG Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135199 D4T3TCEFV 2011 South Africa C 1 1 343 PISPIETVPVKLKPGMDGPRVKQWPLTAEKIKALTEICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPELVIYQYVDDLYVGSDLEIGQHRAKIEQLRDHLLKWGFYTPDKKHQKEPPFLWMGYELHPDTWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGDDQWTYQIYQ Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135200 D4T3TCEFV 2012 South Africa C 1 1 342 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSLNNATPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRVKNPDIIIYQYVDDLYVGSDLEIGQHRAKVEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIRIKNLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGQDQWTYQIY Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135201 D4T3TCEFV 2011 South Africa C 1 1 345 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALREICDEMEKEGKISKIGPENPYNTPVFAIKKKDSAKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTVLDVGDAYFSIPLDEGFRKYTAFTIPSMNNEAPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIIIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTREAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGNDQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135202 D4T3TCEFV 2011 South Africa C 1 1 295 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPL Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135203 D4T3TCEFV 2010 South Africa C 1 1 330 PISPIETVPVKLKPGMDGPRVRQWPLSEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKGNRSVTILDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKNLCKLLRGAKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQ Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135204 D4T3TCEFV 2010 South Africa C 1 1 332 PISPIETIPVKLKPGMDGPKVKQWPLSEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQGSMTKILEPFRTKNPEIVIYQYVDDLFVGSDLEIGQHRAKIEELREHLLKWGFTTPEKKHQKEPPLRWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYGGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQ Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135206 D4T3TCEFV 2011 South Africa C 1 1 350 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKYPDLVIYQYVDDLYVGSDLDIVQHRAIIKELREHLLRWGFTTPDQKHQKEPPFHWMGYDLHPDTWTVEPIQLADKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILREPVHGVFYDPSKELIAEIQKQGHDQWTYQIYQEPFKILK Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135210 ABC3TCEFV 2011 South Africa C 1 1 333 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFVIKRKDKTRWRKLIDFRELNKRTQDFWEVQLGIPHPAGIKRNKSVTVLDVGDAYYSIPLDESFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKVEELRGHLLKWGLTTPDEKHQKEPPFHWMGYELHPDKWTVQPITLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQG Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135211 D4T3TCEFV 2011 South Africa C 1 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDKNFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAQNPEVVIYQYVDDLYVGSDLEIGQHRAKIEKLRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAELQKQG Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135212 ABC3TCEFV 2012 South Africa C 1 1 424 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAFFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIDIYQYVDDLYVASDLEIRQHRAKIEELREHLSKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIRIKQLCKLIRGAKALTDIVQLTEEAELELAENKEILKEPVHGVYYDPSKELIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEVVQKVAVESIVIWGKTPKFRLPIQKETWETWWSDYWQATWIPEWEFVNTPPLVK Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135213 D4T3TCNVP 2011 South Africa C 1 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEDMEKEGKITKIGPENPYNTPVFAIKKKSGTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIIICQYVDDLYVGSDLEIGQHRAKIDELRNHLLKWGLTTPDQKYQKEPPFHWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQG Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135214 D4T3TCEFV 2012 South Africa C 1 1 345 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPIFAIKKKNSDRWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKHNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSVNNETPGVRYQYNVLPQGWKGSPAIFQSTMTRILEPFRARNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDQKHQKEPPFHWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYSGIKVRCLCKLLRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPAKELIAEIQKQGNDQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135215 D4T3TCEFV 2011 South Africa C 1 1 308 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYVDDLYVGSDLEKEQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEIVPLTEEAELELAENRK Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135225 D4T3TCEFV 2012 South Africa C 1 1 427 PISPIKTVPVKLKPGMDGPRIKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGLPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLLVGSDLEIGPHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIIPLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGQDQWTYQIYQEPFKNLKTGKYAKRKTAHTNDVKQLTEAVQKIAMESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWY Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135226 D4T3TCEFV 2010 South Africa C 1 1 331 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMEICEEMEKEGKIEKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSVTILDVGDAYFSVPLDKEFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQK Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135228 D4T3TCEFV 2012 South Africa C 1 1 410 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPEKDLIAEIQKQGLDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLAEAVQKIAMESIVIWGKTPKFRLPIQKETWETWWTDYWQATW Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135232 D4T3TCNVP 2012 South Africa C 1 1 345 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNESPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKENPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRRHLLKWGLTTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPTKDLIAELQKQGNDQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135233 D4T3TCEFV 2012 South Africa C 1 1 435 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLPKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNLLPQGWKGSPAIFQFSMTKILEPFRAKNPDIVIYQYVDDLYVGSDLEIGEHRAKIEELRGHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAEFELAENREILKETVHGVYYDPSKDLIAEIQKQGNDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVRQLTEVVQKIALESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPII Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135234 D4T3TCEFV 2012 South Africa C 1 1 434 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQHPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLVAEIQKQGDDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDVKQLVEAVQKIAMESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135236 D4T3TCEFV 2012 South Africa C 1 1 440 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTRNPEIVIYQYVDDLYVASDLEIGQHRAKIEELRDHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKSLTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGNDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLAAAVQKIARECIVIWGKTPKFRLPIQKEAWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIIGAETF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135237 D4T3TCEFV 2012 South Africa C 1 1 342 PISPIETVPVKLKPGMDGPKVKQWPLTEERVRALTAICEEMEKEGKITKIGPENPYNNPVFAIKKKNSTEWRKISDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGVRYQYNVLPMGWKGSPAIFQYSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDTWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVKQLCKLLRGTKALTDIVPLTEEAEFELAENREILKEPVHGVYYDPSKDLIAELQKQGQDQWTYQIY Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135239 D4T3TCEFV 2011 South Africa C 1 1 332 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLYEDFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPDLVIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLKWGFTTPDKKHQKEPPFLWLGHELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVRQLCKLIRGTKALTDIVPLTAEAELELAENREILKEPVFGVYYDPSKELIAELQKQ Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135241 D4T3TCEFV 2012 South Africa C 1 1 434 PISSIETVPVQLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYVDDLYVGSDLEIGQHREKVEKLREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIHLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVRHLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDSSKELIAELQKQGEDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKIATESIVIWGKIPKFRLPIQKDTWETWWTEYWQATWIPDWEFVNTPPLVKLWYQLEKEPI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135242 D4T3TCEFV 2012 South Africa C 1 1 399 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTQNPEVVIYQYVDDLYVASDLEIGQHRAKIEKLREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGVKALTDIVPLTEEAKLELAENREILKEPVHGVYYDPSKDLIAEIQKQGHGQWTYQVYQEPFKNLKTGKYAKRRTTHTNDVKQLTEAVQKIAMESIVIWGKTPKFRLPIQKETWE Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135244 D4T3TCEFV 2011 South Africa C 1 1 333 PISPIETVPVKLKPGMDGPKIKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSMNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILAPFREKNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135245 D4T3TCEFV 2012 South Africa C 1 1 345 PISTIATVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILDPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIQVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGNDQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135246 D4T3TCEFV 2011 South Africa C 1 1 328 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEELEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLPKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKYPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLWKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENRKVCKEPVHGVYYDPSKDLIAE Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135248 D4T3TCEFV 2011 South Africa C 1 1 429 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALKEICDEMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPEVVIYQYVDDLYVGSDLEIRQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDTWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCRLLRGTKALTDIVTLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGNDQWTYQIYQEPFKNLKTGKYAKKRTAHTNDVRQLTEAVQKIAVESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQL Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135249 D4T3TCEFV 2010 South Africa C 1 1 328 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICEEMEKEGKIEKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDKEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPNKDSWTVNDIQKLVGKLNWASQIYPGIRVRHLCSVFRGTKALPDILQLTEEADFELAENRVILKQSVHGVYYDPSKAIIAK Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135250 D4T3TCEFV 2012 South Africa C 1 1 345 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTEICEEMEKEGKISKIGPENPYNTPIFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIDIYQYVDDLYVGSDLEIGQHRAKVEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVTLTKEAELELAENREILREPVHGVYYDPSKELIAEIQKQGNDQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135251 D4T3TCEFV 2012 South Africa C 1 1 434 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKNKTVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYVDDLYVASDLEIGQHRTKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKYLCKLLRGAKALTDIVPLTREAELELAENREILKEPVHGVYYDPSKDLIAELQKQGNDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDIKQLTEAVQKIATESIVIWGKIPKFRLPIQKEMWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135252 D4T3TCEFV 2011 South Africa C 1 1 350 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPDIVIYQYMDDLYVGSDLEIGQHREKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLK Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135255 D4T3TCEFV 2010 South Africa C 1 1 326 PISPIETVPVKLNPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPELVIYQYVDDLYVGSDLEIEQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVQQLCKLLRGTKALTDIVTLTKEAEFELAENREILKEPVHGVYYDPSKDLI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135260 ABC3TCEFV 2012 South Africa C 1 1 417 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDKNFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIIIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKMRAAHTNDVKQLTEAVQKIAMESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFV Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135261 ABC3TCEFV 2012 South Africa C 1 1 436 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRANNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGDDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKIAMESIVIWGKTPRFRLPIQKETWELWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIAG Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135262 ABC3TCEFV 2011 South Africa C 1 1 343 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIEALKAICEEMEKEGKITKIGPENPYNTPVFVIKRKDSTKWRKLVDFRELNKRTQDFSEVQLGIPHPAGLKRKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRARNPEIVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQ Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135263 D4T3TCEFV 2009 South Africa C 1 1 324 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPGIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDQKHQKEPPLRWLGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKD Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135265 D4T3TCEFV 2012 South Africa C 1 1 345 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRARNPEIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDQKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDVIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGNDQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135266 D4T3TCEFV 2012 South Africa C 1 1 428 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDQKHQKEPPFHWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGNDQWTYQIYQEPFKNLKTGKYAKMRSAHTNDVKQLTEAVQKVATESIVIWGKIPKFRLPIQKETWETWWTDYWQATWIPEWEFVNAPPLVKLWYQ Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135267 D4T3TCEFV 2010 South Africa C 1 1 331 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEETEKEGIITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGAYYDPSKDLIAXIQK Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135269 D4T3TCEFV 2011 South Africa C 1 1 342 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVIDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGNDQWTYQIY Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135271 D4T3TCEFV 2011 South Africa C 1 1 306 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQEFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGKHRAKIEELRKHLLKWGFTTPDRKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDVVPLTEEAELELAEN Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135272 D4T3TCEFV 2011 South Africa C 1 1 345 PISSIKTVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYVDDLYVGSDLEIGQHRAKIDELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYKEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135275 D4T3TCEFV 2012 South Africa C 1 1 434 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICKEMEAEGKITKIGPENPYNTPIFAIKKKNSNRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSRNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGLTTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVEKLNWASQIYPGVRVKNLCKLLRGAKALTDIVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGYDQWTYQIYQEPFKNLKTGKYAKMKSAHTNDVRQLTEVVQKIALESIVIWGKTPKFRLPIQKETWEIWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135276 D4T3TCEFV 2011 South Africa C 1 1 307 PISPIETIPVKLKPGMDGPRVKQWPLTEEKIKALTEICEELEKEGKITKIGPENPYNTPIFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRANNPEIDIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLRWGFTTPDKKHQKEPPLLWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENR Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135277 D4T3TCEFV 2012 South Africa C 1 1 345 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKNNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEVVIYQYVDDLYVGSDLEIEQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGDDQWTYQIFKEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135278 D4T3TCEFV 2012 South Africa C 1 63 322 IKKKNSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPNLVIYQYVDDLCVGSDLEIGQHRAKIEKLREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVRQLCKLLRGAKALTDVVPLTEEAELELAENREILKEPVHGAYYDPA Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135279 D4T3TCEFV 2012 South Africa C 1 1 422 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPELVIYQYVDDLYVGSDLEIGRHRAKIEELRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLIRGTKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKIAQESIVIWGKTPKFRLPIQKETWETWWTEYWQATWIPEWEFVNTPPL Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135280 D4T3TCEFV 2012 South Africa C 1 1 341 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTEICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGARALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135282 D4T3TCEFV 2012 South Africa C 1 1 424 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRKENPDIVIYQYVDDLYVGSDLEIGQHRAKVEELRKHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPAHGVYYDPSKELIAEIQKQGEGQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVRQLTEAVQKIALESIVIWGKTPKFRLPIQKETWDIWWTDYWQATWIPEWEFVNTPPLVK Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135283 D4T3TCEFV 2012 South Africa C 1 1 434 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGHDQWTYQIYQEPFKILKTGKYAKMKSAHTNDVKQLTEAVQKIARESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135284 D4T3TCEFV 2010 South Africa C 1 1 306 PISPIETVPVKLKPGMDGPRVKQWPLTEEKINALKAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPTKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAEN Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135285 D4T3TCEFV 2012 South Africa C 1 1 325 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNKTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYVDDLYVGSDLEIGKHRAKIEELRDHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPITLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEIVTLTKEAELELAENRKILKEPVHGVYYDPSRDL Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135286 D4T3TCEFV 2011 South Africa C 1 1 324 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPDLVIYQYVDDLYVGSDLEIGQHRAKIEDLRNHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEIVPLTEEAELELAENREILKEPVHGVYYDPTKE Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135293 D4T3TCEFV 2011 South Africa C 1 1 335 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLAKKKSVTVLDVGDAYFQFPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTQNPDIVIYQYVDDLHVSSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYPGIQTRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHG Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135294 ABC3TCEFV 2011 South Africa C 1 1 343 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPGLVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPAKDLIAEVQKQGLDQWTYQIYQ Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135295 D4T3TCEFV 2011 South Africa C 1 1 340 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLPKSKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPTKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCRLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGDHQWTYQ Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135296 D4T3TCEFV 2012 South Africa C 1 1 345 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKVADFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVFYDPSKDLIAEIQKQGEDQWTYQIFREP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135297 D4T3TCEFV 2012 South Africa C 1 1 411 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRRHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIKLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKIALESIVIWGKTPKFRLPIQKETWETWWTDYWQATWI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135299 ABC3TCEFV 2012 South Africa C 1 1 433 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGVKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKMLTEAVQKIAMESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEYVNTPPLVKLWYQLEKEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135300 D4T3TCEFV 2012 South Africa C 1 1 364 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLHKNKAVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRTQNPDIVIYQYVDDLYVASDLEIGQHRAKIEELRDHLLRWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGDDQWTYQIYQEPFKNLKTGKYAKRRTAHTND Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135302 D4T3TCEFV 2011 South Africa C 1 1 328 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPELVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFFTPDKKHQKEPPLLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLKGAKALTEIVPLTEEAELELAENRKVCREPVHGVYYDPSKELIAE Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135303 D4T3TCEFV 2012 South Africa C 1 1 342 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKYNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGRHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIQVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIY Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135304 D4T3TCNVP 2011 South Africa C 1 1 345 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRAQNPEIVIYQYVDDLLVGSDLEIGQHRAKIEELRKHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIRVKQLCKLLRGTKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGNDQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135305 ABC3TCEFV 2012 South Africa C 1 1 424 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFCEVQLGIPHPAGLKKKKSMTVLDVGDAFFTVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVICQYVDDLYVASDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGNEQWTYQIYQEPFKNLKTGKYARMKAAHTNDVKMLAEAVQKIALESIVIWGRTPKFRLPIQKETWDIWWTDYWQATWIPEWEFVNTPPLVK Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135307 D4T3TCEFV 2012 South Africa C 1 1 345 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYVDDLYVGSDLEIKQHRAKIDRLREHLLKWGFTTPDRKYQKEPPFQWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCGLIRGTKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHSQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135308 D4T3TCEFV 2011 South Africa C 1 1 345 PISPIETVPVKLKPGMDGPKVKQWPLTKEKIEALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPDIVIYQYVDDLYVGSDLEIRQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIQVRQLCKLLRGAKALTDIVPLTAEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135309 D4T3TCEFV 2010 South Africa C 1 1 304 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFVIKKKDSAKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKNNKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELA Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135311 D4T3TCEFV 2010 South Africa C 1 1 323 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKAITAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRTKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPQKDSWTVNDIQKLVGKLNWASQIYPGIQVKKLCKLLKGTKALTDVVQLTEEAELELAENREILKEPVHGVYYDPSK Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135312 D4T3TCEFV 2012 South Africa C 1 1 424 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSAKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMPKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKKRSAHTNDVKQLTEAVQKIAQESIVIWGKTPKFRLPIQKETWEIWWTDYWQATWIPEWEFVNTPPLVK Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135313 D4T3TCEFV 2011 South Africa C 1 1 345 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRSKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHREKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKENWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLIRGTKALTEIVPLTEEAELELAENREILREPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135315 D4T3TCEFV 2012 South Africa C 1 1 345 PISPIETVPVKLKPGMDGPRVKQWPLSEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKQNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRQNPELVIYQYVDDLYVGSDLEIGQHRAKIEKLREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPILLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVTLTAEAELELAENREILKEPVHGVFYDPSKELIAELQKQGQGQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135316 ABC3TCEFV 2011 South Africa C 1 1 328 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKIEKIGPDNPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQHSMTKILAPFRAQNPDIIIYQYVDDLYVGSDLEIGQHRAKIEELRNHLLKWGFTTPDNKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGTKALTDIVPLTEEAELELAENREILKTPVHGVYYDPSKDLIAK Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135318 ABC3TCEFV 2012 South Africa C 1 1 434 PISPIETVPVQLKPGMDGPKVKQWPLTEEKIKALKEICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKVADFRELNKRTQDFWEVQLGIPHPAGLKRRKTMTVLDVGDAFFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIDIYQYVDDLYVGSDLEIGQHRAKIEQLRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDVVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGQDQWTYQIFQEPFKNLKTGKYAKRRTAHTNDVKQLTEAVQKIAIESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135319 D4T3TCEFV 2009 South Africa C 1 1 324 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICKEMEEEGKITRIGPENPYNTPVFVIKKKGSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMLRILEPFRTKNPEIVIYQYVDDLYIQSDLEIGQHRAKVEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKD Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135321 D4T3TCEFV 2011 South Africa C 1 1 333 PVSTIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAINKKGSTRWRKVVDFRELNKRTQDFWEVQLGLPHPAGIKKNKSVTVLDVGDAYFSIPLDESFRKYTAFTIPSTNNEKPGIRYQYNVLPQGWKGSPAIFQDSMTKILKPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKVKELREHLLKWGLTTPEQKHQKEPPFHWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQG Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135322 D4T3TCEFV 2012 South Africa C 1 1 434 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAMCEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKITDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKVEDLRNHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGTKALTDVVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQERGQWTYQIYQEPFKNLKTGKYAKMRSAHTNDVKQLVEAVQKIAIESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPM Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135325 D4T3TCEFV 2011 South Africa C 1 1 342 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAQNPGIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGTKALTDIIPLTEEAELELAENREILKEPAHGVYYDPSKDLIAEIQKQGHDQWTYQIY Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135326 D4T3TCEFV 2012 South Africa C 1 1 433 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKSKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAENPEIVIYQYVDDLYVGSDLEIGQHRAKIAELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVHPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVSKLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHGQWTYQIYQEPFKNLKTGKYARVRTAHTNDIRQLTEAVQKIATESIVIWGKVPKFRLPIQKETWGTWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135327 D4T3TCEFV 2012 South Africa C 1 1 345 TISPIKTVPVKLKPGMDGPQVKQWPLTEEEIKALTTICDEMKKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYMDDLYVGSDLEIMQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKIVGKLNWASQIYSGIKVKQLCRLLRGAKALTDVVPLTEEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQGNDQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135330 D4T3TCEFV 2012 South Africa C 1 1 413 PISPIETVPVKLKPGMDGPRVRQWPLTEEKIKALTEICAEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRQQNPEIVIYQYVDDLYVGSDLEIGQHRAKIDKLREHLLKWGLTTPDRKYQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAELQKQGQDQWTYQIYQEQFKILKTGKYAKTRTAHTNDVRQLTEAVQKISLECIVIWGKTPKFRLPIQKETWETWWTEYWQATWIPE Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135331 D4T3TCEFV 2010 South Africa C 1 1 308 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFPTPDKKHQKEPPLLWLGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLIRGTKALTDIVPLTEEAELELAENRE Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135333 D4T3TCEFV 2012 South Africa C 1 1 423 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALKEICEEMEKEGKIEKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRANNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRTHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDDWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDVKQLTEAVQKISIECIVIWGKTPKFRLPIQKETWEIWWTDYWQATWIPEWEFVNTPPLV Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135334 D4T3TCEFV 2012 South Africa C 1 1 397 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPDIVIYQYMDDLLVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRELCKLLRGARALTDIVPLTEEAELELAENREILQEPVQGVYYDPSKELIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDVRQLTEAVQKIAVESIVTWGKTPKFRLPIQKET Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135335 D4T3TCEFV 2012 South Africa C 1 1 438 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKGLMEICEELEREGKISKIGPENPYNTPVFAIKKKGGTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKRKTMTVLDVGDAYFSVPLDPDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRTKYPDMDVYQYVDDLYVGSDLEIGQHRAKIDELREHLLKWGLFTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGDGQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKIALESIVIWGKTPKFRLPIQKETWGIWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPILGAE Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135336 D4T3TCEFV 2012 South Africa C 1 1 406 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQASMTKILEPFRTQNPEIDIYQYVDDLYVGSDLEIGQHREKIEQLRDHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDVVQLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGHDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDVKQLTEAVQKIATESIVIWGKTPKFRLPIQKETWETWWTDYW Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135337 ABC3TCEFV 2011 South Africa C 1 1 345 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAFFSIPLCEDFRKYTAFTIPSINNASPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKYPEIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQSIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGNDQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135339 D4T3TCEFV 2009 South Africa C 1 1 324 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFVIKKKDGTKWRKLTDFRELNKRTQDFWEVQLGIPHPAGLKRRKSMTVLDVGDAYFSVPLDEEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFREKYPEIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIQVRQLCKLLKGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKD Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135341 D4T3TCEFV 2012 South Africa C 1 1 333 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHREKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQG Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135342 D4T3TCEFV 2012 South Africa C 1 1 433 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIRKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGQDQWTYQIYQEPFKILKTGKYAKRRTAHTNDVKQLTGAVQKIAMESIVIWGKTPKFRLPIQKETWETWWTNYWQATWIPEWEFVNTPPLVKLWYQLEKEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135344 D4T3TCEFV 2012 South Africa C 1 1 421 PISPIETVPVKLKPGMDGPKVKQWPLSEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEVDIYQYVDDLYVGSDLEIGQHRAKIEELRNHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVRQLTEAVQKIAMESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135345 D4T3TCEFV 2012 South Africa C 1 1 345 PISTIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSIPLDEGFRKYTAFTIPSLNNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDVVPLTEEAELELAENREILKEPVHGVYYDPSKELIAELQKQGHDQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135346 D4T3TCEFV 2012 South Africa C 1 1 423 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKMNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFREQNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEHPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLIRGTKALTAIVPLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKMRSAHTNDIKQLTEVVQKIAQESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLV Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135347 ABC3TCEFV 2012 South Africa C 1 1 345 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKSLTDIVPLTEEAELELAENREILKEPVHGVYYDPTKDLIAEIQKQGHDQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135349 D4T3TCEFV 2010 South Africa C 1 1 324 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPSGLHKKKSMTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRTRNPELVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIVLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTAIVPLTEEAELELAENREILKEPVHGVYYDPSKD Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135350 ABC3TCEFV 2012 South Africa C 1 1 434 PISPIKTVPVKLKPGMDGPKVKQWPLTAEKIKALTDICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPSGIKKNKSMTVLDVGDAYFSVPLDEEFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLDIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLIRGTKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDVKQLTEAVQKIAQESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKDPI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135352 D4T3TCEFV 2012 South Africa C 1 1 345 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLQKKKSVTVLDVGDAFFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPEIVICQYVDDLYVASDLEIGQHRAKIEKLREHLLRWGFTTPDKKYQKEPPFQWMGYELHPDKWTVQPIHLPEKDSWTVNDIQKLVGKLNWASQIYPGIRVRCLCKLLRGAKALTDIVPLTKEAELELAENREILKEPVHGVYYDLSKDLIAEIQKQGEDQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135353 D4T3TCEFV 2012 South Africa C 1 1 430 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSAKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDTYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILDPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLKWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPDKDSWTVDDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQEDSQWTYQIYQEPFKNLKTGKYAKRRTAHTNDLKQLTEAVQKIAQESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLE Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135354 D4T3TCEFV 2012 South Africa C 1 1 440 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIRALKAICEEMEREGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEIVIYQYVDDLYVGSDLEIGQHREKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDTWTVQPIKLPEKTSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGYDQWTYQIYQEPFKILKTGKYAKRRTAHTNDVKQLTEAVQKIAMECIVIWGKTPKFRLPIQKETWETWWTHYWQATWIPEWEFVNTPSLVKLWYQLETEPIAGAETF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135355 D4T3TCEFV 2012 South Africa C 1 1 428 PISPIETVPVKLKPGMDGPKVKQWPLTTEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLPKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKILKTGKYAKMKSAHTNDVKQLTEAVQKIAQESIVIWGKTPKFRLPIQKETWETWWSDYWQATWIPEWEFVNTPPLVKLWYQ Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135358 D4T3TCEFV 2012 South Africa C 1 1 433 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALREICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPDIVIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLKGAKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKILKTGKYAKRRTAHTNDVKQLTEAVQKIAMESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKDP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135359 D4T3TCEFV 2010 South Africa C 1 1 331 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFREQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRQHLLQWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILREPVHGVYYDPSKDLIAEIQK Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135361 D4T3TCNVP 2012 South Africa C 1 1 432 PISPVKTIPVKLKPGVDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSTNNQTPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPDIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIRVKHLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEVQKQGHDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTQVVQKIAQESIVTWGKTPKFRLPIQKDTWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKE Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135366 D4T3TCEFV 2012 South Africa C 1 1 345 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGNDQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135367 D4T3TCEFV 2010 South Africa C 1 1 307 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVIDVGDAYFSVPLYEDFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYVDDLYVQSDLEIGQHRAKIEELREHLLRWGFFTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIQVRHLCKLIRGAKALTDIVPLTEEAELELAENR Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135368 D4T3TCEFV 2011 South Africa C 1 1 292 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEVVIYQYVDDLYVGSDLEIGQHREKIEELREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135370 D4T3TCEFV 2011 South Africa C 1 1 238 PISPIETVPVKLNPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRQNPEMVIYQYVDDLYVGSDLEIGQHRAKIEELRAHLLRWGFYTPDKKHQKEPPFLWMGYELHPDK Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135372 D4T3TCEFV 2009 South Africa C 1 1 440 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMAICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRRKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIDIYQYVDDLYVGSDLEIGQHRTKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPDKESWTVNDIQKLVGKLNWASQIYKGIKVKQLCKLLKGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGNDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKISMESIVIWGKTPKFRLPIQKDTWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135374 D4T3TCEFV 2011 South Africa C 1 1 349 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSLNNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDIVIYQYVDDLYVGSDLEIGQHRTKIEELRGHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNL Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135378 D4T3TCEFV 2011 South Africa C 1 1 343 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIQVKNLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGNDQWTYQIYQ Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135381 D4T3TCEFV 2012 South Africa C 1 1 428 PISPIETIPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGNDQWTYQIYQEPFKNLKTGKYAKMRSAHTNDVKQLTEAVQKIALESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQ Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135383 D4T3TCEFV 2010 South Africa C 1 1 330 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICNEMEKEGKISKIGPENPYNTPIFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRTQNPEIVICQYIDDLYVASDLEIGQHRAKIEELRAHLLKWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQQIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIK Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135384 D4T3TCEFV 2012 South Africa C 1 1 424 PISPIETVPVKLKPGMDGPRVKQWPLSEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGVRVKNLCKLLRGAKALTDIVPLTEEAELELAENREILREPVHGVYYDPSKDLIAEIQKQGQNQWTYQIYQEPFKNLKTGKYAKTRSVHTNDVKQLIEAVQKIAIESIVIWGKTPKFRLPIQKGTWETWWTDYWQATWIPEWEFVNTPPLIK Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135385 D4T3TCEFV 2010 South Africa C 1 1 329 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPELVIYQYVDDLYVGSDLEIMQHRAKIEELREHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIQVKQLCKLLRGTKALTDIVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135386 D4T3TCEFV 2011 South Africa C 1 1 344 PISPIDTVPVKLKPGMDGPKVKQWPLTEEKIRALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNRSVTILDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFHWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVFYDPSKELIAEIQKQGNDQWTYQIYQE Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135388 D4T3TCEFV 2012 South Africa C 1 1 436 PISPIDTVPVKLKPGMDGPKVKQWPLTAEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTKILEPFRTQNPDIVIYQYVDDLYIQSDLEIGQHRAKIEELREYLLRWGFYTPDNKYQKEPPFLWMGYELHPDKWTVQPIQLPDKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLIRGTRALTDIVPLTKEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKMKTAHTNDVKQLTEAVQKIARESIVIWGKIPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLGKEPIAG Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135390 D4T3TCEFV 2012 South Africa C 1 1 341 PISPIKTVPVKLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNATPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIDIYQYVDDLYVGSDLEIGQHRAKIEQLREHLLQWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIQVKQLCKLLRGTKALTDIVPLTAEAELELAENREILKEPVHGAYYDPTKDLIAEIQKQGDSQWTYQI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135396 D4T3TCEFV 2011 South Africa C 1 1 328 PISPIKTIPVKLKPGMDGPKVKQWPLSEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGQRYQYNVLPQGWKGSPAIFQCSMTKILEPFRARNPELVIYQYVDDLYVGSDLEIGQHRAKIEELRDHLLKWGFTTPDQKHQKESPFRWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAE Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135397 D4T3TCEFV 2010 South Africa C 1 1 309 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSIPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIIIYQYVDDLCVGSDLEIKQHRAKIEQLREHLLKWGLTTPDQKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTDVVPLTKEAELELAENRKV Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135398 D4T3TCEFV 2010 South Africa C 1 1 326 PISPIETVPVKLKPGMDGPKVKQWPLTAEKIKALTEICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPSGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQASMLKILEPFRTKNPELVICQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKDLI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135399 D4T3TCEFV 2011 South Africa C 1 1 343 PISPIETVPVKLKPGMDGPKIKQWPLTKEKIEALTAICEELEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLMDFRELNKRTQDFWEVQLGIPHPAGLEKNKSVTILDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFFTPDKKYQKEPPFLWMGYELHPDKWTVQPIELPDKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLIRGTKALTEIVPLTEEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQGQGQWTYQIYQ Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135400 ABC3TCEFV 2012 South Africa C 1 1 428 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIRALTEICDEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELRGHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGNDQWTYQIYQEPFKILKTGKYAKLRSAHTNDVKQLTEVVQKVARESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVKLWYQ Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135403 D4T3TCNVP 2011 South Africa C 1 1 345 PISPIETIPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILAPFRAKNPDIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCRLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGEDQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135407 D4T3TCEFV 2010 South Africa C 1 1 324 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEKLRDHLLKWGFTTPDKKHQKEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKD Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135410 D4T3TCEFV 2012 South Africa C 1 1 433 PISQIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTMLDVGDAYFSVPLDESFRKYTAFTIPSINNEIPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYVDDLYVGSDLEIGQHRAKVEELRAHLLKWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPINLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKNLCKLLRGAKALTEIVPLTEEAELELAENREILKEPVHGVYYDPSKELIADIQKQGNDQWTYQIYQEPFKNLKTGKYARMKTAHTNDVRQLTEVVQKIATESIVIWGKTPKFRLPIQKDTWETWWTDYWQATWIPEWEFVNTPPLVKLWYQLRKNP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135411 D4T3TCEFV 2010 South Africa C 1 1 345 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNEKPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIDIYQYVDDLYVGSDLELGQHRAKIEELREHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGNDQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135413 D4T3TCEFV 2011 South Africa C 1 1 325 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALLEICEEMEKEGKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLRKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNATPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPDMVIYQYVDDLYVESDLEIGQHRAKIEELRDHLLKWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGAYYDPAKDL Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135414 D4T3TCNVP 2012 South Africa C 1 1 426 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALMEICKEMEEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPGIVIYQYVDDLLVGSDLEIGKHREKIEELRRHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLIRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGPEQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEVVQKIALESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPHLVKLW Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135415 D4T3TCEFV 2009 South Africa C 1 1 306 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPRINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPDLVIYQYVDDLYVGSDLEIGQHRAKIEELRNHLLKWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKSLTDIVPLTKEAELELAEN Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135416 D4T3TCEFV 2012 South Africa C 1 1 433 PISTIRTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFSEVQLGIPHPAGLHKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPDIVIYQYVDDLYVSSDLEIGQHRAKIEELREHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGNDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLVGAVQKIAMESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPGWEFVNTPPLVKLWYQLEKEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135418 D4T3TCEFV 2010 South Africa C 1 1 308 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQFSMTKILEPFRTKNPEVVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEHPFNWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENRE Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135419 D4T3TCEFV 2012 South Africa C 1 1 411 PISPIETVPVKLKPGMDGPRVRQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPIFAIKKKNSDKWRKLVDFRELNKRTQDFCEVQLGIPHPAGLKYNKSVTILDVGDAYYSVPLDEDFRKYTAFTIPSRNNETPGIRYQYNVLPMGWKGSPAIFQHSMTKILEPFRTQNPELVIYQYIDDLYVGSDLEIEQHRAKIDQLREHLLKWGLFTPDKKHQQEPPFLWLGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLIRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGEDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDVKQLTEAVQKVALECIVIWGKTPKFKLPILKETWETWWTDYWQATWI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135420 ABC3TCEFV 2011 South Africa C 1 1 345 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKQRKSMTVLDVGDAFFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPELDIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLKWGLTTPDKKHQKEPPFLWMGYELHPNKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGNDQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135421 D4T3TCNVP 2012 South Africa C 1 1 434 PISPIETLPVKLKPGMDGPKIKQWPLTEEKIKALQAICKELEQEGKITRIGPDNPYNTPIFAIKKKNSDRWRKLMDFRELNKRTQDFWEIQLGIPHPAGLRKKKSVTILDVGDAYFSIPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQHSMTKILEPFRTKNPEIVICQYVDDLYVGSDLEIGQHRAKIDELREHLLKWGFFTPDWKHQQEPPFHWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLKGAKALSDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGNDQWTYQIYQEPFKILKTGKYAKRRSTHTNDVKQLTEAVQKIARESIVIWGKTPKFRLPIQKETWEVWWTDYWQATWIPEWEFVNTPPLVKLWYQLEKEPI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135422 D4T3TCEFV 2010 South Africa C 1 1 433 PISSIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRTQNPEIVIYQYVDDLYVASDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYAKTKTAHTNDVKQLTEAVQKISRESIVIWGKTPKFRLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135424 ABC3TCEFV 2012 South Africa C 1 1 434 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICAEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFCEIQLGIPHPAGLKKKKSMTVLDVGDAFFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQASMTRILEPFRAKNPEIDIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKHQKEPPLLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYKGIQVKQLCKLLRGAKALTDIVPLTEEAELEMAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKIAIESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPDWEFVNTPPLVKLWYQLEKEPI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135426 D4T3TCEFV 2012 South Africa C 1 1 424 PISPIETVPVKLKPGMDGPKVKQWPLTEEKLKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLIDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNATPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRAKNPELVIYQYVDDLYVGSDLEIGQHRAKVEELREHLLRWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVRHLCKLLRGAKALTDIVPLTEEAELELAENREILKEPAHGVYYDPSKDLIAEIQKQGCDQWTYQIYQEPFKNLKTGKYAKTRTAHTNDVKQLTEVVQKVALESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVK Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135429 D4T3TCEFV 2012 South Africa C 1 1 342 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKITKIGPDNPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLPKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSMNNATPGIRYQYNVLPQGWKGSPAIFQYSMTKILEPFRTKNPDIIIYQYVDDLYVGSDLEIGQHRAKIAELREHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDIVPLTEEAELELAENREIIKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIY Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135430 D4T3TCEFV 2011 South Africa C 1 1 344 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPDNPYNTPIFAIKKKGGDKWRKLVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYYSVPLDEGFRKYTAFTIPSRNNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRARNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGLTTPDKKHQKEYPLLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIQVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGDGQWTYQIYQE Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135432 ABC3TCEFV 2012 South Africa C 1 1 390 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGIKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRTQNPDMVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGFTTPDKKYQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDVRQLVEVVQKVALESIVIWGKTPKFR Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135434 D4T3TCEFV 2012 South Africa C 1 1 433 PISPIETVPVKLKPGMDGPKVKQWPLSAEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLPKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRAQNPEIIIYQYVDDLYVGSDLEIGQHRKKIEELRAHLLKWGFYTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPDKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDVVPLTEEAELELAENREILKEPVHGVYYDPSKELIAEIQKQDHGQWTYQIYQEPFKNLKTGKYAKIRTAHTNEVKQLTEVVQKIAQESIVIWGKTPKFRLPIQKETWETWWTDYWQVTWIPGWEFVNTPPLVKLWYRLEKEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135435 D4T3TCEFV 2012 South Africa C 1 1 416 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICAEMEKEEKITKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTRNPDIDIYQYVDDLYVGSDLEIGQHRAKVEELRKHLLEWGFTTPDKKYQKEPPLLWMGYELHPDKWTVQPIKLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGDDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDVKQLTEAVQKIAMESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEF Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135437 D4T3TCEFV 2011 South Africa C 1 1 289 PISSIKTVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFVIKKKDSAKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSIPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMIKILEPFRKQNPDIDIYQYVDDLYVGSDLEIGQHRAKIEELRKHLLKWGLTTPDKKHQKEPPLLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKAL Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135438 D4T3TCEFV 2011 South Africa C 1 1 350 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPVFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKRNKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPGIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLRWGLTTPDQKHQKEPPFLWMGYELHPDKWTVQPIQLPEKESWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGAKALTDVVPLTEEAELELAENRKILREPVHGVYYDPAKDLIAEIQKQGHDQWTYQIYQEPFKNLK Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135439 D4T3TCEFV 2012 South Africa C 1 1 345 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRRKNPEICIYQYVDDLLVGSDLEIGQHRAKIEELRAHLLKWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKSSWTVNDIQKLVGKLNWASQIYPGIRVRQLCKLLRGAKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEP Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135445 ABC3TCEFV 2012 South Africa C 1 1 424 PISPIETVPVTLKPGMDGPRVKQWPLTEEKIKALTEICEEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSMTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMLKILEPFRAKNPEVVIYQYVDDLYVGSDLEIGQHRAKIEELRNHLLQWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTREAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGDDQWTYQIYQEPFKNLKTGKYAKRRTAHTNDVRQLTEAVQKIALESIVIWGKTPKFRLPIQKETWDIWWTDYWQATWIPEWEFVNTPPLVK Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135453 D4T3TCEFV 2011 South Africa C 1 1 347 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTEICEEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTQNPEMVIYQYMDDLYVGSDLEIGQHRAKIEKLREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTDVVTLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGCDQWTYQIYQEPFK Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135454 D4T3TCEFV 2012 South Africa C 1 1 424 PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPGGLKKNKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAQNPEIVIYQYVDDLYVGSDLEIGQHRAKIEELREHLLKWGFTTPDQKHQKEHPFLWMGYELHPDKWTVQPIKLPEKDSWTVNDIQKLVGKLNWASQIYPGIKTRNLCKLIRGTKALTDIVPLTEEAELELAENKEILKEPVHGVYYDPAKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKRKAAHTNDVKQLVEAVQKIAMESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTPPLVK Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135455 D4T3TCEFV 2009 South Africa C 1 1 242 PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITRIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLQKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQDSMTRILEPFRKQNPDMVIYQYVDDLYVGSDLEIGEHRAKIEELRAHLLKWGFTTPDKKHQEEPPFLWMGYELHPDKWTVQ Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135456 D4T3TCEFV 2009 South Africa C 1 1 329 PISSIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICEEMEKEGKITKIGPENPYNTPIFAIKRKNSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSMTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPEIDICQYMDDLYVASDLEIGQHRAKVEELREHLLMWGFTTPDEKHQKEPPFRWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2191 135457 ABC3TCEFV 2012 South Africa C 1 1 411 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALTAICDEMEKEGKITKIGPENPYNTPVFAIKKKDSTKWRKVVDFRELNKRTQDFWEVQLGIPHPAGLKKRKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRTKNPEIDIYQYVDDLLVGSDLEIGQHRAKIEELREHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIQVRQLCRLLRGAKALTDIVPLTEEAELELAENREILREPVHGVYYDPSKDLIAEIQKQGHDQWTYQIYQEPFKNLKTGKYAKMRTAHTNDVKQLTEAVQKIALESIVIWGKTPKFRLPIQKETWETWWTDYWQATWI Steegen, K 2014 24816790 PLoS ONE High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. 2193 135532 TDF3TCEFV 2007 Israel A 0 30 247 QIGCTLNFCVEMEKEGKISKIGPENPYNTPVFAIKRKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSITVLDVGDAYFSVPLHESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPEIVICQYVDDLYVSSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIMLP Avidor, B 2013 23469241 PLoS ONE Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy. 2193 135534 TDF3TCEFV 2006 Israel A 0 30 247 QIGCTLNFCKEMEKEGKISKIGPENPYNTPVFAIRKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRSKNPGIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLP Avidor, B 2013 23469241 PLoS ONE Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy. 2193 135535 TDFFTCEFV 2009 Israel A 0 35 247 LNFCTEMEKEGKISKIGPENPYNTPVFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRSKNPEIVIYQYMDDLYVSSDLEIGQHRTKIEELRTHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLP Avidor, B 2013 23469241 PLoS ONE Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy. 2193 135537 TDFFTCEFV 2010 Israel A 0 35 247 LNFCREMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIIIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLP Avidor, B 2013 23469241 PLoS ONE Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy. 2193 135539 TDFFTCEFV 2009 Israel A 0 30 247 QIGCTLNFCADMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQNKSVTILDVGDAYFSVPLHQDFRKYTAFTIPSTNNQTPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRAKNPDLIIYQYVDDLYVGSDLEIGLHRAKIEELRAHLLSWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLP Avidor, B 2013 23469241 PLoS ONE Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy. 2193 135544 AZT3TCEFV 2006 Israel A 0 35 247 LNFCMEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTILDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRLKNPEIVIYQYVDDLYVGSDLEIGQHRAKIDELRAHLLSWGFTTPDKKHQKEHPFLWMGYELHPDKWTVQPIMLP Avidor, B 2013 23469241 PLoS ONE Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy. 2193 135545 AZT3TCEFV 2005 Israel A 0 30 247 QIGCTLNFCKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEIQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPDIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Avidor, B 2013 23469241 PLoS ONE Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy. 2193 135553 AZT3TCEFV 2007 Israel A 0 30 247 QIGCTLNFCNEMEKEGKISKIGPENPYNTPMFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDNWTVQPIMLP Avidor, B 2013 23469241 PLoS ONE Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy. 2193 135554 AZT3TCEFV 2006 Israel A 0 30 247 QIGCTLNFCKEMEKEGKISKIGPENPYNTPVFVIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRLKNPEIVIYQYVDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEHPFHWMGYELHPDKWTVQPIMLP Avidor, B 2013 23469241 PLoS ONE Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy. 2193 135557 AZT3TCEFV 2005 Israel A 0 30 247 QIGCTLNFCKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPLHENFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRSRNPELVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Avidor, B 2013 23469241 PLoS ONE Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy. 2193 135558 TDFFTCNVP 2009 Israel A 0 35 247 LNFCLEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRSKNPGIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIKLP Avidor, B 2013 23469241 PLoS ONE Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy. 2193 135561 ABC3TCNVP 2009 Israel A 0 30 247 QIGCTLNFCTEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNRRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRSKNPEVIIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIQLP Avidor, B 2013 23469241 PLoS ONE Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy. 2193 135563 TDFFTCEFV 2010 Israel A 0 38 247 CQEMEKEGKISKIGPENPYNTPVFAIKKKDGNKWRKIVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPDIIIYQYVDDLYVSSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLP Avidor, B 2013 23469241 PLoS ONE Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy. 2193 135564 AZT3TCEFV 2004 Israel A 0 38 244 CMEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGSKKKKSVTVLDVGDAYFSVPLDENFRKYTAFTIPSIYNETPGIKYQYNVLTQGWKGSPSIFQSSMTKILEPFRSQNPEIVIYQYMDDLYVGSDLEIEQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPI Avidor, B 2013 23469241 PLoS ONE Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy. 2193 135567 AZT3TCEFV 2007 Israel A 0 38 247 CKEMEKEGKISKIGPENPYNTPIFAIKKKDGTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTRILEPFRITNPEIVIYQYMDDLYVGSDLEIGQHRAKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Avidor, B 2013 23469241 PLoS ONE Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy. 2193 135568 AZT3TCEFV 2003 Israel A 0 38 247 CKEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEGFRKYTAFTIPSINNETPGIRYQYNVLPQRWKGSPSIFQSSMTRILEPFRSKNPEIVIYQYMVDLYVGSDLEIGQHRAKIEELRAHLLSWGFTAPDKKHQKEPPFLWMGYELHPDKWTVQPIMLP Avidor, B 2013 23469241 PLoS ONE Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy. 2193 135570 AZT3TCEFV 2007 Israel A 0 38 247 CNEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLHEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRSKNPEIVIYQYVDDLYVSSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFFWMGYELHPDKWTVQPITLP Avidor, B 2013 23469241 PLoS ONE Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy. 2193 135571 TDF3TCEFV 2010 Israel A 0 38 247 CEEMEKEGKISKIGPENPYNTPVFAIKRKDS~KWRKLVDFRELNKRTQDFWEVQLGIPHPAGLEKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSINNETPGTRYQYNVLPQGWKGSPSIFQSSMTKILEPFRSKNPDIVICQYVDDLYVSSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFRWMGYELHPDKWTVQPIMLP Avidor, B 2013 23469241 PLoS ONE Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy. 2193 135574 AZT3TCEFV 2008 Israel A 0 38 247 CMEMEKEGKISKIGPENPYNTPVFAIKKKDSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRAKNPEIVIYQYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Avidor, B 2013 23469241 PLoS ONE Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy. 2193 135577 AZT3TCEFV 2008 Israel A 0 38 247 CLEMEKEGKISKIGPENPYNTPIFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTILDVGDAYFSVPLHESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSQSIIQSSMTRILDPFRARNPEIVIYQYVDDLYIGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLP Avidor, B 2013 23469241 PLoS ONE Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy.